

Approved



Kenya

Country Operational Plan

FY 2014

Note: Italicized sections of narrative text indicate that the content was not submitted in the Lite COP year, but was derived from the previous Full COP year. This includes data in Technical Area Narratives, and Mechanism Overview and Budget Code narratives from continued mechanisms.



Budget Summary Reports

Summary of Planned Funding by Agency and Funding Source

Agency	Funding Source			Total
	GAP	GHP-State	GHP-USAID	
DOD		21,633,574		21,633,574
HHS/CDC	3,320,000	141,867,201		145,187,201
HHS/HRSA		2,445,400		2,445,400
State		911,000		911,000
State/AF		100,956		100,956
USAID		204,721,869		204,721,869
Total	3,320,000	371,680,000	0	375,000,000

Summary of Planned Funding by Budget Code and Agency

Budget Code	Agency								On Hold Amount	Total
	State	DOD	HHS/CDC	HHS/HRSA	PC	State/AF	USAID	AllOther		
CIRC		1,223,859	8,912,476				3,360,021		0	13,496,356
HBHC	12,775	862,197	5,725,195			50,956	36,484,616		0	43,135,739
HKID	12,775	1,141,581	1,008,243			50,000	28,808,469		0	31,021,068
HLAB		1,065,456	6,146,719				3,050,000		0	10,262,175
HMBL			2,557,709				1,500,000		0	4,057,709
HMIN			1,684,613				350,000		0	2,034,613
HTXD							33,229,278		0	33,229,278
HTXS		7,681,972	52,348,569	25,000			38,596,571		0	98,652,112
HVAB			2,120,910	308,000	0		2,309,565		0	4,738,475

Approved



HVCT		1,100,254	9,804,048				14,656,702		0	25,561,004
HVMS	808,800	1,272,273	8,436,301		0		0		0	10,517,374
HVOP		668,768	7,321,627		0		1,389,859		0	9,380,254
HVSI	63,875	1,183,684	6,780,099	2,112,400			8,702,000		0	18,842,058
HVTB		1,211,445	6,884,727				6,403,717		0	14,499,889
IDUP			1,939,977				1,229,520		0	3,169,497
MTCT		2,916,744	13,180,837				9,072,227		0	25,169,808
OHSS	12,775		3,837,154				5,095,000		0	8,944,929
PDCS		430,992	2,224,621				2,927,076		0	5,582,689
PDTX		874,349	4,273,376				7,557,248		0	12,704,973
	911,000	21,633,574	145,187,201	2,445,400	0	100,956	204,721,869	0	0	375,000,000



Budgetary Requirements Worksheet

Redacted

Technical Areas

Technical Area Summary

Technical Area: Care

Budget Code	Budget Code Planned Amount	On Hold Amount
HBHC	43,060,053	0
HKID	31,000,000	0
HVTB	14,407,540	0
PDCS	5,467,169	0
Total Technical Area Planned Funding:	93,934,762	0

Technical Area: Governance and Systems

Budget Code	Budget Code Planned Amount	On Hold Amount
HLAB	10,018,750	0
HVSI	18,138,267	0
OHSS	7,505,875	0
Total Technical Area Planned Funding:	35,662,892	0

Technical Area: Prevention

Budget Code	Budget Code Planned Amount	On Hold Amount
CIRC	13,438,344	0
HMBL	4,000,000	0
HMIN	1,960,417	0
HVAB	4,598,326	0

Approved



HVCT	25,352,723	0
HVOP	9,238,337	0
IDUP	3,144,767	0
MTCT	25,035,528	0
Total Technical Area Planned Funding:	86,768,442	0

Technical Area: Treatment

Budget Code	Budget Code Planned Amount	On Hold Amount
HTXD	33,229,278	0
HTXS	98,483,993	0
PDTX	12,588,140	0
Total Technical Area Planned Funding:	144,301,411	0



Technical Area Summary Indicators and Targets

Indicator Number	Label	2014	2015
SITE_SUPP	Number of unique sites supported by PEPFAR	4,745	6,025
	By program area/support type: HTC Direct Service Delivery (DSD)	2,712	2,800
	By program area/support type: HTC Technical Assistance-only (TA)	2,967	2,529
	By program area/support type: Treatment Direct Service Delivery (DSD)	1,796	1,943
	By program area/support type: Treatment Technical Assistance-only (TA)	334	335
	By program area/support type: Care and Support Direct Service Delivery (DSD)	2,110	2,248
	By program area/support type: Care and Support Technical Assistance-only (TA)	755	756
	By program area/support type: Food and Nutrition Direct Service Delivery (DSD)	2,143	2,204
	By program area/support type: Food and Nutrition Technical Assistance-only (TA)	888	882



	By program area/support type: PMTCT Direct Service Delivery (DSD)	4,200	4,200
	By program area/support type: PMTCT Technical Assistance-only (TA)	0	0
	By program area/support type: TB/HIV Direct Service Delivery (DSD)	1,397	1,471
	By program area/support type: TB/HIV Technical Assistance-only (TA)	852	852
	By program area/support type: VMMC Direct Service Delivery (DSD)	379	379
	By program area/support type: VMMC Technical Assistance-only (TA)	10	10
	By program area/support type: General Population Prevention Direct Service Delivery (DSD)	417	419
	By program area/support type: General Population Prevention Technical Assistance-only (TA)	1,066	1,066
	By program area/support type: Key Populations Prevention Direct Service Delivery (DSD)	87	90
	By program area/support type: Key Populations Prevention Technical Assistance-only (TA)	3	3
	By program area/support	286	290



	type: OVC Direct Service Delivery (DSD)		
	By program area/support type: OVC Technical Assistance-only (TA)	0	0
	By program area/support type: PHDP/Family Planning & Integration Direct Service Delivery (DSD)	1,229	1,384
	By program area/support type: PHDP/Family Planning & Integration Technical Assistance-only (TA)	2,277	2,278
	By program area/support type: Lab Direct Service Delivery (DSD)	2,026	2,081
	By program area/support type: Lab Technical Assistance-only (TA)	2,098	3,693
PMTCT_SITE	PMTCT_SITE Percentage of PEPFAR-supported sites achieving 90% ARV or ART coverage for HIV+ pregnant women	90 %	
	Number of PEPFAR-supported sites achieving 90% ARV or ART coverage for HIV+ pregnant women	4,230	4,333
	Total number of PEPFAR supported sites providing PMTCT services (HTC and ARV or ART services)	4,700	4,815
	By site support type: Direct Service Delivery (DSD):	3,157	3,285



	Number of PEPFAR-supported sites achieving 90% ARV or ART coverage for HIV+ pregnant women		
	By site support type: Technical Assistance-only (TA): Number of PEPFAR-supported sites achieving 90% ARV or ART coverage for HIV+ pregnant women	1,073	1,048
	Sum of Numerator Support Type disaggregates	4,230	4,333
	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR supported sites providing PMTCT services (HTC and ARV or ART services)	3,508	3,650
	By site support type: Technical Assistance-only (TA): Total number of PEPFAR supported sites providing PMTCT services (HTC and ARV or ART services)	1,192	1,165
	Sum of Denominator Support Type disaggregates	4,700	4,815
PMTCT_STAT_DSD	PMTCT_STAT_DSD Number and percentage of pregnant women with known status (includes women who were tested for HIV and received their results) (DSD)	100 %	
	Number of pregnant women	1,065,816	1,119,400



	with known HIV status (includes women who were tested for HIV and received their results)		
	Number of new ANC and L&D clients	1,065,816	1,119,400
	By: Known positives at entry	36,900	39,019
	By: Number of new positives identified	35,110	39,954
	Sum of Positives Status disaggregates	72,010	78,973
	Required only for DREAMS Countries - By Number of new positives: <15		
	Required only for DREAMS Countries - By Number of new positives: 15-19		
	Required only for DREAMS Countries - By Number of new positives: 20-24		
	Required only for DREAMS Countries - By Number of new positives: 25+		
	Required only for DREAMS Countries - By Number of known positives: <15		
	Required only for DREAMS Countries - By Number of known positives: 15-19		
	Required only for DREAMS Countries - By Number of known positives: 20-24		
	Required only for DREAMS Countries - By Number of known positives: 25+		



	Required only for DREAMS Countries - Denominator: <15		
	Required only for DREAMS Countries - Denominator: <15-19		
	Required only for DREAMS Countries - Denominator: 20-24		
	Required only for DREAMS Countries - Denominator: 25+		
PMTCT_STAT_NA	PMTCT_STAT_NA Number and percentage of pregnant women with known status (includes women who were tested for HIV and received their results) (Neither)	n/a	
	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	0	0
	Number of new ANC and L&D clients	0	0
	By: Known positives at entry	0	0
	By: Number of new positives identified	0	0
	Sum of Positives Status disaggregates	0	0
PMTCT_STAT_NGI	PMTCT_STAT_NGI Number and percentage of pregnant women with known status (includes women who were tested for HIV and received	100 %	



	their results) (NGI)		
	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	1,365,000	1,433,000
	Number of new ANC and L&D clients	1,365,000	1,433,000
	By: Known positives at entry	40,371	41,180
	By: Number of new positives identified	45,524	46,437
	Sum of Positives Status disaggregates	85,895	87,617
PMTCT_STAT_TA	PMTCT_STAT_TA Number and percentage of pregnant women with known status (includes women who were tested for HIV and received their results) (TA)	100 %	
	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	299,184	313,600
	Number of new ANC and L&D clients	299,184	313,600
	By: Known positives at entry	3,471	2,161
	By: Number of new positives identified	10,414	6,483
	Sum of Positives Status disaggregates	13,885	8,644
	Required only for DREAMS countries - By known positives: <15		
	Required only for DREAMS		



	countries - By known positives: 15-19		
	Required only for DREAMS countries - By known positives: 20-24		
	Required only for DREAMS countries - By known positives: 25+		
	Required only for DREAMS countries - By new positives: <15		
	Required only for DREAMS countries - By new positives: 15-19		
	Required only for DREAMS countries - By new positives: 20-24		
	Required only for DREAMS countries - By new positives: 25+		
	Required only for DREAMS countries - Denominator: <15		
	Required only for DREAMS countries - Denominator: 15-19		
	Required only for DREAMS countries - Denominator: 20-24		
	Required only for DREAMS countries - Denominator: 25+		
PMTCT_ARV_DSD	PMTCT_ARV_DSD Percentage of HIV-positive pregnant women who received antiretrovirals to reduce risk for	97 %	



	mother-to-child-transmission (MTCT) during pregnancy and delivery (DSD)		
	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	69,793	76,434
	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	72,010	78,973
	Life-long ART (including Option B+)	45,924	50,294
	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	18,007	19,720
	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	27,917	30,574
	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)	0	0
	Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)	23,869	26,140
	Single-dose nevirapine (with or without tail)	0	0



	Sum of Regimen Type disaggregates	69,793	76,434
	Sum of New and Current disaggregates	45,924	50,294
PMTCT_ARV_NA	PMTCT_ARV_NA Percentage of HIV-positive pregnant women who received antiretrovirals to reduce risk for mother-to-child-transmission (MTCT) during pregnancy and delivery (Neither)	n/a	
	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	0	0
	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	0	0
	Life-long ART (including Option B+)	0	0
	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	0	0
	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	0	0
	Maternal triple ARV prophylaxis (provided with	0	0



	the intention to stop at the end of the breastfeeding period)		
	Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)	0	0
	Single-dose nevirapine (with or without tail)	0	0
	Sum of Regimen disaggregates	0	0
	Sum of New and Current disaggregates	0	0
PMTCT_ARV_NGI	PMTCT_ARV_NGI Percentage of HIV-positive pregnant women who received antiretrovirals to reduce risk for mother-to-child-transmission (MTCT) during pregnancy and delivery (NGI)	97 %	
	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	83,318	84,988
	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	85,895	87,617
	Life-long ART (including Option B+)	54,823	55,922



	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	21,496	21,927
	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	33,327	33,995
	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)	0	0
	Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)	28,495	29,066
	Single-dose nevirapine (with or without tail)	0	0
	Sum of Regimen disaggregates	83,318	84,988
	Sum of New and Current disaggregates	54,823	55,922
PMTCT_ARV_TA	PMTCT_ARV_TA Percentage of HIV-positive pregnant women who received antiretrovirals to reduce risk for mother-to-child-transmission (MTCT) during pregnancy and delivery (TA)	97 %	
	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission	13,525	8,554



	(MTCT) during pregnancy and delivery		
	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	13,885	8,644
	Life-long ART (including Option B+)	8,899	5,628
	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	3,489	2,207
	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	5,410	3,421
	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)	0	0
	Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)	4,626	2,926
	Single-dose nevirapine (with or without tail)	0	0
	Sum of Regimen Type disaggregates	13,525	8,554
	Sum of New and Current disaggregates	8,899	5,628
BS_COLL	Number of whole blood collections each year by the N BTS network	200,000	66,667
	By: Number of whole blood	200,000	66,667



	donations screened for HIV in an NBTS network laboratory		
	By: Number of whole blood donations screened for HIV in an NBTS network laboratory that are identified as reactive for HIV	2,000	500
KP_MAT_DSD	KP_MAT_DSD Percentage of people who inject drugs (PWID) on medication assisted therapy (MAT) for at least 6 months	n/a	
	Number of people who inject drugs (PWID) on medication assisted therapy (MAT) for at least 6 months	500	2,169
	Sex: Male	400	1,735
	Sex: Female	100	434
	Sum of Sex disaggregates	500	2,169
VMMC_AE_DSD	Number of males circumcised surgically or by medical device that experienced at least one moderate or severe adverse event(s) (AEs)	190	163
	By AE type: Number of VMMC clients with one or more moderate or severe surgical intra-operative AE(s)	476	475
	Sub-Disag: Surgical intra-operative AE(s) by maximum severity category: Number of clients with one or more moderate surgical	345	366



	intra-operative AE(s), but no severe surgical intra-operative AE(s)		
	Sub-Disag: Surgical intra-operative AE(s) by maximum severity category: Number of clients with one or more severe surgical intra-operative AE(s)	43	45
	By AE Type: Number of VMMC clients with one or more moderate or severe surgical post-operative AE(s)	447	474
	Sub-Disag: By Surgical post-operative AE(s) by maximum severity category: Number of clients with one or more moderate surgical post-operative AE(s), but no severe surgical post-operative AE(s)	396	420
	Sub-Disag: By Surgical post-operative AE(s) by maximum severity category: Number of clients with one or more severe surgical intra-operative AE(s)	48	49
	By AE Type: Number of VMMC clients with one or more moderate or severe medical device-related AE(s)	44	302
	Sub-Disag: By Medical device-based AE(s) by maximum severity category: Number of clients with one or more moderate medical	44	46



	device-related AE(s), but no severe medical device-related AE(s)		
	Sub-Disag: By Medical device-based AE(s) by maximum severity category: Number of clients with one or more severe medical device-related AE(s)	0	0
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	203,447	215,842
	By Age: <1	0	0
	By Age: 1-9	0	0
	By Age: 10-14	73,940	78,950
	By Age: 15-19	80,214	85,183
	By Age: 20-24	25,426	26,667
	By Age: 25-29		
	By Age: 30-49		
	By Age: 50+	366	364
	Sum of age disaggregates	203,447	215,842
	By HIV status: Number of HIV-positive clients (tested HIV positive at VMMC site)	10,715	11,129
	By HIV status: Number of HIV-negative clients (tested HIV negative at VMMC program)	170,482	183,097
	By HIV status: Number of clients with undocumented/indeterminate	10,370	10,421



	HIV status or not tested for HIV at site		
	By circumcision technique: Surgical VMMC	195,505	199,521
	By circumcision technique: Device-based VMMC	2,000	13,458
	By follow-up status: Number of surgically circumcised clients who returned at least once for follow-up care within 14 days of circumcision surgery	151,306	161,615
	By follow-up status: Number of surgically circumcised clients who did NOT return for follow-up care within 14 days of circumcision surgery	39,574	44,649
VMMC_CIRC_NA	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	0	0
	By Age: <1	0	0
	By Age: 1-9	0	0
	By Age: 10-14	0	0
	By Age: 15-19	0	0
	By Age: 20-24	0	0
	By Age: 25-49	0	0
	By Age: 50+	0	0
	Sum of Age disaggregates	0	0
	By HIV status: Number of HIV-positive clients (tested HIV positive at VMMC site)	0	0



	By HIV status: Number of HIV-negative clients (tested HIV negative at VMMC program)	0	0
	By HIV status: Number of clients with undocumented/indeterminate HIV status or not tested for HIV at site	0	0
	By circumcision technique: Surgical VMMC	0	0
	By circumcision technique: Device-based VMMC	0	0
	By follow-up status: Number of surgically circumcised clients who returned at least once for follow-up care within 14 days of circumcision surgery	0	0
	By follow-up status: Number of surgically circumcised clients who did NOT return for follow-up care within 14 days of circumcision surgery	0	0
VMMC_CIRC_NGI	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	203,447	215,842
	By Age: <1	0	0
	By Age: 1-9	0	0
	By Age: 10-14	73,940	78,950
	By Age: 15-19	80,214	85,183
	By Age: 20-24	25,426	26,667



	By Age: 25-49	23,501	24,678
	By Age: 50+	366	364
	Sum of Age disaggregates	203,447	215,842
	By HIV status: Number of HIV-positive clients (tested HIV positive at VMMC site)	10,715	11,129
	By HIV status: Number of HIV-negative clients (tested HIV negative at VMMC program)	170,482	183,097
	By HIV status: Number of clients with undocumented/indeterminate HIV status or not tested for HIV at site	10,370	10,421
	By circumcision technique: Surgical VMMC	195,505	199,521
	By circumcision technique: Device-based VMMC	2,000	13,458
	By follow-up status: Number of surgically circumcised clients who returned at least once for follow-up care within 14 days of circumcision surgery	151,306	161,615
	By follow-up status: Number of surgically circumcised clients who did NOT return for follow-up care within 14 days of circumcision surgery	39,574	44,649
VMMC_CIRC_TA	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within	0	0



	the reporting period		
	By Age: <1	0	0
	By Age: 1-9	0	0
	By Age: 10-14	0	0
	By Age: 15-19	0	0
	By Age: 20-24	0	0
	By Age: 25-29		
	By Age: 30-49		
	By Age: 50+	0	0
	Sum of Age disaggregations	0	0
	By HIV status: Number of HIV-positive clients (tested HIV positive at VMMC site)	0	0
	By HIV status: Number of HIV-negative clients (tested HIV negative at VMMC program)	0	0
	By HIV status: Number of clients with undocumented/indeterminate HIV status or not tested for HIV at site	0	0
	By circumcision technique: Surgical VMMC	0	0
	By circumcision technique: Device-based VMMC	0	0
	By follow-up status: Number of surgically circumcised clients who returned at least once for follow-up care within 14 days of circumcision surgery	0	0
	By follow-up status: Number of surgically circumcised	0	0



	clients who did NOT return for follow-up care within 14 days of circumcision surgery		
PP_PREV_DSD	PP_PREV_DSD Percentage of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period (DSD)	13 %	
	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	728,027	1,242,312
	Total number of people in the target population	5,583,162	5,573,537
	Age/sex: 10-14 Male	130,069	252,197
	Age/sex: 15-19 Male	69,126	77,536
	Age/sex: 20-24 Male	53,570	84,735
	Age/sex: 25-49 Male	100,311	131,363
	Age/sex: 50+ Male	7,566	14,672
	Age/sex: 10-14 Female	151,345	281,509
	Age/sex: 15-19 Female	73,809	138,007
	Age/sex: 20-24 Female	46,460	138,433
	Age/sex: 25-49 Female	85,465	108,302
	Age/sex: 50+ Female	10,306	15,558
	Sum of Age/Sex disaggregates	728,027	1,242,312
PP_PREV_TA	PP_PREV_TA Percentage of the target population who completed a standardized HIV prevention intervention	10 %	



	including the minimum components during the reporting period (TA-only)		
	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	143,870	143,111
	Total number of people in the target population	1,411,299	1,421,299
	Age/sex: 10-14 Male	49,131	45,992
	Age/sex: 15-19 Male	12,879	15,652
	Age/sex: 20-24 Male	3,612	4,903
	Age/sex: 25-49 Male	4,235	5,335
	Age/sex: 50+ Male	560	700
	Age/sex: 10-14 Female	52,536	44,968
	Age/sex: 15-19 Female	14,578	16,936
	Age/sex: 20-24 Female	2,345	3,745
	Age/sex: 25-49 Female	3,568	4,256
	Age/sex: 50+ Female	426	624
	Sum of Age/Sex disaggregates	143,870	143,111
KP_PREV_DSD	KP_PREV_DSD Percentage of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required (DSD)	n/a	
	Number of key populations reached with individual and/or small group level HIV	169,040	195,394



	preventive interventions that are based on evidence and/or meet the minimum standards required		
	Total estimated number of key population in the catchment area		
	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	147,027	173,334
	By key population type: Males who inject drugs (Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	7,673	8,948
	By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	966	1,260



	<p>By key population type: Men who have sex with men/Transgender (MSM/TG) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)</p>	<p>13,374</p>	<p>11,852</p>
	<p>By key population type: MSM/TG who are male sex workers (subset MSM/TG) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)</p>	<p>2,022</p>	<p>1,732</p>
	<p>By key population type: Female sex workers (FSW) (Denominator: Total estimated number of key population in the catchment area)</p>		
	<p>By key population type: Males who inject drugs (Male PWID) (Denominator: Total estimated number of key population in the catchment area)</p>		
	<p>By key population type: Females who inject drugs (Female PWID) (Denominator: Total</p>		



	estimated number of key population in the catchment area)		
	By key population type: Men who have sex with men/Transgender (MSM/TG) (Denominator: Total estimated number of key population in the catchment area)		
	By key population type: MSM/TG who are male sex workers (subset MSM/TG) (Denominator: Total estimated number of key population in the catchment area)		
KP_PREV_TA	KP_PREV_TA Percentage of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required (TA-only)	n/a	
	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	3,984	4,950
	Total estimated number of key population in the catchment area		
	By key population type:	3,895	4,730



	<p>Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)</p>		
	<p>By key population type: Males who inject drugs (Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)</p>	0	0
	<p>By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)</p>	0	0
	<p>By key population type: Men who have sex with men/Transgender (MSM/TG) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based</p>	89	220



	on evidence and/or meet the minimum standards required)		
	By key population type: MSM/TG who are male sex workers (subset MSM/TG) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0	0
	By key population type: Female sex workers (FSW) (Denominator: Total estimated number of key population in the catchment area)		
	By key population type: Males who inject drugs (Male PWID) (Denominator: Total estimated number of key population in the catchment area)		
	By key population type: Females who inject drugs (Female PWID) (Denominator: Total estimated number of key population in the catchment area)		
	By key population type: Men who have sex with men/Transgender (MSM/TG) (Denominator: Total estimated number of key		



	population in the catchment area)		
	By key population type: MSM/TG who are male sex workers (subset MSM/TG) (Denominator: Total estimated number of key population in the catchment area)		
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	3,531,816	4,484,673
	By Test Result: Negative	3,383,372	4,306,353
	By Test Result: Positive	148,444	178,320
	Sum of Test Result disaggregates	3,531,816	4,484,673
	Test Result by Age and Sex: Positive: <1 Male		
	Test Result by Age and Sex: Positive: 1-4 Male		
	Test Result by Age and Sex: Positive: 5-9 Male		
	Test Result by Age and Sex: Positive: 10-14 Male		
	Test Result by Age and Sex: Positive: 15-19 Male		
	Test Result by Age and Sex: Positive: 20-24 Male		
	Test Result by Age and Sex: Positive: 25-49 Male		
	Test Result by Age and Sex: Positive: 50+ Male		



	Test Result by Age and Sex: Positive: <1 Female		
	Test Result by Age and Sex: Positive: 1-4 Female		
	Test Result by Age and Sex: Positive: 5-9 Female		
	Test Result by Age and Sex: Positive: 10-14 Female		
	Test Result by Age and Sex: Positive: 15-19 Female		
	Test Result by Age and Sex: Positive: 20-24 Female		
	Test Result by Age and Sex: Positive: 25-49 Female		
	Test Result by Age and Sex: Positive: 50+ Female		
	Test Result by Age and Sex: Negative: <1 Male		
	Test Result by Age and Sex: Negative: 1-4 Male		
	Test Result by Age and Sex: Negative: 5-9 Male		
	Test Result by Age and Sex: Negative: 10-14 Male		
	Test Result by Age and Sex: Negative: 15-19 Male		
	Test Result by Age and Sex: Negative: 20-24 Male		
	Test Result by Age and Sex: Negative: 25-49 Male		
	Test Result by Age and Sex: Negative: 50+ Male		
	Test Result by Age and Sex: Negative: <1 Female		



	Test Result by Age and Sex: Negative: 1-4 Female		
	Test Result by Age and Sex: Negative: 5-9 Female		
	Test Result by Age and Sex: Negative: 10-14 Female		
	Test Result by Age and Sex: Negative: 15-19 Female		
	Test Result by Age and Sex: Negative: 20-24 Female		
	Test Result by Age and Sex: Negative: 25-49 Female		
	Test Result by Age and Sex: Negative: 50+ Female		
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	268,938	348,629
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	1,506,736	1,840,603
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	247,492	306,140
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	1,508,650	1,989,301
	Sum of Aggregated Age/Sex <15	516,430	654,769
	Sum of Aggregated Age/Sex 15+	3,015,386	3,829,904
	Sum of Aggregated Age/Sex disaggregates	3,531,816	4,484,673
	Service Delivery Point by Result: Antenatal Clinic - All		



	results		
	Service Delivery Point by Result: Antenatal Clinic - Positive		
	Service Delivery Point by Result: Antenatal Clinic - Negative		
	Service Delivery Point by Result: Labor & delivery - All results		
	Service Delivery Point by Result: Labor & delivery - Positive		
	Service Delivery Point by Result: Labor & delivery - Negative		
	Service Delivery Point by Result: Under 5 Clinic – All results		
	Service Delivery Point by Result: Under 5 Clinic - Positive		
	Service Delivery Point by Result: Under 5 Clinic - Negative		
	Service Delivery Point by Result: Maternal and Child Health Clinic – All Results		
	Service Delivery Point by Result: Maternal and Child Health Clinic - Positive		
	Service Delivery Point by Result: Maternal and Child Health Clinic - Negative		
	Service Delivery Point by		



	Result: Tuberculosis – All results		
	Service Delivery Point by Result: Tuberculosis - Positive		
	Service Delivery Point by Result: Tuberculosis - Negative		
	Service Delivery Point by Result: Sexually Transmitted Infections – All Results		
	Service Delivery Point by Result: Sexually Transmitted Infections - Positive		
	Service Delivery Point by Result: Sexually Transmitted Infections - Negative		
	Service Delivery Point by Result: Outpatient Department – All Results		
	Service Delivery Point by Result: Outpatient Department - Positive		
	Service Delivery Point by Result: Outpatient Department - Negative		
	Service Delivery Point by Result: Inpatient – All Results		
	Service Delivery Point by Result: Inpatient - Positive		
	Service Delivery Point by Result: Inpatient - Negative		
	Service Delivery Point by Result: HIV care and		



	treatment clinic – All Results		
	Service Delivery Point by Result: HIV care and treatment clinic - Positive		
	Service Delivery Point by Result: HIV care and treatment clinic - Negative		
	Service Delivery Point by Result: Voluntary Medical Male Circumcision – All Results		
	Service Delivery Point by Result: Voluntary Medical Male Circumcision - Positive		
	Service Delivery Point by Result: Voluntary Medical Male Circumcision - Negative		
	Service Delivery Point by Result: Voluntary Counseling & Testing (co-located) – All Results		
	Service Delivery Point by Result: Voluntary Counseling & Testing (co-located) - Positive		
	Service Delivery Point by Result: Voluntary Counseling & Testing (co-located) - Negative		
	Service Delivery Point by Result: Voluntary Counseling & Testing (stand alone) – All Results		
	Service Delivery Point by Result: Voluntary Counseling		



	& Testing (stand alone) – Positive		
	Service Delivery Point by Result: Voluntary Counseling & Testing (stand alone) – Negative		
	Service Delivery Point by Result: Mobile – All Results		
	Service Delivery Point by Result: Mobile - Positive		
	Service Delivery Point by Result: Mobile - Negative		
	Service Delivery Point by Result: Home-based – All Results		
	Service Delivery Point by Result: Home-based - Positive		
	Service Delivery Point by Result: Home-based - Negative		
	Service Delivery Point by Result: Other – All Results		
	Service Delivery Point by Result: Other - Positive		
	Service Delivery Point by Result: Other - Negative		
HTC_TST_NA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	0	0
	By Test Result: Negative	0	0
	By Test Result: Positive	0	0



	Sum of Test Result disaggregates	0	0
	Age/sex: <1 Male	0	0
	Age/sex: 1-4 Male	0	0
	Age/sex: 5-9 Male	0	0
	Age/sex: 10-14 Male	0	0
	Age/sex: 15-19 Male	0	0
	Age/sex: 20-24 Male	0	0
	Age/sex: 25-49 Male	0	0
	Age/sex: 50+ Male	0	0
	Age/sex: <1 Female	0	0
	Age/sex: 1-4 Female	0	0
	Age/sex: 5-9 Female	0	0
	Age/sex: 10-14 Female	0	0
	Age/sex: 15-19 Female	0	0
	Age/sex: 20-24 Female	0	0
	Age/sex: 25-49 Female	0	0
	Age/sex: 50+ Female	0	0
	Sum of Age/Sex disaggregates	0	0
	Aggregated Age/sex: <15 Male	0	0
	Aggregated Age/sex: 15+ Male	0	0
	Aggregated Age/sex: <15 Female	0	0
	Aggregated Age/sex: 15+ Female	0	0
	Sum of Aggregated Age/Sex <15	0	0
	Sum of Aggregated Age/Sex 15+	0	0
	Sum of Aggregated Age/Sex	0	0



	disaggregates		
HTC_TST_NGI	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	4,948,759	6,149,350
	By Test Result: Negative	4,727,581	5,840,798
	By Test Result: Positive	221,178	308,552
	Sum of Test Result disaggregates	4,948,759	6,149,350
	Age/sex: <1 Male	256	469
	Age/sex: 1-4 Male	165,452	201,602
	Age/sex: 5-9 Male	70,910	86,402
	Age/sex: 10-14 Male	138,592	185,006
	Age/sex: 15-19 Male	259,522	329,559
	Age/sex: 20-24 Male	623,686	737,919
	Age/sex: 25-49 Male	982,744	1,190,349
	Age/sex: 50+ Male	242,985	290,265
	Age/sex: <1 Female	0	0
	Age/sex: 1-4 Female	165,089	200,894
	Age/sex: 5-9 Female	70,754	86,098
	Age/sex: 10-14 Female	117,922	143,999
	Age/sex: 15-19 Female	240,658	334,964
	Age/sex: 20-24 Female	627,637	852,425
	Age/sex: 25-49 Female	995,235	1,209,891
	Age/sex: 50+ Female	247,317	299,508
	Sum of Age/Sex disaggregates	4,948,759	6,149,350
	Aggregated Age/sex: <15 Male	375,208	473,479
	Aggregated Age/sex: 15+ Male	2,108,938	2,548,092
Aggregated Age/sex: <15	353,763	430,991	



	Female		
	Aggregated Age/sex: 15+ Female	2,110,850	2,696,788
	Sum of Aggregated Age/Sex <15	728,971	904,470
	Sum of Aggregated Age/Sex 15+	4,219,788	5,244,880
	Sum of Aggregated Age/Sex disaggregates	4,948,759	6,149,350
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	1,416,943	1,664,677
	By Test Result: Negative	1,344,209	1,534,445
	By Test Result: Positive	72,734	130,232
	Sum of Test Result disaggregates	1,416,943	1,664,677
	Test Result by Age and Sex: Positive: <1 Male		
	Test Result by Age and Sex: Positive: 1-4 Male		
	Test Result by Age and Sex: Positive: 5-9 Male		
	Test Result by Age and Sex: Positive: 10-14 Male		
	Test Result by Age and Sex: Positive: 15-19 Male		
	Test Result by Age and Sex: Positive: 20-24 Male		
	Test Result by Age and Sex: Positive: 25-49 Male		
	Test Result by Age and Sex: Positive: 50+ Male		



	Test Result by Age and Sex: Positive: <1 Female		
	Test Result by Age and Sex: Positive: 1-4 Female		
	Test Result by Age and Sex: Positive: 5-9 Female		
	Test Result by Age and Sex: Positive: 10-14 Female		
	Test Result by Age and Sex: Positive: 15-19 Female		
	Test Result by Age and Sex: Positive: 20-24 Female		
	Test Result by Age and Sex: Positive: 25-49 Female		
	Test Result by Age and Sex: Positive: 50+ Female		
	Test Result by Age and Sex: Negative: <1 Male		
	Test Result by Age and Sex: Negative: 1-4 Male		
	Test Result by Age and Sex: Negative: 5-9 Male		
	Test Result by Age and Sex: Negative: 10-14 Male		
	Test Result by Age and Sex: Negative: 15-19 Male		
	Test Result by Age and Sex: Negative: 20-24 Male		
	Test Result by Age and Sex: Negative: 25-49 Male		
	Test Result by Age and Sex: Negative: 50+ Male		
	Test Result by Age and Sex: Negative: <1 Female		



	Test Result by Age and Sex: Negative: 1-4 Female		
	Test Result by Age and Sex: Negative: 5-9 Female		
	Test Result by Age and Sex: Negative: 10-14 Female		
	Test Result by Age and Sex: Negative: 15-19 Female		
	Test Result by Age and Sex: Negative: 20-24 Female		
	Test Result by Age and Sex: Negative: 25-49 Female		
	Test Result by Age and Sex: Negative: 50+ Female		
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	106,270	124,850
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	602,202	707,489
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	106,271	124,851
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	602,200	707,487
	Sum of Aggregated Age/Sex <15	212,541	249,701
	Sum of Aggregated Age/Sex 15+	1,204,402	1,414,976
	Sum of Aggregated Age/Sex disaggregates	1,416,943	1,664,677
	Service Delivery Point by Result: Antenatal Clinic - All		



	results		
	Service Delivery Point by Result: Antenatal Clinic - Positive		
	Service Delivery Point by Result: Antenatal Clinic - Negative		
	Service Delivery Point by Result: Labor & delivery - All results		
	Service Delivery Point by Result: Labor & delivery - Positive		
	Service Delivery Point by Result: Labor & delivery - Negative		
	Service Delivery Point by Result: Under 5 Clinic – All results		
	Service Delivery Point by Result: Under 5 Clinic - Positive		
	Service Delivery Point by Result: Under 5 Clinic - Negative		
	Service Delivery Point by Result: Maternal and Child Health Clinic – All Results		
	Service Delivery Point by Result: Maternal and Child Health Clinic - Positive		
	Service Delivery Point by Result: Maternal and Child Health Clinic - Negative		
	Service Delivery Point by		



	Result: Tuberculosis – All results		
	Service Delivery Point by Result: Tuberculosis - Positive		
	Service Delivery Point by Result: Tuberculosis - Negative		
	Service Delivery Point by Result: Sexually Transmitted Infections – All Results		
	Service Delivery Point by Result: Sexually Transmitted Infections - Positive		
	Service Delivery Point by Result: Sexually Transmitted Infections - Negative		
	Service Delivery Point by Result: Outpatient Department – All Results		
	Service Delivery Point by Result: Outpatient Department - Positive		
	Service Delivery Point by Result: Outpatient Department - Negative		
	Service Delivery Point by Result: Inpatient – All Results		
	Service Delivery Point by Result: Inpatient - Positive		
	Service Delivery Point by Result: Inpatient - Negative		
	Service Delivery Point by Result: HIV care and		



	treatment clinic – All Results		
	Service Delivery Point by Result: HIV care and treatment clinic - Positive		
	Service Delivery Point by Result: HIV care and treatment clinic - Negative		
	Service Delivery Point by Result: Voluntary Medical Male Circumcision – All Results		
	Service Delivery Point by Result: Voluntary Medical Male Circumcision - Positive		
	Service Delivery Point by Result: Voluntary Medical Male Circumcision - Negative		
	Service Delivery Point by Result: Voluntary Counseling & Testing (co-located) – All Results		
	Service Delivery Point by Result: Voluntary Counseling & Testing (co-located) - Positive		
	Service Delivery Point by Result: Voluntary Counseling & Testing (co-located) - Negative		
	Service Delivery Point by Result: Voluntary Counseling & Testing (standalone) - All		
	Service Delivery Point by Result: Voluntary Counseling & Testing (standalone) -		



	Positive		
	Service Delivery Point by Result: Voluntary Counseling & Testing (standalone) - Negative		
	Service Delivery Point by Result: Mobile – All Results		
	Service Delivery Point by Result: Mobile - Positive		
	Service Delivery Point by Result: Mobile - Negative		
	Service Delivery Point by Result: Home-based – All Results		
	Service Delivery Point by Result: Home-based - Positive		
	Service Delivery Point by Result: Home-based - Negative		
	Service Delivery Point by Result: Other – All Results		
	Service Delivery Point by Result: Other - Positive		
	Service Delivery Point by Result: Other - Negative		
GEND_GBV_DSD	Number of people receiving post-GBV care	14,288	19,009
	Age/Sex: <10 Male		
	Age/Sex: 10-14 Male		
	Age/Sex: 15-17 Male		
	Age/Sex: 18-24 Male		
	Age/Sex: 25+ Male		
	Age/Sex: <10 Female		



	Age/Sex: 10-14 Female		
	Age/Sex: 15-17 Female		
	Age/Sex: 18-24 Female		
	Age/Sex: 25+ Female		
	Sum of Age/Sex Disaggregates		
	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	4,992	7,516
	By type of service: Sexual Violence (Post-Rape Care)	7,381	9,538
	By PEP service provision (related to sexual violence services provided)	3,696	3,901
GEND_NORM_DSD	Number of people completing an intervention pertaining to gender norms, that meets minimum criteria	88,100	74,525
	Age/Sex: <10 Male		
	Age/Sex: 10-14 Male		
	Age/Sex: 15-19 Male		
	Age/Sex: 20-24 Male		
	Age/Sex: 25+ Male		
	Age/Sex: <10 Female		
	Age/Sex: 10-14 Female		
	Age/Sex: 15-19 Female		
	Age/Sex: 20-24 Female		
	Age/Sex: 25+ Female		
	By Age: 0-9	2,500	3,100
	By Age: 10-14	4,600	5,000
	By Age: 15-19	8,500	9,000
	By Age: 20-24	22,900	19,212
By Age: 25+	49,600	38,213	



	Sum of Age disaggregates	88,100	74,525
OVC_ACC_DSD	Number of active beneficiaries receiving support from PEPFAR OVC programs to access HIV services	72,920	73,630
	Age/Sex: <1 Male		
	Age/Sex: 1-4 Male		
	Age/Sex: 5-9 Male		
	Age/Sex: 10-14 Male		
	Age/Sex: 15-17 Male		
	Age/Sex: 18-24 Male		
	Age/Sex: 25+ Male		
	Age/Sex: <1 Female		
	Age/Sex: 1-4 Female		
	Age/Sex: 5-9 Female		
	Age/Sex: 10-14 Female		
	Age/Sex: 15-17 Female		
	Age/Sex: 18+ Female		
	Age/Sex: 18-24 Female		
	Age/Sex: 25+ Female		
	Sum of Age/Sex disaggregates		
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	671,328	675,561
	Age/Sex: <1 Male		
	Age/Sex: 1-4 Male		
	Age/Sex: 5-9 Male		
	Age/Sex: 10-14 Male		
	Age/Sex: 15-17 Male		



	By: Age/sex: Male 18-24		
	By: Age/sex: Male 25+		
	Age/Sex: <1 Female		
	Age/Sex: 1-4 Female		
	Age/Sex: 5-9 Female		
	Age/Sex: 10-14 Female		
	Age/Sex: 15-17 Female		
	By: Age/sex: 18-24 Female		
	By: Age/sex: 25+ Female		
	Sum of Age/Sex disaggregates		
	Required only for DREAMS countries - By service, age and sex: Education Support Female <1		
	Required only for DREAMS countries - By service, age and sex: Education Support Female 1-4		
	Required only for DREAMS countries - By service, age and sex: Education Support Female 5-9		
	Required only for DREAMS countries - By service, age and sex: Education Support Female 10-14		
	Required only for DREAMS countries - By service, age and sex: Education Support Female 15-17		
	Required only for DREAMS countries - By service, age and sex: Education Support		



	Female 18-24		
	Required only for DREAMS countries - By service, age and sex: Education Support Female 25+		
	Required only for DREAMS countries - By service, age and sex: Education Support Male <1		
	Required only for DREAMS countries - By service, age and sex: Education Support Male 1-4		
	Required only for DREAMS countries - By service, age and sex: Education Support Male 5-9		
	Required only for DREAMS countries - By service, age and sex: Education Support Male 10-14		
	Required only for DREAMS countries - By service, age and sex: Education Support Male 15-17		
	Required only for DREAMS countries - By service, age and sex: Education Support Male 18-24		
	Required only for DREAMS countries - By service, age and sex: Education Support Male 25+		
	Required only for DREAMS countries - By service, age		



	and sex: Parenting/Caregiver Programs Female <1		
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 1-4		
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 5-9		
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 10-14		
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 15-17		
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 18-24		
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 25+		
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male <1		
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 1-4		
	Required only for DREAMS		



	countries - By service, age and sex: Parenting/Caregiver Programs Male 5-9		
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 10-14		
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 15-17		
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 18-24		
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 25+		
	Required only for DREAMS countries - By service, age and sex: Social Protection Female <1		
	Required only for DREAMS countries - By service, age and sex: Social Protection Female 1-4		
	Required only for DREAMS countries - By service, age and sex: Social Protection Female 5-9		
	Required only for DREAMS countries - By service, age and sex: Social Protection Female 10-14		



	Required only for DREAMS countries - By service, age and sex: Social Protection Female 15-17		
	Required only for DREAMS countries - By service, age and sex: Social Protection Female 18-24		
	Required only for DREAMS countries - By service, age and sex: Social Protection Female 25+		
	Required only for DREAMS countries - By service, age and sex: Social Protection Male <1		
	Required only for DREAMS countries - By service, age and sex: Social Protection Male 1-4		
	Required only for DREAMS countries - By service, age and sex: Social Protection Male 5-9		
	Required only for DREAMS countries - By service, age and sex: Social Protection Male 10-14		
	Required only for DREAMS countries - By service, age and sex: Social Protection Male 15-17		
	Required only for DREAMS countries - By service, age and sex: Social Protection		



	Male 18-24		
	Required only for DREAMS countries - By service, age and sex: Social Protection Male 25+		
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female <1		
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 1-4		
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 5-9		
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 10-14		
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 15-17		
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 18-24		
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 25+		
	Required only for DREAMS countries - By service, age		



	and sex: Economic Strengthening Male <1		
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 1-4		
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 5-9		
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 10-14		
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 15-17		
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 18-24		
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 25+		
OVC_SERV_TA	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	0	0
	Age/Sex: <1 Male		
	Age/Sex: 1-4 Male		
	Age/Sex: 5-9 Male		
	Age/Sex: 10-14 Male		



	Age/Sex: 15-17 Male		
	By age/sex: 18-24 Male		
	By age/sex: 25+ Male		
	Age/Sex: <1 Female		
	Age/Sex: 1-4 Female		
	Age/Sex: 5-9 Female		
	Age/Sex: 10-14 Female		
	Age/Sex: 15-17 Female		
	By age/sex: 18-24 Female		
	By age/sex: 25+ Female		
	Sum of Age/Sex disaggregates		
	Required only for DREAMS countries: By Service Area, age and sex: Education Support Female <1		
	Required only for DREAMS countries: By Service Area, age and sex: Education Support Female 1-4		
	Required only for DREAMS countries: By Service Area, age and sex: Education Support Female 5-9		
	Required only for DREAMS countries: By Service Area, age and sex: Education Support Female 10-14		
	Required only for DREAMS countries: By Service Area, age and sex: Education Support Female 15-17		
	Required only for DREAMS countries: By Service Area,		



	age and sex: Education Support Female 18-24		
	Required only for DREAMS countries: By Service Area, age and sex: Education Support Female 25+		
	Required only for DREAMS countries: By Service Area, age and sex: Education Support Male <1		
	Required only for DREAMS countries: By Service Area, age and sex: Education Support Male 1-4		
	Required only for DREAMS countries: By Service Area, age and sex: Education Support Male 5-9		
	Required only for DREAMS countries: By Service Area, age and sex: Education Support Male 10-14		
	Required only for DREAMS countries: By Service Area, age and sex: Education Support Male 15-17		
	Required only for DREAMS countries: By Service Area, age and sex: Education Support Male 18-24		
	Required only for DREAMS countries: By Service Area, age and sex: Education Support Male 25+		
	Required only for DREAMS		



	countries: By Service Area, age and sex: Parenting/Caregiver Program Female <1		
	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Female 1-4		
	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Female 5-9		
	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Female 10-14		
	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Female 15-17		
	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Female 18-24		
	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Female 25+		
	Required only for DREAMS countries: By Service Area,		



	age and sex: Parenting/Caregiver Program Male <1		
	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Male 1-4		
	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Male 5-9		
	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Male 10-14		
	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Male 15-17		
	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Male 18-24		
	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Male 25+		
	Required only for DREAMS countries: By Service Area, age and sex: Social		



	Protection Female <1		
	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Female 1-4		
	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Female 5-9		
	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Female 10-14		
	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Female 15-17		
	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Female 18-24		
	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Female 25+		
	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Male <1		
	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Male 1-4		
	Required only for DREAMS countries: By Service Area,		



	age and sex: Social Protection Male 5-9		
	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Male 10-14		
	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Male 15-17		
	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Male 18-24		
	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Male 25+		
	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Female <1		
	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Female 1-4		
	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Female 5-9		
	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Female 10-14		
	Required only for DREAMS		



	countries: By Service Area, age and sex: Economic Strengthening Female 15-17		
	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Female 18-24		
	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Female 25+		
	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Male <1		
	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Male 1-4		
	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Male 5-9		
	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Male 10-14		
	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Male 15-17		
	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Male 18-24		



	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Male 25+		
	Required only for DREAMS countries: By Service Area, age and sex: Other Service Areas Female <1		
	Required only for DREAMS countries: By Service Area, age and sex: Other Service Areas Female 1-4		
	Required only for DREAMS countries: By Service Area, age and sex: Other Service Areas Female 5-9		
	Required only for DREAMS countries: By Service Area, age and sex: Other Service Areas Female 10-14		
	Required only for DREAMS countries: By Service Area, age and sex: Other Service Areas Female 15-17		
	Required only for DREAMS countries: By Service Area, age and sex: Other Service Areas Female 18-24		
	Required only for DREAMS countries: By Service Area, age and sex: Other Service Areas Female 25+		
C2.1.D_DSD	Number of HIV-positive individuals receiving a minimum of one clinical	927,126	1,012,866



	service		
	By Age/Sex: <15 Female	36,137	39,695
	By Age/Sex: <15 Male	33,107	36,354
	By Age/Sex: 15+ Female	439,134	482,984
	By Age/Sex: 15+ Male	239,579	263,488
	Sum of Age/Sex disaggregates	747,957	822,521
	By Age: <15	78,001	86,047
	By Age: 15+	757,528	836,434
	Sum of Age disaggregates	835,529	922,481
	By Sex: Female	529,282	584,235
	By Sex: Male	306,248	338,247
	Sum of Sex disaggregates	835,530	922,482
C2.1.D_NA	Number of HIV-positive individuals receiving a minimum of one clinical service	36,113	39,384
	By Age/Sex: <15 Female	1,625	1,749
	By Age/Sex: <15 Male	1,625	1,749
	By Age/Sex: 15+ Female	21,361	23,618
	By Age/Sex: 15+ Male	11,502	12,718
	Sum of Age/Sex disaggregates	36,113	39,834
	By Age: <15	3,250	3,498
	By Age: 15+	32,863	36,336
	Sum of Age disaggregates	36,113	39,834
	By Sex: Female	22,986	25,367
	By Sex: Male	13,127	14,467
	Sum of Sex disaggregates	36,113	39,834
C2.1.D_NGI	Number of HIV-positive individuals receiving a minimum of one clinical service	958,181	1,047,732



	By Age/Sex: <15 Female	38,573	42,401
	By Age/Sex: <15 Male	39,764	37,272
	By Age/Sex: 15+ Female	454,651	500,277
	By Age/Sex: 15+ Male	289,112	272,821
	Sum of Age/Sex disaggregates	822,100	852,771
	By Age: <15	82,018	90,532
	By Age: 15+	901,811	866,805
	Sum of Age disaggregates	983,829	957,337
	By Sex: Female	549,389	606,692
	By Sex: Male	317,196	350,205
	Sum of Sex disaggregates	866,585	956,897
C2.1.D_TA	Number of HIV-positive individuals receiving a minimum of one clinical service	67,168	74,251
	By Age/Sex: <15 Female	4,060	4,456
	By Age/Sex: <15 Male	8,281	2,667
	By Age/Sex: 15+ Female	36,878	40,911
	By Age/Sex: 15+ Male	61,035	22,052
	Sum of Age/Sex disaggregates	110,254	70,086
	By Age: <15	7,241	7,956
	By Age: 15+	177,146	66,707
	Sum of Age disaggregates	184,387	74,663
	By Sex: Female	43,092	47,824
	By Sex: Male	24,076	26,426
	Sum of Sex disaggregates	67,168	74,250
C2.4.D_DSD	C2.4.D_DSD TB/HIV: Percent of HIV-positive patients who were screened for TB in HIV care or treatment setting	84 %	



	Number of HIV-positive patients who were screened for TB in HIV care or treatment setting	777,016	869,614
	Number of HIV-positive individuals receiving a minimum of one clinical service	927,126	1,012,866
C2.5.D_DSD	C2.5.D_DSD Percent of HIV-positive patients in HIV care or treatment (pre-ART or ART) who started TB treatment	3 %	
	Number of HIV-positive patients in HIV care who started TB treatment	23,418	25,905
	Number of HIV-positive individuals receiving a minimum of one clinical service	927,126	1,012,866
CARE_CURR_DSD	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	908,458	989,172
	Age/sex: <1 Male	2,182	2,400
	Age/sex: 1-4 Male	8,154	9,000
	Age/sex: 5-9 Male	12,504	13,718
	Age/sex: 10-14 Male	10,306	11,344
	Age/sex: 15-19 Male	8,570	9,424
	Age/sex: 20-24 Male	27,442	30,183
	Age/sex: 25-49 Male	143,328	157,598
	Age/sex: 50+ Male	43,921	48,284



	Age/sex: <1 Female	2,975	3,273
	Age/sex: 1-4 Female	8,612	9,508
	Age/sex: 5-9 Female	13,415	14,725
	Age/sex: 10-14 Female	11,251	12,380
	Age/sex: 15-19 Female	15,094	16,605
	Age/sex: 20-24 Female	62,301	68,523
	Age/sex: 25-49 Female	289,069	317,872
	Age/sex: 50+ Female	52,264	57,478
	Sun of Age/Sex disaggregates	711,388	782,315
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	37,686	41,500
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	258,505	284,261
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	40,723	44,844
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	479,946	527,729
	Sum of Aggregated Age/Sex disaggregates	816,860	898,334
CARE_CURR_TA	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	63,161	69,700
	Age/sex: <1 Male	216	236
	Age/sex: 1-4 Male	394	430
	Age/sex: 5-9 Male	856	940



	Age/sex: 10-14 Male	1,836	2,013
	Age/sex: 15-19 Male	2,797	3,058
	Age/sex: 20-24 Male	4,221	4,715
	Age/sex: 25-49 Male	7,957	8,580
	Age/sex: 50+ Male	3,375	3,742
	Age/sex: <1 Female	339	370
	Age/sex: 1-4 Female	521	570
	Age/sex: 5-9 Female	1,124	1,237
	Age/sex: 10-14 Female	2,400	2,633
	Age/sex: 15-19 Female	5,645	6,081
	Age/sex: 20-24 Female	8,559	9,787
	Age/sex: 25-49 Female	16,057	17,758
	Age/sex: 50+ Female	6,864	7,550
	Sum of Age/Sex disaggregates	63,161	69,700
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	3,302	3,619
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	18,350	20,095
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	4,384	4,810
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	37,125	41,176
	Sum of Aggregated Age/Sex disaggregates	63,161	69,700
CARE_NEW_DSD	Number of HIV-infected adults and children newly enrolled in clinical care during the reporting period and received at least one of	193,287	193,388



	the following at enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load		
	Age/sex: <1 Male	511	536
	Age/sex: 1-4 Male	1,606	1,616
	Age/sex: 5-9 Male	2,543	2,559
	Age/sex: 10-14 Male	2,216	2,217
	Age/sex: 15-19 Male	1,942	1,948
	Age/sex: 20-24 Male	7,741	7,739
	Age/sex: 25-49 Male	32,662	32,714
	Age/sex: 50+ Male	6,752	6,781
	Age/sex: <1 Female	711	733
	Age/sex: 1-4 Female	1,739	1,756
	Age/sex: 5-9 Female	2,844	2,852
	Age/sex: 10-14 Female	2,612	2,618
	Age/sex: 15-19 Female	3,996	3,990
	Age/sex: 20-24 Female	11,866	11,864
	Age/sex: 25-49 Female	56,539	56,482
	Age/sex: 50+ Female	17,598	17
	Sum of Age/sex disaggregates	153,878	136,422
	Aggregated Age/sex: <15 Male	7,963	8,014
	Aggregated Age/sex: 15+ Male	56,072	56,156
	Aggregated Age/sex: <15 Female	8,738	8,792
	Aggregated Age/sex: 15+ Female	102,195	102,106
	Sum of Aggregated Age/sex disaggregates	174,968	175,068
CARE_SITE	CARE_SITE Percentage of	97 %	



	PEPFAR-supported HIV clinical care sites at which at least 80% of PLHIV received all of the following during the reporting period: 1) clinical assessment (WHO staging) OR CD4 count OR viral load, AND 2) TB screening at last visit, AND 3) if eligible, cotrimoxazole		
	Number of PEPFAR-supported HIV clinical care sites at which at least 80% of PLHIV received all of the following during the reporting period: 1) clinical assessment (WHO staging) OR CD4 count OR viral load, AND 2) TB screening at last visit, AND 3) if eligible, cotrimoxazole	2,629	2,739
	Total number of PEPFAR supported sites providing clinical care services	2,708	2,813
	By site support type: Direct Service Delivery (DSD): Number of PEPFAR-supported HIV clinical care sites at which at least 80% of PLHIV received all of the following during the reporting period: 1) clinical assessment (WHO staging) OR CD4 count OR viral load, AND 2) TB screening at last visit, AND 3) if eligible,	2,028	2,137



	cotrimoxazole		
	By site support type: Technical Assistance-only (TA): Number of PEPFAR-supported HIV clinical care sites at which at least 80% of PLHIV received all of the following during the reporting period: 1) clinical assessment (WHO staging) OR CD4 count OR viral load, AND 2) TB screening at last visit, AND 3) if eligible, cotrimoxazole	1,193	1,214
	Sum of Numerator Site Support Type disaggregates	3,221	3,351
	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR supported sites providing clinical care services	2,041	2,145
	By site support type: Technical Assistance-only (TA): Total number of PEPFAR supported sites providing clinical care services	1,253	1,274
	Sum of Denominator Site Support Type disaggregates	3,294	3,419
FN_SITE	FN_SITE Percentage of PEPFAR-supported sites achieving 90% of nutrition assessments that result in an accurate categorization of malnutrition	85 %	
	Number of	1,601	1,726



	PEPFAR-supported sites achieving 90% nutrition assessments that result in accurate categorization of malnutrition		
	Total number of PEPFAR-supported sites providing nutrition assessment, counseling and support (NACS) services	1,874	1,929
	By site support type: Direct Service Delivery (DSD): Number of PEPFAR-supported sites achieving 90% nutrition assessments that result in accurate categorization of malnutrition	1,404	1,534
	By site support type: Technical Assistance-only (TA): Number of PEPFAR-supported sites achieving 90% nutrition assessments that result in accurate categorization of malnutrition	97	92
	Sum of Numerator Support Type disaggregates	1,501	1,626
	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported sites providing nutrition assessment, counseling and support (NACS) services	1,555	1,636
	By site support type:	101	95



	Technical Assistance-only (TA): Total number of PEPFAR-supported sites providing nutrition assessment, counseling and support (NACS) services		
	Sum of Denominator Support Type disaggregates	1,656	1,731
FN_THER_DSD	FN_THER_DSD Proportion of clinically undernourished PLHIV who received therapeutic or supplementary food	75 %	
	Number of clinically malnourished PLHIV who received therapeutic and/or supplementary food during the reporting period.	317,225	326,741
	Number of PLHIV who were nutritionally assessed and found to be clinically undernourished.	425,751	438,678
	Age: <1	32,254	32,370
	Age: 1-4	54,432	54,745
	Age: 5-14	26,035	26,802
	Age: 15-17	4,825	5,108
	Age: 18+	199,679	207,717
	Sum of Age disaggregates	317,225	326,742
	Aggregated Age: <18	117,604	119,082
	Aggregated Age: 18+	199,621	207,659
	Sum of Aggregated Age disaggregates	317,225	326,741
	By Pregnancy/Postpartum Status: Pregnant		



	By Pregnancy/Postpartum Status: Postpartum		
TB_ART_DSD	TB_ART_DSD Percentage of HIV-positive new and relapsed registered TB cases on ART during TB treatment	85 %	
	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	33,243	38,611
	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	38,959	43,403
	Age: <1		
	Age: 1-4		
	Age: 5-9		
	Age: 10-14		
	Age: 15-19		
	Age: 20+		
	Sum of Age disaggregates		
	Male	17,523	20,400
	Female	17,383	19,874
	Sum of Sex disaggregates	34,906	40,274
	Newly tested	17,866	21,036
	Known HIV-positive	19,390	21,913
	Sum of Test Status disaggregates	37,256	42,949
	Aggregated Age: <15	3,077	3,577
Aggregated Age: 15+	31,030	35,898	



	Sum of Aggregated Age disaggregates	34,107	39,475
	Timeliness: Art initiation <8 weeks of start of TB treatment		
	Timeliness: Art initiation >8 weeks of start of TB treatment		
TB_ARTSITE	TB_ARTSITE Proportion of PEPFAR-supported TB basic management units at which 80% of registered TB cases who are HIV-positive are on ART	93 %	
	The number of PEPFAR-supported TB basic management units at which 80% of registered TB cases who are HIV-positive are on ART, during the reporting period	1,898	1,943
	The number of PEPFAR-supported TB basic management units	2,038	2,082
	By site support type: Direct Service Delivery (DSD): The number of PEPFAR-supported TB basic management units at which 80% of registered TB cases who are HIV-positive are on ART, during the reporting period	1,501	1,545
	By site support type: Technical Assistance-only (TA): The number of	397	398



	PEPFAR-supported TB basic management units at which 80% of registered TB cases who are HIV-positive are on ART, during the reporting period		
	Sum of Numerator Site Support Type disaggregates	1,898	1,943
	By site support type: Direct Service Delivery (DSD): The number of PEPFAR-supported TB basic management units	1,596	1,640
	By site support type: Technical Assistance-only (TA): The number of PEPFAR-supported TB basic management units	402	402
	Sum of Denominator Site Support Type disaggregates	1,998	2,042
TB_SCREEN_DSD	TB_SCREEN_DSD Percentage of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period.	n/a	
	The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period		
	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment	908,458	989,172



	(WHO staging) OR CD4 count OR viral load		
	Age: <1	3,434	3,817
	Age: 1-4	14,778	16,649
	Age: 5-9	24,706	27,891
	Age: 10-14	21,855	24,430
	Age: 15-19	28,502	30,873
	Age: 20+		
	Sum of Age disaggregates	93,275	103,660
	Aggregated Age - USE WITH HQ PERMISSION ONLY: <15	70,429	78,548
	Aggregated Age - USE WITH HQ PERMISSION ONLY: 15+	641,743	718,603
	Sum of Aggregated Age disaggregates	712,172	797,151
	Sex: Male	247,240	274,049
	Sex: Female	464,933	523,101
	Sum of Sex disaggregates	712,173	797,150
PMTCT_EID_DSD	PMTCT_EID_DSD Percent of infants born to HIV-positive women that receive a virological HIV test within 12 months of birth (DSD)	100 %	
	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	85,895	87,617
	Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive	85,895	87,617



	women at entry into PMTCT)		
	By infants who received a virologic test within 2 months of birth	34,358	17,524
	By infants who received their first virologic HIV test between 2 and 12 months of age	51,537	70,093
	Sum of Infant Age disaggregates	85,895	87,617
	By infants with a positive virologic test result within 12 months of birth		
	Number of infants with a positive virological test result within 2 months of birth		
	Number of infants with a positive virological test result within 12 months of birth		
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	682,909	819,637
	Age/Sex: <1 Male	1,878	892
	Age/Sex: 1-4 Male	6,647	8,552
	Age/Sex: 5-14 Male	19,741	29,492
	Age/Sex: 15-19 Male		
	Age/Sex: 20+ Male		
	Age/Sex: <1 Female	2,569	972
	Age/Sex: 1-4 Female	7,198	8,273
	Age/Sex: 5-14 Female	20,680	30,449
	Age/Sex: 15-19 Female		
	Age/Sex: 20+ Female		
	Aggregated Age/Sex: <1 Male	1,919	892



	Aggregated Age/Sex: <1 Female	2,522	972
	Aggregated Age/Sex: 1-14 Male		
	Aggregated Age/Sex: 15+ Male	194,461	244,663
	Aggregated Age/Sex: 1-14 Female		
	Aggregated Age/Sex: 15+ Female	361,369	496,343
	Sum of Aggregated Age/Sex <15	57,245	78,630
	Sum of Aggregated Age/Sex 15+	555,830	741,006
	Sum of Aggregated Age/Sex disaggregates	613,075	819,636
TX_CURR_NA	Number of adults and children receiving antiretroviral therapy (ART)	0	0
	Age/Sex: <1 Male	0	0
	Age/Sex: 1-4 Male	0	0
	Age/Sex: 5-14 Male	0	0
	Age/Sex: 15+ Male	0	0
	Age/Sex: <1 Female	0	0
	Age/Sex: 1-4 Female	0	0
	Age/Sex: 5-14 Female	0	0
	Age/Sex: 15+ Female	0	0
	Sum of Age/Sex disaggregates	0	0
	Aggregated Age/Sex: <1 Male	0	0
	Aggregated Age/Sex: <1 Female	0	0
	Aggregated Age/Sex: <15	0	0



	Male		
	Aggregated Age/Sex: 15+ Male	0	0
	Aggregated Age/Sex: <15 Female	0	0
	Aggregated Age/Sex: 15+ Female	0	0
	Sum of Aggregated Age/Sex <15	0	0
	Sum of Aggregated Age/Sex 15+	0	0
	Sum of Aggregated Age/Sex disaggregations	0	0
TX_CURR_NGI	Number of adults and children receiving antiretroviral therapy (ART)	729,819	838,075
	Age/Sex: <1 Male	1,992	1,163
	Age/Sex: 1-4 Male	7,183	10,234
	Age/Sex: 5-14 Male	22,435	29,084
	Age/Sex: 15+ Male	213,275	254,291
	Age/Sex: <1 Female	2,762	1,303
	Age/Sex: 1-4 Female	7,839	9,845
	Age/Sex: 5-14 Female	23,794	29,170
	Age/Sex: 15+ Female	375,141	502,983
	Sum of Age/Sex disaggregates	654,421	838,073
	Aggregated Age/Sex: <1 Male	1,327	1,163
	Aggregated Age/Sex: <1 Female	1,655	1,303
	Aggregated Age/Sex: <15 Male	23,467	40,481
	Aggregated Age/Sex: 15+ Male	157,183	254,291



	Aggregated Age/Sex: <15 Female	23,997	40,318
	Aggregated Age/Sex: 15+ Female	301,677	502,983
	Sum of Aggregated Age/Sex disaggregates	506,324	838,073
	Sum of Aggregated Age/Sex <15	47,464	80,799
	Sum of Aggregated Age/Sex 15+	458,860	757,274
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	46,910	18,438
	Age/Sex: <1 Male	114	10
	Age/Sex: 1-4 Male	535	179
	Age/Sex: 5-14 Male	1,928	477
	Age/Sex: 15-19 Male		
	Age/Sex: 20+ Male		
	Age/Sex: <1 Female	193	10
	Age/Sex: 1-4 Female	641	199
	Age/Sex: 5-14 Female	2,456	508
	Age/Sex: 15-19 Female		
	Age/Sex: 20+ Female		
	Sum of Age/Sex disaggregations	5,867	1,383
	Aggregated Age/Sex: <1 Male	100	10
	Aggregated Age/Sex: <1 Female	172	10
	Aggregated Age/Sex: 1-14 Male		
	Aggregated Age/Sex: 15+ Male	6,236	5,580



	Aggregated Age/Sex: 1-14 Female		
	Aggregated Age/Sex: 15+ Female		11,476
	Sum of Aggregated Age/Sex <15	1,865	1,383
	Sum of Aggregated Age/Sex 15+	6,236	17,056
	Sum of Aggregated Age/Sex disaggregates	8,101	18,439
TX_DIST	TX_DIST Percentage of Districts that are PEPFAR supported with documented routine supportive supervision visits to 75% of ART sites in District	93 %	
	Number of Districts with documented routine supportive supervision visits to 75% of HIV care and treatment sites supported by the District	277	333
	Total number of PEPFAR supported District Health Offices	299	360
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	139,999	141,485
	By Age/Sex: <1 Male	1,737	2,215
	By Age/Sex: 1-4 Male	1,296	1,611
	By Age/Sex: 5-9 Male	1,850	2,355
	By Age/Sex: 10-14 Male	1,474	1,875
	By Age/Sex: 15-19 Male	1,681	1,614
	By Age/Sex: 20-24 Male	3,993	3,842



	By Age/Sex: 25-49 Male	25,021	24,231
	By Age/Sex: 50+ Male	7,361	7,104
	By Age/Sex: <1 Female	1,882	2,364
	By Age/Sex: 1-4 Female	1,345	1,701
	By Age/Sex: 5-9 Female	1,996	2,539
	By Age/Sex: 10-14 Female	1,671	2,124
	By Age/Sex: 15-19 Female	3,185	3,088
	By Age/Sex: 20-24 Female	10,392	10,080
	By Age/Sex: 25-49 Female	46,503	44,939
	By Age/Sex: 50+ Female	8,753	8,446
	Sum of Age/Sex disaggregates	120,140	120,128
	Aggregated Grouping by Age: <1 Male	1,870	2,381
	Aggregated Grouping by Age/Sex: 1-14 Male		
	Aggregated Grouping by Age/Sex: 15+ Male	39,639	38,283
	Aggregated Grouping by Age/Sex: <1 Female	2,110	2,626
	Aggregated Grouping by Age/Sex: 1-14 Female		
	Aggregated Grouping by Age/Sex: 15+ Female	73,983	71,533
	Sum of Aggregated Age/Sex disaggregates	127,351	127,356
	Pregnancy status	16,419	17,026
	Breastfeeding status	1,756	1,817
TX_RET_DSD	TX_RET_DSD Percent of adults and children known to be alive and on treatment 12 months after initiation of antiretroviral therapy	85 %	



	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	95,517	119,479
	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	111,792	139,990
	Age/Sex: <5 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)		
	Age/Sex: 5-14 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)		
	Age/Sex: 15-19 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)		
	Age/Sex: 20+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)		



	Age/Sex: <5 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)		
	Age/Sex: 5-14 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)		
	Age/Sex: 15-19 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)		
	Age/Sex: 20+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)		
	Age/Sex: <5 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)		
	Age/Sex: 5-14 Male (Denominator: Total number		



	<p>of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)</p>		
	<p>Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)</p>		
	<p>Age/Sex: 20+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)</p>		
	<p>Age/Sex: <5 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have</p>		



	stopped ART, and those lost to follow-up)		
	Age/Sex: 5-14 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)		
	Age/Sex: 15-19 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)		
	Age/Sex: 20+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)		
	Numerator by Status: Pregnant		
	Numerator by Status: Breastfeeding		



	Denominator by Status: Pregnant		
	Denominator by Status: Breastfeeding		
TX_SITE	TX_SITE Percentage of PEPFAR-supported ART sites achieving a 75% ART retention rate	73 %	
	Number of PEPFAR-supported ART sites with a retention rate of 75% or greater for patients 12 months after ART initiation	1,432	1,547
	Total number of PEPFAR-supported ART sites	1,952	2,100
	By support type: Direct Service Delivery (DSD): Number of PEPFAR-supported ART sites with a retention rate of 75% or greater for patients 12 months after ART initiation	1,212	1,330
	By support type: Technical Assistance (TA-only): Number of PEPFAR-supported ART sites with a retention rate of 75% or greater for patients 12 months after ART initiation	428	449
	Sum of Numerator Site Support Type disaggregates	1,640	1,779



	By support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported ART sites	1,448	1,589
	By support type: Technical Assistance (TA-only): Total number of PEPFAR-supported ART sites	620	641
	Sum of Denominator Site Support Type disaggregates	2,068	2,230
LAB_ACC_DSD	Number of PEPFAR-supported testing facilities (laboratories) that are recognized by national, regional, or international standards for accreditation or have achieved a minimal acceptable level towards attainment of such accreditation	238	281
LAB_CAP_DSD	Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests	2,851	4,261
	By clinical laboratories	49	46
	By Point-of-care testing sites	407	416
LAB_PT_DSD	Percentage of laboratories and POC testing sites that perform HIV diagnostic testing that participate and successfully pass in an analyte-specific proficiency testing (PT) program	75	75



	HIV serologic/diagnostic testing: Number of laboratories that perform this testing	5,937	7,030
	HIV serologic/diagnostic testing: Number of laboratories that participate in this PT program	5,932	7,030
	HIV serologic/diagnostic testing: Number of laboratories that achieve acceptable successful passing criteria in this PT program	4,450	5,280
	CD4: Number of laboratories that perform this testing	781	803
	CD4: Number of laboratories that participate in this PT program	277	311
	CD4: Number of laboratories that achieve acceptable successful passing criteria in this PT program	210	234
	Early infant diagnostics: Number of laboratories that perform this testing	11	15
	Early infant diagnostics: Number of laboratories that participate in this PT program	3	7
	Early infant diagnostics: Number of laboratories that achieve acceptable successful passing criteria in this PT program	3	7



	HIV viral load: Number of laboratories that perform this testing	3	8
	HIV viral load: Number of laboratories that participate in this PT program	5	10
	HIV viral load: Number of laboratories that achieve acceptable successful passing criteria in this PT program	5	10
	TB diagnostics (AFB microscopy): Number of laboratories that perform this testing		
	TB diagnostics (AFB microscopy): Number of laboratories that participate in this PT program		
	TB diagnostics (AFB microscopy): Number of laboratories that achieve acceptable successful passing criteria in this PT program		
	TB diagnostics (Xpert MTB/RIF): Number of laboratories that perform this testing		
	TB diagnostics (Xpert MTB/RIF): Number of laboratories that participate in this PT program		
	TB diagnostics (Xpert MTB/RIF): Number of		



	laboratories that achieve acceptable successful passing criteria in this PT program		
	TB diagnostics (Culture/DST): Number of laboratories that perform this testing		
	TB diagnostics (Culture/DST): Number of laboratories that participate in this PT program		
	TB diagnostics (Culture/DST): Number of laboratories that achieve acceptable successful passing criteria in this PT program		
HRH_PRE	Number of new HCW who graduated from a pre-service training institution or program as a result of PEPFAR-supported strengthening efforts, within the reporting period, by select cadre	3,294	1,265
	By Graduates: Doctors	325	275
	By Graduates: Nurses	1,646	248
	By Graduates: Midwives	60	0
	By Graduates: Social service workers	16	16
	By Graduates: Laboratory professionals	391	311
	By Graduates: Other	856	415
	Sum of Graduates	3,294	1,265



	disaggreagtes		
SC_TRAIN	SC_TRAIN Percentage of individuals who received competency-based, certificate, or higher-level training to conduct or support supply chain, inventory management, supportive supervision or distribution activities	1 %	
	Number of individuals who received competency-based, certificate or higher-level training to conduct or support supply chain, inventory management, supportive supervision or distribution activities	60	60
	Number of individuals who conduct or support supply chain, inventory management, supportive supervision or distribution activities	7,280	7,280
	By: Individuals trained in a nationally- or internationally-recognized pre-service training program	0	0
	By: Individuals who passed a competency-based training to conduct supply chain activities	0	0
	By: Individuals who passed a competency-based training to perform inventory management	0	0



	By: Individuals who passed a competency-based training to develop distribution plans	0	0
	By: Individuals who passed a competency-based training to perform supportive supervision	0	0
	By: Individuals who passed a competency-based training to perform quantification	0	0
FPINT_SITE_DSD	FPINT_SITE_DSD Family Planning and HIV Integration: Percentage of HIV service delivery points supported by PEPFAR that are directly providing integrated voluntary family planning services	79 %	
	Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	1,829	1,882
	Total number of PEPFAR-supported HIV service delivery points: PMTCT, Care and Treatment	2,316	2,367
	Service delivery type: Care and Support		
	Service delivery type: Treatment		
	Service delivery type: PMTCT		
	Sum of Service delivery type		



	(Care, Tx and PMTCT) disaggregates		
QI_SITE	QI_SITE Percentage of PEPFAR-supported clinical service sites with quality improvement activities implemented that address clinical HIV program processes or outcomes and have documented process results in the last 6 months	60 %	
	Number of PEPFAR-supported clinical service sites with a quality improvement activity completed that addresses clinical HIV programs and has documented process results in the last 6 months	2,152	2,262
	Total number of PEPFAR-supported sites for any HIV clinical service including HIV Care, HIV Treatment, TB care, PMTCT, VMMC, and HTC	3,582	3,709
	By site support type: Direct Service Delivery (DSD): Number of PEPFAR-supported clinical service sites with a quality improvement activity completed that addresses clinical HIV programs and has documented results in the last 6 months	1,462	1,563
	By site support type:	540	558



	Technical Assistance-only (TA): Number of PEPFAR-supported clinical service sites with a quality improvement activity completed that addresses clinical HIV programs and has documented results in the last 6 months		
	Sum of Numerator Site Support Type disaggregates	2,002	2,121
	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported sites for any HIV clinical service including HIV Care, HIV Treatment, TB care, PMTCT, VMMC, HTC	1,758	1,872
	By site support type: Technical Assistance-only (TA): Total number of PEPFAR-supported sites for any HIV clinical service including HIV Care, HIV Treatment, TB care, PMTCT, VMMC, and HTC	921	933
	Sum of Denominator Site Support Type disaggregates	2,679	2,805
SC_STOCK	SC_STOCK Storage sites which stock commodities according to plan	n/a	
	Number of stock status observations for one or more tracer commodities that are between the designed		



	minimum and maximum quantities/months of stock from storage sites within at a given level (Central, Regional, etc.) of the system.		
	Total number of stock status observations for one or more tracer commodities from storage sites within at a given level (Central, Regional, etc.) of the system	0	0
	System Level: Central Medical Stores	0	0
	System Level: Regional Medical Stores	0	0
	System Level: District	0	0
	System Level: Health facility	0	0
	Commodity: Condoms	0	0
	Commodity: ARV drugs	0	0
	Commodity: Rapid test kits	0	0
	Commodity: OI drugs	0	0
	Commodity: Other	0	0
SI_HIS	Existence of a national registry of health facilities that is updated annually	1	1
	No common facility list		1
	USG only or Government only facility list		
	Full national facility list coordinated with PEPFAR	1	2
	Full coordinated list made available as a common and managed Registry		1
SI_ME	Existence of a national	1	2

Approved



	HIV/AIDS M&E system based on the UNAIDS 12 components model		
--	---	--	--



Partners and Implementing Mechanisms

Partner List

Mech ID	Partner Name	Organization Type	Agency	Funding Source	Planned Funding
2866	CENTERS FOR HEALTH SOLUTIONS	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	5,072,572
7139	Futures Group	Private Contractor	U.S. Agency for International Development	GHP-State	4,627,995
7142	Chemonics International	Private Contractor	U.S. Agency for International Development	GHP-State	42,029,278
7305	University Research Corporation, LLC	Private Contractor	U.S. Agency for International Development	GHP-State	1,219,281
9039	American Society for Microbiology	Private Contractor	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
9076	ICF Macro	Private Contractor	U.S. Agency for International Development	GHP-State	279,445
9092	Catholic Relief Services	FBO	U.S. Department of Health and	GHP-State	0



			Human Services/Centers for Disease Control and Prevention		
9093	CDC Foundation	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	250,000
9097	University of Nairobi	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
9108	American International Health Alliance Twinning Center	NGO	U.S. Department of Health and Human Services/Health Resources and Services Administration	GHP-State	308,000
9110	Association of Public Health Laboratories	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	450,000
9136	International Medical Corps	NGO	U.S. Department of Health and Human	GHP-State	1,028,798



			Services/Centers for Disease Control and Prevention		
9138	Internews	Private Contractor	U.S. Agency for International Development	GHP-State	400,000
9139	IntraHealth International, Inc	NGO	U.S. Agency for International Development	GHP-State	5,152,112
9143	Henry Jackson Foundation	Private Contractor	U.S. Department of Defense	GHP-State	2,167,403
9150	International Medical Corps	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
9171	Henry Jackson Foundation	Private Contractor	U.S. Department of Defense	GHP-State	16,090,907
10826	Elizabeth Glaser Pediatric AIDS Foundation	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
11406	U.S. Department of State	Other USG Agency	U.S. Department of State/Bureau of African Affairs	GHP-State	100,956
12056	Ananda Marga Universal Relief Teams	NGO	U.S. Agency for International Development	GHP-State	300,000
12082	United Nations	Multi-lateral	U.S. Department	GHP-State	483,857



	High Commissioner for Refugees	Agency	of Health and Human Services/Centers for Disease Control and Prevention		
12083	Liverpool VCT and Care	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	760,048
12530	Nyanza Reproductive Health Society	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	525,515
12540	University of North Carolina	University	U.S. Agency for International Development	GHP-State	3,450,000
12551	University of California at San Francisco	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	9,247,622
12555	University of Nairobi	University	U.S. Department of Health and Human Services/Centers for Disease Control and	GHP-State	3,572,255



			Prevention		
12585	Columbia University Mailman School of Public Health	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	17,456,390
12598	International Rescue Committee	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	802,639
12605	Care International	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	4,418,170
12612	New York AIDS Institute	Other USG Agency	U.S. Department of Health and Human Services/Health Resources and Services Administration	GHP-State	12,400
12637	Futures Group	Private Contractor	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	1,950,000



12656	Eastern Deanery AIDS Relief Program	FBO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	6,769,188
12658	Mkomani Society Clinic	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	3,589,589
12664	African Medical and Research Foundation	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	1,349,245
12970	Johns Hopkins University Bloomberg School of Public Health	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
12994	Management Sciences for Health	NGO	U.S. Agency for International Development	GHP-State	278,607
13025	Impact Research and Development Organization	NGO	U.S. Department of Health and Human Services/Centers for Disease	GHP-State	5,874,311



			Control and Prevention		
13028	Community Housing Foundation	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	500,000
13050	Coptic Hospital	FBO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	4,342,000
13061	MINISTRY OF PUBLIC HEALTH AND SANITATION	Host Country Government Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	3,023,649
13072	TBD	TBD	Redacted	Redacted	Redacted
13097	Liverpool VCT and Care	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
13121	University of Maryland	University	U.S. Department of Health and Human Services/Centers for Disease	GHP-State	700,000



			Control and Prevention		
13164	Management Sciences for Health	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	1,963,887
13179	Association of Schools of Public Health	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	570,000
13210	Global Healthcare Public Foundation	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
13287	Program for Appropriate Technology in Health	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	750,000
13302	Hope Worldwide	FBO	U.S. Department of Health and Human Services/Centers for Disease Control and	GHP-State	789,748



			Prevention		
13307	Impact Research and Development Organization	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	1,940,095
13309	Kenya Medical Research Institute	Host Country Government Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	4,491,178
13312	Abt Associates	Private Contractor	U.S. Agency for International Development	GHP-State	4,252,000
13340	FHI 360	NGO	U.S. Agency for International Development	GHP-State	8,963,225
13346	World Health Organization	Multi-lateral Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	381,000
13354	Kenya Episcopal Conference	FBO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	7,291,386
13366	Christian Health	FBO	U.S. Department	GHP-State	7,417,537



	Association of Kenya		of Health and Human Services/Centers for Disease Control and Prevention		
13385	University of Manitoba	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	3,896,229
13399	University of Maryland	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	5,903,196
13474	Hope Worldwide	FBO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	770,300
13481	University of Nairobi	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	1,000,503
13502	University of California at San	University	U.S. Department of Health and	GHP-State	0



	Francisco		Human Services/Centers for Disease Control and Prevention		
13517	African Medical and Research Foundation	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	525,000
13543	Elizabeth Glaser Pediatric AIDS Foundation	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	9,022,450
13545	U.S. Peace Corps	Other USG Agency	U.S. Peace Corps	GHP-State	0
13546	Henry Jackson Foundation	Private Contractor	U.S. Department of Defense	GHP-State	2,075,264
13548	Management Sciences for Health	NGO	U.S. Agency for International Development	GHP-State	1,124,818
13550	National Blood Transfusion Service, Kenya	Host Country Government Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	1,500,000
13588	Program for Appropriate Technology in	NGO	U.S. Agency for International Development	GHP-State	21,937,858



	Health				
13636	JHPIEGO	University	U.S. Agency for International Development	GHP-State	8,756,081
13701	Kenya Medical Supplies Agency	Host Country Government Agency	U.S. Agency for International Development	GHP-State	36,274,080
13802	University of Nairobi	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	3,349,695
13805	University of Washington	University	U.S. Department of Health and Human Services/Health Resources and Services Administration	GHP-State	2,100,000
13867	Abt Associates	Private Contractor	U.S. Agency for International Development	GHP-State	300,000
13868	Population Services International	NGO	U.S. Agency for International Development	GHP-State	2,053,481
13882	Children of God Relief Institute	FBO	U.S. Agency for International Development	GHP-State	1,806,681
13919	Clinical and Laboratory Standards Institute	NGO	U.S. Department of Health and Human Services/Centers for Disease	GHP-State	450,000



			Control and Prevention		
13922	African Field Epidemiology Network	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	595,000
14009	TBD	TBD	Redacted	Redacted	Redacted
14012	Moi Teaching and Referral Hospital	Parastatal	U.S. Agency for International Development	GHP-State	11,078,596
14015	IntraHealth International, Inc	NGO	U.S. Agency for International Development	GHP-State	5,078,460
14022	African Medical and Research Foundation	NGO	U.S. Agency for International Development	GHP-State	4,599,545
14034	Equity Group Foundation	NGO	U.S. Agency for International Development	GHP-State	2,521,036
16450	Kenya Community Development Foundation	NGO	U.S. Agency for International Development	GHP-State	600,000
16643	Columbia University Mailman School of Public Health	University	U.S. Department of Health and Human Services/Health Resources and Services Administration	GHP-State	25,000
16644	United Nations Children's Fund	Multi-lateral Agency	U.S. Department of Health and Human	GHP-State	0



			Services/Centers for Disease Control and Prevention		
16670	University of Nairobi	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	1,000,000
16679	New Partner	TBD	U.S. Agency for International Development	GHP-State	3,404,964
16682	Kenya National Bureau of Statistics	Host Country Government Agency	U.S. Agency for International Development	GHP-State	400,000
16684	TBD	TBD	Redacted	Redacted	Redacted
16687	New Partner	TBD	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	2,196,797
16698	TBD	TBD	Redacted	Redacted	Redacted
16705	United Nations Office on Drug and Crime (UNODC)	Multi-lateral Agency	U.S. Agency for International Development	GHP-State	1,212,520
16709	New Partner	TBD	U.S. Agency for International Development	GHP-State	2,118,187
16710	Equity Group Foundation	NGO	U.S. Agency for International	GHP-State	651,646



			Development		
16711	IntraHealth International, Inc	NGO	U.S. Agency for International Development	GHP-State	0
17190	Life Skills Promoters	NGO	U.S. Agency for International Development	GHP-State	400,000
17191	Reformed Church of East Africa	FBO	U.S. Agency for International Development	GHP-State	250,000
17707	TBD	TBD	Redacted	Redacted	Redacted
17709	IntraHealth International, Inc	NGO	U.S. Agency for International Development	GHP-State	3,546,673
17710	TBD	TBD	Redacted	Redacted	Redacted
17711	TBD	TBD	Redacted	Redacted	Redacted
17712	TBD	TBD	Redacted	Redacted	Redacted
17717	TBD	TBD	Redacted	Redacted	Redacted
17718	TBD	TBD	Redacted	Redacted	Redacted
17719	TBD	TBD	Redacted	Redacted	Redacted



Implementing Mechanism(s)

Implementing Mechanism Details

Mechanism ID: 17719	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 17718	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 17717	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 17712	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 17711	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 17710	TBD: Yes
REDACTED	



Implementing Mechanism Details

Mechanism ID: 17709	Mechanism Name: Capacity Bridge Mechanism
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: IntraHealth International, Inc	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
Global Fund / Multilateral Engagement: No	
G2G: No	Managing Agency:
Total All Funding Sources: 3,546,673	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 0	
FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount
GHP-State	3,546,673

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

- Malaria (PMI)
- Child Survival Activities
- Safe Motherhood
- TB
- Family Planning

Budget Code Information



Mechanism ID: 17709			
Mechanism Name: Capacity Bridge Mechanism			
Prime Partner Name: IntraHealth International, Inc			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	182,498	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	700,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	463,367	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	2,200,808	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17707	TBD: Yes
REDACTED	



Implementing Mechanism Details

Mechanism ID: 17191	Mechanism Name: Watoto Wazima Initiative)
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Reformed Church of East Africa	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: No	
G2G: No	Managing Agency:

Total All Funding Sources: 250,000	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 0	
FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount
GHP-State	250,000

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

Education	60,000
Economic Strengthening	150,000
Gender: Gender Equality	20,000
Focus Area:	Changing harmful gender norms and promoting positive gender norms
Sub Area:	Implementation
Sub Area:	Capacity building
Focus Area:	Promoting gender-related policies and laws that increase legal protection
Sub Area:	Implementation
Sub Area:	Capacity building
Focus Area:	Increase gender-equitable access to income and



	productive resources, including education
Sub Area:	Implementation
Sub Area:	Capacity building
Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Implementation
Sub Area:	Capacity building

Key Issues

(No data provided.)

Budget Code Information

Mechanism ID: 17191			
Mechanism Name: Watoto Wazima Initiative)			
Prime Partner Name: Reformed Church of East Africa			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	250,000	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2014	2015
SITE_SUPP	Number of unique sites supported by PEPFAR	11	11
SITE_SUPP	By program area/support type: HTC Direct Service Delivery (DSD)	0	0
SITE_SUPP	By program area/support type: HTC Technical Assistance-only (TA)	0	0
SITE_SUPP	By program area/support type: Treatment Direct Service Delivery (DSD)	0	0



SITE_SUPP	By program area/support type: Treatment Technical Assistance-only (TA)	0	0
SITE_SUPP	By program area/support type: Care and Support Direct Service Delivery (DSD)	0	0
SITE_SUPP	By program area/support type: Care and Support Technical Assistance-only (TA)	0	0
SITE_SUPP	By program area/support type: Food and Nutrition Direct Service Delivery (DSD)	0	0
SITE_SUPP	By program area/support type: Food and Nutrition Technical Assistance-only (TA)	0	0
SITE_SUPP	By program area/support type: PMTCT Direct Service Delivery (DSD)	0	0
SITE_SUPP	By program area/support type: PMTCT Technical Assistance-only (TA)	0	0
SITE_SUPP	By program area/support type: TB/HIV Direct Service Delivery (DSD)	0	0
SITE_SUPP	By program area/support type: TB/HIV Technical Assistance-only (TA)	0	0
SITE_SUPP	By program area/support type: VMMC Direct Service Delivery (DSD)	0	0
SITE_SUPP	By program area/support type: VMMC Technical Assistance-only (TA)	0	0
SITE_SUPP	By program area/support type: General Population Prevention Direct Service Delivery (DSD)	0	0
SITE_SUPP	By program area/support type: General Population Prevention Technical Assistance-only (TA)	0	0
SITE_SUPP	By program area/support type: Key Populations Prevention Direct Service Delivery (DSD)	0	0
SITE_SUPP	By program area/support type: Key Populations Prevention Technical Assistance-only (TA)	0	0



SITE_SUPP	By program area/support type: OVC Direct Service Delivery (DSD)	11	11
SITE_SUPP	By program area/support type: OVC Technical Assistance-only (TA)	0	0
SITE_SUPP	By program area/support type: PHDP/Family Planning & Integration Direct Service Delivery (DSD)	0	0
SITE_SUPP	By program area/support type: PHDP/Family Planning & Integration Technical Assistance-only (TA)	0	0
SITE_SUPP	By program area/support type: Lab Direct Service Delivery (DSD)	0	0
SITE_SUPP	By program area/support type: Lab Technical Assistance-only (TA)	0	0
PMTCT_ARV_DSD	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	0	0
PMTCT_ARV_DSD	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	0	0
PMTCT_ARV_NA	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	0	0
PMTCT_ARV_NA	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	0	0
PMTCT_ARV_NGI	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	0	0
PMTCT_ARV_NGI	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	0	0



PMTCT_ARV_TA	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	0	0
PMTCT_ARV_TA	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	0	0
PMTCT_SITE	Number of PEPFAR-supported sites achieving 90% ARV or ART coverage for HIV+ pregnant women	0	0
PMTCT_SITE	Total number of PEPFAR supported sites providing PMTCT services (HTC and ARV or ART services)	0	0
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	0	0
PMTCT_STAT_DSD	Number of new ANC and L&D clients	0	0
PMTCT_STAT_NA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	0	0
PMTCT_STAT_NA	Number of new ANC and L&D clients	0	0
PMTCT_STAT_NGI	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	0	0
PMTCT_STAT_NGI	Number of new ANC and L&D clients	0	0
BS_COLL	Number of whole blood collections each year by the NBTS network	0	0
KP_MAT_DSD	Number of people who inject drugs (PWID) on medication assisted therapy (MAT) for at least 6 months	0	0
VMMC_AE_DSD	Number of males circumcised surgically or by medical device that experienced at least one moderate or severe adverse event(s) (AEs)	0	0
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC)	0	0



	for HIV prevention program within the reporting period		
VMMC_CIRC_NA	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	0	0
VMMC_CIRC_NGI	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	0	0
VMMC_CIRC_TA	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	0	0
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	0	0
PP_PREV_DSD	Total number of people in the target population	0	0
PP_PREV_TA	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	0	0
PP_PREV_TA	Total number of people in the target population	0	0
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	0	0
KP_PREV_TA	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards	0	0



	required		
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	0	0
HTC_TST_NA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	0	0
HTC_TST_NGI	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	0	0
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	0	0
GEND_GBV_DSD	Number of people receiving post-GBV care	0	0
GEND_NORM_DSD	Number of people completing an intervention pertaining to gender norms, that meets minimum criteria	0	0
OVC_ACC_DSD	Number of active beneficiaries receiving support from PEPFAR OVC programs to access HIV services	288	288
OVC_ACC_DSD	Sex: Male	144	144
OVC_ACC_DSD	Sex: Female	144	144
OVC_ACC_DSD	Sum of Sex disaggregates	288	288
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	3,200	3,200
OVC_SERV_DSD	Sex: Male	1,600	1,600
OVC_SERV_DSD	Sex: Female	1,600	1,600
OVC_SERV_DSD	Sum of Sex disaggregates	3,200	3,200
OVC_SERV_DSD	Age: 1-4	200	200
OVC_SERV_DSD	Age: 5-9	500	500
OVC_SERV_DSD	Age: 10-14	1,000	1,000
OVC_SERV_DSD	Age: 15-17	1,500	1,500
OVC_SERV_DSD	Sum of Age disaggregates	3,200	3,200



OVC_SERV_TA	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	0	0
C2.1.D_DSD	Number of HIV-positive individuals receiving a minimum of one clinical service	0	0
C2.1.D_NA	Number of HIV-positive individuals receiving a minimum of one clinical service	0	0
C2.1.D_NGI	Number of HIV-positive individuals receiving a minimum of one clinical service	0	0
C2.1.D_TA	Number of HIV-positive individuals receiving a minimum of one clinical service	0	0
C2.4.D_DSD	Number of HIV-positive patients who were screened for TB in HIV care or treatment setting	0	0
C2.4.D_DSD	Number of HIV-positive individuals receiving a minimum of one clinical service	0	0
C2.5.D_DSD	Number of HIV-positive patients in HIV care who started TB treatment	0	0
C2.5.D_DSD	Number of HIV-positive individuals receiving a minimum of one clinical service	0	0
CARE_CURR_DSD	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	0	0
CARE_CURR_TA	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	0	0
CARE_NEW_DSD	Number of HIV-infected adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count	0	0



	OR viral load		
CARE_SITE	Number of PEPFAR-supported HIV clinical care sites at which at least 80% of PLHIV received all of the following during the reporting period: 1) clinical assessment (WHO staging) OR CD4 count OR viral load, AND 2) TB screening at last visit, AND 3) if eligible, cotrimoxazole	0	0
CARE_SITE	Total number of PEPFAR supported sites providing clinical care services	0	0
FN_SITE	Number of PEPFAR-supported sites achieving 90% nutrition assessments that result in accurate categorization of malnutrition	0	0
FN_SITE	Total number of PEPFAR-supported sites providing nutrition assessment, counseling and support (NACS) services	0	0
FN_THER_DSD	Number of clinically malnourished PLHIV who received therapeutic and/or supplementary food during the reporting period.	0	0
FN_THER_DSD	Number of PLHIV who were nutritionally assessed and found to be clinically undernourished.	0	0
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	0	0
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	0	0
TB_ARTSITE	The number of PEPFAR-supported TB basic management units at which 80% of registered TB cases who are HIV-positive are on ART, during the reporting period	0	0
TB_ARTSITE	The number of PEPFAR-supported TB basic	0	0



	management units		
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	0	0
PMTCT_EID_DSD	Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT)	0	0
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	0	0
TX_CURR_NA	Number of adults and children receiving antiretroviral therapy (ART)	0	0
TX_CURR_NGI	Number of adults and children receiving antiretroviral therapy (ART)	0	0
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	0	0
TX_DIST	Number of Districts with documented routine supportive supervision visits to 75% of HIV care and treatment sites supported by the District	0	0
TX_DIST	Total number of PEPFAR supported District Health Offices	0	0
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	0	0
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	0	0
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	0	0
TX_SITE	Number of PEPFAR-supported ART sites with a retention rate of 75% or greater for patients 12 months after ART initiation	0	0



TX_SITE	Total number of PEPFAR-supported ART sites	0	0
LAB_ACC_DSD	Number of PEPFAR-supported testing facilities (laboratories) that are recognized by national, regional, or international standards for accreditation or have achieved a minimal acceptable level towards attainment of such accreditation	0	0
LAB_CAP_DSD	Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests	0	0
LAB_PT_DSD	Percentage of laboratories and POC testing sites that perform HIV diagnostic testing that participate and successfully pass in an analyte-specific proficiency testing (PT) program	0	0
HRH_PRE	Number of new HCW who graduated from a pre-service training institution or program as a result of PEPFAR-supported strengthening efforts, within the reporting period, by select cadre	0	0
SC_TRAIN	Number of individuals who received competency-based, certificate or higher-level training to conduct or support supply chain, inventory management, supportive supervision or distribution activities	0	0
SC_TRAIN	Number of individuals who conduct or support supply chain, inventory management, supportive supervision or distribution activities	0	0
FPINT_SITE_DSD	Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	0	0
FPINT_SITE_DSD	Total number of PEPFAR-supported HIV service delivery points: PMTCT, Care and	0	0



	Treatment		
QI_SITE	Number of PEPFAR-supported clinical service sites with a quality improvement activity completed that addresses clinical HIV programs and has documented process results in the last 6 months	0	0
QI_SITE	Total number of PEPFAR-supported sites for any HIV clinical service including HIV Care, HIV Treatment, TB care, PMTCT, VMMC, and HTC	0	0
SC_STOCK	Number of stock status observations for one or more tracer commodities that are between the designed minimum and maximum quantities/months of stock from storage sites within at a given level (Central, Regional, etc.) of the system.	0	0
SC_STOCK	Total number of stock status observations for one or more tracer commodities from storage sites within at a given level (Central, Regional, etc.) of the system	0	0
SI_HIS	Existence of a national registry of health facilities that is updated annually	0	0
SI_ME	Existence of a national HIV/AIDS M&E system based on the UNAIDS 12 components model	0	0
TB_SCREEN_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period	0	0
TB_SCREEN_DSD	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	0	0

Implementing Mechanism Details

Mechanism ID: 17190	Mechanism Name: Wezesha Project
----------------------------	--



Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Life Skills Promoters	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: No	
G2G: No	Managing Agency:

Total All Funding Sources: 400,000	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 0	
FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount
GHP-State	400,000

Sub Partner Name(s)

St John's Community Centre		
----------------------------	--	--

Cross-Cutting Budget Attribution(s)

Economic Strengthening	200,000
Education	100,000
Gender: Gender Equality	50,000
Focus Area:	Changing harmful gender norms and promoting positive gender norms
Sub Area:	Implementation
Sub Area:	Capacity building
Focus Area:	Promoting gender-related policies and laws that increase legal protection
Sub Area:	Implementation
Sub Area:	Capacity building
Focus Area:	Increase gender-equitable access to income and productive resources, including education
Sub Area:	Implementation



Sub Area:	Capacity building
Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Implementation
Sub Area:	Capacity building

Key Issues

(No data provided.)

Budget Code Information

Mechanism ID: 17190			
Mechanism Name: Wezesha Project			
Prime Partner Name: Life Skills Promoters			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	400,000	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2014	2015
SITE_SUPP	Number of unique sites supported by PEPFAR	16	16
SITE_SUPP	By program area/support type: HTC Direct Service Delivery (DSD)	0	0
SITE_SUPP	By program area/support type: HTC Technical Assistance-only (TA)	0	0
SITE_SUPP	By program area/support type: Treatment Direct Service Delivery (DSD)	0	0
SITE_SUPP	By program area/support type: Treatment Technical Assistance-only (TA)	0	0



SITE_SUPP	By program area/support type: Care and Support Direct Service Delivery (DSD)	0	0
SITE_SUPP	By program area/support type: Care and Support Technical Assistance-only (TA)	0	0
SITE_SUPP	By program area/support type: Food and Nutrition Direct Service Delivery (DSD)	0	0
SITE_SUPP	By program area/support type: Food and Nutrition Technical Assistance-only (TA)	0	0
SITE_SUPP	By program area/support type: PMTCT Direct Service Delivery (DSD)	0	0
SITE_SUPP	By program area/support type: PMTCT Technical Assistance-only (TA)	0	0
SITE_SUPP	By program area/support type: TB/HIV Direct Service Delivery (DSD)	0	0
SITE_SUPP	By program area/support type: TB/HIV Technical Assistance-only (TA)	0	0
SITE_SUPP	By program area/support type: VMMC Direct Service Delivery (DSD)	0	0
SITE_SUPP	By program area/support type: VMMC Technical Assistance-only (TA)	0	0
SITE_SUPP	By program area/support type: General Population Prevention Direct Service Delivery (DSD)	0	0
SITE_SUPP	By program area/support type: General Population Prevention Technical Assistance-only (TA)	0	0
SITE_SUPP	By program area/support type: Key Populations Prevention Direct Service Delivery (DSD)	0	0
SITE_SUPP	By program area/support type: Key Populations Prevention Technical Assistance-only (TA)	0	0
SITE_SUPP	By program area/support type: OVC Direct Service Delivery (DSD)	16	20



SITE_SUPP	By program area/support type: OVC Technical Assistance-only (TA)	0	0
SITE_SUPP	By program area/support type: PHDP/Family Planning & Integration Direct Service Delivery (DSD)	0	0
SITE_SUPP	By program area/support type: Lab Direct Service Delivery (DSD)	0	0
SITE_SUPP	By program area/support type: Lab Technical Assistance-only (TA)	0	0
PMTCT_ARV_DSD	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	0	0
PMTCT_ARV_DSD	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	0	0
PMTCT_ARV_DSD	Life-long ART (including Option B+)	0	0
PMTCT_ARV_DSD	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	0	0
PMTCT_ARV_DSD	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	0	0
PMTCT_ARV_DSD	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)	0	0
PMTCT_ARV_DSD	Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)	0	0
PMTCT_ARV_DSD	Single-dose nevirapine (with or without tail)	0	0
PMTCT_ARV_DSD	Sum of Regimen Type disaggregates	0	0
PMTCT_ARV_DSD	Sum of New and Current disaggregates	0	0
PMTCT_ARV_NA	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during	0	0



	pregnancy and delivery		
PMTCT_ARV_NA	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	0	0
PMTCT_ARV_NA	Life-long ART (including Option B+)	0	0
PMTCT_ARV_NA	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	0	0
PMTCT_ARV_NA	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	0	0
PMTCT_ARV_NA	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)	0	0
PMTCT_ARV_NA	Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)	0	0
PMTCT_ARV_NA	Single-dose nevirapine (with or without tail)	0	0
PMTCT_ARV_NA	Sum of Regimen disaggregates	0	0
PMTCT_ARV_NA	Sum of New and Current disaggregates	0	0
PMTCT_ARV_NGI	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	0	0
PMTCT_ARV_NGI	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	0	0
PMTCT_ARV_NGI	Life-long ART (including Option B+)	0	0
PMTCT_ARV_NGI	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	0	0
PMTCT_ARV_NGI	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	0	0
PMTCT_ARV_NGI	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the	0	0



	breastfeeding period)		
PMTCT_ARV_NGI	Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)	0	0
PMTCT_ARV_NGI	Single-dose nevirapine (with or without tail)	0	0
PMTCT_ARV_NGI	Sum of Regimen disaggregates	0	0
PMTCT_ARV_NGI	Sum of New and Current disaggregates	0	0
PMTCT_ARV_TA	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	0	0
PMTCT_ARV_TA	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	0	0
PMTCT_ARV_TA	Life-long ART (including Option B+)	0	0
PMTCT_ARV_TA	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	0	0
PMTCT_ARV_TA	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	0	0
PMTCT_ARV_TA	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)	0	0
PMTCT_ARV_TA	Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)	0	0
PMTCT_ARV_TA	Single-dose nevirapine (with or without tail)	0	0
PMTCT_ARV_TA	Sum of Regimen Type disaggregates	0	0
PMTCT_ARV_TA	Sum of New and Current disaggregates	0	0
PMTCT_SITE	Number of PEPFAR-supported sites achieving 90% ARV or ART coverage for HIV+ pregnant women	0	0
PMTCT_SITE	Total number of PEPFAR supported sites providing PMTCT services (HTC and ARV or	0	0



	ART services)		
PMTCT_SITE	By site support type: Direct Service Delivery (DSD): Number of PEPFAR-supported sites achieving 90% ARV or ART coverage for HIV+ pregnant women	0	0
PMTCT_SITE	By site support type: Technical Assistance-only (TA): Number of PEPFAR-supported sites achieving 90% ARV or ART coverage for HIV+ pregnant women	0	0
PMTCT_SITE	Sum of Numerator Support Type disaggregates	0	0
PMTCT_SITE	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR supported sites providing PMTCT services (HTC and ARV or ART services)	0	0
PMTCT_SITE	By site support type: Technical Assistance-only (TA): Total number of PEPFAR supported sites providing PMTCT services (HTC and ARV or ART services)	0	0
PMTCT_SITE	Sum of Denominator Support Type disaggregates	0	0
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	0	0
PMTCT_STAT_DSD	Number of new ANC and L&D clients	0	0
PMTCT_STAT_DSD	By: Known positives at entry	0	0
PMTCT_STAT_DSD	By: Number of new positives identified	0	0
PMTCT_STAT_DSD	Sum of Positives Status disaggregates	0	0
PMTCT_STAT_NA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	0	0
PMTCT_STAT_NA	Number of new ANC and L&D clients	0	0
PMTCT_STAT_NA	By: Known positives at entry	0	0
PMTCT_STAT_NA	By: Number of new positives identified	0	0



PMTCT_STAT_NA	Sum of Positives Status disaggregates	0	0
PMTCT_STAT_NGI	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	0	0
PMTCT_STAT_NGI	Number of new ANC and L&D clients	0	0
PMTCT_STAT_NGI	By: Known positives at entry	0	0
PMTCT_STAT_NGI	By: Number of new positives identified	0	0
PMTCT_STAT_NGI	Sum of Positives Status disaggregates	0	0
BS_COLL	Number of whole blood collections each year by the NBTS network	0	0
BS_COLL	By: Number of whole blood donations screened for HIV in an NBTS network laboratory	0	0
BS_COLL	By: Number of whole blood donations screened for HIV in an NBTS network laboratory that are identified as reactive for HIV	0	0
KP_MAT_DSD	Number of people who inject drugs (PWID) on medication assisted therapy (MAT) for at least 6 months	0	0
KP_MAT_DSD	Sex: Male	0	0
KP_MAT_DSD	Sex: Female	0	0
KP_MAT_DSD	Sum of Sex disaggregates	0	0
VMMC_AE_DSD	Number of males circumcised surgically or by medical device that experienced at least one moderate or severe adverse event(s) (AEs)	0	0
VMMC_AE_DSD	By AE type: Number of VMMC clients with one or more moderate or severe surgical intra-operative AE(s)	0	0
VMMC_AE_DSD	Sub-Disag: Surgical intra-operative AE(s) by maximum severity category: Number of clients with one or more moderate surgical intra-operative AE(s), but no severe surgical intra-operative AE(s)	0	0



VMMC_AE_DSD	Sub-Disag: Surgical intra-operative AE(s) by maximum severity category: Number of clients with one or more severe surgical intra-operative AE(s)	0	0
VMMC_AE_DSD	By AE Type: Number of VMMC clients with one or more moderate or severe surgical post-operative AE(s)	0	0
VMMC_AE_DSD	Sub-Disag: By Surgical post-operative AE(s) by maximum severity category: Number of clients with one or more moderate surgical post-operative AE(s), but no severe surgical post-operative AE(s)	0	0
VMMC_AE_DSD	Sub-Disag: By Surgical post-operative AE(s) by maximum severity category: Number of clients with one or more severe surgical intra-operative AE(s)	0	0
VMMC_AE_DSD	By AE Type: Number of VMMC clients with one or more moderate or severe medical device-related AE(s)	0	0
VMMC_AE_DSD	Sub-Disag: By Medical device-based AE(s) by maximum severity category: Number of clients with one or more moderate medical device-related AE(s), but no severe medical device-related AE(s)	0	0
VMMC_AE_DSD	Sub-Disag: By Medical device-based AE(s) by maximum severity category: Number of clients with one or more severe medical device-related AE(s)	0	0
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	0	0
VMMC_CIRC_DSD	By Age: <1	0	0
VMMC_CIRC_DSD	By Age: 1-9	0	0
VMMC_CIRC_DSD	By Age: 10-14	0	0



VMMC_CIRC_DSD	By Age: 15-19	0	0
VMMC_CIRC_DSD	By Age: 20-24	0	0
VMMC_CIRC_DSD	By Age: 25-49	0	0
VMMC_CIRC_DSD	By Age: 50+	0	0
VMMC_CIRC_DSD	Sum of age disaggregates	0	0
VMMC_CIRC_DSD	By HIV status: Number of HIV-positive clients (tested HIV positive at VMMC site)	0	0
VMMC_CIRC_DSD	By HIV status: Number of HIV-negative clients (tested HIV negative at VMMC program)	0	0
VMMC_CIRC_DSD	By HIV status: Number of clients with undocumented/indeterminate HIV status or not tested for HIV at site	0	0
VMMC_CIRC_DSD	By circumcision technique: Surgical VMMC	0	0
VMMC_CIRC_DSD	By circumcision technique: Device-based VMMC	0	0
VMMC_CIRC_DSD	By follow-up status: Number of surgically circumcised clients who returned at least once for follow-up care within 14 days of circumcision surgery	0	0
VMMC_CIRC_DSD	By follow-up status: Number of surgically circumcised clients who did NOT return for follow-up care within 14 days of circumcision surgery	0	0
VMMC_CIRC_NA	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	0	0
VMMC_CIRC_NA	By Age: <1	0	0
VMMC_CIRC_NA	By Age: 1-9	0	0
VMMC_CIRC_NA	By Age: 10-14	0	0
VMMC_CIRC_NA	By Age: 15-19	0	0
VMMC_CIRC_NA	By Age: 20-24	0	0
VMMC_CIRC_NA	By Age: 25-49	0	0
VMMC_CIRC_NA	By Age: 50+	0	0

VMMC_CIRC_NA	Sum of Age disaggregates	0	0
VMMC_CIRC_NA	By HIV status: Number of HIV-positive clients (tested HIV positive at VMMC site)	0	0
VMMC_CIRC_NA	By HIV status: Number of HIV-negative clients (tested HIV negative at VMMC program)	0	0
VMMC_CIRC_NA	By HIV status: Number of clients with undocumented/indeterminate HIV status or not tested for HIV at site	0	0
VMMC_CIRC_NA	By circumcision technique: Surgical VMMC	0	0
VMMC_CIRC_NA	By circumcision technique: Device-based VMMC	0	0
VMMC_CIRC_NA	By follow-up status: Number of surgically circumcised clients who returned at least once for follow-up care within 14 days of circumcision surgery	0	0
VMMC_CIRC_NA	By follow-up status: Number of surgically circumcised clients who did NOT return for follow-up care within 14 days of circumcision surgery	0	0
VMMC_CIRC_NGI	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	0	0
VMMC_CIRC_NGI	By Age: <1	0	0
VMMC_CIRC_NGI	By Age: 1-9	0	0
VMMC_CIRC_NGI	By Age: 10-14	0	0
VMMC_CIRC_NGI	By Age: 15-19	0	0
VMMC_CIRC_NGI	By Age: 20-24	0	0
VMMC_CIRC_NGI	By Age: 25-49	0	0
VMMC_CIRC_NGI	By Age: 50+	0	0
VMMC_CIRC_NGI	Sum of Age disaggregates	0	0
VMMC_CIRC_NGI	By HIV status: Number of HIV-positive clients (tested HIV positive at VMMC site)	0	0
VMMC_CIRC_NGI	By HIV status: Number of HIV-negative clients	0	0



	(tested HIV negative at VMMC program		
VMMC_CIRC_NGI	By HIV status: Number of clients with undocumented/indeterminate HIV status or not tested for HIV at site	0	0
VMMC_CIRC_NGI	By circumcision technique: Surgical VMMC	0	0
VMMC_CIRC_NGI	By circumcision technique: Device-based VMMC	0	0
VMMC_CIRC_NGI	By follow-up status: Number of surgically circumcised clients who returned at least once for follow-up care within 14 days of circumcision surgery	0	0
VMMC_CIRC_NGI	By follow-up status: Number of surgically circumcised clients who did NOT return for follow-up care within 14 days of circumcision surgery	0	0
VMMC_CIRC_TA	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	0	0
VMMC_CIRC_TA	By Age: <1	0	0
VMMC_CIRC_TA	By Age: 1-9	0	0
VMMC_CIRC_TA	By Age: 10-14	0	0
VMMC_CIRC_TA	By Age: 15-19	0	0
VMMC_CIRC_TA	By Age: 20-24	0	0
VMMC_CIRC_TA	By Age: 25-49	0	0
VMMC_CIRC_TA	By Age: 50+	0	0
VMMC_CIRC_TA	Sum of Age disaggregations	0	0
VMMC_CIRC_TA	By HIV status: Number of HIV-positive clients (tested HIV positive at VMMC site)	0	0
VMMC_CIRC_TA	By HIV status: Number of HIV-negative clients (tested HIV negative at VMMC program	0	0
VMMC_CIRC_TA	By HIV status: Number of clients with undocumented/indeterminate HIV status or not tested for HIV at site	0	0

VMMC_CIRC_TA	By circumcision technique: Surgical VMMC	0	0
VMMC_CIRC_TA	By circumcision technique: Device-based VMMC	0	0
VMMC_CIRC_TA	By follow-up status: Number of surgically circumcised clients who returned at least once for follow-up care within 14 days of circumcision surgery	0	0
VMMC_CIRC_TA	By follow-up status: Number of surgically circumcised clients who did NOT return for follow-up care within 14 days of circumcision surgery	0	0
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	0	0
PP_PREV_DSD	Total number of people in the target population	0	0
PP_PREV_DSD	Age/sex: 10-14 Male	0	0
PP_PREV_DSD	Age/sex: 15-19 Male	0	0
PP_PREV_DSD	Age/sex: 20-24 Male	0	0
PP_PREV_DSD	Age/sex: 25-49 Male	0	0
PP_PREV_DSD	Age/sex: 50+ Male	0	0
PP_PREV_DSD	Age/sex: 10-14 Female	0	0
PP_PREV_DSD	Age/sex: 15-19 Female	0	0
PP_PREV_DSD	Age/sex: 20-24 Female	0	0
PP_PREV_DSD	Age/sex: 25-49 Female	0	0
PP_PREV_DSD	Age/sex: 50+ Female	0	0
PP_PREV_DSD	Sum of Age/Sex disaggregates	0	0
PP_PREV_TA	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	0	0
PP_PREV_TA	Total number of people in the target population	0	0



PP_PREV_TA	Age/sex: 10-14 Male	0	0
PP_PREV_TA	Age/sex: 15-19 Male	0	0
PP_PREV_TA	Age/sex: 20-24 Male	0	0
PP_PREV_TA	Age/sex: 25-49 Male	0	0
PP_PREV_TA	Age/sex: 50+ Male	0	0
PP_PREV_TA	Age/sex: 10-14 Female	0	0
PP_PREV_TA	Age/sex: 15-19 Female	0	0
PP_PREV_TA	Age/sex: 20-24 Female	0	0
PP_PREV_TA	Age/sex: 25-49 Female	0	0
PP_PREV_TA	Age/sex: 50+ Female	0	0
PP_PREV_TA	Sum of Age/Sex disaggregates	0	0
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	0	0
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0	0
KP_PREV_DSD	By key population type: Males who inject drugs (Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0	0
KP_PREV_DSD	By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0	0



KP_PREV_DSD	By key population type: Men who have sex with men/Transgender (MSM/TG) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0	0
KP_PREV_DSD	By key population type: MSM/TG who are male sex workers (subset MSM/TG) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0	0
KP_PREV_TA	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	0	0
KP_PREV_TA	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0	0
KP_PREV_TA	By key population type: Males who inject drugs (Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0	0
KP_PREV_TA	By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the	0	0



	minimum standards required)		
KP_PREV_TA	By key population type: Men who have sex with men/Transgender (MSM/TG) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0	0
KP_PREV_TA	By key population type: MSM/TG who are male sex workers (subset MSM/TG) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0	0
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	0	0
HTC_TST_DSD	By Test Result: Negative	0	0
HTC_TST_DSD	By Test Result: Positive	0	0
HTC_TST_DSD	Sum of Test Result disaggregates	0	0
HTC_TST_DSD	Age/sex: <1 Male	0	0
HTC_TST_DSD	Age/sex: 1-4 Male	0	0
HTC_TST_DSD	Age/sex: 5-9 Male	0	0
HTC_TST_DSD	Age/sex: 10-14 Male	0	0
HTC_TST_DSD	Age/sex: 15-19 Male	0	0
HTC_TST_DSD	Age/sex: 20-24 Male	0	0
HTC_TST_DSD	Age/sex: 25-49 Male	0	0
HTC_TST_DSD	Age/sex: 50+ Male	0	0
HTC_TST_DSD	Age/sex: <1 Female	0	0
HTC_TST_DSD	Age/sex: 1-4 Female	0	0
HTC_TST_DSD	Age/sex: 5-9 Female	0	0
HTC_TST_DSD	Age/sex: 10-14 Female	0	0
HTC_TST_DSD	Age/sex: 15-19 Female	0	0



HTC_TST_DSD	Age/sex: 20-24 Female	0	0
HTC_TST_DSD	Age/sex: 25-49 Female	0	0
HTC_TST_DSD	Age/sex: 50+ Female	0	0
HTC_TST_DSD	Sum of Age/Sex disaggregates	0	0
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	0	0
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	0	0
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	0	0
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	0	0
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	0	0
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	0	0
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	0	0
HTC_TST_NA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	0	0
HTC_TST_NA	By Test Result: Negative	0	0
HTC_TST_NA	By Test Result: Positive	0	0
HTC_TST_NA	Sum of Test Result disaggregates	0	0
HTC_TST_NA	Age/sex: <1 Male	0	0
HTC_TST_NA	Age/sex: 1-4 Male	0	0
HTC_TST_NA	Age/sex: 5-9 Male	0	0
HTC_TST_NA	Age/sex: 10-14 Male	0	0
HTC_TST_NA	Age/sex: 15-19 Male	0	0
HTC_TST_NA	Age/sex: 20-24 Male	0	0
HTC_TST_NA	Age/sex: 25-49 Male	0	0
HTC_TST_NA	Age/sex: 50+ Male	0	0
HTC_TST_NA	Age/sex: <1 Female	0	0
HTC_TST_NA	Age/sex: 1-4 Female	0	0
HTC_TST_NA	Age/sex: 5-9 Female	0	0
HTC_TST_NA	Age/sex: 10-14 Female	0	0



HTC_TST_NA	Age/sex: 15-19 Female	0	0
HTC_TST_NA	Age/sex: 20-24 Female	0	0
HTC_TST_NA	Age/sex: 25-49 Female	0	0
HTC_TST_NA	Age/sex: 50+ Female	0	0
HTC_TST_NA	Sum of Age/Sex disaggregates	0	0
HTC_TST_NA	Aggregated Age/sex: <15 Male	0	0
HTC_TST_NA	Aggregated Age/sex: 15+ Male	0	0
HTC_TST_NA	Aggregated Age/sex: <15 Female	0	0
HTC_TST_NA	Aggregated Age/sex: 15+ Female	0	0
HTC_TST_NA	Sum of Aggregated Age/Sex <15	0	0
HTC_TST_NA	Sum of Aggregated Age/Sex 15+	0	0
HTC_TST_NA	Sum of Aggregated Age/Sex disaggregates	0	0
HTC_TST_NGI	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	0	0
HTC_TST_NGI	By Test Result: Negative	0	0
HTC_TST_NGI	By Test Result: Positive	0	0
HTC_TST_NGI	Sum of Test Result disaggregates	0	0
HTC_TST_NGI	Age/sex: <1 Male	0	0
HTC_TST_NGI	Age/sex: 1-4 Male	0	0
HTC_TST_NGI	Age/sex: 5-9 Male	0	0
HTC_TST_NGI	Age/sex: 10-14 Male	0	0
HTC_TST_NGI	Age/sex: 15-19 Male	0	0
HTC_TST_NGI	Age/sex: 20-24 Male	0	0
HTC_TST_NGI	Age/sex: 25-49 Male	0	0
HTC_TST_NGI	Age/sex: 50+ Male	0	0
HTC_TST_NGI	Age/sex: <1 Female	0	0
HTC_TST_NGI	Age/sex: 1-4 Female	0	0
HTC_TST_NGI	Age/sex: 5-9 Female	0	0
HTC_TST_NGI	Age/sex: 10-14 Female	0	0
HTC_TST_NGI	Age/sex: 15-19 Female	0	0
HTC_TST_NGI	Age/sex: 20-24 Female	0	0



HTC_TST_NGI	Age/sex: 25-49 Female	0	0
HTC_TST_NGI	Age/sex: 50+ Female	0	0
HTC_TST_NGI	Sum of Age/Sex disaggregates	0	0
HTC_TST_NGI	Aggregated Age/sex: <15 Male	0	0
HTC_TST_NGI	Aggregated Age/sex: 15+ Male	0	0
HTC_TST_NGI	Aggregated Age/sex: <15 Female	0	0
HTC_TST_NGI	Aggregated Age/sex: 15+ Female	0	0
HTC_TST_NGI	Sum of Aggregated Age/Sex <15	0	0
HTC_TST_NGI	Sum of Aggregated Age/Sex 15+	0	0
HTC_TST_NGI	Sum of Aggregated Age/Sex disaggregates	0	0
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	0	0
HTC_TST_TA	By Test Result: Negative	0	0
HTC_TST_TA	By Test Result: Positive	0	0
HTC_TST_TA	Sum of Test Result disaggregates	0	0
HTC_TST_TA	Age/sex: <1 Male	0	0
HTC_TST_TA	Age/sex: 1-4 Male	0	0
HTC_TST_TA	Age/sex: 5-9 Male	0	0
HTC_TST_TA	Age/sex: 10-14 Male	0	0
HTC_TST_TA	Age/sex: 15-19 Male	0	0
HTC_TST_TA	Age/sex: 20-24 Male	0	0
HTC_TST_TA	Age/sex: 25-49 Male	0	0
HTC_TST_TA	Age/sex: 50+ Male	0	0
HTC_TST_TA	Age/sex: <1 Female	0	0
HTC_TST_TA	Age/sex: 1-4 Female	0	0
HTC_TST_TA	Age/sex: 5-9 Female	0	0
HTC_TST_TA	Age/sex: 10-14 Female	0	0
HTC_TST_TA	Age/sex: 15-19 Female	0	0
HTC_TST_TA	Age/sex: 20-24 Female	0	0
HTC_TST_TA	Age/sex: 25-49 Female	0	0
HTC_TST_TA	Age/sex: 50+ Female	0	0



HTC_TST_TA	Sum of Age/Sex disaggregates	0	0
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	0	0
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	0	0
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	0	0
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	0	0
HTC_TST_TA	Sum of Aggregated Age/Sex <15	0	0
HTC_TST_TA	Sum of Aggregated Age/Sex 15+	0	0
HTC_TST_TA	Sum of Aggregated Age/Sex disaggregates	0	0
GEND_GBV_DSD	Number of people receiving post-GBV care	0	0
GEND_GBV_DSD	Age: 0-9	0	0
GEND_GBV_DSD	Age: 10-14	0	0
GEND_GBV_DSD	Age: 15-17	0	0
GEND_GBV_DSD	Age: 18-24	0	0
GEND_GBV_DSD	Age: 25+	0	0
GEND_GBV_DSD	Sum of Age disaggregates	0	0
GEND_GBV_DSD	Sex: Male	0	0
GEND_GBV_DSD	Sex: Female	0	0
GEND_GBV_DSD	Sum of Sex disaggregates	0	0
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	0	0
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	0	0
GEND_GBV_DSD	By PEP service provision (related to sexual violence services provided)	0	0
GEND_NORM_DSD	Number of people completing an intervention pertaining to gender norms, that meets minimum criteria	0	0
GEND_NORM_DSD	By Age: 0-9	0	0
GEND_NORM_DSD	By Age: 10-14	0	0



GEND_NORM_DSD	By Age: 15-19	0	0
GEND_NORM_DSD	By Age: 20-24	0	0
GEND_NORM_DSD	By Age: 25+	0	0
GEND_NORM_DSD	Sum of Age disaggregates	0	0
GEND_NORM_DSD	By type of activity: Individual	0	0
GEND_NORM_DSD	By type of activity: Small Group	0	0
GEND_NORM_DSD	By type of activity: Community-level	0	0
OVC_ACC_DSD	Number of active beneficiaries receiving support from PEPFAR OVC programs to access HIV services	549	549
OVC_ACC_DSD	Sex: Male	274	274
OVC_ACC_DSD	Sex: Female	275	275
OVC_ACC_DSD	Sum of Sex disaggregates	549	549
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	6,100	6,100
OVC_SERV_DSD	Sex: Male	3,000	3,000
OVC_SERV_DSD	Sex: Female	3,100	3,100
OVC_SERV_DSD	Sum of Sex disaggregates	6,100	6,100
OVC_SERV_DSD	Age: <1	0	0
OVC_SERV_DSD	Age: 1-4	500	500
OVC_SERV_DSD	Age: 5-9	1,000	1,000
OVC_SERV_DSD	Age: 10-14	2,500	2,500
OVC_SERV_DSD	Age: 15-17	2,100	2,100
OVC_SERV_DSD	Age: 18+	0	0
OVC_SERV_DSD	Sum of Age disaggregates	6,100	6,100
OVC_SERV_TA	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	0	0
OVC_SERV_TA	Sex: Male	0	0
OVC_SERV_TA	Sex: Female	0	0
OVC_SERV_TA	Sum of Sex disaggregates	0	0
OVC_SERV_TA	Age: <1	0	0



OVC_SERV_TA	Age: 1-4	0	0
OVC_SERV_TA	Age: 5-9	0	0
OVC_SERV_TA	Age: 10-14	0	0
OVC_SERV_TA	Age: 15-17	0	0
OVC_SERV_TA	Age: 18+	0	0
OVC_SERV_TA	Sum of Age disaggregates	0	0
C2.1.D_DSD	Number of HIV-positive individuals receiving a minimum of one clinical service	0	0
C2.1.D_DSD	By Age/Sex: <15 Female	0	0
C2.1.D_DSD	By Age/Sex: <15 Male	0	0
C2.1.D_DSD	By Age/Sex: 15+ Female	0	0
C2.1.D_DSD	By Age/Sex: 15+ Male	0	0
C2.1.D_DSD	Sum of Age/Sex disaggregates	0	0
C2.1.D_DSD	By Age: <15	0	0
C2.1.D_DSD	By Age: 15+	0	0
C2.1.D_DSD	Sum of Age disaggregates	0	0
C2.1.D_DSD	By Sex: Female	0	0
C2.1.D_DSD	By Sex: Male	0	0
C2.1.D_DSD	Sum of Sex disaggregates	0	0
C2.1.D_NA	Number of HIV-positive individuals receiving a minimum of one clinical service	0	0
C2.1.D_NA	By Age/Sex: <15 Female	0	0
C2.1.D_NA	By Age/Sex: <15 Male	0	0
C2.1.D_NA	By Age/Sex: 15+ Female	0	0
C2.1.D_NA	By Age/Sex: 15+ Male	0	0
C2.1.D_NA	Sum of Age/Sex disaggregates	0	0
C2.1.D_NGI	Number of HIV-positive individuals receiving a minimum of one clinical service	0	0
C2.1.D_NGI	By Age/Sex: <15 Female	0	0
C2.1.D_NGI	By Age/Sex: <15 Male	0	0
C2.1.D_NGI	By Age/Sex: 15+ Female	0	0
C2.1.D_NGI	By Age/Sex: 15+ Male	0	0



C2.1.D_NGI	Sum of Age/Sex disaggregates	0	0
C2.1.D_NGI	By Age: <15	0	0
C2.1.D_NGI	By Age: 15+	0	0
C2.1.D_NGI	Sum of Age disaggregates	0	0
C2.1.D_NGI	By Sex: Female	0	0
C2.1.D_NGI	By Sex: Male	0	0
C2.1.D_NGI	Sum of Sex disaggregates	0	0
C2.1.D_TA	Number of HIV-positive individuals receiving a minimum of one clinical service	0	0
C2.1.D_TA	By Age/Sex: <15 Female	0	0
C2.1.D_TA	By Age/Sex: <15 Male	0	0
C2.1.D_TA	By Age/Sex: 15+ Female	0	0
C2.1.D_TA	By Age/Sex: 15+ Male	0	0
C2.1.D_TA	Sum of Age/Sex disaggregates	0	0
C2.1.D_TA	By Age: <15	0	0
C2.1.D_TA	By Age: 15+	0	0
C2.1.D_TA	Sum of Age disaggregates	0	0
C2.1.D_TA	By Sex: Female	0	0
C2.1.D_TA	By Sex: Male	0	0
C2.1.D_TA	Sum of Sex disaggregates	0	0
C2.4.D_DSD	Number of HIV-positive patients who were screened for TB in HIV care or treatment setting	0	0
C2.4.D_DSD	Number of HIV-positive individuals receiving a minimum of one clinical service	0	0
C2.5.D_DSD	Number of HIV-positive patients in HIV care who started TB treatment	0	0
C2.5.D_DSD	Number of HIV-positive individuals receiving a minimum of one clinical service	0	0
CARE_CURR_DSD	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count	0	0



	OR viral load		
CARE_CURR_DSD	Age/sex: <1 Male	0	0
CARE_CURR_DSD	Age/sex: 1-4 Male	0	0
CARE_CURR_DSD	Age/sex: 5-9 Male	0	0
CARE_CURR_DSD	Age/sex: 10-14 Male	0	0
CARE_CURR_DSD	Age/sex: 15-19 Male	0	0
CARE_CURR_DSD	Age/sex: 20-24 Male	0	0
CARE_CURR_DSD	Age/sex: 25-49 Male	0	0
CARE_CURR_DSD	Age/sex: 50+ Male	0	0
CARE_CURR_DSD	Age/sex: <1 Female	0	0
CARE_CURR_DSD	Age/sex: 1-4 Female	0	0
CARE_CURR_DSD	Age/sex: 5-9 Female	0	0
CARE_CURR_DSD	Age/sex: 10-14 Female	0	0
CARE_CURR_DSD	Age/sex: 15-19 Female	0	0
CARE_CURR_DSD	Age/sex: 20-24 Female	0	0
CARE_CURR_DSD	Age/sex: 25-49 Female	0	0
CARE_CURR_DSD	Age/sex: 50+ Female	0	0
CARE_CURR_DSD	Sun of Age/Sex disaggregates	0	0
CARE_CURR_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	0	0
CARE_CURR_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	0	0
CARE_CURR_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	0	0
CARE_CURR_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	0	0
CARE_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	0	0
CARE_CURR_TA	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	0	0
CARE_CURR_TA	Age/sex: <1 Male	0	0



CARE_CURR_TA	Age/sex: 1-4 Male	0	0
CARE_CURR_TA	Age/sex: 5-9 Male	0	0
CARE_CURR_TA	Age/sex: 10-14 Male	0	0
CARE_CURR_TA	Age/sex: 15-19 Male	0	0
CARE_CURR_TA	Age/sex: 20-24 Male	0	0
CARE_CURR_TA	Age/sex: 25-49 Male	0	0
CARE_CURR_TA	Age/sex: 50+ Male	0	0
CARE_CURR_TA	Age/sex: <1 Female	0	0
CARE_CURR_TA	Age/sex: 1-4 Female	0	0
CARE_CURR_TA	Age/sex: 5-9 Female	0	0
CARE_CURR_TA	Age/sex: 10-14 Female	0	0
CARE_CURR_TA	Age/sex: 15-19 Female	0	0
CARE_CURR_TA	Age/sex: 20-24 Female	0	0
CARE_CURR_TA	Age/sex: 25-49 Female	0	0
CARE_CURR_TA	Age/sex: 50+ Female	0	0
CARE_CURR_TA	Sum of Age/Sex disaggregates	0	0
CARE_CURR_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	0	0
CARE_CURR_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	0	0
CARE_CURR_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	0	0
CARE_CURR_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	0	0
CARE_CURR_TA	Sum of Aggregated Age/Sex disaggregates	0	0
CARE_NEW_DSD	Number of HIV-infected adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load	0	0
CARE_NEW_DSD	Age/sex: <1 Male	0	0
CARE_NEW_DSD	Age/sex: 1-4 Male	0	0



CARE_NEW_DSD	Age/sex: 5-9 Male	0	0
CARE_NEW_DSD	Age/sex: 10-14 Male	0	0
CARE_NEW_DSD	Age/sex: 15-19 Male	0	0
CARE_NEW_DSD	Age/sex: 20-24 Male	0	0
CARE_NEW_DSD	Age/sex: 25-49 Male	0	0
CARE_NEW_DSD	Age/sex: 50+ Male	0	0
CARE_NEW_DSD	Age/sex: <1 Female	0	0
CARE_NEW_DSD	Age/sex: 1-4 Female	0	0
CARE_NEW_DSD	Age/sex: 5-9 Female	0	0
CARE_NEW_DSD	Age/sex: 10-14 Female	0	0
CARE_NEW_DSD	Age/sex: 15-19 Female	0	0
CARE_NEW_DSD	Age/sex: 20-24 Female	0	0
CARE_NEW_DSD	Age/sex: 25-49 Female	0	0
CARE_NEW_DSD	Age/sex: 50+ Female	0	0
CARE_NEW_DSD	Sum of Age/sex disaggregates	0	0
CARE_NEW_DSD	Aggregated Age/sex: <15 Male	0	0
CARE_NEW_DSD	Aggregated Age/sex: 15+ Male	0	0
CARE_NEW_DSD	Aggregated Age/sex: <15 Female	0	0
CARE_NEW_DSD	Aggregated Age/sex: 15+ Female	0	0
CARE_NEW_DSD	Sum of Aggregated Age/sex disaggregates	0	0
CARE_SITE	Number of PEPFAR-supported HIV clinical care sites at which at least 80% of PLHIV received all of the following during the reporting period: 1) clinical assessment (WHO staging) OR CD4 count OR viral load, AND 2) TB screening at last visit, AND 3) if eligible, cotrimoxazole	0	0
CARE_SITE	Total number of PEPFAR supported sites providing clinical care services	0	0
CARE_SITE	By site support type: Direct Service Delivery (DSD): Number of PEPFAR-supported HIV clinical care sites at which at least 80% of PLHIV received all of the following during the	0	0



	reporting period: 1) clinical assessment (WHO staging) OR CD4 count OR viral load, AND 2) TB screening at last visit, AND 3) if eligible, cotrimoxazole		
CARE_SITE	By site support type: Technical Assistance-only (TA): Number of PEPFAR-supported HIV clinical care sites at which at least 80% of PLHIV received all of the following during the reporting period: 1) clinical assessment (WHO staging) OR CD4 count OR viral load, AND 2) TB screening at last visit, AND 3) if eligible, cotrimoxazole	0	0
CARE_SITE	Sum of Numerator Site Support Type disaggregates	0	0
CARE_SITE	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR supported sites providing clinical care services	0	0
CARE_SITE	By site support type: Technical Assistance-only (TA): Total number of PEPFAR supported sites providing clinical care services	0	0
CARE_SITE	Sum of Denominator Site Support Type disaggregates	0	0
FN_SITE	Number of PEPFAR-supported sites achieving 90% nutrition assessments that result in accurate categorization of malnutrition	0	0
FN_SITE	Total number of PEPFAR-supported sites providing nutrition assessment, counseling and support (NACS) services	0	0
FN_SITE	By site support type: Direct Service Delivery (DSD): Number of PEPFAR-supported sites achieving 90% nutrition assessments that result in accurate categorization of malnutrition	0	0
FN_SITE	By site support type: Technical	0	0



	Assistance-only (TA): Number of PEPFAR-supported sites achieving 90% nutrition assessments that result in accurate categorization of malnutrition		
FN_SITE	Sum of Numerator Support Type disaggregates	0	0
FN_SITE	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported sites providing nutrition assessment, counseling and support (NACS) services	0	0
FN_SITE	By site support type: Technical Assistance-only (TA): Total number of PEPFAR-supported sites providing nutrition assessment, counseling and support (NACS) services	0	0
FN_SITE	Sum of Denominator Support Type disaggregates	0	0
FN_THER_DSD	Number of clinically malnourished PLHIV who received therapeutic and/or supplementary food during the reporting period.	0	0
FN_THER_DSD	Number of PLHIV who were nutritionally assessed and found to be clinically undernourished.	0	0
FN_THER_DSD	Age: <1	0	0
FN_THER_DSD	Age: 1-4	0	0
FN_THER_DSD	Age: 5-14	0	0
FN_THER_DSD	Age: 15-17	0	0
FN_THER_DSD	Age: 18+	0	0
FN_THER_DSD	Sum of Age disaggregates	0	0
FN_THER_DSD	Aggregated Age: <18	0	0
FN_THER_DSD	Aggregated Age: 18+	0	0
FN_THER_DSD	Sum of Aggregated Age disaggregates	0	0
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status	0	0



	whoare on ART during TB treatment during the reporting period		
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	0	0
TB_ARTSITE	The number of PEPFAR-supported TB basic management units at which 80% of registered TB cases who are HIV-positive are on ART, during the reporting period	0	0
TB_ARTSITE	The number of PEPFAR-supported TB basic management units	0	0
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	0	0
PMTCT_EID_DSD	Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT)	0	0
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	0	0
TX_CURR_DSD	Percent children with advanced HIV infection receiving antiretroviral therapy (ART) [CURRENT]	0	0
TX_CURR_NA	Number of adults and children receiving antiretroviral therapy (ART)	0	0
TX_CURR_NA	Aggregated Age/Sex: <1 Male	0	0
TX_CURR_NGI	Number of adults and children receiving antiretroviral therapy (ART)	0	0
TX_CURR_NGI	Aggregated Age/Sex: <1 Male	0	0
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	0	0
TX_CURR_TA	Aggregated Age/Sex: <1 Male	0	0
TX_DIST	Number of Districts with documented routine	0	0



	supportive supervision visits to 75% of HIV care and treatment sites supported by the District		
TX_DIST	Total number of PEPFAR supported District Health Offices	0	0
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	0	0
TX_NEW_DSD	Aggregated Grouping by Age: <1 Male	0	0
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	0	0
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	0	0
TX_SITE	Number of PEPFAR-supported ART sites with a retention rate of 75% or greater for patients 12 months after ART initiation	0	0
TX_SITE	Total number of PEPFAR-supported ART sites	0	0
LAB_CAP_DSD	Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests	0	0
LAB_PT_DSD	Percentage of laboratories and POC testing sites that perform HIV diagnostic testing that participate and successfully pass in an analyte-specific proficiency testing (PT) program	0	0
HRH_PRE	Number of new HCW who graduated from a pre-service training institution or program as a result of PEPFAR-supported strengthening efforts, within the reporting period, by select cadre	0	0
HRH_PRE	By new graduates who are licensed and	0	0



	registered: Doctors		
SC_TRAIN	Number of individuals who received competency-based, certificate or higher-level training to conduct or support supply chain, inventory management, supportive supervision or distribution activities	0	0
FPINT_SITE_DSD	Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	0	0
QI_SITE	Number of PEPFAR-supported clinical service sites with a quality improvement activity completed that addresses clinical HIV programs and has documented process results in the last 6 months	0	0
QI_SITE	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported sites for any HIV clinical service including HIV Care, HIV Treatment, TB care, PMTCT, VMMC, HTC	0	0
QI_SITE	Sum of Denominator Site Support Type disaggregates	0	0
SC_STOCK	System Level: Central Medical Stores	0	0
SI_HIS	Full national facility list coordinated with PEPFAR	1	1
SI_ME	Existence of a national HIV/AIDS M&E system based on the UNAIDS 12 components model	1	1
TB_SCREEN_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period	0	0
TB_SCREEN_DSD	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	0	0

Approved



TB_SCREEN_DSD	Age: <1	0	0
TB_SCREEN_DSD	Sum of Age disaggregates	0	0

Implementing Mechanism Details

Mechanism ID: 16711	Mechanism Name: Capacity Bridge Mechanism
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: IntraHealth International, Inc	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: No	
G2G: No	Managing Agency:

Total All Funding Sources: 0	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 3,664,806	
FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount
GHP-State	0

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

Mobile Population

Workplace Programs

End-of-Program Evaluation

Budget Code Information

Custom

Page 162 of 1199

FACTS Info v3.8.15.8

2015-03-30 11:50 EDT



Mechanism ID: 16711			
Mechanism Name: Capacity Bridge Mechanism			
Prime Partner Name: IntraHealth International, Inc			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 16710	Mechanism Name: Expanding Health Insurance Coverage
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Equity Group Foundation	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: No	
G2G: No	Managing Agency:

Total All Funding Sources: 651,646	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 0	
FY 2013 Burn Rate: Redacted	

Approved



Funding Source	Funding Amount
GHP-State	651,646

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

(No data provided.)

Budget Code Information

Mechanism ID: 16710			
Mechanism Name: Expanding Health Insurance Coverage			
Prime Partner Name: Equity Group Foundation			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	651,646	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 16709	Mechanism Name: Accelerating Progress Against TB
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: New Partner	
Agreement Start Date: Redacted	Agreement End Date: Redacted

Approved



TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: No	
G2G: No	Managing Agency:

Total All Funding Sources: 2,118,187	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 0	
FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount
GHP-State	2,118,187

Sub Partner Name(s)

Program for Appropriate Technology in Health		
---	--	--

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

Child Survival Activities

Mobile Population

TB

Workplace Programs

End-of-Program Evaluation

Budget Code Information

Mechanism ID:	16709		
Mechanism Name:	Accelerating Progress Against TB		
Prime Partner Name:	New Partner		
Strategic Area	Budget Code	Planned Amount	On Hold Amount

Approved



Care	HVTB	2,118,187	0
------	------	-----------	---

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 16705	Mechanism Name: IDU - HIV Combination Prevention
Funding Agency: USAID	Procurement Type: Grant
Prime Partner Name: United Nations Office on Drug and Crime (UNODC)	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: No	
G2G: No	Managing Agency:

Total All Funding Sources: 1,212,520	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 0	
FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount
GHP-State	1,212,520

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

Mobile Population



Family Planning

Budget Code Information

Mechanism ID: 16705			
Mechanism Name: IDU - HIV Combination Prevention			
Prime Partner Name: United Nations Office on Drug and Crime (UNODC)			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	33,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	IDUP	1,179,520	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2014	2015
KP_MAT_DSD	Number of people who inject drugs (PWID) on medication assisted therapy (MAT) for at least 6 months	280	280
KP_MAT_DSD	Sex: Male	224	224
KP_MAT_DSD	Sex: Female	56	56
KP_MAT_DSD	Sum of Sex disaggregates	280	280
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	6,053	6,053
KP_PREV_DSD	By key population type: Males who inject drugs (Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions	140	140



	that are based on evidence and/or meet the minimum standards required)		
KP_PREV_DSD	By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	140	140
KP_PREV_DSD	By key population type: Men who have sex with men/Transgender (MSM/TG) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	2,700	2,700
KP_PREV_DSD	By key population type: MSM/TG who are male sex workers (subset MSM/TG) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	700	700

Implementing Mechanism Details

Mechanism ID: 16698	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 16687	Mechanism Name: Kenya Prison Services
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: New Partner	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: No	



G2G: No	Managing Agency:
Total All Funding Sources: 2,196,797	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 0	
FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount
GHP-State	2,196,797

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

Human Resources for Health	300,000
Food and Nutrition: Policy, Tools, and Service Delivery	10,000
Focus Area:	GBV Prevention
Sub Area:	Implementation
Sub Area:	Monitoring and Evaluation
Focus Area:	Post GBV Care
Sub Area:	Implementation
Sub Area:	Monitoring and Evaluation
Gender: GBV	30,000
Focus Area:	GBV Prevention
Sub Area:	Implementation
Sub Area:	Monitoring and Evaluation
Focus Area:	Post GBV Care
Sub Area:	Implementation
Sub Area:	Monitoring and Evaluation
Gender: Gender Equality	50,000
Focus Area:	Changing harmful gender norms and promoting positive gender norms
Sub Area:	Implementation



Sub Area:	Monitoring and Evaluation
Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Implementation
Sub Area:	Monitoring and Evaluation
Condom programming	15,000

Key Issues

- Child Survival Activities
- Safe Motherhood
- TB
- Workplace Programs
- Family Planning

Budget Code Information

Mechanism ID: 16687			
Mechanism Name: Kenya Prison Services			
Prime Partner Name: New Partner			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	65,165	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	375,899	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	160,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	473,715	0



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	600,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	181,676	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	340,342	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 16684	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 16682	Mechanism Name: Kenya National Bureau of Statistics (KNBS) FARA
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Kenya National Bureau of Statistics	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: No	
G2G: Yes	Managing Agency: USAID

Total All Funding Sources: 400,000	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 0	
FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount

Approved



GHP-State	400,000
-----------	---------

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

(No data provided.)

Budget Code Information

Mechanism ID: 16682			
Mechanism Name: Kenya National Bureau of Statistics (KNBS) FARA			
Prime Partner Name: Kenya National Bureau of Statistics			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	400,000	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 16679	Mechanism Name: Program Support Services
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: New Partner	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No

Approved



Global Fund / Multilateral Engagement: No	
G2G: No	Managing Agency:
Total All Funding Sources: 3,404,964	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 0	
FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount
GHP-State	3,404,964

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

Child Survival Activities
Military Population
Mobile Population
Safe Motherhood
TB
Workplace Programs
End-of-Program Evaluation
Family Planning

Budget Code Information

Mechanism ID: 16679			
Mechanism Name: Program Support Services			
Prime Partner Name: New Partner			
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Care	HKID	1,500,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	700,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVAB	118,543	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	94,480	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	500,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	491,941	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 16670	Mechanism Name: HIV Fellowship Program
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: University of Nairobi	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: No	
G2G: Yes	Managing Agency: HHS/CDC
Total All Funding Sources: 1,000,000	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 0	

Approved



FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount
GHP-State	1,000,000

Sub Partner Name(s)

Management Sciences for Health	University of Washington	
--------------------------------	--------------------------	--

Cross-Cutting Budget Attribution(s)

Human Resources for Health	1,000,000
----------------------------	-----------

Key Issues

(No data provided.)

Budget Code Information

Mechanism ID: 16670			
Mechanism Name: HIV Fellowship Program			
Prime Partner Name: University of Nairobi			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	1,000,000	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 16644	Mechanism Name: UNICEF
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement

Approved



Prime Partner Name: United Nations Children's Fund	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: No	
G2G: No	Managing Agency:

Total All Funding Sources: 0	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 0	
FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount
GHP-State	0

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

(No data provided.)

Budget Code Information

Mechanism ID: 16644			
Mechanism Name: UNICEF			
Prime Partner Name: United Nations Children's Fund			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	0	0

Implementing Mechanism Indicator Information

Approved



(No data provided.)

Implementing Mechanism Details

Mechanism ID: 16643	Mechanism Name: Nursing Capacity Building Program
Funding Agency: HHS/HRSA	Procurement Type: Cooperative Agreement
Prime Partner Name: Columbia University Mailman School of Public Health	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: No	
G2G: No	Managing Agency:

Total All Funding Sources: 25,000	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 0	
FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount
GHP-State	25,000

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

(No data provided.)

Budget Code Information

Mechanism ID: 16643



Mechanism Name:	Nursing Capacity Building Program		
Prime Partner Name:	Columbia University Mailman School of Public Health		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	25,000	

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 16450	Mechanism Name: Global Give Back Circle
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Kenya Community Development Foundation	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: No	
G2G: No	Managing Agency:

Total All Funding Sources: 600,000	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 0	
FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount
GHP-State	600,000

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

Education	600,000
-----------	---------



Key Issues

(No data provided.)

Budget Code Information

Mechanism ID: 16450			
Mechanism Name: Global Give Back Circle			
Prime Partner Name: Kenya Community Development Foundation			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	600,000	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2014	2015
SITE_SUPP	By program area/support type: OVC Direct Service Delivery (DSD)	1	1
PMTCT_ARV_DSD	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	0	0
PMTCT_ARV_DSD	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	0	0
PMTCT_ARV_NA	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	0	0
PMTCT_ARV_NA	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	0	0
PMTCT_ARV_NGI	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of	0	0



	mother-to-child-transmission (MTCT) during pregnancy and delivery		
PMTCT_ARV_NGI	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	0	0
PMTCT_ARV_TA	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	0	0
PMTCT_SITE	Number of PEPFAR-supported sites achieving 90% ARV or ART coverage for HIV+ pregnant women	0	0
PMTCT_SITE	Total number of PEPFAR supported sites providing PMTCT services (HTC and ARV or ART services)	0	0
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	0	0
PMTCT_STAT_DSD	Number of new ANC and L&D clients	0	0
PMTCT_STAT_NA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	0	0
PMTCT_STAT_NA	Number of new ANC and L&D clients	0	0
PMTCT_STAT_NGI	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	0	0
BS_COLL	Number of whole blood collections each year by the NBTS network	0	0
KP_MAT_DSD	Number of people who inject drugs (PWID) on medication assisted therapy (MAT) for at least 6 months	0	0
VMMC_AE_DSD	Number of males circumcised surgically or by medical device that experienced at least one moderate or severe adverse event(s) (AEs)	0	0
VMMC_CIRC_DSD	Number of males circumcised as part of the	0	0

	voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period		
VMMC_CIRC_NA	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	0	0
VMMC_CIRC_NGI	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	0	0
VMMC_CIRC_TA	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	0	0
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	0	0
PP_PREV_DSD	Total number of people in the target population	0	0
PP_PREV_TA	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	0	0
PP_PREV_TA	Total number of people in the target population	0	0
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	0	0
KP_PREV_TA	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on	0	0



	evidence and/or meet the minimum standards required		
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	0	0
HTC_TST_NA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	0	0
HTC_TST_NGI	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	0	0
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	0	0
GEND_GBV_DSD	Number of people receiving post-GBV care	0	0
GEND_NORM_DSD	Number of people completing an intervention pertaining to gender norms, that meets minimum criteria	0	0
OVC_ACC_DSD	Number of active beneficiaries receiving support from PEPFAR OVC programs to access HIV services	0	0
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	570	255
OVC_SERV_DSD	Sex: Male	25	25
OVC_SERV_DSD	Sex: Female	545	230
OVC_SERV_DSD	Sum of Sex disaggregates	570	255
OVC_SERV_DSD	Age: 15-17	570	255
OVC_SERV_DSD	Sum of Age disaggregates	570	255
C2.1.D_DSD	Number of HIV-positive individuals receiving a minimum of one clinical service	0	0
C2.1.D_NA	Number of HIV-positive individuals receiving a minimum of one clinical service	0	0
C2.1.D_NGI	Number of HIV-positive individuals receiving a	0	0



	minimum of one clinical service		
C2.1.D_TA	Number of HIV-positive individuals receiving a minimum of one clinical service	0	0
C2.4.D_DSD	Number of HIV-positive patients who were screened for TB in HIV care or treatment setting	0	0
C2.4.D_DSD	Number of HIV-positive individuals receiving a minimum of one clinical service	0	0
C2.5.D_DSD	Number of HIV-positive patients in HIV care who started TB treatment	0	0
C2.5.D_DSD	Number of HIV-positive individuals receiving a minimum of one clinical service	0	0
CARE_CURR_DSD	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	0	0
CARE_CURR_TA	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	0	0
CARE_NEW_DSD	Number of HIV-infected adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load	0	0
CARE_SITE	Number of PEPFAR-supported HIV clinical care sites at which at least 80% of PLHIV received all of the following during the reporting period: 1) clinical assessment (WHO staging) OR CD4 count OR viral load, AND 2) TB screening at last visit, AND 3) if eligible, cotrimoxazole	0	0



CARE_SITE	Total number of PEPFAR supported sites providing clinical care services	0	0
FN_THER_DSD	Number of clinically malnourished PLHIV who received therapeutic and/or supplementary food during the reporting period.	0	0
FN_THER_DSD	Number of PLHIV who were nutritionally assessed and found to be clinically undernourished.	0	0
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	0	0
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	0	0
TB_ARTSITE	The number of PEPFAR-supported TB basic management units at which 80% of registered TB cases who are HIV-positive are on ART, during the reporting period	0	0
TB_ARTSITE	The number of PEPFAR-supported TB basic management units	0	0
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	0	0
PMTCT_EID_DSD	Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT)	0	0
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	0	0
TX_CURR_NA	Number of adults and children receiving antiretroviral therapy (ART)	0	0
TX_CURR_NGI	Number of adults and children receiving antiretroviral therapy (ART)	0	0



TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	0	0
TX_DIST	Number of Districts with documented routine supportive supervision visits to 75% of HIV care and treatment sites supported by the District	0	0
TX_DIST	Total number of PEPFAR supported District Health Offices	0	0
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	0	0
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	0	0
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	0	0
TX_SITE	Number of PEPFAR-supported ART sites with a retention rate of 75% or greater for patients 12 months after ART initiation	0	0
TX_SITE	Total number of PEPFAR-supported ART sites	0	0
LAB_ACC_DSD	Number of PEPFAR-supported testing facilities (laboratories) that are recognized by national, regional, or international standards for accreditation or have achieved a minimal acceptable level towards attainment of such accreditation	0	0
LAB_CAP_DSD	Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests	0	0
LAB_PT_DSD	Percentage of laboratories and POC testing sites that perform HIV diagnostic testing that participate and successfully pass in an	0	0



	analyte-specific proficiency testing (PT) program		
HRH_PRE	Number of new HCW who graduated from a pre-service training institution or program as a result of PEPFAR-supported strengthening efforts, within the reporting period, by select cadre	0	0
SC_TRAIN	Number of individuals who received competency-based, certificate or higher-level training to conduct or support supply chain, inventory management, supportive supervision or distribution activities	0	0
SC_TRAIN	Number of individuals who conduct or support supply chain, inventory management, supportive supervision or distribution activities	0	0
FPINT_SITE_DSD	Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	0	0
FPINT_SITE_DSD	Total number of PEPFAR-supported HIV service delivery points: PMTCT, Care and Treatment	0	0
QI_SITE	Number of PEPFAR-supported clinical service sites with a quality improvement activity completed that addresses clinical HIV programs and has documented process results in the last 6 months	0	0
QI_SITE	Total number of PEPFAR-supported sites for any HIV clinical service including HIV Care, HIV Treatment, TB care, PMTCT, VMMC, and HTC	0	0
SC_STOCK	Number of stock status observations for one or more tracer commodities that are between the designed minimum and maximum quantities/months of stock from storage sites	0	0



	within at a given level (Central, Regional, etc.) of the system.		
SC_STOCK	Total number of stock status observations for one or more tracer commodities from storage sites within at a given level (Central, Regional, etc.) of the system	0	0
SI_HIS	Existence of a national registry of health facilities that is updated annually	1	1
SI_HIS	Full national facility list coordinated with PEPFAR	1	1
SI_ME	Existence of a national HIV/AIDS M&E system based on the UNAIDS 12 components model	1	1
TB_SCREEN_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period	0	0
TB_SCREEN_DSD	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	0	0

Implementing Mechanism Details

Mechanism ID: 14034	Mechanism Name: The OVC Scholarship and Leadership Program
Funding Agency: USAID	Procurement Type: Grant
Prime Partner Name: Equity Group Foundation	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: No	
G2G: No	Managing Agency:

Total All Funding Sources: 2,521,036	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 478,964	
FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount



GHP-State	2,521,036
-----------	-----------

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

Education	2,521,036
-----------	-----------

Key Issues

Child Survival Activities

Budget Code Information

Mechanism ID: 14034			
Mechanism Name: The OVC Scholarship and Leadership Program			
Prime Partner Name: Equity Group Foundation			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	2,521,036	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2014	2015
SITE_SUPP	By program area/support type: HTC Direct Service Delivery (DSD)	0	0
SITE_SUPP	By program area/support type: HTC Technical Assistance-only (TA)	0	0
SITE_SUPP	By program area/support type: Treatment Direct Service Delivery (DSD)	0	0



SITE_SUPP	By program area/support type: Treatment Technical Assistance-only (TA)	0	0
SITE_SUPP	By program area/support type: Care and Support Direct Service Delivery (DSD)	0	0
SITE_SUPP	By program area/support type: Care and Support Technical Assistance-only (TA)	0	0
SITE_SUPP	By program area/support type: Food and Nutrition Direct Service Delivery (DSD)	0	0
SITE_SUPP	By program area/support type: Food and Nutrition Technical Assistance-only (TA)	0	0
SITE_SUPP	By program area/support type: PMTCT Direct Service Delivery (DSD)	0	0
SITE_SUPP	By program area/support type: PMTCT Technical Assistance-only (TA)	0	0
SITE_SUPP	By program area/support type: TB/HIV Direct Service Delivery (DSD)	0	0
SITE_SUPP	By program area/support type: TB/HIV Technical Assistance-only (TA)	0	0
SITE_SUPP	By program area/support type: VMMC Direct Service Delivery (DSD)	0	0
SITE_SUPP	By program area/support type: VMMC Technical Assistance-only (TA)	0	0
SITE_SUPP	By program area/support type: General Population Prevention Direct Service Delivery (DSD)	0	0
SITE_SUPP	By program area/support type: General Population Prevention Technical Assistance-only (TA)	0	0
SITE_SUPP	By program area/support type: Key Populations Prevention Direct Service Delivery (DSD)	0	0
SITE_SUPP	By program area/support type: Key Populations Prevention Technical Assistance-only (TA)	0	0



SITE_SUPP	By program area/support type: OVC Direct Service Delivery (DSD)	1	1
SITE_SUPP	By program area/support type: OVC Technical Assistance-only (TA)	0	0
SITE_SUPP	By program area/support type: PHDP/Family Planning & Integration Direct Service Delivery (DSD)	0	0
SITE_SUPP	By program area/support type: PHDP/Family Planning & Integration Technical Assistance-only (TA)	0	0
SITE_SUPP	By program area/support type: Lab Direct Service Delivery (DSD)	0	0
SITE_SUPP	By program area/support type: Lab Technical Assistance-only (TA)	0	0
PMTCT_ARV_DSD	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	0	0
PMTCT_ARV_DSD	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	0	0
PMTCT_ARV_NA	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	0	0
PMTCT_ARV_NA	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	0	0
PMTCT_ARV_NGI	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	0	0
PMTCT_ARV_NGI	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	0	0



PMTCT_ARV_TA	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	0	0
PMTCT_ARV_TA	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	0	0
PMTCT_SITE	Number of PEPFAR-supported sites achieving 90% ARV or ART coverage for HIV+ pregnant women	0	0
PMTCT_SITE	Total number of PEPFAR supported sites providing PMTCT services (HTC and ARV or ART services)	0	0
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	0	0
PMTCT_STAT_DSD	Number of new ANC and L&D clients	0	0
PMTCT_STAT_DSD	By: Known positives at entry	0	0
PMTCT_STAT_DSD	By: Number of new positives identified	0	0
PMTCT_STAT_DSD	Sum of Positives Status disaggregates	0	0
PMTCT_STAT_NA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	0	0
PMTCT_STAT_NA	Number of new ANC and L&D clients	0	0
PMTCT_STAT_NGI	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	0	0
PMTCT_STAT_NGI	Number of new ANC and L&D clients	0	0
BS_COLL	Number of whole blood collections each year by the NBTS network	0	0
KP_MAT_DSD	Number of people who inject drugs (PWID) on medication assisted therapy (MAT) for at least 6 months	0	0
VMMC_AE_DSD	Number of males circumcised surgically or by	0	0

	medical device that experienced at least one moderate or severe adverse event(s) (AEs)		
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	0	0
VMMC_CIRC_NA	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	0	0
VMMC_CIRC_NGI	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	0	0
VMMC_CIRC_TA	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	0	0
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	0	0
PP_PREV_DSD	Total number of people in the target population	0	0
PP_PREV_TA	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	0	0
PP_PREV_TA	Total number of people in the target population	0	0
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	0	0



KP_PREV_TA	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	0	0
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	0	0
HTC_TST_NA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	0	0
HTC_TST_NGI	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	0	0
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	0	0
GEND_GBV_DSD	Number of people receiving post-GBV care	0	0
GEND_NORM_DSD	Number of people completing an intervention pertaining to gender norms, that meets minimum criteria	0	0
OVC_ACC_DSD	Number of active beneficiaries receiving support from PEPFAR OVC programs to access HIV services	0	0
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	2,644	1,520
OVC_SERV_DSD	Sex: Male	1,322	760
OVC_SERV_DSD	Sex: Female	1,322	760
OVC_SERV_DSD	Sum of Sex disaggregates	2,644	1,520
OVC_SERV_DSD	Age: 15-17	2,644	1,520
OVC_SERV_DSD	Sum of Age disaggregates	2,644	1,520
OVC_SERV_TA	Number of active beneficiaries served by PEPFAR OVC programs for children and	0	0



	families affected by HIV/AIDS		
C2.1.D_DSD	Number of HIV-positive individuals receiving a minimum of one clinical service	0	0
C2.1.D_NA	Number of HIV-positive individuals receiving a minimum of one clinical service	0	0
C2.1.D_NGI	Number of HIV-positive individuals receiving a minimum of one clinical service	0	0
C2.1.D_TA	Number of HIV-positive individuals receiving a minimum of one clinical service	0	0
C2.4.D_DSD	Number of HIV-positive patients who were screened for TB in HIV care or treatment setting	0	0
C2.4.D_DSD	Number of HIV-positive individuals receiving a minimum of one clinical service	0	0
C2.5.D_DSD	Number of HIV-positive individuals receiving a minimum of one clinical service	0	0
CARE_CURR_DSD	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	0	0
CARE_CURR_TA	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	0	0
CARE_NEW_DSD	Number of HIV-infected adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load	0	0
CARE_SITE	Number of PEPFAR-supported HIV clinical care sites at which at least 80% of PLHIV received all of the following during the	0	



	reporting period: 1) clinical assessment (WHO staging) OR CD4 count OR viral load, AND 2) TB screening at last visit, AND 3) if eligible, cotrimoxazole		
CARE_SITE	Total number of PEPFAR supported sites providing clinical care services	0	0
FN_THER_DSD	Number of clinically malnourished PLHIV who received therapeutic and/or supplementary food during the reporting period.	0	0
FN_THER_DSD	Number of PLHIV who were nutritionally assessed and found to be clinically undernourished.	0	0
TB_ARTSITE	The number of PEPFAR-supported TB basic management units at which 80% of registered TB cases who are HIV-positive are on ART, during the reporting period	0	0
TB_ARTSITE	The number of PEPFAR-supported TB basic management units	0	0
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	0	0
PMTCT_EID_DSD	Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT)	0	0
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	0	0
TX_CURR_NA	Number of adults and children receiving antiretroviral therapy (ART)	0	0
TX_CURR_NGI	Number of adults and children receiving antiretroviral therapy (ART)	0	0
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	0	0
TX_DIST	Number of Districts with documented routine supportive supervision visits to 75% of HIV	0	0



	care and treatment sites supported by the District		
TX_DIST	Total number of PEPFAR supported District Health Offices	0	0
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	0	0
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	0	0
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	0	0
LAB_ACC_DSD	Number of PEPFAR-supported testing facilities (laboratories) that are recognized by national, regional, or international standards for accreditation or have achieved a minimal acceptable level towards attainment of such accreditation	0	0
LAB_PT_DSD	Percentage of laboratories and POC testing sites that perform HIV diagnostic testing that participate and successfully pass in an analyte-specific proficiency testing (PT) program	0	0
HRH_PRE	Number of new HCW who graduated from a pre-service training institution or program as a result of PEPFAR-supported strengthening efforts, within the reporting period, by select cadre	0	0
SC_TRAIN	Number of individuals who received competency-based, certificate or higher-level training to conduct or support supply chain, inventory management, supportive supervision or distribution activities	0	0



SC_TRAIN	Number of individuals who conduct or support supply chain, inventory management, supportive supervision or distribution activities	0	0
FPINT_SITE_DSD	Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	0	0
FPINT_SITE_DSD	Total number of PEPFAR-supported HIV service delivery points: PMTCT, Care and Treatment	0	0
QI_SITE	Number of PEPFAR-supported clinical service sites with a quality improvement activity completed that addresses clinical HIV programs and has documented process results in the last 6 months	0	0
QI_SITE	Total number of PEPFAR-supported sites for any HIV clinical service including HIV Care, HIV Treatment, TB care, PMTCT, VMMC, and HTC	0	0
SC_STOCK	Number of stock status observations for one or more tracer commodities that are between the designed minimum and maximum quantities/months of stock from storage sites within at a given level (Central, Regional, etc.) of the system.	0	0
SC_STOCK	Total number of stock status observations for one or more tracer commodities from storage sites within at a given level (Central, Regional, etc.) of the system	0	0
SI_HIS	Full national facility list coordinated with PEPFAR	1	1
SI_ME	Existence of a national HIV/AIDS M&E system based on the UNAIDS 12 components model	1	1
TB_SCREEN_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV	0	0



	care facility during the reporting period		
TB_SCREEN_DSD	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	0	0

Implementing Mechanism Details

Mechanism ID: 14022	Mechanism Name: APHIAplus Imarisha
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: African Medical and Research Foundation	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: No	
G2G: No	Managing Agency:

Total All Funding Sources: 4,599,545	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 400,000	
FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount
GHP-State	4,599,545

Sub Partner Name(s)

Broadreach	Catholic Relief Services	FHI 360
Land O'Lakes	University of Maryland Baltimore	

Cross-Cutting Budget Attribution(s)

Economic Strengthening	500,000
Gender: Gender Equality	500,000
Focus Area:	Changing harmful gender norms and promoting positive gender norms
Sub Area:	Collection and Use of Gender-related Strategic



	Information
Focus Area:	Promoting gender-related policies and laws that increase legal protection
Focus Area:	Increase gender-equitable access to income and productive resources, including education
Focus Area:	Equity in HIV prevention, care, treatment and support
Food and Nutrition: Policy, Tools, and Service Delivery	200,000
Water	200,000

Key Issues

- Malaria (PMI)
- Child Survival Activities
- Mobile Population
- Safe Motherhood
- TB
- Workplace Programs
- Family Planning

Budget Code Information

Mechanism ID:	14022		
Mechanism Name:	APHIaplus Imarisha		
Prime Partner Name:	African Medical and Research Foundation		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	200,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	1,170,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Care	HVTB	70,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	100,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	65,063	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVAB	137,819	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	600,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	896,663	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	1,200,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	160,000	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2014	2015
SITE_SUPP	Number of unique sites supported by PEPFAR	465	465
SITE_SUPP	By program area/support type: HTC Direct	0	0



	Service Delivery (DSD)		
SITE_SUPP	By program area/support type: HTC Technical Assistance-only (TA)	390	390
SITE_SUPP	By program area/support type: Treatment Direct Service Delivery (DSD)	66	66
SITE_SUPP	By program area/support type: Treatment Technical Assistance-only (TA)	0	0
SITE_SUPP	By program area/support type: Care and Support Direct Service Delivery (DSD)	77	77
SITE_SUPP	By program area/support type: Care and Support Technical Assistance-only (TA)	0	0
SITE_SUPP	By program area/support type: Food and Nutrition Direct Service Delivery (DSD)	80	80
SITE_SUPP	By program area/support type: Food and Nutrition Technical Assistance-only (TA)	50	50
SITE_SUPP	By program area/support type: PMTCT Direct Service Delivery (DSD)	388	388
SITE_SUPP	By program area/support type: PMTCT Technical Assistance-only (TA)	0	0
SITE_SUPP	By program area/support type: TB/HIV Direct Service Delivery (DSD)	0	0
SITE_SUPP	By program area/support type: TB/HIV Technical Assistance-only (TA)	85	85
SITE_SUPP	By program area/support type: VMMC Direct Service Delivery (DSD)	3	3
SITE_SUPP	By program area/support type: VMMC Technical Assistance-only (TA)	0	0
SITE_SUPP	By program area/support type: General Population Prevention Direct Service Delivery (DSD)	29	29
SITE_SUPP	By program area/support type: General Population Prevention Technical Assistance-only (TA)	0	0
SITE_SUPP	By program area/support type: Key	10	10



	Populations Prevention Direct Service Delivery (DSD)		
SITE_SUPP	By program area/support type: OVC Direct Service Delivery (DSD)	31	31
SITE_SUPP	By program area/support type: OVC Technical Assistance-only (TA)	0	0
SITE_SUPP	By program area/support type: PHDP/Family Planning & Integration Direct Service Delivery (DSD)	0	0
SITE_SUPP	By program area/support type: PHDP/Family Planning & Integration Technical Assistance-only (TA)	465	465
SITE_SUPP	By program area/support type: Lab Technical Assistance-only (TA)	390	390
PMTCT_ARV_DSD	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	635	648
PMTCT_ARV_DSD	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	668	682
PMTCT_ARV_DSD	Life-long ART (including Option B+)	312	318
PMTCT_ARV_DSD	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	254	259
PMTCT_ARV_DSD	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	58	59
PMTCT_ARV_DSD	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)	164	330
PMTCT_ARV_DSD	Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)	159	0
PMTCT_ARV_DSD	Single-dose nevirapine (with or without tail)	0	0



PMTCT_ARV_DSD	Sum of Regimen Type disaggregates	635	648
PMTCT_ARV_DSD	Sum of New and Current disaggregates	312	318
PMTCT_ARV_NA	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	0	0
PMTCT_ARV_NA	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	0	0
PMTCT_ARV_NGI	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	635	648
PMTCT_ARV_NGI	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	668	682
PMTCT_ARV_NGI	Life-long ART (including Option B+)	312	318
PMTCT_ARV_NGI	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	254	259
PMTCT_ARV_NGI	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	58	59
PMTCT_ARV_NGI	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)	164	330
PMTCT_ARV_NGI	Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)	159	0
PMTCT_ARV_NGI	Single-dose nevirapine (with or without tail)	0	0
PMTCT_ARV_NGI	Sum of Regimen disaggregates	635	648
PMTCT_ARV_NGI	Sum of New and Current disaggregates	312	318
PMTCT_ARV_TA	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during	0	0



	pregnancy and delivery		
PMTCT_ARV_TA	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	0	0
PMTCT_SITE	Number of PEPFAR-supported sites achieving 90% ARV or ART coverage for HIV+ pregnant women	370	370
PMTCT_SITE	Total number of PEPFAR supported sites providing PMTCT services (HTC and ARV or ART services)	388	388
PMTCT_SITE	By site support type: Direct Service Delivery (DSD): Number of PEPFAR-supported sites achieving 90% ARV or ART coverage for HIV+ pregnant women	370	370
PMTCT_SITE	By site support type: Technical Assistance-only (TA): Number of PEPFAR-supported sites achieving 90% ARV or ART coverage for HIV+ pregnant women	0	0
PMTCT_SITE	Sum of Numerator Support Type disaggregates	370	370
PMTCT_SITE	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR supported sites providing PMTCT services (HTC and ARV or ART services)	388	388
PMTCT_SITE	By site support type: Technical Assistance-only (TA): Total number of PEPFAR supported sites providing PMTCT services (HTC and ARV or ART services)	0	0
PMTCT_SITE	Sum of Denominator Support Type disaggregates	388	388
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	79,453	83,412
PMTCT_STAT_DSD	Number of new ANC and L&D clients	83,635	87,802
PMTCT_STAT_DSD	By: Known positives at entry	1,225	1,286



PMTCT_STAT_DSD	By: Number of new positives identified	2,748	2,885
PMTCT_STAT_DSD	Sum of Positives Status disaggregates	3,973	4,171
PMTCT_STAT_NA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	0	0
PMTCT_STAT_NA	Number of new ANC and L&D clients	0	0
PMTCT_STAT_NGI	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	79,453	83,412
PMTCT_STAT_NGI	Number of new ANC and L&D clients	83,635	87,802
PMTCT_STAT_NGI	By: Known positives at entry	1,225	1,286
PMTCT_STAT_NGI	By: Number of new positives identified	2,748	2,885
PMTCT_STAT_NGI	Sum of Positives Status disaggregates	3,973	4,171
BS_COLL	Number of whole blood collections each year by the NBTS network	0	0
KP_MAT_DSD	Number of people who inject drugs (PWID) on medication assisted therapy (MAT) for at least 6 months	0	0
VMMC_AE_DSD	Number of males circumcised surgically or by medical device that experienced at least one moderate or severe adverse event(s) (AEs)	6	6
VMMC_AE_DSD	By AE type: Number of VMMC clients with one or more moderate or severe surgical intra-operative AE(s)	0	0
VMMC_AE_DSD	Sub-Disag: Surgical intra-operative AE(s) by maximum severity category: Number of clients with one or more moderate surgical intra-operative AE(s), but no severe surgical intra-operative AE(s)	0	0
VMMC_AE_DSD	Sub-Disag: Surgical intra-operative AE(s) by maximum severity category: Number of clients with one or more severe surgical intra-operative AE(s)	0	0
VMMC_AE_DSD	By AE Type: Number of VMMC clients with	6	6



	one or more moderate or severe surgical post-operative AE(s)		
VMMC_AE_DSD	Sub-Disag: By Surgical post-operative AE(s) by maximum severity category: Number of clients with one or more moderate surgical post-operative AE(s), but no severe surgical post-operative AE(s)	6	6
VMMC_AE_DSD	Sub-Disag: By Surgical post-operative AE(s) by maximum severity category: Number of clients with one or more severe surgical intra-operative AE(s)	0	0
VMMC_AE_DSD	By AE Type: Number of VMMC clients with one or more moderate or severe medical device-related AE(s)	0	0
VMMC_AE_DSD	Sub-Disag: By Medical device-based AE(s) by maximum severity category: Number of clients with one or more moderate medical device-related AE(s), but no severe medical device-related AE(s)	0	0
VMMC_AE_DSD	Sub-Disag: By Medical device-based AE(s) by maximum severity category: Number of clients with one or more severe medical device-related AE(s)	0	0
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	1,083	1,083
VMMC_CIRC_DSD	By Age: <1	0	0
VMMC_CIRC_DSD	By Age: 1-9	74	74
VMMC_CIRC_DSD	By Age: 10-14	482	482
VMMC_CIRC_DSD	By Age: 15-19	425	425
VMMC_CIRC_DSD	By Age: 20-24	62	62
VMMC_CIRC_DSD	By Age: 25-49	40	40
VMMC_CIRC_DSD	By Age: 50+	0	0



VMMC_CIRC_DSD	Sum of age disaggregates	1,083	1,083
VMMC_CIRC_DSD	By HIV status: Number of HIV-positive clients (tested HIV positive at VMMC site)	5	5
VMMC_CIRC_DSD	By HIV status: Number of HIV-negative clients (tested HIV negative at VMMC program)	1,078	1,078
VMMC_CIRC_DSD	By HIV status: Number of clients with undocumented/indeterminate HIV status or not tested for HIV at site	0	0
VMMC_CIRC_DSD	By circumcision technique: Surgical VMMC	1,083	1,083
VMMC_CIRC_DSD	By circumcision technique: Device-based VMMC	0	0
VMMC_CIRC_DSD	By follow-up status: Number of surgically circumcised clients who returned at least once for follow-up care within 14 days of circumcision surgery	1,083	1,083
VMMC_CIRC_DSD	By follow-up status: Number of surgically circumcised clients who did NOT return for follow-up care within 14 days of circumcision surgery	0	0
VMMC_CIRC_NA	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	0	0
VMMC_CIRC_NGI	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	1,083	1,083
VMMC_CIRC_NGI	By Age: <1	0	0
VMMC_CIRC_NGI	By Age: 1-9	74	74
VMMC_CIRC_NGI	By Age: 10-14	482	482
VMMC_CIRC_NGI	By Age: 15-19	425	425
VMMC_CIRC_NGI	By Age: 20-24	62	62
VMMC_CIRC_NGI	By Age: 25-49	40	40
VMMC_CIRC_NGI	By Age: 50+	0	0



VMMC_CIRC_NGI	Sum of Age disaggregates	1,083	1,083
VMMC_CIRC_NGI	By HIV status: Number of HIV-positive clients (tested HIV positive at VMMC site)	5	5
VMMC_CIRC_NGI	By HIV status: Number of HIV-negative clients (tested HIV negative at VMMC program)	1,078	1,078
VMMC_CIRC_NGI	By HIV status: Number of clients with undocumented/indeterminate HIV status or not tested for HIV at site	0	0
VMMC_CIRC_NGI	By circumcision technique: Surgical VMMC	1,083	1,083
VMMC_CIRC_NGI	By circumcision technique: Device-based VMMC	0	0
VMMC_CIRC_NGI	By follow-up status: Number of surgically circumcised clients who returned at least once for follow-up care within 14 days of circumcision surgery	1,083	1,083
VMMC_CIRC_NGI	By follow-up status: Number of surgically circumcised clients who did NOT return for follow-up care within 14 days of circumcision surgery	0	0
VMMC_CIRC_TA	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	0	0
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	93,726	39,516
PP_PREV_DSD	Total number of people in the target population	153,308	153,308
PP_PREV_DSD	Age/sex: 10-14 Male	6,561	9,000
PP_PREV_DSD	Age/sex: 15-19 Male	7,123	0
PP_PREV_DSD	Age/sex: 20-24 Male	937	1,000
PP_PREV_DSD	Age/sex: 25-49 Male	3,917	1,575
PP_PREV_DSD	Age/sex: 50+ Male	207	0



PP_PREV_DSD	Age/sex: 10-14 Female	17,995	8,227
PP_PREV_DSD	Age/sex: 15-19 Female	1,500	9,714
PP_PREV_DSD	Age/sex: 20-24 Female	3,749	10,000
PP_PREV_DSD	Age/sex: 25-49 Female	49,150	0
PP_PREV_DSD	Age/sex: 50+ Female	2,587	0
PP_PREV_DSD	Sum of Age/Sex disaggregates	93,726	39,516
PP_PREV_TA	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	0	0
PP_PREV_TA	Total number of people in the target population	0	0
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	4,240	4,240
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	4,240	4,240
KP_PREV_DSD	By key population type: Males who inject drugs (Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0	0
KP_PREV_DSD	By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0	0



KP_PREV_DSD	By key population type: Men who have sex with men/Transgender (MSM/TG) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0	0
KP_PREV_DSD	By key population type: MSM/TG who are male sex workers (subset MSM/TG) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0	0
KP_PREV_TA	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	0	0
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	0	0
HTC_TST_NA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	0	0
HTC_TST_NGI	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	214,295	225,000
HTC_TST_NGI	By Test Result: Negative	205,723	216,000
HTC_TST_NGI	By Test Result: Positive	8,572	9,000
HTC_TST_NGI	Sum of Test Result disaggregates	214,295	225,000
HTC_TST_NGI	Age/sex: <1 Male	0	0
HTC_TST_NGI	Age/sex: 1-4 Male	7,500	7,875
HTC_TST_NGI	Age/sex: 5-9 Male	3,214	3,375
HTC_TST_NGI	Age/sex: 10-14 Male	5,357	5,625



HTC_TST_NGI	Age/sex: 15-19 Male	10,715	11,250
HTC_TST_NGI	Age/sex: 20-24 Male	26,787	28,125
HTC_TST_NGI	Age/sex: 25-49 Male	42,859	45,000
HTC_TST_NGI	Age/sex: 50+ Male	10,715	11,250
HTC_TST_NGI	Age/sex: <1 Female	0	0
HTC_TST_NGI	Age/sex: 1-4 Female	7,500	7,875
HTC_TST_NGI	Age/sex: 5-9 Female	3,214	3,375
HTC_TST_NGI	Age/sex: 10-14 Female	5,357	5,625
HTC_TST_NGI	Age/sex: 15-19 Female	10,715	11,250
HTC_TST_NGI	Age/sex: 20-24 Female	26,787	28,125
HTC_TST_NGI	Age/sex: 25-49 Female	42,859	45,000
HTC_TST_NGI	Age/sex: 50+ Female	10,716	11,250
HTC_TST_NGI	Sum of Age/Sex disaggregates	214,295	225,000
HTC_TST_NGI	Aggregated Age/sex: <15 Male	16,072	16,875
HTC_TST_NGI	Aggregated Age/sex: 15+ Male	91,075	95,625
HTC_TST_NGI	Aggregated Age/sex: <15 Female	16,072	16,875
HTC_TST_NGI	Aggregated Age/sex: 15+ Female	91,076	95,625
HTC_TST_NGI	Sum of Aggregated Age/Sex <15	32,144	33,750
HTC_TST_NGI	Sum of Aggregated Age/Sex 15+	182,151	191,250
HTC_TST_NGI	Sum of Aggregated Age/Sex disaggregates	214,295	225,000
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	214,295	225,000
HTC_TST_TA	By Test Result: Negative	205,723	216,000
HTC_TST_TA	By Test Result: Positive	8,572	9,000
HTC_TST_TA	Sum of Test Result disaggregates	214,295	225,000
HTC_TST_TA	Age/sex: <1 Male	0	0
HTC_TST_TA	Age/sex: 1-4 Male	7,500	7,875
HTC_TST_TA	Age/sex: 5-9 Male	3,214	3,375
HTC_TST_TA	Age/sex: 10-14 Male	5,357	5,625
HTC_TST_TA	Age/sex: 15-19 Male	10,715	11,250
HTC_TST_TA	Age/sex: 20-24 Male	26,787	28,125



HTC_TST_TA	Age/sex: 25-49 Male	42,859	45,000
HTC_TST_TA	Age/sex: 50+ Male	10,715	11,250
HTC_TST_TA	Age/sex: <1 Female	0	0
HTC_TST_TA	Age/sex: 1-4 Female	7,500	7,875
HTC_TST_TA	Age/sex: 5-9 Female	3,214	3,375
HTC_TST_TA	Age/sex: 10-14 Female	5,357	5,625
HTC_TST_TA	Age/sex: 15-19 Female	10,715	11,250
HTC_TST_TA	Age/sex: 20-24 Female	26,787	28,125
HTC_TST_TA	Age/sex: 25-49 Female	42,859	45,000
HTC_TST_TA	Age/sex: 50+ Female	10,716	11,250
HTC_TST_TA	Sum of Age/Sex disaggregates	214,295	225,000
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	16,072	16,875
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	91,075	95,625
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	16,072	16,875
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	91,076	95,625
HTC_TST_TA	Sum of Aggregated Age/Sex <15	32,144	33,750
HTC_TST_TA	Sum of Aggregated Age/Sex 15+	182,151	191,250
HTC_TST_TA	Sum of Aggregated Age/Sex disaggregates	214,295	225,000
GEND_GBV_DSD	Number of people receiving post-GBV care	268	268
GEND_GBV_DSD	Age: 0-9	0	0
GEND_GBV_DSD	Age: 10-14	0	0
GEND_GBV_DSD	Age: 15-17	0	0
GEND_GBV_DSD	Age: 18-24	0	0
GEND_GBV_DSD	Age: 25+	268	268
GEND_GBV_DSD	Sum of Age disaggregates	268	268
GEND_GBV_DSD	Sex: Male	96	96
GEND_GBV_DSD	Sex: Female	172	172
GEND_GBV_DSD	Sum of Sex disaggregates	268	268



GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	268	268
GEND_NORM_DSD	Number of people completing an intervention pertaining to gender norms, that meets minimum criteria	98,644	98,644
GEND_NORM_DSD	By Age: 0-9	0	0
GEND_NORM_DSD	By Age: 10-14	0	0
GEND_NORM_DSD	By Age: 15-19	0	0
GEND_NORM_DSD	By Age: 20-24	24,661	24,661
GEND_NORM_DSD	By Age: 25+	73,983	73,983
GEND_NORM_DSD	Sum of Age disaggregates	98,644	98,644
GEND_NORM_DSD	By Sex: Male	73,983	73,983
GEND_NORM_DSD	By Sex: Female	24,661	24,661
GEND_NORM_DSD	Sum of Sex disaggregates	98,644	98,644
OVC_ACC_DSD	Number of active beneficiaries receiving support from PEPFAR OVC programs to access HIV services	1,500	1,500
OVC_ACC_DSD	Sex: Male	799	799
OVC_ACC_DSD	Sex: Female	701	701
OVC_ACC_DSD	Sum of Sex disaggregates	1,500	1,500
OVC_ACC_DSD	Age: <1	75	75
OVC_ACC_DSD	Age: 1-4	150	150
OVC_ACC_DSD	Age: 5-9	300	300
OVC_ACC_DSD	Age: 10-14	450	450
OVC_ACC_DSD	Age: 15-17	450	450
OVC_ACC_DSD	Age: 18+	75	75
OVC_ACC_DSD	Sum of Age disaggregates	1,500	1,500
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	30,512	30,512
OVC_SERV_DSD	Sex: Male	16,233	16,233
OVC_SERV_DSD	Sex: Female	14,279	14,279
OVC_SERV_DSD	Sum of Sex disaggregates	30,512	30,512



OVC_SERV_DSD	Age: <1	0	0
OVC_SERV_DSD	Age: 1-4	4,500	4,500
OVC_SERV_DSD	Age: 5-9	6,000	6,000
OVC_SERV_DSD	Age: 10-14	9,512	9,512
OVC_SERV_DSD	Age: 15-17	9,000	9,000
OVC_SERV_DSD	Age: 18+	1,500	1,500
OVC_SERV_DSD	Sum of Age disaggregates	30,512	30,512
OVC_SERV_TA	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	0	0
C2.1.D_DSD	Number of HIV-positive individuals receiving a minimum of one clinical service	11,687	12,856
C2.1.D_DSD	By Age/Sex: <15 Female	517	569
C2.1.D_DSD	By Age/Sex: <15 Male	517	569
C2.1.D_DSD	By Age/Sex: 15+ Female	7,037	7,740
C2.1.D_DSD	By Age/Sex: 15+ Male	3,616	3,978
C2.1.D_DSD	Sum of Age/Sex disaggregates	11,687	12,856
C2.1.D_DSD	By Age: <15	1,034	1,138
C2.1.D_DSD	By Age: 15+	10,653	11,718
C2.1.D_DSD	Sum of Age disaggregates	11,687	12,856
C2.1.D_DSD	By Sex: Female	7,554	8,309
C2.1.D_DSD	By Sex: Male	4,133	4,547
C2.1.D_DSD	Sum of Sex disaggregates	11,687	12,856
C2.1.D_NA	Number of HIV-positive individuals receiving a minimum of one clinical service	0	0
C2.1.D_NGI	Number of HIV-positive individuals receiving a minimum of one clinical service	11,687	12,856
C2.1.D_NGI	By Age/Sex: <15 Female	517	569
C2.1.D_NGI	By Age/Sex: <15 Male	517	569
C2.1.D_NGI	By Age/Sex: 15+ Female	7,037	7,740
C2.1.D_NGI	By Age/Sex: 15+ Male	3,616	3,978
C2.1.D_NGI	Sum of Age/Sex disaggregates	11,687	12,856



C2.1.D_NGI	By Age: <15	1,034	1,138
C2.1.D_NGI	By Age: 15+	10,653	11,718
C2.1.D_NGI	Sum of Age disaggregates	11,687	12,856
C2.1.D_NGI	By Sex: Female	7,554	8,309
C2.1.D_NGI	By Sex: Male	4,133	4,547
C2.1.D_NGI	Sum of Sex disaggregates	11,687	12,856
C2.1.D_TA	Number of HIV-positive individuals receiving a minimum of one clinical service	0	0
C2.4.D_DSD	Number of HIV-positive patients who were screened for TB in HIV care or treatment setting	11,687	12,856
C2.4.D_DSD	Number of HIV-positive individuals receiving a minimum of one clinical service	11,687	12,856
C2.5.D_DSD	Number of HIV-positive patients in HIV care who started TB treatment	2,500	2,500
C2.5.D_DSD	Number of HIV-positive individuals receiving a minimum of one clinical service	11,687	12,856
CARE_CURR_DSD	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	11,687	12,856
CARE_CURR_DSD	Age/sex: <1 Male	52	57
CARE_CURR_DSD	Age/sex: 1-4 Male	52	57
CARE_CURR_DSD	Age/sex: 5-9 Male	103	114
CARE_CURR_DSD	Age/sex: 10-14 Male	310	341
CARE_CURR_DSD	Age/sex: 15-19 Male	542	597
CARE_CURR_DSD	Age/sex: 20-24 Male	1,085	1,193
CARE_CURR_DSD	Age/sex: 25-49 Male	1,446	1,591
CARE_CURR_DSD	Age/sex: 50+ Male	542	597
CARE_CURR_DSD	Age/sex: <1 Female	52	57
CARE_CURR_DSD	Age/sex: 1-4 Female	52	57
CARE_CURR_DSD	Age/sex: 5-9 Female	103	114



CARE_CURR_DSD	Age/sex: 10-14 Female	310	341
CARE_CURR_DSD	Age/sex: 15-19 Female	1,056	1,161
CARE_CURR_DSD	Age/sex: 20-24 Female	2,111	2,322
CARE_CURR_DSD	Age/sex: 25-49 Female	2,815	3,096
CARE_CURR_DSD	Age/sex: 50+ Female	1,056	1,161
CARE_CURR_DSD	Sun of Age/Sex disaggregates	11,687	12,856
CARE_CURR_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	517	569
CARE_CURR_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	3,616	3,978
CARE_CURR_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	517	569
CARE_CURR_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	7,037	7,740
CARE_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	11,687	12,856
CARE_CURR_TA	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	0	0
CARE_NEW_DSD	Number of HIV-infected adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load	2,337	2,338
CARE_NEW_DSD	Age/sex: <1 Male	11	11
CARE_NEW_DSD	Age/sex: 1-4 Male	11	11
CARE_NEW_DSD	Age/sex: 5-9 Male	21	21
CARE_NEW_DSD	Age/sex: 10-14 Male	64	64
CARE_NEW_DSD	Age/sex: 15-19 Male	111	112
CARE_NEW_DSD	Age/sex: 20-24 Male	223	224
CARE_NEW_DSD	Age/sex: 25-49 Male	297	299
CARE_NEW_DSD	Age/sex: 50+ Male	111	112



CARE_NEW_DSD	Age/sex: <1 Female	11	11
CARE_NEW_DSD	Age/sex: 1-4 Female	11	11
CARE_NEW_DSD	Age/sex: 5-9 Female	21	21
CARE_NEW_DSD	Age/sex: 10-14 Female	64	64
CARE_NEW_DSD	Age/sex: 15-19 Female	207	207
CARE_NEW_DSD	Age/sex: 20-24 Female	415	415
CARE_NEW_DSD	Age/sex: 25-49 Female	553	553
CARE_NEW_DSD	Age/sex: 50+ Female	207	207
CARE_NEW_DSD	Sum of Age/sex disaggregates	2,338	2,343
CARE_NEW_DSD	Aggregated Age/sex: <15 Male	106	106
CARE_NEW_DSD	Aggregated Age/sex: 15+ Male	743	743
CARE_NEW_DSD	Aggregated Age/sex: <15 Female	106	106
CARE_NEW_DSD	Aggregated Age/sex: 15+ Female	1,382	1,383
CARE_NEW_DSD	Sum of Aggregated Age/sex disaggregates	2,337	2,338
CARE_SITE	Number of PEPFAR-supported HIV clinical care sites at which at least 80% of PLHIV received all of the following during the reporting period: 1) clinical assessment (WHO staging) OR CD4 count OR viral load, AND 2) TB screening at last visit, AND 3) if eligible, cotrimoxazole	73	73
CARE_SITE	Total number of PEPFAR supported sites providing clinical care services	77	77
CARE_SITE	By site support type: Direct Service Delivery (DSD): Number of PEPFAR-supported HIV clinical care sites at which at least 80% of PLHIV received all of the following during the reporting period: 1) clinical assessment (WHO staging) OR CD4 count OR viral load, AND 2) TB screening at last visit, AND 3) if eligible, cotrimoxazole	73	73
CARE_SITE	By site support type: Technical Assistance-only (TA): Number of PEPFAR-supported HIV clinical care sites at	0	0



	which at least 80% of PLHIV received all of the following during the reporting period: 1) clinical assessment (WHO staging) OR CD4 count OR viral load, AND 2) TB screening at last visit, AND 3) if eligible, cotrimoxazole		
CARE_SITE	Sum of Numerator Site Support Type disaggregates	73	73
CARE_SITE	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR supported sites providing clinical care services	77	77
CARE_SITE	By site support type: Technical Assistance-only (TA): Total number of PEPFAR supported sites providing clinical care services	0	0
CARE_SITE	Sum of Denominator Site Support Type disaggregates	77	77
FN_SITE	Number of PEPFAR-supported sites achieving 90% nutrition assessments that result in accurate categorization of malnutrition	130	130
FN_SITE	Total number of PEPFAR-supported sites providing nutrition assessment, counseling and support (NACS) services	130	130
FN_SITE	By site support type: Direct Service Delivery (DSD): Number of PEPFAR-supported sites achieving 90% nutrition assessments that result in accurate categorization of malnutrition	80	80
FN_SITE	By site support type: Technical Assistance-only (TA): Number of PEPFAR-supported sites achieving 90% nutrition assessments that result in accurate categorization of malnutrition	50	50
FN_SITE	Sum of Numerator Support Type disaggregates	130	130
FN_SITE	By site support type: Direct Service Delivery	80	80

	(DSD): Total number of PEPFAR-supported sites providing nutrition assessment, counseling and support (NACS) services		
FN_SITE	By site support type: Technical Assistance-only (TA): Total number of PEPFAR-supported sites providing nutrition assessment, counseling and support (NACS) services	50	50
FN_SITE	Sum of Denominator Support Type disaggregates	130	130
FN_THER_DSD	Number of clinically malnourished PLHIV who received therapeutic and/or supplementary food during the reporting period.	0	0
FN_THER_DSD	Number of PLHIV who were nutritionally assessed and found to be clinically undernourished.	0	0
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	2,500	2,625
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	2,500	2,625
TB_ART_DSD	Age: 0-4	50	52
TB_ART_DSD	Age: 5-14	200	218
TB_ART_DSD	Age: 15+	2,250	2,355
TB_ART_DSD	Male	909	955
TB_ART_DSD	Female	1,591	1,670
TB_ART_DSD	Sum of Sex disaggregates	2,500	2,625
TB_ART_DSD	Newly tested	500	525
TB_ART_DSD	Known HIV-positive	2,000	2,100
TB_ART_DSD	Sum of Test Status disaggregates	2,500	2,625
TB_ART_DSD	Aggregated Age: <15	228	239



TB_ART_DSD	Aggregated Age: 15+	2,272	2,386
TB_ART_DSD	Sum of Aggregated Age disaggregates	2,500	2,625
TB_ARTSITE	The number of PEPFAR-supported TB basic management units at which 80% of registered TB cases who are HIV-positive are on ART, during the reporting period	47	48
TB_ARTSITE	The number of PEPFAR-supported TB basic management units	52	52
TB_ARTSITE	By site support type: Direct Service Delivery (DSD): The number of PEPFAR-supported TB basic management units at which 80% of registered TB cases who are HIV-positive are on ART, during the reporting period	0	0
TB_ARTSITE	By site support type: Technical Assistance-only (TA): The number of PEPFAR-supported TB basic management units at which 80% of registered TB cases who are HIV-positive are on ART, during the reporting period	47	48
TB_ARTSITE	Sum of Numerator Site Support Type disaggregates	47	48
TB_ARTSITE	By site support type: Direct Service Delivery (DSD): The number of PEPFAR-supported TB basic management units	0	0
TB_ARTSITE	By site support type: Technical Assistance-only (TA): The number of PEPFAR-supported TB basic management units	52	52
TB_ARTSITE	Sum of Denominator Site Support Type disaggregates	52	52
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	495	520
PMTCT_EID_DSD	Number of HIV- positive pregnant women identified during the reporting period (include	635	648



	known HIV-positive women at entry into PMTCT)		
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	347	364
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	148	156
PMTCT_EID_DSD	Sum of Infant Age disaggregates	495	520
PMTCT_EID_DSD	By infants with a positive virologic test result within 12 months of birth	25	26
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	8,532	9,700
TX_CURR_DSD	Age/Sex: <1 Male	26	29
TX_CURR_DSD	Age/Sex: 1-4 Male	94	106
TX_CURR_DSD	Age/Sex: 5-14 Male	286	325
TX_CURR_DSD	Age/Sex: 15+ Male	2,702	3,072
TX_CURR_DSD	Age/Sex: <1 Female	25	29
TX_CURR_DSD	Age/Sex: 1-4 Female	94	107
TX_CURR_DSD	Age/Sex: 5-14 Female	286	325
TX_CURR_DSD	Age/Sex: 15+ Female	5,019	5,707
TX_CURR_DSD	Sum of age/sex disaggregates	811	921
TX_CURR_DSD	Percent children with advanced HIV infection receiving antiretroviral therapy (ART) [CURRENT]	5	6
TX_CURR_DSD	Percent women and girls with advanced HIV infection receiving antiretroviral therapy (ART) [CURRENT]	64	63
TX_CURR_DSD	Aggregated Age/Sex: <1 Male	50	86
TX_CURR_DSD	Aggregated Age/Sex: <1 Female	40	82
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	404	595
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	2,699	2,976
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	416	603
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	5,013	5,526
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	820	1,198



TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	7,712	8,502
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	8,532	9,700
TX_CURR_NA	Number of adults and children receiving antiretroviral therapy (ART)	0	0
TX_CURR_NGI	Number of adults and children receiving antiretroviral therapy (ART)	8,532	9,700
TX_CURR_NGI	Aggregated Age/Sex: <1 Male	50	86
TX_CURR_NGI	Aggregated Age/Sex: <1 Female	40	82
TX_CURR_NGI	Aggregated Age/Sex: <15 Male	404	595
TX_CURR_NGI	Aggregated Age/Sex: 15+ Male	2,699	2,976
TX_CURR_NGI	Aggregated Age/Sex: <15 Female	416	603
TX_CURR_NGI	Aggregated Age/Sex: 15+ Female	5,013	5,526
TX_CURR_NGI	Sum of Aggregated Age/Sex disaggregates	8,532	9,700
TX_CURR_NGI	Sum of Aggregated Age/Sex <15	820	1,198
TX_CURR_NGI	Sum of Aggregated Age/Sex 15+	7,712	8,502
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	0	0
TX_DIST	Number of Districts with documented routine supportive supervision visits to 75% of HIV care and treatment sites supported by the District	43	43
TX_DIST	Total number of PEPFAR supported District Health Offices	43	43
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	1,736	1,736
TX_NEW_DSD	By Age/Sex: <1 Male	24	24
TX_NEW_DSD	By Age/Sex: 1-4 Male	19	19
TX_NEW_DSD	By Age/Sex: 5-9 Male	26	26
TX_NEW_DSD	By Age/Sex: 10-14 Male	21	21
TX_NEW_DSD	By Age/Sex: 15-19 Male	24	24
TX_NEW_DSD	By Age/Sex: 20-24 Male	57	57
TX_NEW_DSD	By Age/Sex: 25-49 Male	361	361
TX_NEW_DSD	By Age/Sex: 50+ Male	106	106



TX_NEW_DSD	By Age/Sex: <1 Female	28	28
TX_NEW_DSD	By Age/Sex: 1-4 Female	19	19
TX_NEW_DSD	By Age/Sex: 5-9 Female	30	30
TX_NEW_DSD	By Age/Sex: 10-14 Female	24	24
TX_NEW_DSD	By Age/Sex: 15-19 Female	49	49
TX_NEW_DSD	By Age/Sex: 20-24 Female	149	149
TX_NEW_DSD	By Age/Sex: 25-49 Female	672	672
TX_NEW_DSD	By Age/Sex: 50+ Female	127	127
TX_NEW_DSD	Sum of Age/Sex disaggregates	1,736	1,736
TX_NEW_DSD	Aggregated Grouping by Age: <1 Male	34	43
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	122	166
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	521	487
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <1 Female	40	50
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	126	178
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	967	905
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	1,736	1,736
TX_NEW_DSD	Pregnancy status	186	174
TX_NEW_DSD	Breastfeeding status	167	157
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	1,476	1,845
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	1,736	2,170
TX_RET_DSD	Age: 0-4 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	21	21
TX_RET_DSD	Age: 5-14 (Numerator: Number of adults and children who are still alive and on treatment at	16	16



	12 months after initiating ART)		
TX_RET_DSD	Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	22	22
TX_RET_DSD	Age: 0-4 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	18	18
TX_RET_DSD	Age: 5-14 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	21	21
TX_RET_DSD	Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	49	49
TX_RET_DSD	Aggregated Age: <15 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	24	24
TX_RET_DSD	Aggregated Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	16	16
TX_RET_DSD	Aggregated Age: <15 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	25	25
TX_RET_DSD	Aggregated Age: 15+ (Denominator: Total	21	21



	number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)		
TX_RET_DSD	Pregnancy and breastfeeding status (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	307	307
TX_RET_DSD	Pregnancy and breastfeeding status (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	90	90
TX_SITE	Number of PEPFAR-supported ART sites with a retention rate of 75% or greater for patients 12 months after ART initiation	63	63
TX_SITE	Total number of PEPFAR-supported ART sites	66	66
TX_SITE	By support type: Direct Service Delivery (DSD): Number of PEPFAR-supported ART sites with a retention rate of 75% or greater for patients 12 months after ART initiation	0	0
TX_SITE	By support type: Technical Assistance (TA-only): Number of PEPFAR-supported ART sites with a retention rate of 75% or greater for patients 12 months after ART initiation	63	63
TX_SITE	Sum of Numerator Site Support Type disaggregates	63	63
TX_SITE	By support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported ART sites	0	0



TX_SITE	By support type: Technical Assistance (TA-only): Total number of PEPFAR-supported ART sites	66	66
TX_SITE	Sum of Denominator Site Support Type disaggregates	66	66
LAB_ACC_DSD	Number of PEPFAR-supported testing facilities (laboratories) that are recognized by national, regional, or international standards for accreditation or have achieved a minimal acceptable level towards attainment of such accreditation	0	0
LAB_CAP_DSD	Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests	390	390
LAB_CAP_DSD	By Point-of-care testing sites	390	390
LAB_CAP_DSD	By site support type: Technical Assistance-only (TA)	390	390
LAB_CAP_DSD	Sum of Site Support Type disaggregates	390	390
LAB_PT_DSD	Percentage of laboratories and POC testing sites that perform HIV diagnostic testing that participate and successfully pass in an analyte-specific proficiency testing (PT) program	0	0
HRH_PRE	Number of new HCW who graduated from a pre-service training institution or program as a result of PEPFAR-supported strengthening efforts, within the reporting period, by select cadre	0	0
SC_TRAIN	Number of individuals who received competency-based, certificate or higher-level training to conduct or support supply chain, inventory management, supportive supervision or distribution activities	0	0
SC_TRAIN	Number of individuals who conduct or support supply chain, inventory management,	0	0



	supportive supervision or distribution activities		
FPINT_SITE_DSD	Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	465	465
FPINT_SITE_DSD	Total number of PEPFAR-supported HIV service delivery points: PMTCT, Care and Treatment	465	465
FPINT_SITE_DSD	By site support type: Direct Service Delivery (DSD): Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	31	31
FPINT_SITE_DSD	By site support type: Technical Assistance-only (TA): Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	434	434
FPINT_SITE_DSD	Sum of Numerator Site Support Type disaggregates	465	465
FPINT_SITE_DSD	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported HIV service delivery points	31	31
FPINT_SITE_DSD	By site support type: Technical Assistance-only (TA): Total number of PEPFAR-supported HIV service delivery points	434	434
FPINT_SITE_DSD	Sum of Denominator Site Support Type disaggregates	465	465
FPINT_SITE_DSD	Service delivery type: Community	75	75
FPINT_SITE_DSD	Service delivery type: Clinical	390	390
FPINT_SITE_DSD	Sum of Service Delivery Type disaggregates	465	465
QI_SITE	Number of PEPFAR-supported clinical service sites with a quality improvement activity completed that addresses clinical HIV	55	56



	programs and has documented process results in the last 6 months		
QI_SITE	Total number of PEPFAR-supported sites for any HIV clinical service including HIV Care, HIV Treatment, TB care, PMTCT, VMMC, and HTC	390	390
QI_SITE	By site support type: Direct Service Delivery (DSD): Number of PEPFAR-supported clinical service sites with a quality improvement activity completed that addresses clinical HIV programs and has documented results in the last 6 months	0	0
QI_SITE	By site support type: Technical Assistance-only (TA): Number of PEPFAR-supported clinical service sites with a quality improvement activity completed that addresses clinical HIV programs and has documented results in the last 6 months	55	56
QI_SITE	Sum of Numerator Site Support Type disaggregates	55	56
QI_SITE	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported sites for any HIV clinical service including HIV Care, HIV Treatment, TB care, PMTCT, VMMC, HTC	0	0
QI_SITE	By site support type: Technical Assistance-only (TA): Total number of PEPFAR-supported sites for any HIV clinical service including HIV Care, HIV Treatment, TB care, PMTCT, VMMC, and HTC	390	390
QI_SITE	Sum of Denominator Site Support Type disaggregates	390	390
SI_HIS	Full national facility list coordinated with PEPFAR	1	1
SI_ME	Existence of a national HIV/AIDS M&E system	1	1



	based on the UNAIDS 12 components model		
TB_SCREEN_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period	9,350	10,285
TB_SCREEN_DSD	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	11,687	12,856
TB_SCREEN_DSD	Age: <1	26	28
TB_SCREEN_DSD	Age: 1-4	59	65
TB_SCREEN_DSD	Age: 5-9	170	187
TB_SCREEN_DSD	Age: 10-14	596	655
TB_SCREEN_DSD	Age: 15-19	850	935
TB_SCREEN_DSD	Age: 20-24	1,699	1,869
TB_SCREEN_DSD	Age: 25-49	5,099	5,609
TB_SCREEN_DSD	Age: 50+	851	937
TB_SCREEN_DSD	Sum of Age disaggregates	1,701	1,870
TB_SCREEN_DSD	Aggregated Age - USE WITH HQ PERMISSION ONLY: <15	851	936
TB_SCREEN_DSD	Aggregated Age - USE WITH HQ PERMISSION ONLY: 15+	8,499	9,349
TB_SCREEN_DSD	Sum of Aggregated Age disaggregates	9,350	10,285
TB_SCREEN_DSD	Sex: Male	3,400	3,740
TB_SCREEN_DSD	Sex: Female	5,950	6,545
TB_SCREEN_DSD	Sum of Sex disaggregates	9,350	10,285

Implementing Mechanism Details

Mechanism ID: 14015	Mechanism Name: FUNZO Kenya
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: IntraHealth International, Inc	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No

Approved



Global Fund / Multilateral Engagement: No	
G2G: No	Managing Agency:
Total All Funding Sources: 5,078,460	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 0	
FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount
GHP-State	5,078,460

Sub Partner Name(s)

Moi University	Results for Development	University of North Carolina (UNC)
----------------	-------------------------	------------------------------------

Cross-Cutting Budget Attribution(s)

Human Resources for Health	3,000,000
Education	500,000

Key Issues

End-of-Program Evaluation

Budget Code Information

Mechanism ID:	14015		
Mechanism Name:	FUNZO Kenya		
Prime Partner Name:	IntraHealth International, Inc		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	866,775	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Care	HVTB	229,559	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	300,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	300,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	184,859	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	150,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	2,849,074	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	198,193	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2014	2015
HRH_PRE	Number of new HCW who graduated from a pre-service training institution or program as a result of PEPFAR-supported strengthening efforts, within the reporting period, by select cadre	130	714
HRH_PRE	By Graduates: Nurses	86	223
HRH_PRE	By Graduates: Laboratory professionals	44	104
HRH_PRE	By Graduates: Other	127	387
HRH_PRE	Sum of Graduates disaggreagtes	257	714



SC_TRAIN	Number of individuals who received competency-based, certificate or higher-level training to conduct or support supply chain, inventory management, supportive supervision or distribution activities	60	60
SC_TRAIN	Number of individuals who conduct or support supply chain, inventory management, supportive supervision or distribution activities	7,280	7,280

Implementing Mechanism Details

Mechanism ID: 14012	Mechanism Name: AMPATHplus
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Moi Teaching and Referral Hospital	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: No	
G2G: Yes	Managing Agency: USAID

Total All Funding Sources: 11,078,596	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 2,100,375	
FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount
GHP-State	11,078,596

Sub Partner Name(s)

Indiana University	Moi University	
--------------------	----------------	--

Cross-Cutting Budget Attribution(s)

Human Resources for Health	97,615
Food and Nutrition: Policy, Tools, and Service Delivery	33,598
Key Populations: MSM and TG	69,767



Focus Area:	Training of health workers and community outreach workers
Focus Area:	Implementation of core HIV prevention interventions for MSM/TG that are consistent with the current PEPFAR technical guidance
Focus Area:	Collection and use of strategic information
Focus Area:	Conducting epidemiologic, social science, and operational research among MSM/TG and their sex partners
Economic Strengthening	97,615
Key Populations: FSW	69,767
Focus Area:	Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Collection and use of strategic information on SWs and clients
Focus Area:	Conducting epidemiologic, social science, and operational research among SWs, their partners, and clients
Focus Area:	Monitoring and evaluation of SW programs
Focus Area:	Procurement of condoms, lubricants, and other commodities essential to core HIV services for SWs
Gender: Gender Equality	10,000
Focus Area:	Changing harmful gender norms and promoting positive gender norms
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Sub Area:	Operation Research
Focus Area:	Promoting gender-related policies and laws that



	increase legal protection
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Sub Area:	Operation Research
Focus Area:	Increase gender-equitable access to income and productive resources, including education
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Sub Area:	Operation Research
Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Sub Area:	Operation Research
Education	1,176,000

Key Issues

(No data provided.)

Budget Code Information

Mechanism ID: 14012



Mechanism Name: AMPATHplus			
Prime Partner Name: Moi Teaching and Referral Hospital			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	1,000,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	1,000,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	660,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	400,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	300,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVAB	33,596	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	500,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	185,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	5,000,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Treatment	PDTX	2,000,000	0
-----------	------	-----------	---

Implementing Mechanism Indicator Information

Indicator Number	Label	2014	2015
SITE_SUPP	Number of unique sites supported by PEPFAR	362	362
SITE_SUPP	By program area/support type: HTC Direct Service Delivery (DSD)	212	212
SITE_SUPP	By program area/support type: HTC Technical Assistance-only (TA)	148	148
SITE_SUPP	By program area/support type: Treatment Direct Service Delivery (DSD)	75	104
SITE_SUPP	By program area/support type: Treatment Technical Assistance-only (TA)	3	4
SITE_SUPP	By program area/support type: Care and Support Direct Service Delivery (DSD)	75	104
SITE_SUPP	By program area/support type: Care and Support Technical Assistance-only (TA)	3	4
SITE_SUPP	By program area/support type: Food and Nutrition Direct Service Delivery (DSD)	31	31
SITE_SUPP	By program area/support type: Food and Nutrition Technical Assistance-only (TA)	0	0
SITE_SUPP	By program area/support type: PMTCT Direct Service Delivery (DSD)	359	359
SITE_SUPP	By program area/support type: PMTCT Technical Assistance-only (TA)	3	3
SITE_SUPP	By program area/support type: TB/HIV Direct Service Delivery (DSD)	78	108
SITE_SUPP	By program area/support type: TB/HIV Technical Assistance-only (TA)	0	0
SITE_SUPP	By program area/support type: VMMC Direct Service Delivery (DSD)	0	0



SITE_SUPP	By program area/support type: VMMC Technical Assistance-only (TA)	0	0
SITE_SUPP	By program area/support type: General Population Prevention Direct Service Delivery (DSD)	118	118
SITE_SUPP	By program area/support type: General Population Prevention Technical Assistance-only (TA)	4	4
SITE_SUPP	By program area/support type: Key Populations Prevention Direct Service Delivery (DSD)	3	3
SITE_SUPP	By program area/support type: Key Populations Prevention Technical Assistance-only (TA)	0	0
SITE_SUPP	By program area/support type: OVC Direct Service Delivery (DSD)	32	32
SITE_SUPP	By program area/support type: OVC Technical Assistance-only (TA)	0	0
SITE_SUPP	By program area/support type: PHDP/Family Planning & Integration Direct Service Delivery (DSD)	75	104
SITE_SUPP	By program area/support type: PHDP/Family Planning & Integration Technical Assistance-only (TA)	3	4
SITE_SUPP	By program area/support type: Lab Direct Service Delivery (DSD)	98	98
SITE_SUPP	By program area/support type: Lab Technical Assistance-only (TA)	0	0
PMTCT_ARV_DSD	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	6,764	5,535
PMTCT_ARV_DSD	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	6,764	5,535



PMTCT_ARV_DSD	Life-long ART (including Option B+)	6,764	5,535
PMTCT_ARV_DSD	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	3,282	2,762
PMTCT_ARV_DSD	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	3,482	2,773
PMTCT_ARV_DSD	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)	0	0
PMTCT_ARV_DSD	Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)	0	0
PMTCT_ARV_DSD	Single-dose nevirapine (with or without tail)	0	0
PMTCT_ARV_DSD	Sum of Regimen Type disaggregates	6,764	5,535
PMTCT_ARV_DSD	Sum of New and Current disaggregates	6,764	5,535
PMTCT_ARV_NA	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	0	0
PMTCT_ARV_NA	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	0	0
PMTCT_ARV_NA	Life-long ART (including Option B+)	0	0
PMTCT_ARV_NA	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	0	0
PMTCT_ARV_NA	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	0	0
PMTCT_ARV_NA	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)	0	0
PMTCT_ARV_NA	Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)	0	0



PMTCT_ARV_NA	Single-dose nevirapine (with or without tail)	0	0
PMTCT_ARV_NA	Sum of Regimen disaggregates	0	0
PMTCT_ARV_NA	Sum of New and Current disaggregates	0	0
PMTCT_ARV_NGI	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	6,764	5,535
PMTCT_ARV_NGI	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	6,764	5,535
PMTCT_ARV_NGI	Life-long ART (including Option B+)	6,764	5,535
PMTCT_ARV_NGI	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	3,282	2,762
PMTCT_ARV_NGI	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	3,482	2,773
PMTCT_ARV_NGI	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)	0	0
PMTCT_ARV_NGI	Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)	0	0
PMTCT_ARV_NGI	Single-dose nevirapine (with or without tail)	0	0
PMTCT_ARV_NGI	Sum of Regimen disaggregates	6,764	5,535
PMTCT_ARV_NGI	Sum of New and Current disaggregates	6,764	5,535
PMTCT_ARV_TA	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	24	100
PMTCT_ARV_TA	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	25	108
PMTCT_ARV_TA	Life-long ART (including Option B+)	24	100
PMTCT_ARV_TA	Sub-Disag of Life-long ART: Newly initiated on	3	2



	treatment during the current pregnancy		
PMTCT_ARV_TA	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	21	98
PMTCT_ARV_TA	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)	0	0
PMTCT_ARV_TA	Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)	0	0
PMTCT_ARV_TA	Sum of Regimen Type disaggregates	24	100
PMTCT_ARV_TA	Sum of New and Current disaggregates	24	100
PMTCT_SITE	Number of PEPFAR-supported sites achieving 90% ARV or ART coverage for HIV+ pregnant women	78	108
PMTCT_SITE	Total number of PEPFAR supported sites providing PMTCT services (HTC and ARV or ART services)	362	362
PMTCT_SITE	By site support type: Direct Service Delivery (DSD): Number of PEPFAR-supported sites achieving 90% ARV or ART coverage for HIV+ pregnant women	34	104
PMTCT_SITE	By site support type: Technical Assistance-only (TA): Number of PEPFAR-supported sites achieving 90% ARV or ART coverage for HIV+ pregnant women	44	4
PMTCT_SITE	Sum of Numerator Support Type disaggregates	78	108
PMTCT_SITE	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR supported sites providing PMTCT services (HTC and ARV or ART services)	362	362
PMTCT_SITE	Sum of Denominator Support Type disaggregates	362	362
PMTCT_STAT_DSD	Number of pregnant women with known HIV	131,770	106,080



	status (includes women who were tested for HIV and received their results)		
PMTCT_STAT_DSD	Number of new ANC and L&D clients	131,770	106,080
PMTCT_STAT_DSD	By: Known positives at entry	3,482	2,762
PMTCT_STAT_DSD	By: Number of new positives identified	3,282	2,773
PMTCT_STAT_DSD	Sum of Positives Status disaggregates	6,764	5,535
PMTCT_STAT_NA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	0	0
PMTCT_STAT_NA	Number of new ANC and L&D clients	0	0
PMTCT_STAT_NA	By: Known positives at entry	0	0
PMTCT_STAT_NA	By: Number of new positives identified	0	0
PMTCT_STAT_NA	Sum of Positives Status disaggregates	0	0
PMTCT_STAT_NGI	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	131,770	106,080
PMTCT_STAT_NGI	Number of new ANC and L&D clients	131,770	106,080
PMTCT_STAT_NGI	By: Known positives at entry	3,482	2,762
PMTCT_STAT_NGI	By: Number of new positives identified	3,282	2,773
PMTCT_STAT_NGI	Sum of Positives Status disaggregates	6,764	5,535
BS_COLL	Number of whole blood collections each year by the NBTS network	0	0
BS_COLL	By: Number of whole blood donations screened for HIV in an NBTS network laboratory	0	0
BS_COLL	By: Number of whole blood donations screened for HIV in an NBTS network laboratory that are identified as reactive for HIV	0	0
KP_MAT_DSD	Number of people who inject drugs (PWID) on medication assisted therapy (MAT) for at least 6 months	0	0
VMMC_AE_DSD	Number of males circumcised surgically or by medical device that experienced at least one	0	0



	moderate or severe adverse event(s) (AEs)		
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	0	0
VMMC_CIRC_NA	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	0	0
VMMC_CIRC_NGI	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	0	0
VMMC_CIRC_TA	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	0	0
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	12,236	12,236
PP_PREV_DSD	Total number of people in the target population	47,471	47,471
PP_PREV_DSD	Age/sex: 10-14 Male	2,100	2,100
PP_PREV_DSD	Age/sex: 15-19 Male	0	0
PP_PREV_DSD	Age/sex: 20-24 Male	1,750	1,750
PP_PREV_DSD	Age/sex: 25-49 Male	2,000	2,000
PP_PREV_DSD	Age/sex: 50+ Male	0	0
PP_PREV_DSD	Age/sex: 10-14 Female	2,100	2,100
PP_PREV_DSD	Age/sex: 15-19 Female	2,143	2,143
PP_PREV_DSD	Age/sex: 20-24 Female	2,143	2,143
PP_PREV_DSD	Age/sex: 25-49 Female	0	0
PP_PREV_DSD	Age/sex: 50+ Female	0	0
PP_PREV_DSD	Sum of Age/Sex disaggregates	12,236	12,236



PP_PREV_TA	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	0	0
PP_PREV_TA	Total number of people in the target population	0	0
PP_PREV_TA	Age/sex: 10-14 Male	0	0
PP_PREV_TA	Age/sex: 15-19 Male	0	0
PP_PREV_TA	Age/sex: 20-24 Male	0	0
PP_PREV_TA	Age/sex: 25-49 Male	0	0
PP_PREV_TA	Age/sex: 50+ Male	0	0
PP_PREV_TA	Age/sex: 10-14 Female	0	0
PP_PREV_TA	Age/sex: 15-19 Female	0	0
PP_PREV_TA	Age/sex: 20-24 Female	0	0
PP_PREV_TA	Age/sex: 25-49 Female	0	0
PP_PREV_TA	Age/sex: 50+ Female	0	0
PP_PREV_TA	Sum of Age/Sex disaggregates	0	0
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	149	149
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	149	149
KP_PREV_DSD	By key population type: Males who inject drugs (Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0	0



KP_PREV_DSD	By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0	0
KP_PREV_DSD	By key population type: Men who have sex with men/Transgender (MSM/TG) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0	0
KP_PREV_DSD	By key population type: MSM/TG who are male sex workers (subset MSM/TG) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0	0
KP_PREV_TA	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	0	0
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	168,000	120,631
HTC_TST_DSD	By Test Result: Negative	161,280	115,806
HTC_TST_DSD	By Test Result: Positive	6,720	4,825
HTC_TST_DSD	Sum of Test Result disaggregates	168,000	120,631
HTC_TST_DSD	Age/sex: <1 Male	0	0
HTC_TST_DSD	Age/sex: 1-4 Male	5,880	4,222
HTC_TST_DSD	Age/sex: 5-9 Male	2,520	1,809
HTC_TST_DSD	Age/sex: 10-14 Male	4,200	3,016



HTC_TST_DSD	Age/sex: 15-19 Male	8,400	6,032
HTC_TST_DSD	Age/sex: 20-24 Male	21,000	15,079
HTC_TST_DSD	Age/sex: 25-49 Male	33,600	24,126
HTC_TST_DSD	Age/sex: 50+ Male	8,400	6,032
HTC_TST_DSD	Age/sex: <1 Female	0	0
HTC_TST_DSD	Age/sex: 1-4 Female	5,880	4,222
HTC_TST_DSD	Age/sex: 5-9 Female	2,520	1,809
HTC_TST_DSD	Age/sex: 10-14 Female	4,200	3,016
HTC_TST_DSD	Age/sex: 15-19 Female	8,400	6,032
HTC_TST_DSD	Age/sex: 20-24 Female	21,000	15,079
HTC_TST_DSD	Age/sex: 25-49 Female	33,600	24,126
HTC_TST_DSD	Age/sex: 50+ Female	8,400	6,031
HTC_TST_DSD	Sum of Age/Sex disaggregates	168,000	120,631
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	12,600	9,047
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	71,400	51,268
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	12,600	9,048
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	71,400	51,268
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	25,200	18,095
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	142,800	102,536
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	168,000	120,631
HTC_TST_NA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	0	0
HTC_TST_NGI	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	240,000	172,330
HTC_TST_NGI	By Test Result: Negative	230,400	165,437
HTC_TST_NGI	By Test Result: Positive	9,600	6,893
HTC_TST_NGI	Sum of Test Result disaggregates	240,000	172,330



HTC_TST_NGI	Age/sex: <1 Male	0	0
HTC_TST_NGI	Age/sex: 1-4 Male	8,400	6,032
HTC_TST_NGI	Age/sex: 5-9 Male	3,600	2,585
HTC_TST_NGI	Age/sex: 10-14 Male	6,000	4,308
HTC_TST_NGI	Age/sex: 15-19 Male	12,000	8,617
HTC_TST_NGI	Age/sex: 20-24 Male	30,000	21,541
HTC_TST_NGI	Age/sex: 25-49 Male	48,000	34,466
HTC_TST_NGI	Age/sex: 50+ Male	12,000	8,617
HTC_TST_NGI	Age/sex: <1 Female	0	0
HTC_TST_NGI	Age/sex: 1-4 Female	8,400	6,032
HTC_TST_NGI	Age/sex: 5-9 Female	3,600	2,585
HTC_TST_NGI	Age/sex: 10-14 Female	6,000	4,308
HTC_TST_NGI	Age/sex: 15-19 Female	12,000	8,617
HTC_TST_NGI	Age/sex: 20-24 Female	30,000	21,541
HTC_TST_NGI	Age/sex: 25-49 Female	48,000	34,466
HTC_TST_NGI	Age/sex: 50+ Female	12,000	8,615
HTC_TST_NGI	Sum of Age/Sex disaggregates	240,000	172,330
HTC_TST_NGI	Aggregated Age/sex: <15 Male	18,000	12,925
HTC_TST_NGI	Aggregated Age/sex: 15+ Male	102,000	73,240
HTC_TST_NGI	Aggregated Age/sex: <15 Female	18,000	12,925
HTC_TST_NGI	Aggregated Age/sex: 15+ Female	102,000	73,240
HTC_TST_NGI	Sum of Aggregated Age/Sex <15	36,000	25,850
HTC_TST_NGI	Sum of Aggregated Age/Sex 15+	204,000	146,480
HTC_TST_NGI	Sum of Aggregated Age/Sex disaggregates	240,000	172,330
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	72,000	51,699
HTC_TST_TA	By Test Result: Negative	69,120	49,631
HTC_TST_TA	By Test Result: Positive	2,880	2,068
HTC_TST_TA	Sum of Test Result disaggregates	72,000	51,699
HTC_TST_TA	Age/sex: <1 Male	0	0
HTC_TST_TA	Age/sex: 1-4 Male	2,520	1,809



HTC_TST_TA	Age/sex: 5-9 Male	1,080	775
HTC_TST_TA	Age/sex: 10-14 Male	1,800	1,292
HTC_TST_TA	Age/sex: 15-19 Male	3,600	2,585
HTC_TST_TA	Age/sex: 20-24 Male	9,000	6,462
HTC_TST_TA	Age/sex: 25-49 Male	14,400	10,340
HTC_TST_TA	Age/sex: 50+ Male	3,600	2,585
HTC_TST_TA	Age/sex: <1 Female	0	0
HTC_TST_TA	Age/sex: 1-4 Female	2,520	1,809
HTC_TST_TA	Age/sex: 5-9 Female	1,080	775
HTC_TST_TA	Age/sex: 10-14 Female	1,800	1,294
HTC_TST_TA	Age/sex: 15-19 Female	3,600	2,585
HTC_TST_TA	Age/sex: 20-24 Female	9,000	6,462
HTC_TST_TA	Age/sex: 25-49 Female	14,400	10,340
HTC_TST_TA	Age/sex: 50+ Female	3,600	2,586
HTC_TST_TA	Sum of Age/Sex disaggregates	72,000	51,699
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	5,400	3,877
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	30,600	21,972
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	5,400	3,878
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	30,600	21,972
HTC_TST_TA	Sum of Aggregated Age/Sex <15	10,800	7,755
HTC_TST_TA	Sum of Aggregated Age/Sex 15+	61,200	43,944
HTC_TST_TA	Sum of Aggregated Age/Sex disaggregates	72,000	51,699
GEND_GBV_DSD	Number of people receiving post-GBV care	16	16
GEND_GBV_DSD	Age: 0-9	0	0
GEND_GBV_DSD	Age: 10-14	16	16
GEND_GBV_DSD	Age: 15-17	0	0
GEND_GBV_DSD	Age: 18-24	0	0
GEND_GBV_DSD	Age: 25+	0	0



GEND_GBV_DSD	Sum of Age disaggregates	16	16
GEND_GBV_DSD	Sex: Male	0	0
GEND_GBV_DSD	Sex: Female	16	16
GEND_GBV_DSD	Sum of Sex disaggregates	16	16
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	16	16
GEND_NORM_DSD	Number of people completing an intervention pertaining to gender norms, that meets minimum criteria	1,049	1,049
GEND_NORM_DSD	By Age: 0-9	0	0
GEND_NORM_DSD	By Age: 10-14	0	0
GEND_NORM_DSD	By Age: 15-19	0	0
GEND_NORM_DSD	By Age: 20-24	262	262
GEND_NORM_DSD	By Age: 25+	787	787
GEND_NORM_DSD	Sum of Age disaggregates	1,049	1,049
GEND_NORM_DSD	By Sex: Male	787	787
GEND_NORM_DSD	By Sex: Female	262	262
GEND_NORM_DSD	Sum of Sex disaggregates	1,049	1,049
OVC_ACC_DSD	Number of active beneficiaries receiving support from PEPFAR OVC programs to access HIV services	3,442	3,641
OVC_ACC_DSD	Sex: Male	1,692	1,784
OVC_ACC_DSD	Sex: Female	1,750	1,857
OVC_ACC_DSD	Sum of Sex disaggregates	3,442	3,641
OVC_ACC_DSD	Age: <1	10	11
OVC_ACC_DSD	Age: 1-4	480	506
OVC_ACC_DSD	Age: 5-9	1,209	1,283
OVC_ACC_DSD	Age: 10-14	998	1,054
OVC_ACC_DSD	Age: 15-17	388	410
OVC_ACC_DSD	Age: 18+	357	377
OVC_ACC_DSD	Sum of Age disaggregates	3,442	3,641
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and	29,000	29,000



	families affected by HIV/AIDS		
OVC_SERV_DSD	Sex: Male	14,984	13,483
OVC_SERV_DSD	Sex: Female	14,016	15,517
OVC_SERV_DSD	Sum of Sex disaggregates	29,000	29,000
OVC_SERV_DSD	Age: <1	80	85
OVC_SERV_DSD	Age: 1-4	845	812
OVC_SERV_DSD	Age: 5-9	3,274	3,040
OVC_SERV_DSD	Age: 10-14	10,665	10,112
OVC_SERV_DSD	Age: 15-17	4,471	4,750
OVC_SERV_DSD	Age: 18+	9,665	10,201
OVC_SERV_DSD	Sum of Age disaggregates	29,000	29,000
OVC_SERV_TA	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	0	0
C2.1.D_DSD	Number of HIV-positive individuals receiving a minimum of one clinical service	87,572	99,959
C2.1.D_DSD	By Age/Sex: <15 Female	4,378	4,998
C2.1.D_DSD	By Age/Sex: <15 Male	4,379	4,997
C2.1.D_DSD	By Age/Sex: 15+ Female	47,290	53,978
C2.1.D_DSD	By Age/Sex: 15+ Male	31,525	35,986
C2.1.D_DSD	Sum of Age/Sex disaggregates	87,572	99,959
C2.1.D_DSD	By Age: <15	8,757	9,996
C2.1.D_DSD	By Age: 15+	78,815	89,963
C2.1.D_DSD	Sum of Age disaggregates	87,572	99,959
C2.1.D_DSD	By Sex: Female	51,667	58,976
C2.1.D_DSD	By Sex: Male	35,905	40,983
C2.1.D_DSD	Sum of Sex disaggregates	87,572	99,959
C2.1.D_NA	Number of HIV-positive individuals receiving a minimum of one clinical service	0	0
C2.1.D_NGI	Number of HIV-positive individuals receiving a minimum of one clinical service	91,221	104,124
C2.1.D_NGI	By Age/Sex: <15 Female	4,561	5,206



C2.1.D_NGI	By Age/Sex: <15 Male	4,561	5,206
C2.1.D_NGI	By Age/Sex: 15+ Female	49,259	56,227
C2.1.D_NGI	By Age/Sex: 15+ Male	32,840	37,485
C2.1.D_NGI	Sum of Age/Sex disaggregates	91,221	104,124
C2.1.D_NGI	By Age: <15	9,122	10,412
C2.1.D_NGI	By Age: 15+	82,099	93,712
C2.1.D_NGI	Sum of Age disaggregates	91,221	104,124
C2.1.D_NGI	By Sex: Female	53,820	61,433
C2.1.D_NGI	By Sex: Male	37,401	42,691
C2.1.D_NGI	Sum of Sex disaggregates	91,221	104,124
C2.1.D_TA	Number of HIV-positive individuals receiving a minimum of one clinical service	3,649	4,165
C2.1.D_TA	By Age/Sex: <15 Female	182	208
C2.1.D_TA	By Age/Sex: <15 Male	183	209
C2.1.D_TA	By Age/Sex: 15+ Female	1,971	2,249
C2.1.D_TA	By Age/Sex: 15+ Male	1,313	1,499
C2.1.D_TA	Sum of Age/Sex disaggregates	3,649	4,165
C2.1.D_TA	By Age: <15	365	416
C2.1.D_TA	By Age: 15+	3,284	3,749
C2.1.D_TA	Sum of Age disaggregates	3,649	4,165
C2.1.D_TA	By Sex: Female	2,153	2,457
C2.1.D_TA	By Sex: Male	1,496	1,708
C2.1.D_TA	Sum of Sex disaggregates	3,649	4,165
C2.4.D_DSD	Number of HIV-positive patients who were screened for TB in HIV care or treatment setting	67,984	77,000
C2.4.D_DSD	Number of HIV-positive individuals receiving a minimum of one clinical service	87,572	99,959
C2.5.D_DSD	Number of HIV-positive patients in HIV care who started TB treatment	150	150
C2.5.D_DSD	Number of HIV-positive individuals receiving a minimum of one clinical service	87,572	99,959
CARE_CURR_DSD	Number of HIV positive adults and children	93,784	103,163



	who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load		
CARE_CURR_DSD	Age/sex: <1 Male	466	507
CARE_CURR_DSD	Age/sex: 1-4 Male	467	507
CARE_CURR_DSD	Age/sex: 5-9 Male	913	1,013
CARE_CURR_DSD	Age/sex: 10-14 Male	2,739	3,040
CARE_CURR_DSD	Age/sex: 15-19 Male	4,476	4,924
CARE_CURR_DSD	Age/sex: 20-24 Male	8,952	9,847
CARE_CURR_DSD	Age/sex: 25-49 Male	11,936	13,130
CARE_CURR_DSD	Age/sex: 50+ Male	4,476	4,924
CARE_CURR_DSD	Age/sex: <1 Female	466	507
CARE_CURR_DSD	Age/sex: 1-4 Female	467	507
CARE_CURR_DSD	Age/sex: 5-9 Female	913	1,013
CARE_CURR_DSD	Age/sex: 10-14 Female	2,739	3,040
CARE_CURR_DSD	Age/sex: 15-19 Female	8,222	9,031
CARE_CURR_DSD	Age/sex: 20-24 Female	16,443	18,062
CARE_CURR_DSD	Age/sex: 25-49 Female	21,888	24,080
CARE_CURR_DSD	Age/sex: 50+ Female	8,221	9,031
CARE_CURR_DSD	Sun of Age/Sex disaggregates	93,784	103,163
CARE_CURR_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	4,566	5,066
CARE_CURR_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	29,840	32,824
CARE_CURR_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	4,566	5,066
CARE_CURR_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	54,812	60,207
CARE_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	93,784	103,163
CARE_CURR_TA	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical	0	0



	assessment (WHO staging) OR CD4 count OR viral load		
CARE_NEW_DSD	Number of HIV-infected adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load	18,757	18,757
CARE_NEW_DSD	Age/sex: <1 Male	94	94
CARE_NEW_DSD	Age/sex: 1-4 Male	94	94
CARE_NEW_DSD	Age/sex: 5-9 Male	187	187
CARE_NEW_DSD	Age/sex: 10-14 Male	562	562
CARE_NEW_DSD	Age/sex: 15-19 Male	887	887
CARE_NEW_DSD	Age/sex: 20-24 Male	1,773	1,773
CARE_NEW_DSD	Age/sex: 25-49 Male	2,364	2,364
CARE_NEW_DSD	Age/sex: 50+ Male	887	887
CARE_NEW_DSD	Age/sex: <1 Female	94	94
CARE_NEW_DSD	Age/sex: 1-4 Female	94	94
CARE_NEW_DSD	Age/sex: 5-9 Female	187	187
CARE_NEW_DSD	Age/sex: 10-14 Female	562	562
CARE_NEW_DSD	Age/sex: 15-19 Female	1,646	1,646
CARE_NEW_DSD	Age/sex: 20-24 Female	3,292	3,292
CARE_NEW_DSD	Age/sex: 25-49 Female	4,389	4,389
CARE_NEW_DSD	Age/sex: 50+ Female	1,645	1,645
CARE_NEW_DSD	Sum of Age/sex disaggregates	18,757	18,757
CARE_NEW_DSD	Aggregated Age/sex: <15 Male	937	937
CARE_NEW_DSD	Aggregated Age/sex: 15+ Male	5,910	5,910
CARE_NEW_DSD	Aggregated Age/sex: <15 Female	937	937
CARE_NEW_DSD	Aggregated Age/sex: 15+ Female	10,973	10,973
CARE_NEW_DSD	Sum of Aggregated Age/sex disaggregates	18,757	18,757
CARE_SITE	Number of PEPFAR-supported HIV clinical care sites at which at least 80% of PLHIV received all of the following during the	78	108



	reporting period: 1) clinical assessment (WHO staging) OR CD4 count OR viral load, AND 2) TB screening at last visit, AND 3) if eligible, cotrimoxazole		
CARE_SITE	Total number of PEPFAR supported sites providing clinical care services	78	108
CARE_SITE	By site support type: Direct Service Delivery (DSD): Number of PEPFAR-supported HIV clinical care sites at which at least 80% of PLHIV received all of the following during the reporting period: 1) clinical assessment (WHO staging) OR CD4 count OR viral load, AND 2) TB screening at last visit, AND 3) if eligible, cotrimoxazole	75	104
CARE_SITE	By site support type: Technical Assistance-only (TA): Number of PEPFAR-supported HIV clinical care sites at which at least 80% of PLHIV received all of the following during the reporting period: 1) clinical assessment (WHO staging) OR CD4 count OR viral load, AND 2) TB screening at last visit, AND 3) if eligible, cotrimoxazole	3	4
CARE_SITE	Sum of Numerator Site Support Type disaggregates	78	108
CARE_SITE	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR supported sites providing clinical care services	75	104
CARE_SITE	By site support type: Technical Assistance-only (TA): Total number of PEPFAR supported sites providing clinical care services	3	4
CARE_SITE	Sum of Denominator Site Support Type disaggregates	78	108
FN_SITE	Number of PEPFAR-supported sites achieving 90% nutrition assessments that result in	0	0

	accurate categorization of malnutrition		
FN_THER_DSD	Number of clinically malnourished PLHIV who received therapeutic and/or supplementary food during the reporting period.	0	0
FN_THER_DSD	Number of PLHIV who were nutritionally assessed and found to be clinically undernourished.	0	0
FN_THER_DSD	Age: <1	0	0
FN_THER_DSD	Age: 1-4	0	0
FN_THER_DSD	Age: 5-14	0	0
FN_THER_DSD	Age: 15-17	0	0
FN_THER_DSD	Age: 18+	0	0
FN_THER_DSD	Sum of Age disaggregates	0	0
FN_THER_DSD	Aggregated Age: <18	0	0
FN_THER_DSD	Aggregated Age: 18+	0	0
FN_THER_DSD	Sum of Aggregated Age disaggregates	0	0
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	0	0
TB_ARTSITE	The number of PEPFAR-supported TB basic management units at which 80% of registered TB cases who are HIV-positive are on ART, during the reporting period	0	0
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	6,764	6,764
PMTCT_EID_DSD	Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT)	6,764	5,535
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	4,734	3,875
PMTCT_EID_DSD	By infants who received their first virologic HIV	2,030	1,660

	test between 2 and 12 months of age		
PMTCT_EID_DSD	Sum of Infant Age disaggregates	6,764	5,535
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	65,813	75,126
TX_CURR_DSD	Age/Sex: <1 Male	197	225
TX_CURR_DSD	Age/Sex: 1-4 Male	724	826
TX_CURR_DSD	Age/Sex: 5-14 Male	2,205	2,516
TX_CURR_DSD	Age/Sex: 15+ Male	20,846	23,796
TX_CURR_DSD	Age/Sex: <1 Female	198	226
TX_CURR_DSD	Age/Sex: 1-4 Female	724	827
TX_CURR_DSD	Age/Sex: 5-14 Female	2,204	2,517
TX_CURR_DSD	Age/Sex: 15+ Female	38,715	44,193
TX_CURR_DSD	Sum of age/sex disaggregates	6,252	7,137
TX_CURR_DSD	Percent children with advanced HIV infection receiving antiretroviral therapy (ART) [CURRENT]	10	10
TX_CURR_DSD	Percent women and girls with advanced HIV infection receiving antiretroviral therapy (ART) [CURRENT]	59	59
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	3,180	3,756
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	23,898	27,045
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	3,181	3,757
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	35,554	40,568
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	6,361	7,513
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	59,452	67,613
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	65,813	75,126
TX_CURR_NA	Number of adults and children receiving antiretroviral therapy (ART)	0	0
TX_CURR_NGI	Number of adults and children receiving antiretroviral therapy (ART)	68,463	78,256
TX_CURR_NGI	Age/Sex: <1 Male	0	0
TX_CURR_NGI	Age/Sex: 1-4 Male	0	0
TX_CURR_NGI	Age/Sex: 5-14 Male	3,313	3,913



TX_CURR_NGI	Age/Sex: 15+ Male	24,852	28,172
TX_CURR_NGI	Age/Sex: <1 Female	0	0
TX_CURR_NGI	Age/Sex: 1-4 Female	0	0
TX_CURR_NGI	Age/Sex: 5-14 Female	3,313	3,913
TX_CURR_NGI	Age/Sex: 15+ Female	36,985	42,258
TX_CURR_NGI	Sum of Age/Sex disaggregates	68,463	78,256
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	2,650	3,130
TX_CURR_TA	Age/Sex: 5-14 Male	132	156
TX_CURR_TA	Age/Sex: 15+ Male	954	1,127
TX_CURR_TA	Age/Sex: 5-14 Female	133	157
TX_CURR_TA	Age/Sex: 15+ Female	1,431	1,690
TX_CURR_TA	Sum of Age/Sex disaggregations	265	313
TX_CURR_TA	Aggregated Age/Sex: <15 Male	132	156
TX_CURR_TA	Aggregated Age/Sex: 15+ Male	954	1,127
TX_CURR_TA	Aggregated Age/Sex: <15 Female	133	157
TX_CURR_TA	Aggregated Age/Sex: 15+ Female	1,431	1,690
TX_CURR_TA	Sum of Aggregated Age/Sex <15	265	313
TX_CURR_TA	Sum of Aggregated Age/Sex 15+	2,385	2,817
TX_CURR_TA	Sum of Aggregated Age/Sex disaggregates	2,650	3,130
TX_DIST	Number of Districts with documented routine supportive supervision visits to 75% of HIV care and treatment sites supported by the District	23	23
TX_DIST	Total number of PEPFAR supported District Health Offices	23	23
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	12,903	12,903
TX_NEW_DSD	By Age/Sex: <1 Male	134	134
TX_NEW_DSD	By Age/Sex: 1-4 Male	209	209
TX_NEW_DSD	By Age/Sex: 5-9 Male	269	269
TX_NEW_DSD	By Age/Sex: 10-14 Male	149	149
TX_NEW_DSD	By Age/Sex: 15-19 Male	75	75



TX_NEW_DSD	By Age/Sex: 20-24 Male	90	90
TX_NEW_DSD	By Age/Sex: 25-49 Male	3,092	3,092
TX_NEW_DSD	By Age/Sex: 50+ Male	627	627
TX_NEW_DSD	By Age/Sex: <1 Female	120	120
TX_NEW_DSD	By Age/Sex: 1-4 Female	134	134
TX_NEW_DSD	By Age/Sex: 5-9 Female	299	299
TX_NEW_DSD	By Age/Sex: 10-14 Female	134	134
TX_NEW_DSD	By Age/Sex: 15-19 Female	239	239
TX_NEW_DSD	By Age/Sex: 20-24 Female	821	821
TX_NEW_DSD	By Age/Sex: 25-49 Female	5,630	5,630
TX_NEW_DSD	By Age/Sex: 50+ Female	881	881
TX_NEW_DSD	Sum of Age/Sex disaggregates	12,903	12,903
TX_NEW_DSD	Aggregated Grouping by Age: <1 Male	134	134
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	761	761
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	3,884	3,884
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <1 Female	209	209
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	687	687
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	7,571	7,571
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	12,903	12,903
TX_NEW_DSD	Pregnancy status	1,574	1,574
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	10,968	10,968
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	12,903	12,903
TX_RET_DSD	Age: 0-4 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	425	425



TX_RET_DSD	Age: 5-14 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	710	710
TX_RET_DSD	Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	9,833	11,022
TX_RET_DSD	Age: 0-4 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	597	597
TX_RET_DSD	Age: 5-14 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	852	852
TX_RET_DSD	Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	11,454	11,454
TX_RET_DSD	Aggregated Age: <15 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,135	1,135
TX_RET_DSD	Aggregated Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	9,833	9,833
TX_RET_DSD	Aggregated Age: <15 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,200	1,200



TX_RET_DSD	Aggregated Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	11,703	11,703
TX_RET_DSD	Pregnancy and breastfeeding status (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	983	983
TX_RET_DSD	Pregnancy and breastfeeding status (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,145	1,145
TX_SITE	Number of PEPFAR-supported ART sites with a retention rate of 75% or greater for patients 12 months after ART initiation	24	40
TX_SITE	Total number of PEPFAR-supported ART sites	78	108
TX_SITE	By support type: Direct Service Delivery (DSD): Number of PEPFAR-supported ART sites with a retention rate of 75% or greater for patients 12 months after ART initiation	21	36
TX_SITE	By support type: Technical Assistance (TA-only): Number of PEPFAR-supported ART sites with a retention rate of 75% or greater for patients 12 months after ART initiation	3	4
TX_SITE	Sum of Numerator Site Support Type disaggregates	24	40
TX_SITE	By support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported	75	104



	ART sites		
TX_SITE	By support type: Technical Assistance (TA-only): Total number of PEPFAR-supported ART sites	3	4
TX_SITE	Sum of Denominator Site Support Type disaggregates	78	108
LAB_ACC_DSD	Number of PEPFAR-supported testing facilities (laboratories) that are recognized by national, regional, or international standards for accreditation or have achieved a minimal acceptable level towards attainment of such accreditation	98	98
LAB_CAP_DSD	Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests	0	0
LAB_PT_DSD	Percentage of laboratories and POC testing sites that perform HIV diagnostic testing that participate and successfully pass in an analyte-specific proficiency testing (PT) program	0	0
HRH_PRE	Number of new HCW who graduated from a pre-service training institution or program as a result of PEPFAR-supported strengthening efforts, within the reporting period, by select cadre	0	0
SC_TRAIN	Number of individuals who received competency-based, certificate or higher-level training to conduct or support supply chain, inventory management, supportive supervision or distribution activities	0	0
FPINT_SITE_DSD	Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	0	0
QI_SITE	Number of PEPFAR-supported clinical service	0	0



	sites with a quality improvement activity completed that addresses clinical HIV programs and has documented process results in the last 6 months		
SC_STOCK	Number of stock status observations for one or more tracer commodities that are between the designed minimum and maximum quantities/months of stock from storage sites within at a given level (Central, Regional, etc.) of the system.	0	0
SC_STOCK	System Level: Central Medical Stores	0	0
SI_HIS	Existence of a national registry of health facilities that is updated annually	1	1
SI_HIS	Full national facility list coordinated with PEPFAR	1	1
SI_ME	Existence of a national HIV/AIDS M&E system based on the UNAIDS 12 components model	1	1
TB_SCREEN_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period	57,234	67,983
TB_SCREEN_DSD	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	93,784	103,163
TB_SCREEN_DSD	Age: <1	109	109
TB_SCREEN_DSD	Age: 1-4	1,024	1,024
TB_SCREEN_DSD	Age: 5-9	2,192	2,192
TB_SCREEN_DSD	Age: 10-14	2,118	2,118
TB_SCREEN_DSD	Age: 15-19	1,259	2,259
TB_SCREEN_DSD	Age: 20-24	1,884	3,633
TB_SCREEN_DSD	Age: 25-49	38,146	44,146
TB_SCREEN_DSD	Age: 50+	10,502	12,502
TB_SCREEN_DSD	Sum of Age disaggregates	6,702	7,702



TB_SCREEN_DSD	Aggregated Age - USE WITH HQ PERMISSION ONLY: <15	5,443	5,443
TB_SCREEN_DSD	Aggregated Age - USE WITH HQ PERMISSION ONLY: 15+	51,791	62,540
TB_SCREEN_DSD	Sum of Aggregated Age disaggregates	57,234	67,983
TB_SCREEN_DSD	Sex: Male	18,670	22,185
TB_SCREEN_DSD	Sex: Female	38,564	45,798
TB_SCREEN_DSD	Sum of Sex disaggregates	57,234	67,983

Implementing Mechanism Details

Mechanism ID: 14009	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 13922	Mechanism Name: Laboratory Leadership Training
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: African Field Epidemiology Network	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: No	
G2G: No	Managing Agency:

Total All Funding Sources: 595,000	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 0	
FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount
GHP-State	595,000

Sub Partner Name(s)

(No data provided.)



Cross-Cutting Budget Attribution(s)

Human Resources for Health	370,000
----------------------------	---------

Key Issues

TB

Budget Code Information

Mechanism ID: 13922			
Mechanism Name: Laboratory Leadership Training			
Prime Partner Name: African Field Epidemiology Network			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	275,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	320,000	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2014	2015	Planning Budget Targets
SITE_SUPP	Number of unique sites supported by PEPFAR	7	8	Redacted
SITE_SUPP	By program area/support type: Lab Direct Service Delivery (DSD)	7	8	Redacted
SITE_SUPP	By program area/support type: Lab	0	0	Redacted



	Technical Assistance-only (TA)			
LAB_ACC_DSD	Number of PEPFAR-supported testing facilities (laboratories) that are recognized by national, regional, or international standards for accreditation or have achieved a minimal acceptable level towards attainment of such accreditation	7	8	Redacted
LAB_ACC_DSD	By site support type: Direct Service Delivery (DSD)	7	8	Redacted
LAB_ACC_DSD	Sum of Support Type disaggregates	7	8	Redacted
LAB_CAP_DSD	Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests	7	8	Redacted
LAB_CAP_DSD	By site support type: Technical Assistance-only (TA)	7	8	Redacted
LAB_CAP_DSD	Sum of Site Support Type disaggregates	7	8	Redacted
HRH_PRE	Number of new HCW who graduated from a pre-service training institution or program as a result of PEPFAR-supported strengthening efforts, within the reporting period, by select cadre	8	8	Redacted
HRH_PRE	By Graduates: Laboratory professionals	2	2	Redacted
HRH_PRE	By Graduates: Other	6	6	Redacted
HRH_PRE	Sum of Graduates disaggreagtes	8	8	Redacted

Implementing Mechanism Details

Mechanism ID: 13919	Mechanism Name: Laboratory Regulatory Support
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Clinical and Laboratory Standards Institute	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No

Approved



Global Fund / Multilateral Engagement: No	
G2G: No	Managing Agency:
Total All Funding Sources: 450,000	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 0	
FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount
GHP-State	450,000

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

(No data provided.)

Budget Code Information

Mechanism ID:	13919		
Mechanism Name:	Laboratory Regulatory Support		
Prime Partner Name:	Clinical and Laboratory Standards Institute		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	450,000	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2014	2015	Planning
------------------	-------	------	------	----------



				Budget Targets
SITE_SUPP	Number of unique sites supported by PEPFAR	6	8	Redacted
SITE_SUPP	By program area/support type: Lab Technical Assistance-only (TA)	6	8	Redacted
LAB_ACC_DSD	Number of PEPFAR-supported testing facilities (laboratories) that are recognized by national, regional, or international standards for accreditation or have achieved a minimal acceptable level towards attainment of such accreditation	6	8	Redacted
LAB_ACC_DSD	By site support type: Direct Service Delivery (DSD)	6	8	Redacted
LAB_ACC_DSD	By site support type: Technical Assistance-only (TA)	0	0	Redacted
LAB_ACC_DSD	Sum of Support Type disaggregates	6	8	Redacted
LAB_CAP_DSD	Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests	6	8	Redacted
LAB_CAP_DSD	By clinical laboratories	0	0	Redacted
LAB_CAP_DSD	By Point-of-care testing sites	0	0	Redacted
LAB_CAP_DSD	By site support type: Direct Service Delivery (DSD)	0	0	Redacted
LAB_CAP_DSD	By site support type: Technical Assistance-only (TA)	6	8	Redacted
LAB_CAP_DSD	Sum of Site Support Type disaggregates	6	8	Redacted

Implementing Mechanism Details

Mechanism ID: 13882	Mechanism Name: Integrated Program for both HIV infected and affected children and their households
Funding Agency: USAID	Procurement Type: Cooperative Agreement

Approved



Prime Partner Name: Children of God Relief Institute	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: No	
G2G: No	Managing Agency:

Total All Funding Sources: 1,806,681	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 0	
FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount
GHP-State	1,806,681

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

Economic Strengthening	200,000
Education	100,000
Gender: Gender Equality	50,000
Focus Area:	Changing harmful gender norms and promoting positive gender norms
Sub Area:	Implementation
Focus Area:	Increase gender-equitable access to income and productive resources, including education
Sub Area:	Capacity building
Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Implementation
Sub Area:	Capacity building



Key Issues

Malaria (PMI)

TB

End-of-Program Evaluation

Budget Code Information

Mechanism ID:	13882		
Mechanism Name:	Integrated Program for both HIV infected and affected children and their households		
Prime Partner Name:	Children of God Relief Institute		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	400,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	150,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	250,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	6,681	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	1,000,000	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2014	2015
SITE_SUPP	Number of unique sites supported by PEPFAR	9	9
SITE_SUPP	By program area/support type: HTC Direct	9	9



	Service Delivery (DSD)		
SITE_SUPP	By program area/support type: Treatment Direct Service Delivery (DSD)	9	9
SITE_SUPP	By program area/support type: Care and Support Direct Service Delivery (DSD)	9	9
SITE_SUPP	By program area/support type: Food and Nutrition Direct Service Delivery (DSD)	9	9
SITE_SUPP	By program area/support type: PMTCT Direct Service Delivery (DSD)	0	0
SITE_SUPP	By program area/support type: TB/HIV Direct Service Delivery (DSD)	9	9
SITE_SUPP	By program area/support type: General Population Prevention Direct Service Delivery (DSD)	9	9
SITE_SUPP	By program area/support type: OVC Direct Service Delivery (DSD)	9	9
SITE_SUPP	By program area/support type: Lab Direct Service Delivery (DSD)	2	2
PMTCT_ARV_DSD	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	0	0
PMTCT_ARV_DSD	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	0	0
PMTCT_ARV_NA	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	0	0
PMTCT_ARV_NA	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	0	0
PMTCT_ARV_NGI	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during	0	0



	pregnancy and delivery		
PMTCT_ARV_NGI	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	0	0
PMTCT_ARV_TA	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	0	0
PMTCT_ARV_TA	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	0	0
PMTCT_SITE	Number of PEPFAR-supported sites achieving 90% ARV or ART coverage for HIV+ pregnant women	0	0
PMTCT_SITE	Total number of PEPFAR supported sites providing PMTCT services (HTC and ARV or ART services)	0	0
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	0	0
PMTCT_STAT_DSD	Number of new ANC and L&D clients	0	0
PMTCT_STAT_NA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	0	0
PMTCT_STAT_NA	Number of new ANC and L&D clients	0	0
PMTCT_STAT_NGI	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	0	0
PMTCT_STAT_NGI	Number of new ANC and L&D clients	0	0
BS_COLL	Number of whole blood collections each year by the NBTS network	0	0
VMMC_AE_DSD	Number of males circumcised surgically or by medical device that experienced at least one moderate or severe adverse event(s) (AEs)	0	0

VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	0	0
VMMC_CIRC_NA	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	0	0
VMMC_CIRC_NGI	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	0	0
VMMC_CIRC_TA	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	0	0
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	2,406	2,406
PP_PREV_DSD	Total number of people in the target population	2,406	2,406
PP_PREV_DSD	Age/sex: 10-14 Male	614	614
PP_PREV_DSD	Age/sex: 15-19 Male	435	435
PP_PREV_DSD	Age/sex: 20-24 Male	60	60
PP_PREV_DSD	Age/sex: 25-49 Male	2	2
PP_PREV_DSD	Age/sex: 50+ Male	6	6
PP_PREV_DSD	Age/sex: 10-14 Female	652	652
PP_PREV_DSD	Age/sex: 15-19 Female	491	491
PP_PREV_DSD	Age/sex: 20-24 Female	53	53
PP_PREV_DSD	Age/sex: 25-49 Female	1	1
PP_PREV_DSD	Age/sex: 50+ Female	92	92
PP_PREV_DSD	Sum of Age/Sex disaggregates	2,406	2,406
PP_PREV_TA	Number of the target population who	0	0



	completed a standardized HIV prevention intervention including the minimum components during the reporting period.		
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	0	0
KP_PREV_TA	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	0	0
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	1,952	2,278
HTC_TST_DSD	By Test Result: Negative	1,819	2,123
HTC_TST_DSD	By Test Result: Positive	133	155
HTC_TST_DSD	Sum of Test Result disaggregates	1,952	2,278
HTC_TST_DSD	Age/sex: <1 Male	36	42
HTC_TST_DSD	Age/sex: 1-4 Male	62	72
HTC_TST_DSD	Age/sex: 5-9 Male	162	189
HTC_TST_DSD	Age/sex: 10-14 Male	132	154
HTC_TST_DSD	Age/sex: 15-19 Male	107	125
HTC_TST_DSD	Age/sex: 20-24 Male	222	259
HTC_TST_DSD	Age/sex: 25-49 Male	213	248
HTC_TST_DSD	Age/sex: 50+ Male	58	68
HTC_TST_DSD	Age/sex: <1 Female	34	39
HTC_TST_DSD	Age/sex: 1-4 Female	71	83
HTC_TST_DSD	Age/sex: 5-9 Female	105	122
HTC_TST_DSD	Age/sex: 10-14 Female	106	124
HTC_TST_DSD	Age/sex: 15-19 Female	150	175
HTC_TST_DSD	Age/sex: 20-24 Female	248	289



HTC_TST_DSD	Age/sex: 25-49 Female	184	215
HTC_TST_DSD	Age/sex: 50+ Female	62	74
HTC_TST_DSD	Sum of Age/Sex disaggregates	1,952	2,278
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	392	457
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	600	700
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	316	369
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	644	752
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	708	826
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	1,244	1,452
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	1,952	2,278
HTC_TST_NA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	0	0
HTC_TST_NGI	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	1,952	2,278
HTC_TST_NGI	By Test Result: Negative	1,788	2,087
HTC_TST_NGI	By Test Result: Positive	164	191
HTC_TST_NGI	Sum of Test Result disaggregates	1,952	2,278
HTC_TST_NGI	Age/sex: <1 Male	36	44
HTC_TST_NGI	Age/sex: 1-4 Male	62	72
HTC_TST_NGI	Age/sex: 5-9 Male	162	189
HTC_TST_NGI	Age/sex: 10-14 Male	132	154
HTC_TST_NGI	Age/sex: 15-19 Male	107	125
HTC_TST_NGI	Age/sex: 20-24 Male	222	259
HTC_TST_NGI	Age/sex: 25-49 Male	213	248
HTC_TST_NGI	Age/sex: 50+ Male	58	68
HTC_TST_NGI	Age/sex: <1 Female	34	39
HTC_TST_NGI	Age/sex: 1-4 Female	71	83



HTC_TST_NGI	Age/sex: 5-9 Female	105	122
HTC_TST_NGI	Age/sex: 10-14 Female	106	125
HTC_TST_NGI	Age/sex: 15-19 Female	150	175
HTC_TST_NGI	Age/sex: 20-24 Female	248	289
HTC_TST_NGI	Age/sex: 25-49 Female	184	215
HTC_TST_NGI	Age/sex: 50+ Female	62	71
HTC_TST_NGI	Sum of Age/Sex disaggregates	1,952	2,278
HTC_TST_NGI	Aggregated Age/sex: <15 Male	392	457
HTC_TST_NGI	Aggregated Age/sex: 15+ Male	600	700
HTC_TST_NGI	Aggregated Age/sex: <15 Female	316	369
HTC_TST_NGI	Aggregated Age/sex: 15+ Female	644	752
HTC_TST_NGI	Sum of Aggregated Age/Sex <15	708	826
HTC_TST_NGI	Sum of Aggregated Age/Sex 15+	1,244	1,452
HTC_TST_NGI	Sum of Aggregated Age/Sex disaggregates	1,952	2,278
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	0	0
GEND_GBV_DSD	Number of people receiving post-GBV care	0	0
GEND_NORM_DSD	Number of people completing an intervention pertaining to gender norms, that meets minimum criteria	0	0
OVC_ACC_DSD	Number of active beneficiaries receiving support from PEPFAR OVC programs to access HIV services	3,149	3,474
OVC_ACC_DSD	Sex: Male	1,515	1,671
OVC_ACC_DSD	Sex: Female	1,634	1,803
OVC_ACC_DSD	Sum of Sex disaggregates	3,149	3,474
OVC_ACC_DSD	Age: <1	143	158
OVC_ACC_DSD	Age: 1-4	609	672
OVC_ACC_DSD	Age: 5-9	812	896
OVC_ACC_DSD	Age: 10-14	760	774
OVC_ACC_DSD	Age: 15-17	776	880
OVC_ACC_DSD	Age: 18+	49	94



OVC_ACC_DSD	Sum of Age disaggregates	3,149	3,474
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	9,600	9,600
OVC_SERV_DSD	Sex: Male	4,029	4,029
OVC_SERV_DSD	Sex: Female	5,571	5,571
OVC_SERV_DSD	Sum of Sex disaggregates	9,600	9,600
OVC_SERV_DSD	Age: <1	0	0
OVC_SERV_DSD	Age: 1-4	1,302	1,302
OVC_SERV_DSD	Age: 5-9	1,367	1,367
OVC_SERV_DSD	Age: 10-14	1,655	1,655
OVC_SERV_DSD	Age: 15-17	2,187	2,187
OVC_SERV_DSD	Age: 18+	3,089	3,089
OVC_SERV_DSD	Sum of Age disaggregates	9,600	9,600
OVC_SERV_TA	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	0	0
C2.1.D_DSD	Number of HIV-positive individuals receiving a minimum of one clinical service	3,149	3,474
C2.1.D_DSD	By Age/Sex: <15 Female	1,305	1,440
C2.1.D_DSD	By Age/Sex: <15 Male	1,265	1,395
C2.1.D_DSD	By Age/Sex: 15+ Female	329	363
C2.1.D_DSD	By Age/Sex: 15+ Male	250	276
C2.1.D_DSD	Sum of Age/Sex disaggregates	3,149	3,474
C2.1.D_DSD	By Age: <15	2,570	2,835
C2.1.D_DSD	By Age: 15+	579	639
C2.1.D_DSD	Sum of Age disaggregates	3,149	3,474
C2.1.D_DSD	By Sex: Female	1,634	1,803
C2.1.D_DSD	By Sex: Male	1,515	1,671
C2.1.D_DSD	Sum of Sex disaggregates	3,149	3,474
C2.1.D_NA	Number of HIV-positive individuals receiving a minimum of one clinical service	0	0
C2.1.D_NGI	Number of HIV-positive individuals receiving a	0	0



	minimum of one clinical service		
C2.1.D_TA	Number of HIV-positive individuals receiving a minimum of one clinical service	0	0
C2.4.D_DSD	Number of HIV-positive patients who were screened for TB in HIV care or treatment setting	3,149	3,149
C2.4.D_DSD	Number of HIV-positive individuals receiving a minimum of one clinical service	3,149	3,474
C2.5.D_DSD	Number of HIV-positive patients in HIV care who started TB treatment	12	14
C2.5.D_DSD	Number of HIV-positive individuals receiving a minimum of one clinical service	3,149	3,474
CARE_CURR_DSD	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	3,149	3,474
CARE_CURR_DSD	Age/sex: <1 Male	76	84
CARE_CURR_DSD	Age/sex: 1-4 Male	294	324
CARE_CURR_DSD	Age/sex: 5-9 Male	416	459
CARE_CURR_DSD	Age/sex: 10-14 Male	479	528
CARE_CURR_DSD	Age/sex: 15-19 Male	219	242
CARE_CURR_DSD	Age/sex: 20-24 Male	23	25
CARE_CURR_DSD	Age/sex: 25-49 Male	8	9
CARE_CURR_DSD	Age/sex: 50+ Male	0	0
CARE_CURR_DSD	Age/sex: <1 Female	67	74
CARE_CURR_DSD	Age/sex: 1-4 Female	315	348
CARE_CURR_DSD	Age/sex: 5-9 Female	396	437
CARE_CURR_DSD	Age/sex: 10-14 Female	529	584
CARE_CURR_DSD	Age/sex: 15-19 Female	273	300
CARE_CURR_DSD	Age/sex: 20-24 Female	25	28
CARE_CURR_DSD	Age/sex: 25-49 Female	26	29
CARE_CURR_DSD	Age/sex: 50+ Female	3	3



CARE_CURR_DSD	Sun of Age/Sex disaggregates	3,149	3,474
CARE_CURR_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	1,265	1,396
CARE_CURR_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	250	276
CARE_CURR_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	1,307	1,442
CARE_CURR_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	327	360
CARE_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	3,149	3,474
CARE_CURR_TA	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	0	0
CARE_NEW_DSD	Number of HIV-infected adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load	183	206
CARE_NEW_DSD	Age/sex: <1 Male	35	45
CARE_NEW_DSD	Age/sex: 1-4 Male	20	15
CARE_NEW_DSD	Age/sex: 5-9 Male	23	27
CARE_NEW_DSD	Age/sex: 10-14 Male	10	11
CARE_NEW_DSD	Age/sex: 15-19 Male	1	2
CARE_NEW_DSD	Age/sex: 20-24 Male	0	0
CARE_NEW_DSD	Age/sex: 25-49 Male	0	0
CARE_NEW_DSD	Age/sex: 50+ Male	0	0
CARE_NEW_DSD	Age/sex: <1 Female	35	44
CARE_NEW_DSD	Age/sex: 1-4 Female	25	31
CARE_NEW_DSD	Age/sex: 5-9 Female	24	21
CARE_NEW_DSD	Age/sex: 10-14 Female	10	10
CARE_NEW_DSD	Age/sex: 15-19 Female	0	0



CARE_NEW_DSD	Age/sex: 20-24 Female	0	0
CARE_NEW_DSD	Age/sex: 25-49 Female	0	0
CARE_NEW_DSD	Age/sex: 50+ Female	0	0
CARE_NEW_DSD	Sum of Age/sex disaggregates	183	206
CARE_NEW_DSD	Aggregated Age/sex: <15 Male	88	97
CARE_NEW_DSD	Aggregated Age/sex: 15+ Male	1	2
CARE_NEW_DSD	Aggregated Age/sex: <15 Female	94	105
CARE_NEW_DSD	Aggregated Age/sex: 15+ Female	0	2
CARE_NEW_DSD	Sum of Aggregated Age/sex disaggregates	183	206
CARE_SITE	Number of PEPFAR-supported HIV clinical care sites at which at least 80% of PLHIV received all of the following during the reporting period: 1) clinical assessment (WHO staging) OR CD4 count OR viral load, AND 2) TB screening at last visit, AND 3) if eligible, cotrimoxazole	9	9
CARE_SITE	Total number of PEPFAR supported sites providing clinical care services	9	9
CARE_SITE	By site support type: Direct Service Delivery (DSD): Number of PEPFAR-supported HIV clinical care sites at which at least 80% of PLHIV received all of the following during the reporting period: 1) clinical assessment (WHO staging) OR CD4 count OR viral load, AND 2) TB screening at last visit, AND 3) if eligible, cotrimoxazole	9	9
CARE_SITE	By site support type: Technical Assistance-only (TA): Number of PEPFAR-supported HIV clinical care sites at which at least 80% of PLHIV received all of the following during the reporting period: 1) clinical assessment (WHO staging) OR CD4 count OR viral load, AND 2) TB screening at last visit, AND 3) if eligible, cotrimoxazole	0	
CARE_SITE	Sum of Numerator Site Support Type	9	9



	disaggregates		
CARE_SITE	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR supported sites providing clinical care services	9	9
CARE_SITE	By site support type: Technical Assistance-only (TA): Total number of PEPFAR supported sites providing clinical care services	0	0
CARE_SITE	Sum of Denominator Site Support Type disaggregates	9	9
FN_SITE	Number of PEPFAR-supported sites achieving 90% nutrition assessments that result in accurate categorization of malnutrition	9	9
FN_SITE	Total number of PEPFAR-supported sites providing nutrition assessment, counseling and support (NACS) services	9	9
FN_SITE	By site support type: Direct Service Delivery (DSD): Number of PEPFAR-supported sites achieving 90% nutrition assessments that result in accurate categorization of malnutrition	9	9
FN_SITE	By site support type: Technical Assistance-only (TA): Number of PEPFAR-supported sites achieving 90% nutrition assessments that result in accurate categorization of malnutrition	0	
FN_SITE	Sum of Numerator Support Type disaggregates	9	9
FN_SITE	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported sites providing nutrition assessment, counseling and support (NACS) services	9	9
FN_SITE	By site support type: Technical Assistance-only (TA): Total number of PEPFAR-supported sites providing nutrition	0	0

	assessment, counseling and support (NACS) services		
FN_SITE	Sum of Denominator Support Type disaggregates	9	9
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	126	140
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	126	140
TB_ART_DSD	Age: 0-4	18	20
TB_ART_DSD	Age: 5-14	70	78
TB_ART_DSD	Age: 15+	38	42
TB_ART_DSD	Male	63	70
TB_ART_DSD	Female	63	70
TB_ART_DSD	Sum of Sex disaggregates	126	140
TB_ART_DSD	Newly tested	50	56
TB_ART_DSD	Known HIV-positive	76	84
TB_ART_DSD	Sum of Test Status disaggregates	126	140
TB_ART_DSD	Aggregated Age: <15	88	98
TB_ART_DSD	Aggregated Age: 15+	38	42
TB_ART_DSD	Sum of Aggregated Age disaggregates	126	140
TB_ARTSITE	The number of PEPFAR-supported TB basic management units at which 80% of registered TB cases who are HIV-positive are on ART, during the reporting period	9	9
TB_ARTSITE	The number of PEPFAR-supported TB basic management units	9	9
TB_ARTSITE	By site support type: Direct Service Delivery (DSD): The number of PEPFAR-supported TB basic management units at which 80% of registered TB cases who are HIV-positive are	9	9



	on ART, during the reporting period		
TB_ARTSITE	By site support type: Technical Assistance-only (TA): The number of PEPFAR-supported TB basic management units at which 80% of registered TB cases who are HIV-positive are on ART, during the reporting period	0	
TB_ARTSITE	Sum of Numerator Site Support Type disaggregates	9	9
TB_ARTSITE	By site support type: Direct Service Delivery (DSD): The number of PEPFAR-supported TB basic management units	9	9
TB_ARTSITE	By site support type: Technical Assistance-only (TA): The number of PEPFAR-supported TB basic management units	0	0
TB_ARTSITE	Sum of Denominator Site Support Type disaggregates	9	9
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	0	0
PMTCT_EID_DSD	Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT)	0	0
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	2,305	2,626
TX_CURR_DSD	Age/Sex: <1 Male	5	6
TX_CURR_DSD	Age/Sex: 1-4 Male	145	165
TX_CURR_DSD	Age/Sex: 5-14 Male	736	838
TX_CURR_DSD	Age/Sex: 15+ Male	230	262
TX_CURR_DSD	Age/Sex: <1 Female	9	10
TX_CURR_DSD	Age/Sex: 1-4 Female	160	182
TX_CURR_DSD	Age/Sex: 5-14 Female	738	841



TX_CURR_DSD	Age/Sex: 15+ Female	282	322
TX_CURR_DSD	Sum of age/sex disaggregates	1,793	2,042
TX_CURR_DSD	Percent children with advanced HIV infection receiving antiretroviral therapy (ART) [CURRENT]	78	78
TX_CURR_DSD	Percent women and girls with advanced HIV infection receiving antiretroviral therapy (ART) [CURRENT]	51	51
TX_CURR_DSD	Aggregated Age/Sex: <1 Male	5	6
TX_CURR_DSD	Aggregated Age/Sex: <1 Female	9	10
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	886	1,009
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	230	262
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	907	1,033
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	282	322
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	1,793	2,042
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	512	584
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	2,305	2,626
TX_CURR_NA	Number of adults and children receiving antiretroviral therapy (ART)	0	0
TX_CURR_NGI	Number of adults and children receiving antiretroviral therapy (ART)	2,305	2,626
TX_CURR_NGI	Age/Sex: <1 Male	5	6
TX_CURR_NGI	Age/Sex: 1-4 Male	145	165
TX_CURR_NGI	Age/Sex: 5-14 Male	736	839
TX_CURR_NGI	Age/Sex: 15+ Male	230	262
TX_CURR_NGI	Age/Sex: <1 Female	9	10
TX_CURR_NGI	Age/Sex: 1-4 Female	160	182
TX_CURR_NGI	Age/Sex: 5-14 Female	738	840
TX_CURR_NGI	Age/Sex: 15+ Female	282	322
TX_CURR_NGI	Sum of Age/Sex disaggregates	2,305	2,626
TX_CURR_NGI	Aggregated Age/Sex: <1 Male	5	6
TX_CURR_NGI	Aggregated Age/Sex: <1 Female	9	10
TX_CURR_NGI	Aggregated Age/Sex: <15 Male	886	1,009



TX_CURR_NGI	Aggregated Age/Sex: 15+ Male	230	262
TX_CURR_NGI	Aggregated Age/Sex: <15 Female	907	1,033
TX_CURR_NGI	Aggregated Age/Sex: 15+ Female	282	322
TX_CURR_NGI	Sum of Aggregated Age/Sex disaggregates	2,305	2,626
TX_CURR_NGI	Sum of Aggregated Age/Sex <15	1,793	2,042
TX_CURR_NGI	Sum of Aggregated Age/Sex 15+	512	584
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	0	0
TX_DIST	Number of Districts with documented routine supportive supervision visits to 75% of HIV care and treatment sites supported by the District	0	0
TX_DIST	Total number of PEPFAR supported District Health Offices	0	0
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	137	137
TX_NEW_DSD	By Age/Sex: <1 Male	9	9
TX_NEW_DSD	By Age/Sex: 1-4 Male	11	11
TX_NEW_DSD	By Age/Sex: 5-9 Male	12	12
TX_NEW_DSD	By Age/Sex: 10-14 Male	22	22
TX_NEW_DSD	By Age/Sex: 15-19 Male	12	12
TX_NEW_DSD	By Age/Sex: 20-24 Male	0	0
TX_NEW_DSD	By Age/Sex: 25-49 Male	0	0
TX_NEW_DSD	By Age/Sex: 50+ Male	0	0
TX_NEW_DSD	By Age/Sex: <1 Female	9	9
TX_NEW_DSD	By Age/Sex: 1-4 Female	12	12
TX_NEW_DSD	By Age/Sex: 5-9 Female	13	13
TX_NEW_DSD	By Age/Sex: 10-14 Female	23	23
TX_NEW_DSD	By Age/Sex: 15-19 Female	14	14
TX_NEW_DSD	By Age/Sex: 20-24 Female	0	0
TX_NEW_DSD	By Age/Sex: 25-49 Female	0	0
TX_NEW_DSD	By Age/Sex: 50+ Female	0	0
TX_NEW_DSD	Sum of Age/Sex disaggregates	137	137



TX_NEW_DSD	Aggregated Grouping by Age: <1 Male	23	23
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	68	68
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	0	0
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <1 Female	23	23
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	69	69
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	0	0
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	137	137
TX_NEW_DSD	Pregnancy status	0	0
TX_NEW_DSD	Breastfeeding status	0	0
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	123	123
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	137	137
TX_RET_DSD	Age: 0-4 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	37	37
TX_RET_DSD	Age: 5-14 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	64	64
TX_RET_DSD	Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	24	24
TX_RET_DSD	Age: 0-4 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	41	41



TX_RET_DSD	Age: 5-14 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	70	70
TX_RET_DSD	Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	26	26
TX_RET_DSD	Aggregated Age: <15 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	101	101
TX_RET_DSD	Aggregated Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	22	22
TX_RET_DSD	Aggregated Age: <15 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	111	111
TX_RET_DSD	Aggregated Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	26	26
TX_RET_DSD	Pregnancy and breastfeeding status (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	0	0
TX_RET_DSD	Pregnancy and breastfeeding status (Denominator: Total number of adults and	0	0



	children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)		
TX_SITE	Number of PEPFAR-supported ART sites with a retention rate of 75% or greater for patients 12 months after ART initiation	9	9
TX_SITE	Total number of PEPFAR-supported ART sites	9	9
TX_SITE	By support type: Direct Service Delivery (DSD): Number of PEPFAR-supported ART sites with a retention rate of 75% or greater for patients 12 months after ART initiation	9	9
TX_SITE	By support type: Technical Assistance (TA-only): Number of PEPFAR-supported ART sites with a retention rate of 75% or greater for patients 12 months after ART initiation	0	
TX_SITE	Sum of Numerator Site Support Type disaggregates	9	9
TX_SITE	By support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported ART sites	9	9
TX_SITE	By support type: Technical Assistance (TA-only): Total number of PEPFAR-supported ART sites	0	0
TX_SITE	Sum of Denominator Site Support Type disaggregates	9	9
LAB_ACC_DSD	Number of PEPFAR-supported testing facilities (laboratories) that are recognized by national, regional, or international standards for accreditation or have achieved a minimal acceptable level towards attainment of such accreditation	0	0



LAB_CAP_DSD	Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests	0	0
LAB_PT_DSD	Percentage of laboratories and POC testing sites that perform HIV diagnostic testing that participate and successfully pass in an analyte-specific proficiency testing (PT) program	0	0
HRH_PRE	Number of new HCW who graduated from a pre-service training institution or program as a result of PEPFAR-supported strengthening efforts, within the reporting period, by select cadre	0	0
SC_TRAIN	Number of individuals who received competency-based, certificate or higher-level training to conduct or support supply chain, inventory management, supportive supervision or distribution activities	0	0
SC_TRAIN	Number of individuals who conduct or support supply chain, inventory management, supportive supervision or distribution activities	0	0
FPINT_SITE_DSD	Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	0	0
FPINT_SITE_DSD	Total number of PEPFAR-supported HIV service delivery points: PMTCT, Care and Treatment	0	0
QI_SITE	Number of PEPFAR-supported clinical service sites with a quality improvement activity completed that addresses clinical HIV programs and has documented process results in the last 6 months	0	0
QI_SITE	Total number of PEPFAR-supported sites for any HIV clinical service including HIV Care,	0	0

	HIV Treatment, TB care, PMTCT, VMMC, and HTC		
SC_STOCK	Number of stock status observations for one or more tracer commodities that are between the designed minimum and maximum quantities/months of stock from storage sites within at a given level (Central, Regional, etc.) of the system.	0	0
SC_STOCK	Total number of stock status observations for one or more tracer commodities from storage sites within at a given level (Central, Regional, etc.) of the system	0	0
SI_HIS	Existence of a national registry of health facilities that is updated annually	1	1
SI_HIS	Full national facility list coordinated with PEPFAR	1	1
SI_ME	Existence of a national HIV/AIDS M&E system based on the UNAIDS 12 components model	1	1
TB_SCREEN_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period	3,149	3,474
TB_SCREEN_DSD	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	3,149	3,474
TB_SCREEN_DSD	Age: <1	143	158
TB_SCREEN_DSD	Age: 1-4	609	671
TB_SCREEN_DSD	Age: 5-9	812	896
TB_SCREEN_DSD	Age: 10-14	1,008	1,112
TB_SCREEN_DSD	Age: 15-19	492	543
TB_SCREEN_DSD	Age: 20-24	48	53
TB_SCREEN_DSD	Age: 25-49	34	38
TB_SCREEN_DSD	Age: 50+	3	3



TB_SCREEN_DSD	Sum of Age disaggregates	3,064	3,380
TB_SCREEN_DSD	Aggregated Age - USE WITH HQ PERMISSION ONLY: <15	2,572	2,837
TB_SCREEN_DSD	Aggregated Age - USE WITH HQ PERMISSION ONLY: 15+	577	637
TB_SCREEN_DSD	Sum of Aggregated Age disaggregates	3,149	3,474
TB_SCREEN_DSD	Sex: Male	1,515	1,671
TB_SCREEN_DSD	Sex: Female	1,634	1,803
TB_SCREEN_DSD	Sum of Sex disaggregates	3,149	3,474

Implementing Mechanism Details

Mechanism ID: 13868	Mechanism Name: APHIAplus Health Communication and Marketing (APHIAplus HCM)
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Population Services International	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: No	
G2G: No	Managing Agency:

Total All Funding Sources: 2,053,481	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 650,000	
FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount
GHP-State	2,053,481

Sub Partner Name(s)

Liverpool VCT and Care	Population Services International	
------------------------	-----------------------------------	--

Cross-Cutting Budget Attribution(s)

(No data provided.)



Key Issues

- Malaria (PMI)
- Child Survival Activities
- TB
- Workplace Programs
- End-of-Program Evaluation
- Family Planning

Budget Code Information

Mechanism ID: 13868			
Mechanism Name: APHIAplus Health Communication and Marketing (APHIAplus HCM)			
Prime Partner Name: Population Services International			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	50,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	25,357	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	525,861	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	150,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVAB	375,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	375,000	0



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	222,263	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	300,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	30,000	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2014	2015
SITE_SUPP	By program area/support type: HTC Direct Service Delivery (DSD)	0	0
SITE_SUPP	By program area/support type: HTC Technical Assistance-only (TA)	486	0
SITE_SUPP	By program area/support type: Treatment Direct Service Delivery (DSD)	0	0
SITE_SUPP	By program area/support type: Treatment Technical Assistance-only (TA)	76	0
SITE_SUPP	By program area/support type: Care and Support Direct Service Delivery (DSD)	0	0
SITE_SUPP	By program area/support type: Care and Support Technical Assistance-only (TA)	486	0
SITE_SUPP	By program area/support type: Food and Nutrition Direct Service Delivery (DSD)	0	0
SITE_SUPP	By program area/support type: Food and Nutrition Technical Assistance-only (TA)	0	0
SITE_SUPP	By program area/support type: PMTCT Direct	0	0



	Service Delivery (DSD)		
SITE_SUPP	By program area/support type: PMTCT Technical Assistance-only (TA)	91	0
SITE_SUPP	By program area/support type: TB/HIV Direct Service Delivery (DSD)	0	0
SITE_SUPP	By program area/support type: TB/HIV Technical Assistance-only (TA)	0	0
SITE_SUPP	By program area/support type: VMMC Direct Service Delivery (DSD)	0	0
SITE_SUPP	By program area/support type: VMMC Technical Assistance-only (TA)	10	0
SITE_SUPP	By program area/support type: General Population Prevention Direct Service Delivery (DSD)	0	0
SITE_SUPP	By program area/support type: General Population Prevention Technical Assistance-only (TA)	0	0
SITE_SUPP	By program area/support type: Key Populations Prevention Direct Service Delivery (DSD)	0	0
SITE_SUPP	By program area/support type: Key Populations Prevention Technical Assistance-only (TA)	0	0
SITE_SUPP	By program area/support type: OVC Direct Service Delivery (DSD)	0	0
SITE_SUPP	By program area/support type: OVC Technical Assistance-only (TA)	0	0
SITE_SUPP	By program area/support type: PHDP/Family Planning & Integration Direct Service Delivery (DSD)	0	0
SITE_SUPP	By program area/support type: PHDP/Family Planning & Integration Technical Assistance-only (TA)	0	0
SITE_SUPP	By program area/support type: Lab Direct	0	0



	Service Delivery (DSD)		
SITE_SUPP	By program area/support type: Lab Technical Assistance-only (TA)	0	0
PMTCT_ARV_DSD	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	0	0
PMTCT_ARV_NA	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	0	0
PMTCT_ARV_NA	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	0	0
PMTCT_ARV_NGI	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	302	0
PMTCT_ARV_NGI	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	302	0
PMTCT_ARV_NGI	Life-long ART (including Option B+)	242	0
PMTCT_ARV_NGI	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	121	0
PMTCT_ARV_NGI	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	121	0
PMTCT_ARV_NGI	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)	0	0
PMTCT_ARV_NGI	Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)	60	0
PMTCT_ARV_NGI	Single-dose nevirapine (with or without tail)	0	0
PMTCT_ARV_NGI	Sum of Regimen disaggregates	302	0

PMTCT_ARV_NGI	Sum of New and Current disaggregates	242	0
PMTCT_ARV_TA	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	302	0
PMTCT_ARV_TA	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	302	0
PMTCT_ARV_TA	Life-long ART (including Option B+)	242	0
PMTCT_ARV_TA	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	121	0
PMTCT_ARV_TA	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	121	0
PMTCT_ARV_TA	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)	0	0
PMTCT_ARV_TA	Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)	60	0
PMTCT_ARV_TA	Single-dose nevirapine (with or without tail)	0	0
PMTCT_ARV_TA	Sum of Regimen Type disaggregates	302	0
PMTCT_ARV_TA	Sum of New and Current disaggregates	242	0
PMTCT_SITE	Number of PEPFAR-supported sites achieving 90% ARV or ART coverage for HIV+ pregnant women	27	0
PMTCT_SITE	Total number of PEPFAR supported sites providing PMTCT services (HTC and ARV or ART services)	46	0
PMTCT_SITE	By site support type: Direct Service Delivery (DSD): Number of PEPFAR-supported sites achieving 90% ARV or ART coverage for HIV+ pregnant women	0	0
PMTCT_SITE	By site support type: Technical	27	0



	Assistance-only (TA): Number of PEPFAR-supported sites achieving 90% ARV or ART coverage for HIV+ pregnant women		
PMTCT_SITE	Sum of Numerator Support Type disaggregates	27	0
PMTCT_SITE	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR supported sites providing PMTCT services (HTC and ARV or ART services)	0	0
PMTCT_SITE	By site support type: Technical Assistance-only (TA): Total number of PEPFAR supported sites providing PMTCT services (HTC and ARV or ART services)	46	0
PMTCT_SITE	Sum of Denominator Support Type disaggregates	46	0
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	0	0
PMTCT_STAT_NGI	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	6,000	0
PMTCT_STAT_NGI	Number of new ANC and L&D clients	6,000	0
PMTCT_STAT_NGI	By: Known positives at entry	121	0
PMTCT_STAT_NGI	By: Number of new positives identified	181	0
PMTCT_STAT_NGI	Sum of Positives Status disaggregates	302	0
VMMC_AE_DSD	Number of males circumcised surgically or by medical device that experienced at least one moderate or severe adverse event(s) (AEs)	0	0
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	0	0
VMMC_CIRC_NA	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the	0	0

	reporting period		
VMMC_CIRC_NGI	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	510	510
VMMC_CIRC_NGI	By Age: <1	0	0
VMMC_CIRC_NGI	By Age: 1-9	10	10
VMMC_CIRC_NGI	By Age: 10-14	10	10
VMMC_CIRC_NGI	By Age: 15-19	80	80
VMMC_CIRC_NGI	By Age: 20-24	200	200
VMMC_CIRC_NGI	By Age: 25-49	200	200
VMMC_CIRC_NGI	By Age: 50+	10	10
VMMC_CIRC_NGI	Sum of Age disaggregates	510	510
VMMC_CIRC_NGI	By HIV status: Number of HIV-positive clients (tested HIV positive at VMMC site)	28	28
VMMC_CIRC_NGI	By HIV status: Number of HIV-negative clients (tested HIV negative at VMMC program)	482	482
VMMC_CIRC_NGI	By HIV status: Number of clients with undocumented/indeterminate HIV status or not tested for HIV at site	0	0
VMMC_CIRC_NGI	By circumcision technique: Surgical VMMC	510	510
VMMC_CIRC_NGI	By circumcision technique: Device-based VMMC	0	0
VMMC_CIRC_NGI	By follow-up status: Number of surgically circumcised clients who returned at least once for follow-up care within 14 days of circumcision surgery	306	306
VMMC_CIRC_NGI	By follow-up status: Number of surgically circumcised clients who did NOT return for follow-up care within 14 days of circumcision surgery	201	204
VMMC_CIRC_TA	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the	510	510



	reporting period		
VMMC_CIRC_TA	By Age: <1	0	0
VMMC_CIRC_TA	By Age: 1-9	10	10
VMMC_CIRC_TA	By Age: 10-14	10	10
VMMC_CIRC_TA	By Age: 15-19	80	80
VMMC_CIRC_TA	By Age: 20-24	200	200
VMMC_CIRC_TA	By Age: 25-49	200	200
VMMC_CIRC_TA	By Age: 50+	10	10
VMMC_CIRC_TA	Sum of Age disaggregations	510	510
VMMC_CIRC_TA	By HIV status: Number of HIV-positive clients (tested HIV positive at VMMC site)	28	28
VMMC_CIRC_TA	By HIV status: Number of HIV-negative clients (tested HIV negative at VMMC program)	482	482
VMMC_CIRC_TA	By HIV status: Number of clients with undocumented/indeterminate HIV status or not tested for HIV at site	0	0
VMMC_CIRC_TA	By circumcision technique: Surgical VMMC	510	510
VMMC_CIRC_TA	By circumcision technique: Device-based VMMC	0	0
VMMC_CIRC_TA	By follow-up status: Number of surgically circumcised clients who returned at least once for follow-up care within 14 days of circumcision surgery	306	306
VMMC_CIRC_TA	By follow-up status: Number of surgically circumcised clients who did NOT return for follow-up care within 14 days of circumcision surgery	201	204
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	0	0
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results	0	0



	during the past 12 months		
HTC_TST_NA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	0	0
HTC_TST_NGI	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	140,000	140,000
HTC_TST_NGI	By Test Result: Negative	134,400	134,400
HTC_TST_NGI	By Test Result: Positive	5,600	5,600
HTC_TST_NGI	Sum of Test Result disaggregates	140,000	140,000
HTC_TST_NGI	Age/sex: <1 Male	0	0
HTC_TST_NGI	Age/sex: 1-4 Male	4,900	4,900
HTC_TST_NGI	Age/sex: 5-9 Male	2,100	2,100
HTC_TST_NGI	Age/sex: 10-14 Male	3,500	3,500
HTC_TST_NGI	Age/sex: 15-19 Male	7,000	7,000
HTC_TST_NGI	Age/sex: 20-24 Male	17,500	17,500
HTC_TST_NGI	Age/sex: 25-49 Male	28,000	28,000
HTC_TST_NGI	Age/sex: 50+ Male	7,000	7,000
HTC_TST_NGI	Age/sex: <1 Female	0	0
HTC_TST_NGI	Age/sex: 1-4 Female	4,900	4,900
HTC_TST_NGI	Age/sex: 5-9 Female	2,100	2,100
HTC_TST_NGI	Age/sex: 10-14 Female	3,500	3,500
HTC_TST_NGI	Age/sex: 15-19 Female	7,000	7,000
HTC_TST_NGI	Age/sex: 20-24 Female	17,500	17,500
HTC_TST_NGI	Age/sex: 25-49 Female	28,000	28,000
HTC_TST_NGI	Age/sex: 50+ Female	7,000	7,000
HTC_TST_NGI	Sum of Age/Sex disaggregates	140,000	140,000
HTC_TST_NGI	Aggregated Age/sex: <15 Male	10,500	10,500
HTC_TST_NGI	Aggregated Age/sex: 15+ Male	59,500	59,500
HTC_TST_NGI	Aggregated Age/sex: <15 Female	10,500	10,500
HTC_TST_NGI	Aggregated Age/sex: 15+ Female	59,500	59,500
HTC_TST_NGI	Sum of Aggregated Age/Sex <15	21,000	21,000



HTC_TST_NGI	Sum of Aggregated Age/Sex 15+	119,000	119,000
HTC_TST_NGI	Sum of Aggregated Age/Sex disaggregates	140,000	140,000
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	140,000	140,000
HTC_TST_TA	By Test Result: Negative	134,400	134,400
HTC_TST_TA	By Test Result: Positive	5,600	5,600
HTC_TST_TA	Sum of Test Result disaggregates	140,000	140,000
HTC_TST_TA	Age/sex: <1 Male	0	0
HTC_TST_TA	Age/sex: 1-4 Male	4,900	4,900
HTC_TST_TA	Age/sex: 5-9 Male	2,100	2,100
HTC_TST_TA	Age/sex: 10-14 Male	3,500	3,500
HTC_TST_TA	Age/sex: 15-19 Male	7,000	7,000
HTC_TST_TA	Age/sex: 20-24 Male	17,500	17,500
HTC_TST_TA	Age/sex: 25-49 Male	28,000	28,000
HTC_TST_TA	Age/sex: 50+ Male	7,000	7,000
HTC_TST_TA	Age/sex: <1 Female	0	0
HTC_TST_TA	Age/sex: 1-4 Female	4,900	4,900
HTC_TST_TA	Age/sex: 5-9 Female	2,100	2,100
HTC_TST_TA	Age/sex: 10-14 Female	3,500	3,500
HTC_TST_TA	Age/sex: 15-19 Female	7,000	7,000
HTC_TST_TA	Age/sex: 20-24 Female	17,500	17,500
HTC_TST_TA	Age/sex: 25-49 Female	28,000	28,000
HTC_TST_TA	Age/sex: 50+ Female	7,000	7,000
HTC_TST_TA	Sum of Age/Sex disaggregates	140,000	140,000
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	10,500	10,500
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	59,500	59,500
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	10,500	10,500
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	59,500	59,500



HTC_TST_TA	Sum of Aggregated Age/Sex <15	21,000	21,000
HTC_TST_TA	Sum of Aggregated Age/Sex 15+	119,000	119,000
HTC_TST_TA	Sum of Aggregated Age/Sex disaggregates	140,000	140,000
GEND_GBV_DSD	Number of people receiving post-GBV care	0	0
OVC_ACC_DSD	Number of active beneficiaries receiving support from PEPFAR OVC programs to access HIV services	0	0
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	0	0
C2.1.D_NGI	Number of HIV-positive individuals receiving a minimum of one clinical service	4,832	5,294
C2.1.D_NGI	By Age/Sex: <15 Female	235	235
C2.1.D_NGI	By Age/Sex: <15 Male	234	234
C2.1.D_NGI	By Age/Sex: 15+ Female	2,588	3,052
C2.1.D_NGI	By Age/Sex: 15+ Male	1,775	1,773
C2.1.D_NGI	Sum of Age/Sex disaggregates	4,832	5,294
C2.1.D_NGI	By Age: <15	469	469
C2.1.D_NGI	By Age: 15+	4,363	4,825
C2.1.D_NGI	Sum of Age disaggregates	4,832	5,294
C2.1.D_NGI	By Sex: Female	2,823	3,287
C2.1.D_NGI	By Sex: Male	2,009	2,007
C2.1.D_NGI	Sum of Sex disaggregates	4,832	5,294
C2.1.D_TA	Number of HIV-positive individuals receiving a minimum of one clinical service	4,832	5,294
C2.1.D_TA	By Age/Sex: <15 Female	235	235
C2.1.D_TA	By Age/Sex: <15 Male	234	234
C2.1.D_TA	By Age/Sex: 15+ Female	2,588	3,052
C2.1.D_TA	By Age/Sex: 15+ Male	1,775	1,773
C2.1.D_TA	Sum of Age/Sex disaggregates	4,832	5,294
C2.1.D_TA	By Age: <15	469	469
C2.1.D_TA	By Age: 15+	4,363	4,825
C2.1.D_TA	Sum of Age disaggregates	4,832	5,294



C2.1.D_TA	By Sex: Female	2,823	3,287
C2.1.D_TA	By Sex: Male	2,009	2,007
C2.1.D_TA	Sum of Sex disaggregates	4,832	5,294
CARE_CURR_DSD	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	0	0
CARE_CURR_TA	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	4,812	5,294
CARE_CURR_TA	Age/sex: <1 Male	34	34
CARE_CURR_TA	Age/sex: 1-4 Male	50	50
CARE_CURR_TA	Age/sex: 5-9 Male	50	50
CARE_CURR_TA	Age/sex: 10-14 Male	100	100
CARE_CURR_TA	Age/sex: 15-19 Male	200	200
CARE_CURR_TA	Age/sex: 20-24 Male	300	400
CARE_CURR_TA	Age/sex: 25-49 Male	1,200	1,100
CARE_CURR_TA	Age/sex: 50+ Male	55	73
CARE_CURR_TA	Age/sex: <1 Female	35	35
CARE_CURR_TA	Age/sex: 1-4 Female	50	50
CARE_CURR_TA	Age/sex: 5-9 Female	50	50
CARE_CURR_TA	Age/sex: 10-14 Female	100	100
CARE_CURR_TA	Age/sex: 15-19 Female	300	200
CARE_CURR_TA	Age/sex: 20-24 Female	400	800
CARE_CURR_TA	Age/sex: 25-49 Female	1,822	2,000
CARE_CURR_TA	Age/sex: 50+ Female	66	52
CARE_CURR_TA	Sum of Age/Sex disaggregates	4,812	5,294
CARE_CURR_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	234	234
CARE_CURR_TA	Aggregated Age/sex - USE WITH HQ	1,755	1,773



	PERMISSION ONLY: 15+ Male		
CARE_CURR_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	235	235
CARE_CURR_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	2,588	3,052
CARE_CURR_TA	Sum of Aggregated Age/Sex disaggregates	4,812	5,294
CARE_NEW_DSD	Number of HIV-infected adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load	962	957
CARE_NEW_DSD	Age/sex: <1 Male	1	1
CARE_NEW_DSD	Age/sex: 1-4 Male	1	1
CARE_NEW_DSD	Age/sex: 5-9 Male	1	1
CARE_NEW_DSD	Age/sex: 10-14 Male	1	1
CARE_NEW_DSD	Age/sex: 15-19 Male	48	48
CARE_NEW_DSD	Age/sex: 20-24 Male	53	50
CARE_NEW_DSD	Age/sex: 25-49 Male	100	100
CARE_NEW_DSD	Age/sex: 50+ Male	104	104
CARE_NEW_DSD	Age/sex: <1 Female	2	2
CARE_NEW_DSD	Age/sex: 1-4 Female	1	1
CARE_NEW_DSD	Age/sex: 5-9 Female	1	1
CARE_NEW_DSD	Age/sex: 10-14 Female	1	1
CARE_NEW_DSD	Age/sex: 15-19 Female	96	96
CARE_NEW_DSD	Age/sex: 20-24 Female	200	200
CARE_NEW_DSD	Age/sex: 25-49 Female	300	300
CARE_NEW_DSD	Age/sex: 50+ Female	52	50
CARE_NEW_DSD	Sum of Age/sex disaggregates	962	957
CARE_NEW_DSD	Aggregated Age/sex: <15 Male	4	4
CARE_NEW_DSD	Aggregated Age/sex: 15+ Male	305	302
CARE_NEW_DSD	Aggregated Age/sex: <15 Female	5	5
CARE_NEW_DSD	Aggregated Age/sex: 15+ Female	648	646



CARE_NEW_DSD	Sum of Aggregated Age/sex disaggregates	962	957
CARE_SITE	Number of PEPFAR-supported HIV clinical care sites at which at least 80% of PLHIV received all of the following during the reporting period: 1) clinical assessment (WHO staging) OR CD4 count OR viral load, AND 2) TB screening at last visit, AND 3) if eligible, cotrimoxazole	437	437
CARE_SITE	Total number of PEPFAR supported sites providing clinical care services	486	486
CARE_SITE	By site support type: Direct Service Delivery (DSD): Number of PEPFAR-supported HIV clinical care sites at which at least 80% of PLHIV received all of the following during the reporting period: 1) clinical assessment (WHO staging) OR CD4 count OR viral load, AND 2) TB screening at last visit, AND 3) if eligible, cotrimoxazole	0	0
CARE_SITE	By site support type: Technical Assistance-only (TA): Number of PEPFAR-supported HIV clinical care sites at which at least 80% of PLHIV received all of the following during the reporting period: 1) clinical assessment (WHO staging) OR CD4 count OR viral load, AND 2) TB screening at last visit, AND 3) if eligible, cotrimoxazole	437	437
CARE_SITE	Sum of Numerator Site Support Type disaggregates	437	437
CARE_SITE	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR supported sites providing clinical care services	0	0
CARE_SITE	By site support type: Technical Assistance-only (TA): Total number of PEPFAR supported sites providing clinical care services	486	486



CARE_SITE	Sum of Denominator Site Support Type disaggregates	486	486
FN_SITE	Number of PEPFAR-supported sites achieving 90% nutrition assessments that result in accurate categorization of malnutrition	0	0
FN_SITE	Total number of PEPFAR-supported sites providing nutrition assessment, counseling and support (NACS) services	0	0
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	3,080	3,080
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	3,850	3,850
TB_ART_DSD	Age: 0-4	20	20
TB_ART_DSD	Age: 5-14	8	8
TB_ART_DSD	Age: 15+	3,052	3,052
TB_ART_DSD	Male	1,080	1,080
TB_ART_DSD	Female	2,000	2,000
TB_ART_DSD	Sum of Sex disaggregates	3,080	3,080
TB_ART_DSD	Newly tested	1,221	1,221
TB_ART_DSD	Known HIV-positive	1,859	1,859
TB_ART_DSD	Sum of Test Status disaggregates	3,080	3,080
TB_ART_DSD	Aggregated Age: <15	28	28
TB_ART_DSD	Aggregated Age: 15+	3,052	3,052
TB_ART_DSD	Sum of Aggregated Age disaggregates	3,080	3,080
TB_ARTSITE	The number of PEPFAR-supported TB basic management units at which 80% of registered TB cases who are HIV-positive are on ART, during the reporting period	160	160
TB_ARTSITE	The number of PEPFAR-supported TB basic management units	160	160



TB_ARTSITE	By site support type: Direct Service Delivery (DSD): The number of PEPFAR-supported TB basic management units at which 80% of registered TB cases who are HIV-positive are on ART, during the reporting period	0	0
TB_ARTSITE	By site support type: Technical Assistance-only (TA): The number of PEPFAR-supported TB basic management units at which 80% of registered TB cases who are HIV-positive are on ART, during the reporting period	160	160
TB_ARTSITE	Sum of Numerator Site Support Type disaggregates	160	160
TB_ARTSITE	By site support type: Direct Service Delivery (DSD): The number of PEPFAR-supported TB basic management units	0	0
TB_ARTSITE	By site support type: Technical Assistance-only (TA): The number of PEPFAR-supported TB basic management units	160	160
TB_ARTSITE	Sum of Denominator Site Support Type disaggregates	160	160
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	0	0
TX_CURR_NA	Number of adults and children receiving antiretroviral therapy (ART)	0	0
TX_CURR_NGI	Number of adults and children receiving antiretroviral therapy (ART)	3,513	3,885
TX_CURR_NGI	Age/Sex: <1 Male	10	20
TX_CURR_NGI	Age/Sex: 1-4 Male	50	60
TX_CURR_NGI	Age/Sex: 5-14 Male	86	109
TX_CURR_NGI	Age/Sex: 15+ Male	1,078	1,227
TX_CURR_NGI	Age/Sex: <1 Female	10	20
TX_CURR_NGI	Age/Sex: 1-4 Female	50	60



TX_CURR_NGI	Age/Sex: 5-14 Female	86	109
TX_CURR_NGI	Age/Sex: 15+ Female	2,143	2,280
TX_CURR_NGI	Sum of Age/Sex disaggregates	3,513	3,885
TX_CURR_NGI	Aggregated Age/Sex: <1 Male	10	20
TX_CURR_NGI	Aggregated Age/Sex: <1 Female	10	20
TX_CURR_NGI	Aggregated Age/Sex: <15 Male	146	189
TX_CURR_NGI	Aggregated Age/Sex: 15+ Male	1,078	1,227
TX_CURR_NGI	Aggregated Age/Sex: <15 Female	146	189
TX_CURR_NGI	Aggregated Age/Sex: 15+ Female	2,143	2,280
TX_CURR_NGI	Sum of Aggregated Age/Sex disaggregates	3,513	3,885
TX_CURR_NGI	Sum of Aggregated Age/Sex <15	292	378
TX_CURR_NGI	Sum of Aggregated Age/Sex 15+	3,221	3,507
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	3,513	3,885
TX_CURR_TA	Age/Sex: <1 Male	10	20
TX_CURR_TA	Age/Sex: 1-4 Male	50	60
TX_CURR_TA	Age/Sex: 5-14 Male	86	109
TX_CURR_TA	Age/Sex: 15+ Male	1,078	1,227
TX_CURR_TA	Age/Sex: <1 Female	10	20
TX_CURR_TA	Age/Sex: 1-4 Female	50	60
TX_CURR_TA	Age/Sex: 5-14 Female	86	109
TX_CURR_TA	Age/Sex: 15+ Female	2,143	2,280
TX_CURR_TA	Sum of Age/Sex disaggregations	292	378
TX_CURR_TA	Aggregated Age/Sex: <1 Male	10	20
TX_CURR_TA	Aggregated Age/Sex: <1 Female	10	20
TX_CURR_TA	Aggregated Age/Sex: <15 Male	146	189
TX_CURR_TA	Aggregated Age/Sex: 15+ Male	1,078	1,227
TX_CURR_TA	Aggregated Age/Sex: <15 Female	146	189
TX_CURR_TA	Aggregated Age/Sex: 15+ Female	2,143	2,280
TX_CURR_TA	Sum of Aggregated Age/Sex <15	292	378
TX_CURR_TA	Sum of Aggregated Age/Sex 15+	3,221	3,507
TX_CURR_TA	Sum of Aggregated Age/Sex disaggregates	3,513	3,885



TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	899	891
TX_NEW_DSD	By Age/Sex: <1 Male	9	10
TX_NEW_DSD	By Age/Sex: 1-4 Male	7	10
TX_NEW_DSD	By Age/Sex: 5-9 Male	7	10
TX_NEW_DSD	By Age/Sex: 10-14 Male	8	11
TX_NEW_DSD	By Age/Sex: 15-19 Male	53	40
TX_NEW_DSD	By Age/Sex: 20-24 Male	100	100
TX_NEW_DSD	By Age/Sex: 25-49 Male	100	100
TX_NEW_DSD	By Age/Sex: 50+ Male	40	43
TX_NEW_DSD	By Age/Sex: <1 Female	9	10
TX_NEW_DSD	By Age/Sex: 1-4 Female	7	10
TX_NEW_DSD	By Age/Sex: 5-9 Female	7	10
TX_NEW_DSD	By Age/Sex: 10-14 Female	8	11
TX_NEW_DSD	By Age/Sex: 15-19 Female	100	80
TX_NEW_DSD	By Age/Sex: 20-24 Female	200	200
TX_NEW_DSD	By Age/Sex: 25-49 Female	200	200
TX_NEW_DSD	By Age/Sex: 50+ Female	44	46
TX_NEW_DSD	Sum of Age/Sex disaggregates	899	891
TX_NEW_DSD	Aggregated Grouping by Age: <1 Male	9	10
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	15	31
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	293	283
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <1 Female	9	10
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	15	31
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	544	526
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	867	871
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	764	757
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the	899	891



	beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up		
TX_RET_DSD	Age: 0-4 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	27	34
TX_RET_DSD	Age: 5-14 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	26	36
TX_RET_DSD	Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	711	688
TX_RET_DSD	Age: 0-4 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	32	40
TX_RET_DSD	Age: 5-14 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	30	42
TX_RET_DSD	Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	837	809
TX_RET_DSD	Aggregated Age: <15 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	53	70
TX_RET_DSD	Aggregated Age: 15+ (Numerator: Number of adults and children who are still alive and on	711	688

	treatment at 12 months after initiating ART)		
TX_RET_DSD	Aggregated Age: <15 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	30	62
TX_RET_DSD	Aggregated Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	837	809
TX_RET_DSD	Pregnancy and breastfeeding status (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	0	0
TX_RET_DSD	Pregnancy and breastfeeding status (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	0	0
SI_HIS	Existence of a national registry of health facilities that is updated annually	1	1
SI_HIS	Full national facility list coordinated with PEPFAR	1	1
SI_ME	Existence of a national HIV/AIDS M&E system based on the UNAIDS 12 components model	1	1
TB_SCREEN_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period	3,850	3,850
TB_SCREEN_DSD	Number of HIV positive adults and children who received at least one of the following	0	0



	during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load		
TB_SCREEN_DSD	Age: <1	20	20
TB_SCREEN_DSD	Age: 1-4	65	65
TB_SCREEN_DSD	Age: 5-9	100	100
TB_SCREEN_DSD	Age: 10-14	200	200
TB_SCREEN_DSD	Age: 15-19	300	300
TB_SCREEN_DSD	Age: 20-24	1,500	1,500
TB_SCREEN_DSD	Age: 25-49	1,500	1,500
TB_SCREEN_DSD	Age: 50+	165	165
TB_SCREEN_DSD	Sum of Age disaggregates	685	685

Implementing Mechanism Details

Mechanism ID: 13867	Mechanism Name: Strengthening Health Outcomes through the Private Sector (SHOPS)
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Abt Associates	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: No	
G2G: No	Managing Agency:

Total All Funding Sources: 300,000	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 0	
FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount
GHP-State	300,000

Sub Partner Name(s)

Banyan Global	JHPIEGO	Marie Stopes International
Monitoring Task Group	O'Hanlon Health Consulting	

Approved



Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

Malaria (PMI)
Child Survival Activities
Safe Motherhood
TB
Workplace Programs
Family Planning

Budget Code Information

Mechanism ID:	13867		
Mechanism Name:	Strengthening Health Outcomes through the Private Sector (SHOPS)		
Prime Partner Name:	Abt Associates		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	300,000	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 13805	Mechanism Name: International Training and Education Center for Health (ITECH)
Funding Agency: HHS/HRSA	Procurement Type: Cooperative Agreement
Prime Partner Name: University of Washington	
Agreement Start Date: Redacted	Agreement End Date: Redacted

Approved



TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: No	
G2G: No	Managing Agency:
Total All Funding Sources: 2,100,000	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 0	
FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount
GHP-State	2,100,000

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

(No data provided.)

Budget Code Information

Mechanism ID:	13805		
Mechanism Name:	International Training and Education Center for Health (ITECH)		
Prime Partner Name:	University of Washington		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	2,100,000	0

Implementing Mechanism Indicator Information

(No data provided.)



Implementing Mechanism Details

Mechanism ID: 13802	Mechanism Name: Central Province (CRISSP)
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: University of Nairobi	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: No	
G2G: Yes	Managing Agency: HHS/CDC

Total All Funding Sources: 3,349,695	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 275,000	
FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount
GHP-State	3,349,695

Sub Partner Name(s)

Futures Group	Strathmore University Business School	University of Maryland, Institute of Human Virology
---------------	---------------------------------------	---

Cross-Cutting Budget Attribution(s)

Motor Vehicles: Purchased	47,500
---------------------------	--------

Key Issues

(No data provided.)

Budget Code Information

Mechanism ID: 13802



Mechanism Name:	Central Province (CRISSP)		
Prime Partner Name:	University of Nairobi		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	74,879	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	250,428	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	133,036	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	213,129	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	312,548	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	2,236,849	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	128,826	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2014	2015	Planning Budget Targets
SITE_SUPP	Number of unique sites supported by PEPFAR	56	56	Redacted
SITE_SUPP	By program area/support type: HTC Direct Service Delivery (DSD)	56	56	Redacted



SITE_SUPP	By program area/support type: HTC Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: Treatment Direct Service Delivery (DSD)	56	56	Redacted
SITE_SUPP	By program area/support type: Treatment Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: Care and Support Direct Service Delivery (DSD)	56	56	Redacted
SITE_SUPP	By program area/support type: Care and Support Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: Food and Nutrition Direct Service Delivery (DSD)	56	56	Redacted
SITE_SUPP	By program area/support type: Food and Nutrition Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: PMTCT Direct Service Delivery (DSD)	56	56	Redacted
SITE_SUPP	By program area/support type: PMTCT Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: TB/HIV Direct Service Delivery (DSD)	56	56	Redacted
SITE_SUPP	By program area/support type: TB/HIV Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: VMMC Direct Service Delivery (DSD)	0	0	Redacted
SITE_SUPP	By program area/support type: VMMC Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: General Population Prevention Direct Service Delivery (DSD)	0	0	Redacted



SITE_SUPP	By program area/support type: General Population Prevention Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: Key Populations Prevention Direct Service Delivery (DSD)	0	0	Redacted
SITE_SUPP	By program area/support type: Key Populations Prevention Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: OVC Direct Service Delivery (DSD)	0	0	Redacted
SITE_SUPP	By program area/support type: OVC Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: PHDP/Family Planning & Integration Direct Service Delivery (DSD)	56	56	Redacted
SITE_SUPP	By program area/support type: PHDP/Family Planning & Integration Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: Lab Direct Service Delivery (DSD)	48	48	Redacted
SITE_SUPP	By program area/support type: Lab Technical Assistance-only (TA)	0	0	Redacted
PMTCT_ARV_DS D	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	1,152	1,175	Redacted
PMTCT_ARV_DS D	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	1,152	1,175	Redacted
PMTCT_ARV_DS D	Life-long ART (including Option B+)	864	881	Redacted
PMTCT_ARV_DS D	Sub-Disag of Life-long ART: Newly initiated on treatment during the current	403	411	Redacted



	pregnancy			
PMTCT_ARV_DS D	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	461	470	Redacted
PMTCT_ARV_DS D	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)	0	0	Redacted
PMTCT_ARV_DS D	Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)	288	294	Redacted
PMTCT_ARV_DS D	Single-dose nevirapine (with or without tail)	0	0	Redacted
PMTCT_ARV_DS D	Sum of Regimen Type disaggregates	1,152	1,175	Redacted
PMTCT_ARV_DS D	Sum of New and Current disaggregates	864	881	Redacted
PMTCT_ARV_NGI	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	1,152	1,175	Redacted
PMTCT_ARV_NGI	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	1,152	1,175	Redacted
PMTCT_ARV_NGI	Life-long ART (including Option B+)	864	881	Redacted
PMTCT_ARV_NGI	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	403	411	Redacted
PMTCT_ARV_NGI	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	461	470	Redacted
PMTCT_ARV_NGI	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)	0	0	Redacted
PMTCT_ARV_NGI	Maternal AZT (prophylaxis component	288	294	Redacted



	of WHO Option A during pregnancy and delivery)			
PMTCT_ARV_NGI	Single-dose nevirapine (with or without tail)	0	0	Redacted
PMTCT_ARV_NGI	Sum of Regimen disaggregates	1,152	1,175	Redacted
PMTCT_ARV_NGI	Sum of New and Current disaggregates	864	881	Redacted
PMTCT_SITE	Number of PEPFAR-supported sites achieving 90% ARV or ART coverage for HIV+ pregnant women	56	56	Redacted
PMTCT_SITE	Total number of PEPFAR supported sites providing PMTCT services (HTC and ARV or ART services)	56	56	Redacted
PMTCT_SITE	By site support type: Direct Service Delivery (DSD): Number of PEPFAR-supported sites achieving 90% ARV or ART coverage for HIV+ pregnant women	56	56	Redacted
PMTCT_SITE	By site support type: Technical Assistance-only (TA): Number of PEPFAR-supported sites achieving 90% ARV or ART coverage for HIV+ pregnant women	0	0	Redacted
PMTCT_SITE	Sum of Numerator Support Type disaggregates	56	56	Redacted
PMTCT_SITE	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR supported sites providing PMTCT services (HTC and ARV or ART services)	56	56	Redacted
PMTCT_SITE	By site support type: Technical Assistance-only (TA): Total number of PEPFAR supported sites providing PMTCT services (HTC and ARV or ART services)	0	0	Redacted
PMTCT_SITE	Sum of Denominator Support Type	56	56	Redacted

	disaggregates			
PMTCT_STAT_DS D	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	17,954	17,233	Redacted
PMTCT_STAT_DS D	Number of new ANC and L&D clients	17,954	17,233	Redacted
PMTCT_STAT_DS D	By: Known positives at entry	542	552	Redacted
PMTCT_STAT_DS D	By: Number of new positives identified	610	623	Redacted
PMTCT_STAT_DS D	Sum of Positives Status disaggregates	1,152	1,175	Redacted
PMTCT_STAT_NG I	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	17,954	17,233	Redacted
PMTCT_STAT_NG I	Number of new ANC and L&D clients	17,954	17,233	Redacted
PMTCT_STAT_NG I	By: Known positives at entry	542	552	Redacted
PMTCT_STAT_NG I	By: Number of new positives identified	610	623	Redacted
PMTCT_STAT_NG I	Sum of Positives Status disaggregates	1,152	1,175	Redacted
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	76,500	75,493	Redacted
HTC_TST_DSD	By Test Result: Negative	73,440	72,473	Redacted
HTC_TST_DSD	By Test Result: Positive	3,060	3,020	Redacted
HTC_TST_DSD	Sum of Test Result disaggregates	76,500	75,493	Redacted
HTC_TST_DSD	Age/sex: <1 Male	0	0	Redacted
HTC_TST_DSD	Age/sex: 1-4 Male	2,677	2,642	Redacted
HTC_TST_DSD	Age/sex: 5-9 Male	1,147	1,133	Redacted



HTC_TST_DSD	Age/sex: 10-14 Male	1,913	1,887	Redacted
HTC_TST_DSD	Age/sex: 15-19 Male	3,825	3,774	Redacted
HTC_TST_DSD	Age/sex: 20-24 Male	9,563	9,437	Redacted
HTC_TST_DSD	Age/sex: 25-49 Male	15,300	15,099	Redacted
HTC_TST_DSD	Age/sex: 50+ Male	3,825	3,774	Redacted
HTC_TST_DSD	Age/sex: <1 Female	0	0	Redacted
HTC_TST_DSD	Age/sex: 1-4 Female	2,677	2,642	Redacted
HTC_TST_DSD	Age/sex: 5-9 Female	1,147	1,133	Redacted
HTC_TST_DSD	Age/sex: 10-14 Female	1,913	1,887	Redacted
HTC_TST_DSD	Age/sex: 15-19 Female	3,825	3,774	Redacted
HTC_TST_DSD	Age/sex: 20-24 Female	9,563	9,437	Redacted
HTC_TST_DSD	Age/sex: 25-49 Female	15,300	15,099	Redacted
HTC_TST_DSD	Age/sex: 50+ Female	3,825	3,775	Redacted
HTC_TST_DSD	Sum of Age/Sex disaggregates	76,500	75,493	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	5,737	5,662	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	32,513	32,084	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	5,737	5,662	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	32,513	32,085	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	11,474	11,324	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	65,026	64,169	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	76,500	75,493	Redacted
HTC_TST_NGI	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	76,500	75,493	Redacted
HTC_TST_NGI	By Test Result: Negative	73,440	72,473	Redacted
HTC_TST_NGI	By Test Result: Positive	3,060	3,020	Redacted
HTC_TST_NGI	Sum of Test Result disaggregates	76,500	75,493	Redacted
HTC_TST_NGI	Age/sex: <1 Male	0	0	Redacted



HTC_TST_NGI	Age/sex: 1-4 Male	2,677	2,642	Redacted
HTC_TST_NGI	Age/sex: 5-9 Male	1,147	1,133	Redacted
HTC_TST_NGI	Age/sex: 10-14 Male	1,913	1,887	Redacted
HTC_TST_NGI	Age/sex: 15-19 Male	3,825	3,774	Redacted
HTC_TST_NGI	Age/sex: 20-24 Male	9,563	9,437	Redacted
HTC_TST_NGI	Age/sex: 25-49 Male	15,300	15,099	Redacted
HTC_TST_NGI	Age/sex: 50+ Male	3,825	3,774	Redacted
HTC_TST_NGI	Age/sex: <1 Female	0	0	Redacted
HTC_TST_NGI	Age/sex: 1-4 Female	2,677	2,642	Redacted
HTC_TST_NGI	Age/sex: 5-9 Female	1,147	1,133	Redacted
HTC_TST_NGI	Age/sex: 10-14 Female	1,913	1,887	Redacted
HTC_TST_NGI	Age/sex: 15-19 Female	3,825	3,774	Redacted
HTC_TST_NGI	Age/sex: 20-24 Female	9,563	9,437	Redacted
HTC_TST_NGI	Age/sex: 25-49 Female	15,300	15,099	Redacted
HTC_TST_NGI	Age/sex: 50+ Female	3,825	3,775	Redacted
HTC_TST_NGI	Sum of Age/Sex disaggregates	76,500	75,493	Redacted
HTC_TST_NGI	Aggregated Age/sex: <15 Male	5,737	5,662	Redacted
HTC_TST_NGI	Aggregated Age/sex: 15+ Male	32,513	32,084	Redacted
HTC_TST_NGI	Aggregated Age/sex: <15 Female	5,737	5,662	Redacted
HTC_TST_NGI	Aggregated Age/sex: 15+ Female	32,513	32,085	Redacted
HTC_TST_NGI	Sum of Aggregated Age/Sex <15	11,474	11,324	Redacted
HTC_TST_NGI	Sum of Aggregated Age/Sex 15+	65,026	64,169	Redacted
HTC_TST_NGI	Sum of Aggregated Age/Sex disaggregates	76,500	75,493	Redacted
C2.1.D_DSD	Number of HIV-positive individuals receiving a minimum of one clinical service	9,777	10,687	Redacted
C2.1.D_DSD	By Age/Sex: <15 Female	440	482	Redacted
C2.1.D_DSD	By Age/Sex: <15 Male	440	482	Redacted
C2.1.D_DSD	By Age/Sex: 15+ Female	5,872	6,417	Redacted
C2.1.D_DSD	By Age/Sex: 15+ Male	3,025	3,306	Redacted
C2.1.D_DSD	Sum of Age/Sex disaggregates	9,777	10,687	Redacted

C2.1.D_DSD	By Age: <15	880	964	Redacted
C2.1.D_DSD	By Age: 15+	8,897	9,723	Redacted
C2.1.D_DSD	Sum of Age disaggregates	9,777	10,687	Redacted
C2.1.D_DSD	By Sex: Female	6,312	6,899	Redacted
C2.1.D_DSD	By Sex: Male	3,465	3,788	Redacted
C2.1.D_DSD	Sum of Sex disaggregates	9,777	10,687	Redacted
C2.1.D_NGI	Number of HIV-positive individuals receiving a minimum of one clinical service	9,777	10,687	Redacted
C2.1.D_NGI	By Age/Sex: <15 Female	440	482	Redacted
C2.1.D_NGI	By Age/Sex: <15 Male	440	482	Redacted
C2.1.D_NGI	By Age/Sex: 15+ Female	5,872	6,417	Redacted
C2.1.D_NGI	By Age/Sex: 15+ Male	3,025	3,306	Redacted
C2.1.D_NGI	Sum of Age/Sex disaggregates	9,777	10,687	Redacted
C2.1.D_NGI	By Age: <15	880	964	Redacted
C2.1.D_NGI	By Age: 15+	8,897	9,723	Redacted
C2.1.D_NGI	Sum of Age disaggregates	9,777	10,687	Redacted
C2.1.D_NGI	By Sex: Female	6,312	6,899	Redacted
C2.1.D_NGI	By Sex: Male	3,465	3,788	Redacted
C2.1.D_NGI	Sum of Sex disaggregates	9,777	10,687	Redacted
C2.4.D_DSD	Number of HIV-positive patients who were screened for TB in HIV care or treatment setting	8,799	10,152	Redacted
C2.4.D_DSD	Number of HIV-positive individuals receiving a minimum of one clinical service	9,777	10,687	Redacted
C2.5.D_DSD	Number of HIV-positive patients in HIV care who started TB treatment	176	203	Redacted
C2.5.D_DSD	Number of HIV-positive individuals receiving a minimum of one clinical service	9,777	10,687	Redacted
CARE_CURR_DS D	Number of HIV positive adults and children who received at least one of	9,288	10,152	Redacted



	the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load			
CARE_CURR_DS D	Age/sex: <1 Male	14	16	Redacted
CARE_CURR_DS D	Age/sex: 1-4 Male	100	110	Redacted
CARE_CURR_DS D	Age/sex: 5-9 Male	170	186	Redacted
CARE_CURR_DS D	Age/sex: 10-14 Male	134	146	Redacted
CARE_CURR_DS D	Age/sex: 15-19 Male	71	78	Redacted
CARE_CURR_DS D	Age/sex: 20-24 Male	132	144	Redacted
CARE_CURR_DS D	Age/sex: 25-49 Male	1,985	2,169	Redacted
CARE_CURR_DS D	Age/sex: 50+ Male	686	749	Redacted
CARE_CURR_DS D	Age/sex: <1 Female	14	16	Redacted
CARE_CURR_DS D	Age/sex: 1-4 Female	95	105	Redacted
CARE_CURR_DS D	Age/sex: 5-9 Female	176	192	Redacted
CARE_CURR_DS D	Age/sex: 10-14 Female	133	145	Redacted
CARE_CURR_DS D	Age/sex: 15-19 Female	118	129	Redacted
CARE_CURR_DS D	Age/sex: 20-24 Female	488	534	Redacted
CARE_CURR_DS D	Age/sex: 25-49 Female	4,171	4,558	Redacted
CARE_CURR_DS	Age/sex: 50+ Female	801	875	Redacted



D				
CARE_CURR_DS D	Sun of Age/Sex disaggregates	9,288	10,152	Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	418	458	Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	2,874	3,140	Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	418	458	Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	5,578	6,096	Redacted
CARE_CURR_DS D	Sum of Aggregated Age/Sex disaggregates	9,288	10,152	Redacted
CARE_NEW_DSD	Number of HIV-infected adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load	1,858	1,846	Redacted
CARE_NEW_DSD	Age/sex: <1 Male	3	3	Redacted
CARE_NEW_DSD	Age/sex: 1-4 Male	20	20	Redacted
CARE_NEW_DSD	Age/sex: 5-9 Male	34	34	Redacted
CARE_NEW_DSD	Age/sex: 10-14 Male	27	26	Redacted
CARE_NEW_DSD	Age/sex: 15-19 Male	12	12	Redacted
CARE_NEW_DSD	Age/sex: 20-24 Male	50	50	Redacted
CARE_NEW_DSD	Age/sex: 25-49 Male	430	427	Redacted
CARE_NEW_DSD	Age/sex: 50+ Male	82	83	Redacted
CARE_NEW_DSD	Age/sex: <1 Female	3	3	Redacted
CARE_NEW_DSD	Age/sex: 1-4 Female	19	19	Redacted
CARE_NEW_DSD	Age/sex: 5-9 Female	35	35	Redacted
CARE_NEW_DSD	Age/sex: 10-14 Female	27	26	Redacted
CARE_NEW_DSD	Age/sex: 15-19 Female	28	27	Redacted
CARE_NEW_DSD	Age/sex: 20-24 Female	51	51	Redacted



CARE_NEW_DSD	Age/sex: 25-49 Female	771	766	Redacted
CARE_NEW_DSD	Age/sex: 50+ Female	266	264	Redacted
CARE_NEW_DSD	Sum of Age/sex disaggregates	1,858	1,846	Redacted
CARE_NEW_DSD	Aggregated Age/sex: <15 Male	84	83	Redacted
CARE_NEW_DSD	Aggregated Age/sex: 15+ Male	574	572	Redacted
CARE_NEW_DSD	Aggregated Age/sex: <15 Female	84	83	Redacted
CARE_NEW_DSD	Aggregated Age/sex: 15+ Female	1,116	1,108	Redacted
CARE_NEW_DSD	Sum of Aggregated Age/sex disaggregates	1,858	1,846	Redacted
CARE_SITE	Number of PEPFAR-supported HIV clinical care sites at which at least 80% of PLHIV received all of the following during the reporting period: 1) clinical assessment (WHO staging) OR CD4 count OR viral load, AND 2) TB screening at last visit, AND 3) if eligible, cotrimoxazole	56	56	Redacted
CARE_SITE	Total number of PEPFAR supported sites providing clinical care services	56	56	Redacted
CARE_SITE	By site support type: Direct Service Delivery (DSD): Number of PEPFAR-supported HIV clinical care sites at which at least 80% of PLHIV received all of the following during the reporting period: 1) clinical assessment (WHO staging) OR CD4 count OR viral load, AND 2) TB screening at last visit, AND 3) if eligible, cotrimoxazole	56	56	Redacted
CARE_SITE	By site support type: Technical Assistance-only (TA): Number of PEPFAR-supported HIV clinical care sites at which at least 80% of PLHIV received all of the following during the reporting period: 1) clinical assessment (WHO staging) OR CD4 count OR viral	0	0	Redacted



	load, AND 2) TB screening at last visit, AND 3) if eligible, cotrimoxazole			
CARE_SITE	Sum of Numerator Site Support Type disaggregates	56	56	Redacted
CARE_SITE	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR supported sites providing clinical care services	56	56	Redacted
CARE_SITE	By site support type: Technical Assistance-only (TA): Total number of PEPFAR supported sites providing clinical care services	0	0	Redacted
CARE_SITE	Sum of Denominator Site Support Type disaggregates	56	56	Redacted
FN_SITE	Number of PEPFAR-supported sites achieving 90% nutrition assessments that result in accurate categorization of malnutrition	11	11	Redacted
FN_SITE	Total number of PEPFAR-supported sites providing nutrition assessment, counseling and support (NACS) services	12	12	Redacted
FN_SITE	By site support type: Direct Service Delivery (DSD): Number of PEPFAR-supported sites achieving 90% nutrition assessments that result in accurate categorization of malnutrition	11	11	Redacted
FN_SITE	By site support type: Technical Assistance-only (TA): Number of PEPFAR-supported sites achieving 90% nutrition assessments that result in accurate categorization of malnutrition	0	0	Redacted
FN_SITE	Sum of Numerator Support Type	11	11	Redacted

	disaggregates			
FN_SITE	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported sites providing nutrition assessment, counseling and support (NACS) services	12	12	Redacted
FN_SITE	By site support type: Technical Assistance-only (TA): Total number of PEPFAR-supported sites providing nutrition assessment, counseling and support (NACS) services	0	0	Redacted
FN_SITE	Sum of Denominator Support Type disaggregates	12	12	Redacted
FN_THER_DSD	Number of clinically malnourished PLHIV who received therapeutic and/or supplementary food during the reporting period.	1,467	1,603	Redacted
FN_THER_DSD	Number of PLHIV who were nutritionally assessed and found to be clinically undernourished.	1,955	2,137	Redacted
FN_THER_DSD	Age: <1	5	5	Redacted
FN_THER_DSD	Age: 1-4	32	35	Redacted
FN_THER_DSD	Age: 5-14	98	108	Redacted
FN_THER_DSD	Age: 15-17	30	32	Redacted
FN_THER_DSD	Age: 18+	1,302	1,423	Redacted
FN_THER_DSD	Sum of Age disaggregates	1,467	1,603	Redacted
FN_THER_DSD	Aggregated Age: <18	165	180	Redacted
FN_THER_DSD	Aggregated Age: 18+	1,302	1,423	Redacted
FN_THER_DSD	Sum of Aggregated Age disaggregates	1,467	1,603	Redacted
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	374	457	Redacted

TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	440	508	Redacted
TB_ART_DSD	Age: 0-4	9	11	Redacted
TB_ART_DSD	Age: 5-14	25	31	Redacted
TB_ART_DSD	Age: 15+	340	415	Redacted
TB_ART_DSD	Male	202	247	Redacted
TB_ART_DSD	Female	172	210	Redacted
TB_ART_DSD	Sum of Sex disaggregates	374	457	Redacted
TB_ART_DSD	Newly tested	224	274	Redacted
TB_ART_DSD	Known HIV-positive	150	183	Redacted
TB_ART_DSD	Sum of Test Status disaggregates	374	457	Redacted
TB_ART_DSD	Aggregated Age: <15	34	42	Redacted
TB_ART_DSD	Aggregated Age: 15+	340	415	Redacted
TB_ART_DSD	Sum of Aggregated Age disaggregates	374	457	Redacted
TB_ARTSITE	The number of PEPFAR-supported TB basic management units at which 80% of registered TB cases who are HIV-positive are on ART, during the reporting period	56	56	Redacted
TB_ARTSITE	The number of PEPFAR-supported TB basic management units	56	56	Redacted
TB_ARTSITE	By site support type: Direct Service Delivery (DSD): The number of PEPFAR-supported TB basic management units at which 80% of registered TB cases who are HIV-positive are on ART, during the reporting period	56	56	Redacted
TB_ARTSITE	By site support type: Technical Assistance-only (TA): The number of PEPFAR-supported TB basic management units at which 80% of	0	0	Redacted

	registered TB cases who are HIV-positive are on ART, during the reporting period			
TB_ARTSITE	Sum of Numerator Site Support Type disaggregates	56	56	Redacted
TB_ARTSITE	By site support type: Direct Service Delivery (DSD): The number of PEPFAR-supported TB basic management units	56	56	Redacted
TB_ARTSITE	By site support type: Technical Assistance-only (TA): The number of PEPFAR-supported TB basic management units	0	0	Redacted
TB_ARTSITE	Sum of Denominator Site Support Type disaggregates	56	56	Redacted
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	921	940	Redacted
PMTCT_EID_DSD	Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT)	1,152	1,175	Redacted
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	691	705	Redacted
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	230	235	Redacted
PMTCT_EID_DSD	Sum of Infant Age disaggregates	921	940	Redacted
PMTCT_EID_DSD	By infants with a positive virologic test result within 12 months of birth	46	47	Redacted
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	7,622	8,663	Redacted
TX_CURR_DSD	Age/Sex: <1 Male	12	14	Redacted
TX_CURR_DSD	Age/Sex: 1-4 Male	80	90	Redacted

TX_CURR_DSD	Age/Sex: 5-14 Male	251	286	Redacted
TX_CURR_DSD	Age/Sex: 15+ Male	2,358	2,759	Redacted
TX_CURR_DSD	Age/Sex: <1 Female	12	14	Redacted
TX_CURR_DSD	Age/Sex: 1-4 Female	80	91	Redacted
TX_CURR_DSD	Age/Sex: 5-14 Female	251	286	Redacted
TX_CURR_DSD	Age/Sex: 15+ Female	4,578	5,123	Redacted
TX_CURR_DSD	Sum of age/sex disaggregates	686	781	Redacted
TX_CURR_DSD	Percent children with advanced HIV infection receiving antiretroviral therapy (ART) [CURRENT]	1	1	Redacted
TX_CURR_DSD	Percent women and girls with advanced HIV infection receiving antiretroviral therapy (ART) [CURRENT]	1	1	Redacted
TX_CURR_DSD	Aggregated Age/Sex: <1 Male	12	14	Redacted
TX_CURR_DSD	Aggregated Age/Sex: <1 Female	12	14	Redacted
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	343	390	Redacted
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	2,358	2,759	Redacted
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	343	391	Redacted
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	4,578	5,123	Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	686	781	Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	6,936	7,882	Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	7,622	8,663	Redacted
TX_CURR_NGI	Number of adults and children receiving antiretroviral therapy (ART)	7,622	8,663	Redacted
TX_CURR_NGI	Age/Sex: <1 Male	12	14	Redacted
TX_CURR_NGI	Age/Sex: 1-4 Male	80	90	Redacted
TX_CURR_NGI	Age/Sex: 5-14 Male	251	286	Redacted
TX_CURR_NGI	Age/Sex: 15+ Male	2,358	2,759	Redacted
TX_CURR_NGI	Age/Sex: <1 Female	12	14	Redacted
TX_CURR_NGI	Age/Sex: 1-4 Female	80	91	Redacted
TX_CURR_NGI	Age/Sex: 5-14 Female	251	286	Redacted

TX_CURR_NGI	Age/Sex: 15+ Female	4,578	5,123	Redacted
TX_CURR_NGI	Sum of Age/Sex disaggregates	7,622	8,663	Redacted
TX_CURR_NGI	Aggregated Age/Sex: <1 Male	12	14	Redacted
TX_CURR_NGI	Aggregated Age/Sex: <1 Female	12	14	Redacted
TX_CURR_NGI	Aggregated Age/Sex: <15 Male	343	390	Redacted
TX_CURR_NGI	Aggregated Age/Sex: 15+ Male	2,358	2,759	Redacted
TX_CURR_NGI	Aggregated Age/Sex: <15 Female	343	391	Redacted
TX_CURR_NGI	Aggregated Age/Sex: 15+ Female	4,578	5,123	Redacted
TX_CURR_NGI	Sum of Aggregated Age/Sex disaggregates	7,622	8,663	Redacted
TX_CURR_NGI	Sum of Aggregated Age/Sex <15	686	781	Redacted
TX_CURR_NGI	Sum of Aggregated Age/Sex 15+	6,936	7,882	Redacted
TX_DIST	Number of Districts with documented routine supportive supervision visits to 75% of HIV care and treatment sites supported by the District	2	2	Redacted
TX_DIST	Total number of PEPFAR supported District Health Offices	2	2	Redacted
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	1,235	1,219	Redacted
TX_NEW_DSD	By Age/Sex: <1 Male	19	26	Redacted
TX_NEW_DSD	By Age/Sex: 1-4 Male	11	15	Redacted
TX_NEW_DSD	By Age/Sex: 5-9 Male	19	25	Redacted
TX_NEW_DSD	By Age/Sex: 10-14 Male	15	20	Redacted
TX_NEW_DSD	By Age/Sex: 15-19 Male	10	9	Redacted
TX_NEW_DSD	By Age/Sex: 20-24 Male	18	17	Redacted
TX_NEW_DSD	By Age/Sex: 25-49 Male	268	253	Redacted
TX_NEW_DSD	By Age/Sex: 50+ Male	92	87	Redacted
TX_NEW_DSD	By Age/Sex: <1 Female	19	26	Redacted
TX_NEW_DSD	By Age/Sex: 1-4 Female	11	15	Redacted
TX_NEW_DSD	By Age/Sex: 5-9 Female	19	25	Redacted
TX_NEW_DSD	By Age/Sex: 10-14 Female	15	20	Redacted
TX_NEW_DSD	By Age/Sex: 15-19 Female	15	14	Redacted

TX_NEW_DSD	By Age/Sex: 20-24 Female	63	60	Redacted
TX_NEW_DSD	By Age/Sex: 25-49 Female	538	509	Redacted
TX_NEW_DSD	By Age/Sex: 50+ Female	103	98	Redacted
TX_NEW_DSD	Sum of Age/Sex disaggregates	1,235	1,219	Redacted
TX_NEW_DSD	Aggregated Grouping by Age: <1 Male	19	26	Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	64	86	Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	388	366	Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <1 Female	19	26	Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	64	86	Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	719	681	Redacted
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	1,235	1,219	Redacted
TX_NEW_DSD	Pregnancy status	363	370	Redacted
TX_NEW_DSD	Breastfeeding status	40	41	Redacted
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	931	1,050	Redacted
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	1,095	1,235	Redacted
TX_RET_DSD	Age: 0-4 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	23	26	Redacted
TX_RET_DSD	Age: 5-14 (Numerator: Number of adults and children who are still alive	63	71	Redacted

	and on treatment at 12 months after initiating ART)			
TX_RET_DSD	Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	845	953	Redacted
TX_RET_DSD	Age: 0-4 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	27	31	Redacted
TX_RET_DSD	Age: 5-14 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	74	83	Redacted
TX_RET_DSD	Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	994	1,121	Redacted
TX_RET_DSD	Aggregated Age: <15 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	86	97	Redacted
TX_RET_DSD	Aggregated Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	845	953	Redacted
TX_RET_DSD	Aggregated Age: <15 (Denominator:	101	114	Redacted

	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)			
TX_RET_DSD	Aggregated Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	994	1,121	Redacted
TX_RET_DSD	Pregnancy and breastfeeding status (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	367	734	Redacted
TX_RET_DSD	Pregnancy and breastfeeding status (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	432	864	Redacted
TX_SITE	Number of PEPFAR-supported ART sites with a retention rate of 75% or greater for patients 12 months after ART initiation	39	39	Redacted
TX_SITE	Total number of PEPFAR-supported ART sites	56	56	Redacted
TX_SITE	By support type: Direct Service Delivery (DSD): Number of PEPFAR-supported ART sites with a retention rate of 75% or greater for patients 12 months after ART initiation	39	39	Redacted



TX_SITE	By support type: Technical Assistance (TA-only): Number of PEPFAR-supported ART sites with a retention rate of 75% or greater for patients 12 months after ART initiation	0	0	Redacted
TX_SITE	Sum of Numerator Site Support Type disaggregates	39	39	Redacted
TX_SITE	By support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported ART sites	56	56	Redacted
TX_SITE	By support type: Technical Assistance (TA-only): Total number of PEPFAR-supported ART sites	0	0	Redacted
TX_SITE	Sum of Denominator Site Support Type disaggregates	56	56	Redacted
LAB_CAP_DSD	Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests	48	48	Redacted
LAB_CAP_DSD	By site support type: Direct Service Delivery (DSD)	48	48	Redacted
LAB_CAP_DSD	Sum of Site Support Type disaggregates	48	48	Redacted
FPINT_SITE_DSD	Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	42	42	Redacted
FPINT_SITE_DSD	Total number of PEPFAR-supported HIV service delivery points: PMTCT, Care and Treatment	56	56	Redacted
FPINT_SITE_DSD	By site support type: Direct Service Delivery (DSD): Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	42	42	Redacted



FPINT_SITE_DSD	By site support type: Technical Assistance-only (TA): Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	0	0	Redacted
FPINT_SITE_DSD	Sum of Numerator Site Support Type disaggregates	42	42	Redacted
FPINT_SITE_DSD	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported HIV service delivery points	56	56	Redacted
FPINT_SITE_DSD	By site support type: Technical Assistance-only (TA): Total number of PEPFAR-supported HIV service delivery points	0	0	Redacted
FPINT_SITE_DSD	Sum of Denominator Site Support Type disaggregates	56	56	Redacted
FPINT_SITE_DSD	Service delivery type: Clinical	42	42	Redacted
FPINT_SITE_DSD	Sum of Service Delivery Type disaggregates	42	42	Redacted
QI_SITE	Number of PEPFAR-supported clinical service sites with a quality improvement activity completed that addresses clinical HIV programs and has documented process results in the last 6 months	45	45	Redacted
QI_SITE	Total number of PEPFAR-supported sites for any HIV clinical service including HIV Care, HIV Treatment, TB care, PMTCT, VMMC, and HTC	56	56	Redacted
QI_SITE	By site support type: Direct Service Delivery (DSD): Number of PEPFAR-supported clinical service sites with a quality improvement activity	45	45	Redacted



	completed that addresses clinical HIV programs and has documented results in the last 6 months			
QI_SITE	By site support type: Technical Assistance-only (TA): Number of PEPFAR-supported clinical service sites with a quality improvement activity completed that addresses clinical HIV programs and has documented results in the last 6 months	0	0	Redacted
QI_SITE	Sum of Numerator Site Support Type disaggregates	45	45	Redacted
QI_SITE	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported sites for any HIV clinical service including HIV Care, HIV Treatment, TB care, PMTCT, VMMC, HTC	56	56	Redacted
QI_SITE	By site support type: Technical Assistance-only (TA): Total number of PEPFAR-supported sites for any HIV clinical service including HIV Care, HIV Treatment, TB care, PMTCT, VMMC, and HTC	0	0	Redacted
QI_SITE	Sum of Denominator Site Support Type disaggregates	56	56	Redacted
TB_SCREEN_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period	8,359	9,645	Redacted
TB_SCREEN_DSD	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	9,288	10,152	Redacted



TB_SCREEN_DSD	Age: <1	27	31	Redacted
TB_SCREEN_DSD	Age: 1-4	180	208	Redacted
TB_SCREEN_DSD	Age: 5-9	318	367	Redacted
TB_SCREEN_DSD	Age: 10-14	245	283	Redacted
TB_SCREEN_DSD	Age: 15-19	169	195	Redacted
TB_SCREEN_DSD	Age: 20-24	564	650	Redacted
TB_SCREEN_DSD	Age: 25-49	5,536	6,387	Redacted
TB_SCREEN_DSD	Age: 50+	1,320	1,524	Redacted
TB_SCREEN_DSD	Sum of Age disaggregates	939	1,084	Redacted
TB_SCREEN_DSD	Aggregated Age - USE WITH HQ PERMISSION ONLY: <15	770	889	Redacted
TB_SCREEN_DSD	Aggregated Age - USE WITH HQ PERMISSION ONLY: 15+	7,589	8,756	Redacted
TB_SCREEN_DSD	Sum of Aggregated Age disaggregates	8,359	9,645	Redacted
TB_SCREEN_DSD	Sex: Male	2,965	3,421	Redacted
TB_SCREEN_DSD	Sex: Female	5,394	6,224	Redacted
TB_SCREEN_DSD	Sum of Sex disaggregates	8,359	9,645	Redacted

Implementing Mechanism Details

Mechanism ID: 13701	Mechanism Name: KEMSA/FARA
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: Kenya Medical Supplies Agency	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: TA	
G2G: No	Managing Agency:

Total All Funding Sources: 36,274,080	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 0	
FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount
GHP-State	36,274,080



Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

(No data provided.)

Budget Code Information

Mechanism ID: 13701			
Mechanism Name: KEMSA/FARA			
Prime Partner Name: Kenya Medical Supplies Agency			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	17,450,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	1,752,139	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	1,400,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HMBL	1,500,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HMIN	350,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	6,172,541	0



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	2,662,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXD	700,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	2,376,688	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	1,910,712	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 13636	Mechanism Name: APHIAplus Central/Eastern
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: JHPIEGO	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: No	
G2G: No	Managing Agency:

Total All Funding Sources: 8,756,081	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 2,168,118	
FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount
GHP-State	8,756,081

Sub Partner Name(s)



African Medical and Research Foundation	Christian Health Association of Kenya	International Center for AIDS Care and Treatment Programs, Columbia University
Kenya Red Cross Society	Land O'Lakes	Liverpool VCT and Care
National Organisation for Peer Educators (NOPE)	Program for Appropriate Technology in Health	

Cross-Cutting Budget Attribution(s)

Economic Strengthening	300,000
Human Resources for Health	200,000

Key Issues

- Child Survival Activities
- Mobile Population
- Safe Motherhood
- TB
- Workplace Programs
- Family Planning

Budget Code Information

Mechanism ID:	13636		
Mechanism Name:	APHIAplus Central/Eastern		
Prime Partner Name:	JHPIEGO		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	388,648	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	2,797,433	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Care	HVTB	220,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	200,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	1,100,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	3,700,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	350,000	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2014	2015
SITE_SUPP	Number of unique sites supported by PEPFAR	1,060	1,060
SITE_SUPP	By program area/support type: HTC Direct Service Delivery (DSD)	0	0
SITE_SUPP	By program area/support type: HTC Technical Assistance-only (TA)	418	418
SITE_SUPP	By program area/support type: Treatment Direct Service Delivery (DSD)	8	8
SITE_SUPP	By program area/support type: Treatment	126	126



	Technical Assistance-only (TA)		
SITE_SUPP	By program area/support type: Care and Support Direct Service Delivery (DSD)	8	8
SITE_SUPP	By program area/support type: Care and Support Technical Assistance-only (TA)	126	126
SITE_SUPP	By program area/support type: Food and Nutrition Direct Service Delivery (DSD)	54	54
SITE_SUPP	By program area/support type: Food and Nutrition Technical Assistance-only (TA)	127	127
SITE_SUPP	By program area/support type: PMTCT Direct Service Delivery (DSD)	18	18
SITE_SUPP	By program area/support type: PMTCT Technical Assistance-only (TA)	461	461
SITE_SUPP	By program area/support type: TB/HIV Direct Service Delivery (DSD)	0	0
SITE_SUPP	By program area/support type: TB/HIV Technical Assistance-only (TA)	134	134
SITE_SUPP	By program area/support type: VMMC Direct Service Delivery (DSD)	0	0
SITE_SUPP	By program area/support type: VMMC Technical Assistance-only (TA)	0	0
SITE_SUPP	By program area/support type: General Population Prevention Direct Service Delivery (DSD)	0	0
SITE_SUPP	By program area/support type: General Population Prevention Technical Assistance-only (TA)	460	460
SITE_SUPP	By program area/support type: Key Populations Prevention Direct Service Delivery (DSD)	3	3
SITE_SUPP	By program area/support type: Key Populations Prevention Technical Assistance-only (TA)	3	3
SITE_SUPP	By program area/support type: OVC Direct	34	34



	Service Delivery (DSD)		
SITE_SUPP	By program area/support type: OVC Technical Assistance-only (TA)	0	0
SITE_SUPP	By program area/support type: PHDP/Family Planning & Integration Direct Service Delivery (DSD)	0	0
SITE_SUPP	By program area/support type: PHDP/Family Planning & Integration Technical Assistance-only (TA)	1,060	1,060
SITE_SUPP	By program area/support type: Lab Direct Service Delivery (DSD)	2	2
SITE_SUPP	By program area/support type: Lab Technical Assistance-only (TA)	132	132
PMTCT_ARV_DSD	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	157	113
PMTCT_ARV_DSD	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	169	118
PMTCT_ARV_DSD	Life-long ART (including Option B+)	126	94
PMTCT_ARV_DSD	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	63	47
PMTCT_ARV_DSD	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	63	47
PMTCT_ARV_DSD	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)	0	0
PMTCT_ARV_DSD	Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)	31	19
PMTCT_ARV_DSD	Single-dose nevirapine (with or without tail)	0	0
PMTCT_ARV_DSD	Sum of Regimen Type disaggregates	157	113

PMTCT_ARV_DSD	Sum of New and Current disaggregates	126	94
PMTCT_ARV_NA	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	0	0
PMTCT_ARV_NA	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	0	0
PMTCT_ARV_NGI	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	3,317	3,417
PMTCT_ARV_NGI	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	3,567	3,567
PMTCT_ARV_NGI	Life-long ART (including Option B+)	2,488	3,075
PMTCT_ARV_NGI	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	1,161	1,708
PMTCT_ARV_NGI	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	1,327	1,367
PMTCT_ARV_NGI	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)	0	0
PMTCT_ARV_NGI	Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)	829	342
PMTCT_ARV_NGI	Single-dose nevirapine (with or without tail)	0	0
PMTCT_ARV_NGI	Sum of Regimen disaggregates	3,317	3,417
PMTCT_ARV_NGI	Sum of New and Current disaggregates	2,488	3,075
PMTCT_ARV_TA	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	3,185	3,280



PMTCT_ARV_TA	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	3,424	3,424
PMTCT_ARV_TA	Life-long ART (including Option B+)	2,389	2,952
PMTCT_ARV_TA	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	1,115	1,640
PMTCT_ARV_TA	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	1,274	1,312
PMTCT_ARV_TA	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)	0	0
PMTCT_ARV_TA	Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)	796	328
PMTCT_ARV_TA	Single-dose nevirapine (with or without tail)	0	0
PMTCT_ARV_TA	Sum of Regimen Type disaggregates	3,185	3,280
PMTCT_ARV_TA	Sum of New and Current disaggregates	2,389	2,952
PMTCT_SITE	Number of PEPFAR-supported sites achieving 90% ARV or ART coverage for HIV+ pregnant women	410	479
PMTCT_SITE	Total number of PEPFAR supported sites providing PMTCT services (HTC and ARV or ART services)	479	479
PMTCT_SITE	By site support type: Direct Service Delivery (DSD): Number of PEPFAR-supported sites achieving 90% ARV or ART coverage for HIV+ pregnant women	16	18
PMTCT_SITE	By site support type: Technical Assistance-only (TA): Number of PEPFAR-supported sites achieving 90% ARV or ART coverage for HIV+ pregnant women	394	461
PMTCT_SITE	Sum of Numerator Support Type disaggregates	410	479



PMTCT_SITE	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR supported sites providing PMTCT services (HTC and ARV or ART services)	18	18
PMTCT_SITE	By site support type: Technical Assistance-only (TA): Total number of PEPFAR supported sites providing PMTCT services (HTC and ARV or ART services)	461	461
PMTCT_SITE	Sum of Denominator Support Type disaggregates	479	479
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	3,743	3,783
PMTCT_STAT_DSD	Number of new ANC and L&D clients	3,818	3,859
PMTCT_STAT_DSD	By: Known positives at entry	64	68
PMTCT_STAT_DSD	By: Number of new positives identified	78	86
PMTCT_STAT_DSD	Sum of Positives Status disaggregates	142	154
PMTCT_STAT_NA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	0	0
PMTCT_STAT_NA	Number of new ANC and L&D clients	0	0
PMTCT_STAT_NGI	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	93,585	94,585
PMTCT_STAT_NGI	Number of new ANC and L&D clients	95,457	96,477
PMTCT_STAT_NGI	By: Known positives at entry	1,605	1,705
PMTCT_STAT_NGI	By: Number of new positives identified	1,962	2,158
PMTCT_STAT_NGI	Sum of Positives Status disaggregates	3,567	3,863
BS_COLL	Number of whole blood collections each year by the NBTS network	0	0
KP_MAT_DSD	Number of people who inject drugs (PWID) on medication assisted therapy (MAT) for at least 6 months	0	0
VMMC_AE_DSD	Number of males circumcised surgically or by	0	0

	medical device that experienced at least one moderate or severe adverse event(s) (AEs)		
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	0	0
VMMC_CIRC_NA	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	0	0
VMMC_CIRC_NGI	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	0	0
VMMC_CIRC_TA	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	0	0
PP_PREV_TA	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	101,854	121,450
PP_PREV_TA	Total number of people in the target population	452,253	452,253
PP_PREV_TA	Age/sex: 10-14 Male	28,123	0
PP_PREV_TA	Age/sex: 15-19 Male	12,879	0
PP_PREV_TA	Age/sex: 20-24 Male	3,612	0
PP_PREV_TA	Age/sex: 25-49 Male	4,235	0
PP_PREV_TA	Age/sex: 50+ Male	560	0
PP_PREV_TA	Age/sex: 10-14 Female	31,528	0
PP_PREV_TA	Age/sex: 15-19 Female	14,578	50,000
PP_PREV_TA	Age/sex: 20-24 Female	2,345	66,571
PP_PREV_TA	Age/sex: 25-49 Female	3,568	4,256
PP_PREV_TA	Age/sex: 50+ Female	426	623



PP_PREV_TA	Sum of Age/Sex disaggregates	101,854	121,450
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	5,975	7,217
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	5,842	7,095
KP_PREV_DSD	By key population type: Males who inject drugs (Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0	0
KP_PREV_DSD	By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0	0
KP_PREV_DSD	By key population type: Men who have sex with men/Transgender (MSM/TG) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	133	122
KP_PREV_DSD	By key population type: MSM/TG who are male sex workers (subset MSM/TG) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are	0	0



	based on evidence and/or meet the minimum standards required)		
KP_PREV_TA	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	3,984	4,950
KP_PREV_TA	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	3,895	4,730
KP_PREV_TA	By key population type: Men who have sex with men/Transgender (MSM/TG) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	89	220
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	0	0
HTC_TST_NA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	0	0
HTC_TST_NGI	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	394,807	434,288
HTC_TST_NGI	By Test Result: Negative	379,015	416,916
HTC_TST_NGI	By Test Result: Positive	15,792	17,372
HTC_TST_NGI	Sum of Test Result disaggregates	394,807	434,288
HTC_TST_NGI	Age/sex: <1 Male	0	0
HTC_TST_NGI	Age/sex: 1-4 Male	13,818	15,200
HTC_TST_NGI	Age/sex: 5-9 Male	5,922	6,514



HTC_TST_NGI	Age/sex: 10-14 Male	9,870	10,857
HTC_TST_NGI	Age/sex: 15-19 Male	19,740	21,714
HTC_TST_NGI	Age/sex: 20-24 Male	49,351	54,286
HTC_TST_NGI	Age/sex: 25-49 Male	78,961	86,858
HTC_TST_NGI	Age/sex: 50+ Male	19,740	21,714
HTC_TST_NGI	Age/sex: <1 Female	0	0
HTC_TST_NGI	Age/sex: 1-4 Female	13,818	15,200
HTC_TST_NGI	Age/sex: 5-9 Female	5,922	6,514
HTC_TST_NGI	Age/sex: 10-14 Female	9,870	10,857
HTC_TST_NGI	Age/sex: 15-19 Female	19,740	21,714
HTC_TST_NGI	Age/sex: 20-24 Female	49,351	54,286
HTC_TST_NGI	Age/sex: 25-49 Female	78,961	86,857
HTC_TST_NGI	Age/sex: 50+ Female	19,743	21,717
HTC_TST_NGI	Sum of Age/Sex disaggregates	394,807	434,288
HTC_TST_NGI	Aggregated Age/sex: <15 Male	29,611	32,572
HTC_TST_NGI	Aggregated Age/sex: 15+ Male	167,793	184,572
HTC_TST_NGI	Aggregated Age/sex: <15 Female	29,611	32,572
HTC_TST_NGI	Aggregated Age/sex: 15+ Female	167,792	184,572
HTC_TST_NGI	Sum of Aggregated Age/Sex <15	59,222	65,144
HTC_TST_NGI	Sum of Aggregated Age/Sex 15+	335,585	369,144
HTC_TST_NGI	Sum of Aggregated Age/Sex disaggregates	394,807	434,288
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	394,807	434,288
HTC_TST_TA	By Test Result: Negative	379,015	416,916
HTC_TST_TA	By Test Result: Positive	15,792	17,372
HTC_TST_TA	Sum of Test Result disaggregates	394,807	434,288
HTC_TST_TA	Age/sex: <1 Male	0	0
HTC_TST_TA	Age/sex: 1-4 Male	13,818	15,200
HTC_TST_TA	Age/sex: 5-9 Male	5,922	6,514
HTC_TST_TA	Age/sex: 10-14 Male	9,870	10,857
HTC_TST_TA	Age/sex: 15-19 Male	19,740	21,714



HTC_TST_TA	Age/sex: 20-24 Male	49,351	54,286
HTC_TST_TA	Age/sex: 25-49 Male	78,961	86,858
HTC_TST_TA	Age/sex: 50+ Male	19,740	21,714
HTC_TST_TA	Age/sex: <1 Female	0	0
HTC_TST_TA	Age/sex: 1-4 Female	13,818	15,200
HTC_TST_TA	Age/sex: 5-9 Female	5,922	6,514
HTC_TST_TA	Age/sex: 10-14 Female	9,870	10,857
HTC_TST_TA	Age/sex: 15-19 Female	19,740	21,714
HTC_TST_TA	Age/sex: 20-24 Female	49,351	54,286
HTC_TST_TA	Age/sex: 25-49 Female	78,961	86,857
HTC_TST_TA	Age/sex: 50+ Female	19,743	21,717
HTC_TST_TA	Sum of Age/Sex disaggregates	394,807	434,288
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	29,611	32,572
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	167,793	184,572
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	29,611	32,572
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	167,792	184,572
HTC_TST_TA	Sum of Aggregated Age/Sex <15	59,222	65,144
HTC_TST_TA	Sum of Aggregated Age/Sex 15+	335,585	369,144
HTC_TST_TA	Sum of Aggregated Age/Sex disaggregates	394,807	434,288
GEND_GBV_DSD	Number of people receiving post-GBV care	986	986
GEND_GBV_DSD	Age: 0-9	86	86
GEND_GBV_DSD	Age: 10-14	450	450
GEND_GBV_DSD	Age: 15-17	450	450
GEND_GBV_DSD	Age: 18-24	0	0
GEND_GBV_DSD	Age: 25+	0	0
GEND_GBV_DSD	Sum of Age disaggregates	986	986
GEND_GBV_DSD	Sex: Male	50	50
GEND_GBV_DSD	Sex: Female	936	936



GEND_GBV_DSD	Sum of Sex disaggregates	986	986
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	986	986
GEND_GBV_DSD	By PEP service provision (related to sexual violence services provided)	1,100	1,100
GEND_NORM_DSD	Number of people completing an intervention pertaining to gender norms, that meets minimum criteria	29,431	29,431
GEND_NORM_DSD	By Age: 0-9	0	0
GEND_NORM_DSD	By Age: 10-14	0	0
GEND_NORM_DSD	By Age: 15-19	0	0
GEND_NORM_DSD	By Age: 20-24	7,358	7,358
GEND_NORM_DSD	By Age: 25+	22,073	22,073
GEND_NORM_DSD	Sum of Age disaggregates	29,431	29,431
GEND_NORM_DSD	By Sex: Male	22,073	22,073
GEND_NORM_DSD	By Sex: Female	7,358	7,358
GEND_NORM_DSD	Sum of Sex disaggregates	29,431	29,431
OVC_ACC_DSD	Number of active beneficiaries receiving support from PEPFAR OVC programs to access HIV services	31,656	31,656
OVC_ACC_DSD	Sex: Male	14,274	14,274
OVC_ACC_DSD	Sex: Female	17,382	17,382
OVC_ACC_DSD	Sum of Sex disaggregates	31,656	31,656
OVC_ACC_DSD	Age: <1	0	0
OVC_ACC_DSD	Age: 1-4	217	217
OVC_ACC_DSD	Age: 5-9	1,582	1,582
OVC_ACC_DSD	Age: 10-14	25,325	25,325
OVC_ACC_DSD	Age: 15-17	4,432	4,432
OVC_ACC_DSD	Age: 18+	100	100
OVC_ACC_DSD	Sum of Age disaggregates	31,656	31,656
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	134,824	134,824



OVC_SERV_DSD	Sex: Male	67,412	67,412
OVC_SERV_DSD	Sex: Female	67,412	67,412
OVC_SERV_DSD	Sum of Sex disaggregates	134,824	134,824
OVC_SERV_DSD	Age: <1	0	0
OVC_SERV_DSD	Age: 1-4	1,347	1,347
OVC_SERV_DSD	Age: 5-9	6,736	6,736
OVC_SERV_DSD	Age: 10-14	107,779	107,779
OVC_SERV_DSD	Age: 15-17	18,861	18,861
OVC_SERV_DSD	Age: 18+	101	101
OVC_SERV_DSD	Sum of Age disaggregates	134,824	134,824
OVC_SERV_TA	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	0	0
C2.1.D_DSD	Number of HIV-positive individuals receiving a minimum of one clinical service	2,366	2,602
C2.1.D_DSD	By Age/Sex: <15 Female	148	163
C2.1.D_DSD	By Age/Sex: <15 Male	79	87
C2.1.D_DSD	By Age/Sex: 15+ Female	1,390	1,529
C2.1.D_DSD	By Age/Sex: 15+ Male	749	823
C2.1.D_DSD	Sum of Age/Sex disaggregates	2,366	2,602
C2.1.D_DSD	By Age: <15	228	250
C2.1.D_DSD	By Age: 15+	2,138	2,352
C2.1.D_DSD	Sum of Age disaggregates	2,366	2,602
C2.1.D_DSD	By Sex: Female	1,538	1,692
C2.1.D_DSD	By Sex: Male	828	910
C2.1.D_DSD	Sum of Sex disaggregates	2,366	2,602
C2.1.D_NA	Number of HIV-positive individuals receiving a minimum of one clinical service	0	0
C2.1.D_NGI	Number of HIV-positive individuals receiving a minimum of one clinical service	39,433	43,376
C2.1.D_NGI	By Age/Sex: <15 Female	2,464	2,710
C2.1.D_NGI	By Age/Sex: <15 Male	1,327	1,460



C2.1.D_NGI	By Age/Sex: 15+ Female	23,167	25,484
C2.1.D_NGI	By Age/Sex: 15+ Male	12,475	13,722
C2.1.D_NGI	Sum of Age/Sex disaggregates	39,433	43,376
C2.1.D_NGI	By Age: <15	4,195	4,614
C2.1.D_NGI	By Age: 15+	35,238	38,762
C2.1.D_NGI	Sum of Age disaggregates	39,433	43,376
C2.1.D_NGI	By Sex: Female	25,632	28,195
C2.1.D_NGI	By Sex: Male	13,801	15,181
C2.1.D_NGI	Sum of Sex disaggregates	39,433	43,376
C2.1.D_TA	Number of HIV-positive individuals receiving a minimum of one clinical service	37,066	40,774
C2.1.D_TA	By Age/Sex: <15 Female	2,316	2,548
C2.1.D_TA	By Age/Sex: <15 Male	1,247	1,372
C2.1.D_TA	By Age/Sex: 15+ Female	21,777	23,955
C2.1.D_TA	By Age/Sex: 15+ Male	11,726	12,899
C2.1.D_TA	Sum of Age/Sex disaggregates	37,066	40,774
C2.1.D_TA	By Age: <15	3,943	4,337
C2.1.D_TA	By Age: 15+	33,123	36,437
C2.1.D_TA	Sum of Age disaggregates	37,066	40,774
C2.1.D_TA	By Sex: Female	24,094	26,503
C2.1.D_TA	By Sex: Male	12,972	14,271
C2.1.D_TA	Sum of Sex disaggregates	37,066	40,774
C2.4.D_DSD	Number of HIV-positive patients who were screened for TB in HIV care or treatment setting	2,129	2,342
C2.4.D_DSD	Number of HIV-positive individuals receiving a minimum of one clinical service	2,366	2,602
C2.5.D_DSD	Number of HIV-positive patients in HIV care who started TB treatment	82	91
C2.5.D_DSD	Number of HIV-positive individuals receiving a minimum of one clinical service	2,366	2,602
CARE_CURR_DSD	Number of HIV positive adults and children who received at least one of the following	2,363	2,599



	during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load		
CARE_CURR_DSD	Age/sex: <1 Male	2	2
CARE_CURR_DSD	Age/sex: 1-4 Male	11	12
CARE_CURR_DSD	Age/sex: 5-9 Male	34	37
CARE_CURR_DSD	Age/sex: 10-14 Male	88	97
CARE_CURR_DSD	Age/sex: 15-19 Male	96	106
CARE_CURR_DSD	Age/sex: 20-24 Male	128	141
CARE_CURR_DSD	Age/sex: 25-49 Male	244	268
CARE_CURR_DSD	Age/sex: 50+ Male	173	190
CARE_CURR_DSD	Age/sex: <1 Female	3	3
CARE_CURR_DSD	Age/sex: 1-4 Female	13	15
CARE_CURR_DSD	Age/sex: 5-9 Female	42	47
CARE_CURR_DSD	Age/sex: 10-14 Female	110	121
CARE_CURR_DSD	Age/sex: 15-19 Female	213	234
CARE_CURR_DSD	Age/sex: 20-24 Female	284	312
CARE_CURR_DSD	Age/sex: 25-49 Female	539	593
CARE_CURR_DSD	Age/sex: 50+ Female	383	421
CARE_CURR_DSD	Sun of Age/Sex disaggregates	2,363	2,599
CARE_CURR_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	135	149
CARE_CURR_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	642	704
CARE_CURR_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	169	186
CARE_CURR_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	1,417	1,560
CARE_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	2,363	2,599
CARE_CURR_TA	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count	37,064	40,770



	OR viral load		
CARE_CURR_TA	Age/sex: <1 Male	42	47
CARE_CURR_TA	Age/sex: 1-4 Male	170	187
CARE_CURR_TA	Age/sex: 5-9 Male	532	585
CARE_CURR_TA	Age/sex: 10-14 Male	1,384	1,522
CARE_CURR_TA	Age/sex: 15-19 Male	1,508	1,659
CARE_CURR_TA	Age/sex: 20-24 Male	2,011	2,212
CARE_CURR_TA	Age/sex: 25-49 Male	3,821	4,202
CARE_CURR_TA	Age/sex: 50+ Male	2,714	2,986
CARE_CURR_TA	Age/sex: <1 Female	53	58
CARE_CURR_TA	Age/sex: 1-4 Female	212	233
CARE_CURR_TA	Age/sex: 5-9 Female	664	730
CARE_CURR_TA	Age/sex: 10-14 Female	1,726	1,899
CARE_CURR_TA	Age/sex: 15-19 Female	3,334	3,667
CARE_CURR_TA	Age/sex: 20-24 Female	4,445	4,890
CARE_CURR_TA	Age/sex: 25-49 Female	8,447	9,291
CARE_CURR_TA	Age/sex: 50+ Female	6,001	6,602
CARE_CURR_TA	Sum of Age/Sex disaggregates	37,064	40,770
CARE_CURR_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	2,129	2,341
CARE_CURR_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	10,054	11,059
CARE_CURR_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	2,655	2,921
CARE_CURR_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	22,226	24,449
CARE_CURR_TA	Sum of Aggregated Age/Sex disaggregates	37,064	40,770
CARE_NEW_DSD	Number of HIV-infected adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load	7,886	7,886



CARE_NEW_DSD	Age/sex: <1 Male	3	3
CARE_NEW_DSD	Age/sex: 1-4 Male	15	15
CARE_NEW_DSD	Age/sex: 5-9 Male	78	78
CARE_NEW_DSD	Age/sex: 10-14 Male	215	215
CARE_NEW_DSD	Age/sex: 15-19 Male	117	117
CARE_NEW_DSD	Age/sex: 20-24 Male	468	468
CARE_NEW_DSD	Age/sex: 25-49 Male	1,055	1,055
CARE_NEW_DSD	Age/sex: 50+ Male	703	703
CARE_NEW_DSD	Age/sex: <1 Female	3	3
CARE_NEW_DSD	Age/sex: 1-4 Female	10	10
CARE_NEW_DSD	Age/sex: 5-9 Female	190	190
CARE_NEW_DSD	Age/sex: 10-14 Female	353	353
CARE_NEW_DSD	Age/sex: 15-19 Female	374	374
CARE_NEW_DSD	Age/sex: 20-24 Female	1,169	1,169
CARE_NEW_DSD	Age/sex: 25-49 Female	1,870	1,870
CARE_NEW_DSD	Age/sex: 50+ Female	1,263	1,263
CARE_NEW_DSD	Sum of Age/sex disaggregates	7,886	7,886
CARE_NEW_DSD	Aggregated Age/sex: <15 Male	310	310
CARE_NEW_DSD	Aggregated Age/sex: 15+ Male	2,344	2,344
CARE_NEW_DSD	Aggregated Age/sex: <15 Female	372	372
CARE_NEW_DSD	Aggregated Age/sex: 15+ Female	4,860	4,860
CARE_NEW_DSD	Sum of Aggregated Age/sex disaggregates	7,886	7,886
CARE_SITE	Number of PEPFAR-supported HIV clinical care sites at which at least 80% of PLHIV received all of the following during the reporting period: 1) clinical assessment (WHO staging) OR CD4 count OR viral load, AND 2) TB screening at last visit, AND 3) if eligible, cotrimoxazole	125	130
CARE_SITE	Total number of PEPFAR supported sites providing clinical care services	134	134
CARE_SITE	By site support type: Direct Service Delivery (DSD): Number of PEPFAR-supported HIV	125	130



	clinical care sites at which at least 80% of PLHIV received all of the following during the reporting period: 1) clinical assessment (WHO staging) OR CD4 count OR viral load, AND 2) TB screening at last visit, AND 3) if eligible, cotrimoxazole		
CARE_SITE	By site support type: Technical Assistance-only (TA): Number of PEPFAR-supported HIV clinical care sites at which at least 80% of PLHIV received all of the following during the reporting period: 1) clinical assessment (WHO staging) OR CD4 count OR viral load, AND 2) TB screening at last visit, AND 3) if eligible, cotrimoxazole	0	0
CARE_SITE	Sum of Numerator Site Support Type disaggregates	125	130
CARE_SITE	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR supported sites providing clinical care services	134	134
CARE_SITE	By site support type: Technical Assistance-only (TA): Total number of PEPFAR supported sites providing clinical care services	0	0
CARE_SITE	Sum of Denominator Site Support Type disaggregates	134	134
FN_SITE	Number of PEPFAR-supported sites achieving 90% nutrition assessments that result in accurate categorization of malnutrition	127	181
FN_SITE	Total number of PEPFAR-supported sites providing nutrition assessment, counseling and support (NACS) services	181	181
FN_SITE	By site support type: Direct Service Delivery (DSD): Number of PEPFAR-supported sites achieving 90% nutrition assessments that result in accurate categorization of	127	181



	malnutrition		
FN_SITE	By site support type: Technical Assistance-only (TA): Number of PEPFAR-supported sites achieving 90% nutrition assessments that result in accurate categorization of malnutrition	0	0
FN_SITE	Sum of Numerator Support Type disaggregates	127	181
FN_SITE	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported sites providing nutrition assessment, counseling and support (NACS) services	181	181
FN_SITE	By site support type: Technical Assistance-only (TA): Total number of PEPFAR-supported sites providing nutrition assessment, counseling and support (NACS) services	0	0
FN_SITE	Sum of Denominator Support Type disaggregates	181	181
FN_THER_DSD	Number of clinically malnourished PLHIV who received therapeutic and/or supplementary food during the reporting period.	0	0
FN_THER_DSD	Number of PLHIV who were nutritionally assessed and found to be clinically undernourished.	0	0
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	450	450
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	450	450
TB_ART_DSD	Age: 0-4	0	0
TB_ART_DSD	Age: 5-14	95	95



TB_ART_DSD	Age: 15+	355	355
TB_ART_DSD	Male	202	202
TB_ART_DSD	Female	248	248
TB_ART_DSD	Sum of Sex disaggregates	450	450
TB_ART_DSD	Newly tested	157	157
TB_ART_DSD	Known HIV-positive	293	293
TB_ART_DSD	Sum of Test Status disaggregates	450	450
TB_ART_DSD	Aggregated Age: <15	45	45
TB_ART_DSD	Aggregated Age: 15+	405	405
TB_ART_DSD	Sum of Aggregated Age disaggregates	450	450
TB_ARTSITE	The number of PEPFAR-supported TB basic management units at which 80% of registered TB cases who are HIV-positive are on ART, during the reporting period	134	134
TB_ARTSITE	The number of PEPFAR-supported TB basic management units	134	134
TB_ARTSITE	By site support type: Direct Service Delivery (DSD): The number of PEPFAR-supported TB basic management units at which 80% of registered TB cases who are HIV-positive are on ART, during the reporting period	0	0
TB_ARTSITE	By site support type: Technical Assistance-only (TA): The number of PEPFAR-supported TB basic management units at which 80% of registered TB cases who are HIV-positive are on ART, during the reporting period	134	134
TB_ARTSITE	Sum of Numerator Site Support Type disaggregates	134	134
TB_ARTSITE	By site support type: Direct Service Delivery (DSD): The number of PEPFAR-supported TB basic management units	0	0
TB_ARTSITE	By site support type: Technical Assistance-only (TA): The number of	134	134



	PEPFAR-supported TB basic management units		
TB_ARTSITE	Sum of Denominator Site Support Type disaggregates	134	134
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	2,000	2,250
PMTCT_EID_DSD	Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT)	2,500	2,500
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	1,400	1,800
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	600	450
PMTCT_EID_DSD	Sum of Infant Age disaggregates	2,000	2,250
PMTCT_EID_DSD	By infants with a positive virologic test result within 12 months of birth	100	90
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	1,725	1,964
TX_CURR_DSD	Age/Sex: <1 Male	1	3
TX_CURR_DSD	Age/Sex: 1-4 Male	24	27
TX_CURR_DSD	Age/Sex: 5-14 Male	92	96
TX_CURR_DSD	Age/Sex: 15+ Male	526	574
TX_CURR_DSD	Age/Sex: <1 Female	1	2
TX_CURR_DSD	Age/Sex: 1-4 Female	28	30
TX_CURR_DSD	Age/Sex: 5-14 Female	110	124
TX_CURR_DSD	Age/Sex: 15+ Female	943	1,108
TX_CURR_DSD	Sum of age/sex disaggregates	256	282
TX_CURR_DSD	Percent children with advanced HIV infection receiving antiretroviral therapy (ART) [CURRENT]	15	14
TX_CURR_DSD	Percent women and girls with advanced HIV infection receiving antiretroviral therapy (ART)	85	86



	[CURRENT]		
TX_CURR_NA	Number of adults and children receiving antiretroviral therapy (ART)	0	0
TX_CURR_NGI	Number of adults and children receiving antiretroviral therapy (ART)	28,786	32,729
TX_CURR_NGI	Age/Sex: <1 Male	15	25
TX_CURR_NGI	Age/Sex: 1-4 Male	400	460
TX_CURR_NGI	Age/Sex: 5-14 Male	1,530	1,606
TX_CURR_NGI	Age/Sex: 15+ Male	8,770	9,571
TX_CURR_NGI	Age/Sex: <1 Female	22	30
TX_CURR_NGI	Age/Sex: 1-4 Female	450	500
TX_CURR_NGI	Age/Sex: 5-14 Female	1,846	2,070
TX_CURR_NGI	Age/Sex: 15+ Female	15,753	18,467
TX_CURR_NGI	Sum of Age/Sex disaggregates	28,786	32,729
TX_CURR_NGI	Aggregated Age/Sex: <1 Male	15	25
TX_CURR_NGI	Aggregated Age/Sex: <1 Female	22	30
TX_CURR_NGI	Aggregated Age/Sex: <15 Male	1,945	2,091
TX_CURR_NGI	Aggregated Age/Sex: 15+ Male	8,770	9,571
TX_CURR_NGI	Aggregated Age/Sex: <15 Female	2,318	2,600
TX_CURR_NGI	Aggregated Age/Sex: 15+ Female	15,753	18,467
TX_CURR_NGI	Sum of Aggregated Age/Sex disaggregates	28,786	32,729
TX_CURR_NGI	Sum of Aggregated Age/Sex <15	4,263	4,691
TX_CURR_NGI	Sum of Aggregated Age/Sex 15+	24,523	28,038
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	27,061	30,765
TX_CURR_TA	Age/Sex: <1 Male	14	24
TX_CURR_TA	Age/Sex: 1-4 Male	376	432
TX_CURR_TA	Age/Sex: 5-14 Male	1,438	1,510
TX_CURR_TA	Age/Sex: 15+ Male	8,244	8,996
TX_CURR_TA	Age/Sex: <1 Female	21	28
TX_CURR_TA	Age/Sex: 1-4 Female	423	470
TX_CURR_TA	Age/Sex: 5-14 Female	1,735	1,946



TX_CURR_TA	Age/Sex: 15+ Female	14,810	17,359
TX_CURR_TA	Sum of Age/Sex disaggregations	4,007	4,410
TX_CURR_TA	Aggregated Age/Sex: <1 Male	14	24
TX_CURR_TA	Aggregated Age/Sex: <1 Female	21	28
TX_CURR_TA	Aggregated Age/Sex: <15 Male	1,828	1,966
TX_CURR_TA	Aggregated Age/Sex: 15+ Male	8,244	8,996
TX_CURR_TA	Aggregated Age/Sex: <15 Female	2,179	2,444
TX_CURR_TA	Aggregated Age/Sex: 15+ Female	14,810	17,359
TX_CURR_TA	Sum of Aggregated Age/Sex <15	4,007	4,410
TX_CURR_TA	Sum of Aggregated Age/Sex 15+	23,054	26,355
TX_CURR_TA	Sum of Aggregated Age/Sex disaggregates	27,061	30,765
TX_DIST	Number of Districts with documented routine supportive supervision visits to 75% of HIV care and treatment sites supported by the District	54	60
TX_DIST	Total number of PEPFAR supported District Health Offices	60	60
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	5,586	5,586
TX_NEW_DSD	By Age/Sex: <1 Male	78	78
TX_NEW_DSD	By Age/Sex: 1-4 Male	61	61
TX_NEW_DSD	By Age/Sex: 5-9 Male	84	84
TX_NEW_DSD	By Age/Sex: 10-14 Male	67	67
TX_NEW_DSD	By Age/Sex: 15-19 Male	78	78
TX_NEW_DSD	By Age/Sex: 20-24 Male	184	184
TX_NEW_DSD	By Age/Sex: 25-49 Male	1,162	1,162
TX_NEW_DSD	By Age/Sex: 50+ Male	341	341
TX_NEW_DSD	By Age/Sex: <1 Female	89	89
TX_NEW_DSD	By Age/Sex: 1-4 Female	61	61
TX_NEW_DSD	By Age/Sex: 5-9 Female	95	95
TX_NEW_DSD	By Age/Sex: 10-14 Female	78	78
TX_NEW_DSD	By Age/Sex: 15-19 Female	151	151



TX_NEW_DSD	By Age/Sex: 20-24 Female	480	480
TX_NEW_DSD	By Age/Sex: 25-49 Female	2,162	2,162
TX_NEW_DSD	By Age/Sex: 50+ Female	408	408
TX_NEW_DSD	Sum of Age/Sex disaggregates	5,579	5,579
TX_NEW_DSD	Aggregated Grouping by Age: <1 Male	69	69
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	270	270
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	1,743	1,743
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <1 Female	69	69
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	278	278
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	3,296	3,296
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	5,587	5,587
TX_NEW_DSD	Pregnancy status	300	300
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	4,748	4,748
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	5,586	5,586
TX_RET_DSD	Age: 0-4 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	66	66
TX_RET_DSD	Age: 5-14 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	52	52
TX_RET_DSD	Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	71	71
TX_RET_DSD	Age: 0-4 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the	57	57



	reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)		
TX_RET_DSD	Age: 5-14 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	66	66
TX_RET_DSD	Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	157	157
TX_RET_DSD	Aggregated Age: <15 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	76	76
TX_RET_DSD	Aggregated Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	52	52
TX_RET_DSD	Aggregated Age: <15 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	81	81
TX_RET_DSD	Aggregated Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	66	66
TX_RET_DSD	Pregnancy and breastfeeding status (Numerator: Number of adults and children who are still alive and on treatment at 12	988	988



	months after initiating ART)		
TX_RET_DSD	Pregnancy and breastfeeding status (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	290	290
TX_SITE	Number of PEPFAR-supported ART sites with a retention rate of 75% or greater for patients 12 months after ART initiation	107	120
TX_SITE	Total number of PEPFAR-supported ART sites	134	134
TX_SITE	By support type: Direct Service Delivery (DSD): Number of PEPFAR-supported ART sites with a retention rate of 75% or greater for patients 12 months after ART initiation	107	120
TX_SITE	By support type: Technical Assistance (TA-only): Number of PEPFAR-supported ART sites with a retention rate of 75% or greater for patients 12 months after ART initiation	0	0
TX_SITE	Sum of Numerator Site Support Type disaggregates	107	120
TX_SITE	By support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported ART sites	0	0
TX_SITE	By support type: Technical Assistance (TA-only): Total number of PEPFAR-supported ART sites	134	134
TX_SITE	Sum of Denominator Site Support Type disaggregates	134	134
LAB_ACC_DSD	Number of PEPFAR-supported testing facilities (laboratories) that are recognized by national, regional, or international standards	5	7



	for accreditation or have achieved a minimal acceptable level towards attainment of such accreditation		
LAB_ACC_DSD	By site support type: Direct Service Delivery (DSD)	0	0
LAB_ACC_DSD	By site support type: Technical Assistance-only (TA)	5	7
LAB_ACC_DSD	Sum of Support Type disaggregates	5	7
LAB_CAP_DSD	Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests	122	134
LAB_CAP_DSD	By clinical laboratories	0	0
LAB_CAP_DSD	By Point-of-care testing sites	4	7
LAB_CAP_DSD	By site support type: Direct Service Delivery (DSD)	0	0
LAB_CAP_DSD	By site support type: Technical Assistance-only (TA)	122	134
LAB_CAP_DSD	Sum of Site Support Type disaggregates	122	134
LAB_PT_DSD	Percentage of laboratories and POC testing sites that perform HIV diagnostic testing that participate and successfully pass in an analyte-specific proficiency testing (PT) program	0	0
HRH_PRE	Number of new HCW who graduated from a pre-service training institution or program as a result of PEPFAR-supported strengthening efforts, within the reporting period, by select cadre	0	0
SC_TRAIN	Number of individuals who received competency-based, certificate or higher-level training to conduct or support supply chain, inventory management, supportive supervision or distribution activities	0	0
FPINT_SITE_DSD	Number of service delivery points supported by PEPFAR for HIV services that are directly	107	120



	providing integrated voluntary family planning services		
FPINT_SITE_DSD	Total number of PEPFAR-supported HIV service delivery points: PMTCT, Care and Treatment	134	134
FPINT_SITE_DSD	By site support type: Direct Service Delivery (DSD): Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	0	0
FPINT_SITE_DSD	By site support type: Technical Assistance-only (TA): Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	107	120
FPINT_SITE_DSD	Sum of Numerator Site Support Type disaggregates	107	120
FPINT_SITE_DSD	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported HIV service delivery points	0	0
FPINT_SITE_DSD	By site support type: Technical Assistance-only (TA): Total number of PEPFAR-supported HIV service delivery points	134	134
FPINT_SITE_DSD	Sum of Denominator Site Support Type disaggregates	134	134
FPINT_SITE_DSD	Service delivery type: Community	0	0
FPINT_SITE_DSD	Service delivery type: Clinical	134	134
FPINT_SITE_DSD	Sum of Service Delivery Type disaggregates	134	134
QI_SITE	Number of PEPFAR-supported clinical service sites with a quality improvement activity completed that addresses clinical HIV programs and has documented process results in the last 6 months	450	480
QI_SITE	Total number of PEPFAR-supported sites for	500	500



	any HIV clinical service including HIV Care, HIV Treatment, TB care, PMTCT, VMMC, and HTC		
SC_STOCK	Number of stock status observations for one or more tracer commodities that are between the designed minimum and maximum quantities/months of stock from storage sites within at a given level (Central, Regional, etc.) of the system.	0	0
SC_STOCK	Total number of stock status observations for one or more tracer commodities from storage sites within at a given level (Central, Regional, etc.) of the system	0	0
SI_HIS	Existence of a national registry of health facilities that is updated annually	1	1
SI_HIS	Full national facility list coordinated with PEPFAR	1	1
SI_ME	Existence of a national HIV/AIDS M&E system based on the UNAIDS 12 components model	1	1
TB_SCREEN_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period	2,129	2,342
TB_SCREEN_DSD	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	2,363	2,599
TB_SCREEN_DSD	Age: <1	4	5
TB_SCREEN_DSD	Age: 1-4	15	17
TB_SCREEN_DSD	Age: 5-9	76	80
TB_SCREEN_DSD	Age: 10-14	110	121
TB_SCREEN_DSD	Age: 15-19	289	319
TB_SCREEN_DSD	Age: 20-24	385	425
TB_SCREEN_DSD	Age: 25-49	1,154	1,274



TB_SCREEN_DSD	Age: 50+	96	101
TB_SCREEN_DSD	Sum of Age disaggregates	494	542
TB_SCREEN_DSD	Aggregated Age - USE WITH HQ PERMISSION ONLY: <15	205	225
TB_SCREEN_DSD	Aggregated Age - USE WITH HQ PERMISSION ONLY: 15+	1,924	2,117
TB_SCREEN_DSD	Sum of Aggregated Age disaggregates	2,129	2,342
TB_SCREEN_DSD	Sex: Male	1,384	1,522
TB_SCREEN_DSD	Sex: Female	745	820
TB_SCREEN_DSD	Sum of Sex disaggregates	2,129	2,342

Implementing Mechanism Details

Mechanism ID: 13588	Mechanism Name: APHIAplus Nyanza/Western
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Program for Appropriate Technology in Health	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: No	
G2G: No	Managing Agency:

Total All Funding Sources: 21,937,858	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 3,364,496	
FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount
GHP-State	21,937,858

Sub Partner Name(s)

Broadreach	Elizabeth Glaser Pediatric AIDS Foundation	JHPIEGO
World Vision International		

Cross-Cutting Budget Attribution(s)

Approved



Economic Strengthening	1,000,000
Education	300,000
Gender: GBV	100,000
Focus Area:	GBV Prevention
Sub Area:	Implementation
Sub Area:	Capacity building

Key Issues

- Malaria (PMI)
- Child Survival Activities
- Safe Motherhood
- TB
- Workplace Programs
- End-of-Program Evaluation
- Family Planning

Budget Code Information

Mechanism ID: 13588			
Mechanism Name: APHIAplus Nyanza/Western			
Prime Partner Name: Program for Appropriate Technology in Health			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	890,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	6,800,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	450,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Care	PDCS	400,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	2,632,699	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVAB	806,816	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	1,700,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	670,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	810,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	6,200,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	578,343	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2014	2015
SITE_SUPP	Number of unique sites supported by PEPFAR	804	804
SITE_SUPP	By program area/support type: HTC Direct Service Delivery (DSD)	629	629
SITE_SUPP	By program area/support type: HTC Technical Assistance-only (TA)	0	0
SITE_SUPP	By program area/support type: Treatment	384	410



	Direct Service Delivery (DSD)		
SITE_SUPP	By program area/support type: Treatment Technical Assistance-only (TA)	0	0
SITE_SUPP	By program area/support type: Care and Support Direct Service Delivery (DSD)	624	678
SITE_SUPP	By program area/support type: Care and Support Technical Assistance-only (TA)	0	0
SITE_SUPP	By program area/support type: Food and Nutrition Direct Service Delivery (DSD)	0	0
SITE_SUPP	By program area/support type: Food and Nutrition Technical Assistance-only (TA)	599	599
SITE_SUPP	By program area/support type: PMTCT Direct Service Delivery (DSD)	599	678
SITE_SUPP	By program area/support type: PMTCT Technical Assistance-only (TA)	0	0
SITE_SUPP	By program area/support type: TB/HIV Direct Service Delivery (DSD)	0	0
SITE_SUPP	By program area/support type: TB/HIV Technical Assistance-only (TA)	477	477
SITE_SUPP	By program area/support type: VMMC Direct Service Delivery (DSD)	29	29
SITE_SUPP	By program area/support type: VMMC Technical Assistance-only (TA)	0	0
SITE_SUPP	By program area/support type: General Population Prevention Direct Service Delivery (DSD)	71	71
SITE_SUPP	By program area/support type: General Population Prevention Technical Assistance-only (TA)	602	602
SITE_SUPP	By program area/support type: Key Populations Prevention Direct Service Delivery (DSD)	9	9
SITE_SUPP	By program area/support type: Key Populations Prevention Technical	0	0



	Assistance-only (TA)		
SITE_SUPP	By program area/support type: OVC Direct Service Delivery (DSD)	75	75
SITE_SUPP	By program area/support type: OVC Technical Assistance-only (TA)	0	0
SITE_SUPP	By program area/support type: PHDP/Family Planning & Integration Direct Service Delivery (DSD)	0	0
SITE_SUPP	By program area/support type: PHDP/Family Planning & Integration Technical Assistance-only (TA)	384	384
SITE_SUPP	By program area/support type: Lab Direct Service Delivery (DSD)	397	410
SITE_SUPP	By program area/support type: Lab Technical Assistance-only (TA)	0	0
PMTCT_ARV_DSD	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	9,607	10,405
PMTCT_ARV_DSD	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	9,607	10,405
PMTCT_ARV_DSD	Life-long ART (including Option B+)	7,685	10,405
PMTCT_ARV_DSD	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	3,843	6,243
PMTCT_ARV_DSD	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	3,843	4,162
PMTCT_ARV_DSD	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)	0	0
PMTCT_ARV_DSD	Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)	1,489	1,573



PMTCT_ARV_DSD	Single-dose nevirapine (with or without tail)	0	0
PMTCT_ARV_DSD	Sum of Regimen Type disaggregates	9,174	11,978
PMTCT_ARV_DSD	Sum of New and Current disaggregates	7,686	10,405
PMTCT_ARV_NA	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	0	0
PMTCT_ARV_NA	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	0	0
PMTCT_ARV_NA	Life-long ART (including Option B+)	0	0
PMTCT_ARV_NA	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	0	0
PMTCT_ARV_NA	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	0	0
PMTCT_ARV_NA	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)	0	0
PMTCT_ARV_NA	Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)	0	0
PMTCT_ARV_NA	Single-dose nevirapine (with or without tail)	0	0
PMTCT_ARV_NA	Sum of Regimen disaggregates	0	0
PMTCT_ARV_NA	Sum of New and Current disaggregates	0	0
PMTCT_ARV_NGI	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	9,607	10,405
PMTCT_ARV_NGI	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	9,607	10,405
PMTCT_ARV_NGI	Life-long ART (including Option B+)	7,685	10,404
PMTCT_ARV_NGI	Sub-Disag of Life-long ART: Newly initiated on	3,843	6,243



	treatment during the current pregnancy		
PMTCT_ARV_NGI	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	3,843	4,162
PMTCT_ARV_NGI	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)	0	0
PMTCT_ARV_NGI	Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)	1,489	1,573
PMTCT_ARV_NGI	Single-dose nevirapine (with or without tail)	0	0
PMTCT_ARV_NGI	Sum of Regimen disaggregates	9,174	11,977
PMTCT_ARV_NGI	Sum of New and Current disaggregates	7,686	10,405
PMTCT_ARV_TA	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	0	0
PMTCT_ARV_TA	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	0	0
PMTCT_ARV_TA	Life-long ART (including Option B+)	0	0
PMTCT_ARV_TA	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	0	0
PMTCT_ARV_TA	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	0	0
PMTCT_ARV_TA	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)	0	0
PMTCT_ARV_TA	Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)	0	0
PMTCT_ARV_TA	Single-dose nevirapine (with or without tail)	0	0
PMTCT_ARV_TA	Sum of Regimen Type disaggregates	0	0



PMTCT_ARV_TA	Sum of New and Current disaggregates	0	0
PMTCT_SITE	Number of PEPFAR-supported sites achieving 90% ARV or ART coverage for HIV+ pregnant women	480	610
PMTCT_SITE	Total number of PEPFAR supported sites providing PMTCT services (HTC and ARV or ART services)	599	678
PMTCT_SITE	By site support type: Direct Service Delivery (DSD): Number of PEPFAR-supported sites achieving 90% ARV or ART coverage for HIV+ pregnant women	480	610
PMTCT_SITE	By site support type: Technical Assistance-only (TA): Number of PEPFAR-supported sites achieving 90% ARV or ART coverage for HIV+ pregnant women	0	0
PMTCT_SITE	Sum of Numerator Support Type disaggregates	480	610
PMTCT_SITE	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR supported sites providing PMTCT services (HTC and ARV or ART services)	599	678
PMTCT_SITE	By site support type: Technical Assistance-only (TA): Total number of PEPFAR supported sites providing PMTCT services (HTC and ARV or ART services)	0	0
PMTCT_SITE	Sum of Denominator Support Type disaggregates	599	678
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	167,382	182,507
PMTCT_STAT_DSD	Number of new ANC and L&D clients	167,382	182,507
PMTCT_STAT_DSD	By: Known positives at entry	3,843	4,162
PMTCT_STAT_DSD	By: Number of new positives identified	5,764	6,243
PMTCT_STAT_DSD	Sum of Positives Status disaggregates	9,607	10,405



PMTCT_STAT_NA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	0	0
PMTCT_STAT_NA	Number of new ANC and L&D clients	0	0
PMTCT_STAT_NA	By: Known positives at entry	0	0
PMTCT_STAT_NA	By: Number of new positives identified	0	0
PMTCT_STAT_NA	Sum of Positives Status disaggregates	0	0
PMTCT_STAT_NGI	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	167,382	182,507
PMTCT_STAT_NGI	Number of new ANC and L&D clients	167,382	182,507
PMTCT_STAT_NGI	By: Known positives at entry	3,843	4,162
PMTCT_STAT_NGI	By: Number of new positives identified	5,764	6,243
PMTCT_STAT_NGI	Sum of Positives Status disaggregates	9,607	10,405
BS_COLL	Number of whole blood collections each year by the NBTS network	0	0
BS_COLL	By: Number of whole blood donations screened for HIV in an NBTS network laboratory	0	0
BS_COLL	By: Number of whole blood donations screened for HIV in an NBTS network laboratory that are identified as reactive for HIV	0	0
KP_MAT_DSD	Number of people who inject drugs (PWID) on medication assisted therapy (MAT) for at least 6 months	0	0
KP_MAT_DSD	Sex: Male	0	0
KP_MAT_DSD	Sex: Female	0	0
KP_MAT_DSD	Sum of Sex disaggregates	0	0
VMMC_AE_DSD	Number of males circumcised surgically or by medical device that experienced at least one moderate or severe adverse event(s) (AEs)	16	16
VMMC_AE_DSD	By AE type: Number of VMMC clients with one or more moderate or severe surgical	0	0



	intra-operative AE(s)		
VMMC_AE_DSD	Sub-Disag: Surgical intra-operative AE(s) by maximum severity category: Number of clients with one or more moderate surgical intra-operative AE(s), but no severe surgical intra-operative AE(s)	0	0
VMMC_AE_DSD	Sub-Disag: Surgical intra-operative AE(s) by maximum severity category: Number of clients with one or more severe surgical intra-operative AE(s)	0	0
VMMC_AE_DSD	By AE Type: Number of VMMC clients with one or more moderate or severe surgical post-operative AE(s)	16	16
VMMC_AE_DSD	Sub-Disag: By Surgical post-operative AE(s) by maximum severity category: Number of clients with one or more moderate surgical post-operative AE(s), but no severe surgical post-operative AE(s)	16	16
VMMC_AE_DSD	Sub-Disag: By Surgical post-operative AE(s) by maximum severity category: Number of clients with one or more severe surgical intra-operative AE(s)	0	0
VMMC_AE_DSD	By AE Type: Number of VMMC clients with one or more moderate or severe medical device-related AE(s)	8	8
VMMC_AE_DSD	Sub-Disag: By Medical device-based AE(s) by maximum severity category: Number of clients with one or more moderate medical device-related AE(s), but no severe medical device-related AE(s)	8	8
VMMC_AE_DSD	Sub-Disag: By Medical device-based AE(s) by maximum severity category: Number of clients with one or more severe medical device-related AE(s)	0	0
VMMC_CIRC_DSD	Number of males circumcised as part of the	45,000	45,000



	voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period		
VMMC_CIRC_DSD	By Age: 1-9	1,739	1,739
VMMC_CIRC_DSD	By Age: 10-14	9,664	9,664
VMMC_CIRC_DSD	By Age: 15-19	16,931	16,931
VMMC_CIRC_DSD	By Age: 20-24	8,700	8,700
VMMC_CIRC_DSD	By Age: 25-49	7,669	7,669
VMMC_CIRC_DSD	By Age: 50+	297	297
VMMC_CIRC_DSD	Sum of age disaggregates	45,000	45,000
VMMC_CIRC_DSD	By HIV status: Number of HIV-positive clients (tested HIV positive at VMMC site)	604	604
VMMC_CIRC_DSD	By HIV status: Number of HIV-negative clients (tested HIV negative at VMMC program)	37,220	37,220
VMMC_CIRC_DSD	By HIV status: Number of clients with undocumented/indeterminate HIV status or not tested for HIV at site	5,335	5,335
VMMC_CIRC_DSD	By circumcision technique: Surgical VMMC	42,159	42,159
VMMC_CIRC_DSD	By circumcision technique: Device-based VMMC	1,000	1,000
VMMC_CIRC_DSD	By follow-up status: Number of surgically circumcised clients who returned at least once for follow-up care within 14 days of circumcision surgery	26,327	26,327
VMMC_CIRC_DSD	By follow-up status: Number of surgically circumcised clients who did NOT return for follow-up care within 14 days of circumcision surgery	16,832	16,832
VMMC_CIRC_NA	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	0	0
VMMC_CIRC_NA	By Age: <1	0	0
VMMC_CIRC_NA	By Age: 1-9	0	0



VMMC_CIRC_NA	By Age: 10-14	0	0
VMMC_CIRC_NA	By Age: 15-19	0	0
VMMC_CIRC_NA	By Age: 20-24	0	0
VMMC_CIRC_NA	By Age: 25-49	0	0
VMMC_CIRC_NA	By Age: 50+	0	0
VMMC_CIRC_NA	Sum of Age disaggregates	0	0
VMMC_CIRC_NA	By HIV status: Number of HIV-positive clients (tested HIV positive at VMMC site)	0	0
VMMC_CIRC_NA	By HIV status: Number of HIV-negative clients (tested HIV negative at VMMC program)	0	0
VMMC_CIRC_NA	By HIV status: Number of clients with undocumented/indeterminate HIV status or not tested for HIV at site	0	0
VMMC_CIRC_NA	By circumcision technique: Surgical VMMC	0	0
VMMC_CIRC_NA	By circumcision technique: Device-based VMMC	0	0
VMMC_CIRC_NA	By follow-up status: Number of surgically circumcised clients who returned at least once for follow-up care within 14 days of circumcision surgery	0	0
VMMC_CIRC_NA	By follow-up status: Number of surgically circumcised clients who did NOT return for follow-up care within 14 days of circumcision surgery	0	0
VMMC_CIRC_NGI	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	45,000	45,000
VMMC_CIRC_NGI	By Age: <1	0	0
VMMC_CIRC_NGI	By Age: 1-9	1,739	1,739
VMMC_CIRC_NGI	By Age: 10-14	9,664	9,664
VMMC_CIRC_NGI	By Age: 15-19	16,931	16,931
VMMC_CIRC_NGI	By Age: 20-24	8,700	8,700
VMMC_CIRC_NGI	By Age: 25-49	7,669	7,669

VMMC_CIRC_NGI	By Age: 50+	297	297
VMMC_CIRC_NGI	Sum of Age disaggregates	45,000	45,000
VMMC_CIRC_NGI	By HIV status: Number of HIV-positive clients (tested HIV positive at VMMC site)	100	100
VMMC_CIRC_NGI	By HIV status: Number of HIV-negative clients (tested HIV negative at VMMC program)	1,739	1,739
VMMC_CIRC_NGI	By HIV status: Number of clients with undocumented/indeterminate HIV status or not tested for HIV at site	9,564	9,564
VMMC_CIRC_NGI	By circumcision technique: Surgical VMMC	16,931	16,931
VMMC_CIRC_NGI	By circumcision technique: Device-based VMMC	8,700	8,700
VMMC_CIRC_NGI	By follow-up status: Number of surgically circumcised clients who returned at least once for follow-up care within 14 days of circumcision surgery	7,669	7,669
VMMC_CIRC_NGI	By follow-up status: Number of surgically circumcised clients who did NOT return for follow-up care within 14 days of circumcision surgery	297	297
VMMC_CIRC_TA	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	0	0
VMMC_CIRC_TA	By Age: <1	0	0
VMMC_CIRC_TA	By Age: 1-9	0	0
VMMC_CIRC_TA	By Age: 10-14	0	0
VMMC_CIRC_TA	By Age: 15-19	0	0
VMMC_CIRC_TA	By Age: 20-24	0	0
VMMC_CIRC_TA	By Age: 25-49	0	0
VMMC_CIRC_TA	By Age: 50+	0	0
VMMC_CIRC_TA	Sum of Age disaggregations	0	0
VMMC_CIRC_TA	By HIV status: Number of HIV-positive clients (tested HIV positive at VMMC site)	0	0

VMMC_CIRC_TA	By HIV status: Number of HIV-negative clients (tested HIV negative at VMMC program)	0	0
VMMC_CIRC_TA	By HIV status: Number of clients with undocumented/indeterminate HIV status or not tested for HIV at site	0	0
VMMC_CIRC_TA	By circumcision technique: Surgical VMMC	0	0
VMMC_CIRC_TA	By circumcision technique: Device-based VMMC	0	0
VMMC_CIRC_TA	By follow-up status: Number of surgically circumcised clients who returned at least once for follow-up care within 14 days of circumcision surgery	0	0
VMMC_CIRC_TA	By follow-up status: Number of surgically circumcised clients who did NOT return for follow-up care within 14 days of circumcision surgery	0	0
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	161,531	161,531
PP_PREV_DSD	Total number of people in the target population	626,682	626,682
PP_PREV_DSD	Age/sex: 10-14 Male	50,852	50,852
PP_PREV_DSD	Age/sex: 20-24 Male	4,000	4,000
PP_PREV_DSD	Age/sex: 25-49 Male	4,250	4,250
PP_PREV_DSD	Age/sex: 10-14 Female	50,000	50,000
PP_PREV_DSD	Age/sex: 15-19 Female	25,000	25,000
PP_PREV_DSD	Age/sex: 20-24 Female	27,429	27,429
PP_PREV_DSD	Age/sex: 25-49 Female	0	0
PP_PREV_DSD	Age/sex: 50+ Female	0	0
PP_PREV_DSD	Sum of Age/Sex disaggregates	161,531	161,531
PP_PREV_TA	Number of the target population who completed a standardized HIV prevention intervention including the minimum	0	0



	components during the reporting period.		
PP_PREV_TA	Total number of people in the target population	0	0
PP_PREV_TA	Age/sex: 10-14 Male	0	0
PP_PREV_TA	Age/sex: 15-19 Male	0	0
PP_PREV_TA	Age/sex: 20-24 Male	0	0
PP_PREV_TA	Age/sex: 25-49 Male	0	0
PP_PREV_TA	Age/sex: 50+ Male	0	0
PP_PREV_TA	Age/sex: 10-14 Female	0	0
PP_PREV_TA	Age/sex: 15-19 Female	0	0
PP_PREV_TA	Age/sex: 20-24 Female	0	0
PP_PREV_TA	Age/sex: 25-49 Female	0	0
PP_PREV_TA	Age/sex: 50+ Female	0	0
PP_PREV_TA	Sum of Age/Sex disaggregates	0	0
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	28,241	28,241
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	27,197	27,197
KP_PREV_DSD	By key population type: Males who inject drugs (Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0	0
KP_PREV_DSD	By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or	0	0



	small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)		
KP_PREV_DSD	By key population type: Men who have sex with men/Transgender (MSM/TG) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	1,500	1,500
KP_PREV_DSD	By key population type: MSM/TG who are male sex workers (subset MSM/TG) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	250	250
KP_PREV_TA	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	0	0
KP_PREV_TA	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0	0
KP_PREV_TA	By key population type: Males who inject drugs (Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0	0
KP_PREV_TA	By key population type: Females who inject drugs (Female PWID) (Numerator: Number of	0	0

	key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)		
KP_PREV_TA	By key population type: Men who have sex with men/Transgender (MSM/TG) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0	0
KP_PREV_TA	By key population type: MSM/TG who are male sex workers (subset MSM/TG) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0	0
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	658,954	658,954
HTC_TST_DSD	By Test Result: Negative	632,596	632,596
HTC_TST_DSD	By Test Result: Positive	26,358	26,358
HTC_TST_DSD	Sum of Test Result disaggregates	658,954	658,954
HTC_TST_DSD	Age/sex: <1 Male	0	0
HTC_TST_DSD	Age/sex: 1-4 Male	23,063	23,063
HTC_TST_DSD	Age/sex: 5-9 Male	9,884	9,884
HTC_TST_DSD	Age/sex: 10-14 Male	16,474	16,474
HTC_TST_DSD	Age/sex: 15-19 Male	32,948	32,948
HTC_TST_DSD	Age/sex: 20-24 Male	82,369	82,369
HTC_TST_DSD	Age/sex: 25-49 Male	131,791	131,791
HTC_TST_DSD	Age/sex: 50+ Male	32,948	32,948
HTC_TST_DSD	Age/sex: <1 Female	0	0
HTC_TST_DSD	Age/sex: 1-4 Female	23,063	23,063



HTC_TST_DSD	Age/sex: 5-9 Female	9,884	9,884
HTC_TST_DSD	Age/sex: 10-14 Female	16,474	16,474
HTC_TST_DSD	Age/sex: 15-19 Female	32,948	32,948
HTC_TST_DSD	Age/sex: 20-24 Female	82,369	82,369
HTC_TST_DSD	Age/sex: 25-49 Female	131,791	131,791
HTC_TST_DSD	Age/sex: 50+ Female	32,948	32,948
HTC_TST_DSD	Sum of Age/Sex disaggregates	658,954	658,954
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	49,422	49,422
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	280,055	280,055
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	49,422	49,422
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	280,055	280,055
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	98,844	98,844
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	560,110	560,110
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	658,954	658,954
HTC_TST_NA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	0	0
HTC_TST_NA	By Test Result: Negative	0	0
HTC_TST_NA	By Test Result: Positive	0	0
HTC_TST_NA	Sum of Test Result disaggregates	0	0
HTC_TST_NA	Age/sex: <1 Male	0	0
HTC_TST_NA	Age/sex: 1-4 Male	0	0
HTC_TST_NA	Age/sex: 5-9 Male	0	0
HTC_TST_NA	Age/sex: 10-14 Male	0	0
HTC_TST_NA	Age/sex: 15-19 Male	0	0
HTC_TST_NA	Age/sex: 20-24 Male	0	0
HTC_TST_NA	Age/sex: 25-49 Male	0	0
HTC_TST_NA	Age/sex: 50+ Male	0	0
HTC_TST_NA	Age/sex: <1 Female	0	0



HTC_TST_NA	Age/sex: 1-4 Female	0	0
HTC_TST_NA	Age/sex: 5-9 Female	0	0
HTC_TST_NA	Age/sex: 10-14 Female	0	0
HTC_TST_NA	Age/sex: 15-19 Female	0	0
HTC_TST_NA	Age/sex: 20-24 Female	0	0
HTC_TST_NA	Age/sex: 25-49 Female	0	0
HTC_TST_NA	Age/sex: 50+ Female	0	0
HTC_TST_NA	Sum of Age/Sex disaggregates	0	0
HTC_TST_NA	Aggregated Age/sex: <15 Male	0	0
HTC_TST_NA	Aggregated Age/sex: 15+ Male	0	0
HTC_TST_NA	Aggregated Age/sex: <15 Female	0	0
HTC_TST_NA	Aggregated Age/sex: 15+ Female	0	0
HTC_TST_NA	Sum of Aggregated Age/Sex <15	0	0
HTC_TST_NA	Sum of Aggregated Age/Sex 15+	0	0
HTC_TST_NA	Sum of Aggregated Age/Sex disaggregates	0	0
HTC_TST_NGI	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	658,954	658,954
HTC_TST_NGI	By Test Result: Negative	632,596	632,596
HTC_TST_NGI	By Test Result: Positive	26,358	26,358
HTC_TST_NGI	Sum of Test Result disaggregates	658,954	658,954
HTC_TST_NGI	Age/sex: <1 Male	0	0
HTC_TST_NGI	Age/sex: 1-4 Male	23,063	23,063
HTC_TST_NGI	Age/sex: 5-9 Male	9,884	9,884
HTC_TST_NGI	Age/sex: 10-14 Male	16,474	16,474
HTC_TST_NGI	Age/sex: 15-19 Male	32,948	32,948
HTC_TST_NGI	Age/sex: 20-24 Male	82,369	82,369
HTC_TST_NGI	Age/sex: 25-49 Male	131,791	131,791
HTC_TST_NGI	Age/sex: 50+ Male	32,948	32,948
HTC_TST_NGI	Age/sex: <1 Female	0	0
HTC_TST_NGI	Age/sex: 1-4 Female	23,063	23,063
HTC_TST_NGI	Age/sex: 5-9 Female	9,884	9,884



HTC_TST_NGI	Age/sex: 10-14 Female	16,474	16,474
HTC_TST_NGI	Age/sex: 15-19 Female	32,948	32,948
HTC_TST_NGI	Age/sex: 20-24 Female	82,369	82,369
HTC_TST_NGI	Age/sex: 25-49 Female	131,791	131,791
HTC_TST_NGI	Age/sex: 50+ Female	32,948	32,948
HTC_TST_NGI	Sum of Age/Sex disaggregates	658,954	658,954
HTC_TST_NGI	Aggregated Age/sex: <15 Male	49,422	49,422
HTC_TST_NGI	Aggregated Age/sex: 15+ Male	280,055	280,055
HTC_TST_NGI	Aggregated Age/sex: <15 Female	49,422	49,422
HTC_TST_NGI	Aggregated Age/sex: 15+ Female	280,055	280,055
HTC_TST_NGI	Sum of Aggregated Age/Sex <15	98,844	98,844
HTC_TST_NGI	Sum of Aggregated Age/Sex 15+	560,110	560,110
HTC_TST_NGI	Sum of Aggregated Age/Sex disaggregates	658,954	658,954
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	0	0
HTC_TST_TA	By Test Result: Negative	0	0
HTC_TST_TA	By Test Result: Positive	0	0
HTC_TST_TA	Sum of Test Result disaggregates	0	0
HTC_TST_TA	Age/sex: <1 Male	0	0
HTC_TST_TA	Age/sex: 1-4 Male	0	0
HTC_TST_TA	Age/sex: 5-9 Male	0	0
HTC_TST_TA	Age/sex: 10-14 Male	0	0
HTC_TST_TA	Age/sex: 15-19 Male	0	0
HTC_TST_TA	Age/sex: 20-24 Male	0	0
HTC_TST_TA	Age/sex: 25-49 Male	0	0
HTC_TST_TA	Age/sex: 50+ Male	0	0
HTC_TST_TA	Age/sex: <1 Female	0	0
HTC_TST_TA	Age/sex: 1-4 Female	0	0
HTC_TST_TA	Age/sex: 5-9 Female	0	0
HTC_TST_TA	Age/sex: 10-14 Female	0	0
HTC_TST_TA	Age/sex: 15-19 Female	0	0



HTC_TST_TA	Age/sex: 20-24 Female	0	0
HTC_TST_TA	Age/sex: 25-49 Female	0	0
HTC_TST_TA	Age/sex: 50+ Female	0	0
HTC_TST_TA	Sum of Age/Sex disaggregates	0	0
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	0	0
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	0	0
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	0	0
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	0	0
HTC_TST_TA	Sum of Aggregated Age/Sex <15	0	0
HTC_TST_TA	Sum of Aggregated Age/Sex 15+	0	0
HTC_TST_TA	Sum of Aggregated Age/Sex disaggregates	0	0
GEND_GBV_DSD	Number of people receiving post-GBV care	6,850	8,550
GEND_GBV_DSD	Age: 0-9	200	300
GEND_GBV_DSD	Age: 10-14	300	400
GEND_GBV_DSD	Age: 15-17	350	450
GEND_GBV_DSD	Age: 18-24	1,500	2,200
GEND_GBV_DSD	Age: 25+	4,500	5,200
GEND_GBV_DSD	Sum of Age disaggregates	6,850	8,550
GEND_GBV_DSD	Sex: Male	2,200	3,250
GEND_GBV_DSD	Sex: Female	4,650	5,300
GEND_GBV_DSD	Sum of Sex disaggregates	6,850	8,550
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	5,832	5,832
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	893	893
GEND_GBV_DSD	By PEP service provision (related to sexual violence services provided)	1,018	1,018
GEND_NORM_DSD	Number of people completing an intervention pertaining to gender norms, that meets	36,000	40,000



	minimum criteria		
GEND_NORM_DSD	By Age: 0-9	2,400	3,000
GEND_NORM_DSD	By Age: 10-14	3,600	4,000
GEND_NORM_DSD	By Age: 15-19	5,500	6,000
GEND_NORM_DSD	By Age: 20-24	9,500	10,000
GEND_NORM_DSD	By Age: 25+	15,000	17,000
GEND_NORM_DSD	Sum of Age disaggregates	36,000	40,000
GEND_NORM_DSD	By Sex: Male	15,500	15,000
GEND_NORM_DSD	By Sex: Female	20,500	25,000
GEND_NORM_DSD	Sum of Sex disaggregates	36,000	40,000
GEND_NORM_DSD	By type of activity: Individual	3,000	4,500
GEND_NORM_DSD	By type of activity: Small Group	12,000	14,000
GEND_NORM_DSD	By type of activity: Community-level	21,000	21,500
OVC_ACC_DSD	Number of active beneficiaries receiving support from PEPFAR OVC programs to access HIV services	3,000	3,000
OVC_ACC_DSD	Sex: Male	1,800	1,800
OVC_ACC_DSD	Sex: Female	1,200	1,200
OVC_ACC_DSD	Sum of Sex disaggregates	3,000	3,000
OVC_ACC_DSD	Age: <1	250	250
OVC_ACC_DSD	Age: 1-4	350	350
OVC_ACC_DSD	Age: 5-9	850	850
OVC_ACC_DSD	Age: 10-14	820	820
OVC_ACC_DSD	Age: 15-17	730	730
OVC_ACC_DSD	Age: 18+	0	0
OVC_ACC_DSD	Sum of Age disaggregates	3,000	3,000
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	180,000	180,000
OVC_SERV_DSD	Sex: Male	92,000	92,000
OVC_SERV_DSD	Sex: Female	88,000	88,000
OVC_SERV_DSD	Sum of Sex disaggregates	180,000	180,000



OVC_SERV_DSD	Age: <1	2,500	2,500
OVC_SERV_DSD	Age: 1-4	3,500	3,500
OVC_SERV_DSD	Age: 5-9	28,000	28,000
OVC_SERV_DSD	Age: 10-14	77,000	77,000
OVC_SERV_DSD	Age: 15-17	69,000	69,000
OVC_SERV_DSD	Age: 18+	0	0
OVC_SERV_DSD	Sum of Age disaggregates	180,000	180,000
OVC_SERV_TA	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	0	0
OVC_SERV_TA	Sex: Male	0	0
OVC_SERV_TA	Sex: Female	0	0
OVC_SERV_TA	Sum of Sex disaggregates	0	0
OVC_SERV_TA	Age: <1	0	0
OVC_SERV_TA	Age: 1-4	0	0
OVC_SERV_TA	Age: 5-9	0	0
OVC_SERV_TA	Age: 10-14	0	0
OVC_SERV_TA	Age: 15-17	0	0
OVC_SERV_TA	Age: 18+	0	0
OVC_SERV_TA	Sum of Age disaggregates	0	0
C2.1.D_DSD	Number of HIV-positive individuals receiving a minimum of one clinical service	99,208	109,130
C2.1.D_DSD	By Age/Sex: <15 Female	5,952	6,548
C2.1.D_DSD	By Age/Sex: <15 Male	3,968	4,364
C2.1.D_DSD	By Age/Sex: 15+ Female	53,572	58,932
C2.1.D_DSD	By Age/Sex: 15+ Male	35,716	39,286
C2.1.D_DSD	Sum of Age/Sex disaggregates	99,208	109,130
C2.1.D_DSD	By Age: <15	9,920	10,912
C2.1.D_DSD	By Age: 15+	89,288	98,218
C2.1.D_DSD	Sum of Age disaggregates	99,208	109,130
C2.1.D_DSD	By Sex: Female	59,524	65,480
C2.1.D_DSD	By Sex: Male	39,684	43,650



C2.1.D_DSD	Sum of Sex disaggregates	99,208	109,130
C2.1.D_NA	Number of HIV-positive individuals receiving a minimum of one clinical service	0	0
C2.1.D_NA	By Age/Sex: <15 Female	0	0
C2.1.D_NA	By Age/Sex: <15 Male	0	0
C2.1.D_NA	By Age/Sex: 15+ Female	0	0
C2.1.D_NA	By Age/Sex: 15+ Male	0	0
C2.1.D_NA	Sum of Age/Sex disaggregates	0	0
C2.1.D_NA	By Age: <15	0	0
C2.1.D_NA	By Age: 15+	0	0
C2.1.D_NA	Sum of Age disaggregates	0	0
C2.1.D_NA	By Sex: Female	0	0
C2.1.D_NA	By Sex: Male	0	0
C2.1.D_NA	Sum of Sex disaggregates	0	0
C2.1.D_NGI	Number of HIV-positive individuals receiving a minimum of one clinical service	99,208	109,130
C2.1.D_NGI	By Age/Sex: <15 Female	5,952	6,548
C2.1.D_NGI	By Age/Sex: <15 Male	3,968	4,364
C2.1.D_NGI	By Age/Sex: 15+ Female	53,572	58,932
C2.1.D_NGI	By Age/Sex: 15+ Male	35,716	39,286
C2.1.D_NGI	Sum of Age/Sex disaggregates	99,208	109,130
C2.1.D_NGI	By Age: <15	9,920	10,912
C2.1.D_NGI	By Age: 15+	89,288	98,218
C2.1.D_NGI	Sum of Age disaggregates	99,208	109,130
C2.1.D_NGI	By Sex: Female	59,524	65,480
C2.1.D_NGI	By Sex: Male	39,684	43,650
C2.1.D_NGI	Sum of Sex disaggregates	99,208	109,130
C2.1.D_TA	Number of HIV-positive individuals receiving a minimum of one clinical service	0	0
C2.1.D_TA	By Age/Sex: <15 Female	0	0
C2.1.D_TA	By Age/Sex: <15 Male	0	0
C2.1.D_TA	By Age/Sex: 15+ Female	0	0



C2.1.D_TA	By Age/Sex: 15+ Male	0	0
C2.1.D_TA	Sum of Age/Sex disaggregates	0	0
C2.1.D_TA	By Age: <15	0	0
C2.1.D_TA	By Age: 15+	0	0
C2.1.D_TA	Sum of Age disaggregates	0	0
C2.1.D_TA	By Sex: Female	0	0
C2.1.D_TA	By Sex: Male	0	0
C2.1.D_TA	Sum of Sex disaggregates	0	0
C2.4.D_DSD	Number of HIV-positive patients who were screened for TB in HIV care or treatment setting	79,367	79,367
C2.4.D_DSD	Number of HIV-positive individuals receiving a minimum of one clinical service	99,208	109,130
C2.5.D_DSD	Number of HIV-positive patients in HIV care who started TB treatment	1,984	1,984
C2.5.D_DSD	Number of HIV-positive individuals receiving a minimum of one clinical service	99,208	109,130
CARE_CURR_DSD	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	99,208	109,130
CARE_CURR_DSD	Age/sex: <1 Male	992	1,091
CARE_CURR_DSD	Age/sex: 1-4 Male	992	1,091
CARE_CURR_DSD	Age/sex: 5-9 Male	992	1,091
CARE_CURR_DSD	Age/sex: 10-14 Male	992	1,091
CARE_CURR_DSD	Age/sex: 15-19 Male	1,984	2,182
CARE_CURR_DSD	Age/sex: 20-24 Male	15,874	17,461
CARE_CURR_DSD	Age/sex: 25-49 Male	15,874	17,461
CARE_CURR_DSD	Age/sex: 50+ Male	1,984	2,182
CARE_CURR_DSD	Age/sex: <1 Female	1,488	1,637
CARE_CURR_DSD	Age/sex: 1-4 Female	1,488	1,637
CARE_CURR_DSD	Age/sex: 5-9 Female	1,488	1,637



CARE_CURR_DSD	Age/sex: 10-14 Female	1,488	1,637
CARE_CURR_DSD	Age/sex: 15-19 Female	2,976	3,275
CARE_CURR_DSD	Age/sex: 20-24 Female	23,810	26,191
CARE_CURR_DSD	Age/sex: 25-49 Female	23,810	26,191
CARE_CURR_DSD	Age/sex: 50+ Female	2,976	3,275
CARE_CURR_DSD	Sun of Age/Sex disaggregates	99,208	109,130
CARE_CURR_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	3,968	4,364
CARE_CURR_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	35,716	39,286
CARE_CURR_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	5,952	6,548
CARE_CURR_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	53,572	58,932
CARE_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	99,208	109,130
CARE_CURR_TA	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	0	0
CARE_CURR_TA	Age/sex: <1 Male	0	0
CARE_CURR_TA	Age/sex: 1-4 Male	0	0
CARE_CURR_TA	Age/sex: 5-9 Male	0	0
CARE_CURR_TA	Age/sex: 10-14 Male	0	0
CARE_CURR_TA	Age/sex: 15-19 Male	0	0
CARE_CURR_TA	Age/sex: 20-24 Male	0	0
CARE_CURR_TA	Age/sex: 25-49 Male	0	0
CARE_CURR_TA	Age/sex: 50+ Male	0	0
CARE_CURR_TA	Age/sex: <1 Female	0	0
CARE_CURR_TA	Age/sex: 1-4 Female	0	0
CARE_CURR_TA	Age/sex: 5-9 Female	0	0
CARE_CURR_TA	Age/sex: 10-14 Female	0	0
CARE_CURR_TA	Age/sex: 15-19 Female	0	0



CARE_CURR_TA	Age/sex: 20-24 Female	0	0
CARE_CURR_TA	Age/sex: 25-49 Female	0	0
CARE_CURR_TA	Age/sex: 50+ Female	0	0
CARE_CURR_TA	Sum of Age/Sex disaggregates	0	0
CARE_CURR_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	0	0
CARE_CURR_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	0	0
CARE_CURR_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	0	0
CARE_CURR_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	0	0
CARE_CURR_TA	Sum of Aggregated Age/Sex disaggregates	0	0
CARE_NEW_DSD	Number of HIV-infected adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load	19,846	19,846
CARE_NEW_DSD	Age/sex: <1 Male	199	199
CARE_NEW_DSD	Age/sex: 1-4 Male	199	199
CARE_NEW_DSD	Age/sex: 5-9 Male	199	199
CARE_NEW_DSD	Age/sex: 10-14 Male	199	199
CARE_NEW_DSD	Age/sex: 15-19 Male	397	397
CARE_NEW_DSD	Age/sex: 20-24 Male	3,175	3,175
CARE_NEW_DSD	Age/sex: 25-49 Male	3,175	3,175
CARE_NEW_DSD	Age/sex: 50+ Male	397	397
CARE_NEW_DSD	Age/sex: <1 Female	298	298
CARE_NEW_DSD	Age/sex: 1-4 Female	298	298
CARE_NEW_DSD	Age/sex: 5-9 Female	298	298
CARE_NEW_DSD	Age/sex: 10-14 Female	298	298
CARE_NEW_DSD	Age/sex: 15-19 Female	595	595
CARE_NEW_DSD	Age/sex: 20-24 Female	4,762	4,762



CARE_NEW_DSD	Age/sex: 25-49 Female	4,762	4,762
CARE_NEW_DSD	Age/sex: 50+ Female	595	595
CARE_NEW_DSD	Sum of Age/sex disaggregates	19,846	19,846
CARE_NEW_DSD	Aggregated Age/sex: <15 Male	796	796
CARE_NEW_DSD	Aggregated Age/sex: 15+ Male	7,144	7,144
CARE_NEW_DSD	Aggregated Age/sex: <15 Female	1,192	1,192
CARE_NEW_DSD	Aggregated Age/sex: 15+ Female	10,714	10,714
CARE_NEW_DSD	Sum of Aggregated Age/sex disaggregates	19,846	19,846
CARE_SITE	Number of PEPFAR-supported HIV clinical care sites at which at least 80% of PLHIV received all of the following during the reporting period: 1) clinical assessment (WHO staging) OR CD4 count OR viral load, AND 2) TB screening at last visit, AND 3) if eligible, cotrimoxazole	624	644
CARE_SITE	Total number of PEPFAR supported sites providing clinical care services	624	644
CARE_SITE	By site support type: Direct Service Delivery (DSD): Number of PEPFAR-supported HIV clinical care sites at which at least 80% of PLHIV received all of the following during the reporting period: 1) clinical assessment (WHO staging) OR CD4 count OR viral load, AND 2) TB screening at last visit, AND 3) if eligible, cotrimoxazole	624	644
CARE_SITE	By site support type: Technical Assistance-only (TA): Number of PEPFAR-supported HIV clinical care sites at which at least 80% of PLHIV received all of the following during the reporting period: 1) clinical assessment (WHO staging) OR CD4 count OR viral load, AND 2) TB screening at last visit, AND 3) if eligible, cotrimoxazole	624	644
CARE_SITE	Sum of Numerator Site Support Type disaggregates	1,248	1,288



CARE_SITE	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR supported sites providing clinical care services	624	644
CARE_SITE	By site support type: Technical Assistance-only (TA): Total number of PEPFAR supported sites providing clinical care services	624	644
CARE_SITE	Sum of Denominator Site Support Type disaggregates	1,248	1,288
FN_SITE	Number of PEPFAR-supported sites achieving 90% nutrition assessments that result in accurate categorization of malnutrition	0	0
FN_SITE	Total number of PEPFAR-supported sites providing nutrition assessment, counseling and support (NACS) services	0	0
FN_SITE	By site support type: Direct Service Delivery (DSD): Number of PEPFAR-supported sites achieving 90% nutrition assessments that result in accurate categorization of malnutrition	0	0
FN_SITE	By site support type: Technical Assistance-only (TA): Number of PEPFAR-supported sites achieving 90% nutrition assessments that result in accurate categorization of malnutrition	0	0
FN_SITE	Sum of Numerator Support Type disaggregates	0	0
FN_SITE	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported sites providing nutrition assessment, counseling and support (NACS) services	0	0
FN_SITE	By site support type: Technical Assistance-only (TA): Total number of PEPFAR-supported sites providing nutrition assessment, counseling and support (NACS)	0	0

	services		
FN_SITE	Sum of Denominator Support Type disaggregates	0	0
FN_THER_DSD	Number of clinically malnourished PLHIV who received therapeutic and/or supplementary food during the reporting period.	0	0
FN_THER_DSD	Number of PLHIV who were nutritionally assessed and found to be clinically undernourished.	0	0
FN_THER_DSD	Age: <1	0	0
FN_THER_DSD	Age: 1-4	0	0
FN_THER_DSD	Age: 5-14	0	0
FN_THER_DSD	Age: 15-17	0	0
FN_THER_DSD	Age: 18+	0	0
FN_THER_DSD	Sum of Age disaggregates	0	0
FN_THER_DSD	Aggregated Age: <18	0	0
FN_THER_DSD	Aggregated Age: 18+	0	0
FN_THER_DSD	Sum of Aggregated Age disaggregates	0	0
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	3,570	3,570
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	4,462	4,462
TB_ART_DSD	Age: 0-4	171	171
TB_ART_DSD	Age: 5-14	257	257
TB_ART_DSD	Age: 15+	3,142	3,142
TB_ART_DSD	Male	1,428	1,428
TB_ART_DSD	Female	2,142	2,142
TB_ART_DSD	Sum of Sex disaggregates	3,570	3,570
TB_ART_DSD	Newly tested	1,427	1,427



TB_ART_DSD	Known HIV-positive	2,143	2,143
TB_ART_DSD	Sum of Test Status disaggregates	3,570	3,570
TB_ART_DSD	Aggregated Age: <15	428	428
TB_ART_DSD	Aggregated Age: 15+	3,142	3,142
TB_ART_DSD	Sum of Aggregated Age disaggregates	3,570	3,570
TB_ARTSITE	The number of PEPFAR-supported TB basic management units at which 80% of registered TB cases who are HIV-positive are on ART, during the reporting period	382	382
TB_ARTSITE	The number of PEPFAR-supported TB basic management units	477	477
TB_ARTSITE	By site support type: Direct Service Delivery (DSD): The number of PEPFAR-supported TB basic management units at which 80% of registered TB cases who are HIV-positive are on ART, during the reporting period	382	382
TB_ARTSITE	By site support type: Technical Assistance-only (TA): The number of PEPFAR-supported TB basic management units at which 80% of registered TB cases who are HIV-positive are on ART, during the reporting period	0	0
TB_ARTSITE	Sum of Numerator Site Support Type disaggregates	382	382
TB_ARTSITE	By site support type: Direct Service Delivery (DSD): The number of PEPFAR-supported TB basic management units	477	477
TB_ARTSITE	By site support type: Technical Assistance-only (TA): The number of PEPFAR-supported TB basic management units	0	0
TB_ARTSITE	Sum of Denominator Site Support Type disaggregates	477	477
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting	9,607	10,405



	period		
PMTCT_EID_DSD	Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT)	9,607	10,405
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	6,724	7,284
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	2,883	3,121
PMTCT_EID_DSD	Sum of Infant Age disaggregates	9,607	10,405
PMTCT_EID_DSD	By infants with a positive virologic test result within 12 months of birth	397	350
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	72,423	82,343
TX_CURR_DSD	Age/Sex: <1 Male	912	1,037
TX_CURR_DSD	Age/Sex: 1-4 Male	912	1,037
TX_CURR_DSD	Age/Sex: 5-14 Male	912	1,037
TX_CURR_DSD	Age/Sex: 15+ Male	23,113	26,217
TX_CURR_DSD	Age/Sex: <1 Female	1,368	1,556
TX_CURR_DSD	Age/Sex: 1-4 Female	1,368	1,556
TX_CURR_DSD	Age/Sex: 5-14 Female	1,368	1,556
TX_CURR_DSD	Age/Sex: 15+ Female	42,470	48,347
TX_CURR_DSD	Sum of age/sex disaggregates	6,840	7,779
TX_CURR_DSD	Percent children with advanced HIV infection receiving antiretroviral therapy (ART) [CURRENT]	9	9
TX_CURR_DSD	Percent women and girls with advanced HIV infection receiving antiretroviral therapy (ART) [CURRENT]	64	64
TX_CURR_DSD	Aggregated Age/Sex: <1 Male	912	1,037
TX_CURR_DSD	Aggregated Age/Sex: <1 Female	1,368	1,556
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	2,736	3,111
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	23,113	26,217



TX_CURR_DSD	Aggregated Age/Sex: <15 Female	4,104	4,668
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	42,470	48,347
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	6,840	7,779
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	65,583	74,564
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	72,423	82,343
TX_CURR_NA	Number of adults and children receiving antiretroviral therapy (ART)	0	0
TX_CURR_NA	Age/Sex: <1 Male	0	0
TX_CURR_NA	Age/Sex: 1-4 Male	0	0
TX_CURR_NA	Age/Sex: 5-14 Male	0	0
TX_CURR_NA	Age/Sex: 15+ Male	0	0
TX_CURR_NA	Age/Sex: <1 Female	0	0
TX_CURR_NA	Age/Sex: 1-4 Female	0	0
TX_CURR_NA	Age/Sex: 5-14 Female	0	0
TX_CURR_NA	Age/Sex: 15+ Female	0	0
TX_CURR_NA	Sum of Age/Sex disaggregates	0	0
TX_CURR_NA	Aggregated Age/Sex: <1 Male	0	0
TX_CURR_NA	Aggregated Age/Sex: <1 Female	0	0
TX_CURR_NA	Aggregated Age/Sex: <15 Male	0	0
TX_CURR_NA	Aggregated Age/Sex: 15+ Male	0	0
TX_CURR_NA	Aggregated Age/Sex: <15 Female	0	0
TX_CURR_NA	Aggregated Age/Sex: 15+ Female	0	0
TX_CURR_NA	Sum of Aggregated Age/Sex <15	0	0
TX_CURR_NA	Sum of Aggregated Age/Sex 15+	0	0
TX_CURR_NA	Sum of Aggregated Age/Sex disaggregations	0	0
TX_CURR_NGI	Number of adults and children receiving antiretroviral therapy (ART)	72,423	82,343
TX_CURR_NGI	Age/Sex: <1 Male	912	1,037
TX_CURR_NGI	Age/Sex: 1-4 Male	912	1,037
TX_CURR_NGI	Age/Sex: 5-14 Male	912	1,037
TX_CURR_NGI	Age/Sex: 15+ Male	23,113	26,217
TX_CURR_NGI	Age/Sex: <1 Female	1,368	1,556



TX_CURR_NGI	Age/Sex: 1-4 Female	1,368	1,556
TX_CURR_NGI	Age/Sex: 5-14 Female	1,368	1,556
TX_CURR_NGI	Age/Sex: 15+ Female	42,470	48,347
TX_CURR_NGI	Sum of Age/Sex disaggregates	72,423	82,343
TX_CURR_NGI	Aggregated Age/Sex: <1 Male	912	1,037
TX_CURR_NGI	Aggregated Age/Sex: <1 Female	1,368	1,556
TX_CURR_NGI	Aggregated Age/Sex: <15 Male	2,736	3,111
TX_CURR_NGI	Aggregated Age/Sex: 15+ Male	23,113	26,217
TX_CURR_NGI	Aggregated Age/Sex: <15 Female	4,104	4,668
TX_CURR_NGI	Aggregated Age/Sex: 15+ Female	42,470	48,347
TX_CURR_NGI	Sum of Aggregated Age/Sex disaggregates	72,423	82,343
TX_CURR_NGI	Sum of Aggregated Age/Sex <15	6,840	7,779
TX_CURR_NGI	Sum of Aggregated Age/Sex 15+	65,583	74,564
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	0	0
TX_CURR_TA	Age/Sex: <1 Male	0	0
TX_CURR_TA	Age/Sex: 1-4 Male	0	0
TX_CURR_TA	Age/Sex: 5-14 Male	0	0
TX_CURR_TA	Age/Sex: 15+ Male	0	0
TX_CURR_TA	Age/Sex: <1 Female	0	0
TX_CURR_TA	Age/Sex: 1-4 Female	0	0
TX_CURR_TA	Age/Sex: 5-14 Female	0	0
TX_CURR_TA	Age/Sex: 15+ Female	0	0
TX_CURR_TA	Sum of Age/Sex disaggregations	0	0
TX_CURR_TA	Aggregated Age/Sex: <1 Male	0	0
TX_CURR_TA	Aggregated Age/Sex: <1 Female	0	0
TX_CURR_TA	Aggregated Age/Sex: <15 Male	0	0
TX_CURR_TA	Aggregated Age/Sex: 15+ Male	0	0
TX_CURR_TA	Aggregated Age/Sex: <15 Female	0	0
TX_CURR_TA	Aggregated Age/Sex: 15+ Female	0	0
TX_CURR_TA	Sum of Aggregated Age/Sex <15	0	0
TX_CURR_TA	Sum of Aggregated Age/Sex 15+	0	0



TX_CURR_TA	Sum of Aggregated Age/Sex disaggregates	0	0
TX_DIST	Number of Districts with documented routine supportive supervision visits to 75% of HIV care and treatment sites supported by the District	39	39
TX_DIST	Total number of PEPFAR supported District Health Offices	39	39
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	14,546	14,546
TX_NEW_DSD	By Age/Sex: <1 Male	220	260
TX_NEW_DSD	By Age/Sex: 1-4 Male	171	239
TX_NEW_DSD	By Age/Sex: 5-9 Male	171	239
TX_NEW_DSD	By Age/Sex: 10-14 Male	171	239
TX_NEW_DSD	By Age/Sex: 15-19 Male	445	420
TX_NEW_DSD	By Age/Sex: 20-24 Male	1,780	1,678
TX_NEW_DSD	By Age/Sex: 25-49 Male	1,780	1,678
TX_NEW_DSD	By Age/Sex: 50+ Male	445	420
TX_NEW_DSD	By Age/Sex: <1 Female	329	374
TX_NEW_DSD	By Age/Sex: 1-4 Female	256	363
TX_NEW_DSD	By Age/Sex: 5-9 Female	256	363
TX_NEW_DSD	By Age/Sex: 10-14 Female	246	363
TX_NEW_DSD	By Age/Sex: 15-19 Female	827	791
TX_NEW_DSD	By Age/Sex: 20-24 Female	3,311	3,164
TX_NEW_DSD	By Age/Sex: 25-49 Female	3,311	3,164
TX_NEW_DSD	By Age/Sex: 50+ Female	827	791
TX_NEW_DSD	Sum of Age/Sex disaggregates	14,546	14,546
TX_NEW_DSD	Aggregated Grouping by Age: <1 Male	220	260
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	733	977
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	4,450	4,196
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <1 Female	329	374
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	1,087	1,463
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+	8,276	7,910



	Female		
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	14,546	14,546
TX_NEW_DSD	Pregnancy status	0	0
TX_NEW_DSD	Breastfeeding status	0	0
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	13,091	13,091
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	14,546	14,546
TX_RET_DSD	Age: 0-4 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	655	655
TX_RET_DSD	Age: 5-14 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	655	655
TX_RET_DSD	Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	11,782	11,782
TX_RET_DSD	Age: 0-4 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	728	728
TX_RET_DSD	Age: 5-14 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	728	728
TX_RET_DSD	Age: 15+ (Denominator: Total number of adults and children who initiated ART in the	13,091	13,091



	12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)		
TX_RET_DSD	Aggregated Age: <15 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,310	1,310
TX_RET_DSD	Aggregated Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	11,782	11,782
TX_RET_DSD	Aggregated Age: <15 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,456	1,456
TX_RET_DSD	Aggregated Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	13,091	13,091
TX_RET_DSD	Pregnancy and breastfeeding status (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,178	1,178
TX_RET_DSD	Pregnancy and breastfeeding status (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,309	1,309
TX_SITE	Number of PEPFAR-supported ART sites with a retention rate of 75% or greater for patients 12 months after ART initiation	288	308



TX_SITE	Total number of PEPFAR-supported ART sites	384	410
TX_SITE	By support type: Direct Service Delivery (DSD): Number of PEPFAR-supported ART sites with a retention rate of 75% or greater for patients 12 months after ART initiation	288	308
TX_SITE	By support type: Technical Assistance (TA-only): Number of PEPFAR-supported ART sites with a retention rate of 75% or greater for patients 12 months after ART initiation	0	0
TX_SITE	Sum of Numerator Site Support Type disaggregates	288	308
TX_SITE	By support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported ART sites	288	308
TX_SITE	By support type: Technical Assistance (TA-only): Total number of PEPFAR-supported ART sites	288	308
TX_SITE	Sum of Denominator Site Support Type disaggregates	576	616
LAB_ACC_DSD	Number of PEPFAR-supported testing facilities (laboratories) that are recognized by national, regional, or international standards for accreditation or have achieved a minimal acceptable level towards attainment of such accreditation	6	10
LAB_ACC_DSD	By site support type: Direct Service Delivery (DSD)	3	5
LAB_ACC_DSD	By site support type: Technical Assistance-only (TA)	3	5
LAB_ACC_DSD	Sum of Support Type disaggregates	6	10
LAB_CAP_DSD	Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests	40	48



LAB_CAP_DSD	By clinical laboratories	15	17
LAB_CAP_DSD	By Point-of-care testing sites	5	7
LAB_CAP_DSD	By site support type: Direct Service Delivery (DSD)	20	24
LAB_CAP_DSD	By site support type: Technical Assistance-only (TA)	20	24
LAB_CAP_DSD	Sum of Site Support Type disaggregates	40	48
LAB_PT_DSD	Percentage of laboratories and POC testing sites that perform HIV diagnostic testing that participate and successfully pass in an analyte-specific proficiency testing (PT) program	0	0
LAB_PT_DSD	HIV serologic/diagnostic testing: Number of laboratories that perform this testing	0	0
LAB_PT_DSD	HIV serologic/diagnostic testing: Number of laboratories that participate in this PT program	0	0
LAB_PT_DSD	HIV serologic/diagnostic testing: Number of laboratories that achieve acceptable successful passing criteria in this PT program	0	0
LAB_PT_DSD	CD4: Number of laboratories that perform this testing	0	0
LAB_PT_DSD	CD4: Number of laboratories that participate in this PT program	0	0
LAB_PT_DSD	CD4: Number of laboratories that achieve acceptable successful passing criteria in this PT program	0	0
LAB_PT_DSD	Early infant diagnostics: Number of laboratories that perform this testing	0	0
LAB_PT_DSD	Early infant diagnostics: Number of laboratories that participate in this PT program	0	0
LAB_PT_DSD	Early infant diagnostics: Number of laboratories that achieve acceptable successful passing criteria in this PT program	0	0
LAB_PT_DSD	HIV viral load: Number of laboratories that	0	0



	perform this testing		
LAB_PT_DSD	HIV viral load: Number of laboratories that participate in this PT program	0	0
LAB_PT_DSD	HIV viral load: Number of laboratories that achieve acceptable successful passing criteria in this PT program	0	0
LAB_PT_DSD	TB diagnostics (AFB microscopy, Xpert MTB/RIF, Culture/DST): Number of laboratories that perform this testing	0	0
LAB_PT_DSD	TB diagnostics (AFB microscopy, Xpert MTB/RIF, Culture/DST): Number of laboratories that participate in this PT program	0	0
LAB_PT_DSD	TB diagnostics (AFB microscopy, Xpert MTB/RIF, Culture/DST): Number of laboratories that achieve acceptable successful passing criteria in this PT program	0	0
HRH_PRE	Number of new HCW who graduated from a pre-service training institution or program as a result of PEPFAR-supported strengthening efforts, within the reporting period, by select cadre	0	0
HRH_PRE	By Graduates: Doctors	0	0
HRH_PRE	By Graduates: Nurses	0	0
HRH_PRE	By Graduates: Midwives	0	0
HRH_PRE	By Graduates: Social service workers	0	0
HRH_PRE	By Graduates: Laboratory professionals	0	0
HRH_PRE	By Graduates: Other	0	0
HRH_PRE	Sum of Graduates disaggregated	0	0
HRH_PRE	By new graduates who are licensed and registered: Doctors	0	0
HRH_PRE	By new graduates who are licensed and registered: Nurses	0	0
HRH_PRE	By new graduates who are licensed and registered: Midwives	0	0



HRH_PRE	By new graduates who are licensed and registered: Social service workers	0	0
HRH_PRE	By new graduates who are licensed and registered: Laboratorians	0	0
HRH_PRE	By new graduates who are licensed and registered: Other (where applicable)	0	0
SC_TRAIN	Number of individuals who received competency-based, certificate or higher-level training to conduct or support supply chain, inventory management, supportive supervision or distribution activities	0	0
SC_TRAIN	Number of individuals who conduct or support supply chain, inventory management, supportive supervision or distribution activities	0	0
SC_TRAIN	By: Individuals trained in a nationally- or internationally-recognized pre-service training program	0	0
SC_TRAIN	By: Individuals who passed a competency-based training to conduct supply chain activities	0	0
SC_TRAIN	By: Individuals who passed a competency-based training to perform inventory management	0	0
SC_TRAIN	By: Individuals who passed a competency-based training to develop distribution plans	0	0
SC_TRAIN	By: Individuals who passed a competency-based training to perform supportive supervision	0	0
SC_TRAIN	By: Individuals who passed a competency-based training to perform quantification	0	0
FPINT_SITE_DSD	Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning	0	0



	services		
FPINT_SITE_DSD	Total number of PEPFAR-supported HIV service delivery points: PMTCT, Care and Treatment	0	0
FPINT_SITE_DSD	By site support type: Direct Service Delivery (DSD): Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	0	0
FPINT_SITE_DSD	By site support type: Technical Assistance-only (TA): Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	0	0
FPINT_SITE_DSD	Sum of Numerator Site Support Type disaggregates	0	0
FPINT_SITE_DSD	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported HIV service delivery points	0	0
FPINT_SITE_DSD	By site support type: Technical Assistance-only (TA): Total number of PEPFAR-supported HIV service delivery points	0	0
FPINT_SITE_DSD	Sum of Denominator Site Support Type disaggregates	0	0
FPINT_SITE_DSD	Service delivery type: Community	0	0
FPINT_SITE_DSD	Service delivery type: Clinical	0	0
FPINT_SITE_DSD	Sum of Service Delivery Type disaggregates	0	0
QI_SITE	Number of PEPFAR-supported clinical service sites with a quality improvement activity completed that addresses clinical HIV programs and has documented process results in the last 6 months	300	339
QI_SITE	Total number of PEPFAR-supported sites for any HIV clinical service including HIV Care,	599	678



	HIV Treatment, TB care, PMTCT, VMMC, and HTC		
QI_SITE	By site support type: Direct Service Delivery (DSD): Number of PEPFAR-supported clinical service sites with a quality improvement activity completed that addresses clinical HIV programs and has documented results in the last 6 months	300	339
QI_SITE	By site support type: Technical Assistance-only (TA): Number of PEPFAR-supported clinical service sites with a quality improvement activity completed that addresses clinical HIV programs and has documented results in the last 6 months	0	0
QI_SITE	Sum of Numerator Site Support Type disaggregates	300	339
QI_SITE	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported sites for any HIV clinical service including HIV Care, HIV Treatment, TB care, PMTCT, VMMC, HTC	300	339
QI_SITE	By site support type: Technical Assistance-only (TA): Total number of PEPFAR-supported sites for any HIV clinical service including HIV Care, HIV Treatment, TB care, PMTCT, VMMC, and HTC	300	339
QI_SITE	Sum of Denominator Site Support Type disaggregates	600	678
SC_STOCK	Number of stock status observations for one or more tracer commodities that are between the designed minimum and maximum quantities/months of stock from storage sites within at a given level (Central, Regional, etc.) of the system.	0	0
SC_STOCK	Total number of stock status observations for	0	0



	one or more tracer commodities from storage sites within at a given level (Central, Regional, etc.) of the system		
SC_STOCK	System Level: Central Medical Stores	0	0
SC_STOCK	System Level: Regional Medical Stores	0	0
SC_STOCK	System Level: District	0	0
SC_STOCK	System Level: Health facility	0	0
SC_STOCK	Commodity: Condoms	0	0
SC_STOCK	Commodity: ARV drugs	0	0
SC_STOCK	Commodity: Rapid test kits	0	0
SC_STOCK	Commodity: OI drugs	0	0
SC_STOCK	Commodity: Other	0	0
SI_HIS	Full national facility list coordinated with PEPFAR	1	1
SI_ME	Existence of a national HIV/AIDS M&E system based on the UNAIDS 12 components model	1	1
TB_SCREEN_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period	79,367	79,367
TB_SCREEN_DSD	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	99,208	109,130
TB_SCREEN_DSD	Age: <1	400	400
TB_SCREEN_DSD	Age: 1-4	1,000	1,000
TB_SCREEN_DSD	Age: 5-9	1,200	1,200
TB_SCREEN_DSD	Age: 10-14	2,000	2,000
TB_SCREEN_DSD	Age: 15-19	7,200	7,200
TB_SCREEN_DSD	Age: 20-24	31,467	31,467
TB_SCREEN_DSD	Age: 25-49	31,500	31,500
TB_SCREEN_DSD	Age: 50+	4,600	4,600
TB_SCREEN_DSD	Sum of Age disaggregates	11,800	11,800



TB_SCREEN_DSD	Aggregated Age - USE WITH HQ PERMISSION ONLY: <15	4,600	4,600
TB_SCREEN_DSD	Aggregated Age - USE WITH HQ PERMISSION ONLY: 15+	74,767	74,767
TB_SCREEN_DSD	Sum of Aggregated Age disaggregates	79,367	79,367
TB_SCREEN_DSD	Sex: Male	31,747	31,747
TB_SCREEN_DSD	Sex: Female	47,620	47,620
TB_SCREEN_DSD	Sum of Sex disaggregates	79,367	79,367

Implementing Mechanism Details

Mechanism ID: 13550	Mechanism Name: Implementation and Expansion of Blood Safety Activities in Kenya
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: National Blood Transfusion Service, Kenya	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: No	
G2G: No	Managing Agency:

Total All Funding Sources: 1,500,000	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 0	
FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount
GHP-State	1,500,000

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

Human Resources for Health	900,000
----------------------------	---------



Key Issues

Malaria (PMI)

Safe Motherhood

Budget Code Information

Mechanism ID:	13550		
Mechanism Name:	Implementation and Expansion of Blood Safety Activities in Kenya		
Prime Partner Name:	National Blood Transfusion Service, Kenya		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HMBL	1,500,000	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2014	2015	Planning Budget Targets
SITE_SUPP	Number of unique sites supported by PEPFAR	340	0	Redacted
SITE_SUPP	By program area/support type: Lab Direct Service Delivery (DSD)	340	0	Redacted
BS_COLL	Number of whole blood collections each year by the NBTS network	200,000	0	Redacted
BS_COLL	By: Number of whole blood donations screened for HIV in an NBTS network laboratory	200,000	0	Redacted
BS_COLL	By: Number of whole blood donations screened for HIV in an NBTS network laboratory that are identified as reactive for HIV	2,000	0	Redacted



Implementing Mechanism Details

Mechanism ID: 13548	Mechanism Name: Health Commodities & Services Management Project
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Management Sciences for Health	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: No	
G2G: No	Managing Agency:

Total All Funding Sources: 1,124,818	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 0	
FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount
GHP-State	1,124,818

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

Human Resources for Health	200,000
Condom procurement	10,000

Key Issues

Malaria (PMI)
 Child Survival Activities
 Safe Motherhood
 TB
 Workplace Programs
 Family Planning



Budget Code Information

Mechanism ID: 13548			
Mechanism Name: Health Commodities & Services Management Project			
Prime Partner Name: Management Sciences for Health			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	123,825	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	650,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	60,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	290,993	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2014	2015
SITE_SUPP	By program area/support type: HTC Direct Service Delivery (DSD)	0	0
SITE_SUPP	By program area/support type: HTC Technical Assistance-only (TA)	486	486
SITE_SUPP	By program area/support type: Treatment Direct Service Delivery (DSD)	0	0
SITE_SUPP	By program area/support type: Treatment Technical Assistance-only (TA)	76	76
SITE_SUPP	By program area/support type: Care and Support Direct Service Delivery (DSD)	0	0



SITE_SUPP	By program area/support type: Care and Support Technical Assistance-only (TA)	486	486
SITE_SUPP	By program area/support type: Food and Nutrition Direct Service Delivery (DSD)	0	0
SITE_SUPP	By program area/support type: Food and Nutrition Technical Assistance-only (TA)	0	0
SITE_SUPP	By program area/support type: PMTCT Direct Service Delivery (DSD)	0	0
SITE_SUPP	By program area/support type: PMTCT Technical Assistance-only (TA)	91	91
SITE_SUPP	By program area/support type: TB/HIV Direct Service Delivery (DSD)	0	0
SITE_SUPP	By program area/support type: TB/HIV Technical Assistance-only (TA)	0	0
SITE_SUPP	By program area/support type: VMMC Direct Service Delivery (DSD)	0	0
SITE_SUPP	By program area/support type: VMMC Technical Assistance-only (TA)	10	10
SITE_SUPP	By program area/support type: General Population Prevention Direct Service Delivery (DSD)	0	0
SITE_SUPP	By program area/support type: General Population Prevention Technical Assistance-only (TA)	0	0
SITE_SUPP	By program area/support type: Key Populations Prevention Direct Service Delivery (DSD)	0	0
SITE_SUPP	By program area/support type: Key Populations Prevention Technical Assistance-only (TA)	0	0
SITE_SUPP	By program area/support type: OVC Direct Service Delivery (DSD)	0	0
SITE_SUPP	By program area/support type: OVC Technical Assistance-only (TA)	0	0



SITE_SUPP	By program area/support type: PHDP/Family Planning & Integration Direct Service Delivery (DSD)	0	0
SITE_SUPP	By program area/support type: PHDP/Family Planning & Integration Technical Assistance-only (TA)	0	0
SITE_SUPP	By program area/support type: Lab Direct Service Delivery (DSD)	0	0
SITE_SUPP	By program area/support type: Lab Technical Assistance-only (TA)	0	0
PMTCT_ARV_DSD	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	0	0
PMTCT_ARV_DSD	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	0	0
PMTCT_ARV_NA	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	0	0
PMTCT_ARV_NA	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	0	0
PMTCT_ARV_NGI	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	0	0
PMTCT_ARV_NGI	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	0	0
PMTCT_ARV_NGI	Life-long ART (including Option B+)	0	0
PMTCT_ARV_NGI	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	0	0
PMTCT_ARV_NGI	Sub-Disag of Life-long ART: Already on	0	0



	treatment at the beginning of the current pregnancy		
PMTCT_ARV_NGI	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)	0	0
PMTCT_ARV_NGI	Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)	0	0
PMTCT_ARV_NGI	Single-dose nevirapine (with or without tail)	0	0
PMTCT_ARV_NGI	Sum of Regimen disaggregates	0	0
PMTCT_ARV_NGI	Sum of New and Current disaggregates	0	0
PMTCT_ARV_TA	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	0	0
PMTCT_ARV_TA	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	0	0
PMTCT_ARV_TA	Life-long ART (including Option B+)	0	0
PMTCT_ARV_TA	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	0	0
PMTCT_ARV_TA	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	0	0
PMTCT_ARV_TA	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)	0	0
PMTCT_ARV_TA	Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)	0	0
PMTCT_ARV_TA	Single-dose nevirapine (with or without tail)	0	0
PMTCT_ARV_TA	Sum of Regimen Type disaggregates	0	0
PMTCT_ARV_TA	Sum of New and Current disaggregates	0	0
PMTCT_SITE	Number of PEPFAR-supported sites achieving	0	0



	90% ARV or ART coverage for HIV+ pregnant women		
PMTCT_SITE	Total number of PEPFAR supported sites providing PMTCT services (HTC and ARV or ART services)	0	0
PMTCT_SITE	By site support type: Direct Service Delivery (DSD): Number of PEPFAR-supported sites achieving 90% ARV or ART coverage for HIV+ pregnant women	0	0
PMTCT_SITE	By site support type: Technical Assistance-only (TA): Number of PEPFAR-supported sites achieving 90% ARV or ART coverage for HIV+ pregnant women	0	0
PMTCT_SITE	Sum of Numerator Support Type disaggregates	0	0
PMTCT_SITE	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR supported sites providing PMTCT services (HTC and ARV or ART services)	0	0
PMTCT_SITE	By site support type: Technical Assistance-only (TA): Total number of PEPFAR supported sites providing PMTCT services (HTC and ARV or ART services)	0	0
PMTCT_SITE	Sum of Denominator Support Type disaggregates	0	0
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	0	0
PMTCT_STAT_DSD	Number of new ANC and L&D clients	0	0
PMTCT_STAT_NA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	0	0
PMTCT_STAT_NA	Number of new ANC and L&D clients	0	0
PMTCT_STAT_NGI	Number of pregnant women with known HIV status (includes women who were tested for	0	0



	HIV and received their results)		
PMTCT_STAT_NGI	Number of new ANC and L&D clients	0	0
PMTCT_STAT_NGI	By: Known positives at entry	0	0
PMTCT_STAT_NGI	By: Number of new positives identified	0	0
PMTCT_STAT_NGI	Sum of Positives Status disaggregates	0	0
BS_COLL	Number of whole blood collections each year by the NBTS network	0	0
KP_MAT_DSD	Number of people who inject drugs (PWID) on medication assisted therapy (MAT) for at least 6 months	0	0
VMMC_AE_DSD	Number of males circumcised surgically or by medical device that experienced at least one moderate or severe adverse event(s) (AEs)	0	0
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	0	0
VMMC_CIRC_NA	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	0	0
VMMC_CIRC_NGI	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	0	0
VMMC_CIRC_NGI	By Age: <1	0	0
VMMC_CIRC_NGI	By Age: 1-9	0	0
VMMC_CIRC_NGI	By Age: 10-14	0	0
VMMC_CIRC_NGI	By Age: 15-19	0	0
VMMC_CIRC_NGI	By Age: 20-24	0	0
VMMC_CIRC_NGI	By Age: 25-49	0	0
VMMC_CIRC_NGI	By Age: 50+	0	0
VMMC_CIRC_NGI	Sum of Age disaggregates	0	0
VMMC_CIRC_NGI	By HIV status: Number of HIV-positive clients	0	0



	(tested HIV positive at VMMC site)		
VMMC_CIRC_NGI	By HIV status: Number of HIV-negative clients (tested HIV negative at VMMC program)	0	0
VMMC_CIRC_NGI	By HIV status: Number of clients with undocumented/indeterminate HIV status or not tested for HIV at site	0	0
VMMC_CIRC_NGI	By circumcision technique: Surgical VMMC	0	0
VMMC_CIRC_NGI	By circumcision technique: Device-based VMMC	0	0
VMMC_CIRC_NGI	By follow-up status: Number of surgically circumcised clients who returned at least once for follow-up care within 14 days of circumcision surgery	0	0
VMMC_CIRC_NGI	By follow-up status: Number of surgically circumcised clients who did NOT return for follow-up care within 14 days of circumcision surgery	0	0
VMMC_CIRC_TA	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	0	0
VMMC_CIRC_TA	By Age: <1	0	0
VMMC_CIRC_TA	By Age: 1-9	0	0
VMMC_CIRC_TA	By Age: 10-14	0	0
VMMC_CIRC_TA	By Age: 15-19	0	0
VMMC_CIRC_TA	By Age: 20-24	0	0
VMMC_CIRC_TA	By Age: 25-49	0	0
VMMC_CIRC_TA	By Age: 50+	0	0
VMMC_CIRC_TA	Sum of Age disaggregations	0	0
VMMC_CIRC_TA	By HIV status: Number of HIV-positive clients (tested HIV positive at VMMC site)	0	0
VMMC_CIRC_TA	By HIV status: Number of HIV-negative clients (tested HIV negative at VMMC program)	0	0
VMMC_CIRC_TA	By HIV status: Number of clients with	0	0



	undocumented/indeterminate HIV status or not tested for HIV at site		
VMMC_CIRC_TA	By circumcision technique: Surgical VMMC	0	0
VMMC_CIRC_TA	By circumcision technique: Device-based VMMC	0	0
VMMC_CIRC_TA	By follow-up status: Number of surgically circumcised clients who returned at least once for follow-up care within 14 days of circumcision surgery	0	0
VMMC_CIRC_TA	By follow-up status: Number of surgically circumcised clients who did NOT return for follow-up care within 14 days of circumcision surgery	0	0
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	0	0
PP_PREV_DSD	Total number of people in the target population	0	0
PP_PREV_TA	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	0	0
PP_PREV_TA	Total number of people in the target population	0	0
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	0	0
KP_PREV_TA	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	0	0



HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	0	0
HTC_TST_NA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	0	0
HTC_TST_NGI	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	0	0
HTC_TST_NGI	By Test Result: Negative	0	0
HTC_TST_NGI	By Test Result: Positive	0	0
HTC_TST_NGI	Sum of Test Result disaggregates	0	0
HTC_TST_NGI	Age/sex: <1 Male	0	0
HTC_TST_NGI	Age/sex: 1-4 Male	0	0
HTC_TST_NGI	Age/sex: 5-9 Male	0	0
HTC_TST_NGI	Age/sex: 10-14 Male	0	0
HTC_TST_NGI	Age/sex: 15-19 Male	0	0
HTC_TST_NGI	Age/sex: 20-24 Male	0	0
HTC_TST_NGI	Age/sex: 25-49 Male	0	0
HTC_TST_NGI	Age/sex: 50+ Male	0	0
HTC_TST_NGI	Age/sex: <1 Female	0	0
HTC_TST_NGI	Age/sex: 1-4 Female	0	0
HTC_TST_NGI	Age/sex: 5-9 Female	0	0
HTC_TST_NGI	Age/sex: 10-14 Female	0	0
HTC_TST_NGI	Age/sex: 15-19 Female	0	0
HTC_TST_NGI	Age/sex: 20-24 Female	0	0
HTC_TST_NGI	Age/sex: 25-49 Female	0	0
HTC_TST_NGI	Age/sex: 50+ Female	0	0
HTC_TST_NGI	Sum of Age/Sex disaggregates	0	0
HTC_TST_NGI	Aggregated Age/sex: <15 Male	0	0
HTC_TST_NGI	Aggregated Age/sex: 15+ Male	0	0
HTC_TST_NGI	Aggregated Age/sex: <15 Female	0	0
HTC_TST_NGI	Aggregated Age/sex: 15+ Female	0	0



HTC_TST_NGI	Sum of Aggregated Age/Sex <15	0	0
HTC_TST_NGI	Sum of Aggregated Age/Sex 15+	0	0
HTC_TST_NGI	Sum of Aggregated Age/Sex disaggregates	0	0
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	0	0
HTC_TST_TA	By Test Result: Negative	0	0
HTC_TST_TA	By Test Result: Positive	0	0
HTC_TST_TA	Sum of Test Result disaggregates	0	0
HTC_TST_TA	Age/sex: <1 Male	0	0
HTC_TST_TA	Age/sex: 1-4 Male	0	0
HTC_TST_TA	Age/sex: 5-9 Male	0	0
HTC_TST_TA	Age/sex: 10-14 Male	0	0
HTC_TST_TA	Age/sex: 15-19 Male	0	0
HTC_TST_TA	Age/sex: 20-24 Male	0	0
HTC_TST_TA	Age/sex: 25-49 Male	0	0
HTC_TST_TA	Age/sex: 50+ Male	0	0
HTC_TST_TA	Age/sex: <1 Female	0	0
HTC_TST_TA	Age/sex: 1-4 Female	0	0
HTC_TST_TA	Age/sex: 5-9 Female	0	0
HTC_TST_TA	Age/sex: 10-14 Female	0	0
HTC_TST_TA	Age/sex: 15-19 Female	0	0
HTC_TST_TA	Age/sex: 20-24 Female	0	0
HTC_TST_TA	Age/sex: 25-49 Female	0	0
HTC_TST_TA	Age/sex: 50+ Female	0	0
HTC_TST_TA	Sum of Age/Sex disaggregates	0	0
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	0	0
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	0	0
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	0	0



HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	0	0
HTC_TST_TA	Sum of Aggregated Age/Sex <15	0	0
HTC_TST_TA	Sum of Aggregated Age/Sex 15+	0	0
HTC_TST_TA	Sum of Aggregated Age/Sex disaggregates	0	0
GEND_GBV_DSD	Number of people receiving post-GBV care	0	0
GEND_NORM_DSD	Number of people completing an intervention pertaining to gender norms, that meets minimum criteria	0	0
OVC_ACC_DSD	Number of active beneficiaries receiving support from PEPFAR OVC programs to access HIV services	0	0
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	0	0
OVC_SERV_TA	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	0	0
C2.1.D_DSD	Number of HIV-positive individuals receiving a minimum of one clinical service	0	0
C2.1.D_NA	Number of HIV-positive individuals receiving a minimum of one clinical service	0	0
C2.1.D_NGI	Number of HIV-positive individuals receiving a minimum of one clinical service	0	0
C2.1.D_NGI	By Age/Sex: <15 Female	0	0
C2.1.D_NGI	By Age/Sex: <15 Male	0	0
C2.1.D_NGI	By Age/Sex: 15+ Female	0	0
C2.1.D_NGI	By Age/Sex: 15+ Male	0	0
C2.1.D_NGI	Sum of Age/Sex disaggregates	0	0
C2.1.D_NGI	By Age: <15	0	0
C2.1.D_NGI	By Age: 15+	0	0
C2.1.D_NGI	Sum of Age disaggregates	0	0
C2.1.D_NGI	By Sex: Female	0	0



C2.1.D_NGI	By Sex: Male	0	0
C2.1.D_NGI	Sum of Sex disaggregates	0	0
C2.1.D_TA	Number of HIV-positive individuals receiving a minimum of one clinical service	0	0
C2.1.D_TA	By Age/Sex: <15 Female	0	0
C2.1.D_TA	By Age/Sex: <15 Male	0	0
C2.1.D_TA	By Age/Sex: 15+ Female	0	0
C2.1.D_TA	By Age/Sex: 15+ Male	0	0
C2.1.D_TA	Sum of Age/Sex disaggregates	0	0
C2.1.D_TA	By Age: <15	0	0
C2.1.D_TA	By Age: 15+	0	0
C2.1.D_TA	Sum of Age disaggregates	0	0
C2.1.D_TA	By Sex: Female	0	0
C2.1.D_TA	By Sex: Male	0	0
C2.1.D_TA	Sum of Sex disaggregates	0	0
C2.4.D_DSD	Number of HIV-positive patients who were screened for TB in HIV care or treatment setting	0	0
C2.4.D_DSD	Number of HIV-positive individuals receiving a minimum of one clinical service	0	0
C2.5.D_DSD	Number of HIV-positive patients in HIV care who started TB treatment	0	0
C2.5.D_DSD	Number of HIV-positive individuals receiving a minimum of one clinical service	0	0
CARE_CURR_DSD	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	0	0
CARE_CURR_TA	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	0	0



CARE_CURR_TA	Age/sex: <1 Male	0	0
CARE_CURR_TA	Age/sex: 1-4 Male	0	0
CARE_CURR_TA	Age/sex: 5-9 Male	0	0
CARE_CURR_TA	Age/sex: 10-14 Male	0	0
CARE_CURR_TA	Age/sex: 15-19 Male	0	0
CARE_CURR_TA	Age/sex: 20-24 Male	0	0
CARE_CURR_TA	Age/sex: 25-49 Male	0	0
CARE_CURR_TA	Age/sex: 50+ Male	0	0
CARE_CURR_TA	Age/sex: <1 Female	0	0
CARE_CURR_TA	Age/sex: 1-4 Female	0	0
CARE_CURR_TA	Age/sex: 5-9 Female	0	0
CARE_CURR_TA	Age/sex: 10-14 Female	0	0
CARE_CURR_TA	Age/sex: 15-19 Female	0	0
CARE_CURR_TA	Age/sex: 20-24 Female	0	0
CARE_CURR_TA	Age/sex: 25-49 Female	0	0
CARE_CURR_TA	Age/sex: 50+ Female	0	0
CARE_CURR_TA	Sum of Age/Sex disaggregates	0	0
CARE_CURR_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	0	0
CARE_CURR_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	0	0
CARE_CURR_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	0	0
CARE_CURR_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	0	0
CARE_CURR_TA	Sum of Aggregated Age/Sex disaggregates	0	0
CARE_NEW_DSD	Number of HIV-infected adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load	0	0
CARE_NEW_DSD	Age/sex: <1 Male	0	0



CARE_NEW_DSD	Age/sex: 1-4 Male	0	0
CARE_NEW_DSD	Age/sex: 5-9 Male	0	0
CARE_NEW_DSD	Age/sex: 10-14 Male	0	0
CARE_NEW_DSD	Age/sex: 15-19 Male	0	0
CARE_NEW_DSD	Age/sex: 20-24 Male	0	0
CARE_NEW_DSD	Age/sex: 25-49 Male	0	0
CARE_NEW_DSD	Age/sex: 50+ Male	0	0
CARE_NEW_DSD	Age/sex: <1 Female	0	0
CARE_NEW_DSD	Age/sex: 1-4 Female	0	0
CARE_NEW_DSD	Age/sex: 5-9 Female	0	0
CARE_NEW_DSD	Age/sex: 10-14 Female	0	0
CARE_NEW_DSD	Age/sex: 15-19 Female	0	0
CARE_NEW_DSD	Age/sex: 20-24 Female	0	0
CARE_NEW_DSD	Age/sex: 25-49 Female	0	0
CARE_NEW_DSD	Age/sex: 50+ Female	0	0
CARE_NEW_DSD	Sum of Age/sex disaggregates	0	0
CARE_NEW_DSD	Aggregated Age/sex: <15 Male	0	0
CARE_NEW_DSD	Aggregated Age/sex: 15+ Male	0	0
CARE_NEW_DSD	Aggregated Age/sex: <15 Female	0	0
CARE_NEW_DSD	Aggregated Age/sex: 15+ Female	0	0
CARE_NEW_DSD	Sum of Aggregated Age/sex disaggregates	0	0
CARE_SITE	Number of PEPFAR-supported HIV clinical care sites at which at least 80% of PLHIV received all of the following during the reporting period: 1) clinical assessment (WHO staging) OR CD4 count OR viral load, AND 2) TB screening at last visit, AND 3) if eligible, cotrimoxazole	0	0
CARE_SITE	Total number of PEPFAR supported sites providing clinical care services	0	0
CARE_SITE	By site support type: Direct Service Delivery (DSD): Number of PEPFAR-supported HIV clinical care sites at which at least 80% of	0	0



	PLHIV received all of the following during the reporting period: 1) clinical assessment (WHO staging) OR CD4 count OR viral load, AND 2) TB screening at last visit, AND 3) if eligible, cotrimoxazole		
CARE_SITE	By site support type: Technical Assistance-only (TA): Number of PEPFAR-supported HIV clinical care sites at which at least 80% of PLHIV received all of the following during the reporting period: 1) clinical assessment (WHO staging) OR CD4 count OR viral load, AND 2) TB screening at last visit, AND 3) if eligible, cotrimoxazole	0	0
CARE_SITE	Sum of Numerator Site Support Type disaggregates	0	0
CARE_SITE	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR supported sites providing clinical care services	0	0
CARE_SITE	By site support type: Technical Assistance-only (TA): Total number of PEPFAR supported sites providing clinical care services	0	0
CARE_SITE	Sum of Denominator Site Support Type disaggregates	0	0
FN_SITE	Number of PEPFAR-supported sites achieving 90% nutrition assessments that result in accurate categorization of malnutrition	0	0
FN_SITE	Total number of PEPFAR-supported sites providing nutrition assessment, counseling and support (NACS) services	0	0
FN_THER_DSD	Number of clinically malnourished PLHIV who received therapeutic and/or supplementary food during the reporting period.	0	0
FN_THER_DSD	Number of PLHIV who were nutritionally assessed and found to be clinically	0	0



	undernourished.		
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	0	0
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	0	0
TB_ART_DSD	Age: 0-4	0	0
TB_ART_DSD	Age: 5-14	0	0
TB_ART_DSD	Age: 15+	0	0
TB_ART_DSD	Male	1,850	1,850
TB_ART_DSD	Female	2,000	2,000
TB_ART_DSD	Sum of Sex disaggregates	3,850	3,850
TB_ART_DSD	Newly tested	1,221	1,221
TB_ART_DSD	Known HIV-positive	1,831	1,831
TB_ART_DSD	Sum of Test Status disaggregates	3,052	3,052
TB_ART_DSD	Aggregated Age: <15	28	28
TB_ART_DSD	Aggregated Age: 15+	3,024	3,024
TB_ART_DSD	Sum of Aggregated Age disaggregates	3,052	3,052
TB_ARTSITE	The number of PEPFAR-supported TB basic management units at which 80% of registered TB cases who are HIV-positive are on ART, during the reporting period	0	0
TB_ARTSITE	The number of PEPFAR-supported TB basic management units	0	0
TB_ARTSITE	By site support type: Direct Service Delivery (DSD): The number of PEPFAR-supported TB basic management units at which 80% of registered TB cases who are HIV-positive are on ART, during the reporting period	0	0
TB_ARTSITE	By site support type: Technical Assistance-only (TA): The number of	0	0



	PEPFAR-supported TB basic management units at which 80% of registered TB cases who are HIV-positive are on ART, during the reporting period		
TB_ARTSITE	Sum of Numerator Site Support Type disaggregates	0	0
TB_ARTSITE	By site support type: Direct Service Delivery (DSD): The number of PEPFAR-supported TB basic management units	0	0
TB_ARTSITE	By site support type: Technical Assistance-only (TA): The number of PEPFAR-supported TB basic management units	0	0
TB_ARTSITE	Sum of Denominator Site Support Type disaggregates	0	0
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	0	0
PMTCT_EID_DSD	Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT)	0	0
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	0	0
TX_CURR_NA	Number of adults and children receiving antiretroviral therapy (ART)	0	0
TX_CURR_NGI	Number of adults and children receiving antiretroviral therapy (ART)	0	0
TX_CURR_NGI	Age/Sex: <1 Male	0	0
TX_CURR_NGI	Age/Sex: 1-4 Male	0	0
TX_CURR_NGI	Age/Sex: 5-14 Male	0	0
TX_CURR_NGI	Age/Sex: 15+ Male	0	0
TX_CURR_NGI	Age/Sex: <1 Female	0	0
TX_CURR_NGI	Age/Sex: 1-4 Female	0	0



TX_CURR_NGI	Age/Sex: 5-14 Female	0	0
TX_CURR_NGI	Age/Sex: 15+ Female	0	0
TX_CURR_NGI	Sum of Age/Sex disaggregates	0	0
TX_CURR_NGI	Aggregated Age/Sex: <1 Male	0	0
TX_CURR_NGI	Aggregated Age/Sex: <1 Female	0	0
TX_CURR_NGI	Aggregated Age/Sex: <15 Male	0	0
TX_CURR_NGI	Aggregated Age/Sex: 15+ Male	0	0
TX_CURR_NGI	Aggregated Age/Sex: <15 Female	0	0
TX_CURR_NGI	Aggregated Age/Sex: 15+ Female	0	0
TX_CURR_NGI	Sum of Aggregated Age/Sex disaggregates	0	0
TX_CURR_NGI	Sum of Aggregated Age/Sex <15	0	0
TX_CURR_NGI	Sum of Aggregated Age/Sex 15+	0	0
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	0	0
TX_CURR_TA	Age/Sex: <1 Male	0	0
TX_CURR_TA	Age/Sex: 1-4 Male	0	0
TX_CURR_TA	Age/Sex: 5-14 Male	0	0
TX_CURR_TA	Age/Sex: 15+ Male	0	0
TX_CURR_TA	Age/Sex: <1 Female	0	0
TX_CURR_TA	Age/Sex: 1-4 Female	0	0
TX_CURR_TA	Age/Sex: 5-14 Female	0	0
TX_CURR_TA	Age/Sex: 15+ Female	0	0
TX_CURR_TA	Sum of Age/Sex disaggregations	0	0
TX_CURR_TA	Aggregated Age/Sex: <1 Male	0	0
TX_CURR_TA	Aggregated Age/Sex: <1 Female	0	0
TX_CURR_TA	Aggregated Age/Sex: <15 Male	0	0
TX_CURR_TA	Aggregated Age/Sex: 15+ Male	0	0
TX_CURR_TA	Aggregated Age/Sex: <15 Female	0	0
TX_CURR_TA	Aggregated Age/Sex: 15+ Female	0	0
TX_CURR_TA	Sum of Aggregated Age/Sex <15	0	0
TX_CURR_TA	Sum of Aggregated Age/Sex 15+	0	0
TX_CURR_TA	Sum of Aggregated Age/Sex disaggregates	0	0



TX_DIST	Number of Districts with documented routine supportive supervision visits to 75% of HIV care and treatment sites supported by the District	0	0
TX_DIST	Total number of PEPFAR supported District Health Offices	0	0
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	0	0
TX_NEW_DSD	By Age/Sex: <1 Male	0	0
TX_NEW_DSD	By Age/Sex: 1-4 Male	0	0
TX_NEW_DSD	By Age/Sex: 5-9 Male	0	0
TX_NEW_DSD	By Age/Sex: 10-14 Male	0	0
TX_NEW_DSD	By Age/Sex: 15-19 Male	0	0
TX_NEW_DSD	By Age/Sex: 20-24 Male	0	0
TX_NEW_DSD	By Age/Sex: 25-49 Male	0	0
TX_NEW_DSD	By Age/Sex: 50+ Male	0	0
TX_NEW_DSD	By Age/Sex: <1 Female	0	0
TX_NEW_DSD	By Age/Sex: 1-4 Female	0	0
TX_NEW_DSD	By Age/Sex: 5-9 Female	0	0
TX_NEW_DSD	By Age/Sex: 10-14 Female	0	0
TX_NEW_DSD	By Age/Sex: 15-19 Female	0	0
TX_NEW_DSD	By Age/Sex: 20-24 Female	0	0
TX_NEW_DSD	By Age/Sex: 25-49 Female	0	0
TX_NEW_DSD	By Age/Sex: 50+ Female	0	0
TX_NEW_DSD	Sum of Age/Sex disaggregates	0	0
TX_NEW_DSD	Aggregated Grouping by Age: <1 Male	0	0
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	0	0
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	0	0
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <1 Female	0	0
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	0	0
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	0	0



TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	0	0
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	0	0
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	0	0
TX_RET_DSD	Age: 0-4 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	0	0
TX_RET_DSD	Age: 5-14 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	0	0
TX_RET_DSD	Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	0	0
TX_RET_DSD	Age: 0-4 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	0	0
TX_RET_DSD	Age: 5-14 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	0	0
TX_RET_DSD	Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	0	0



	lost to follow-up)		
TX_RET_DSD	Aggregated Age: <15 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	0	0
TX_RET_DSD	Aggregated Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	0	0
TX_RET_DSD	Aggregated Age: <15 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	0	0
TX_RET_DSD	Aggregated Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	0	0
TX_RET_DSD	Pregnancy and breastfeeding status (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	0	0
TX_RET_DSD	Pregnancy and breastfeeding status (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	0	0
TX_SITE	Number of PEPFAR-supported ART sites with a retention rate of 75% or greater for patients 12 months after ART initiation	0	0
TX_SITE	Total number of PEPFAR-supported ART sites	0	0



LAB_ACC_DSD	Number of PEPFAR-supported testing facilities (laboratories) that are recognized by national, regional, or international standards for accreditation or have achieved a minimal acceptable level towards attainment of such accreditation	0	0
LAB_CAP_DSD	Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests	0	0
LAB_PT_DSD	Percentage of laboratories and POC testing sites that perform HIV diagnostic testing that participate and successfully pass in an analyte-specific proficiency testing (PT) program	0	0
HRH_PRE	Number of new HCW who graduated from a pre-service training institution or program as a result of PEPFAR-supported strengthening efforts, within the reporting period, by select cadre	0	0
SC_TRAIN	Number of individuals who received competency-based, certificate or higher-level training to conduct or support supply chain, inventory management, supportive supervision or distribution activities	104	104
SC_TRAIN	Number of individuals who conduct or support supply chain, inventory management, supportive supervision or distribution activities	130	130
FPINT_SITE_DSD	Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	0	0
FPINT_SITE_DSD	Total number of PEPFAR-supported HIV service delivery points: PMTCT, Care and Treatment	0	0
QI_SITE	Number of PEPFAR-supported clinical service	0	0



	sites with a quality improvement activity completed that addresses clinical HIV programs and has documented process results in the last 6 months		
QI_SITE	Total number of PEPFAR-supported sites for any HIV clinical service including HIV Care, HIV Treatment, TB care, PMTCT, VMMC, and HTC	0	0
SC_STOCK	Number of stock status observations for one or more tracer commodities that are between the designed minimum and maximum quantities/months of stock from storage sites within at a given level (Central, Regional, etc.) of the system.	681	908
SC_STOCK	Total number of stock status observations for one or more tracer commodities from storage sites within at a given level (Central, Regional, etc.) of the system	1,135	1,135
SI_HIS	Full national facility list coordinated with PEPFAR	1	1
SI_ME	Existence of a national HIV/AIDS M&E system based on the UNAIDS 12 components model	1	1
TB_SCREEN_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period	0	0
TB_SCREEN_DSD	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	0	0
TB_SCREEN_DSD	Age: <1	0	0
TB_SCREEN_DSD	Age: 1-4	0	0
TB_SCREEN_DSD	Age: 5-9	0	0
TB_SCREEN_DSD	Age: 10-14	0	0
TB_SCREEN_DSD	Age: 15-19	0	0



TB_SCREEN_DSD	Age: 20-24	0	0
TB_SCREEN_DSD	Age: 25-49	0	0
TB_SCREEN_DSD	Age: 50+	0	0
TB_SCREEN_DSD	Sum of Age disaggregates	0	0
TB_SCREEN_DSD	Aggregated Age - USE WITH HQ PERMISSION ONLY: <15	0	0
TB_SCREEN_DSD	Aggregated Age - USE WITH HQ PERMISSION ONLY: 15+	0	0
TB_SCREEN_DSD	Sum of Aggregated Age disaggregates	0	0
TB_SCREEN_DSD	Sex: Male	0	0
TB_SCREEN_DSD	Sex: Female	0	0
TB_SCREEN_DSD	Sum of Sex disaggregates	0	0

Implementing Mechanism Details

Mechanism ID: 13546	Mechanism Name: Kisumu West
Funding Agency: DOD	Procurement Type: Cooperative Agreement
Prime Partner Name: Henry Jackson Foundation	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: TA	
G2G: No	Managing Agency:

Total All Funding Sources: 2,075,264	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 0	
FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount
GHP-State	2,075,264

Sub Partner Name(s)

Kombewa District Hospital	Pamoja Community Based Organization	Participatory Research and Development Program
St. Francis Oriang' Development		



Program		
---------	--	--

Cross-Cutting Budget Attribution(s)

Human Resources for Health	290,000
Food and Nutrition: Policy, Tools, and Service Delivery	75,000
Food and Nutrition: Commodities	50,000
Economic Strengthening	15,000
Key Populations: MSM and TG	850
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Monitoring and evaluation of MSM/TG programs
Key Populations: FSW	1,045
Focus Area:	Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention
Focus Area:	Conducting epidemiologic, social science, and operational research among SWs, their partners, and clients
Focus Area:	Monitoring and evaluation of SW programs
Gender: GBV	15,000
Focus Area:	GBV Prevention
Sub Area:	Implementation
Gender: Gender Equality	35,000
Focus Area:	Changing harmful gender norms and promoting positive gender norms
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Capacity building
Focus Area:	Promoting gender-related policies and laws that increase legal protection
Sub Area:	Collection and Use of Gender-related Strategic Information



Sub Area:	Capacity building
Focus Area:	Increase gender-equitable access to income and productive resources, including education
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Capacity building
Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building

Key Issues

Child Survival Activities
 Safe Motherhood
 TB

Budget Code Information

Mechanism ID: 13546			
Mechanism Name: Kisumu West			
Prime Partner Name: Henry Jackson Foundation			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	110,632	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	240,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Care	HVTB	154,936	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	64,795	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	332,389	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	56,925	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	254,299	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	784,946	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	76,342	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2014	2015
SITE_SUPP	Number of unique sites supported by PEPFAR	19	19
SITE_SUPP	By program area/support type: HTC Direct Service Delivery (DSD)	18	18
SITE_SUPP	By program area/support type: HTC Technical Assistance-only (TA)	0	0
SITE_SUPP	By program area/support type: Treatment Direct Service Delivery (DSD)	10	10
SITE_SUPP	By program area/support type: Treatment	0	0



	Technical Assistance-only (TA)		
SITE_SUPP	By program area/support type: Care and Support Direct Service Delivery (DSD)	10	10
SITE_SUPP	By program area/support type: Care and Support Technical Assistance-only (TA)	0	0
SITE_SUPP	By program area/support type: Food and Nutrition Direct Service Delivery (DSD)	9	9
SITE_SUPP	By program area/support type: Food and Nutrition Technical Assistance-only (TA)	0	0
SITE_SUPP	By program area/support type: PMTCT Direct Service Delivery (DSD)	19	19
SITE_SUPP	By program area/support type: PMTCT Technical Assistance-only (TA)	0	0
SITE_SUPP	By program area/support type: TB/HIV Direct Service Delivery (DSD)	16	16
SITE_SUPP	By program area/support type: OVC Direct Service Delivery (DSD)	3	3
SITE_SUPP	By program area/support type: Lab Direct Service Delivery (DSD)	5	5
SITE_SUPP	By program area/support type: Lab Technical Assistance-only (TA)	2	2
PMTCT_ARV_DSD	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	989	1,199
PMTCT_ARV_DSD	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	989	1,199
PMTCT_ARV_DSD	Life-long ART (including Option B+)	741	899
PMTCT_ARV_DSD	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	410	524
PMTCT_ARV_DSD	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	331	375



PMTCT_ARV_DSD	Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)	248	300
PMTCT_ARV_DSD	Single-dose nevirapine (with or without tail)	0	
PMTCT_ARV_DSD	Sum of Regimen Type disaggregates	989	1,199
PMTCT_ARV_DSD	Sum of New and Current disaggregates	741	899
PMTCT_ARV_NGI	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	989	1,199
PMTCT_ARV_NGI	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	989	1,199
PMTCT_ARV_NGI	Life-long ART (including Option B+)	741	899
PMTCT_ARV_NGI	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	410	524
PMTCT_ARV_NGI	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	331	375
PMTCT_ARV_NGI	Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)	248	300
PMTCT_ARV_NGI	Single-dose nevirapine (with or without tail)	0	
PMTCT_ARV_NGI	Sum of Regimen disaggregates	989	1,199
PMTCT_ARV_NGI	Sum of New and Current disaggregates	741	899
PMTCT_SITE	Number of PEPFAR-supported sites achieving 90% ARV or ART coverage for HIV+ pregnant women	19	19
PMTCT_SITE	Total number of PEPFAR supported sites providing PMTCT services (HTC and ARV or ART services)	19	19
PMTCT_SITE	By site support type: Direct Service Delivery (DSD): Number of PEPFAR-supported sites achieving 90% ARV or ART coverage for	19	19



	HIV+ pregnant women		
PMTCT_SITE	By site support type: Technical Assistance-only (TA): Number of PEPFAR-supported sites achieving 90% ARV or ART coverage for HIV+ pregnant women	0	0
PMTCT_SITE	Sum of Numerator Support Type disaggregates	19	19
PMTCT_SITE	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR supported sites providing PMTCT services (HTC and ARV or ART services)	19	19
PMTCT_SITE	By site support type: Technical Assistance-only (TA): Total number of PEPFAR supported sites providing PMTCT services (HTC and ARV or ART services)	0	0
PMTCT_SITE	Sum of Denominator Support Type disaggregates	19	19
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	6,728	8,020
PMTCT_STAT_DSD	Number of new ANC and L&D clients	6,728	8,020
PMTCT_STAT_DSD	By: Known positives at entry	465	619
PMTCT_STAT_DSD	By: Number of new positives identified	576	700
PMTCT_STAT_DSD	Sum of Positives Status disaggregates	1,041	1,319
PMTCT_STAT_NGI	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	6,728	8,020
PMTCT_STAT_NGI	Number of new ANC and L&D clients	6,728	8,020
PMTCT_STAT_NGI	By: Known positives at entry	465	619
PMTCT_STAT_NGI	By: Number of new positives identified	576	700
PMTCT_STAT_NGI	Sum of Positives Status disaggregates	1,041	1,319
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	18,995	18,995



HTC_TST_DSD	By Test Result: Negative	18,235	18,235
HTC_TST_DSD	By Test Result: Positive	760	760
HTC_TST_DSD	Sum of Test Result disaggregates	18,995	18,995
HTC_TST_DSD	Age/sex: <1 Male	0	0
HTC_TST_DSD	Age/sex: 1-4 Male	664	664
HTC_TST_DSD	Age/sex: 5-9 Male	285	285
HTC_TST_DSD	Age/sex: 10-14 Male	475	475
HTC_TST_DSD	Age/sex: 15-19 Male	950	950
HTC_TST_DSD	Age/sex: 20-24 Male	2,374	2,374
HTC_TST_DSD	Age/sex: 25-49 Male	3,799	3,799
HTC_TST_DSD	Age/sex: 50+ Male	950	950
HTC_TST_DSD	Age/sex: <1 Female	0	0
HTC_TST_DSD	Age/sex: 1-4 Female	665	665
HTC_TST_DSD	Age/sex: 5-9 Female	285	285
HTC_TST_DSD	Age/sex: 10-14 Female	475	475
HTC_TST_DSD	Age/sex: 15-19 Female	950	950
HTC_TST_DSD	Age/sex: 20-24 Female	2,374	2,374
HTC_TST_DSD	Age/sex: 25-49 Female	3,799	3,799
HTC_TST_DSD	Age/sex: 50+ Female	950	950
HTC_TST_DSD	Sum of Age/Sex disaggregates	18,995	18,995
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	1,424	1,424
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	8,073	8,073
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	1,425	1,425
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	8,073	8,073
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	2,849	2,849
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	16,146	16,146
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	18,995	18,995
HTC_TST_NGI	Number of individuals who received T&C	18,995	18,995



	services for HIV and received their test results during the past 12 months		
HTC_TST_NGI	By Test Result: Negative	18,235	18,235
HTC_TST_NGI	By Test Result: Positive	760	760
HTC_TST_NGI	Sum of Test Result disaggregates	18,995	18,995
HTC_TST_NGI	Age/sex: <1 Male	0	0
HTC_TST_NGI	Age/sex: 1-4 Male	664	664
HTC_TST_NGI	Age/sex: 5-9 Male	285	285
HTC_TST_NGI	Age/sex: 10-14 Male	475	475
HTC_TST_NGI	Age/sex: 15-19 Male	950	950
HTC_TST_NGI	Age/sex: 20-24 Male	2,374	2,374
HTC_TST_NGI	Age/sex: 25-49 Male	3,799	3,799
HTC_TST_NGI	Age/sex: 50+ Male	950	950
HTC_TST_NGI	Age/sex: <1 Female	0	0
HTC_TST_NGI	Age/sex: 1-4 Female	665	665
HTC_TST_NGI	Age/sex: 5-9 Female	285	285
HTC_TST_NGI	Age/sex: 10-14 Female	475	475
HTC_TST_NGI	Age/sex: 15-19 Female	950	950
HTC_TST_NGI	Age/sex: 20-24 Female	2,374	2,374
HTC_TST_NGI	Age/sex: 25-49 Female	3,799	3,799
HTC_TST_NGI	Age/sex: 50+ Female	950	950
HTC_TST_NGI	Sum of Age/Sex disaggregates	18,995	18,995
HTC_TST_NGI	Aggregated Age/sex: <15 Male	1,424	1,424
HTC_TST_NGI	Aggregated Age/sex: 15+ Male	8,073	8,073
HTC_TST_NGI	Aggregated Age/sex: <15 Female	1,425	1,425
HTC_TST_NGI	Aggregated Age/sex: 15+ Female	8,073	8,073
HTC_TST_NGI	Sum of Aggregated Age/Sex <15	2,849	2,849
HTC_TST_NGI	Sum of Aggregated Age/Sex 15+	16,146	16,146
HTC_TST_NGI	Sum of Aggregated Age/Sex disaggregates	18,995	18,995
OVC_ACC_DSD	Number of active beneficiaries receiving support from PEPFAR OVC programs to access HIV services	4,200	4,200



OVC_ACC_DSD	Sex: Male	2,100	2,100
OVC_ACC_DSD	Sex: Female	2,100	2,100
OVC_ACC_DSD	Sum of Sex disaggregates	4,200	4,200
OVC_ACC_DSD	Age: <1	84	84
OVC_ACC_DSD	Age: 1-4	504	504
OVC_ACC_DSD	Age: 5-9	1,050	1,050
OVC_ACC_DSD	Age: 10-14	1,512	1,512
OVC_ACC_DSD	Age: 15-17	840	840
OVC_ACC_DSD	Age: 18+	210	210
OVC_ACC_DSD	Sum of Age disaggregates	4,200	4,200
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	4,200	4,200
OVC_SERV_DSD	Sex: Male	2,100	2,100
OVC_SERV_DSD	Sex: Female	2,100	2,100
OVC_SERV_DSD	Sum of Sex disaggregates	4,200	4,200
OVC_SERV_DSD	Age: <1	42	42
OVC_SERV_DSD	Age: 1-4	462	462
OVC_SERV_DSD	Age: 5-9	1,008	1,008
OVC_SERV_DSD	Age: 10-14	1,449	1,449
OVC_SERV_DSD	Age: 15-17	819	819
OVC_SERV_DSD	Age: 18+	420	420
OVC_SERV_DSD	Sum of Age disaggregates	4,200	4,200
C2.1.D_DSD	Number of HIV-positive individuals receiving a minimum of one clinical service	8,679	9,537
C2.1.D_DSD	By Age/Sex: <15 Female	434	468
C2.1.D_DSD	By Age/Sex: <15 Male	433	467
C2.1.D_DSD	By Age/Sex: 15+ Female	2,734	3,011
C2.1.D_DSD	By Age/Sex: 15+ Male	5,078	5,591
C2.1.D_DSD	Sum of Age/Sex disaggregates	8,679	9,537
C2.1.D_DSD	By Age: <15	867	935
C2.1.D_DSD	By Age: 15+	7,812	8,602



C2.1.D_DSD	Sum of Age disaggregates	8,679	9,537
C2.1.D_DSD	By Sex: Female	5,512	6,059
C2.1.D_DSD	By Sex: Male	3,167	3,478
C2.1.D_DSD	Sum of Sex disaggregates	8,679	9,537
C2.1.D_NGI	Number of HIV-positive individuals receiving a minimum of one clinical service	8,679	9,537
C2.1.D_NGI	By Age/Sex: <15 Female	434	468
C2.1.D_NGI	By Age/Sex: <15 Male	433	467
C2.1.D_NGI	By Age/Sex: 15+ Female	2,734	3,011
C2.1.D_NGI	By Age/Sex: 15+ Male	5,078	5,591
C2.1.D_NGI	Sum of Age/Sex disaggregates	8,679	9,537
C2.1.D_NGI	By Age: <15	867	935
C2.1.D_NGI	By Age: 15+	7,812	8,602
C2.1.D_NGI	Sum of Age disaggregates	8,679	9,537
C2.1.D_NGI	By Sex: Female	5,512	6,059
C2.1.D_NGI	By Sex: Male	3,167	3,478
C2.1.D_NGI	Sum of Sex disaggregates	8,679	9,537
C2.4.D_DSD	Number of HIV-positive patients who were screened for TB in HIV care or treatment setting	6,943	8,659
C2.4.D_DSD	Number of HIV-positive individuals receiving a minimum of one clinical service	8,679	9,537
C2.5.D_DSD	Number of HIV-positive patients in HIV care who started TB treatment	519	587
C2.5.D_DSD	Number of HIV-positive individuals receiving a minimum of one clinical service	8,679	9,537
CARE_CURR_DSD	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	8,679	9,537
CARE_CURR_DSD	Age/sex: <1 Male	14	15
CARE_CURR_DSD	Age/sex: 1-4 Male	93	103



CARE_CURR_DSD	Age/sex: 5-9 Male	159	175
CARE_CURR_DSD	Age/sex: 10-14 Male	125	137
CARE_CURR_DSD	Age/sex: 15-19 Male	67	73
CARE_CURR_DSD	Age/sex: 20-24 Male	123	136
CARE_CURR_DSD	Age/sex: 25-49 Male	1,855	2,038
CARE_CURR_DSD	Age/sex: 50+ Male	641	704
CARE_CURR_DSD	Age/sex: <1 Female	13	15
CARE_CURR_DSD	Age/sex: 1-4 Female	89	98
CARE_CURR_DSD	Age/sex: 5-9 Female	164	180
CARE_CURR_DSD	Age/sex: 10-14 Female	124	136
CARE_CURR_DSD	Age/sex: 15-19 Female	110	121
CARE_CURR_DSD	Age/sex: 20-24 Female	456	501
CARE_CURR_DSD	Age/sex: 25-49 Female	3,897	4,282
CARE_CURR_DSD	Age/sex: 50+ Female	749	823
CARE_CURR_DSD	Sun of Age/Sex disaggregates	8,679	9,537
CARE_CURR_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	391	429
CARE_CURR_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	2,685	2,951
CARE_CURR_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	390	429
CARE_CURR_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	5,213	5,728
CARE_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	8,679	9,537
CARE_NEW_DSD	Number of HIV-infected adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load	1,716	1,716
CARE_NEW_DSD	Age/sex: <1 Male	27	27
CARE_NEW_DSD	Age/sex: 1-4 Male	15	15
CARE_NEW_DSD	Age/sex: 5-9 Male	27	27



CARE_NEW_DSD	Age/sex: 10-14 Male	20	20
CARE_NEW_DSD	Age/sex: 15-19 Male	13	13
CARE_NEW_DSD	Age/sex: 20-24 Male	25	25
CARE_NEW_DSD	Age/sex: 25-49 Male	372	372
CARE_NEW_DSD	Age/sex: 50+ Male	128	128
CARE_NEW_DSD	Age/sex: <1 Female	27	27
CARE_NEW_DSD	Age/sex: 1-4 Female	15	15
CARE_NEW_DSD	Age/sex: 5-9 Female	27	27
CARE_NEW_DSD	Age/sex: 10-14 Female	20	20
CARE_NEW_DSD	Age/sex: 15-19 Female	21	21
CARE_NEW_DSD	Age/sex: 20-24 Female	88	88
CARE_NEW_DSD	Age/sex: 25-49 Female	748	748
CARE_NEW_DSD	Age/sex: 50+ Female	143	143
CARE_NEW_DSD	Sum of Age/sex disaggregates	1,716	1,716
CARE_NEW_DSD	Aggregated Age/sex: <15 Male	89	89
CARE_NEW_DSD	Aggregated Age/sex: 15+ Male	538	538
CARE_NEW_DSD	Aggregated Age/sex: <15 Female	89	89
CARE_NEW_DSD	Aggregated Age/sex: 15+ Female	1,000	1,000
CARE_NEW_DSD	Sum of Aggregated Age/sex disaggregates	1,716	1,716
CARE_SITE	Number of PEPFAR-supported HIV clinical care sites at which at least 80% of PLHIV received all of the following during the reporting period: 1) clinical assessment (WHO staging) OR CD4 count OR viral load, AND 2) TB screening at last visit, AND 3) if eligible, cotrimoxazole	10	10
CARE_SITE	Total number of PEPFAR supported sites providing clinical care services	10	10
CARE_SITE	By site support type: Direct Service Delivery (DSD): Number of PEPFAR-supported HIV clinical care sites at which at least 80% of PLHIV received all of the following during the reporting period: 1) clinical assessment (WHO	10	10



	staging) OR CD4 count OR viral load, AND 2) TB screening at last visit, AND 3) if eligible, cotrimoxazole		
CARE_SITE	By site support type: Technical Assistance-only (TA): Number of PEPFAR-supported HIV clinical care sites at which at least 80% of PLHIV received all of the following during the reporting period: 1) clinical assessment (WHO staging) OR CD4 count OR viral load, AND 2) TB screening at last visit, AND 3) if eligible, cotrimoxazole	0	0
CARE_SITE	Sum of Numerator Site Support Type disaggregates	10	10
CARE_SITE	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR supported sites providing clinical care services	10	10
CARE_SITE	Sum of Denominator Site Support Type disaggregates	10	10
FN_SITE	Number of PEPFAR-supported sites achieving 90% nutrition assessments that result in accurate categorization of malnutrition	9	9
FN_SITE	Total number of PEPFAR-supported sites providing nutrition assessment, counseling and support (NACS) services	10	10
FN_SITE	By site support type: Direct Service Delivery (DSD): Number of PEPFAR-supported sites achieving 90% nutrition assessments that result in accurate categorization of malnutrition	9	9
FN_SITE	By site support type: Technical Assistance-only (TA): Number of PEPFAR-supported sites achieving 90% nutrition assessments that result in accurate categorization of malnutrition	0	0
FN_SITE	Sum of Numerator Support Type	9	9



	disaggregates		
FN_SITE	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported sites providing nutrition assessment, counseling and support (NACS) services	10	10
FN_SITE	Sum of Denominator Support Type disaggregates	10	10
FN_THER_DSD	Number of clinically malnourished PLHIV who received therapeutic and/or supplementary food during the reporting period.	2,428	2,720
FN_THER_DSD	Number of PLHIV who were nutritionally assessed and found to be clinically undernourished.	2,428	2,720
FN_THER_DSD	Age: <1	8	9
FN_THER_DSD	Age: 1-4	52	59
FN_THER_DSD	Age: 5-14	164	183
FN_THER_DSD	Age: 15-17	49	55
FN_THER_DSD	Age: 18+	2,155	2,414
FN_THER_DSD	Sum of Age disaggregates	2,428	2,720
FN_THER_DSD	Aggregated Age: <18	273	306
FN_THER_DSD	Aggregated Age: 18+	2,155	2,414
FN_THER_DSD	Sum of Aggregated Age disaggregates	2,428	2,720
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	519	587
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	519	587
TB_ART_DSD	Age: 0-4	13	14
TB_ART_DSD	Age: 5-14	35	40
TB_ART_DSD	Age: 15+	471	533
TB_ART_DSD	Male	280	317



TB_ART_DSD	Female	239	270
TB_ART_DSD	Sum of Sex disaggregates	519	587
TB_ART_DSD	Newly tested	311	352
TB_ART_DSD	Known HIV-positive	208	235
TB_ART_DSD	Sum of Test Status disaggregates	519	587
TB_ART_DSD	Aggregated Age: <15	48	54
TB_ART_DSD	Aggregated Age: 15+	471	533
TB_ART_DSD	Sum of Aggregated Age disaggregates	519	587
TB_ARTSITE	The number of PEPFAR-supported TB basic management units at which 80% of registered TB cases who are HIV-positive are on ART, during the reporting period	16	16
TB_ARTSITE	The number of PEPFAR-supported TB basic management units	16	16
TB_ARTSITE	By site support type: Direct Service Delivery (DSD): The number of PEPFAR-supported TB basic management units at which 80% of registered TB cases who are HIV-positive are on ART, during the reporting period	16	16
TB_ARTSITE	By site support type: Technical Assistance-only (TA): The number of PEPFAR-supported TB basic management units at which 80% of registered TB cases who are HIV-positive are on ART, during the reporting period	0	0
TB_ARTSITE	Sum of Numerator Site Support Type disaggregates	16	16
TB_ARTSITE	By site support type: Direct Service Delivery (DSD): The number of PEPFAR-supported TB basic management units	16	16
TB_ARTSITE	Sum of Denominator Site Support Type disaggregates	16	16
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting	424	424

	period		
PMTCT_EID_DSD	Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT)	989	1,199
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	240	240
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	184	184
PMTCT_EID_DSD	Sum of Infant Age disaggregates	424	424
PMTCT_EID_DSD	By infants with a positive virologic test result within 12 months of birth	24	24
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	6,262	9,654
TX_CURR_DSD	Age/Sex: <1 Male	10	11
TX_CURR_DSD	Age/Sex: 1-4 Male	66	78
TX_CURR_DSD	Age/Sex: 5-14 Male	206	243
TX_CURR_DSD	Age/Sex: 15+ Male	1,937	3,213
TX_CURR_DSD	Age/Sex: <1 Female	10	11
TX_CURR_DSD	Age/Sex: 1-4 Female	66	78
TX_CURR_DSD	Age/Sex: 5-14 Female	206	243
TX_CURR_DSD	Age/Sex: 15+ Female	3,761	5,777
TX_CURR_DSD	Sum of age/sex disaggregates	564	664
TX_CURR_DSD	Percent children with advanced HIV infection receiving antiretroviral therapy (ART) [CURRENT]	0	0
TX_CURR_DSD	Percent women and girls with advanced HIV infection receiving antiretroviral therapy (ART) [CURRENT]	0	0
TX_CURR_DSD	Aggregated Age/Sex: <1 Male	10	11
TX_CURR_DSD	Aggregated Age/Sex: <1 Female	10	11
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	282	332
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	1,937	3,213



TX_CURR_DSD	Aggregated Age/Sex: <15 Female	282	332
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	3,761	5,777
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	564	664
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	5,698	8,990
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	6,262	9,654
TX_CURR_NGI	Number of adults and children receiving antiretroviral therapy (ART)	6,262	7,375
TX_CURR_NGI	Age/Sex: <1 Male	10	11
TX_CURR_NGI	Age/Sex: 1-4 Male	66	78
TX_CURR_NGI	Age/Sex: 5-14 Male	206	243
TX_CURR_NGI	Age/Sex: 15+ Male	1,937	2,282
TX_CURR_NGI	Age/Sex: <1 Female	10	11
TX_CURR_NGI	Age/Sex: 1-4 Female	66	78
TX_CURR_NGI	Age/Sex: 5-14 Female	206	243
TX_CURR_NGI	Age/Sex: 15+ Female	3,761	4,429
TX_CURR_NGI	Sum of Age/Sex disaggregates	6,262	7,375
TX_CURR_NGI	Aggregated Age/Sex: <1 Male	10	11
TX_CURR_NGI	Aggregated Age/Sex: <1 Female	10	11
TX_CURR_NGI	Aggregated Age/Sex: <15 Male	282	332
TX_CURR_NGI	Aggregated Age/Sex: 15+ Male	1,937	2,282
TX_CURR_NGI	Aggregated Age/Sex: <15 Female	282	332
TX_CURR_NGI	Aggregated Age/Sex: 15+ Female	3,761	4,429
TX_CURR_NGI	Sum of Aggregated Age/Sex disaggregates	6,262	7,375
TX_CURR_NGI	Sum of Aggregated Age/Sex <15	564	664
TX_CURR_NGI	Sum of Aggregated Age/Sex 15+	5,698	6,711
TX_DIST	Number of Districts with documented routine supportive supervision visits to 75% of HIV care and treatment sites supported by the District	1	1
TX_DIST	Total number of PEPFAR supported District Health Offices	1	1
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	1,024	933



TX_NEW_DSD	By Age/Sex: <1 Male	16	14
TX_NEW_DSD	By Age/Sex: 1-4 Male	9	8
TX_NEW_DSD	By Age/Sex: 5-9 Male	16	14
TX_NEW_DSD	By Age/Sex: 10-14 Male	12	11
TX_NEW_DSD	By Age/Sex: 15-19 Male	8	7
TX_NEW_DSD	By Age/Sex: 20-24 Male	15	13
TX_NEW_DSD	By Age/Sex: 25-49 Male	222	203
TX_NEW_DSD	By Age/Sex: 50+ Male	77	70
TX_NEW_DSD	By Age/Sex: <1 Female	16	14
TX_NEW_DSD	By Age/Sex: 1-4 Female	9	8
TX_NEW_DSD	By Age/Sex: 5-9 Female	16	14
TX_NEW_DSD	By Age/Sex: 10-14 Female	12	11
TX_NEW_DSD	By Age/Sex: 15-19 Female	13	11
TX_NEW_DSD	By Age/Sex: 20-24 Female	52	48
TX_NEW_DSD	By Age/Sex: 25-49 Female	445	409
TX_NEW_DSD	By Age/Sex: 50+ Female	86	78
TX_NEW_DSD	Sum of Age/Sex disaggregates	1,024	933
TX_NEW_DSD	Aggregated Grouping by Age: <1 Male	16	14
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	53	47
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	321	293
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <1 Female	16	14
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	53	47
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	597	546
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	1,024	933
TX_NEW_DSD	Pregnancy status	182	166
TX_NEW_DSD	Breastfeeding status	20	18
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	870	793
TX_RET_DSD	Total number of adults and children who	1,024	933



	initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up		
TX_RET_DSD	Age: 0-4 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	22	20
TX_RET_DSD	Age: 5-14 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	59	53
TX_RET_DSD	Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	870	793
TX_RET_DSD	Age: 0-4 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	25	23
TX_RET_DSD	Age: 5-14 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	69	63
TX_RET_DSD	Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,024	933
TX_RET_DSD	Aggregated Age: <15 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	80	73
TX_RET_DSD	Aggregated Age: 15+ (Numerator: Number of	870	793



	adults and children who are still alive and on treatment at 12 months after initiating ART)		
TX_RET_DSD	Aggregated Age: <15 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	94	86
TX_RET_DSD	Aggregated Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,024	933
TX_RET_DSD	Pregnancy and breastfeeding status (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	286	260
TX_RET_DSD	Pregnancy and breastfeeding status (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	286	260
TX_SITE	Number of PEPFAR-supported ART sites with a retention rate of 75% or greater for patients 12 months after ART initiation	8	9
TX_SITE	Total number of PEPFAR-supported ART sites	10	10
TX_SITE	By support type: Direct Service Delivery (DSD): Number of PEPFAR-supported ART sites with a retention rate of 75% or greater for patients 12 months after ART initiation	8	9
TX_SITE	By support type: Technical Assistance	0	0



	(TA-only): Number of PEPFAR-supported ART sites with a retention rate of 75% or greater for patients 12 months after ART initiation		
TX_SITE	Sum of Numerator Site Support Type disaggregates	8	9
TX_SITE	By support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported ART sites	10	10
TX_SITE	Sum of Denominator Site Support Type disaggregates	10	10
LAB_ACC_DSD	Number of PEPFAR-supported testing facilities (laboratories) that are recognized by national, regional, or international standards for accreditation or have achieved a minimal acceptable level towards attainment of such accreditation	1	2
LAB_ACC_DSD	By site support type: Direct Service Delivery (DSD)	1	2
LAB_ACC_DSD	By site support type: Technical Assistance-only (TA)	0	0
LAB_ACC_DSD	Sum of Support Type disaggregates	1	2
LAB_CAP_DSD	Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests	7	7
LAB_CAP_DSD	By clinical laboratories	2	2
LAB_CAP_DSD	By Point-of-care testing sites	0	0
LAB_CAP_DSD	By site support type: Direct Service Delivery (DSD)	5	5
LAB_CAP_DSD	By site support type: Technical Assistance-only (TA)	2	2
LAB_CAP_DSD	Sum of Site Support Type disaggregates	7	7
QI_SITE	Number of PEPFAR-supported clinical service sites with a quality improvement activity	5	5



	completed that addresses clinical HIV programs and has documented process results in the last 6 months		
QI_SITE	Total number of PEPFAR-supported sites for any HIV clinical service including HIV Care, HIV Treatment, TB care, PMTCT, VMMC, and HTC	19	19
QI_SITE	By site support type: Direct Service Delivery (DSD): Number of PEPFAR-supported clinical service sites with a quality improvement activity completed that addresses clinical HIV programs and has documented results in the last 6 months	5	5
QI_SITE	By site support type: Technical Assistance-only (TA): Number of PEPFAR-supported clinical service sites with a quality improvement activity completed that addresses clinical HIV programs and has documented results in the last 6 months	0	0
QI_SITE	Sum of Numerator Site Support Type disaggregates	5	5
QI_SITE	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported sites for any HIV clinical service including HIV Care, HIV Treatment, TB care, PMTCT, VMMC, HTC	19	19
QI_SITE	Sum of Denominator Site Support Type disaggregates	19	19
TB_SCREEN_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period	6,943	7,630
TB_SCREEN_DSD	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count	8,679	9,537



	OR viral load		
TB_SCREEN_DSD	Age: <1	22	24
TB_SCREEN_DSD	Age: 1-4	150	165
TB_SCREEN_DSD	Age: 5-9	264	291
TB_SCREEN_DSD	Age: 10-14	204	224
TB_SCREEN_DSD	Age: 15-19	140	154
TB_SCREEN_DSD	Age: 20-24	468	514
TB_SCREEN_DSD	Age: 25-49	4,598	5,053
TB_SCREEN_DSD	Age: 50+	1,097	1,205
TB_SCREEN_DSD	Sum of Age disaggregates	780	858
TB_SCREEN_DSD	Aggregated Age - USE WITH HQ PERMISSION ONLY: <15	640	703
TB_SCREEN_DSD	Aggregated Age - USE WITH HQ PERMISSION ONLY: 15+	6,303	6,927
TB_SCREEN_DSD	Sum of Aggregated Age disaggregates	6,943	7,630
TB_SCREEN_DSD	Sex: Male	2,325	2,747
TB_SCREEN_DSD	Sex: Female	4,618	4,883
TB_SCREEN_DSD	Sum of Sex disaggregates	6,943	7,630

Implementing Mechanism Details

Mechanism ID: 13545	Mechanism Name: Peace Corps
Funding Agency: PC	Procurement Type: USG Core
Prime Partner Name: U.S. Peace Corps	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: No	
G2G: No	Managing Agency:

Total All Funding Sources: 0	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 907,000	
FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount
GHP-State	0



Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

- Malaria (PMI)
- Child Survival Activities
- Safe Motherhood
- TB

Budget Code Information

Mechanism ID: 13545			
Mechanism Name: Peace Corps			
Prime Partner Name: U.S. Peace Corps			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVAB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	0	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2014	2015
PP_PREV_TA	Number of the target population who completed a standardized HIV prevention	14,500	14,500



	intervention including the minimum components during the reporting period.		
PP_PREV_TA	Total number of people in the target population	18,000	18,000
PP_PREV_TA	Age/sex: 10-14 Male	2,000	2,000
PP_PREV_TA	Age/sex: 15-19 Male	1,000	1,000
PP_PREV_TA	Age/sex: 20-24 Male	1,500	1,500
PP_PREV_TA	Age/sex: 25-49 Male	500	500
PP_PREV_TA	Age/sex: 50+ Male	0	0
PP_PREV_TA	Age/sex: 10-14 Female	4,000	4,000
PP_PREV_TA	Age/sex: 15-19 Female	2,500	2,500
PP_PREV_TA	Age/sex: 20-24 Female	1,500	1,500
PP_PREV_TA	Age/sex: 25-49 Female	1,500	1,500
PP_PREV_TA	Age/sex: 50+ Female	0	0
PP_PREV_TA	Sum of Age/Sex disaggregates	14,500	14,500
KP_PREV_TA	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	595	470
KP_PREV_TA	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	45	50
KP_PREV_TA	By key population type: Males who inject drugs (Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	20	20
KP_PREV_TA	By key population type: Females who inject drugs (Female PWID) (Numerator: Number of	20	10



	key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)		
KP_PREV_TA	By key population type: Men who have sex with men/Transgender (MSM/TG) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	500	300
KP_PREV_TA	By key population type: MSM/TG who are male sex workers (subset MSM/TG) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	10	10

Implementing Mechanism Details

Mechanism ID: 13543	Mechanism Name: PAMOJA
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Elizabeth Glaser Pediatric AIDS Foundation	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: No	
G2G: No	Managing Agency:

Total All Funding Sources: 9,022,450	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 0	
FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount
GHP-State	9,022,450

Sub Partner Name(s)

Custom



African Brotherhood Church	Diocese of Lodwar	Gethsemane Garden of Hope for Africa (GGCHA)
International Rescue Committee	Our Lady of Perpetual Support for People Living with AIDS & Orphans, Kenya	

Cross-Cutting Budget Attribution(s)

Human Resources for Health	2,018,160
Gender: GBV	206,764
Focus Area:	GBV Prevention
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Monitoring and Evaluation
Gender: Gender Equality	206,764
Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Monitoring and Evaluation
Economic Strengthening	1,467,752
Education	3,000,000

Key Issues

Malaria (PMI)
 Child Survival Activities
 Safe Motherhood
 TB
 Family Planning



Budget Code Information

Mechanism ID: 13543			
Mechanism Name: PAMOJA			
Prime Partner Name: Elizabeth Glaser Pediatric AIDS Foundation			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	554,965	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	800,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	530,072	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	149,200	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	1,047,198	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	1,367,758	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	4,294,883	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	278,374	0

Implementing Mechanism Indicator Information



Indicator Number	Label	2014	2015	Planning Budget Targets
SITE_SUPP	Number of unique sites supported by PEPFAR	96	196	Redacted
SITE_SUPP	By program area/support type: HTC Direct Service Delivery (DSD)	96	166	Redacted
SITE_SUPP	By program area/support type: HTC Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: Treatment Direct Service Delivery (DSD)	73	143	Redacted
SITE_SUPP	By program area/support type: Treatment Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: Care and Support Direct Service Delivery (DSD)	82	152	Redacted
SITE_SUPP	By program area/support type: Care and Support Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: Food and Nutrition Direct Service Delivery (DSD)	82	152	Redacted
SITE_SUPP	By program area/support type: Food and Nutrition Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: PMTCT Direct Service Delivery (DSD)	82	152	Redacted
SITE_SUPP	By program area/support type: PMTCT Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: TB/HIV Direct Service Delivery (DSD)	82	148	Redacted
SITE_SUPP	By program area/support type: TB/HIV Technical Assistance-only (TA)	0	0	Redacted



SITE_SUPP	By program area/support type: PHDP/Family Planning & Integration Direct Service Delivery (DSD)	82	152	Redacted
PMTCT_ARV_DS D	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	4,711	5,482	Redacted
PMTCT_ARV_DS D	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	4,711	5,482	Redacted
PMTCT_ARV_DS D	Life-long ART (including Option B+)	3,533	4,112	Redacted
PMTCT_ARV_DS D	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	1,649	1,919	Redacted
PMTCT_ARV_DS D	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	1,884	2,193	Redacted
PMTCT_ARV_DS D	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)	0	0	Redacted
PMTCT_ARV_DS D	Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)	1,178	1,370	Redacted
PMTCT_ARV_DS D	Single-dose nevirapine (with or without tail)	0	0	Redacted
PMTCT_ARV_DS D	Sum of Regimen Type disaggregates	4,711	5,482	Redacted
PMTCT_ARV_DS D	Sum of New and Current disaggregates	3,533	4,112	Redacted
PMTCT_ARV_NGI	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT)	4,711	5,482	Redacted



	during pregnancy and delivery			
PMTCT_ARV_NGI	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	4,711	5,482	Redacted
PMTCT_ARV_NGI	Life-long ART (including Option B+)	3,533	4,112	Redacted
PMTCT_ARV_NGI	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	1,649	1,919	Redacted
PMTCT_ARV_NGI	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	1,884	2,193	Redacted
PMTCT_ARV_NGI	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)	0	0	Redacted
PMTCT_ARV_NGI	Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)	1,178	1,370	Redacted
PMTCT_ARV_NGI	Single-dose nevirapine (with or without tail)	0	0	Redacted
PMTCT_ARV_NGI	Sum of Regimen disaggregates	4,711	5,482	Redacted
PMTCT_ARV_NGI	Sum of New and Current disaggregates	3,533	4,112	Redacted
PMTCT_SITE	Number of PEPFAR-supported sites achieving 90% ARV or ART coverage for HIV+ pregnant women	82	152	Redacted
PMTCT_SITE	Total number of PEPFAR supported sites providing PMTCT services (HTC and ARV or ART services)	82	152	Redacted
PMTCT_SITE	By site support type: Direct Service Delivery (DSD): Number of PEPFAR-supported sites achieving 90% ARV or ART coverage for HIV+ pregnant women	82	152	Redacted
PMTCT_SITE	By site support type: Technical Assistance-only (TA): Number of PEPFAR-supported sites achieving	0	0	Redacted



	90% ARV or ART coverage for HIV+ pregnant women			
PMTCT_SITE	Sum of Numerator Support Type disaggregates	82	152	Redacted
PMTCT_SITE	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR supported sites providing PMTCT services (HTC and ARV or ART services)	82	152	Redacted
PMTCT_SITE	By site support type: Technical Assistance-only (TA): Total number of PEPFAR supported sites providing PMTCT services (HTC and ARV or ART services)	0	0	Redacted
PMTCT_SITE	Sum of Denominator Support Type disaggregates	82	152	Redacted
PMTCT_STAT_DS D	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	25,123	46,955	Redacted
PMTCT_STAT_DS D	Number of new ANC and L&D clients	25,123	46,955	Redacted
PMTCT_STAT_DS D	By: Known positives at entry	2,214	2,577	Redacted
PMTCT_STAT_DS D	By: Number of new positives identified	2,497	2,905	Redacted
PMTCT_STAT_DS D	Sum of Positives Status disaggregates	4,711	5,482	Redacted
PMTCT_STAT_NG I	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	25,123	46,955	Redacted
PMTCT_STAT_NG I	Number of new ANC and L&D clients	25,123	46,955	Redacted
PMTCT_STAT_NG	By: Known positives at entry	2,214	2,577	Redacted



I				
PMTCT_STAT_NG I	By: Number of new positives identified	2,497	2,905	Redacted
PMTCT_STAT_NG I	Sum of Positives Status disaggregates	4,711	5,482	Redacted
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	125,100	333,678	Redacted
HTC_TST_DSD	By Test Result: Negative	120,096	320,331	Redacted
HTC_TST_DSD	By Test Result: Positive	5,004	13,347	Redacted
HTC_TST_DSD	Sum of Test Result disaggregates	125,100	333,678	Redacted
HTC_TST_DSD	Age/sex: <1 Male	0	0	Redacted
HTC_TST_DSD	Age/sex: 1-4 Male	4,379	11,679	Redacted
HTC_TST_DSD	Age/sex: 5-9 Male	1,876	5,005	Redacted
HTC_TST_DSD	Age/sex: 10-14 Male	3,128	8,342	Redacted
HTC_TST_DSD	Age/sex: 15-19 Male	6,255	16,684	Redacted
HTC_TST_DSD	Age/sex: 20-24 Male	15,638	41,709	Redacted
HTC_TST_DSD	Age/sex: 25-49 Male	25,020	66,735	Redacted
HTC_TST_DSD	Age/sex: 50+ Male	6,255	16,685	Redacted
HTC_TST_DSD	Age/sex: <1 Female	0	0	Redacted
HTC_TST_DSD	Age/sex: 1-4 Female	4,379	11,679	Redacted
HTC_TST_DSD	Age/sex: 5-9 Female	1,876	5,005	Redacted
HTC_TST_DSD	Age/sex: 10-14 Female	3,128	8,342	Redacted
HTC_TST_DSD	Age/sex: 15-19 Female	6,255	16,684	Redacted
HTC_TST_DSD	Age/sex: 20-24 Female	15,638	41,709	Redacted
HTC_TST_DSD	Age/sex: 25-49 Female	25,022	66,735	Redacted
HTC_TST_DSD	Age/sex: 50+ Female	6,251	16,685	Redacted
HTC_TST_DSD	Sum of Age/Sex disaggregates	125,100	333,678	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	9,383	25,026	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	53,168	141,813	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ	9,383	25,026	Redacted



	PERMISSION ONLY: <15 Female			
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	53,166	141,813	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	18,766	50,052	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	106,334	283,626	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	125,100	333,678	Redacted
HTC_TST_NGI	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	125,100	333,678	Redacted
HTC_TST_NGI	By Test Result: Negative	120,096	320,331	Redacted
HTC_TST_NGI	By Test Result: Positive	5,004	13,347	Redacted
HTC_TST_NGI	Sum of Test Result disaggregates	125,100	333,678	Redacted
HTC_TST_NGI	Age/sex: <1 Male	0	0	Redacted
HTC_TST_NGI	Age/sex: 1-4 Male	4,379	11,679	Redacted
HTC_TST_NGI	Age/sex: 5-9 Male	1,876	5,005	Redacted
HTC_TST_NGI	Age/sex: 10-14 Male	3,128	8,342	Redacted
HTC_TST_NGI	Age/sex: 15-19 Male	6,255	16,684	Redacted
HTC_TST_NGI	Age/sex: 20-24 Male	15,638	41,709	Redacted
HTC_TST_NGI	Age/sex: 25-49 Male	25,020	66,735	Redacted
HTC_TST_NGI	Age/sex: 50+ Male	6,255	16,685	Redacted
HTC_TST_NGI	Age/sex: <1 Female	0	0	Redacted
HTC_TST_NGI	Age/sex: 1-4 Female	4,379	11,679	Redacted
HTC_TST_NGI	Age/sex: 5-9 Female	1,876	5,005	Redacted
HTC_TST_NGI	Age/sex: 10-14 Female	3,128	8,342	Redacted
HTC_TST_NGI	Age/sex: 15-19 Female	6,255	16,684	Redacted
HTC_TST_NGI	Age/sex: 20-24 Female	15,638	41,709	Redacted
HTC_TST_NGI	Age/sex: 25-49 Female	25,022	66,735	Redacted
HTC_TST_NGI	Age/sex: 50+ Female	6,251	16,685	Redacted
HTC_TST_NGI	Sum of Age/Sex disaggregates	125,100	333,678	Redacted
HTC_TST_NGI	Aggregated Age/sex: <15 Male	9,383	25,026	Redacted
HTC_TST_NGI	Aggregated Age/sex: 15+ Male	53,168	141,813	Redacted

HTC_TST_NGI	Aggregated Age/sex: <15 Female	9,383	25,026	Redacted
HTC_TST_NGI	Aggregated Age/sex: 15+ Female	53,166	141,813	Redacted
HTC_TST_NGI	Sum of Aggregated Age/Sex <15	18,766	50,052	Redacted
HTC_TST_NGI	Sum of Aggregated Age/Sex 15+	106,334	283,626	Redacted
HTC_TST_NGI	Sum of Aggregated Age/Sex disaggregates	125,100	333,678	Redacted
C2.1.D_DSD	Number of HIV-positive individuals receiving a minimum of one clinical service	42,496	55,540	Redacted
C2.1.D_DSD	By Age/Sex: <15 Female	1,913	2,505	Redacted
C2.1.D_DSD	By Age/Sex: <15 Male	1,912	2,505	Redacted
C2.1.D_DSD	By Age/Sex: 15+ Female	25,523	33,350	Redacted
C2.1.D_DSD	By Age/Sex: 15+ Male	13,148	17,180	Redacted
C2.1.D_DSD	Sum of Age/Sex disaggregates	42,496	55,540	Redacted
C2.1.D_DSD	By Age: <15	3,825	5,010	Redacted
C2.1.D_DSD	By Age: 15+	38,671	50,530	Redacted
C2.1.D_DSD	Sum of Age disaggregates	42,496	55,540	Redacted
C2.1.D_DSD	By Sex: Female	27,436	35,855	Redacted
C2.1.D_DSD	By Sex: Male	15,060	19,685	Redacted
C2.1.D_DSD	Sum of Sex disaggregates	42,496	55,540	Redacted
C2.1.D_NGI	Number of HIV-positive individuals receiving a minimum of one clinical service	42,496	55,540	Redacted
C2.1.D_NGI	By Age/Sex: <15 Female	1,913	2,505	Redacted
C2.1.D_NGI	By Age/Sex: <15 Male	1,912	2,505	Redacted
C2.1.D_NGI	By Age/Sex: 15+ Female	25,523	33,350	Redacted
C2.1.D_NGI	By Age/Sex: 15+ Male	13,148	17,180	Redacted
C2.1.D_NGI	Sum of Age/Sex disaggregates	42,496	55,540	Redacted
C2.1.D_NGI	By Age: <15	3,825	5,010	Redacted
C2.1.D_NGI	By Age: 15+	38,671	50,530	Redacted
C2.1.D_NGI	Sum of Age disaggregates	42,496	55,540	Redacted
C2.1.D_NGI	By Sex: Female	27,436	35,855	Redacted



C2.1.D_NGI	By Sex: Male	15,060	19,685	Redacted
C2.1.D_NGI	Sum of Sex disaggregates	42,496	55,540	Redacted
C2.4.D_DSD	Number of HIV-positive patients who were screened for TB in HIV care or treatment setting	38,247	52,763	Redacted
C2.4.D_DSD	Number of HIV-positive individuals receiving a minimum of one clinical service	42,496	55,540	Redacted
C2.5.D_DSD	Number of HIV-positive patients in HIV care who started TB treatment	765	1,055	Redacted
C2.5.D_DSD	Number of HIV-positive individuals receiving a minimum of one clinical service	42,496	55,540	Redacted
CARE_CURR_DS D	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	40,371	52,763	Redacted
CARE_CURR_DS D	Age/sex: <1 Male	63	82	Redacted
CARE_CURR_DS D	Age/sex: 1-4 Male	436	572	Redacted
CARE_CURR_DS D	Age/sex: 5-9 Male	738	966	Redacted
CARE_CURR_DS D	Age/sex: 10-14 Male	580	760	Redacted
CARE_CURR_DS D	Age/sex: 15-19 Male	310	405	Redacted
CARE_CURR_DS D	Age/sex: 20-24 Male	574	750	Redacted
CARE_CURR_DS D	Age/sex: 25-49 Male	8,627	11,272	Redacted
CARE_CURR_DS D	Age/sex: 50+ Male	2,980	3,894	Redacted



CARE_CURR_DS D	Age/sex: <1 Female	63	82	Redacted
CARE_CURR_DS D	Age/sex: 1-4 Female	415	543	Redacted
CARE_CURR_DS D	Age/sex: 5-9 Female	763	1,000	Redacted
CARE_CURR_DS D	Age/sex: 10-14 Female	576	755	Redacted
CARE_CURR_DS D	Age/sex: 15-19 Female	512	670	Redacted
CARE_CURR_DS D	Age/sex: 20-24 Female	2,123	2,773	Redacted
CARE_CURR_DS D	Age/sex: 25-49 Female	18,128	23,687	Redacted
CARE_CURR_DS D	Age/sex: 50+ Female	3,483	4,552	Redacted
CARE_CURR_DS D	Sun of Age/Sex disaggregates	40,371	52,763	Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	1,817	2,380	Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	12,491	16,321	Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	1,817	2,380	Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	24,246	31,682	Redacted
CARE_CURR_DS D	Sum of Aggregated Age/Sex disaggregates	40,371	52,763	Redacted
CARE_NEW_DSD	Number of HIV-infected adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load	8,074	9,594	Redacted



CARE_NEW_DSD	Age/sex: <1 Male	13	15	Redacted
CARE_NEW_DSD	Age/sex: 1-4 Male	83	99	Redacted
CARE_NEW_DSD	Age/sex: 5-9 Male	153	182	Redacted
CARE_NEW_DSD	Age/sex: 10-14 Male	115	137	Redacted
CARE_NEW_DSD	Age/sex: 15-19 Male	53	63	Redacted
CARE_NEW_DSD	Age/sex: 20-24 Male	219	260	Redacted
CARE_NEW_DSD	Age/sex: 25-49 Male	1,868	2,218	Redacted
CARE_NEW_DSD	Age/sex: 50+ Male	358	426	Redacted
CARE_NEW_DSD	Age/sex: <1 Female	13	15	Redacted
CARE_NEW_DSD	Age/sex: 1-4 Female	87	104	Redacted
CARE_NEW_DSD	Age/sex: 5-9 Female	148	176	Redacted
CARE_NEW_DSD	Age/sex: 10-14 Female	116	138	Redacted
CARE_NEW_DSD	Age/sex: 15-19 Female	120	143	Redacted
CARE_NEW_DSD	Age/sex: 20-24 Female	223	265	Redacted
CARE_NEW_DSD	Age/sex: 25-49 Female	3,349	3,978	Redacted
CARE_NEW_DSD	Age/sex: 50+ Female	1,156	1,375	Redacted
CARE_NEW_DSD	Sum of Age/sex disaggregates	8,074	9,594	Redacted
CARE_NEW_DSD	Aggregated Age/sex: <15 Male	364	433	Redacted
CARE_NEW_DSD	Aggregated Age/sex: 15+ Male	2,498	2,967	Redacted
CARE_NEW_DSD	Aggregated Age/sex: <15 Female	364	433	Redacted
CARE_NEW_DSD	Aggregated Age/sex: 15+ Female	4,848	5,761	Redacted
CARE_NEW_DSD	Sum of Aggregated Age/sex disaggregates	8,074	9,594	Redacted
CARE_SITE	Number of PEPFAR-supported HIV clinical care sites at which at least 80% of PLHIV received all of the following during the reporting period: 1) clinical assessment (WHO staging) OR CD4 count OR viral load, AND 2) TB screening at last visit, AND 3) if eligible, cotrimoxazole	82	152	Redacted
CARE_SITE	Total number of PEPFAR supported sites providing clinical care services	82	152	Redacted



CARE_SITE	By site support type: Direct Service Delivery (DSD): Number of PEPFAR-supported HIV clinical care sites at which at least 80% of PLHIV received all of the following during the reporting period: 1) clinical assessment (WHO staging) OR CD4 count OR viral load, AND 2) TB screening at last visit, AND 3) if eligible, cotrimoxazole	82	152	Redacted
CARE_SITE	By site support type: Technical Assistance-only (TA): Number of PEPFAR-supported HIV clinical care sites at which at least 80% of PLHIV received all of the following during the reporting period: 1) clinical assessment (WHO staging) OR CD4 count OR viral load, AND 2) TB screening at last visit, AND 3) if eligible, cotrimoxazole	0	0	Redacted
CARE_SITE	Sum of Numerator Site Support Type disaggregates	82	152	Redacted
CARE_SITE	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR supported sites providing clinical care services	82	152	Redacted
CARE_SITE	By site support type: Technical Assistance-only (TA): Total number of PEPFAR supported sites providing clinical care services	0	0	Redacted
CARE_SITE	Sum of Denominator Site Support Type disaggregates	82	152	Redacted
FN_SITE	Number of PEPFAR-supported sites achieving 90% nutrition assessments that result in accurate categorization of malnutrition	74	137	Redacted
FN_SITE	Total number of PEPFAR-supported sites providing nutrition assessment,	82	152	Redacted

	counseling and support (NACS) services			
FN_SITE	By site support type: Direct Service Delivery (DSD): Number of PEPFAR-supported sites achieving 90% nutrition assessments that result in accurate categorization of malnutrition	74	137	Redacted
FN_SITE	By site support type: Technical Assistance-only (TA): Number of PEPFAR-supported sites achieving 90% nutrition assessments that result in accurate categorization of malnutrition	0	0	Redacted
FN_SITE	Sum of Numerator Support Type disaggregates	74	137	Redacted
FN_SITE	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported sites providing nutrition assessment, counseling and support (NACS) services	82	152	Redacted
FN_SITE	By site support type: Technical Assistance-only (TA): Total number of PEPFAR-supported sites providing nutrition assessment, counseling and support (NACS) services	0	0	Redacted
FN_SITE	Sum of Denominator Support Type disaggregates	82	152	Redacted
FN_THER_DSD	Number of clinically malnourished PLHIV who received therapeutic and/or supplementary food during the reporting period.	6,374	8,331	Redacted
FN_THER_DSD	Number of PLHIV who were nutritionally assessed and found to be clinically undernourished.	8,499	11,108	Redacted



FN_THER_DSD	Age: <1	20	27	Redacted
FN_THER_DSD	Age: 1-4	137	180	Redacted
FN_THER_DSD	Age: 5-14	430	560	Redacted
FN_THER_DSD	Age: 15-17	129	169	Redacted
FN_THER_DSD	Age: 18+	5,658	7,395	Redacted
FN_THER_DSD	Sum of Age disaggregates	6,374	8,331	Redacted
FN_THER_DSD	Aggregated Age: <18	716	936	Redacted
FN_THER_DSD	Aggregated Age: 18+	5,658	7,395	Redacted
FN_THER_DSD	Sum of Aggregated Age disaggregates	6,374	8,331	Redacted
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	1,625	2,374	Redacted
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	1,912	2,638	Redacted
TB_ART_DSD	Age: 0-4	40	59	Redacted
TB_ART_DSD	Age: 5-14	110	160	Redacted
TB_ART_DSD	Age: 15+	1,475	2,155	Redacted
TB_ART_DSD	Male	878	1,282	Redacted
TB_ART_DSD	Female	747	1,092	Redacted
TB_ART_DSD	Sum of Sex disaggregates	1,625	2,374	Redacted
TB_ART_DSD	Newly tested	975	1,424	Redacted
TB_ART_DSD	Known HIV-positive	650	950	Redacted
TB_ART_DSD	Sum of Test Status disaggregates	1,625	2,374	Redacted
TB_ART_DSD	Aggregated Age: <15	150	219	Redacted
TB_ART_DSD	Aggregated Age: 15+	1,475	2,155	Redacted
TB_ART_DSD	Sum of Aggregated Age disaggregates	1,625	2,374	Redacted
TB_ARTSITE	The number of PEPFAR-supported TB basic management units at which 80% of registered TB cases who are	82	148	Redacted



	HIV-positive are on ART, during the reporting period			
TB_ARTSITE	The number of PEPFAR-supported TB basic management units	82	148	Redacted
TB_ARTSITE	By site support type: Direct Service Delivery (DSD): The number of PEPFAR-supported TB basic management units at which 80% of registered TB cases who are HIV-positive are on ART, during the reporting period	82	148	Redacted
TB_ARTSITE	By site support type: Technical Assistance-only (TA): The number of PEPFAR-supported TB basic management units at which 80% of registered TB cases who are HIV-positive are on ART, during the reporting period	0	0	Redacted
TB_ARTSITE	Sum of Numerator Site Support Type disaggregates	82	148	Redacted
TB_ARTSITE	By site support type: Direct Service Delivery (DSD): The number of PEPFAR-supported TB basic management units	82	148	Redacted
TB_ARTSITE	By site support type: Technical Assistance-only (TA): The number of PEPFAR-supported TB basic management units	0	0	Redacted
TB_ARTSITE	Sum of Denominator Site Support Type disaggregates	82	148	Redacted
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	3,769	4,386	Redacted
PMTCT_EID_DSD	Number of HIV- positive pregnant women identified during the reporting	4,711	5,482	Redacted

	period (include known HIV-positive women at entry into PMTCT)			
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	2,827	3,289	Redacted
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	942	1,097	Redacted
PMTCT_EID_DSD	Sum of Infant Age disaggregates	3,769	4,386	Redacted
PMTCT_EID_DSD	By infants with a positive virologic test result within 12 months of birth	188	219	Redacted
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	20,714	31,402	Redacted
TX_CURR_DSD	Age/Sex: <1 Male	32	49	Redacted
TX_CURR_DSD	Age/Sex: 1-4 Male	218	331	Redacted
TX_CURR_DSD	Age/Sex: 5-14 Male	682	1,036	Redacted
TX_CURR_DSD	Age/Sex: 15+ Male	6,409	10,000	Redacted
TX_CURR_DSD	Age/Sex: <1 Female	32	49	Redacted
TX_CURR_DSD	Age/Sex: 1-4 Female	218	331	Redacted
TX_CURR_DSD	Age/Sex: 5-14 Female	682	1,035	Redacted
TX_CURR_DSD	Age/Sex: 15+ Female	12,441	18,571	Redacted
TX_CURR_DSD	Sum of age/sex disaggregates	1,864	2,831	Redacted
TX_CURR_DSD	Percent children with advanced HIV infection receiving antiretroviral therapy (ART) [CURRENT]	0	1	Redacted
TX_CURR_DSD	Percent women and girls with advanced HIV infection receiving antiretroviral therapy (ART) [CURRENT]	0	1	Redacted
TX_CURR_DSD	Aggregated Age/Sex: <1 Male	32	49	Redacted
TX_CURR_DSD	Aggregated Age/Sex: <1 Female	32	49	Redacted
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	932	1,416	Redacted
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	6,409	10,000	Redacted
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	932	1,415	Redacted



TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	12,441	18,571	Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	1,864	2,831	Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	18,850	28,571	Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	20,714	31,402	Redacted
TX_CURR_NGI	Number of adults and children receiving antiretroviral therapy (ART)	20,714	31,402	Redacted
TX_CURR_NGI	Age/Sex: <1 Male	32	49	Redacted
TX_CURR_NGI	Age/Sex: 1-4 Male	218	331	Redacted
TX_CURR_NGI	Age/Sex: 5-14 Male	682	1,036	Redacted
TX_CURR_NGI	Age/Sex: 15+ Male	6,409	10,000	Redacted
TX_CURR_NGI	Age/Sex: <1 Female	32	49	Redacted
TX_CURR_NGI	Age/Sex: 1-4 Female	218	331	Redacted
TX_CURR_NGI	Age/Sex: 5-14 Female	682	1,035	Redacted
TX_CURR_NGI	Age/Sex: 15+ Female	12,441	18,571	Redacted
TX_CURR_NGI	Sum of Age/Sex disaggregates	20,714	31,402	Redacted
TX_CURR_NGI	Aggregated Age/Sex: <1 Male	32	49	Redacted
TX_CURR_NGI	Aggregated Age/Sex: <1 Female	32	49	Redacted
TX_CURR_NGI	Aggregated Age/Sex: <15 Male	932	1,416	Redacted
TX_CURR_NGI	Aggregated Age/Sex: 15+ Male	6,409	10,000	Redacted
TX_CURR_NGI	Aggregated Age/Sex: <15 Female	932	1,415	Redacted
TX_CURR_NGI	Aggregated Age/Sex: 15+ Female	12,441	18,571	Redacted
TX_CURR_NGI	Sum of Aggregated Age/Sex disaggregates	20,714	31,402	Redacted
TX_CURR_NGI	Sum of Aggregated Age/Sex <15	1,864	2,831	Redacted
TX_CURR_NGI	Sum of Aggregated Age/Sex 15+	18,850	28,571	Redacted
TX_DIST	Number of Districts with documented routine supportive supervision visits to 75% of HIV care and treatment sites supported by the District	1	5	Redacted
TX_DIST	Total number of PEPFAR supported District Health Offices	1	6	Redacted
TX_NEW_DSD	Number of adults and children newly	3,858	5,432	Redacted



	enrolled on antiretroviral therapy (ART)			
TX_NEW_DSD	By Age/Sex: <1 Male	60	115	Redacted
TX_NEW_DSD	By Age/Sex: 1-4 Male	34	65	Redacted
TX_NEW_DSD	By Age/Sex: 5-9 Male	60	115	Redacted
TX_NEW_DSD	By Age/Sex: 10-14 Male	45	88	Redacted
TX_NEW_DSD	By Age/Sex: 15-19 Male	30	40	Redacted
TX_NEW_DSD	By Age/Sex: 20-24 Male	56	75	Redacted
TX_NEW_DSD	By Age/Sex: 25-49 Male	836	1,128	Redacted
TX_NEW_DSD	By Age/Sex: 50+ Male	289	390	Redacted
TX_NEW_DSD	By Age/Sex: <1 Female	60	115	Redacted
TX_NEW_DSD	By Age/Sex: 1-4 Female	33	65	Redacted
TX_NEW_DSD	By Age/Sex: 5-9 Female	60	115	Redacted
TX_NEW_DSD	By Age/Sex: 10-14 Female	46	88	Redacted
TX_NEW_DSD	By Age/Sex: 15-19 Female	47	64	Redacted
TX_NEW_DSD	By Age/Sex: 20-24 Female	197	266	Redacted
TX_NEW_DSD	By Age/Sex: 25-49 Female	1,681	2,267	Redacted
TX_NEW_DSD	By Age/Sex: 50+ Female	324	436	Redacted
TX_NEW_DSD	Sum of Age/Sex disaggregates	3,858	5,432	Redacted
TX_NEW_DSD	Aggregated Grouping by Age: <1 Male	60	115	Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	199	383	Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	1,211	1,633	Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <1 Female	60	115	Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	199	383	Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	2,249	3,033	Redacted
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	3,858	5,432	Redacted
TX_NEW_DSD	Pregnancy status	1,484	1,727	Redacted
TX_NEW_DSD	Breastfeeding status	165	192	Redacted



TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	2,599	3,279	Redacted
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	3,058	3,858	Redacted
TX_RET_DSD	Age: 0-4 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	65	81	Redacted
TX_RET_DSD	Age: 5-14 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	175	221	Redacted
TX_RET_DSD	Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	2,360	2,977	Redacted
TX_RET_DSD	Age: 0-4 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	76	96	Redacted
TX_RET_DSD	Age: 5-14 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	206	260	Redacted
TX_RET_DSD	Age: 15+ (Denominator: Total number	2,776	3,502	Redacted



	of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)			
TX_RET_DSD	Aggregated Age: <15 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	240	302	Redacted
TX_RET_DSD	Aggregated Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	2,360	2,977	Redacted
TX_RET_DSD	Aggregated Age: <15 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	282	356	Redacted
TX_RET_DSD	Aggregated Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	2,776	3,502	Redacted
TX_RET_DSD	Pregnancy and breastfeeding status (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,502	3,003	Redacted
TX_RET_DSD	Pregnancy and breastfeeding status (Denominator: Total number of adults and children who initiated ART in the	1,767	3,533	Redacted



	12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)			
TX_SITE	Number of PEPFAR-supported ART sites with a retention rate of 75% or greater for patients 12 months after ART initiation	51	100	Redacted
TX_SITE	Total number of PEPFAR-supported ART sites	73	143	Redacted
TX_SITE	By support type: Direct Service Delivery (DSD): Number of PEPFAR-supported ART sites with a retention rate of 75% or greater for patients 12 months after ART initiation	51	100	Redacted
TX_SITE	By support type: Technical Assistance (TA-only): Number of PEPFAR-supported ART sites with a retention rate of 75% or greater for patients 12 months after ART initiation	0	0	Redacted
TX_SITE	Sum of Numerator Site Support Type disaggregates	51	100	Redacted
TX_SITE	By support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported ART sites	73	143	Redacted
TX_SITE	By support type: Technical Assistance (TA-only): Total number of PEPFAR-supported ART sites	0	0	Redacted
TX_SITE	Sum of Denominator Site Support Type disaggregates	73	143	Redacted
FPINT_SITE_DSD	Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	62	114	Redacted
FPINT_SITE_DSD	Total number of PEPFAR-supported	82	152	Redacted



	HIV service delivery points: PMTCT, Care and Treatment			
FPINT_SITE_DSD	By site support type: Direct Service Delivery (DSD): Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	62	114	Redacted
FPINT_SITE_DSD	By site support type: Technical Assistance-only (TA): Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	0	0	Redacted
FPINT_SITE_DSD	Sum of Numerator Site Support Type disaggregates	62	114	Redacted
FPINT_SITE_DSD	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported HIV service delivery points	82	152	Redacted
FPINT_SITE_DSD	By site support type: Technical Assistance-only (TA): Total number of PEPFAR-supported HIV service delivery points	0	0	Redacted
FPINT_SITE_DSD	Sum of Denominator Site Support Type disaggregates	82	152	Redacted
FPINT_SITE_DSD	Service delivery type: Clinical	62	114	Redacted
FPINT_SITE_DSD	Sum of Service Delivery Type disaggregates	62	114	Redacted
QI_SITE	Number of PEPFAR-supported clinical service sites with a quality improvement activity completed that addresses clinical HIV programs and has documented process results in the last 6 months	66	122	Redacted



QI_SITE	Total number of PEPFAR-supported sites for any HIV clinical service including HIV Care, HIV Treatment, TB care, PMTCT, VMMC, and HTC	82	152	Redacted
QI_SITE	By site support type: Direct Service Delivery (DSD): Number of PEPFAR-supported clinical service sites with a quality improvement activity completed that addresses clinical HIV programs and has documented results in the last 6 months	66	122	Redacted
QI_SITE	By site support type: Technical Assistance-only (TA): Number of PEPFAR-supported clinical service sites with a quality improvement activity completed that addresses clinical HIV programs and has documented results in the last 6 months	0	0	Redacted
QI_SITE	Sum of Numerator Site Support Type disaggregates	66	122	Redacted
QI_SITE	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported sites for any HIV clinical service including HIV Care, HIV Treatment, TB care, PMTCT, VMMC, HTC	82	152	Redacted
QI_SITE	By site support type: Technical Assistance-only (TA): Total number of PEPFAR-supported sites for any HIV clinical service including HIV Care, HIV Treatment, TB care, PMTCT, VMMC, and HTC	0	0	Redacted
QI_SITE	Sum of Denominator Site Support Type disaggregates	82	152	Redacted
TB_SCREEN_DSD	The number of PLHIV who were screened for TB symptoms at the last	36,334	50,125	Redacted



	clinical visit to an HIV care facility during the reporting period			
TB_SCREEN_DSD	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	40,371	52,763	Redacted
TB_SCREEN_DSD	Age: <1	116	160	Redacted
TB_SCREEN_DSD	Age: 1-4	784	1,082	Redacted
TB_SCREEN_DSD	Age: 5-9	1,384	1,908	Redacted
TB_SCREEN_DSD	Age: 10-14	1,065	1,470	Redacted
TB_SCREEN_DSD	Age: 15-19	735	1,014	Redacted
TB_SCREEN_DSD	Age: 20-24	2,450	3,379	Redacted
TB_SCREEN_DSD	Age: 25-49	24,060	33,195	Redacted
TB_SCREEN_DSD	Age: 50+	5,740	7,917	Redacted
TB_SCREEN_DSD	Sum of Age disaggregates	4,084	5,634	Redacted
TB_SCREEN_DSD	Aggregated Age - USE WITH HQ PERMISSION ONLY: <15	3,349	4,620	Redacted
TB_SCREEN_DSD	Aggregated Age - USE WITH HQ PERMISSION ONLY: 15+	32,985	45,505	Redacted
TB_SCREEN_DSD	Sum of Aggregated Age disaggregates	36,334	50,125	Redacted
TB_SCREEN_DSD	Sex: Male	3,349	4,620	Redacted
TB_SCREEN_DSD	Sex: Female	32,985	45,505	Redacted
TB_SCREEN_DSD	Sum of Sex disaggregates	36,334	50,125	Redacted

Implementing Mechanism Details

Mechanism ID: 13517	Mechanism Name: Strengthening Strategic Information Activities in the Republic of Kenya
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: African Medical and Research Foundation	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: No	

Approved



G2G: No	Managing Agency:
---------	------------------

Total All Funding Sources: 525,000	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 75,000	
FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount
GHP-State	525,000

Sub Partner Name(s)

Afri Arya	Danya International, Inc	
-----------	--------------------------	--

Cross-Cutting Budget Attribution(s)

Human Resources for Health	525,000
----------------------------	---------

Key Issues

(No data provided.)

Budget Code Information

Mechanism ID: 13517			
Mechanism Name: Strengthening Strategic Information Activities in the Republic of Kenya			
Prime Partner Name: African Medical and Research Foundation			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	525,000	0

Implementing Mechanism Indicator Information

(No data provided.)



Implementing Mechanism Details

Mechanism ID: 13502	Mechanism Name: Strengthening HIV Strategic Information Activities in the Republic of Kenya
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: University of California at San Francisco	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: No	
G2G: No	Managing Agency:

Total All Funding Sources: 0	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 1,300,000	
FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount
GHP-State	0

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

(No data provided.)

Budget Code Information

Mechanism ID:	13502
Mechanism Name:	Strengthening HIV Strategic Information Activities in the Republic of Kenya
Prime Partner Name:	University of California at San Francisco



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 13481	Mechanism Name: Prevention for MARPs-Central and Eastern
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: University of Nairobi	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: No	
G2G: Yes	Managing Agency: HHS/CDC

Total All Funding Sources: 1,000,503	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 0	
FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount
GHP-State	1,000,503

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

Key Populations: MSM and TG	44,400
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Implementation of core HIV prevention interventions



	for MSM/TG that are consistent with the current PEPFAR technical guidance
Focus Area:	Collection and use of strategic information
Focus Area:	Monitoring and evaluation of MSM/TG programs
Key Populations: FSW	731,000
Focus Area:	Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Collection and use of strategic information on SWs and clients
Focus Area:	Monitoring and evaluation of SW programs
Gender: Gender Equality	79,200
Focus Area:	Changing harmful gender norms and promoting positive gender norms
Sub Area:	Implementation
Sub Area:	Monitoring and Evaluation
Focus Area:	Increase gender-equitable access to income and productive resources, including education
Sub Area:	Implementation
Sub Area:	Monitoring and Evaluation
Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Implementation
Sub Area:	Monitoring and Evaluation
Human Resources for Health	400,000
Gender: GBV	111,000
Focus Area:	GBV Prevention
Sub Area:	Implementation
Sub Area:	Monitoring and Evaluation
Focus Area:	Post GBV Care
Sub Area:	Implementation



Sub Area:	Monitoring and Evaluation
Condom programming	79,200

Key Issues

Family Planning

Budget Code Information

Mechanism ID:	13481		
Mechanism Name:	Prevention for MARPs-Central and Eastern		
Prime Partner Name:	University of Nairobi		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	25,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	83,503	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	792,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	100,000	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2014	2015	Planning Budget Targets
SITE_SUPP	Number of unique sites supported by	10	10	Redacted



	PEPFAR			
SITE_SUPP	By program area/support type: HTC Direct Service Delivery (DSD)	10	10	Redacted
SITE_SUPP	By program area/support type: General Population Prevention Direct Service Delivery (DSD)	6	6	Redacted
SITE_SUPP	By program area/support type: Key Populations Prevention Direct Service Delivery (DSD)	10	10	Redacted
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	1,000	1,420	Redacted
PP_PREV_DSD	Total number of people in the target population	5,509	5,509	Redacted
PP_PREV_DSD	Age/sex: 10-14 Female	500	710	Redacted
PP_PREV_DSD	Age/sex: 15-19 Female	500	710	Redacted
PP_PREV_DSD	Sum of Age/Sex disaggregates	1,000	1,420	Redacted
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	20,200	17,448	Redacted
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	18,000	16,537	Redacted
KP_PREV_DSD	By key population type: Men who have sex with men/Transgender (MSM/TG) (Numerator: Number of key populations reached with individual and/or small	2,200	911	Redacted

	group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)			
KP_PREV_DSD	By key population type: MSM/TG who are male sex workers (subset MSM/TG) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	480	364	Redacted
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	20,700	25,525	Redacted
HTC_TST_DSD	By Test Result: Negative	19,872	24,504	Redacted
HTC_TST_DSD	By Test Result: Positive	828	1,021	Redacted
HTC_TST_DSD	Sum of Test Result disaggregates	20,700	25,525	Redacted
HTC_TST_DSD	Age/sex: 15-19 Male	200	114	Redacted
HTC_TST_DSD	Age/sex: 20-24 Male	800	455	Redacted
HTC_TST_DSD	Age/sex: 25-49 Male	1,000	569	Redacted
HTC_TST_DSD	Age/sex: 15-19 Female	1,870	2,439	Redacted
HTC_TST_DSD	Age/sex: 20-24 Female	7,480	9,755	Redacted
HTC_TST_DSD	Age/sex: 25-49 Female	8,415	10,974	Redacted
HTC_TST_DSD	Age/sex: 50+ Female	935	1,219	Redacted
HTC_TST_DSD	Sum of Age/Sex disaggregates	20,700	25,525	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	2,000	1,138	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	18,700	24,387	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	20,700	25,525	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	20,700	25,525	Redacted
HTC_TST_NGI	Number of individuals who received	20,700	25,525	Redacted

	T&C services for HIV and received their test results during the past 12 months			
HTC_TST_NGI	By Test Result: Negative	19,872	24,504	Redacted
HTC_TST_NGI	By Test Result: Positive	828	1,021	Redacted
HTC_TST_NGI	Sum of Test Result disaggregates	20,700	25,525	Redacted
HTC_TST_NGI	Age/sex: 15-19 Male	200	114	Redacted
HTC_TST_NGI	Age/sex: 20-24 Male	800	455	Redacted
HTC_TST_NGI	Age/sex: 25-49 Male	1,000	569	Redacted
HTC_TST_NGI	Age/sex: 15-19 Female	1,870	2,439	Redacted
HTC_TST_NGI	Age/sex: 20-24 Female	7,480	9,755	Redacted
HTC_TST_NGI	Age/sex: 25-49 Female	8,415	10,974	Redacted
HTC_TST_NGI	Age/sex: 50+ Female	935	1,219	Redacted
HTC_TST_NGI	Sum of Age/Sex disaggregates	20,700	25,525	Redacted
HTC_TST_NGI	Aggregated Age/sex: 15+ Male	2,000	1,138	Redacted
HTC_TST_NGI	Aggregated Age/sex: 15+ Female	18,700	24,387	Redacted
HTC_TST_NGI	Sum of Aggregated Age/Sex 15+	20,700	25,525	Redacted
HTC_TST_NGI	Sum of Aggregated Age/Sex disaggregates	20,700	25,525	Redacted
GEND_GBV_DSD	Number of people receiving post-GBV care	1,050	1,470	Redacted
GEND_GBV_DSD	Age: 10-14	400	284	Redacted
GEND_GBV_DSD	Age: 15-17	600	1,136	Redacted
GEND_GBV_DSD	Age: 18-24	25	25	Redacted
GEND_GBV_DSD	Age: 25+	25	25	Redacted
GEND_GBV_DSD	Sum of Age disaggregates	1,050	1,470	Redacted
GEND_GBV_DSD	Sex: Male	250	334	Redacted
GEND_GBV_DSD	Sex: Female	800	1,136	Redacted
GEND_GBV_DSD	Sum of Sex disaggregates	1,050	1,470	Redacted
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	200	284	Redacted
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	800	1,136	Redacted



GEND_GBVDSD	By PEP service provision (related to sexual violence services provided)	50	50	Redacted
-------------	---	----	----	----------

Implementing Mechanism Details

Mechanism ID: 13474		Mechanism Name: HIV Prevention for MARPs		
Funding Agency: HHS/CDC		Procurement Type: Cooperative Agreement		
Prime Partner Name: Hope Worldwide				
Agreement Start Date: Redacted		Agreement End Date: Redacted		
TBD: No		New Mechanism: No		
Global Fund / Multilateral Engagement: PR/SR				
G2G: No		Managing Agency:		

Total All Funding Sources: 770,300		Total Mechanism Pipeline: Redacted		
Applied Pipeline Amount: 0				
FY 2013 Burn Rate: Redacted				
Funding Source		Funding Amount		
GHP-State		770,300		

Sub Partner Name(s)

FHOK	German Foundation for World Population Consortium	Kenya AIDS NGO Consortium
------	---	---------------------------

Cross-Cutting Budget Attribution(s)

Key Populations: MSM and TG	38,550
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Implementation of core HIV prevention interventions for MSM/TG that are consistent with the current PEPFAR technical guidance
Focus Area:	Collection and use of strategic information
Focus Area:	Monitoring and evaluation of MSM/TG programs
Focus Area:	Procurement of condoms, lubricants, and other



	commodities essential to core HIV services for MSM/TG
Key Populations: FSW	729,750
Focus Area:	Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Collection and use of strategic information on SWs and clients
Focus Area:	Monitoring and evaluation of SW programs
Focus Area:	Procurement of condoms, lubricants, and other commodities essential to core HIV services for SWs
Gender: GBV	30,000
Focus Area:	GBV Prevention
Sub Area:	Implementation
Sub Area:	Monitoring and Evaluation
Focus Area:	Post GBV Care
Sub Area:	Implementation
Sub Area:	Monitoring and Evaluation
Gender: Gender Equality	60,000
Focus Area:	Changing harmful gender norms and promoting positive gender norms
Sub Area:	Implementation
Sub Area:	Monitoring and Evaluation
Focus Area:	Increase gender-equitable access to income and productive resources, including education
Sub Area:	Implementation
Sub Area:	Monitoring and Evaluation
Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Implementation
Sub Area:	Operation Research



Human Resources for Health	400,000
Food and Nutrition: Policy, Tools, and Service Delivery	10,000
Condom programming	60,000

Key Issues

TB

Family Planning

Budget Code Information

Mechanism ID: 13474			
Mechanism Name: HIV Prevention for MARPs			
Prime Partner Name: Hope Worldwide			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	25,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	45,300	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	600,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	100,000	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2014	2015	Planning
------------------	-------	------	------	----------



				Budget Targets
SITE_SUPP	Number of unique sites supported by PEPFAR	12	6	Redacted
SITE_SUPP	By program area/support type: HTC Direct Service Delivery (DSD)	12	6	Redacted
SITE_SUPP	By program area/support type: General Population Prevention Direct Service Delivery (DSD)	12		Redacted
SITE_SUPP	By program area/support type: Key Populations Prevention Direct Service Delivery (DSD)	6	6	Redacted
SITE_SUPP	By program area/support type: PHDP/Family Planning & Integration Direct Service Delivery (DSD)	5	5	Redacted
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	8,000		Redacted
PP_PREV_DSD	Total number of people in the target population	10,000		Redacted
PP_PREV_DSD	Age/sex: 20-24 Male	2,000		Redacted
PP_PREV_DSD	Age/sex: 25-49 Male	6,000		Redacted
PP_PREV_DSD	Sum of Age/Sex disaggregates	8,000		Redacted
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	12,000	14,604	Redacted
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on	11,000	13,937	Redacted



	evidence and/or meet the minimum standards required)			
KP_PREV_DSD	By key population type: Men who have sex with men/Transgender (MSM/TG) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	1,000	667	Redacted
KP_PREV_DSD	By key population type: MSM/TG who are male sex workers (subset MSM/TG) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	400	266	Redacted
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	107,100	15,122	Redacted
HTC_TST_DSD	By Test Result: Negative	102,816	14,517	Redacted
HTC_TST_DSD	By Test Result: Positive	4,284	605	Redacted
HTC_TST_DSD	Sum of Test Result disaggregates	107,100	15,122	Redacted
HTC_TST_DSD	Age/sex: <1 Male	0		Redacted
HTC_TST_DSD	Age/sex: 1-4 Male	3,749		Redacted
HTC_TST_DSD	Age/sex: 5-9 Male	1,606		Redacted
HTC_TST_DSD	Age/sex: 10-14 Male	2,677		Redacted
HTC_TST_DSD	Age/sex: 15-19 Male	5,355	76	Redacted
HTC_TST_DSD	Age/sex: 20-24 Male	13,388	304	Redacted
HTC_TST_DSD	Age/sex: 25-49 Male	21,420	380	Redacted
HTC_TST_DSD	Age/sex: 50+ Male	5,355		Redacted
HTC_TST_DSD	Age/sex: <1 Female	0		Redacted
HTC_TST_DSD	Age/sex: 1-4 Female	3,749		Redacted



HTC_TST_DSD	Age/sex: 5-9 Female	1,606		Redacted
HTC_TST_DSD	Age/sex: 10-14 Female	2,677		Redacted
HTC_TST_DSD	Age/sex: 15-19 Female	5,355	1,436	Redacted
HTC_TST_DSD	Age/sex: 20-24 Female	13,387	5,745	Redacted
HTC_TST_DSD	Age/sex: 25-49 Female	21,421	6,463	Redacted
HTC_TST_DSD	Age/sex: 50+ Female	5,355	718	Redacted
HTC_TST_DSD	Sum of Age/Sex disaggregates	107,100	15,122	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	8,032		Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	45,518	760	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	8,032		Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	45,518	14,362	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	16,064		Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	91,036	15,122	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	107,100	15,122	Redacted
HTC_TST_NGI	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	107,100	15,122	Redacted
HTC_TST_NGI	By Test Result: Negative	102,816	14,517	Redacted
HTC_TST_NGI	By Test Result: Positive	4,284	605	Redacted
HTC_TST_NGI	Sum of Test Result disaggregates	107,100	15,122	Redacted
HTC_TST_NGI	Age/sex: <1 Male	0		Redacted
HTC_TST_NGI	Age/sex: 1-4 Male	3,749		Redacted
HTC_TST_NGI	Age/sex: 5-9 Male	1,606		Redacted
HTC_TST_NGI	Age/sex: 10-14 Male	2,677		Redacted
HTC_TST_NGI	Age/sex: 15-19 Male	5,355	76	Redacted
HTC_TST_NGI	Age/sex: 20-24 Male	13,388	304	Redacted
HTC_TST_NGI	Age/sex: 25-49 Male	21,420	380	Redacted
HTC_TST_NGI	Age/sex: 50+ Male	5,355		Redacted



HTC_TST_NGI	Age/sex: <1 Female	0		Redacted
HTC_TST_NGI	Age/sex: 1-4 Female	3,749		Redacted
HTC_TST_NGI	Age/sex: 5-9 Female	1,606		Redacted
HTC_TST_NGI	Age/sex: 10-14 Female	2,677		Redacted
HTC_TST_NGI	Age/sex: 15-19 Female	5,355	1,436	Redacted
HTC_TST_NGI	Age/sex: 20-24 Female	13,387	5,745	Redacted
HTC_TST_NGI	Age/sex: 25-49 Female	21,421	6,463	Redacted
HTC_TST_NGI	Age/sex: 50+ Female	5,355	718	Redacted
HTC_TST_NGI	Sum of Age/Sex disaggregates	107,100	15,122	Redacted
HTC_TST_NGI	Aggregated Age/sex: <15 Male	8,032		Redacted
HTC_TST_NGI	Aggregated Age/sex: 15+ Male	45,518	760	Redacted
HTC_TST_NGI	Aggregated Age/sex: <15 Female	8,032		Redacted
HTC_TST_NGI	Aggregated Age/sex: 15+ Female	45,518	14,362	Redacted
HTC_TST_NGI	Sum of Aggregated Age/Sex <15	16,064		Redacted
HTC_TST_NGI	Sum of Aggregated Age/Sex 15+	91,036	15,122	Redacted
HTC_TST_NGI	Sum of Aggregated Age/Sex disaggregates	107,100	15,122	Redacted
GEND_GBV_DSD	Number of people receiving post-GBV care	85	85	Redacted
GEND_GBV_DSD	Age: 15-17	10	10	Redacted
GEND_GBV_DSD	Age: 18-24	35	35	Redacted
GEND_GBV_DSD	Age: 25+	40	40	Redacted
GEND_GBV_DSD	Sum of Age disaggregates	85	85	Redacted
GEND_GBV_DSD	Sex: Male	5	5	Redacted
GEND_GBV_DSD	Sex: Female	80	80	Redacted
GEND_GBV_DSD	Sum of Sex disaggregates	85	85	Redacted
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	40	40	Redacted
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	45	45	Redacted
GEND_GBV_DSD	By PEP service provision (related to sexual violence services provided)	45	45	Redacted



Implementing Mechanism Details

Mechanism ID: 13399	Mechanism Name: Partnership for Advanced Care and Treatment (PACT)
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: University of Maryland	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: No	
G2G: No	Managing Agency:

Total All Funding Sources: 5,903,196	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 48,500	
FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount
GHP-State	5,903,196

Sub Partner Name(s)

Dream Kenya	Futures Group	Health Strat Kenya
Liverpool VCT and Care	University of Nairobi	

Cross-Cutting Budget Attribution(s)

Human Resources for Health	908,233
Gender: GBV	125,683
Focus Area:	Post GBV Care
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Renovation	150,000
Gender: Gender Equality	125,683
Focus Area:	Equity in HIV prevention, care, treatment and



	support
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation

Key Issues

- Malaria (PMI)
- Child Survival Activities
- Safe Motherhood
- TB
- Family Planning

Budget Code Information

Mechanism ID: 13399			
Mechanism Name: Partnership for Advanced Care and Treatment (PACT)			
Prime Partner Name: University of Maryland			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	207,150	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	250,428	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	133,215	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	342,984	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Prevention	IDUP	709,590	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	1,177,572	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	2,983,160	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	99,097	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2014	2015	Planning Budget Targets
SITE_SUPP	Number of unique sites supported by PEPFAR	41	41	Redacted
SITE_SUPP	By program area/support type: HTC Direct Service Delivery (DSD)	13	13	Redacted
SITE_SUPP	By program area/support type: HTC Technical Assistance-only (TA)	29	29	Redacted
SITE_SUPP	By program area/support type: Treatment Direct Service Delivery (DSD)	16	16	Redacted
SITE_SUPP	By program area/support type: Treatment Technical Assistance-only (TA)	25	25	Redacted
SITE_SUPP	By program area/support type: Care and Support Direct Service Delivery (DSD)	16	16	Redacted
SITE_SUPP	By program area/support type: Care and Support Technical Assistance-only	25	25	Redacted



	(TA)			
SITE_SUPP	By program area/support type: Food and Nutrition Direct Service Delivery (DSD)	16	16	Redacted
SITE_SUPP	By program area/support type: Food and Nutrition Technical Assistance-only (TA)	25	25	Redacted
SITE_SUPP	By program area/support type: PMTCT Direct Service Delivery (DSD)	16	16	Redacted
SITE_SUPP	By program area/support type: PMTCT Technical Assistance-only (TA)	25	25	Redacted
SITE_SUPP	By program area/support type: TB/HIV Direct Service Delivery (DSD)	16	16	Redacted
SITE_SUPP	By program area/support type: TB/HIV Technical Assistance-only (TA)	25	25	Redacted
SITE_SUPP	By program area/support type: Key Populations Prevention Direct Service Delivery (DSD)	2	2	Redacted
SITE_SUPP	By program area/support type: Key Populations Prevention Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: OVC Direct Service Delivery (DSD)	0	0	Redacted
SITE_SUPP	By program area/support type: OVC Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: PHDP/Family Planning & Integration Direct Service Delivery (DSD)	16	16	Redacted
SITE_SUPP	By program area/support type: PHDP/Family Planning & Integration Technical Assistance-only (TA)	25	25	Redacted
SITE_SUPP	By program area/support type: Lab Direct Service Delivery (DSD)	7	7	Redacted
SITE_SUPP	By program area/support type: Lab	13	13	Redacted

	Technical Assistance-only (TA)			
PMTCT_ARV_DS D	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	1,207	1,274	Redacted
PMTCT_ARV_DS D	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	1,207	1,274	Redacted
PMTCT_ARV_DS D	Life-long ART (including Option B+)	906	955	Redacted
PMTCT_ARV_DS D	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	423	446	Redacted
PMTCT_ARV_DS D	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	483	509	Redacted
PMTCT_ARV_DS D	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)	0	0	Redacted
PMTCT_ARV_DS D	Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)	301	319	Redacted
PMTCT_ARV_DS D	Single-dose nevirapine (with or without tail)	0	0	Redacted
PMTCT_ARV_DS D	Sum of Regimen Type disaggregates	1,207	1,274	Redacted
PMTCT_ARV_DS D	Sum of New and Current disaggregates	906	955	Redacted
PMTCT_ARV_NGI	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	1,886	1,990	Redacted
PMTCT_ARV_NGI	Number of HIV- positive pregnant	1,886	1,990	Redacted

	women identified in the reporting period (including known HIV-positive at entry)			
PMTCT_ARV_NGI	Life-long ART (including Option B+)	1,416	1,492	Redacted
PMTCT_ARV_NGI	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	661	696	Redacted
PMTCT_ARV_NGI	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	755	796	Redacted
PMTCT_ARV_NGI	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)	0	0	Redacted
PMTCT_ARV_NGI	Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)	470	498	Redacted
PMTCT_ARV_NGI	Single-dose nevirapine (with or without tail)	0	0	Redacted
PMTCT_ARV_NGI	Sum of Regimen disaggregates	1,886	1,990	Redacted
PMTCT_ARV_NGI	Sum of New and Current disaggregates	1,416	1,492	Redacted
PMTCT_ARV_TA	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	679	716	Redacted
PMTCT_ARV_TA	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	679	716	Redacted
PMTCT_ARV_TA	Life-long ART (including Option B+)	510	537	Redacted
PMTCT_ARV_TA	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	238	250	Redacted
PMTCT_ARV_TA	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	272	287	Redacted

PMTCT_ARV_TA	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)	0	0	Redacted
PMTCT_ARV_TA	Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)	169	179	Redacted
PMTCT_ARV_TA	Single-dose nevirapine (with or without tail)	0	0	Redacted
PMTCT_ARV_TA	Sum of Regimen Type disaggregates	679	716	Redacted
PMTCT_ARV_TA	Sum of New and Current disaggregates	510	537	Redacted
PMTCT_SITE	Number of PEPFAR-supported sites achieving 90% ARV or ART coverage for HIV+ pregnant women	41	41	Redacted
PMTCT_SITE	Total number of PEPFAR supported sites providing PMTCT services (HTC and ARV or ART services)	41	41	Redacted
PMTCT_SITE	By site support type: Direct Service Delivery (DSD): Number of PEPFAR-supported sites achieving 90% ARV or ART coverage for HIV+ pregnant women	16	16	Redacted
PMTCT_SITE	By site support type: Technical Assistance-only (TA): Number of PEPFAR-supported sites achieving 90% ARV or ART coverage for HIV+ pregnant women	25	25	Redacted
PMTCT_SITE	Sum of Numerator Support Type disaggregates	41	41	Redacted
PMTCT_SITE	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR supported sites providing PMTCT services (HTC and ARV or ART services)	16	16	Redacted
PMTCT_SITE	By site support type: Technical Assistance-only (TA): Total number of	25	25	Redacted

	PEPFAR supported sites providing PMTCT services (HTC and ARV or ART services)			
PMTCT_SITE	Sum of Denominator Support Type disaggregates	41	41	Redacted
PMTCT_STAT_DS D	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	17,316	18,371	Redacted
PMTCT_STAT_DS D	Number of new ANC and L&D clients	17,316	18,371	Redacted
PMTCT_STAT_DS D	By: Known positives at entry	567	599	Redacted
PMTCT_STAT_DS D	By: Number of new positives identified	640	675	Redacted
PMTCT_STAT_DS D	Sum of Positives Status disaggregates	1,207	1,274	Redacted
PMTCT_STAT_NG I	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	27,056	28,704	Redacted
PMTCT_STAT_NG I	Number of new ANC and L&D clients	27,056	28,704	Redacted
PMTCT_STAT_NG I	By: Known positives at entry	886	935	Redacted
PMTCT_STAT_NG I	By: Number of new positives identified	1,000	1,055	Redacted
PMTCT_STAT_NG I	Sum of Positives Status disaggregates	1,886	1,990	Redacted
KP_MAT_DSD	Number of people who inject drugs (PWID) on medication assisted therapy (MAT) for at least 6 months	120	1,430	Redacted
KP_MAT_DSD	Sex: Male	96	1,144	Redacted
KP_MAT_DSD	Sex: Female	24	286	Redacted



KP_MAT_DSD	Sum of Sex disaggregates	120	1,430	Redacted
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	2,765	3,338	Redacted
KP_PREV_DSD	By key population type: Males who inject drugs (Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	2,212	2,670	Redacted
KP_PREV_DSD	By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	553	668	Redacted
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	40,153	99,808	Redacted
HTC_TST_DSD	By Test Result: Negative	38,547	95,816	Redacted
HTC_TST_DSD	By Test Result: Positive	1,606	3,992	Redacted
HTC_TST_DSD	Sum of Test Result disaggregates	40,153	99,808	Redacted
HTC_TST_DSD	Age/sex: <1 Male	0	0	Redacted
HTC_TST_DSD	Age/sex: 1-4 Male	1,405	3,493	Redacted
HTC_TST_DSD	Age/sex: 5-9 Male	602	1,497	Redacted
HTC_TST_DSD	Age/sex: 10-14 Male	1,004	2,495	Redacted
HTC_TST_DSD	Age/sex: 15-19 Male	2,008	4,990	Redacted
HTC_TST_DSD	Age/sex: 20-24 Male	5,019	12,476	Redacted
HTC_TST_DSD	Age/sex: 25-49 Male	8,031	19,962	Redacted



HTC_TST_DSD	Age/sex: 50+ Male	2,008	4,991	Redacted
HTC_TST_DSD	Age/sex: <1 Female	0	0	Redacted
HTC_TST_DSD	Age/sex: 1-4 Female	1,405	3,493	Redacted
HTC_TST_DSD	Age/sex: 5-9 Female	602	1,497	Redacted
HTC_TST_DSD	Age/sex: 10-14 Female	1,004	2,495	Redacted
HTC_TST_DSD	Age/sex: 15-19 Female	2,006	4,990	Redacted
HTC_TST_DSD	Age/sex: 20-24 Female	5,019	12,476	Redacted
HTC_TST_DSD	Age/sex: 25-49 Female	8,031	19,962	Redacted
HTC_TST_DSD	Age/sex: 50+ Female	2,009	4,991	Redacted
HTC_TST_DSD	Sum of Age/Sex disaggregates	40,153	99,808	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	3,011	7,485	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	17,066	42,419	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	3,011	7,485	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	17,065	42,419	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	6,022	14,970	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	34,131	84,838	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	40,153	99,808	Redacted
HTC_TST_NGI	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	45,994	114,328	Redacted
HTC_TST_NGI	By Test Result: Negative	44,154	109,755	Redacted
HTC_TST_NGI	By Test Result: Positive	1,840	4,573	Redacted
HTC_TST_NGI	Sum of Test Result disaggregates	45,994	114,328	Redacted
HTC_TST_NGI	Age/sex: <1 Male	0	0	Redacted
HTC_TST_NGI	Age/sex: 1-4 Male	1,609	4,001	Redacted
HTC_TST_NGI	Age/sex: 5-9 Male	690	1,715	Redacted
HTC_TST_NGI	Age/sex: 10-14 Male	1,149	2,858	Redacted
HTC_TST_NGI	Age/sex: 15-19 Male	2,300	5,716	Redacted



HTC_TST_NGI	Age/sex: 20-24 Male	5,749	14,291	Redacted
HTC_TST_NGI	Age/sex: 25-49 Male	9,199	22,866	Redacted
HTC_TST_NGI	Age/sex: 50+ Male	2,301	5,717	Redacted
HTC_TST_NGI	Age/sex: <1 Female	0	0	Redacted
HTC_TST_NGI	Age/sex: 1-4 Female	1,609	4,001	Redacted
HTC_TST_NGI	Age/sex: 5-9 Female	690	1,715	Redacted
HTC_TST_NGI	Age/sex: 10-14 Female	1,150	2,858	Redacted
HTC_TST_NGI	Age/sex: 15-19 Female	2,298	5,716	Redacted
HTC_TST_NGI	Age/sex: 20-24 Female	5,749	14,291	Redacted
HTC_TST_NGI	Age/sex: 25-49 Female	9,199	22,866	Redacted
HTC_TST_NGI	Age/sex: 50+ Female	2,302	5,717	Redacted
HTC_TST_NGI	Sum of Age/Sex disaggregates	45,994	114,328	Redacted
HTC_TST_NGI	Aggregated Age/sex: <15 Male	3,448	8,574	Redacted
HTC_TST_NGI	Aggregated Age/sex: 15+ Male	19,549	48,590	Redacted
HTC_TST_NGI	Aggregated Age/sex: <15 Female	3,449	8,574	Redacted
HTC_TST_NGI	Aggregated Age/sex: 15+ Female	19,548	48,590	Redacted
HTC_TST_NGI	Sum of Aggregated Age/Sex <15	6,897	17,148	Redacted
HTC_TST_NGI	Sum of Aggregated Age/Sex 15+	39,097	97,180	Redacted
HTC_TST_NGI	Sum of Aggregated Age/Sex disaggregates	45,994	114,328	Redacted
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	5,841	14,520	Redacted
HTC_TST_TA	By Test Result: Negative	5,607	13,939	Redacted
HTC_TST_TA	By Test Result: Positive	234	581	Redacted
HTC_TST_TA	Sum of Test Result disaggregates	5,841	14,520	Redacted
HTC_TST_TA	Age/sex: <1 Male	0	0	Redacted
HTC_TST_TA	Age/sex: 1-4 Male	204	508	Redacted
HTC_TST_TA	Age/sex: 5-9 Male	88	218	Redacted
HTC_TST_TA	Age/sex: 10-14 Male	145	363	Redacted
HTC_TST_TA	Age/sex: 15-19 Male	292	726	Redacted
HTC_TST_TA	Age/sex: 20-24 Male	730	1,815	Redacted

HTC_TST_TA	Age/sex: 25-49 Male	1,168	2,904	Redacted
HTC_TST_TA	Age/sex: 50+ Male	293	726	Redacted
HTC_TST_TA	Age/sex: <1 Female	0	0	Redacted
HTC_TST_TA	Age/sex: 1-4 Female	204	508	Redacted
HTC_TST_TA	Age/sex: 5-9 Female	88	218	Redacted
HTC_TST_TA	Age/sex: 10-14 Female	146	363	Redacted
HTC_TST_TA	Age/sex: 15-19 Female	292	726	Redacted
HTC_TST_TA	Age/sex: 20-24 Female	730	1,815	Redacted
HTC_TST_TA	Age/sex: 25-49 Female	1,168	2,904	Redacted
HTC_TST_TA	Age/sex: 50+ Female	293	726	Redacted
HTC_TST_TA	Sum of Age/Sex disaggregates	5,841	14,520	Redacted
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	437	1,089	Redacted
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	2,483	6,171	Redacted
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	438	1,089	Redacted
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	2,483	6,171	Redacted
HTC_TST_TA	Sum of Aggregated Age/Sex <15	875	2,178	Redacted
HTC_TST_TA	Sum of Aggregated Age/Sex 15+	4,966	12,342	Redacted
HTC_TST_TA	Sum of Aggregated Age/Sex disaggregates	5,841	14,520	Redacted
C2.1.D_DSD	Number of HIV-positive individuals receiving a minimum of one clinical service	14,646	17,597	Redacted
C2.1.D_DSD	By Age/Sex: <15 Female	659	794	Redacted
C2.1.D_DSD	By Age/Sex: <15 Male	660	794	Redacted
C2.1.D_DSD	By Age/Sex: 15+ Female	8,796	10,566	Redacted
C2.1.D_DSD	By Age/Sex: 15+ Male	4,531	5,443	Redacted
C2.1.D_DSD	Sum of Age/Sex disaggregates	14,646	17,597	Redacted
C2.1.D_DSD	By Age: <15	1,319	1,588	Redacted
C2.1.D_DSD	By Age: 15+	13,327	16,009	Redacted



C2.1.D_DSD	Sum of Age disaggregates	14,646	17,597	Redacted
C2.1.D_DSD	By Sex: Female	9,455	11,360	Redacted
C2.1.D_DSD	By Sex: Male	5,191	6,237	Redacted
C2.1.D_DSD	Sum of Sex disaggregates	14,646	17,597	Redacted
C2.1.D_NGI	Number of HIV-positive individuals receiving a minimum of one clinical service	17,230	20,703	Redacted
C2.1.D_NGI	By Age/Sex: <15 Female	775	934	Redacted
C2.1.D_NGI	By Age/Sex: <15 Male	776	934	Redacted
C2.1.D_NGI	By Age/Sex: 15+ Female	10,348	12,431	Redacted
C2.1.D_NGI	By Age/Sex: 15+ Male	5,331	6,404	Redacted
C2.1.D_NGI	Sum of Age/Sex disaggregates	17,230	20,703	Redacted
C2.1.D_NGI	By Age: <15	1,551	1,868	Redacted
C2.1.D_NGI	By Age: 15+	15,679	18,835	Redacted
C2.1.D_NGI	Sum of Age disaggregates	17,230	20,703	Redacted
C2.1.D_NGI	By Sex: Female	11,123	13,365	Redacted
C2.1.D_NGI	By Sex: Male	6,107	7,338	Redacted
C2.1.D_NGI	Sum of Sex disaggregates	17,230	20,703	Redacted
C2.1.D_TA	Number of HIV-positive individuals receiving a minimum of one clinical service	2,584	3,106	Redacted
C2.1.D_TA	By Age/Sex: <15 Female	116	140	Redacted
C2.1.D_TA	By Age/Sex: <15 Male	116	140	Redacted
C2.1.D_TA	By Age/Sex: 15+ Female	1,552	1,865	Redacted
C2.1.D_TA	By Age/Sex: 15+ Male	800	961	Redacted
C2.1.D_TA	Sum of Age/Sex disaggregates	2,584	3,106	Redacted
C2.1.D_TA	By Age: <15	232	280	Redacted
C2.1.D_TA	By Age: 15+	2,352	2,826	Redacted
C2.1.D_TA	Sum of Age disaggregates	2,584	3,106	Redacted
C2.1.D_TA	By Sex: Female	1,668	2,005	Redacted
C2.1.D_TA	By Sex: Male	916	1,101	Redacted
C2.1.D_TA	Sum of Sex disaggregates	2,584	3,106	Redacted



C2.4.D_DSD	Number of HIV-positive patients who were screened for TB in HIV care or treatment setting	13,181	16,718	Redacted
C2.4.D_DSD	Number of HIV-positive individuals receiving a minimum of one clinical service	14,646	17,597	Redacted
C2.5.D_DSD	Number of HIV-positive patients in HIV care who started TB treatment	264	334	Redacted
C2.5.D_DSD	Number of HIV-positive individuals receiving a minimum of one clinical service	14,646	17,597	Redacted
CARE_CURR_DS D	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	13,913	16,718	Redacted
CARE_CURR_DS D	Age/sex: <1 Male	22	26	Redacted
CARE_CURR_DS D	Age/sex: 1-4 Male	150	181	Redacted
CARE_CURR_DS D	Age/sex: 5-9 Male	254	306	Redacted
CARE_CURR_DS D	Age/sex: 10-14 Male	200	241	Redacted
CARE_CURR_DS D	Age/sex: 15-19 Male	107	128	Redacted
CARE_CURR_DS D	Age/sex: 20-24 Male	198	238	Redacted
CARE_CURR_DS D	Age/sex: 25-49 Male	2,973	3,571	Redacted
CARE_CURR_DS D	Age/sex: 50+ Male	1,027	1,234	Redacted
CARE_CURR_DS D	Age/sex: <1 Female	22	26	Redacted



CARE_CURR_DS D	Age/sex: 1-4 Female	143	172	Redacted
CARE_CURR_DS D	Age/sex: 5-9 Female	263	317	Redacted
CARE_CURR_DS D	Age/sex: 10-14 Female	198	239	Redacted
CARE_CURR_DS D	Age/sex: 15-19 Female	176	212	Redacted
CARE_CURR_DS D	Age/sex: 20-24 Female	732	879	Redacted
CARE_CURR_DS D	Age/sex: 25-49 Female	6,247	7,505	Redacted
CARE_CURR_DS D	Age/sex: 50+ Female	1,201	1,443	Redacted
CARE_CURR_DS D	Sun of Age/Sex disaggregates	13,913	16,718	Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	626	754	Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	4,305	5,171	Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	626	754	Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	8,356	10,039	Redacted
CARE_CURR_DS D	Sum of Aggregated Age/Sex disaggregates	13,913	16,718	Redacted
CARE_CURR_TA	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	2,455	2,950	Redacted
CARE_CURR_TA	Age/sex: <1 Male	4	5	Redacted
CARE_CURR_TA	Age/sex: 1-4 Male	27	32	Redacted
CARE_CURR_TA	Age/sex: 5-9 Male	45	54	Redacted



CARE_CURR_TA	Age/sex: 10-14 Male	35	42	Redacted
CARE_CURR_TA	Age/sex: 15-19 Male	19	23	Redacted
CARE_CURR_TA	Age/sex: 20-24 Male	35	42	Redacted
CARE_CURR_TA	Age/sex: 25-49 Male	525	630	Redacted
CARE_CURR_TA	Age/sex: 50+ Male	181	218	Redacted
CARE_CURR_TA	Age/sex: <1 Female	4	5	Redacted
CARE_CURR_TA	Age/sex: 1-4 Female	25	30	Redacted
CARE_CURR_TA	Age/sex: 5-9 Female	46	56	Redacted
CARE_CURR_TA	Age/sex: 10-14 Female	35	42	Redacted
CARE_CURR_TA	Age/sex: 15-19 Female	31	37	Redacted
CARE_CURR_TA	Age/sex: 20-24 Female	129	155	Redacted
CARE_CURR_TA	Age/sex: 25-49 Female	1,102	1,324	Redacted
CARE_CURR_TA	Age/sex: 50+ Female	212	255	Redacted
CARE_CURR_TA	Sum of Age/Sex disaggregates	2,455	2,950	Redacted
CARE_CURR_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	111	133	Redacted
CARE_CURR_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	760	913	Redacted
CARE_CURR_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	110	133	Redacted
CARE_CURR_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	1,474	1,771	Redacted
CARE_CURR_TA	Sum of Aggregated Age/Sex disaggregates	2,455	2,950	Redacted
CARE_NEW_DSD	Number of HIV-infected adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load	3,274	3,576	Redacted
CARE_NEW_DSD	Age/sex: <1 Male	5	6	Redacted
CARE_NEW_DSD	Age/sex: 1-4 Male	35	39	Redacted
CARE_NEW_DSD	Age/sex: 5-9 Male	60	65	Redacted



CARE_NEW_DSD	Age/sex: 10-14 Male	47	51	Redacted
CARE_NEW_DSD	Age/sex: 15-19 Male	49	53	Redacted
CARE_NEW_DSD	Age/sex: 20-24 Male	90	99	Redacted
CARE_NEW_DSD	Age/sex: 25-49 Male	1,358	1,483	Redacted
CARE_NEW_DSD	Age/sex: 50+ Male	469	512	Redacted
CARE_NEW_DSD	Age/sex: <1 Female	5	6	Redacted
CARE_NEW_DSD	Age/sex: 1-4 Female	34	37	Redacted
CARE_NEW_DSD	Age/sex: 5-9 Female	62	68	Redacted
CARE_NEW_DSD	Age/sex: 10-14 Female	47	51	Redacted
CARE_NEW_DSD	Age/sex: 15-19 Female	21	23	Redacted
CARE_NEW_DSD	Age/sex: 20-24 Female	89	97	Redacted
CARE_NEW_DSD	Age/sex: 25-49 Female	757	827	Redacted
CARE_NEW_DSD	Age/sex: 50+ Female	146	159	Redacted
CARE_NEW_DSD	Sum of Age/sex disaggregates	3,274	3,576	Redacted
CARE_NEW_DSD	Aggregated Age/sex: <15 Male	147	161	Redacted
CARE_NEW_DSD	Aggregated Age/sex: 15+ Male	1,966	2,147	Redacted
CARE_NEW_DSD	Aggregated Age/sex: <15 Female	148	162	Redacted
CARE_NEW_DSD	Aggregated Age/sex: 15+ Female	1,013	1,106	Redacted
CARE_NEW_DSD	Sum of Aggregated Age/sex disaggregates	3,274	3,576	Redacted
CARE_SITE	Number of PEPFAR-supported HIV clinical care sites at which at least 80% of PLHIV received all of the following during the reporting period: 1) clinical assessment (WHO staging) OR CD4 count OR viral load, AND 2) TB screening at last visit, AND 3) if eligible, cotrimoxazole	41	41	Redacted
CARE_SITE	Total number of PEPFAR supported sites providing clinical care services	41	41	Redacted
CARE_SITE	By site support type: Direct Service Delivery (DSD): Number of PEPFAR-supported HIV clinical care	16	16	Redacted



	sites at which at least 80% of PLHIV received all of the following during the reporting period: 1) clinical assessment (WHO staging) OR CD4 count OR viral load, AND 2) TB screening at last visit, AND 3) if eligible, cotrimoxazole			
CARE_SITE	By site support type: Technical Assistance-only (TA): Number of PEPFAR-supported HIV clinical care sites at which at least 80% of PLHIV received all of the following during the reporting period: 1) clinical assessment (WHO staging) OR CD4 count OR viral load, AND 2) TB screening at last visit, AND 3) if eligible, cotrimoxazole	25	25	Redacted
CARE_SITE	Sum of Numerator Site Support Type disaggregates	41	41	Redacted
CARE_SITE	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR supported sites providing clinical care services	16	16	Redacted
CARE_SITE	By site support type: Technical Assistance-only (TA): Total number of PEPFAR supported sites providing clinical care services	25	25	Redacted
CARE_SITE	Sum of Denominator Site Support Type disaggregates	41	41	Redacted
FN_SITE	Number of PEPFAR-supported sites achieving 90% nutrition assessments that result in accurate categorization of malnutrition	37	37	Redacted
FN_SITE	Total number of PEPFAR-supported sites providing nutrition assessment, counseling and support (NACS) services	41	41	Redacted



FN_SITE	By site support type: Direct Service Delivery (DSD): Number of PEPFAR-supported sites achieving 90% nutrition assessments that result in accurate categorization of malnutrition	14	14	Redacted
FN_SITE	By site support type: Technical Assistance-only (TA): Number of PEPFAR-supported sites achieving 90% nutrition assessments that result in accurate categorization of malnutrition	23	23	Redacted
FN_SITE	Sum of Numerator Support Type disaggregates	37	37	Redacted
FN_SITE	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported sites providing nutrition assessment, counseling and support (NACS) services	16	16	Redacted
FN_SITE	By site support type: Technical Assistance-only (TA): Total number of PEPFAR-supported sites providing nutrition assessment, counseling and support (NACS) services	25	25	Redacted
FN_SITE	Sum of Denominator Support Type disaggregates	41	41	Redacted
FN_THER_DSD	Number of clinically malnourished PLHIV who received therapeutic and/or supplementary food during the reporting period.	2,584	3,106	Redacted
FN_THER_DSD	Number of PLHIV who were nutritionally assessed and found to be clinically undernourished.	3,446	4,141	Redacted
FN_THER_DSD	Age: <1	8	10	Redacted
FN_THER_DSD	Age: 1-4	56	67	Redacted

FN_THER_DSD	Age: 5-14	174	209	Redacted
FN_THER_DSD	Age: 15-17	52	64	Redacted
FN_THER_DSD	Age: 18+	2,294	2,756	Redacted
FN_THER_DSD	Sum of Age disaggregates	2,584	3,106	Redacted
FN_THER_DSD	Aggregated Age: <18	290	350	Redacted
FN_THER_DSD	Aggregated Age: 18+	2,294	2,756	Redacted
FN_THER_DSD	Sum of Aggregated Age disaggregates	2,584	3,106	Redacted
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	560	752	Redacted
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	659	836	Redacted
TB_ART_DSD	Age: 0-4	14	19	Redacted
TB_ART_DSD	Age: 5-14	38	50	Redacted
TB_ART_DSD	Age: 15+	508	683	Redacted
TB_ART_DSD	Male	302	406	Redacted
TB_ART_DSD	Female	258	346	Redacted
TB_ART_DSD	Sum of Sex disaggregates	560	752	Redacted
TB_ART_DSD	Newly tested	336	451	Redacted
TB_ART_DSD	Known HIV-positive	224	301	Redacted
TB_ART_DSD	Sum of Test Status disaggregates	560	752	Redacted
TB_ART_DSD	Aggregated Age: <15	52	69	Redacted
TB_ART_DSD	Aggregated Age: 15+	508	683	Redacted
TB_ART_DSD	Sum of Aggregated Age disaggregates	560	752	Redacted
TB_ARTSITE	The number of PEPFAR-supported TB basic management units at which 80% of registered TB cases who are HIV-positive are on ART, during the reporting period	41	41	Redacted



TB_ARTSITE	The number of PEPFAR-supported TB basic management units	41	41	Redacted
TB_ARTSITE	By site support type: Direct Service Delivery (DSD): The number of PEPFAR-supported TB basic management units at which 80% of registered TB cases who are HIV-positive are on ART, during the reporting period	16	16	Redacted
TB_ARTSITE	By site support type: Technical Assistance-only (TA): The number of PEPFAR-supported TB basic management units at which 80% of registered TB cases who are HIV-positive are on ART, during the reporting period	25	25	Redacted
TB_ARTSITE	Sum of Numerator Site Support Type disaggregates	41	41	Redacted
TB_ARTSITE	By site support type: Direct Service Delivery (DSD): The number of PEPFAR-supported TB basic management units	16	16	Redacted
TB_ARTSITE	By site support type: Technical Assistance-only (TA): The number of PEPFAR-supported TB basic management units	25	25	Redacted
TB_ARTSITE	Sum of Denominator Site Support Type disaggregates	41	41	Redacted
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	1,509	1,592	Redacted
PMTCT_EID_DSD	Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT)	1,886	1,990	Redacted



PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	1,132	1,194	Redacted
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	377	398	Redacted
PMTCT_EID_DSD	Sum of Infant Age disaggregates	1,509	1,592	Redacted
PMTCT_EID_DSD	By infants with a positive virologic test result within 12 months of birth	75	80	Redacted
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	11,179	12,706	Redacted
TX_CURR_DSD	Age/Sex: <1 Male	17	20	Redacted
TX_CURR_DSD	Age/Sex: 1-4 Male	118	134	Redacted
TX_CURR_DSD	Age/Sex: 5-14 Male	368	419	Redacted
TX_CURR_DSD	Age/Sex: 15+ Male	3,459	4,046	Redacted
TX_CURR_DSD	Age/Sex: <1 Female	17	20	Redacted
TX_CURR_DSD	Age/Sex: 1-4 Female	118	134	Redacted
TX_CURR_DSD	Age/Sex: 5-14 Female	368	419	Redacted
TX_CURR_DSD	Age/Sex: 15+ Female	6,714	7,514	Redacted
TX_CURR_DSD	Sum of age/sex disaggregates	1,006	1,146	Redacted
TX_CURR_DSD	Percent children with advanced HIV infection receiving antiretroviral therapy (ART) [CURRENT]	76	72	Redacted
TX_CURR_DSD	Percent women and girls with advanced HIV infection receiving antiretroviral therapy (ART) [CURRENT]	76	71	Redacted
TX_CURR_DSD	Aggregated Age/Sex: <1 Male	17	20	Redacted
TX_CURR_DSD	Aggregated Age/Sex: <1 Female	17	20	Redacted
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	503	573	Redacted
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	3,459	4,046	Redacted
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	503	573	Redacted
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	6,714	7,514	Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	1,006	1,146	Redacted



TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	10,173	11,560	Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	11,179	12,706	Redacted
TX_CURR_NGI	Number of adults and children receiving antiretroviral therapy (ART)	13,152	14,948	Redacted
TX_CURR_NGI	Age/Sex: <1 Male	20	23	Redacted
TX_CURR_NGI	Age/Sex: 1-4 Male	139	158	Redacted
TX_CURR_NGI	Age/Sex: 5-14 Male	433	493	Redacted
TX_CURR_NGI	Age/Sex: 15+ Male	4,069	4,760	Redacted
TX_CURR_NGI	Age/Sex: <1 Female	20	23	Redacted
TX_CURR_NGI	Age/Sex: 1-4 Female	139	158	Redacted
TX_CURR_NGI	Age/Sex: 5-14 Female	433	493	Redacted
TX_CURR_NGI	Age/Sex: 15+ Female	7,899	8,840	Redacted
TX_CURR_NGI	Sum of Age/Sex disaggregates	13,152	14,948	Redacted
TX_CURR_NGI	Aggregated Age/Sex: <1 Male	20	23	Redacted
TX_CURR_NGI	Aggregated Age/Sex: <1 Female	20	23	Redacted
TX_CURR_NGI	Aggregated Age/Sex: <15 Male	592	674	Redacted
TX_CURR_NGI	Aggregated Age/Sex: 15+ Male	4,069	4,760	Redacted
TX_CURR_NGI	Aggregated Age/Sex: <15 Female	592	674	Redacted
TX_CURR_NGI	Aggregated Age/Sex: 15+ Female	7,899	8,840	Redacted
TX_CURR_NGI	Sum of Aggregated Age/Sex disaggregates	13,152	14,948	Redacted
TX_CURR_NGI	Sum of Aggregated Age/Sex <15	1,184	1,348	Redacted
TX_CURR_NGI	Sum of Aggregated Age/Sex 15+	11,968	13,600	Redacted
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	1,973	2,242	Redacted
TX_CURR_TA	Age/Sex: <1 Male	3	3	Redacted
TX_CURR_TA	Age/Sex: 1-4 Male	21	24	Redacted
TX_CURR_TA	Age/Sex: 5-14 Male	65	74	Redacted
TX_CURR_TA	Age/Sex: 15+ Male	610	714	Redacted
TX_CURR_TA	Age/Sex: <1 Female	3	3	Redacted
TX_CURR_TA	Age/Sex: 1-4 Female	21	24	Redacted



TX_CURR_TA	Age/Sex: 5-14 Female	65	74	Redacted
TX_CURR_TA	Age/Sex: 15+ Female	1,185	1,326	Redacted
TX_CURR_TA	Sum of Age/Sex disaggregations	178	202	Redacted
TX_CURR_TA	Aggregated Age/Sex: <1 Male	3	3	Redacted
TX_CURR_TA	Aggregated Age/Sex: <1 Female	3	3	Redacted
TX_CURR_TA	Aggregated Age/Sex: <15 Male	89	101	Redacted
TX_CURR_TA	Aggregated Age/Sex: 15+ Male	610	714	Redacted
TX_CURR_TA	Aggregated Age/Sex: <15 Female	89	101	Redacted
TX_CURR_TA	Aggregated Age/Sex: 15+ Female	1,185	1,326	Redacted
TX_CURR_TA	Sum of Aggregated Age/Sex <15	178	202	Redacted
TX_CURR_TA	Sum of Aggregated Age/Sex 15+	1,795	2,040	Redacted
TX_CURR_TA	Sum of Aggregated Age/Sex disaggregates	1,973	2,242	Redacted
TX_DIST	Number of Districts with documented routine supportive supervision visits to 75% of HIV care and treatment sites supported by the District	1	1	Redacted
TX_DIST	Total number of PEPFAR supported District Health Offices	1	1	Redacted
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	3,675	3,798	Redacted
TX_NEW_DSD	By Age/Sex: <1 Male	57	80	Redacted
TX_NEW_DSD	By Age/Sex: 1-4 Male	32	45	Redacted
TX_NEW_DSD	By Age/Sex: 5-9 Male	57	80	Redacted
TX_NEW_DSD	By Age/Sex: 10-14 Male	44	62	Redacted
TX_NEW_DSD	By Age/Sex: 15-19 Male	29	28	Redacted
TX_NEW_DSD	By Age/Sex: 20-24 Male	53	52	Redacted
TX_NEW_DSD	By Age/Sex: 25-49 Male	797	789	Redacted
TX_NEW_DSD	By Age/Sex: 50+ Male	274	273	Redacted
TX_NEW_DSD	By Age/Sex: <1 Female	57	80	Redacted
TX_NEW_DSD	By Age/Sex: 1-4 Female	32	45	Redacted
TX_NEW_DSD	By Age/Sex: 5-9 Female	57	80	Redacted
TX_NEW_DSD	By Age/Sex: 10-14 Female	44	63	Redacted

TX_NEW_DSD	By Age/Sex: 15-19 Female	45	45	Redacted
TX_NEW_DSD	By Age/Sex: 20-24 Female	188	186	Redacted
TX_NEW_DSD	By Age/Sex: 25-49 Female	1,601	1,585	Redacted
TX_NEW_DSD	By Age/Sex: 50+ Female	308	305	Redacted
TX_NEW_DSD	Sum of Age/Sex disaggregates	3,675	3,798	Redacted
TX_NEW_DSD	Aggregated Grouping by Age: <1 Male	57	80	Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	190	267	Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	1,153	1,142	Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <1 Female	57	80	Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	190	268	Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	2,142	2,121	Redacted
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	3,675	3,798	Redacted
TX_NEW_DSD	Pregnancy status	594	627	Redacted
TX_NEW_DSD	Breastfeeding status	66	70	Redacted
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	2,059	3,124	Redacted
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	2,422	3,675	Redacted
TX_RET_DSD	Age: 0-4 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	51	77	Redacted
TX_RET_DSD	Age: 5-14 (Numerator: Number of	139	211	Redacted



	adults and children who are still alive and on treatment at 12 months after initiating ART)			
TX_RET_DSD	Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,869	2,836	Redacted
TX_RET_DSD	Age: 0-4 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	60	91	Redacted
TX_RET_DSD	Age: 5-14 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	163	248	Redacted
TX_RET_DSD	Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	2,199	3,336	Redacted
TX_RET_DSD	Aggregated Age: <15 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	190	288	Redacted
TX_RET_DSD	Aggregated Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,869	2,836	Redacted

TX_RET_DSD	Aggregated Age: <15 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	223	339	Redacted
TX_RET_DSD	Aggregated Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	2,199	3,336	Redacted
TX_RET_DSD	Pregnancy and breastfeeding status (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	601	1,202	Redacted
TX_RET_DSD	Pregnancy and breastfeeding status (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	707	1,415	Redacted
TX_SITE	Number of PEPFAR-supported ART sites with a retention rate of 75% or greater for patients 12 months after ART initiation	29	29	Redacted
TX_SITE	Total number of PEPFAR-supported ART sites	41	41	Redacted
TX_SITE	By support type: Direct Service Delivery (DSD): Number of PEPFAR-supported ART sites with a retention rate of 75% or greater for patients 12 months after	11	11	Redacted

	ART initiation			
TX_SITE	By support type: Technical Assistance (TA-only): Number of PEPFAR-supported ART sites with a retention rate of 75% or greater for patients 12 months after ART initiation	18	18	Redacted
TX_SITE	Sum of Numerator Site Support Type disaggregates	29	29	Redacted
TX_SITE	By support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported ART sites	16	16	Redacted
TX_SITE	By support type: Technical Assistance (TA-only): Total number of PEPFAR-supported ART sites	25	25	Redacted
TX_SITE	Sum of Denominator Site Support Type disaggregates	41	41	Redacted
LAB_CAP_DSD	Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests	20	20	Redacted
LAB_CAP_DSD	By site support type: Direct Service Delivery (DSD)	7	7	Redacted
LAB_CAP_DSD	By site support type: Technical Assistance-only (TA)	13	13	Redacted
LAB_CAP_DSD	Sum of Site Support Type disaggregates	20	20	Redacted
FPINT_SITE_DSD	Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	31	31	Redacted
FPINT_SITE_DSD	Total number of PEPFAR-supported HIV service delivery points: PMTCT, Care and Treatment	41	41	Redacted
FPINT_SITE_DSD	By site support type: Direct Service Delivery (DSD): Number of service delivery points supported by PEPFAR	12	12	Redacted



	for HIV services that are directly providing integrated voluntary family planning services			
FPINT_SITE_DSD	By site support type: Technical Assistance-only (TA): Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	19	19	Redacted
FPINT_SITE_DSD	Sum of Numerator Site Support Type disaggregates	31	31	Redacted
FPINT_SITE_DSD	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported HIV service delivery points	16	16	Redacted
FPINT_SITE_DSD	By site support type: Technical Assistance-only (TA): Total number of PEPFAR-supported HIV service delivery points	25	25	Redacted
FPINT_SITE_DSD	Sum of Denominator Site Support Type disaggregates	41	41	Redacted
FPINT_SITE_DSD	Service delivery type: Clinical	31	31	Redacted
FPINT_SITE_DSD	Sum of Service Delivery Type disaggregates	31	31	Redacted
QI_SITE	Number of PEPFAR-supported clinical service sites with a quality improvement activity completed that addresses clinical HIV programs and has documented process results in the last 6 months	33	33	Redacted
QI_SITE	Total number of PEPFAR-supported sites for any HIV clinical service including HIV Care, HIV Treatment, TB care, PMTCT, VMMC, and HTC	41	41	Redacted
QI_SITE	By site support type: Direct Service	13	13	Redacted



	Delivery (DSD): Number of PEPFAR-supported clinical service sites with a quality improvement activity completed that addresses clinical HIV programs and has documented results in the last 6 months			
QI_SITE	By site support type: Technical Assistance-only (TA): Number of PEPFAR-supported clinical service sites with a quality improvement activity completed that addresses clinical HIV programs and has documented results in the last 6 months	20	20	Redacted
QI_SITE	Sum of Numerator Site Support Type disaggregates	33	33	Redacted
QI_SITE	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported sites for any HIV clinical service including HIV Care, HIV Treatment, TB care, PMTCT, VMMC, HTC	16	16	Redacted
QI_SITE	By site support type: Technical Assistance-only (TA): Total number of PEPFAR-supported sites for any HIV clinical service including HIV Care, HIV Treatment, TB care, PMTCT, VMMC, and HTC	25	25	Redacted
QI_SITE	Sum of Denominator Site Support Type disaggregates	41	41	Redacted
TB_SCREEN_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period	12,522	15,882	Redacted
TB_SCREEN_DSD	Number of HIV positive adults and children who received at least one of the following during the reporting	13,913	16,718	Redacted



	period: clinical assessment (WHO staging) OR CD4 count OR viral load			
TB_SCREEN_DSD	Age: <1	40	51	Redacted
TB_SCREEN_DSD	Age: 1-4	270	343	Redacted
TB_SCREEN_DSD	Age: 5-9	477	605	Redacted
TB_SCREEN_DSD	Age: 10-14	367	465	Redacted
TB_SCREEN_DSD	Age: 15-19	253	321	Redacted
TB_SCREEN_DSD	Age: 20-24	844	1,071	Redacted
TB_SCREEN_DSD	Age: 25-49	8,292	10,517	Redacted
TB_SCREEN_DSD	Age: 50+	1,979	2,509	Redacted
TB_SCREEN_DSD	Sum of Age disaggregates	1,407	1,785	Redacted
TB_SCREEN_DSD	Aggregated Age - USE WITH HQ PERMISSION ONLY: <15	1,154	1,464	Redacted
TB_SCREEN_DSD	Aggregated Age - USE WITH HQ PERMISSION ONLY: 15+	11,368	14,418	Redacted
TB_SCREEN_DSD	Sum of Aggregated Age disaggregates	12,522	15,882	Redacted
TB_SCREEN_DSD	Sex: Male	4,442	5,634	Redacted
TB_SCREEN_DSD	Sex: Female	8,080	10,248	Redacted
TB_SCREEN_DSD	Sum of Sex disaggregates	12,522	15,882	Redacted

Implementing Mechanism Details

Mechanism ID: 13385	Mechanism Name: Prevention for MARPS
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: University of Manitoba	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: No	
G2G: No	Managing Agency:

Total All Funding Sources: 3,896,229	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 0	
FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount



GHP-State	3,896,229
-----------	-----------

Sub Partner Name(s)

Kenya Pediatric Association (KPA)	University of Nairobi	
-----------------------------------	-----------------------	--

Cross-Cutting Budget Attribution(s)

Human Resources for Health	500,000
Key Populations: MSM and TG	300,000
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Implementation of core HIV prevention interventions for MSM/TG that are consistent with the current PEPFAR technical guidance
Focus Area:	Collection and use of strategic information
Focus Area:	Conducting epidemiologic, social science, and operational research among MSM/TG and their sex partners
Focus Area:	Monitoring and evaluation of MSM/TG programs
Focus Area:	Procurement of condoms, lubricants, and other commodities essential to core HIV services for MSM/TG
Key Populations: FSW	2,100,000
Focus Area:	Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Collection and use of strategic information on SWs and clients
Focus Area:	Conducting epidemiologic, social science, and operational research among SWs, their partners, and clients



Focus Area:	Monitoring and evaluation of SW programs
Focus Area:	Procurement of condoms, lubricants, and other commodities essential to core HIV services for SWs
Gender: GBV	100,000
Focus Area:	GBV Prevention
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Focus Area:	Post GBV Care
Sub Area:	Implementation
Sub Area:	Capacity building
Gender: Gender Equality	178,100
Focus Area:	Changing harmful gender norms and promoting positive gender norms
Sub Area:	Implementation
Sub Area:	Capacity building
Focus Area:	Promoting gender-related policies and laws that increase legal protection
Focus Area:	Increase gender-equitable access to income and productive resources, including education
Sub Area:	Implementation
Focus Area:	Equity in HIV prevention, care, treatment and support
Renovation	150,000
Condom programming	178,100

Key Issues

TB

Family Planning

Custom



Budget Code Information

Mechanism ID: 13385			
Mechanism Name: Prevention for MARPS			
Prime Partner Name: University of Manitoba			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	130,329	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	83,476	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	39,964	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	155,901	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	1,781,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	IDUP	654,110	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	12,355	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	925,344	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	113,750	0



Implementing Mechanism Indicator Information

Indicator Number	Label	2014	2015	Planning Budget Targets
SITE_SUPP	Number of unique sites supported by PEPFAR	10	10	Redacted
SITE_SUPP	By program area/support type: HTC Direct Service Delivery (DSD)	10	10	Redacted
SITE_SUPP	By program area/support type: Treatment Direct Service Delivery (DSD)	10	10	Redacted
SITE_SUPP	By program area/support type: Care and Support Direct Service Delivery (DSD)	10	10	Redacted
SITE_SUPP	By program area/support type: Food and Nutrition Direct Service Delivery (DSD)	10	10	Redacted
SITE_SUPP	By program area/support type: PMTCT Direct Service Delivery (DSD)	10	10	Redacted
SITE_SUPP	By program area/support type: TB/HIV Direct Service Delivery (DSD)	10	10	Redacted
SITE_SUPP	By program area/support type: Key Populations Prevention Direct Service Delivery (DSD)	10	10	Redacted
SITE_SUPP	By program area/support type: PHDP/Family Planning & Integration Direct Service Delivery (DSD)	10	10	Redacted
SITE_SUPP	By program area/support type: Lab Direct Service Delivery (DSD)	1	1	Redacted
PMTCT_ARV_DS D	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT)	290	295	Redacted



	during pregnancy and delivery			
PMTCT_ARV_DS D	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	290	295	Redacted
PMTCT_ARV_DS D	Life-long ART (including Option B+)	218	221	Redacted
PMTCT_ARV_DS D	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	102	103	Redacted
PMTCT_ARV_DS D	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	116	118	Redacted
PMTCT_ARV_DS D	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)	0	0	Redacted
PMTCT_ARV_DS D	Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)	72	74	Redacted
PMTCT_ARV_DS D	Single-dose nevirapine (with or without tail)	0	0	Redacted
PMTCT_ARV_DS D	Sum of Regimen Type disaggregates	290	295	Redacted
PMTCT_ARV_DS D	Sum of New and Current disaggregates	218	221	Redacted
PMTCT_ARV_NGI	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	290	295	Redacted
PMTCT_ARV_NGI	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	290	295	Redacted
PMTCT_ARV_NGI	Life-long ART (including Option B+)	218	221	Redacted
PMTCT_ARV_NGI	Sub-Disag of Life-long ART: Newly initiated on treatment during the current	102	103	Redacted



	pregnancy			
PMTCT_ARV_NGI	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	116	118	Redacted
PMTCT_ARV_NGI	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)	0	0	Redacted
PMTCT_ARV_NGI	Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)	72	74	Redacted
PMTCT_ARV_NGI	Single-dose nevirapine (with or without tail)	0	0	Redacted
PMTCT_ARV_NGI	Sum of Regimen disaggregates	290	295	Redacted
PMTCT_ARV_NGI	Sum of New and Current disaggregates	218	221	Redacted
PMTCT_SITE	Number of PEPFAR-supported sites achieving 90% ARV or ART coverage for HIV+ pregnant women	10	10	Redacted
PMTCT_SITE	Total number of PEPFAR supported sites providing PMTCT services (HTC and ARV or ART services)	10	10	Redacted
PMTCT_SITE	By site support type: Direct Service Delivery (DSD): Number of PEPFAR-supported sites achieving 90% ARV or ART coverage for HIV+ pregnant women	10	10	Redacted
PMTCT_SITE	By site support type: Technical Assistance-only (TA): Number of PEPFAR-supported sites achieving 90% ARV or ART coverage for HIV+ pregnant women	0	0	Redacted
PMTCT_SITE	Sum of Numerator Support Type disaggregates	10	10	Redacted
PMTCT_SITE	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR supported sites providing	10	10	Redacted



	PMTCT services (HTC and ARV or ART services)			
PMTCT_SITE	By site support type: Technical Assistance-only (TA): Total number of PEPFAR supported sites providing PMTCT services (HTC and ARV or ART services)	0	0	Redacted
PMTCT_SITE	Sum of Denominator Support Type disaggregates	10	10	Redacted
PMTCT_STAT_DS D	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	1,222	1,283	Redacted
PMTCT_STAT_DS D	Number of new ANC and L&D clients	1,222	1,283	Redacted
PMTCT_STAT_DS D	By: Known positives at entry	136	139	Redacted
PMTCT_STAT_DS D	By: Number of new positives identified	154	156	Redacted
PMTCT_STAT_DS D	Sum of Positives Status disaggregates	290	295	Redacted
PMTCT_STAT_NG I	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	1,222	1,283	Redacted
PMTCT_STAT_NG I	Number of new ANC and L&D clients	1,222	1,283	Redacted
PMTCT_STAT_NG I	By: Known positives at entry	136	139	Redacted
PMTCT_STAT_NG I	By: Number of new positives identified	154	156	Redacted
PMTCT_STAT_NG I	Sum of Positives Status disaggregates	290	295	Redacted
KP_PREV_DSD	Number of key populations reached with individual and/or small group level	19,618	43,162	Redacted

	HIV preventive interventions that are based on evidence and/or meet the minimum standards required			
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	16,888	40,221	Redacted
KP_PREV_DSD	By key population type: Males who inject drugs (Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	1,044	1,144	Redacted
KP_PREV_DSD	By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	286	286	Redacted
KP_PREV_DSD	By key population type: Men who have sex with men/Transgender (MSM/TG) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	1,400	1,511	Redacted
KP_PREV_DSD	By key population type: MSM/TG who are male sex workers (subset MSM/TG) (Numerator: Number of key	560	604	Redacted



	populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)			
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	25,000	51,901	Redacted
HTC_TST_DSD	By Test Result: Negative	24,000	49,825	Redacted
HTC_TST_DSD	By Test Result: Positive	1,000	2,076	Redacted
HTC_TST_DSD	Sum of Test Result disaggregates	25,000	51,901	Redacted
HTC_TST_DSD	Age/sex: <1 Male	0	0	Redacted
HTC_TST_DSD	Age/sex: 1-4 Male	0	0	Redacted
HTC_TST_DSD	Age/sex: 5-9 Male	0	0	Redacted
HTC_TST_DSD	Age/sex: 10-14 Male	0	0	Redacted
HTC_TST_DSD	Age/sex: 15-19 Male	50	102	Redacted
HTC_TST_DSD	Age/sex: 20-24 Male	825	1,682	Redacted
HTC_TST_DSD	Age/sex: 25-49 Male	1,500	3,971	Redacted
HTC_TST_DSD	Age/sex: 50+ Male	125	255	Redacted
HTC_TST_DSD	Age/sex: <1 Female	0	0	Redacted
HTC_TST_DSD	Age/sex: 1-4 Female	0	0	Redacted
HTC_TST_DSD	Age/sex: 5-9 Female	0	0	Redacted
HTC_TST_DSD	Age/sex: 10-14 Female	0	0	Redacted
HTC_TST_DSD	Age/sex: 15-19 Female	450	918	Redacted
HTC_TST_DSD	Age/sex: 20-24 Female	4,500	9,178	Redacted
HTC_TST_DSD	Age/sex: 25-49 Female	13,500	27,535	Redacted
HTC_TST_DSD	Age/sex: 50+ Female	4,050	8,260	Redacted
HTC_TST_DSD	Sum of Age/Sex disaggregates	25,000	51,901	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	0	0	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	2,500	6,010	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ	0	0	Redacted



	PERMISSION ONLY: <15 Female			
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	22,500	45,891	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	0	0	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	25,000	51,901	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	25,000	51,901	Redacted
HTC_TST_NGI	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	25,000	51,901	Redacted
HTC_TST_NGI	By Test Result: Negative	24,000	49,825	Redacted
HTC_TST_NGI	By Test Result: Positive	1,000	2,076	Redacted
HTC_TST_NGI	Sum of Test Result disaggregates	25,000	51,901	Redacted
HTC_TST_NGI	Age/sex: <1 Male	0	0	Redacted
HTC_TST_NGI	Age/sex: 1-4 Male	0	0	Redacted
HTC_TST_NGI	Age/sex: 5-9 Male	0	0	Redacted
HTC_TST_NGI	Age/sex: 10-14 Male	0	0	Redacted
HTC_TST_NGI	Age/sex: 15-19 Male	50	102	Redacted
HTC_TST_NGI	Age/sex: 20-24 Male	825	1,682	Redacted
HTC_TST_NGI	Age/sex: 25-49 Male	1,500	3,971	Redacted
HTC_TST_NGI	Age/sex: 50+ Male	125	255	Redacted
HTC_TST_NGI	Age/sex: <1 Female	0	0	Redacted
HTC_TST_NGI	Age/sex: 1-4 Female	0	0	Redacted
HTC_TST_NGI	Age/sex: 5-9 Female	0	0	Redacted
HTC_TST_NGI	Age/sex: 10-14 Female	0	0	Redacted
HTC_TST_NGI	Age/sex: 15-19 Female	450	918	Redacted
HTC_TST_NGI	Age/sex: 20-24 Female	4,500	9,178	Redacted
HTC_TST_NGI	Age/sex: 25-49 Female	13,500	27,535	Redacted
HTC_TST_NGI	Age/sex: 50+ Female	4,050	8,260	Redacted
HTC_TST_NGI	Sum of Age/Sex disaggregates	25,000	51,901	Redacted
HTC_TST_NGI	Aggregated Age/sex: <15 Male	0	0	Redacted
HTC_TST_NGI	Aggregated Age/sex: 15+ Male	2,500	6,010	Redacted



HTC_TST_NGI	Aggregated Age/sex: <15 Female	0	0	Redacted
HTC_TST_NGI	Aggregated Age/sex: 15+ Female	22,500	45,891	Redacted
HTC_TST_NGI	Sum of Aggregated Age/Sex <15	0	0	Redacted
HTC_TST_NGI	Sum of Aggregated Age/Sex 15+	25,000	51,901	Redacted
HTC_TST_NGI	Sum of Aggregated Age/Sex disaggregates	25,000	51,901	Redacted
GEND_GBV_DSD	Number of people receiving post-GBV care	50	50	Redacted
GEND_GBV_DSD	Age: 18-24	20	20	Redacted
GEND_GBV_DSD	Age: 25+	30	30	Redacted
GEND_GBV_DSD	Sum of Age disaggregates	50	50	Redacted
GEND_GBV_DSD	Sex: Male	5	5	Redacted
GEND_GBV_DSD	Sex: Female	45	45	Redacted
GEND_GBV_DSD	Sum of Sex disaggregates	50	50	Redacted
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	50	50	Redacted
GEND_GBV_DSD	By PEP service provision (related to sexual violence services provided)	50	50	Redacted
C2.1.D_DSD	Number of HIV-positive individuals receiving a minimum of one clinical service	11,737	12,830	Redacted
C2.1.D_DSD	By Age/Sex: <15 Female	528	579	Redacted
C2.1.D_DSD	By Age/Sex: <15 Male	528	578	Redacted
C2.1.D_DSD	By Age/Sex: 15+ Female	7,049	7,704	Redacted
C2.1.D_DSD	By Age/Sex: 15+ Male	3,632	3,969	Redacted
C2.1.D_DSD	Sum of Age/Sex disaggregates	11,737	12,830	Redacted
C2.1.D_DSD	By Age: <15	1,056	1,157	Redacted
C2.1.D_DSD	By Age: 15+	10,681	11,673	Redacted
C2.1.D_DSD	Sum of Age disaggregates	11,737	12,830	Redacted
C2.1.D_DSD	By Sex: Female	7,577	8,283	Redacted
C2.1.D_DSD	By Sex: Male	4,160	4,547	Redacted
C2.1.D_DSD	Sum of Sex disaggregates	11,737	12,830	Redacted
C2.1.D_NGI	Number of HIV-positive individuals	11,737	12,830	Redacted



	receiving a minimum of one clinical service			
C2.1.D_NGI	By Age/Sex: <15 Female	528	579	Redacted
C2.1.D_NGI	By Age/Sex: <15 Male	528	578	Redacted
C2.1.D_NGI	By Age/Sex: 15+ Female	7,049	7,704	Redacted
C2.1.D_NGI	By Age/Sex: 15+ Male	3,632	3,969	Redacted
C2.1.D_NGI	Sum of Age/Sex disaggregates	11,737	12,830	Redacted
C2.1.D_NGI	By Age: <15	1,056	1,157	Redacted
C2.1.D_NGI	By Age: 15+	10,681	11,673	Redacted
C2.1.D_NGI	Sum of Age disaggregates	11,737	12,830	Redacted
C2.1.D_NGI	By Sex: Female	7,577	8,283	Redacted
C2.1.D_NGI	By Sex: Male	4,160	4,547	Redacted
C2.1.D_NGI	Sum of Sex disaggregates	11,737	12,830	Redacted
C2.4.D_DSD	Number of HIV-positive patients who were screened for TB in HIV care or treatment setting	10,563	12,189	Redacted
C2.4.D_DSD	Number of HIV-positive individuals receiving a minimum of one clinical service	11,737	12,830	Redacted
C2.5.D_DSD	Number of HIV-positive patients in HIV care who started TB treatment	211	244	Redacted
C2.5.D_DSD	Number of HIV-positive individuals receiving a minimum of one clinical service	11,737	12,830	Redacted
CARE_CURR_DS D	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	11,150	12,188	Redacted
CARE_CURR_DS D	Age/sex: <1 Male	17	19	Redacted
CARE_CURR_DS D	Age/sex: 1-4 Male	121	132	Redacted
CARE_CURR_DS	Age/sex: 5-9 Male	204	223	Redacted



D				
CARE_CURR_DS D	Age/sex: 10-14 Male	160	175	Redacted
CARE_CURR_DS D	Age/sex: 15-19 Male	86	93	Redacted
CARE_CURR_DS D	Age/sex: 20-24 Male	159	173	Redacted
CARE_CURR_DS D	Age/sex: 25-49 Male	2,383	2,604	Redacted
CARE_CURR_DS D	Age/sex: 50+ Male	823	900	Redacted
CARE_CURR_DS D	Age/sex: <1 Female	17	19	Redacted
CARE_CURR_DS D	Age/sex: 1-4 Female	114	125	Redacted
CARE_CURR_DS D	Age/sex: 5-9 Female	211	231	Redacted
CARE_CURR_DS D	Age/sex: 10-14 Female	159	174	Redacted
CARE_CURR_DS D	Age/sex: 15-19 Female	141	154	Redacted
CARE_CURR_DS D	Age/sex: 20-24 Female	586	641	Redacted
CARE_CURR_DS D	Age/sex: 25-49 Female	5,006	5,472	Redacted
CARE_CURR_DS D	Age/sex: 50+ Female	963	1,053	Redacted
CARE_CURR_DS D	Sun of Age/Sex disaggregates	11,150	12,188	Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	502	549	Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	3,451	3,770	Redacted
CARE_CURR_DS	Aggregated Age/sex - USE WITH HQ	501	549	Redacted



D	PERMISSION ONLY: <15 Female			
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	6,696	7,320	Redacted
CARE_CURR_DS D	Sum of Aggregated Age/Sex disaggregates	11,150	12,188	Redacted
CARE_NEW_DSD	Number of HIV-infected adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load	2,230	2,215	Redacted
CARE_NEW_DSD	Age/sex: <1 Male	3	3	Redacted
CARE_NEW_DSD	Age/sex: 1-4 Male	24	24	Redacted
CARE_NEW_DSD	Age/sex: 5-9 Male	41	40	Redacted
CARE_NEW_DSD	Age/sex: 10-14 Male	32	33	Redacted
CARE_NEW_DSD	Age/sex: 15-19 Male	15	14	Redacted
CARE_NEW_DSD	Age/sex: 20-24 Male	60	60	Redacted
CARE_NEW_DSD	Age/sex: 25-49 Male	516	512	Redacted
CARE_NEW_DSD	Age/sex: 50+ Male	99	99	Redacted
CARE_NEW_DSD	Age/sex: <1 Female	3	3	Redacted
CARE_NEW_DSD	Age/sex: 1-4 Female	23	23	Redacted
CARE_NEW_DSD	Age/sex: 5-9 Female	42	42	Redacted
CARE_NEW_DSD	Age/sex: 10-14 Female	32	32	Redacted
CARE_NEW_DSD	Age/sex: 15-19 Female	33	33	Redacted
CARE_NEW_DSD	Age/sex: 20-24 Female	62	61	Redacted
CARE_NEW_DSD	Age/sex: 25-49 Female	925	918	Redacted
CARE_NEW_DSD	Age/sex: 50+ Female	320	318	Redacted
CARE_NEW_DSD	Sum of Age/sex disaggregates	2,230	2,215	Redacted
CARE_NEW_DSD	Aggregated Age/sex: <15 Male	100	100	Redacted
CARE_NEW_DSD	Aggregated Age/sex: 15+ Male	690	685	Redacted
CARE_NEW_DSD	Aggregated Age/sex: <15 Female	100	100	Redacted
CARE_NEW_DSD	Aggregated Age/sex: 15+ Female	1,340	1,330	Redacted
CARE_NEW_DSD	Sum of Aggregated Age/sex	2,230	2,215	Redacted



	disaggregates			
CARE_SITE	Number of PEPFAR-supported HIV clinical care sites at which at least 80% of PLHIV received all of the following during the reporting period: 1) clinical assessment (WHO staging) OR CD4 count OR viral load, AND 2) TB screening at last visit, AND 3) if eligible, cotrimoxazole	10	10	Redacted
CARE_SITE	Total number of PEPFAR supported sites providing clinical care services	10	10	Redacted
CARE_SITE	By site support type: Direct Service Delivery (DSD): Number of PEPFAR-supported HIV clinical care sites at which at least 80% of PLHIV received all of the following during the reporting period: 1) clinical assessment (WHO staging) OR CD4 count OR viral load, AND 2) TB screening at last visit, AND 3) if eligible, cotrimoxazole	10	10	Redacted
CARE_SITE	By site support type: Technical Assistance-only (TA): Number of PEPFAR-supported HIV clinical care sites at which at least 80% of PLHIV received all of the following during the reporting period: 1) clinical assessment (WHO staging) OR CD4 count OR viral load, AND 2) TB screening at last visit, AND 3) if eligible, cotrimoxazole	0	0	Redacted
CARE_SITE	Sum of Numerator Site Support Type disaggregates	10	10	Redacted
CARE_SITE	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR supported sites providing clinical care services	10	10	Redacted
CARE_SITE	By site support type: Technical	0	0	Redacted



	Assistance-only (TA): Total number of PEPFAR supported sites providing clinical care services			
CARE_SITE	Sum of Denominator Site Support Type disaggregates	10	10	Redacted
FN_SITE	Number of PEPFAR-supported sites achieving 90% nutrition assessments that result in accurate categorization of malnutrition	9	9	Redacted
FN_SITE	Total number of PEPFAR-supported sites providing nutrition assessment, counseling and support (NACS) services	10	10	Redacted
FN_SITE	By site support type: Direct Service Delivery (DSD): Number of PEPFAR-supported sites achieving 90% nutrition assessments that result in accurate categorization of malnutrition	9	9	Redacted
FN_SITE	By site support type: Technical Assistance-only (TA): Number of PEPFAR-supported sites achieving 90% nutrition assessments that result in accurate categorization of malnutrition	0	0	Redacted
FN_SITE	Sum of Numerator Support Type disaggregates	9	9	Redacted
FN_SITE	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported sites providing nutrition assessment, counseling and support (NACS) services	10	10	Redacted
FN_SITE	By site support type: Technical Assistance-only (TA): Total number of PEPFAR-supported sites providing	0	0	Redacted

	nutrition assessment, counseling and support (NACS) services			
FN_SITE	Sum of Denominator Support Type disaggregates	10	10	Redacted
FN_THER_DSD	Number of clinically malnourished PLHIV who received therapeutic and/or supplementary food during the reporting period.	1,761	1,925	Redacted
FN_THER_DSD	Number of PLHIV who were nutritionally assessed and found to be clinically undernourished.	2,374	2,566	Redacted
FN_THER_DSD	Age: <1	6	6	Redacted
FN_THER_DSD	Age: 1-4	38	42	Redacted
FN_THER_DSD	Age: 5-14	118	130	Redacted
FN_THER_DSD	Age: 15-17	36	39	Redacted
FN_THER_DSD	Age: 18+	1,563	1,708	Redacted
FN_THER_DSD	Sum of Age disaggregates	1,761	1,925	Redacted
FN_THER_DSD	Aggregated Age: <18	198	217	Redacted
FN_THER_DSD	Aggregated Age: 18+	1,563	1,708	Redacted
FN_THER_DSD	Sum of Aggregated Age disaggregates	1,761	1,925	Redacted
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	449	548	Redacted
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	528	609	Redacted
TB_ART_DSD	Age: 0-4	11	14	Redacted
TB_ART_DSD	Age: 5-14	30	36	Redacted
TB_ART_DSD	Age: 15+	408	498	Redacted
TB_ART_DSD	Male	242	296	Redacted
TB_ART_DSD	Female	207	252	Redacted



TB_ART_DSD	Sum of Sex disaggregates	449	548	Redacted
TB_ART_DSD	Newly tested	269	329	Redacted
TB_ART_DSD	Known HIV-positive	180	219	Redacted
TB_ART_DSD	Sum of Test Status disaggregates	449	548	Redacted
TB_ART_DSD	Aggregated Age: <15	41	50	Redacted
TB_ART_DSD	Aggregated Age: 15+	408	498	Redacted
TB_ART_DSD	Sum of Aggregated Age disaggregates	449	548	Redacted
TB_ARTSITE	The number of PEPFAR-supported TB basic management units at which 80% of registered TB cases who are HIV-positive are on ART, during the reporting period	10	10	Redacted
TB_ARTSITE	The number of PEPFAR-supported TB basic management units	10	10	Redacted
TB_ARTSITE	By site support type: Direct Service Delivery (DSD): The number of PEPFAR-supported TB basic management units at which 80% of registered TB cases who are HIV-positive are on ART, during the reporting period	10	10	Redacted
TB_ARTSITE	By site support type: Technical Assistance-only (TA): The number of PEPFAR-supported TB basic management units at which 80% of registered TB cases who are HIV-positive are on ART, during the reporting period	0	0	Redacted
TB_ARTSITE	Sum of Numerator Site Support Type disaggregates	10	10	Redacted
TB_ARTSITE	By site support type: Direct Service Delivery (DSD): The number of PEPFAR-supported TB basic management units	10	10	Redacted
TB_ARTSITE	By site support type: Technical	0	0	Redacted

	Assistance-only (TA): The number of PEPFAR-supported TB basic management units			
TB_ARTSITE	Sum of Denominator Site Support Type disaggregates	10	10	Redacted
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	232	236	Redacted
PMTCT_EID_DSD	Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT)	290	295	Redacted
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	174	177	Redacted
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	58	59	Redacted
PMTCT_EID_DSD	Sum of Infant Age disaggregates	232	236	Redacted
PMTCT_EID_DSD	By infants with a positive virologic test result within 12 months of birth	12	12	Redacted
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	6,478	7,363	Redacted
TX_CURR_DSD	Age/Sex: <1 Male	10	11	Redacted
TX_CURR_DSD	Age/Sex: 1-4 Male	68	78	Redacted
TX_CURR_DSD	Age/Sex: 5-14 Male	213	243	Redacted
TX_CURR_DSD	Age/Sex: 15+ Male	2,004	2,345	Redacted
TX_CURR_DSD	Age/Sex: <1 Female	10	11	Redacted
TX_CURR_DSD	Age/Sex: 1-4 Female	68	78	Redacted
TX_CURR_DSD	Age/Sex: 5-14 Female	213	243	Redacted
TX_CURR_DSD	Age/Sex: 15+ Female	3,892	4,354	Redacted
TX_CURR_DSD	Sum of age/sex disaggregates	582	664	Redacted
TX_CURR_DSD	Percent children with advanced HIV infection receiving antiretroviral therapy (ART) [CURRENT]	55	57	Redacted



TX_CURR_DSD	Percent women and girls with advanced HIV infection receiving antiretroviral therapy (ART) [CURRENT]	55	57	Redacted
TX_CURR_DSD	Aggregated Age/Sex: <1 Male	10	11	Redacted
TX_CURR_DSD	Aggregated Age/Sex: <1 Female	10	11	Redacted
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	291	332	Redacted
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	2,004	2,345	Redacted
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	291	332	Redacted
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	3,892	4,354	Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	582	664	Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	5,896	6,699	Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	6,478	7,363	Redacted
TX_CURR_NGI	Number of adults and children receiving antiretroviral therapy (ART)	6,478	7,363	Redacted
TX_CURR_NGI	Age/Sex: <1 Male	10	11	Redacted
TX_CURR_NGI	Age/Sex: 1-4 Male	68	78	Redacted
TX_CURR_NGI	Age/Sex: 5-14 Male	213	243	Redacted
TX_CURR_NGI	Age/Sex: 15+ Male	2,004	2,345	Redacted
TX_CURR_NGI	Age/Sex: <1 Female	10	11	Redacted
TX_CURR_NGI	Age/Sex: 1-4 Female	68	78	Redacted
TX_CURR_NGI	Age/Sex: 5-14 Female	213	243	Redacted
TX_CURR_NGI	Age/Sex: 15+ Female	3,892	4,354	Redacted
TX_CURR_NGI	Sum of Age/Sex disaggregates	6,478	7,363	Redacted
TX_CURR_NGI	Aggregated Age/Sex: <1 Male	10	11	Redacted
TX_CURR_NGI	Aggregated Age/Sex: <1 Female	10	11	Redacted
TX_CURR_NGI	Aggregated Age/Sex: <15 Male	291	332	Redacted
TX_CURR_NGI	Aggregated Age/Sex: 15+ Male	2,004	2,345	Redacted
TX_CURR_NGI	Aggregated Age/Sex: <15 Female	291	332	Redacted
TX_CURR_NGI	Aggregated Age/Sex: 15+ Female	3,892	4,354	Redacted
TX_CURR_NGI	Sum of Aggregated Age/Sex disaggregates	6,478	7,363	Redacted



TX_CURR_NGI	Sum of Aggregated Age/Sex <15	582	664	Redacted
TX_CURR_NGI	Sum of Aggregated Age/Sex 15+	5,896	6,699	Redacted
TX_DIST	Number of Districts with documented routine supportive supervision visits to 75% of HIV care and treatment sites supported by the District	1	1	Redacted
TX_DIST	Total number of PEPFAR supported District Health Offices	1	1	Redacted
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	1,511	1,491	Redacted
TX_NEW_DSD	By Age/Sex: <1 Male	24	31	Redacted
TX_NEW_DSD	By Age/Sex: 1-4 Male	13	18	Redacted
TX_NEW_DSD	By Age/Sex: 5-9 Male	23	31	Redacted
TX_NEW_DSD	By Age/Sex: 10-14 Male	18	25	Redacted
TX_NEW_DSD	By Age/Sex: 15-19 Male	12	11	Redacted
TX_NEW_DSD	By Age/Sex: 20-24 Male	22	21	Redacted
TX_NEW_DSD	By Age/Sex: 25-49 Male	327	309	Redacted
TX_NEW_DSD	By Age/Sex: 50+ Male	113	107	Redacted
TX_NEW_DSD	By Age/Sex: <1 Female	24	31	Redacted
TX_NEW_DSD	By Age/Sex: 1-4 Female	13	19	Redacted
TX_NEW_DSD	By Age/Sex: 5-9 Female	23	31	Redacted
TX_NEW_DSD	By Age/Sex: 10-14 Female	18	24	Redacted
TX_NEW_DSD	By Age/Sex: 15-19 Female	19	18	Redacted
TX_NEW_DSD	By Age/Sex: 20-24 Female	77	73	Redacted
TX_NEW_DSD	By Age/Sex: 25-49 Female	659	623	Redacted
TX_NEW_DSD	By Age/Sex: 50+ Female	126	119	Redacted
TX_NEW_DSD	Sum of Age/Sex disaggregates	1,511	1,491	Redacted
TX_NEW_DSD	Aggregated Grouping by Age: <1 Male	24	31	Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	78	105	Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	474	448	Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <1	24	31	Redacted

	Female			
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	78	105	Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	881	833	Redacted
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	1,511	1,491	Redacted
TX_NEW_DSD	Pregnancy status	91	93	Redacted
TX_NEW_DSD	Breastfeeding status	10	10	Redacted
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	1,018	1,284	Redacted
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	1,198	1,511	Redacted
TX_RET_DSD	Age: 0-4 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	25	31	Redacted
TX_RET_DSD	Age: 5-14 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	69	87	Redacted
TX_RET_DSD	Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	924	1,166	Redacted
TX_RET_DSD	Age: 0-4 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have	30	37	Redacted



	stopped ART, and those lost to follow-up)			
TX_RET_DSD	Age: 5-14 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	80	102	Redacted
TX_RET_DSD	Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,088	1,372	Redacted
TX_RET_DSD	Aggregated Age: <15 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	94	118	Redacted
TX_RET_DSD	Aggregated Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	924	1,166	Redacted
TX_RET_DSD	Aggregated Age: <15 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	110	139	Redacted
TX_RET_DSD	Aggregated Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died,	1,088	1,372	Redacted



	those who have stopped ART, and those lost to follow-up)			
TX_RET_DSD	Pregnancy and breastfeeding status (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	92	185	Redacted
TX_RET_DSD	Pregnancy and breastfeeding status (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	109	218	Redacted
TX_SITE	Number of PEPFAR-supported ART sites with a retention rate of 75% or greater for patients 12 months after ART initiation	7	7	Redacted
TX_SITE	Total number of PEPFAR-supported ART sites	10	10	Redacted
TX_SITE	By support type: Direct Service Delivery (DSD): Number of PEPFAR-supported ART sites with a retention rate of 75% or greater for patients 12 months after ART initiation	7	7	Redacted
TX_SITE	By support type: Technical Assistance (TA-only): Number of PEPFAR-supported ART sites with a retention rate of 75% or greater for patients 12 months after ART initiation	0	0	Redacted
TX_SITE	Sum of Numerator Site Support Type disaggregates	7	7	Redacted
TX_SITE	By support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported ART sites	10	10	Redacted

TX_SITE	By support type: Technical Assistance (TA-only): Total number of PEPFAR-supported ART sites	0	0	Redacted
TX_SITE	Sum of Denominator Site Support Type disaggregates	10	10	Redacted
LAB_CAP_DSD	Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests	1	1	Redacted
LAB_CAP_DSD	By site support type: Direct Service Delivery (DSD)	1	1	Redacted
LAB_CAP_DSD	Sum of Site Support Type disaggregates	1	1	Redacted
FPINT_SITE_DSD	Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	8	8	Redacted
FPINT_SITE_DSD	Total number of PEPFAR-supported HIV service delivery points: PMTCT, Care and Treatment	10	10	Redacted
FPINT_SITE_DSD	By site support type: Direct Service Delivery (DSD): Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	8	8	Redacted
FPINT_SITE_DSD	By site support type: Technical Assistance-only (TA): Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	0	0	Redacted
FPINT_SITE_DSD	Sum of Numerator Site Support Type disaggregates	8	8	Redacted
FPINT_SITE_DSD	By site support type: Direct Service Delivery (DSD): Total number of	10	10	Redacted



	PEPFAR-supported HIV service delivery points			
FPINT_SITE_DSD	By site support type: Technical Assistance-only (TA): Total number of PEPFAR-supported HIV service delivery points	0	0	Redacted
FPINT_SITE_DSD	Sum of Denominator Site Support Type disaggregates	10	10	Redacted
FPINT_SITE_DSD	Service delivery type: Clinical	8	8	Redacted
FPINT_SITE_DSD	Sum of Service Delivery Type disaggregates	8	8	Redacted
QI_SITE	Number of PEPFAR-supported clinical service sites with a quality improvement activity completed that addresses clinical HIV programs and has documented process results in the last 6 months	8	8	Redacted
QI_SITE	Total number of PEPFAR-supported sites for any HIV clinical service including HIV Care, HIV Treatment, TB care, PMTCT, VMMC, and HTC	10	10	Redacted
QI_SITE	By site support type: Direct Service Delivery (DSD): Number of PEPFAR-supported clinical service sites with a quality improvement activity completed that addresses clinical HIV programs and has documented results in the last 6 months	8	8	Redacted
QI_SITE	By site support type: Technical Assistance-only (TA): Number of PEPFAR-supported clinical service sites with a quality improvement activity completed that addresses clinical HIV programs and has documented results in the last 6 months	0	0	Redacted



QI_SITE	Sum of Numerator Site Support Type disaggregates	8	8	Redacted
QI_SITE	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported sites for any HIV clinical service including HIV Care, HIV Treatment, TB care, PMTCT, VMMC, HTC	10	10	Redacted
QI_SITE	By site support type: Technical Assistance-only (TA): Total number of PEPFAR-supported sites for any HIV clinical service including HIV Care, HIV Treatment, TB care, PMTCT, VMMC, and HTC	0	0	Redacted
QI_SITE	Sum of Denominator Site Support Type disaggregates	10	10	Redacted
TB_SCREEN_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period	10,035	11,579	Redacted
TB_SCREEN_DSD	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	11,150	12,188	Redacted
TB_SCREEN_DSD	Age: <1	32	37	Redacted
TB_SCREEN_DSD	Age: 1-4	217	250	Redacted
TB_SCREEN_DSD	Age: 5-9	382	441	Redacted
TB_SCREEN_DSD	Age: 10-14	294	340	Redacted
TB_SCREEN_DSD	Age: 15-19	203	234	Redacted
TB_SCREEN_DSD	Age: 20-24	677	781	Redacted
TB_SCREEN_DSD	Age: 25-49	6,645	7,668	Redacted
TB_SCREEN_DSD	Age: 50+	1,585	1,828	Redacted
TB_SCREEN_DSD	Sum of Age disaggregates	1,128	1,302	Redacted



TB_SCREEN_DSD	Aggregated Age - USE WITH HQ PERMISSION ONLY: <15	925	1,068	Redacted
TB_SCREEN_DSD	Aggregated Age - USE WITH HQ PERMISSION ONLY: 15+	9,110	10,511	Redacted
TB_SCREEN_DSD	Sum of Aggregated Age disaggregates	10,035	11,579	Redacted
TB_SCREEN_DSD	Sex: Male	3,560	4,108	Redacted
TB_SCREEN_DSD	Sex: Female	6,475	7,471	Redacted
TB_SCREEN_DSD	Sum of Sex disaggregates	10,035	11,579	Redacted

Implementing Mechanism Details

Mechanism ID: 13366	Mechanism Name: Expanding High Quality HIV Prevention, Care and Treatment within Faith-Based Health Facilities
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Christian Health Association of Kenya	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: No	
G2G: No	Managing Agency:

Total All Funding Sources: 7,417,537	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 0	
FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount
GHP-State	7,417,537

Sub Partner Name(s)

Catholic Medical Mission Board	Futures Group	Health Strat Kenya
Mission for Essential Drugs and Supplies		

Cross-Cutting Budget Attribution(s)



Human Resources for Health	2,460,000
Gender: GBV	185,688
Focus Area:	Post GBV Care
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Monitoring and Evaluation
Gender: Gender Equality	185,688
Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Monitoring and Evaluation
Motor Vehicles: Purchased	60,000

Key Issues

- Malaria (PMI)
- Child Survival Activities
- Safe Motherhood
- TB
- Family Planning

Budget Code Information

Mechanism ID:	13366		
Mechanism Name:	Expanding High Quality HIV Prevention, Care and Treatment within		
Prime Partner Name:	Faith-Based Health Facilities		
Prime Partner Name:	Christian Health Association of Kenya		
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Care	HBHC	358,405	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	500,856	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	199,822	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	549,685	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	334,158	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	5,177,321	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	297,290	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2014	2015	Planning Budget Targets
SITE_SUPP	Number of unique sites supported by PEPFAR	57	57	Redacted
SITE_SUPP	By program area/support type: HTC Direct Service Delivery (DSD)	57	57	Redacted
SITE_SUPP	By program area/support type: HTC Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: Treatment Direct Service Delivery	57	57	Redacted



	(DSD)			
SITE_SUPP	By program area/support type: Treatment Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: Care and Support Direct Service Delivery (DSD)	57	57	Redacted
SITE_SUPP	By program area/support type: Care and Support Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: Food and Nutrition Direct Service Delivery (DSD)	57	57	Redacted
SITE_SUPP	By program area/support type: Food and Nutrition Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: PMTCT Direct Service Delivery (DSD)	30	30	Redacted
SITE_SUPP	By program area/support type: PMTCT Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: TB/HIV Direct Service Delivery (DSD)	30	30	Redacted
SITE_SUPP	By program area/support type: TB/HIV Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: VMMC Direct Service Delivery (DSD)	0	0	Redacted
SITE_SUPP	By program area/support type: VMMC Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: General Population Prevention Direct Service Delivery (DSD)	0	0	Redacted
SITE_SUPP	By program area/support type: General Population Prevention Technical Assistance-only (TA)	0	0	Redacted



SITE_SUPP	By program area/support type: Key Populations Prevention Direct Service Delivery (DSD)	0	0	Redacted
SITE_SUPP	By program area/support type: Key Populations Prevention Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: OVC Direct Service Delivery (DSD)	0	0	Redacted
SITE_SUPP	By program area/support type: OVC Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: PHDP/Family Planning & Integration Direct Service Delivery (DSD)	57	57	Redacted
SITE_SUPP	By program area/support type: PHDP/Family Planning & Integration Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: Lab Direct Service Delivery (DSD)	30	30	Redacted
SITE_SUPP	By program area/support type: Lab Technical Assistance-only (TA)	0	0	Redacted
PMTCT_ARV_DS D	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	1,138	2,065	Redacted
PMTCT_ARV_DS D	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	1,138	2,065	Redacted
PMTCT_ARV_DS D	Life-long ART (including Option B+)	853	1,549	Redacted
PMTCT_ARV_DS D	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	398	723	Redacted
PMTCT_ARV_DS D	Sub-Disag of Life-long ART: Already on treatment at the beginning of the	455	826	Redacted



	current pregnancy			
PMTCT_ARV_DS D	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)	0	0	Redacted
PMTCT_ARV_DS D	Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)	285	516	Redacted
PMTCT_ARV_DS D	Single-dose nevirapine (with or without tail)	0	0	Redacted
PMTCT_ARV_DS D	Sum of Regimen Type disaggregates	1,138	2,065	Redacted
PMTCT_ARV_DS D	Sum of New and Current disaggregates	853	1,549	Redacted
PMTCT_ARV_NGI	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	1,138	2,065	Redacted
PMTCT_ARV_NGI	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	1,138	2,065	Redacted
PMTCT_ARV_NGI	Life-long ART (including Option B+)	853	1,549	Redacted
PMTCT_ARV_NGI	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	398	723	Redacted
PMTCT_ARV_NGI	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	455	826	Redacted
PMTCT_ARV_NGI	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)	0	0	Redacted
PMTCT_ARV_NGI	Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)	285	516	Redacted
PMTCT_ARV_NGI	Single-dose nevirapine (with or without	0	0	Redacted



	tail)			
PMTCT_ARV_NGI	Sum of Regimen disaggregates	1,138	2,065	Redacted
PMTCT_ARV_NGI	Sum of New and Current disaggregates	853	1,549	Redacted
PMTCT_SITE	Number of PEPFAR-supported sites achieving 90% ARV or ART coverage for HIV+ pregnant women	30	30	Redacted
PMTCT_SITE	Total number of PEPFAR supported sites providing PMTCT services (HTC and ARV or ART services)	30	30	Redacted
PMTCT_SITE	By site support type: Direct Service Delivery (DSD): Number of PEPFAR-supported sites achieving 90% ARV or ART coverage for HIV+ pregnant women	30	30	Redacted
PMTCT_SITE	By site support type: Technical Assistance-only (TA): Number of PEPFAR-supported sites achieving 90% ARV or ART coverage for HIV+ pregnant women	0	0	Redacted
PMTCT_SITE	Sum of Numerator Support Type disaggregates	30	30	Redacted
PMTCT_SITE	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR supported sites providing PMTCT services (HTC and ARV or ART services)	30	30	Redacted
PMTCT_SITE	By site support type: Technical Assistance-only (TA): Total number of PEPFAR supported sites providing PMTCT services (HTC and ARV or ART services)	0	0	Redacted
PMTCT_SITE	Sum of Denominator Support Type disaggregates	30	30	Redacted
PMTCT_STAT_DS D	Number of pregnant women with known HIV status (includes women who were	21,730	22,918	Redacted

	tested for HIV and received their results)			
PMTCT_STAT_DS D	Number of new ANC and L&D clients	21,730	22,918	Redacted
PMTCT_STAT_DS D	By: Known positives at entry	535	971	Redacted
PMTCT_STAT_DS D	By: Number of new positives identified	603	1,094	Redacted
PMTCT_STAT_DS D	Sum of Positives Status disaggregates	1,138	2,065	Redacted
PMTCT_STAT_NG I	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	21,730	22,918	Redacted
PMTCT_STAT_NG I	Number of new ANC and L&D clients	21,730	22,918	Redacted
PMTCT_STAT_NG I	By: Known positives at entry	535	971	Redacted
PMTCT_STAT_NG I	By: Number of new positives identified	603	1,094	Redacted
PMTCT_STAT_NG I	Sum of Positives Status disaggregates	1,138	2,065	Redacted
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	117,986	183,228	Redacted
HTC_TST_DSD	By Test Result: Negative	113,267	175,899	Redacted
HTC_TST_DSD	By Test Result: Positive	4,719	7,329	Redacted
HTC_TST_DSD	Sum of Test Result disaggregates	117,986	183,228	Redacted
HTC_TST_DSD	Age/sex: <1 Male	0	0	Redacted
HTC_TST_DSD	Age/sex: 1-4 Male	4,130	6,413	Redacted
HTC_TST_DSD	Age/sex: 5-9 Male	1,770	2,748	Redacted
HTC_TST_DSD	Age/sex: 10-14 Male	2,950	4,581	Redacted
HTC_TST_DSD	Age/sex: 15-19 Male	5,899	9,161	Redacted
HTC_TST_DSD	Age/sex: 20-24 Male	14,748	22,904	Redacted



HTC_TST_DSD	Age/sex: 25-49 Male	23,597	36,646	Redacted
HTC_TST_DSD	Age/sex: 50+ Male	5,899	9,161	Redacted
HTC_TST_DSD	Age/sex: <1 Female	0	0	Redacted
HTC_TST_DSD	Age/sex: 1-4 Female	4,130	6,413	Redacted
HTC_TST_DSD	Age/sex: 5-9 Female	1,770	2,748	Redacted
HTC_TST_DSD	Age/sex: 10-14 Female	2,950	4,581	Redacted
HTC_TST_DSD	Age/sex: 15-19 Female	5,899	9,161	Redacted
HTC_TST_DSD	Age/sex: 20-24 Female	14,748	22,904	Redacted
HTC_TST_DSD	Age/sex: 25-49 Female	23,597	36,646	Redacted
HTC_TST_DSD	Age/sex: 50+ Female	5,899	9,161	Redacted
HTC_TST_DSD	Sum of Age/Sex disaggregates	117,986	183,228	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	8,850	13,742	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	50,143	77,872	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	8,850	13,742	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	50,143	77,872	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	17,700	27,484	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	100,286	155,744	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	117,986	183,228	Redacted
HTC_TST_NGI	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	117,986	183,228	Redacted
HTC_TST_NGI	By Test Result: Negative	113,267	175,899	Redacted
HTC_TST_NGI	By Test Result: Positive	4,719	7,329	Redacted
HTC_TST_NGI	Sum of Test Result disaggregates	117,986	183,228	Redacted
HTC_TST_NGI	Age/sex: <1 Male	0	0	Redacted
HTC_TST_NGI	Age/sex: 1-4 Male	4,130	6,413	Redacted
HTC_TST_NGI	Age/sex: 5-9 Male	1,770	2,748	Redacted
HTC_TST_NGI	Age/sex: 10-14 Male	2,950	4,581	Redacted

HTC_TST_NGI	Age/sex: 15-19 Male	5,899	9,161	Redacted
HTC_TST_NGI	Age/sex: 20-24 Male	14,748	22,904	Redacted
HTC_TST_NGI	Age/sex: 25-49 Male	23,597	36,646	Redacted
HTC_TST_NGI	Age/sex: 50+ Male	5,899	9,161	Redacted
HTC_TST_NGI	Age/sex: <1 Female	0	0	Redacted
HTC_TST_NGI	Age/sex: 1-4 Female	4,130	6,413	Redacted
HTC_TST_NGI	Age/sex: 5-9 Female	1,770	2,748	Redacted
HTC_TST_NGI	Age/sex: 10-14 Female	2,950	4,581	Redacted
HTC_TST_NGI	Age/sex: 15-19 Female	5,899	9,161	Redacted
HTC_TST_NGI	Age/sex: 20-24 Female	14,748	22,904	Redacted
HTC_TST_NGI	Age/sex: 25-49 Female	23,597	36,646	Redacted
HTC_TST_NGI	Age/sex: 50+ Female	5,899	9,161	Redacted
HTC_TST_NGI	Sum of Age/Sex disaggregates	117,986	183,228	Redacted
HTC_TST_NGI	Aggregated Age/sex: <15 Male	8,850	13,742	Redacted
HTC_TST_NGI	Aggregated Age/sex: 15+ Male	50,143	77,872	Redacted
HTC_TST_NGI	Aggregated Age/sex: <15 Female	8,850	13,742	Redacted
HTC_TST_NGI	Aggregated Age/sex: 15+ Female	50,143	77,872	Redacted
HTC_TST_NGI	Sum of Aggregated Age/Sex <15	17,700	27,484	Redacted
HTC_TST_NGI	Sum of Aggregated Age/Sex 15+	100,286	155,744	Redacted
HTC_TST_NGI	Sum of Aggregated Age/Sex disaggregates	117,986	183,228	Redacted
C2.1.D_DSD	Number of HIV-positive individuals receiving a minimum of one clinical service	44,719	49,410	Redacted
C2.1.D_DSD	By Age/Sex: <15 Female	2,012	2,229	Redacted
C2.1.D_DSD	By Age/Sex: <15 Male	2,012	2,229	Redacted
C2.1.D_DSD	By Age/Sex: 15+ Female	26,859	29,669	Redacted
C2.1.D_DSD	By Age/Sex: 15+ Male	13,836	15,283	Redacted
C2.1.D_DSD	Sum of Age/Sex disaggregates	44,719	49,410	Redacted
C2.1.D_DSD	By Age: <15	4,024	4,458	Redacted
C2.1.D_DSD	By Age: 15+	40,695	44,952	Redacted
C2.1.D_DSD	Sum of Age disaggregates	44,719	49,410	Redacted



C2.1.D_DSD	By Sex: Female	28,871	31,898	Redacted
C2.1.D_DSD	By Sex: Male	15,848	17,512	Redacted
C2.1.D_DSD	Sum of Sex disaggregates	44,719	49,410	Redacted
C2.1.D_NGI	Number of HIV-positive individuals receiving a minimum of one clinical service	44,719	49,410	Redacted
C2.1.D_NGI	By Age/Sex: <15 Female	2,012	2,229	Redacted
C2.1.D_NGI	By Age/Sex: <15 Male	2,012	2,229	Redacted
C2.1.D_NGI	By Age/Sex: 15+ Female	26,859	29,669	Redacted
C2.1.D_NGI	By Age/Sex: 15+ Male	13,836	15,283	Redacted
C2.1.D_NGI	Sum of Age/Sex disaggregates	44,719	49,410	Redacted
C2.1.D_NGI	By Age: <15	4,024	4,458	Redacted
C2.1.D_NGI	By Age: 15+	40,695	44,952	Redacted
C2.1.D_NGI	Sum of Age disaggregates	44,719	49,410	Redacted
C2.1.D_NGI	By Sex: Female	28,871	31,898	Redacted
C2.1.D_NGI	By Sex: Male	15,848	17,512	Redacted
C2.1.D_NGI	Sum of Sex disaggregates	44,719	49,410	Redacted
C2.4.D_DSD	Number of HIV-positive patients who were screened for TB in HIV care or treatment setting	40,247	46,940	Redacted
C2.4.D_DSD	Number of HIV-positive individuals receiving a minimum of one clinical service	44,719	49,410	Redacted
C2.5.D_DSD	Number of HIV-positive patients in HIV care who started TB treatment	805	939	Redacted
C2.5.D_DSD	Number of HIV-positive individuals receiving a minimum of one clinical service	44,719	49,410	Redacted
CARE_CURR_DS D	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	42,483	46,940	Redacted
CARE_CURR_DS	Age/sex: <1 Male	66	73	Redacted



D				
CARE_CURR_DS D	Age/sex: 1-4 Male	459	509	Redacted
CARE_CURR_DS D	Age/sex: 5-9 Male	776	860	Redacted
CARE_CURR_DS D	Age/sex: 10-14 Male	610	676	Redacted
CARE_CURR_DS D	Age/sex: 15-19 Male	326	360	Redacted
CARE_CURR_DS D	Age/sex: 20-24 Male	604	667	Redacted
CARE_CURR_DS D	Age/sex: 25-49 Male	9,078	10,028	Redacted
CARE_CURR_DS D	Age/sex: 50+ Male	3,137	3,465	Redacted
CARE_CURR_DS D	Age/sex: <1 Female	66	73	Redacted
CARE_CURR_DS D	Age/sex: 1-4 Female	436	483	Redacted
CARE_CURR_DS D	Age/sex: 5-9 Female	803	889	Redacted
CARE_CURR_DS D	Age/sex: 10-14 Female	606	673	Redacted
CARE_CURR_DS D	Age/sex: 15-19 Female	538	595	Redacted
CARE_CURR_DS D	Age/sex: 20-24 Female	2,234	2,467	Redacted
CARE_CURR_DS D	Age/sex: 25-49 Female	19,077	21,072	Redacted
CARE_CURR_DS D	Age/sex: 50+ Female	3,667	4,050	Redacted
CARE_CURR_DS D	Sun of Age/Sex disaggregates	42,483	46,940	Redacted
CARE_CURR_DS	Aggregated Age/sex - USE WITH HQ	1,911	2,118	Redacted



D	PERMISSION ONLY: <15 Male			
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	13,145	14,520	Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	1,911	2,118	Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	25,516	28,184	Redacted
CARE_CURR_DS D	Sum of Aggregated Age/Sex disaggregates	42,483	46,940	Redacted
CARE_NEW_DSD	Number of HIV-infected adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load	8,497	8,535	Redacted
CARE_NEW_DSD	Age/sex: <1 Male	13	13	Redacted
CARE_NEW_DSD	Age/sex: 1-4 Male	87	88	Redacted
CARE_NEW_DSD	Age/sex: 5-9 Male	161	162	Redacted
CARE_NEW_DSD	Age/sex: 10-14 Male	121	122	Redacted
CARE_NEW_DSD	Age/sex: 15-19 Male	55	56	Redacted
CARE_NEW_DSD	Age/sex: 20-24 Male	230	231	Redacted
CARE_NEW_DSD	Age/sex: 25-49 Male	1,965	1,974	Redacted
CARE_NEW_DSD	Age/sex: 50+ Male	379	380	Redacted
CARE_NEW_DSD	Age/sex: <1 Female	13	13	Redacted
CARE_NEW_DSD	Age/sex: 1-4 Female	92	92	Redacted
CARE_NEW_DSD	Age/sex: 5-9 Female	155	156	Redacted
CARE_NEW_DSD	Age/sex: 10-14 Female	122	124	Redacted
CARE_NEW_DSD	Age/sex: 15-19 Female	127	127	Redacted
CARE_NEW_DSD	Age/sex: 20-24 Female	234	235	Redacted
CARE_NEW_DSD	Age/sex: 25-49 Female	3,524	3,539	Redacted
CARE_NEW_DSD	Age/sex: 50+ Female	1,219	1,223	Redacted
CARE_NEW_DSD	Sum of Age/sex disaggregates	8,497	8,535	Redacted
CARE_NEW_DSD	Aggregated Age/sex: <15 Male	382	385	Redacted

CARE_NEW_DSD	Aggregated Age/sex: 15+ Male	2,629	2,641	Redacted
CARE_NEW_DSD	Aggregated Age/sex: <15 Female	382	385	Redacted
CARE_NEW_DSD	Aggregated Age/sex: 15+ Female	5,104	5,124	Redacted
CARE_NEW_DSD	Sum of Aggregated Age/sex disaggregates	8,497	8,535	Redacted
CARE_SITE	Number of PEPFAR-supported HIV clinical care sites at which at least 80% of PLHIV received all of the following during the reporting period: 1) clinical assessment (WHO staging) OR CD4 count OR viral load, AND 2) TB screening at last visit, AND 3) if eligible, cotrimoxazole	57	57	Redacted
CARE_SITE	Total number of PEPFAR supported sites providing clinical care services	57	57	Redacted
CARE_SITE	By site support type: Direct Service Delivery (DSD): Number of PEPFAR-supported HIV clinical care sites at which at least 80% of PLHIV received all of the following during the reporting period: 1) clinical assessment (WHO staging) OR CD4 count OR viral load, AND 2) TB screening at last visit, AND 3) if eligible, cotrimoxazole	57	57	Redacted
CARE_SITE	By site support type: Technical Assistance-only (TA): Number of PEPFAR-supported HIV clinical care sites at which at least 80% of PLHIV received all of the following during the reporting period: 1) clinical assessment (WHO staging) OR CD4 count OR viral load, AND 2) TB screening at last visit, AND 3) if eligible, cotrimoxazole	0	0	Redacted
CARE_SITE	Sum of Numerator Site Support Type disaggregates	57	57	Redacted



CARE_SITE	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR supported sites providing clinical care services	57	57	Redacted
CARE_SITE	By site support type: Technical Assistance-only (TA): Total number of PEPFAR supported sites providing clinical care services	0	0	Redacted
CARE_SITE	Sum of Denominator Site Support Type disaggregates	57	57	Redacted
FN_SITE	Number of PEPFAR-supported sites achieving 90% nutrition assessments that result in accurate categorization of malnutrition	51	51	Redacted
FN_SITE	Total number of PEPFAR-supported sites providing nutrition assessment, counseling and support (NACS) services	57	57	Redacted
FN_SITE	By site support type: Direct Service Delivery (DSD): Number of PEPFAR-supported sites achieving 90% nutrition assessments that result in accurate categorization of malnutrition	51	51	Redacted
FN_SITE	By site support type: Technical Assistance-only (TA): Number of PEPFAR-supported sites achieving 90% nutrition assessments that result in accurate categorization of malnutrition	0	0	Redacted
FN_SITE	Sum of Numerator Support Type disaggregates	51	51	Redacted
FN_SITE	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported sites providing	57	57	Redacted



	nutrition assessment, counseling and support (NACS) services			
FN_SITE	By site support type: Technical Assistance-only (TA): Total number of PEPFAR-supported sites providing nutrition assessment, counseling and support (NACS) services	0	0	Redacted
FN_SITE	Sum of Denominator Support Type disaggregates	57	57	Redacted
FN_THER_DSD	Number of clinically malnourished PLHIV who received therapeutic and/or supplementary food during the reporting period.	6,708	7,412	Redacted
FN_THER_DSD	Number of PLHIV who were nutritionally assessed and found to be clinically undernourished.	8,944	9,882	Redacted
FN_THER_DSD	Age: <1	21	24	Redacted
FN_THER_DSD	Age: 1-4	145	160	Redacted
FN_THER_DSD	Age: 5-14	452	500	Redacted
FN_THER_DSD	Age: 15-17	136	150	Redacted
FN_THER_DSD	Age: 18+	5,954	6,578	Redacted
FN_THER_DSD	Sum of Age disaggregates	6,708	7,412	Redacted
FN_THER_DSD	Aggregated Age: <18	754	834	Redacted
FN_THER_DSD	Aggregated Age: 18+	5,954	6,578	Redacted
FN_THER_DSD	Sum of Aggregated Age disaggregates	6,708	7,412	Redacted
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	1,711	2,112	Redacted
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	2,012	2,347	Redacted



TB_ART_DSD	Age: 0-4	42	52	Redacted
TB_ART_DSD	Age: 5-14	116	143	Redacted
TB_ART_DSD	Age: 15+	1,553	1,917	Redacted
TB_ART_DSD	Male	924	1,140	Redacted
TB_ART_DSD	Female	787	972	Redacted
TB_ART_DSD	Sum of Sex disaggregates	1,711	2,112	Redacted
TB_ART_DSD	Newly tested	1,027	1,267	Redacted
TB_ART_DSD	Known HIV-positive	684	845	Redacted
TB_ART_DSD	Sum of Test Status disaggregates	1,711	2,112	Redacted
TB_ART_DSD	Aggregated Age: <15	158	195	Redacted
TB_ART_DSD	Aggregated Age: 15+	1,553	1,917	Redacted
TB_ART_DSD	Sum of Aggregated Age disaggregates	1,711	2,112	Redacted
TB_ARTSITE	The number of PEPFAR-supported TB basic management units at which 80% of registered TB cases who are HIV-positive are on ART, during the reporting period	30	30	Redacted
TB_ARTSITE	The number of PEPFAR-supported TB basic management units	30	30	Redacted
TB_ARTSITE	By site support type: Direct Service Delivery (DSD): The number of PEPFAR-supported TB basic management units at which 80% of registered TB cases who are HIV-positive are on ART, during the reporting period	30	30	Redacted
TB_ARTSITE	By site support type: Technical Assistance-only (TA): The number of PEPFAR-supported TB basic management units at which 80% of registered TB cases who are HIV-positive are on ART, during the reporting period	0	0	Redacted
TB_ARTSITE	Sum of Numerator Site Support Type	30	30	Redacted

	disaggregates			
TB_ARTSITE	By site support type: Direct Service Delivery (DSD): The number of PEPFAR-supported TB basic management units	30	30	Redacted
TB_ARTSITE	By site support type: Technical Assistance-only (TA): The number of PEPFAR-supported TB basic management units	0	0	Redacted
TB_ARTSITE	Sum of Denominator Site Support Type disaggregates	30	30	Redacted
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	910	1,652	Redacted
PMTCT_EID_DSD	Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT)	1,138	2,061	Redacted
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	682	1,239	Redacted
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	228	413	Redacted
PMTCT_EID_DSD	Sum of Infant Age disaggregates	910	1,652	Redacted
PMTCT_EID_DSD	By infants with a positive virologic test result within 12 months of birth	46	83	Redacted
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	39,976	45,830	Redacted
TX_CURR_DSD	Age/Sex: <1 Male	62	71	Redacted
TX_CURR_DSD	Age/Sex: 1-4 Male	421	484	Redacted
TX_CURR_DSD	Age/Sex: 5-14 Male	1,315	1,511	Redacted
TX_CURR_DSD	Age/Sex: 15+ Male	12,369	14,594	Redacted
TX_CURR_DSD	Age/Sex: <1 Female	62	71	Redacted
TX_CURR_DSD	Age/Sex: 1-4 Female	421	484	Redacted



TX_CURR_DSD	Age/Sex: 5-14 Female	1,316	1,511	Redacted
TX_CURR_DSD	Age/Sex: 15+ Female	24,010	27,104	Redacted
TX_CURR_DSD	Sum of age/sex disaggregates	3,597	4,132	Redacted
TX_CURR_DSD	Percent children with advanced HIV infection receiving antiretroviral therapy (ART) [CURRENT]	1	1	Redacted
TX_CURR_DSD	Percent women and girls with advanced HIV infection receiving antiretroviral therapy (ART) [CURRENT]	1	1	Redacted
TX_CURR_DSD	Aggregated Age/Sex: <1 Male	62	71	Redacted
TX_CURR_DSD	Aggregated Age/Sex: <1 Female	62	71	Redacted
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	1,798	2,066	Redacted
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	12,369	14,594	Redacted
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	1,799	2,066	Redacted
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	24,010	27,104	Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	3,597	4,132	Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	36,379	41,698	Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	39,976	45,830	Redacted
TX_CURR_NGI	Number of adults and children receiving antiretroviral therapy (ART)	39,976	45,830	Redacted
TX_CURR_NGI	Age/Sex: <1 Male	62	71	Redacted
TX_CURR_NGI	Age/Sex: 1-4 Male	421	484	Redacted
TX_CURR_NGI	Age/Sex: 5-14 Male	1,316	1,511	Redacted
TX_CURR_NGI	Age/Sex: 15+ Male	12,369	14,594	Redacted
TX_CURR_NGI	Age/Sex: <1 Female	62	71	Redacted
TX_CURR_NGI	Age/Sex: 1-4 Female	421	484	Redacted
TX_CURR_NGI	Age/Sex: 5-14 Female	1,316	1,511	Redacted
TX_CURR_NGI	Age/Sex: 15+ Female	24,009	27,104	Redacted
TX_CURR_NGI	Sum of Age/Sex disaggregates	39,976	45,830	Redacted
TX_CURR_NGI	Aggregated Age/Sex: <1 Male	62	71	Redacted
TX_CURR_NGI	Aggregated Age/Sex: <1 Female	62	71	Redacted



TX_CURR_NGI	Aggregated Age/Sex: <15 Male	1,799	2,066	Redacted
TX_CURR_NGI	Aggregated Age/Sex: 15+ Male	12,369	14,594	Redacted
TX_CURR_NGI	Aggregated Age/Sex: <15 Female	1,799	2,066	Redacted
TX_CURR_NGI	Aggregated Age/Sex: 15+ Female	24,009	27,104	Redacted
TX_CURR_NGI	Sum of Aggregated Age/Sex disaggregates	39,976	45,830	Redacted
TX_CURR_NGI	Sum of Aggregated Age/Sex <15	3,598	4,132	Redacted
TX_CURR_NGI	Sum of Aggregated Age/Sex 15+	36,378	41,698	Redacted
TX_DIST	Number of Districts with documented routine supportive supervision visits to 75% of HIV care and treatment sites supported by the District	13	13	Redacted
TX_DIST	Total number of PEPFAR supported District Health Offices	16	16	Redacted
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	5,663	5,640	Redacted
TX_NEW_DSD	By Age/Sex: <1 Male	88	119	Redacted
TX_NEW_DSD	By Age/Sex: 1-4 Male	50	67	Redacted
TX_NEW_DSD	By Age/Sex: 5-9 Male	88	119	Redacted
TX_NEW_DSD	By Age/Sex: 10-14 Male	68	92	Redacted
TX_NEW_DSD	By Age/Sex: 15-19 Male	44	42	Redacted
TX_NEW_DSD	By Age/Sex: 20-24 Male	82	78	Redacted
TX_NEW_DSD	By Age/Sex: 25-49 Male	1,227	1,171	Redacted
TX_NEW_DSD	By Age/Sex: 50+ Male	423	405	Redacted
TX_NEW_DSD	By Age/Sex: <1 Female	88	119	Redacted
TX_NEW_DSD	By Age/Sex: 1-4 Female	50	67	Redacted
TX_NEW_DSD	By Age/Sex: 5-9 Female	88	119	Redacted
TX_NEW_DSD	By Age/Sex: 10-14 Female	67	92	Redacted
TX_NEW_DSD	By Age/Sex: 15-19 Female	70	66	Redacted
TX_NEW_DSD	By Age/Sex: 20-24 Female	289	276	Redacted
TX_NEW_DSD	By Age/Sex: 25-49 Female	2,468	2,354	Redacted
TX_NEW_DSD	By Age/Sex: 50+ Female	473	454	Redacted
TX_NEW_DSD	Sum of Age/Sex disaggregates	5,663	5,640	Redacted

TX_NEW_DSD	Aggregated Grouping by Age: <1 Male	88	119	Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	294	397	Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	1,776	1,696	Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <1 Female	88	119	Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	293	397	Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	3,300	3,150	Redacted
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	5,663	5,640	Redacted
TX_NEW_DSD	Pregnancy status	358	650	Redacted
TX_NEW_DSD	Breastfeeding status	40	72	Redacted
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	3,434	4,813	Redacted
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	4,040	5,663	Redacted
TX_RET_DSD	Age: 0-4 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	85	119	Redacted
TX_RET_DSD	Age: 5-14 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	231	324	Redacted
TX_RET_DSD	Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating	3,118	4,370	Redacted



	ART)			
TX_RET_DSD	Age: 0-4 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	100	140	Redacted
TX_RET_DSD	Age: 5-14 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	272	382	Redacted
TX_RET_DSD	Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	3,668	5,141	Redacted
TX_RET_DSD	Aggregated Age: <15 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	316	444	Redacted
TX_RET_DSD	Aggregated Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	3,118	4,369	Redacted
TX_RET_DSD	Aggregated Age: <15 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and	372	522	Redacted

	those lost to follow-up)			
TX_RET_DSD	Aggregated Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	3,668	5,141	Redacted
TX_RET_DSD	Pregnancy and breastfeeding status (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	363	725	Redacted
TX_RET_DSD	Pregnancy and breastfeeding status (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	427	853	Redacted
TX_SITE	Number of PEPFAR-supported ART sites with a retention rate of 75% or greater for patients 12 months after ART initiation	40	40	Redacted
TX_SITE	Total number of PEPFAR-supported ART sites	57	57	Redacted
TX_SITE	By support type: Direct Service Delivery (DSD): Number of PEPFAR-supported ART sites with a retention rate of 75% or greater for patients 12 months after ART initiation	40	40	Redacted
TX_SITE	By support type: Technical Assistance (TA-only): Number of PEPFAR-supported ART sites with a retention rate of 75% or greater for patients 12 months after ART initiation	0	0	Redacted

TX_SITE	Sum of Numerator Site Support Type disaggregates	40	40	Redacted
TX_SITE	By support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported ART sites	57	57	Redacted
TX_SITE	By support type: Technical Assistance (TA-only): Total number of PEPFAR-supported ART sites	0	0	Redacted
TX_SITE	Sum of Denominator Site Support Type disaggregates	57	57	Redacted
LAB_CAP_DSD	Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests	30	30	Redacted
LAB_CAP_DSD	By site support type: Direct Service Delivery (DSD)	30	30	Redacted
LAB_CAP_DSD	Sum of Site Support Type disaggregates	30	30	Redacted
FPINT_SITE_DSD	Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	43	43	Redacted
FPINT_SITE_DSD	Total number of PEPFAR-supported HIV service delivery points: PMTCT, Care and Treatment	57	57	Redacted
FPINT_SITE_DSD	By site support type: Direct Service Delivery (DSD): Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	43	43	Redacted
FPINT_SITE_DSD	By site support type: Technical Assistance-only (TA): Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary	0	0	Redacted



	family planning services			
FPINT_SITE_DSD	Sum of Numerator Site Support Type disaggregates	43	43	Redacted
FPINT_SITE_DSD	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported HIV service delivery points	57	57	Redacted
FPINT_SITE_DSD	By site support type: Technical Assistance-only (TA): Total number of PEPFAR-supported HIV service delivery points	0	0	Redacted
FPINT_SITE_DSD	Sum of Denominator Site Support Type disaggregates	57	57	Redacted
FPINT_SITE_DSD	Service delivery type: Clinical	43	43	Redacted
FPINT_SITE_DSD	Sum of Service Delivery Type disaggregates	43	43	Redacted
QI_SITE	Number of PEPFAR-supported clinical service sites with a quality improvement activity completed that addresses clinical HIV programs and has documented process results in the last 6 months	46	46	Redacted
QI_SITE	Total number of PEPFAR-supported sites for any HIV clinical service including HIV Care, HIV Treatment, TB care, PMTCT, VMMC, and HTC	57	57	Redacted
QI_SITE	By site support type: Direct Service Delivery (DSD): Number of PEPFAR-supported clinical service sites with a quality improvement activity completed that addresses clinical HIV programs and has documented results in the last 6 months	46	46	Redacted
QI_SITE	By site support type: Technical Assistance-only (TA): Number of	0	0	Redacted



	PEPFAR-supported clinical service sites with a quality improvement activity completed that addresses clinical HIV programs and has documented results in the last 6 months			
QI_SITE	Sum of Numerator Site Support Type disaggregates	46	46	Redacted
QI_SITE	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported sites for any HIV clinical service including HIV Care, HIV Treatment, TB care, PMTCT, VMMC, HTC	57	57	Redacted
QI_SITE	By site support type: Technical Assistance-only (TA): Total number of PEPFAR-supported sites for any HIV clinical service including HIV Care, HIV Treatment, TB care, PMTCT, VMMC, and HTC	0	0	Redacted
QI_SITE	Sum of Denominator Site Support Type disaggregates	57	57	Redacted
TB_SCREEN_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period	38,235	44,593	Redacted
TB_SCREEN_DSD	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	42,483	46,940	Redacted
TB_SCREEN_DSD	Age: <1	122	142	Redacted
TB_SCREEN_DSD	Age: 1-4	825	962	Redacted
TB_SCREEN_DSD	Age: 5-9	1,456	1,698	Redacted
TB_SCREEN_DSD	Age: 10-14	1,121	1,308	Redacted
TB_SCREEN_DSD	Age: 15-19	773	902	Redacted



TB_SCREEN_DSD	Age: 20-24	2,578	3,006	Redacted
TB_SCREEN_DSD	Age: 25-49	25,320	29,530	Redacted
TB_SCREEN_DSD	Age: 50+	6,040	7,045	Redacted
TB_SCREEN_DSD	Sum of Age disaggregates	4,297	5,012	Redacted
TB_SCREEN_DSD	Aggregated Age - USE WITH HQ PERMISSION ONLY: <15	3,524	4,110	Redacted
TB_SCREEN_DSD	Aggregated Age - USE WITH HQ PERMISSION ONLY: 15+	34,711	40,483	Redacted
TB_SCREEN_DSD	Sum of Aggregated Age disaggregates	38,235	44,593	Redacted
TB_SCREEN_DSD	Sex: Male	13,564	15,819	Redacted
TB_SCREEN_DSD	Sex: Female	24,671	28,774	Redacted
TB_SCREEN_DSD	Sum of Sex disaggregates	38,235	44,593	Redacted

Implementing Mechanism Details

Mechanism ID: 13354	Mechanism Name: Kenya AIDS Response (KARP)
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Kenya Episcopal Conference	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: No	
G2G: Yes	Managing Agency: HHS/CDC

Total All Funding Sources: 7,291,386	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 61,750	
FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount
GHP-State	7,291,386

Sub Partner Name(s)

(No data provided.)



Cross-Cutting Budget Attribution(s)

Human Resources for Health	2,261,693
Gender: GBV	169,134
Focus Area:	Post GBV Care
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Gender: Gender Equality	169,134
Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation

Key Issues

Malaria (PMI)
 Child Survival Activities
 Safe Motherhood
 TB
 Family Planning

Budget Code Information

Mechanism ID:	13354		
Mechanism Name:	Kenya AIDS Response (KARP)		
Prime Partner Name:	Kenya Episcopal Conference		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	231,408	0



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	250,428	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	78,066	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	279,657	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	449,887	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	5,753,295	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	248,645	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2014	2015	Planning Budget Targets
SITE_SUPP	Number of unique sites supported by PEPFAR	57	57	Redacted
SITE_SUPP	By program area/support type: HTC Direct Service Delivery (DSD)	57	57	Redacted
SITE_SUPP	By program area/support type: HTC Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: Treatment Direct Service Delivery (DSD)	57	57	Redacted



SITE_SUPP	By program area/support type: Treatment Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: Care and Support Direct Service Delivery (DSD)	57	57	Redacted
SITE_SUPP	By program area/support type: Care and Support Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: Food and Nutrition Direct Service Delivery (DSD)	57	57	Redacted
SITE_SUPP	By program area/support type: Food and Nutrition Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: PMTCT Direct Service Delivery (DSD)	57	57	Redacted
SITE_SUPP	By program area/support type: PMTCT Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: TB/HIV Direct Service Delivery (DSD)	57	57	Redacted
SITE_SUPP	By program area/support type: TB/HIV Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: VMMC Direct Service Delivery (DSD)	0	0	Redacted
SITE_SUPP	By program area/support type: VMMC Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: General Population Prevention Direct Service Delivery (DSD)	0	0	Redacted
SITE_SUPP	By program area/support type: General Population Prevention Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: Key Populations Prevention Direct Service	0	0	Redacted



	Delivery (DSD)			
SITE_SUPP	By program area/support type: Key Populations Prevention Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: OVC Direct Service Delivery (DSD)	0	0	Redacted
SITE_SUPP	By program area/support type: OVC Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: PHDP/Family Planning & Integration Direct Service Delivery (DSD)	57	57	Redacted
SITE_SUPP	By program area/support type: PHDP/Family Planning & Integration Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: Lab Direct Service Delivery (DSD)	57	57	Redacted
SITE_SUPP	By program area/support type: Lab Technical Assistance-only (TA)	0	0	Redacted
PMTCT_ARV_DS D	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	1,884	1,922	Redacted
PMTCT_ARV_DS D	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	1,884	1,922	Redacted
PMTCT_ARV_DS D	Life-long ART (including Option B+)	1,413	1,441	Redacted
PMTCT_ARV_DS D	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	659	673	Redacted
PMTCT_ARV_DS D	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	754	768	Redacted
PMTCT_ARV_DS	Maternal triple ARV prophylaxis	0	0	Redacted

D	(provided with the intention to stop at the end of the breastfeeding period)			
PMTCT_ARV_DS D	Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)	471	481	Redacted
PMTCT_ARV_DS D	Single-dose nevirapine (with or without tail)	0	0	Redacted
PMTCT_ARV_DS D	Sum of Regimen Type disaggregates	1,884	1,922	Redacted
PMTCT_ARV_DS D	Sum of New and Current disaggregates	1,413	1,441	Redacted
PMTCT_ARV_NGI	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	1,884	1,922	Redacted
PMTCT_ARV_NGI	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	1,884	1,922	Redacted
PMTCT_ARV_NGI	Life-long ART (including Option B+)	1,413	1,441	Redacted
PMTCT_ARV_NGI	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	659	673	Redacted
PMTCT_ARV_NGI	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	754	768	Redacted
PMTCT_ARV_NGI	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)	0	0	Redacted
PMTCT_ARV_NGI	Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)	471	481	Redacted
PMTCT_ARV_NGI	Single-dose nevirapine (with or without tail)	0	0	Redacted
PMTCT_ARV_NGI	Sum of Regimen disaggregates	1,884	1,922	Redacted



PMTCT_ARV_NGI	Sum of New and Current disaggregates	1,413	1,441	Redacted
PMTCT_SITE	Number of PEPFAR-supported sites achieving 90% ARV or ART coverage for HIV+ pregnant women	57	57	Redacted
PMTCT_SITE	Total number of PEPFAR supported sites providing PMTCT services (HTC and ARV or ART services)	57	57	Redacted
PMTCT_SITE	By site support type: Direct Service Delivery (DSD): Number of PEPFAR-supported sites achieving 90% ARV or ART coverage for HIV+ pregnant women	57	57	Redacted
PMTCT_SITE	By site support type: Technical Assistance-only (TA): Number of PEPFAR-supported sites achieving 90% ARV or ART coverage for HIV+ pregnant women	0	0	Redacted
PMTCT_SITE	Sum of Numerator Support Type disaggregates	57	57	Redacted
PMTCT_SITE	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR supported sites providing PMTCT services (HTC and ARV or ART services)	57	57	Redacted
PMTCT_SITE	By site support type: Technical Assistance-only (TA): Total number of PEPFAR supported sites providing PMTCT services (HTC and ARV or ART services)	0	0	Redacted
PMTCT_SITE	Sum of Denominator Support Type disaggregates	57	57	Redacted
PMTCT_STAT_DS D	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	16,694	19,142	Redacted

PMTCT_STAT_DS D	Number of new ANC and L&D clients	16,694	19,142	Redacted
PMTCT_STAT_DS D	By: Known positives at entry	886	904	Redacted
PMTCT_STAT_DS D	By: Number of new positives identified	998	1,018	Redacted
PMTCT_STAT_DS D	Sum of Positives Status disaggregates	1,884	1,922	Redacted
PMTCT_STAT_NG I	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	16,694	19,142	Redacted
PMTCT_STAT_NG I	Number of new ANC and L&D clients	16,694	19,142	Redacted
PMTCT_STAT_NG I	By: Known positives at entry	886	904	Redacted
PMTCT_STAT_NG I	By: Number of new positives identified	998	1,018	Redacted
PMTCT_STAT_NG I	Sum of Positives Status disaggregates	1,884	1,922	Redacted
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	51,300	93,219	Redacted
HTC_TST_DSD	By Test Result: Negative	49,248	89,490	Redacted
HTC_TST_DSD	By Test Result: Positive	2,052	3,729	Redacted
HTC_TST_DSD	Sum of Test Result disaggregates	51,300	93,219	Redacted
HTC_TST_DSD	Age/sex: <1 Male	0	0	Redacted
HTC_TST_DSD	Age/sex: 1-4 Male	1,795	3,263	Redacted
HTC_TST_DSD	Age/sex: 5-9 Male	770	1,398	Redacted
HTC_TST_DSD	Age/sex: 10-14 Male	1,282	2,330	Redacted
HTC_TST_DSD	Age/sex: 15-19 Male	2,565	4,661	Redacted
HTC_TST_DSD	Age/sex: 20-24 Male	6,413	11,652	Redacted
HTC_TST_DSD	Age/sex: 25-49 Male	10,260	18,644	Redacted
HTC_TST_DSD	Age/sex: 50+ Male	2,565	4,661	Redacted



HTC_TST_DSD	Age/sex: <1 Female	0	0	Redacted
HTC_TST_DSD	Age/sex: 1-4 Female	1,795	3,263	Redacted
HTC_TST_DSD	Age/sex: 5-9 Female	770	1,398	Redacted
HTC_TST_DSD	Age/sex: 10-14 Female	1,282	2,330	Redacted
HTC_TST_DSD	Age/sex: 15-19 Female	2,565	4,661	Redacted
HTC_TST_DSD	Age/sex: 20-24 Female	6,413	11,652	Redacted
HTC_TST_DSD	Age/sex: 25-49 Female	10,260	18,644	Redacted
HTC_TST_DSD	Age/sex: 50+ Female	2,565	4,662	Redacted
HTC_TST_DSD	Sum of Age/Sex disaggregates	51,300	93,219	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	3,847	6,991	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	21,803	39,618	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	3,847	6,991	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	21,803	39,619	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	7,694	13,982	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	43,606	79,237	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	51,300	93,219	Redacted
HTC_TST_NGI	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	51,300	93,219	Redacted
HTC_TST_NGI	By Test Result: Negative	49,248	89,490	Redacted
HTC_TST_NGI	By Test Result: Positive	2,052	3,729	Redacted
HTC_TST_NGI	Sum of Test Result disaggregates	51,300	93,219	Redacted
HTC_TST_NGI	Age/sex: <1 Male	0	0	Redacted
HTC_TST_NGI	Age/sex: 1-4 Male	1,795	3,263	Redacted
HTC_TST_NGI	Age/sex: 5-9 Male	770	1,398	Redacted
HTC_TST_NGI	Age/sex: 10-14 Male	1,282	2,330	Redacted
HTC_TST_NGI	Age/sex: 15-19 Male	2,565	4,661	Redacted
HTC_TST_NGI	Age/sex: 20-24 Male	6,413	11,652	Redacted



HTC_TST_NGI	Age/sex: 25-49 Male	10,260	18,644	Redacted
HTC_TST_NGI	Age/sex: 50+ Male	2,565	4,661	Redacted
HTC_TST_NGI	Age/sex: <1 Female	0	0	Redacted
HTC_TST_NGI	Age/sex: 1-4 Female	1,795	3,263	Redacted
HTC_TST_NGI	Age/sex: 5-9 Female	770	1,398	Redacted
HTC_TST_NGI	Age/sex: 10-14 Female	1,282	2,330	Redacted
HTC_TST_NGI	Age/sex: 15-19 Female	2,565	4,661	Redacted
HTC_TST_NGI	Age/sex: 20-24 Female	6,413	11,652	Redacted
HTC_TST_NGI	Age/sex: 25-49 Female	10,260	18,644	Redacted
HTC_TST_NGI	Age/sex: 50+ Female	2,565	4,662	Redacted
HTC_TST_NGI	Sum of Age/Sex disaggregates	51,300	93,219	Redacted
HTC_TST_NGI	Aggregated Age/sex: <15 Male	3,847	6,991	Redacted
HTC_TST_NGI	Aggregated Age/sex: 15+ Male	21,803	39,618	Redacted
HTC_TST_NGI	Aggregated Age/sex: <15 Female	3,847	6,991	Redacted
HTC_TST_NGI	Aggregated Age/sex: 15+ Female	21,803	39,619	Redacted
HTC_TST_NGI	Sum of Aggregated Age/Sex <15	7,694	13,982	Redacted
HTC_TST_NGI	Sum of Aggregated Age/Sex 15+	43,606	79,237	Redacted
HTC_TST_NGI	Sum of Aggregated Age/Sex disaggregates	51,300	93,219	Redacted
C2.1.D_DSD	Number of HIV-positive individuals receiving a minimum of one clinical service	51,168	55,931	Redacted
C2.1.D_DSD	By Age/Sex: <15 Female	2,303	2,523	Redacted
C2.1.D_DSD	By Age/Sex: <15 Male	2,303	2,523	Redacted
C2.1.D_DSD	By Age/Sex: 15+ Female	30,731	33,584	Redacted
C2.1.D_DSD	By Age/Sex: 15+ Male	15,831	17,301	Redacted
C2.1.D_DSD	Sum of Age/Sex disaggregates	51,168	55,931	Redacted
C2.1.D_DSD	By Age: <15	4,606	5,046	Redacted
C2.1.D_DSD	By Age: 15+	46,562	50,885	Redacted
C2.1.D_DSD	Sum of Age disaggregates	51,168	55,931	Redacted
C2.1.D_DSD	By Sex: Female	33,034	36,107	Redacted
C2.1.D_DSD	By Sex: Male	18,134	19,824	Redacted



C2.1.D_DSD	Sum of Sex disaggregates	51,168	55,931	Redacted
C2.1.D_NGI	Number of HIV-positive individuals receiving a minimum of one clinical service	51,168	55,931	Redacted
C2.1.D_NGI	By Age/Sex: <15 Female	2,303	2,523	Redacted
C2.1.D_NGI	By Age/Sex: <15 Male	2,303	2,523	Redacted
C2.1.D_NGI	By Age/Sex: 15+ Female	30,731	33,584	Redacted
C2.1.D_NGI	By Age/Sex: 15+ Male	15,831	17,301	Redacted
C2.1.D_NGI	Sum of Age/Sex disaggregates	51,168	55,931	Redacted
C2.1.D_NGI	By Age: <15	4,606	5,046	Redacted
C2.1.D_NGI	By Age: 15+	46,562	50,885	Redacted
C2.1.D_NGI	Sum of Age disaggregates	51,168	55,931	Redacted
C2.1.D_NGI	By Sex: Female	33,034	36,107	Redacted
C2.1.D_NGI	By Sex: Male	18,134	19,824	Redacted
C2.1.D_NGI	Sum of Sex disaggregates	51,168	55,931	Redacted
C2.4.D_DSD	Number of HIV-positive patients who were screened for TB in HIV care or treatment setting	46,051	53,135	Redacted
C2.4.D_DSD	Number of HIV-positive individuals receiving a minimum of one clinical service	51,168	55,931	Redacted
C2.5.D_DSD	Number of HIV-positive patients in HIV care who started TB treatment	921	1,063	Redacted
C2.5.D_DSD	Number of HIV-positive individuals receiving a minimum of one clinical service	51,168	55,931	Redacted
CARE_CURR_DS D	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	48,610	53,135	Redacted
CARE_CURR_DS D	Age/sex: <1 Male	76	83	Redacted
CARE_CURR_DS	Age/sex: 1-4 Male	499	576	Redacted



D				
CARE_CURR_DS D	Age/sex: 5-9 Male	919	973	Redacted
CARE_CURR_DS D	Age/sex: 10-14 Male	693	765	Redacted
CARE_CURR_DS D	Age/sex: 15-19 Male	373	408	Redacted
CARE_CURR_DS D	Age/sex: 20-24 Male	691	755	Redacted
CARE_CURR_DS D	Age/sex: 25-49 Male	10,387	11,351	Redacted
CARE_CURR_DS D	Age/sex: 50+ Male	3,590	3,922	Redacted
CARE_CURR_DS D	Age/sex: <1 Female	76	83	Redacted
CARE_CURR_DS D	Age/sex: 1-4 Female	499	576	Redacted
CARE_CURR_DS D	Age/sex: 5-9 Female	919	973	Redacted
CARE_CURR_DS D	Age/sex: 10-14 Female	693	765	Redacted
CARE_CURR_DS D	Age/sex: 15-19 Female	616	673	Redacted
CARE_CURR_DS D	Age/sex: 20-24 Female	2,556	2,793	Redacted
CARE_CURR_DS D	Age/sex: 25-49 Female	21,828	23,854	Redacted
CARE_CURR_DS D	Age/sex: 50+ Female	4,195	4,585	Redacted
CARE_CURR_DS D	Sun of Age/Sex disaggregates	48,610	53,135	Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	2,187	2,397	Redacted
CARE_CURR_DS	Aggregated Age/sex - USE WITH HQ	15,041	16,436	Redacted



D	PERMISSION ONLY: 15+ Male			
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	2,187	2,397	Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	29,195	31,905	Redacted
CARE_CURR_DS D	Sum of Aggregated Age/Sex disaggregates	48,610	53,135	Redacted
CARE_NEW_DSD	Number of HIV-infected adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load	9,722	9,661	Redacted
CARE_NEW_DSD	Age/sex: <1 Male	15	15	Redacted
CARE_NEW_DSD	Age/sex: 1-4 Male	105	105	Redacted
CARE_NEW_DSD	Age/sex: 5-9 Male	178	177	Redacted
CARE_NEW_DSD	Age/sex: 10-14 Male	139	139	Redacted
CARE_NEW_DSD	Age/sex: 15-19 Male	63	63	Redacted
CARE_NEW_DSD	Age/sex: 20-24 Male	263	262	Redacted
CARE_NEW_DSD	Age/sex: 25-49 Male	2,250	2,234	Redacted
CARE_NEW_DSD	Age/sex: 50+ Male	433	430	Redacted
CARE_NEW_DSD	Age/sex: <1 Female	15	15	Redacted
CARE_NEW_DSD	Age/sex: 1-4 Female	100	99	Redacted
CARE_NEW_DSD	Age/sex: 5-9 Female	184	183	Redacted
CARE_NEW_DSD	Age/sex: 10-14 Female	138	139	Redacted
CARE_NEW_DSD	Age/sex: 15-19 Female	145	144	Redacted
CARE_NEW_DSD	Age/sex: 20-24 Female	268	267	Redacted
CARE_NEW_DSD	Age/sex: 25-49 Female	4,033	4,006	Redacted
CARE_NEW_DSD	Age/sex: 50+ Female	1,393	1,383	Redacted
CARE_NEW_DSD	Sum of Age/sex disaggregates	9,722	9,661	Redacted
CARE_NEW_DSD	Aggregated Age/sex: <15 Male	437	436	Redacted
CARE_NEW_DSD	Aggregated Age/sex: 15+ Male	3,009	2,989	Redacted
CARE_NEW_DSD	Aggregated Age/sex: <15 Female	437	436	Redacted



CARE_NEW_DSD	Aggregated Age/sex: 15+ Female	5,839	5,800	Redacted
CARE_NEW_DSD	Sum of Aggregated Age/sex disaggregates	9,722	9,661	Redacted
CARE_SITE	Number of PEPFAR-supported HIV clinical care sites at which at least 80% of PLHIV received all of the following during the reporting period: 1) clinical assessment (WHO staging) OR CD4 count OR viral load, AND 2) TB screening at last visit, AND 3) if eligible, cotrimoxazole	57	57	Redacted
CARE_SITE	Total number of PEPFAR supported sites providing clinical care services	57	57	Redacted
CARE_SITE	By site support type: Direct Service Delivery (DSD): Number of PEPFAR-supported HIV clinical care sites at which at least 80% of PLHIV received all of the following during the reporting period: 1) clinical assessment (WHO staging) OR CD4 count OR viral load, AND 2) TB screening at last visit, AND 3) if eligible, cotrimoxazole	57	57	Redacted
CARE_SITE	By site support type: Technical Assistance-only (TA): Number of PEPFAR-supported HIV clinical care sites at which at least 80% of PLHIV received all of the following during the reporting period: 1) clinical assessment (WHO staging) OR CD4 count OR viral load, AND 2) TB screening at last visit, AND 3) if eligible, cotrimoxazole	0	0	Redacted
CARE_SITE	Sum of Numerator Site Support Type disaggregates	57	57	Redacted
CARE_SITE	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR supported sites providing	57	57	Redacted

	clinical care services			
CARE_SITE	By site support type: Technical Assistance-only (TA): Total number of PEPFAR supported sites providing clinical care services	0	0	Redacted
CARE_SITE	Sum of Denominator Site Support Type disaggregates	57	57	Redacted
FN_SITE	Number of PEPFAR-supported sites achieving 90% nutrition assessments that result in accurate categorization of malnutrition	51	51	Redacted
FN_SITE	Total number of PEPFAR-supported sites providing nutrition assessment, counseling and support (NACS) services	57	57	Redacted
FN_SITE	By site support type: Direct Service Delivery (DSD): Number of PEPFAR-supported sites achieving 90% nutrition assessments that result in accurate categorization of malnutrition	51	51	Redacted
FN_SITE	By site support type: Technical Assistance-only (TA): Number of PEPFAR-supported sites achieving 90% nutrition assessments that result in accurate categorization of malnutrition	0	0	Redacted
FN_SITE	Sum of Numerator Support Type disaggregates	51	51	Redacted
FN_SITE	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported sites providing nutrition assessment, counseling and support (NACS) services	57	57	Redacted
FN_SITE	By site support type: Technical	0	0	Redacted

	Assistance-only (TA): Total number of PEPFAR-supported sites providing nutrition assessment, counseling and support (NACS) services			
FN_SITE	Sum of Denominator Support Type disaggregates	57	57	Redacted
FN_THER_DSD	Number of clinically malnourished PLHIV who received therapeutic and/or supplementary food during the reporting period.	7,675	8,390	Redacted
FN_THER_DSD	Number of PLHIV who were nutritionally assessed and found to be clinically undernourished.	10,234	11,186	Redacted
FN_THER_DSD	Age: <1	24	27	Redacted
FN_THER_DSD	Age: 1-4	166	181	Redacted
FN_THER_DSD	Age: 5-14	517	565	Redacted
FN_THER_DSD	Age: 15-17	155	170	Redacted
FN_THER_DSD	Age: 18+	6,813	7,447	Redacted
FN_THER_DSD	Sum of Age disaggregates	7,675	8,390	Redacted
FN_THER_DSD	Aggregated Age: <18	862	943	Redacted
FN_THER_DSD	Aggregated Age: 18+	6,813	7,447	Redacted
FN_THER_DSD	Sum of Aggregated Age disaggregates	7,675	8,390	Redacted
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	1,957	2,391	Redacted
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	2,303	2,657	Redacted
TB_ART_DSD	Age: 0-4	48	59	Redacted
TB_ART_DSD	Age: 5-14	132	161	Redacted
TB_ART_DSD	Age: 15+	1,777	2,171	Redacted



TB_ART_DSD	Male	1,057	1,291	Redacted
TB_ART_DSD	Female	900	1,100	Redacted
TB_ART_DSD	Sum of Sex disaggregates	1,957	2,391	Redacted
TB_ART_DSD	Newly tested	1,174	1,435	Redacted
TB_ART_DSD	Known HIV-positive	783	956	Redacted
TB_ART_DSD	Sum of Test Status disaggregates	1,957	2,391	Redacted
TB_ART_DSD	Aggregated Age: <15	180	220	Redacted
TB_ART_DSD	Aggregated Age: 15+	1,777	2,171	Redacted
TB_ART_DSD	Sum of Aggregated Age disaggregates	1,957	2,391	Redacted
TB_ARTSITE	The number of PEPFAR-supported TB basic management units at which 80% of registered TB cases who are HIV-positive are on ART, during the reporting period	57	57	Redacted
TB_ARTSITE	The number of PEPFAR-supported TB basic management units	57	57	Redacted
TB_ARTSITE	By site support type: Direct Service Delivery (DSD): The number of PEPFAR-supported TB basic management units at which 80% of registered TB cases who are HIV-positive are on ART, during the reporting period	57	57	Redacted
TB_ARTSITE	By site support type: Technical Assistance-only (TA): The number of PEPFAR-supported TB basic management units at which 80% of registered TB cases who are HIV-positive are on ART, during the reporting period	0	0	Redacted
TB_ARTSITE	Sum of Numerator Site Support Type disaggregates	57	57	Redacted
TB_ARTSITE	By site support type: Direct Service Delivery (DSD): The number of	57	57	Redacted



	PEPFAR-supported TB basic management units			
TB_ARTSITE	By site support type: Technical Assistance-only (TA): The number of PEPFAR-supported TB basic management units	0	0	Redacted
TB_ARTSITE	Sum of Denominator Site Support Type disaggregates	57	57	Redacted
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	1,507	1,537	Redacted
PMTCT_EID_DSD	Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT)	1,884	1,922	Redacted
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	1,130	1,153	Redacted
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	377	384	Redacted
PMTCT_EID_DSD	Sum of Infant Age disaggregates	1,507	1,537	Redacted
PMTCT_EID_DSD	By infants with a positive virologic test result within 12 months of birth	75	77	Redacted
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	43,898	52,332	Redacted
TX_CURR_DSD	Age/Sex: <1 Male	68	82	Redacted
TX_CURR_DSD	Age/Sex: 1-4 Male	462	553	Redacted
TX_CURR_DSD	Age/Sex: 5-14 Male	1,445	1,725	Redacted
TX_CURR_DSD	Age/Sex: 15+ Male	13,582	16,664	Redacted
TX_CURR_DSD	Age/Sex: <1 Female	68	82	Redacted
TX_CURR_DSD	Age/Sex: 1-4 Female	462	553	Redacted
TX_CURR_DSD	Age/Sex: 5-14 Female	1,445	1,725	Redacted
TX_CURR_DSD	Age/Sex: 15+ Female	26,366	30,948	Redacted
TX_CURR_DSD	Sum of age/sex disaggregates	3,950	4,720	Redacted



TX_CURR_DSD	Percent children with advanced HIV infection receiving antiretroviral therapy (ART) [CURRENT]	1	1	Redacted
TX_CURR_DSD	Percent women and girls with advanced HIV infection receiving antiretroviral therapy (ART) [CURRENT]	1	1	Redacted
TX_CURR_DSD	Aggregated Age/Sex: <1 Male	68	82	Redacted
TX_CURR_DSD	Aggregated Age/Sex: <1 Female	68	82	Redacted
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	1,975	2,360	Redacted
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	13,582	16,664	Redacted
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	1,975	2,360	Redacted
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	26,366	30,948	Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	3,950	4,720	Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	39,948	47,612	Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	43,898	52,332	Redacted
TX_CURR_NGI	Number of adults and children receiving antiretroviral therapy (ART)	43,898	52,332	Redacted
TX_CURR_NGI	Age/Sex: <1 Male	68	82	Redacted
TX_CURR_NGI	Age/Sex: 1-4 Male	462	553	Redacted
TX_CURR_NGI	Age/Sex: 5-14 Male	1,445	1,725	Redacted
TX_CURR_NGI	Age/Sex: 15+ Male	13,582	16,664	Redacted
TX_CURR_NGI	Age/Sex: <1 Female	68	82	Redacted
TX_CURR_NGI	Age/Sex: 1-4 Female	463	553	Redacted
TX_CURR_NGI	Age/Sex: 5-14 Female	1,445	1,725	Redacted
TX_CURR_NGI	Age/Sex: 15+ Female	26,365	30,948	Redacted
TX_CURR_NGI	Sum of Age/Sex disaggregates	43,898	52,332	Redacted
TX_CURR_NGI	Aggregated Age/Sex: <1 Male	68	82	Redacted
TX_CURR_NGI	Aggregated Age/Sex: <1 Female	68	82	Redacted
TX_CURR_NGI	Aggregated Age/Sex: <15 Male	1,975	2,360	Redacted
TX_CURR_NGI	Aggregated Age/Sex: 15+ Male	13,583	16,664	Redacted
TX_CURR_NGI	Aggregated Age/Sex: <15 Female	1,975	2,360	Redacted



TX_CURR_NGI	Aggregated Age/Sex: 15+ Female	26,365	30,948	Redacted
TX_CURR_NGI	Sum of Aggregated Age/Sex disaggregates	43,898	52,332	Redacted
TX_CURR_NGI	Sum of Aggregated Age/Sex <15	3,950	4,720	Redacted
TX_CURR_NGI	Sum of Aggregated Age/Sex 15+	39,948	47,612	Redacted
TX_DIST	Number of Districts with documented routine supportive supervision visits to 75% of HIV care and treatment sites supported by the District	7	7	Redacted
TX_DIST	Total number of PEPFAR supported District Health Offices	9	9	Redacted
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	6,267	6,184	Redacted
TX_NEW_DSD	By Age/Sex: <1 Male	97	131	Redacted
TX_NEW_DSD	By Age/Sex: 1-4 Male	55	74	Redacted
TX_NEW_DSD	By Age/Sex: 5-9 Male	97	131	Redacted
TX_NEW_DSD	By Age/Sex: 10-14 Male	75	100	Redacted
TX_NEW_DSD	By Age/Sex: 15-19 Male	49	46	Redacted
TX_NEW_DSD	By Age/Sex: 20-24 Male	90	85	Redacted
TX_NEW_DSD	By Age/Sex: 25-49 Male	1,358	1,283	Redacted
TX_NEW_DSD	By Age/Sex: 50+ Male	470	445	Redacted
TX_NEW_DSD	By Age/Sex: <1 Female	97	131	Redacted
TX_NEW_DSD	By Age/Sex: 1-4 Female	55	74	Redacted
TX_NEW_DSD	By Age/Sex: 5-9 Female	97	130	Redacted
TX_NEW_DSD	By Age/Sex: 10-14 Female	75	101	Redacted
TX_NEW_DSD	By Age/Sex: 15-19 Female	77	73	Redacted
TX_NEW_DSD	By Age/Sex: 20-24 Female	320	302	Redacted
TX_NEW_DSD	By Age/Sex: 25-49 Female	2,730	2,582	Redacted
TX_NEW_DSD	By Age/Sex: 50+ Female	525	496	Redacted
TX_NEW_DSD	Sum of Age/Sex disaggregates	6,267	6,184	Redacted
TX_NEW_DSD	Aggregated Grouping by Age: <1 Male	97	131	Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	324	436	Redacted

TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	1,967	1,859	Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <1 Female	97	131	Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	324	436	Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	3,652	3,453	Redacted
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	6,267	6,184	Redacted
TX_NEW_DSD	Pregnancy status	593	605	Redacted
TX_NEW_DSD	Breastfeeding status	66	67	Redacted
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	4,223	5,327	Redacted
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	4,968	6,267	Redacted
TX_RET_DSD	Age: 0-4 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	105	132	Redacted
TX_RET_DSD	Age: 5-14 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	285	359	Redacted
TX_RET_DSD	Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	3,834	4,836	Redacted
TX_RET_DSD	Age: 0-4 (Denominator: Total number of adults and children who initiated ART)	123	155	Redacted

	in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)			
TX_RET_DSD	Age: 5-14 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	335	422	Redacted
TX_RET_DSD	Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	4,510	5,690	Redacted
TX_RET_DSD	Aggregated Age: <15 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	389	491	Redacted
TX_RET_DSD	Aggregated Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	3,834	4,836	Redacted
TX_RET_DSD	Aggregated Age: <15 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	458	578	Redacted
TX_RET_DSD	Aggregated Age: 15+ (Denominator: Total number of adults and children	4,510	5,690	Redacted

	who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)			
TX_RET_DSD	Pregnancy and breastfeeding status (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	600	1,201	Redacted
TX_RET_DSD	Pregnancy and breastfeeding status (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	706	1,413	Redacted
TX_SITE	Number of PEPFAR-supported ART sites with a retention rate of 75% or greater for patients 12 months after ART initiation	40	40	Redacted
TX_SITE	Total number of PEPFAR-supported ART sites	57	57	Redacted
TX_SITE	By support type: Direct Service Delivery (DSD): Number of PEPFAR-supported ART sites with a retention rate of 75% or greater for patients 12 months after ART initiation	40	40	Redacted
TX_SITE	By support type: Technical Assistance (TA-only): Number of PEPFAR-supported ART sites with a retention rate of 75% or greater for patients 12 months after ART initiation	0	0	Redacted
TX_SITE	Sum of Numerator Site Support Type disaggregates	40	40	Redacted



TX_SITE	By support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported ART sites	57	57	Redacted
TX_SITE	By support type: Technical Assistance (TA-only): Total number of PEPFAR-supported ART sites	0	0	Redacted
TX_SITE	Sum of Denominator Site Support Type disaggregates	57	57	Redacted
LAB_CAP_DSD	Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests	57	57	Redacted
LAB_CAP_DSD	By site support type: Direct Service Delivery (DSD)	57	57	Redacted
LAB_CAP_DSD	Sum of Site Support Type disaggregates	57	57	Redacted
FPINT_SITE_DSD	Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	44	44	Redacted
FPINT_SITE_DSD	Total number of PEPFAR-supported HIV service delivery points: PMTCT, Care and Treatment	57	57	Redacted
FPINT_SITE_DSD	By site support type: Direct Service Delivery (DSD): Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	44	44	Redacted
FPINT_SITE_DSD	By site support type: Technical Assistance-only (TA): Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	0	0	Redacted
FPINT_SITE_DSD	Sum of Numerator Site Support Type	44	44	Redacted



	disaggregates			
FPINT_SITE_DSD	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported HIV service delivery points	57	57	Redacted
FPINT_SITE_DSD	By site support type: Technical Assistance-only (TA): Total number of PEPFAR-supported HIV service delivery points	0	0	Redacted
FPINT_SITE_DSD	Sum of Denominator Site Support Type disaggregates	57	57	Redacted
FPINT_SITE_DSD	Service delivery type: Clinical	44	44	Redacted
FPINT_SITE_DSD	Sum of Service Delivery Type disaggregates	44	44	Redacted
QI_SITE	Number of PEPFAR-supported clinical service sites with a quality improvement activity completed that addresses clinical HIV programs and has documented process results in the last 6 months	46	46	Redacted
QI_SITE	Total number of PEPFAR-supported sites for any HIV clinical service including HIV Care, HIV Treatment, TB care, PMTCT, VMMC, and HTC	57	57	Redacted
QI_SITE	By site support type: Direct Service Delivery (DSD): Number of PEPFAR-supported clinical service sites with a quality improvement activity completed that addresses clinical HIV programs and has documented results in the last 6 months	46	46	Redacted
QI_SITE	By site support type: Technical Assistance-only (TA): Number of PEPFAR-supported clinical service sites with a quality improvement activity	0	0	Redacted



	completed that addresses clinical HIV programs and has documented results in the last 6 months			
QI_SITE	Sum of Numerator Site Support Type disaggregates	46	46	Redacted
QI_SITE	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported sites for any HIV clinical service including HIV Care, HIV Treatment, TB care, PMTCT, VMMC, HTC	57	57	Redacted
QI_SITE	By site support type: Technical Assistance-only (TA): Total number of PEPFAR-supported sites for any HIV clinical service including HIV Care, HIV Treatment, TB care, PMTCT, VMMC, and HTC	0	0	Redacted
QI_SITE	Sum of Denominator Site Support Type disaggregates	57	57	Redacted
TB_SCREEN_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period	43,749	50,478	Redacted
TB_SCREEN_DSD	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	48,610	53,135	Redacted
TB_SCREEN_DSD	Age: <1	139	161	Redacted
TB_SCREEN_DSD	Age: 1-4	944	1,089	Redacted
TB_SCREEN_DSD	Age: 5-9	1,666	1,922	Redacted
TB_SCREEN_DSD	Age: 10-14	1,283	1,480	Redacted
TB_SCREEN_DSD	Age: 15-19	885	1,021	Redacted
TB_SCREEN_DSD	Age: 20-24	2,950	3,403	Redacted
TB_SCREEN_DSD	Age: 25-49	28,971	33,427	Redacted



TB_SCREEN_DSD	Age: 50+	6,911	7,975	Redacted
TB_SCREEN_DSD	Sum of Age disaggregates	4,917	5,673	Redacted
TB_SCREEN_DSD	Aggregated Age - USE WITH HQ PERMISSION ONLY: <15	4,032	4,652	Redacted
TB_SCREEN_DSD	Aggregated Age - USE WITH HQ PERMISSION ONLY: 15+	39,717	45,826	Redacted
TB_SCREEN_DSD	Sum of Aggregated Age disaggregates	43,749	50,478	Redacted
TB_SCREEN_DSD	Sex: Male	15,520	17,907	Redacted
TB_SCREEN_DSD	Sex: Female	28,229	32,571	Redacted
TB_SCREEN_DSD	Sum of Sex disaggregates	43,749	50,478	Redacted

Implementing Mechanism Details

Mechanism ID: 13346	Mechanism Name: Support Services for HIV Pandemic
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: World Health Organization	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: No	
G2G: No	Managing Agency:

Total All Funding Sources: 381,000	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 0	
FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount
GHP-State	381,000

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

Human Resources for Health	381,000
----------------------------	---------



Key Issues

- Child Survival Activities
- Safe Motherhood
- TB
- Family Planning

Budget Code Information

Mechanism ID: 13346			
Mechanism Name: Support Services for HIV Pandemic			
Prime Partner Name: World Health Organization			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	100,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	35,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	60,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	IDUP	36,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	150,000	0

Implementing Mechanism Indicator Information

(No data provided.)



Implementing Mechanism Details

Mechanism ID: 13340	Mechanism Name: APHIAPlus Rift Valley
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: FHI 360	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: No	
G2G: No	Managing Agency:
Total All Funding Sources: 8,963,225	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 2,196,655	
FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount
GHP-State	8,963,225

Sub Partner Name(s)

African Medical and Research Foundation, Kenya	Catholic Relief Services	Liverpool VCT and Care
National Organisation for Peer Educators (NOPE)		

Cross-Cutting Budget Attribution(s)

Economic Strengthening	900,000
Education	200,000
Gender: GBV	100,000
Focus Area:	GBV Prevention
Sub Area:	Implementation
Sub Area:	Capacity building



Key Issues

(No data provided.)

Budget Code Information

Mechanism ID: 13340			
Mechanism Name: APHIAPlus Rift Valley			
Prime Partner Name: FHI 360			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	350,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	3,220,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	170,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	200,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	62,098	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	1,000,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	3,661,127	0



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	300,000	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2014	2015
SITE_SUPP	By program area/support type: HTC Direct Service Delivery (DSD)	26	26
SITE_SUPP	By program area/support type: HTC Technical Assistance-only (TA)	453	453
SITE_SUPP	By program area/support type: Treatment Direct Service Delivery (DSD)	29	29
SITE_SUPP	By program area/support type: Treatment Technical Assistance-only (TA)	84	84
SITE_SUPP	By program area/support type: Care and Support Direct Service Delivery (DSD)	18	18
SITE_SUPP	By program area/support type: Care and Support Technical Assistance-only (TA)	95	95
SITE_SUPP	By program area/support type: Food and Nutrition Direct Service Delivery (DSD)	17	17
SITE_SUPP	By program area/support type: Food and Nutrition Technical Assistance-only (TA)	36	36
SITE_SUPP	By program area/support type: PMTCT Direct Service Delivery (DSD)	18	18
SITE_SUPP	By program area/support type: PMTCT Technical Assistance-only (TA)	402	402
SITE_SUPP	By program area/support type: TB/HIV Direct Service Delivery (DSD)	0	0
SITE_SUPP	By program area/support type: TB/HIV Technical Assistance-only (TA)	100	100
SITE_SUPP	By program area/support type: VMMC Direct Service Delivery (DSD)	5	5



SITE_SUPP	By program area/support type: VMMC Technical Assistance-only (TA)	0	0
SITE_SUPP	By program area/support type: General Population Prevention Direct Service Delivery (DSD)	8	8
SITE_SUPP	By program area/support type: General Population Prevention Technical Assistance-only (TA)	0	0
SITE_SUPP	By program area/support type: Key Populations Prevention Direct Service Delivery (DSD)	2	2
SITE_SUPP	By program area/support type: Key Populations Prevention Technical Assistance-only (TA)	0	0
SITE_SUPP	By program area/support type: OVC Direct Service Delivery (DSD)	16	16
SITE_SUPP	By program area/support type: OVC Technical Assistance-only (TA)	0	0
SITE_SUPP	By program area/support type: PHDP/Family Planning & Integration Direct Service Delivery (DSD)	29	29
SITE_SUPP	By program area/support type: PHDP/Family Planning & Integration Technical Assistance-only (TA)	71	71
SITE_SUPP	By program area/support type: Lab Direct Service Delivery (DSD)	0	0
SITE_SUPP	By program area/support type: Lab Technical Assistance-only (TA)	73	73
PMTCT_ARV_DSD	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	266	188
PMTCT_ARV_DSD	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	271	196



PMTCT_ARV_DSD	Life-long ART (including Option B+)	212	156
PMTCT_ARV_DSD	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	106	78
PMTCT_ARV_DSD	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	106	78
PMTCT_ARV_DSD	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)	0	0
PMTCT_ARV_DSD	Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)	54	32
PMTCT_ARV_DSD	Single-dose nevirapine (with or without tail)	0	0
PMTCT_ARV_DSD	Sum of Regimen Type disaggregates	266	188
PMTCT_ARV_DSD	Sum of New and Current disaggregates	212	156
PMTCT_ARV_NGI	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	6,652	4,694
PMTCT_ARV_NGI	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	6,785	4,890
PMTCT_ARV_NGI	Life-long ART (including Option B+)	5,322	3,912
PMTCT_ARV_NGI	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	2,661	1,956
PMTCT_ARV_NGI	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	2,661	1,956
PMTCT_ARV_NGI	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)	0	0
PMTCT_ARV_NGI	Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)	1,330	782



PMTCT_ARV_NGI	Single-dose nevirapine (with or without tail)	0	0
PMTCT_ARV_NGI	Sum of Regimen disaggregates	6,652	4,694
PMTCT_ARV_NGI	Sum of New and Current disaggregates	5,322	3,912
PMTCT_ARV_TA	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	6,386	4,507
PMTCT_ARV_TA	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	6,514	4,694
PMTCT_ARV_TA	Life-long ART (including Option B+)	5,108	3,756
PMTCT_ARV_TA	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	2,554	1,878
PMTCT_ARV_TA	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	2,554	1,878
PMTCT_ARV_TA	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)	0	0
PMTCT_ARV_TA	Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)	1,278	751
PMTCT_ARV_TA	Single-dose nevirapine (with or without tail)	0	0
PMTCT_ARV_TA	Sum of Regimen Type disaggregates	6,386	4,507
PMTCT_ARV_TA	Sum of New and Current disaggregates	5,108	3,756
PMTCT_SITE	Number of PEPFAR-supported sites achieving 90% ARV or ART coverage for HIV+ pregnant women	220	220
PMTCT_SITE	Total number of PEPFAR supported sites providing PMTCT services (HTC and ARV or ART services)	420	420
PMTCT_SITE	By site support type: Technical Assistance-only (TA): Number of PEPFAR-supported sites achieving 90% ARV	220	220



	or ART coverage for HIV+ pregnant women		
PMTCT_SITE	Sum of Numerator Support Type disaggregates	220	220
PMTCT_SITE	By site support type: Technical Assistance-only (TA): Total number of PEPFAR supported sites providing PMTCT services (HTC and ARV or ART services)	420	420
PMTCT_SITE	Sum of Denominator Support Type disaggregates	420	420
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	5,860	6,152
PMTCT_STAT_DSD	Number of new ANC and L&D clients	5,978	6,275
PMTCT_STAT_DSD	By: Known positives at entry	109	78
PMTCT_STAT_DSD	By: Number of new positives identified	163	117
PMTCT_STAT_DSD	Sum of Positives Status disaggregates	272	195
PMTCT_STAT_NGI	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	146,509	153,808
PMTCT_STAT_NGI	Number of new ANC and L&D clients	149,439	156,884
PMTCT_STAT_NGI	By: Known positives at entry	2,714	1,956
PMTCT_STAT_NGI	By: Number of new positives identified	4,071	2,934
PMTCT_STAT_NGI	Sum of Positives Status disaggregates	6,785	4,890
VMMC_AE_DSD	Number of males circumcised surgically or by medical device that experienced at least one moderate or severe adverse event(s) (AEs)	23	23
VMMC_AE_DSD	By AE type: Number of VMMC clients with one or more moderate or severe surgical intra-operative AE(s)	3	3
VMMC_AE_DSD	By AE Type: Number of VMMC clients with one or more moderate or severe surgical post-operative AE(s)	20	20
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC)	1,018	1,018

	for HIV prevention program within the reporting period		
VMMC_CIRC_DSD	By Age: <1	0	0
VMMC_CIRC_DSD	By Age: 1-9	0	0
VMMC_CIRC_DSD	By Age: 10-14	102	102
VMMC_CIRC_DSD	By Age: 15-19	305	305
VMMC_CIRC_DSD	By Age: 20-24	407	407
VMMC_CIRC_DSD	By Age: 25-49	153	153
VMMC_CIRC_DSD	By Age: 50+	51	51
VMMC_CIRC_DSD	Sum of age disaggregates	1,018	1,018
VMMC_CIRC_DSD	By circumcision technique: Surgical VMMC	1,018	1,018
VMMC_CIRC_NGI	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	1,018	1,018
VMMC_CIRC_NGI	By Age: <1	0	0
VMMC_CIRC_NGI	By Age: 1-9	0	0
VMMC_CIRC_NGI	By Age: 10-14	102	102
VMMC_CIRC_NGI	By Age: 15-19	305	305
VMMC_CIRC_NGI	By Age: 20-24	407	407
VMMC_CIRC_NGI	By Age: 25-49	153	153
VMMC_CIRC_NGI	By Age: 50+	51	51
VMMC_CIRC_NGI	Sum of Age disaggregates	1,018	1,018
VMMC_CIRC_NGI	By circumcision technique: Surgical VMMC	1,081	1,081
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	50,000	48,000
PP_PREV_DSD	Total number of people in the target population	186,233	186,233
PP_PREV_DSD	Age/sex: 10-14 Male	750	0
PP_PREV_DSD	Age/sex: 15-19 Male	5,000	0
PP_PREV_DSD	Age/sex: 20-24 Male	12,500	0



PP_PREV_DSD	Age/sex: 25-49 Male	20,000	0
PP_PREV_DSD	Age/sex: 50+ Male	0	0
PP_PREV_DSD	Age/sex: 10-14 Female	750	0
PP_PREV_DSD	Age/sex: 15-19 Female	2,500	10,500
PP_PREV_DSD	Age/sex: 20-24 Female	6,000	37,500
PP_PREV_DSD	Age/sex: 25-49 Female	2,500	0
PP_PREV_DSD	Age/sex: 50+ Female	0	0
PP_PREV_DSD	Sum of Age/Sex disaggregates	50,000	48,000
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	2,130	2,130
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	1,819	1,819
KP_PREV_DSD	By key population type: Males who inject drugs (Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0	0
KP_PREV_DSD	By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0	0
KP_PREV_DSD	By key population type: Men who have sex with men/Transgender (MSM/TG) (Numerator: Number of key populations reached with individual and/or small group level HIV	311	311



	preventive interventions that are based on evidence and/or meet the minimum standards required)		
KP_PREV_DSD	By key population type: MSM/TG who are male sex workers (subset MSM/TG) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0	0
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	148,298	148,298
HTC_TST_DSD	By Test Result: Negative	142,366	142,366
HTC_TST_DSD	By Test Result: Positive	5,932	5,932
HTC_TST_DSD	Sum of Test Result disaggregates	148,298	148,298
HTC_TST_DSD	Age/sex: <1 Male	0	0
HTC_TST_DSD	Age/sex: 1-4 Male	5,190	5,190
HTC_TST_DSD	Age/sex: 5-9 Male	2,224	2,224
HTC_TST_DSD	Age/sex: 10-14 Male	3,707	3,707
HTC_TST_DSD	Age/sex: 15-19 Male	7,415	7,415
HTC_TST_DSD	Age/sex: 20-24 Male	18,537	18,537
HTC_TST_DSD	Age/sex: 25-49 Male	29,660	29,660
HTC_TST_DSD	Age/sex: 50+ Male	7,415	7,415
HTC_TST_DSD	Age/sex: <1 Female	0	0
HTC_TST_DSD	Age/sex: 1-4 Female	5,190	5,190
HTC_TST_DSD	Age/sex: 5-9 Female	2,224	2,224
HTC_TST_DSD	Age/sex: 10-14 Female	3,707	3,707
HTC_TST_DSD	Age/sex: 15-19 Female	7,415	7,415
HTC_TST_DSD	Age/sex: 20-24 Female	18,537	18,537
HTC_TST_DSD	Age/sex: 25-49 Female	29,660	29,660
HTC_TST_DSD	Age/sex: 50+ Female	7,417	7,417
HTC_TST_DSD	Sum of Age/Sex disaggregates	148,298	148,298



HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	11,122	11,122
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	63,027	63,027
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	11,122	11,122
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	63,027	63,027
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	22,244	22,244
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	126,054	126,054
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	148,298	148,298
HTC_TST_NGI	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	344,878	344,878
HTC_TST_NGI	By Test Result: Negative	331,083	331,083
HTC_TST_NGI	By Test Result: Positive	13,795	13,795
HTC_TST_NGI	Sum of Test Result disaggregates	344,878	344,878
HTC_TST_NGI	Age/sex: <1 Male	0	0
HTC_TST_NGI	Age/sex: 1-4 Male	12,071	12,071
HTC_TST_NGI	Age/sex: 5-9 Male	5,173	5,173
HTC_TST_NGI	Age/sex: 10-14 Male	8,622	8,622
HTC_TST_NGI	Age/sex: 15-19 Male	17,244	17,244
HTC_TST_NGI	Age/sex: 20-24 Male	43,110	43,110
HTC_TST_NGI	Age/sex: 25-49 Male	68,976	68,976
HTC_TST_NGI	Age/sex: 50+ Male	17,244	17,244
HTC_TST_NGI	Age/sex: <1 Female	0	0
HTC_TST_NGI	Age/sex: 1-4 Female	12,071	12,071
HTC_TST_NGI	Age/sex: 5-9 Female	5,173	5,173
HTC_TST_NGI	Age/sex: 10-14 Female	8,622	8,622
HTC_TST_NGI	Age/sex: 15-19 Female	17,244	17,244
HTC_TST_NGI	Age/sex: 20-24 Female	43,110	43,110
HTC_TST_NGI	Age/sex: 25-49 Female	68,976	68,976
HTC_TST_NGI	Age/sex: 50+ Female	17,242	17,242



HTC_TST_NGI	Sum of Age/Sex disaggregates	344,878	344,878
HTC_TST_NGI	Aggregated Age/sex: <15 Male	25,866	25,866
HTC_TST_NGI	Aggregated Age/sex: 15+ Male	146,573	146,573
HTC_TST_NGI	Aggregated Age/sex: <15 Female	25,866	25,866
HTC_TST_NGI	Aggregated Age/sex: 15+ Female	146,573	146,573
HTC_TST_NGI	Sum of Aggregated Age/Sex <15	51,732	51,732
HTC_TST_NGI	Sum of Aggregated Age/Sex 15+	293,146	293,146
HTC_TST_NGI	Sum of Aggregated Age/Sex disaggregates	344,878	344,878
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	196,580	196,580
HTC_TST_TA	By Test Result: Negative	188,717	188,717
HTC_TST_TA	By Test Result: Positive	7,863	7,863
HTC_TST_TA	Sum of Test Result disaggregates	196,580	196,580
HTC_TST_TA	Age/sex: <1 Male	0	0
HTC_TST_TA	Age/sex: 1-4 Male	6,880	6,880
HTC_TST_TA	Age/sex: 5-9 Male	2,949	2,949
HTC_TST_TA	Age/sex: 10-14 Male	4,915	4,915
HTC_TST_TA	Age/sex: 15-19 Male	9,829	9,829
HTC_TST_TA	Age/sex: 20-24 Male	24,573	24,573
HTC_TST_TA	Age/sex: 25-49 Male	39,316	39,316
HTC_TST_TA	Age/sex: 50+ Male	9,829	9,829
HTC_TST_TA	Age/sex: <1 Female	0	0
HTC_TST_TA	Age/sex: 1-4 Female	6,880	6,880
HTC_TST_TA	Age/sex: 5-9 Female	2,949	2,949
HTC_TST_TA	Age/sex: 10-14 Female	4,915	4,915
HTC_TST_TA	Age/sex: 15-19 Female	9,829	9,829
HTC_TST_TA	Age/sex: 20-24 Female	24,573	24,573
HTC_TST_TA	Age/sex: 25-49 Female	39,316	39,316
HTC_TST_TA	Age/sex: 50+ Female	9,827	9,827
HTC_TST_TA	Sum of Age/Sex disaggregates	196,580	196,580
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ	14,744	14,744



	PERMISSION ONLY: <15 Male		
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	83,547	83,547
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	14,744	14,744
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	83,545	83,545
HTC_TST_TA	Sum of Aggregated Age/Sex <15	29,488	29,488
HTC_TST_TA	Sum of Aggregated Age/Sex 15+	167,092	167,092
HTC_TST_TA	Sum of Aggregated Age/Sex disaggregates	196,580	196,580
GEND_GBV_DSD	Number of people receiving post-GBV care	1,210	1,210
GEND_GBV_DSD	Age: 0-9	210	210
GEND_GBV_DSD	Age: 10-14	500	500
GEND_GBV_DSD	Age: 15-17	500	500
GEND_GBV_DSD	Sum of Age disaggregates	1,210	1,210
GEND_GBV_DSD	Sex: Male	60	60
GEND_GBV_DSD	Sex: Female	1,150	1,150
GEND_GBV_DSD	Sum of Sex disaggregates	1,210	1,210
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	1,210	1,210
GEND_NORM_DSD	Number of people completing an intervention pertaining to gender norms, that meets minimum criteria	44,353	44,353
GEND_NORM_DSD	By Age: 0-9	0	0
GEND_NORM_DSD	By Age: 10-14	0	0
GEND_NORM_DSD	By Age: 15-19	0	0
GEND_NORM_DSD	By Age: 20-24	11,088	11,088
GEND_NORM_DSD	By Age: 25+	33,265	33,265
GEND_NORM_DSD	Sum of Age disaggregates	44,353	44,353
GEND_NORM_DSD	By Sex: Male	33,265	33,265
GEND_NORM_DSD	By Sex: Female	11,088	11,088
GEND_NORM_DSD	Sum of Sex disaggregates	44,353	44,353
OVC_ACC_DSD	Number of active beneficiaries receiving	9,311	9,477



	support from PEPFAR OVC programs to access HIV services		
OVC_ACC_DSD	Sex: Male	4,562	4,644
OVC_ACC_DSD	Sex: Female	4,749	4,833
OVC_ACC_DSD	Sum of Sex disaggregates	9,311	9,477
OVC_ACC_DSD	Age: <1	0	0
OVC_ACC_DSD	Age: 1-4	559	569
OVC_ACC_DSD	Age: 5-9	1,862	1,895
OVC_ACC_DSD	Age: 10-14	2,980	3,033
OVC_ACC_DSD	Age: 15-17	2,048	2,085
OVC_ACC_DSD	Age: 18+	1,862	1,895
OVC_ACC_DSD	Sum of Age disaggregates	9,311	9,477
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	89,000	89,000
OVC_SERV_DSD	Sex: Male	43,610	43,610
OVC_SERV_DSD	Sex: Female	45,390	45,390
OVC_SERV_DSD	Sum of Sex disaggregates	89,000	89,000
OVC_SERV_DSD	Age: <1	0	0
OVC_SERV_DSD	Age: 1-4	5,340	5,340
OVC_SERV_DSD	Age: 5-9	17,800	17,800
OVC_SERV_DSD	Age: 10-14	28,480	28,480
OVC_SERV_DSD	Age: 15-17	19,580	19,580
OVC_SERV_DSD	Age: 18+	17,800	17,800
OVC_SERV_DSD	Sum of Age disaggregates	89,000	89,000
C2.1.D_DSD	Number of HIV-positive individuals receiving a minimum of one clinical service	26,376	29,013
C2.1.D_DSD	By Age/Sex: <15 Female	2,143	2,357
C2.1.D_DSD	By Age/Sex: <15 Male	1,154	1,269
C2.1.D_DSD	By Age/Sex: 15+ Female	15,001	16,501
C2.1.D_DSD	By Age/Sex: 15+ Male	8,078	8,886
C2.1.D_DSD	Sum of Age/Sex disaggregates	26,376	29,013



C2.1.D_DSD	By Age: <15	3,297	3,627
C2.1.D_DSD	By Age: 15+	23,079	25,386
C2.1.D_DSD	Sum of Age disaggregates	26,376	29,013
C2.1.D_DSD	By Sex: Female	17,144	18,858
C2.1.D_DSD	By Sex: Male	9,232	10,155
C2.1.D_DSD	Sum of Sex disaggregates	26,376	29,013
C2.1.D_NGI	Number of HIV-positive individuals receiving a minimum of one clinical service	41,212	45,333
C2.1.D_NGI	By Age/Sex: <15 Female	3,348	3,683
C2.1.D_NGI	By Age/Sex: <15 Male	1,649	1,983
C2.1.D_NGI	By Age/Sex: 15+ Female	22,703	25,783
C2.1.D_NGI	By Age/Sex: 15+ Male	13,512	13,884
C2.1.D_NGI	Sum of Age/Sex disaggregates	41,212	45,333
C2.1.D_NGI	By Age: <15	5,152	5,667
C2.1.D_NGI	By Age: 15+	36,060	39,666
C2.1.D_NGI	Sum of Age disaggregates	41,212	45,333
C2.1.D_NGI	By Sex: Female	26,787	29,466
C2.1.D_NGI	By Sex: Male	14,425	15,867
C2.1.D_NGI	Sum of Sex disaggregates	41,212	45,333
C2.1.D_TA	Number of HIV-positive individuals receiving a minimum of one clinical service	14,836	16,320
C2.1.D_TA	By Age/Sex: <15 Female	1,205	1,326
C2.1.D_TA	By Age/Sex: <15 Male	495	714
C2.1.D_TA	By Age/Sex: 15+ Female	8,702	9,282
C2.1.D_TA	By Age/Sex: 15+ Male	4,434	4,998
C2.1.D_TA	Sum of Age/Sex disaggregates	14,836	16,320
C2.1.D_TA	By Age: <15	2,011	2,040
C2.1.D_TA	By Age: 15+	12,825	14,280
C2.1.D_TA	Sum of Age disaggregates	14,836	16,320
C2.1.D_TA	By Sex: Female	9,643	10,608
C2.1.D_TA	By Sex: Male	5,193	5,712
C2.1.D_TA	Sum of Sex disaggregates	14,836	16,320



C2.4.D_DSD	Number of HIV-positive patients who were screened for TB in HIV care or treatment setting	26,376	29,013
C2.4.D_DSD	Number of HIV-positive individuals receiving a minimum of one clinical service	26,376	29,013
C2.5.D_DSD	Number of HIV-positive patients in HIV care who started TB treatment	6,182	6,800
C2.5.D_DSD	Number of HIV-positive individuals receiving a minimum of one clinical service	26,376	29,013
CARE_CURR_DSD	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	26,376	29,013
CARE_CURR_DSD	Age/sex: <1 Male	231	254
CARE_CURR_DSD	Age/sex: 1-4 Male	185	203
CARE_CURR_DSD	Age/sex: 5-9 Male	277	305
CARE_CURR_DSD	Age/sex: 10-14 Male	462	508
CARE_CURR_DSD	Age/sex: 15-19 Male	1,846	2,031
CARE_CURR_DSD	Age/sex: 20-24 Male	3,231	3,554
CARE_CURR_DSD	Age/sex: 25-49 Male	2,770	3,047
CARE_CURR_DSD	Age/sex: 50+ Male	231	254
CARE_CURR_DSD	Age/sex: <1 Female	429	471
CARE_CURR_DSD	Age/sex: 1-4 Female	343	377
CARE_CURR_DSD	Age/sex: 5-9 Female	514	566
CARE_CURR_DSD	Age/sex: 10-14 Female	857	943
CARE_CURR_DSD	Age/sex: 15-19 Female	3,429	3,772
CARE_CURR_DSD	Age/sex: 20-24 Female	6,000	6,600
CARE_CURR_DSD	Age/sex: 25-49 Female	5,143	5,657
CARE_CURR_DSD	Age/sex: 50+ Female	428	471
CARE_CURR_DSD	Sun of Age/Sex disaggregates	26,376	29,013
CARE_CURR_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	1,154	1,269



CARE_CURR_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	8,078	8,886
CARE_CURR_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	2,143	2,357
CARE_CURR_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	15,001	16,501
CARE_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	26,376	29,013
CARE_CURR_TA	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	14,836	16,320
CARE_CURR_TA	Age/sex: <1 Male	130	143
CARE_CURR_TA	Age/sex: 1-4 Male	104	114
CARE_CURR_TA	Age/sex: 5-9 Male	156	171
CARE_CURR_TA	Age/sex: 10-14 Male	260	286
CARE_CURR_TA	Age/sex: 15-19 Male	1,039	1,142
CARE_CURR_TA	Age/sex: 20-24 Male	1,818	1,999
CARE_CURR_TA	Age/sex: 25-49 Male	1,558	1,714
CARE_CURR_TA	Age/sex: 50+ Male	130	143
CARE_CURR_TA	Age/sex: <1 Female	241	265
CARE_CURR_TA	Age/sex: 1-4 Female	193	212
CARE_CURR_TA	Age/sex: 5-9 Female	289	318
CARE_CURR_TA	Age/sex: 10-14 Female	482	530
CARE_CURR_TA	Age/sex: 15-19 Female	1,929	2,122
CARE_CURR_TA	Age/sex: 20-24 Female	3,375	3,713
CARE_CURR_TA	Age/sex: 25-49 Female	2,891	3,184
CARE_CURR_TA	Age/sex: 50+ Female	241	264
CARE_CURR_TA	Sum of Age/Sex disaggregates	14,836	16,320
CARE_CURR_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	649	714
CARE_CURR_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	4,544	4,998



CARE_CURR_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	1,205	1,326
CARE_CURR_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	8,438	9,282
CARE_CURR_TA	Sum of Aggregated Age/Sex disaggregates	14,836	16,320
CARE_NEW_DSD	Number of HIV-infected adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load	8,242	8,243
CARE_NEW_DSD	Age/sex: <1 Male	72	72
CARE_NEW_DSD	Age/sex: 1-4 Male	58	58
CARE_NEW_DSD	Age/sex: 5-9 Male	87	87
CARE_NEW_DSD	Age/sex: 10-14 Male	144	144
CARE_NEW_DSD	Age/sex: 15-19 Male	577	577
CARE_NEW_DSD	Age/sex: 20-24 Male	1,010	1,010
CARE_NEW_DSD	Age/sex: 25-49 Male	866	866
CARE_NEW_DSD	Age/sex: 50+ Male	72	72
CARE_NEW_DSD	Age/sex: <1 Female	134	134
CARE_NEW_DSD	Age/sex: 1-4 Female	107	107
CARE_NEW_DSD	Age/sex: 5-9 Female	161	161
CARE_NEW_DSD	Age/sex: 10-14 Female	268	268
CARE_NEW_DSD	Age/sex: 15-19 Female	1,071	1,071
CARE_NEW_DSD	Age/sex: 20-24 Female	1,875	1,875
CARE_NEW_DSD	Age/sex: 25-49 Female	1,607	1,607
CARE_NEW_DSD	Age/sex: 50+ Female	133	134
CARE_NEW_DSD	Sum of Age/sex disaggregates	8,242	8,243
CARE_NEW_DSD	Aggregated Age/sex: <15 Male	361	361
CARE_NEW_DSD	Aggregated Age/sex: 15+ Male	2,524	2,524
CARE_NEW_DSD	Aggregated Age/sex: <15 Female	670	670
CARE_NEW_DSD	Aggregated Age/sex: 15+ Female	4,687	4,688
CARE_NEW_DSD	Sum of Aggregated Age/sex disaggregates	8,242	8,243



CARE_SITE	Number of PEPFAR-supported HIV clinical care sites at which at least 80% of PLHIV received all of the following during the reporting period: 1) clinical assessment (WHO staging) OR CD4 count OR viral load, AND 2) TB screening at last visit, AND 3) if eligible, cotrimoxazole	100	100
CARE_SITE	Total number of PEPFAR supported sites providing clinical care services	113	113
CARE_SITE	By site support type: Direct Service Delivery (DSD): Number of PEPFAR-supported HIV clinical care sites at which at least 80% of PLHIV received all of the following during the reporting period: 1) clinical assessment (WHO staging) OR CD4 count OR viral load, AND 2) TB screening at last visit, AND 3) if eligible, cotrimoxazole	18	18
CARE_SITE	By site support type: Technical Assistance-only (TA): Number of PEPFAR-supported HIV clinical care sites at which at least 80% of PLHIV received all of the following during the reporting period: 1) clinical assessment (WHO staging) OR CD4 count OR viral load, AND 2) TB screening at last visit, AND 3) if eligible, cotrimoxazole	84	84
CARE_SITE	Sum of Numerator Site Support Type disaggregates	102	102
CARE_SITE	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR supported sites providing clinical care services	18	18
CARE_SITE	By site support type: Technical Assistance-only (TA): Total number of PEPFAR supported sites providing clinical care services	95	95
CARE_SITE	Sum of Denominator Site Support Type disaggregates	113	113

FN_SITE	Number of PEPFAR-supported sites achieving 90% nutrition assessments that result in accurate categorization of malnutrition	100	100
FN_SITE	Total number of PEPFAR-supported sites providing nutrition assessment, counseling and support (NACS) services	113	113
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	2,375	2,640
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	2,640	2,640
TB_ART_DSD	Age: 0-4	107	132
TB_ART_DSD	Age: 5-14	190	240
TB_ART_DSD	Age: 15+	2,078	2,268
TB_ART_DSD	Male	1,306	1,465
TB_ART_DSD	Female	1,069	1,175
TB_ART_DSD	Sum of Sex disaggregates	2,375	2,640
TB_ART_DSD	Newly tested	1,781	1,958
TB_ART_DSD	Known HIV-positive	594	682
TB_ART_DSD	Sum of Test Status disaggregates	2,375	2,640
TB_ART_DSD	Aggregated Age: <15	297	355
TB_ART_DSD	Aggregated Age: 15+	2,078	2,285
TB_ART_DSD	Sum of Aggregated Age disaggregates	2,375	2,640
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	5,025	5,275
PMTCT_EID_DSD	Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT)	5,128	5,383
PMTCT_EID_DSD	By infants who received a virologic test within	4,522	4,748



	2 months of birth		
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	503	527
PMTCT_EID_DSD	Sum of Infant Age disaggregates	5,025	5,275
PMTCT_EID_DSD	By infants with a positive virologic test result within 12 months of birth	250	264
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	20,458	23,259
TX_CURR_DSD	Age/Sex: <1 Male	179	204
TX_CURR_DSD	Age/Sex: 1-4 Male	143	163
TX_CURR_DSD	Age/Sex: 5-14 Male	573	651
TX_CURR_DSD	Age/Sex: 15+ Male	6,265	7,123
TX_CURR_DSD	Age/Sex: <1 Female	332	378
TX_CURR_DSD	Age/Sex: 1-4 Female	266	302
TX_CURR_DSD	Age/Sex: 5-14 Female	1,064	1,210
TX_CURR_DSD	Age/Sex: 15+ Female	11,636	13,228
TX_CURR_DSD	Sum of age/sex disaggregates	2,557	2,908
TX_CURR_DSD	Percent children with advanced HIV infection receiving antiretroviral therapy (ART) [CURRENT]	13	13
TX_CURR_DSD	Percent women and girls with advanced HIV infection receiving antiretroviral therapy (ART) [CURRENT]	57	57
TX_CURR_DSD	Aggregated Age/Sex: <1 Male	179	204
TX_CURR_DSD	Aggregated Age/Sex: <1 Female	332	378
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	716	814
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	6,265	7,123
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	598	680
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	12,879	14,642
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	1,314	1,494
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	19,144	21,765
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	20,458	23,259
TX_CURR_NGI	Number of adults and children receiving	30,085	34,206



	antiretroviral therapy (ART)		
TX_CURR_NGI	Age/Sex: <1 Male	263	300
TX_CURR_NGI	Age/Sex: 1-4 Male	210	240
TX_CURR_NGI	Age/Sex: 5-14 Male	843	957
TX_CURR_NGI	Age/Sex: 15+ Male	9,213	10,475
TX_CURR_NGI	Age/Sex: <1 Female	488	556
TX_CURR_NGI	Age/Sex: 1-4 Female	391	444
TX_CURR_NGI	Age/Sex: 5-14 Female	1,565	1,779
TX_CURR_NGI	Age/Sex: 15+ Female	17,112	19,455
TX_CURR_NGI	Sum of Age/Sex disaggregates	30,085	34,206
TX_CURR_NGI	Aggregated Age/Sex: <1 Male	263	300
TX_CURR_NGI	Aggregated Age/Sex: <1 Female	488	556
TX_CURR_NGI	Aggregated Age/Sex: <15 Male	1,053	1,197
TX_CURR_NGI	Aggregated Age/Sex: 15+ Male	9,213	10,475
TX_CURR_NGI	Aggregated Age/Sex: <15 Female	1,224	1,392
TX_CURR_NGI	Aggregated Age/Sex: 15+ Female	18,595	21,142
TX_CURR_NGI	Sum of Aggregated Age/Sex disaggregates	30,085	34,206
TX_CURR_NGI	Sum of Aggregated Age/Sex <15	2,277	2,589
TX_CURR_NGI	Sum of Aggregated Age/Sex 15+	27,808	31,617
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	9,543	10,769
TX_CURR_TA	Age/Sex: <1 Male	84	96
TX_CURR_TA	Age/Sex: 1-4 Male	67	77
TX_CURR_TA	Age/Sex: 5-14 Male	270	306
TX_CURR_TA	Age/Sex: 15+ Male	2,948	3,352
TX_CURR_TA	Age/Sex: <1 Female	156	178
TX_CURR_TA	Age/Sex: 1-4 Female	125	142
TX_CURR_TA	Age/Sex: 5-14 Female	501	569
TX_CURR_TA	Age/Sex: 15+ Female	5,392	6,226
TX_CURR_TA	Sum of Age/Sex disaggregations	1,203	1,368
TX_CURR_TA	Aggregated Age/Sex: <1 Male	84	96
TX_CURR_TA	Aggregated Age/Sex: <1 Female	156	178



TX_CURR_TA	Aggregated Age/Sex: <15 Male	337	479
TX_CURR_TA	Aggregated Age/Sex: 15+ Male	2,948	3,352
TX_CURR_TA	Aggregated Age/Sex: <15 Female	782	712
TX_CURR_TA	Aggregated Age/Sex: 15+ Female	5,476	6,226
TX_CURR_TA	Sum of Aggregated Age/Sex <15	1,119	1,191
TX_CURR_TA	Sum of Aggregated Age/Sex 15+	8,424	9,578
TX_CURR_TA	Sum of Aggregated Age/Sex disaggregates	9,543	10,769
TX_DIST	Number of Districts with documented routine supportive supervision visits to 75% of HIV care and treatment sites supported by the District	24	24
TX_DIST	Total number of PEPFAR supported District Health Offices	24	24
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	6,702	6,702
TX_NEW_DSD	By Age/Sex: <1 Male	59	59
TX_NEW_DSD	By Age/Sex: 1-4 Male	47	47
TX_NEW_DSD	By Age/Sex: 5-9 Male	70	70
TX_NEW_DSD	By Age/Sex: 10-14 Male	117	117
TX_NEW_DSD	By Age/Sex: 15-19 Male	469	469
TX_NEW_DSD	By Age/Sex: 20-24 Male	821	821
TX_NEW_DSD	By Age/Sex: 25-49 Male	704	704
TX_NEW_DSD	By Age/Sex: 50+ Male	59	59
TX_NEW_DSD	By Age/Sex: <1 Female	109	109
TX_NEW_DSD	By Age/Sex: 1-4 Female	87	87
TX_NEW_DSD	By Age/Sex: 5-9 Female	131	131
TX_NEW_DSD	By Age/Sex: 10-14 Female	218	218
TX_NEW_DSD	By Age/Sex: 15-19 Female	871	871
TX_NEW_DSD	By Age/Sex: 20-24 Female	1,525	1,525
TX_NEW_DSD	By Age/Sex: 25-49 Female	1,306	1,305
TX_NEW_DSD	By Age/Sex: 50+ Female	109	110
TX_NEW_DSD	Sum of Age/Sex disaggregates	6,702	6,702



TX_NEW_DSD	Aggregated Grouping by Age: <1 Male	59	59
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	235	235
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	2,053	2,053
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <1 Female	109	109
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	436	436
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	3,812	3,812
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	6,536	6,536
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	5,696	5,696
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	6,702	6,702
TX_RET_DSD	Age: 0-4 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	50	50
TX_RET_DSD	Age: 5-14 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	40	40
TX_RET_DSD	Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	60	60
TX_RET_DSD	Age: 0-4 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	99	99
TX_RET_DSD	Age: 5-14 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the	399	399

	reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)		
TX_RET_DSD	Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	698	698
TX_RET_DSD	Aggregated Age: <15 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	93	93
TX_RET_DSD	Aggregated Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	74	74
TX_RET_DSD	Aggregated Age: <15 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	111	111
TX_RET_DSD	Aggregated Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	185	185
TX_RET_DSD	Pregnancy and breastfeeding status (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	598	598
TX_RET_DSD	Pregnancy and breastfeeding status (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who	50	50



	have stopped ART, and those lost to follow-up)		
TX_SITE	Number of PEPFAR-supported ART sites with a retention rate of 75% or greater for patients 12 months after ART initiation	79	79
TX_SITE	Total number of PEPFAR-supported ART sites	113	113
TX_SITE	By support type: Direct Service Delivery (DSD): Number of PEPFAR-supported ART sites with a retention rate of 75% or greater for patients 12 months after ART initiation	21	21
TX_SITE	By support type: Technical Assistance (TA-only): Number of PEPFAR-supported ART sites with a retention rate of 75% or greater for patients 12 months after ART initiation	42	42
TX_SITE	Sum of Numerator Site Support Type disaggregates	63	63
TX_SITE	By support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported ART sites	29	29
TX_SITE	By support type: Technical Assistance (TA-only): Total number of PEPFAR-supported ART sites	84	84
TX_SITE	Sum of Denominator Site Support Type disaggregates	113	113
LAB_ACC_DSD	Number of PEPFAR-supported testing facilities (laboratories) that are recognized by national, regional, or international standards for accreditation or have achieved a minimal acceptable level towards attainment of such accreditation	5	5
LAB_ACC_DSD	By site support type: Direct Service Delivery (DSD)	0	0
LAB_ACC_DSD	By site support type: Technical	5	5



	Assistance-only (TA)		
LAB_ACC_DSD	Sum of Support Type disaggregates	5	5
LAB_CAP_DSD	Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests	0	0
LAB_PT_DSD	Percentage of laboratories and POC testing sites that perform HIV diagnostic testing that participate and successfully pass in an analyte-specific proficiency testing (PT) program	0	0
HRH_PRE	Number of new HCW who graduated from a pre-service training institution or program as a result of PEPFAR-supported strengthening efforts, within the reporting period, by select cadre	0	0
SC_TRAIN	Number of individuals who received competency-based, certificate or higher-level training to conduct or support supply chain, inventory management, supportive supervision or distribution activities	0	0
SC_TRAIN	Number of individuals who conduct or support supply chain, inventory management, supportive supervision or distribution activities	0	0
FPINT_SITE_DSD	Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	0	0
FPINT_SITE_DSD	Total number of PEPFAR-supported HIV service delivery points: PMTCT, Care and Treatment	0	0
QI_SITE	Number of PEPFAR-supported clinical service sites with a quality improvement activity completed that addresses clinical HIV programs and has documented process results in the last 6 months	0	0



QI_SITE	Total number of PEPFAR-supported sites for any HIV clinical service including HIV Care, HIV Treatment, TB care, PMTCT, VMMC, and HTC	0	0
SC_STOCK	Number of stock status observations for one or more tracer commodities that are between the designed minimum and maximum quantities/months of stock from storage sites within at a given level (Central, Regional, etc.) of the system.	0	0
SC_STOCK	Total number of stock status observations for one or more tracer commodities from storage sites within at a given level (Central, Regional, etc.) of the system	0	0
SI_HIS	Existence of a national registry of health facilities that is updated annually	1	1
SI_ME	Existence of a national HIV/AIDS M&E system based on the UNAIDS 12 components model	1	1
TB_SCREEN_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period	26,376	29,013
TB_SCREEN_DSD	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	26,376	29,013
TB_SCREEN_DSD	Age: <1	659	725
TB_SCREEN_DSD	Age: 1-4	528	580
TB_SCREEN_DSD	Age: 5-9	791	870
TB_SCREEN_DSD	Age: 10-14	1,319	1,451
TB_SCREEN_DSD	Age: 15-19	5,275	5,803
TB_SCREEN_DSD	Age: 20-24	9,232	10,155
TB_SCREEN_DSD	Age: 25-49	7,913	8,704
TB_SCREEN_DSD	Age: 50+	659	725



TB_SCREEN_DSD	Sum of Age disaggregates	8,572	9,429
TB_SCREEN_DSD	Aggregated Age - USE WITH HQ PERMISSION ONLY: <15	3,297	3,627
TB_SCREEN_DSD	Aggregated Age - USE WITH HQ PERMISSION ONLY: 15+	23,079	25,386
TB_SCREEN_DSD	Sum of Aggregated Age disaggregates	26,376	29,013
TB_SCREEN_DSD	Sex: Male	9,232	10,155
TB_SCREEN_DSD	Sex: Female	17,144	18,858
TB_SCREEN_DSD	Sum of Sex disaggregates	26,376	29,013

Implementing Mechanism Details

Mechanism ID: 13312	Mechanism Name: Afyainfo
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: Abt Associates	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: No	
G2G: No	Managing Agency:

Total All Funding Sources: 4,252,000	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 0	
FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount
GHP-State	4,252,000

Sub Partner Name(s)

CENTERS FOR HEALTH SOLUTIONS	ICF Macro	Training Resources Group
University of Nairobi		

Cross-Cutting Budget Attribution(s)

Human Resources for Health	150,000
----------------------------	---------



Education	300,000
-----------	---------

Key Issues

Malaria (PMI)
 Child Survival Activities
 Safe Motherhood
 TB
 End-of-Program Evaluation
 Family Planning

Budget Code Information

Mechanism ID: 13312 Mechanism Name: Afyainfo Prime Partner Name: Abt Associates			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	4,252,000	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2014	2015
SI_HIS	Full national facility list coordinated with PEPFAR	1	1
SI_ME	Existence of a national HIV/AIDS M&E system based on the UNAIDS 12 components model	1	1

Implementing Mechanism Details

Mechanism ID: 13309	Mechanism Name: Kenya Medical Research Institute
----------------------------	---



Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Kenya Medical Research Institute	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: No	
G2G: Yes	Managing Agency: HHS/CDC

Total All Funding Sources: 4,491,178	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 1,209,345	
FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount
GHP-State	4,491,178

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

Human Resources for Health	688,253
Gender: GBV	186,473
Focus Area:	GBV Prevention
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Focus Area:	Post GBV Care
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Monitoring and Evaluation
Gender: Gender Equality	81,973
Focus Area:	Changing harmful gender norms and promoting



	positive gender norms
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Focus Area:	Promoting gender-related policies and laws that increase legal protection
Sub Area:	Implementation
Sub Area:	Capacity building
Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Condom programming	25,500

Key Issues

- Malaria (PMI)
- Child Survival Activities
- Mobile Population
- Safe Motherhood
- TB
- Family Planning

Budget Code Information

Mechanism ID:	13309		
Mechanism Name:	Kenya Medical Research Institute		
Prime Partner Name:	Kenya Medical Research Institute		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	192,369	0



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	567,380	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	106,572	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	1,400,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	589,034	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HMIN	350,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVAB	50,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	236,588	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	205,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	195,590	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	450,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	148,645	0



Implementing Mechanism Indicator Information

Indicator Number	Label	2014	2015	Planning Budget Targets
SITE_SUPP	Number of unique sites supported by PEPFAR	3	2	Redacted
SITE_SUPP	By program area/support type: HTC Direct Service Delivery (DSD)	3	1	Redacted
SITE_SUPP	By program area/support type: HTC Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: Treatment Direct Service Delivery (DSD)	2	2	Redacted
SITE_SUPP	By program area/support type: Treatment Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: Care and Support Direct Service Delivery (DSD)	2	2	Redacted
SITE_SUPP	By program area/support type: Care and Support Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: Food and Nutrition Direct Service Delivery (DSD)	2	2	Redacted
SITE_SUPP	By program area/support type: Food and Nutrition Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: PMTCT Direct Service Delivery (DSD)	2	2	Redacted
SITE_SUPP	By program area/support type: PMTCT Technical Assistance-only (TA)	0	0	Redacted



SITE_SUPP	By program area/support type: TB/HIV Direct Service Delivery (DSD)	2	2	Redacted
SITE_SUPP	By program area/support type: TB/HIV Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: VMMC Direct Service Delivery (DSD)	0	0	Redacted
SITE_SUPP	By program area/support type: VMMC Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: General Population Prevention Direct Service Delivery (DSD)	1	1	Redacted
SITE_SUPP	By program area/support type: General Population Prevention Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: Key Populations Prevention Direct Service Delivery (DSD)	0	0	Redacted
SITE_SUPP	By program area/support type: Key Populations Prevention Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: OVC Direct Service Delivery (DSD)	0	0	Redacted
SITE_SUPP	By program area/support type: OVC Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: PHDP/Family Planning & Integration Direct Service Delivery (DSD)	2	2	Redacted
SITE_SUPP	By program area/support type: PHDP/Family Planning & Integration Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: Lab Direct Service Delivery (DSD)	5	5	Redacted
SITE_SUPP	By program area/support type: Lab Technical Assistance-only (TA)	9	12	Redacted



PMTCT_ARV_DS D	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	1,203	1,228	Redacted
PMTCT_ARV_DS D	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	1,203	1,228	Redacted
PMTCT_ARV_DS D	Life-long ART (including Option B+)	903	921	Redacted
PMTCT_ARV_DS D	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	422	430	Redacted
PMTCT_ARV_DS D	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	481	491	Redacted
PMTCT_ARV_DS D	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)	0	0	Redacted
PMTCT_ARV_DS D	Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)	300	307	Redacted
PMTCT_ARV_DS D	Single-dose nevirapine (with or without tail)	0	0	Redacted
PMTCT_ARV_DS D	Sum of Regimen Type disaggregates	1,203	1,228	Redacted
PMTCT_ARV_DS D	Sum of New and Current disaggregates	903	921	Redacted
PMTCT_ARV_NGI	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	1,203	1,228	Redacted
PMTCT_ARV_NGI	Number of HIV- positive pregnant women identified in the reporting period	1,203	1,228	Redacted



	(including known HIV-positive at entry)			
PMTCT_ARV_NGI	Life-long ART (including Option B+)	903	921	Redacted
PMTCT_ARV_NGI	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	422	430	Redacted
PMTCT_ARV_NGI	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	481	491	Redacted
PMTCT_ARV_NGI	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)	0	0	Redacted
PMTCT_ARV_NGI	Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)	300	307	Redacted
PMTCT_ARV_NGI	Single-dose nevirapine (with or without tail)	0	0	Redacted
PMTCT_ARV_NGI	Sum of Regimen disaggregates	1,203	1,228	Redacted
PMTCT_ARV_NGI	Sum of New and Current disaggregates	903	921	Redacted
PMTCT_SITE	Number of PEPFAR-supported sites achieving 90% ARV or ART coverage for HIV+ pregnant women	2	2	Redacted
PMTCT_SITE	Total number of PEPFAR supported sites providing PMTCT services (HTC and ARV or ART services)	2	2	Redacted
PMTCT_SITE	By site support type: Direct Service Delivery (DSD): Number of PEPFAR-supported sites achieving 90% ARV or ART coverage for HIV+ pregnant women	2	2	Redacted
PMTCT_SITE	By site support type: Technical Assistance-only (TA): Number of PEPFAR-supported sites achieving 90% ARV or ART coverage for HIV+ pregnant women	0	0	Redacted
PMTCT_SITE	Sum of Numerator Support Type	2	2	Redacted



	disaggregates			
PMTCT_SITE	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR supported sites providing PMTCT services (HTC and ARV or ART services)	2	2	Redacted
PMTCT_SITE	By site support type: Technical Assistance-only (TA): Total number of PEPFAR supported sites providing PMTCT services (HTC and ARV or ART services)	0	0	Redacted
PMTCT_SITE	Sum of Denominator Support Type disaggregates	2	2	Redacted
PMTCT_STAT_DS D	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	4,068	4,270	Redacted
PMTCT_STAT_DS D	Number of new ANC and L&D clients	4,068	4,270	Redacted
PMTCT_STAT_DS D	By: Known positives at entry	566	577	Redacted
PMTCT_STAT_DS D	By: Number of new positives identified	637	651	Redacted
PMTCT_STAT_DS D	Sum of Positives Status disaggregates	1,203	1,228	Redacted
PMTCT_STAT_NG I	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	4,068	4,270	Redacted
PMTCT_STAT_NG I	Number of new ANC and L&D clients	4,068	4,270	Redacted
PMTCT_STAT_NG I	By: Known positives at entry	566	577	Redacted
PMTCT_STAT_NG I	By: Number of new positives identified	637	651	Redacted

PMTCT_STAT_NG I	Sum of Positives Status disaggregates	1,203	1,228	Redacted
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	92,700	62,196	Redacted
HTC_TST_DSD	By Test Result: Negative	88,992	59,708	Redacted
HTC_TST_DSD	By Test Result: Positive	3,708	2,488	Redacted
HTC_TST_DSD	Sum of Test Result disaggregates	92,700	62,196	Redacted
HTC_TST_DSD	Age/sex: <1 Male	0	0	Redacted
HTC_TST_DSD	Age/sex: 1-4 Male	3,245	2,177	Redacted
HTC_TST_DSD	Age/sex: 5-9 Male	1,390	933	Redacted
HTC_TST_DSD	Age/sex: 10-14 Male	2,317	1,555	Redacted
HTC_TST_DSD	Age/sex: 15-19 Male	4,635	3,110	Redacted
HTC_TST_DSD	Age/sex: 20-24 Male	11,588	7,775	Redacted
HTC_TST_DSD	Age/sex: 25-49 Male	18,540	12,438	Redacted
HTC_TST_DSD	Age/sex: 50+ Male	4,635	3,110	Redacted
HTC_TST_DSD	Age/sex: <1 Female	0	0	Redacted
HTC_TST_DSD	Age/sex: 1-4 Female	3,245	2,177	Redacted
HTC_TST_DSD	Age/sex: 5-9 Female	1,390	933	Redacted
HTC_TST_DSD	Age/sex: 10-14 Female	2,317	1,555	Redacted
HTC_TST_DSD	Age/sex: 15-19 Female	4,635	3,110	Redacted
HTC_TST_DSD	Age/sex: 20-24 Female	11,588	7,775	Redacted
HTC_TST_DSD	Age/sex: 25-49 Female	18,540	12,438	Redacted
HTC_TST_DSD	Age/sex: 50+ Female	4,635	3,110	Redacted
HTC_TST_DSD	Sum of Age/Sex disaggregates	92,700	62,196	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	6,952	4,665	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	39,398	26,433	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	6,952	4,665	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	39,398	26,433	Redacted



HTC_TST_DSD	Sum of Aggregated Age/Sex <15	13,904	9,330	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	78,796	52,866	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	92,700	62,196	Redacted
HTC_TST_NGI	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	92,700	62,196	Redacted
HTC_TST_NGI	By Test Result: Negative	88,992	59,708	Redacted
HTC_TST_NGI	By Test Result: Positive	3,708	2,488	Redacted
HTC_TST_NGI	Sum of Test Result disaggregates	92,700	62,196	Redacted
HTC_TST_NGI	Age/sex: <1 Male	0	0	Redacted
HTC_TST_NGI	Age/sex: 1-4 Male	3,245	2,177	Redacted
HTC_TST_NGI	Age/sex: 5-9 Male	1,390	933	Redacted
HTC_TST_NGI	Age/sex: 10-14 Male	2,317	1,555	Redacted
HTC_TST_NGI	Age/sex: 15-19 Male	4,635	3,110	Redacted
HTC_TST_NGI	Age/sex: 20-24 Male	11,588	7,775	Redacted
HTC_TST_NGI	Age/sex: 25-49 Male	18,540	12,438	Redacted
HTC_TST_NGI	Age/sex: 50+ Male	4,635	3,110	Redacted
HTC_TST_NGI	Age/sex: <1 Female	0	0	Redacted
HTC_TST_NGI	Age/sex: 1-4 Female	3,245	2,177	Redacted
HTC_TST_NGI	Age/sex: 5-9 Female	1,390	933	Redacted
HTC_TST_NGI	Age/sex: 10-14 Female	2,317	1,555	Redacted
HTC_TST_NGI	Age/sex: 15-19 Female	4,635	3,110	Redacted
HTC_TST_NGI	Age/sex: 20-24 Female	11,588	7,775	Redacted
HTC_TST_NGI	Age/sex: 25-49 Female	18,540	12,438	Redacted
HTC_TST_NGI	Age/sex: 50+ Female	4,635	3,110	Redacted
HTC_TST_NGI	Sum of Age/Sex disaggregates	92,700	62,196	Redacted
HTC_TST_NGI	Aggregated Age/sex: <15 Male	6,952	4,665	Redacted
HTC_TST_NGI	Aggregated Age/sex: 15+ Male	39,398	26,433	Redacted
HTC_TST_NGI	Aggregated Age/sex: <15 Female	6,952	4,665	Redacted
HTC_TST_NGI	Aggregated Age/sex: 15+ Female	39,398	26,433	Redacted
HTC_TST_NGI	Sum of Aggregated Age/Sex <15	13,904	9,330	Redacted



HTC_TST_NGI	Sum of Aggregated Age/Sex 15+	78,796	52,866	Redacted
HTC_TST_NGI	Sum of Aggregated Age/Sex disaggregates	92,700	62,196	Redacted
GEND_GBV_DSD	Number of people receiving post-GBV care	720	720	Redacted
GEND_GBV_DSD	Age: 0-9	115	115	Redacted
GEND_GBV_DSD	Age: 10-14	108	108	Redacted
GEND_GBV_DSD	Age: 15-17	65	65	Redacted
GEND_GBV_DSD	Age: 18-24	252	252	Redacted
GEND_GBV_DSD	Age: 25+	180	180	Redacted
GEND_GBV_DSD	Sum of Age disaggregates	720	720	Redacted
GEND_GBV_DSD	Sex: Male	172	172	Redacted
GEND_GBV_DSD	Sex: Female	548	548	Redacted
GEND_GBV_DSD	Sum of Sex disaggregates	720	720	Redacted
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	302	302	Redacted
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	418	418	Redacted
GEND_GBV_DSD	By PEP service provision (related to sexual violence services provided)	576	576	Redacted
C2.1.D_DSD	Number of HIV-positive individuals receiving a minimum of one clinical service	8,141	8,899	Redacted
C2.1.D_DSD	By Age/Sex: <15 Female	366	402	Redacted
C2.1.D_DSD	By Age/Sex: <15 Male	366	401	Redacted
C2.1.D_DSD	By Age/Sex: 15+ Female	4,890	5,343	Redacted
C2.1.D_DSD	By Age/Sex: 15+ Male	2,519	2,753	Redacted
C2.1.D_DSD	Sum of Age/Sex disaggregates	8,141	8,899	Redacted
C2.1.D_DSD	By Age: <15	732	803	Redacted
C2.1.D_DSD	By Age: 15+	7,409	8,096	Redacted
C2.1.D_DSD	Sum of Age disaggregates	8,141	8,899	Redacted
C2.1.D_DSD	By Sex: Female	5,256	5,745	Redacted

C2.1.D_DSD	By Sex: Male	2,885	3,154	Redacted
C2.1.D_DSD	Sum of Sex disaggregates	8,141	8,899	Redacted
C2.1.D_NGI	Number of HIV-positive individuals receiving a minimum of one clinical service	8,141	8,899	Redacted
C2.1.D_NGI	By Age/Sex: <15 Female	366	402	Redacted
C2.1.D_NGI	By Age/Sex: <15 Male	366	401	Redacted
C2.1.D_NGI	By Age/Sex: 15+ Female	4,890	5,343	Redacted
C2.1.D_NGI	By Age/Sex: 15+ Male	2,519	2,753	Redacted
C2.1.D_NGI	Sum of Age/Sex disaggregates	8,141	8,899	Redacted
C2.1.D_NGI	By Age: <15	732	803	Redacted
C2.1.D_NGI	By Age: 15+	7,409	8,096	Redacted
C2.1.D_NGI	Sum of Age disaggregates	8,141	8,899	Redacted
C2.1.D_NGI	By Sex: Female	5,256	5,745	Redacted
C2.1.D_NGI	By Sex: Male	2,885	3,154	Redacted
C2.1.D_NGI	Sum of Sex disaggregates	8,141	8,899	Redacted
C2.4.D_DSD	Number of HIV-positive patients who were screened for TB in HIV care or treatment setting	7,327	8,454	Redacted
C2.4.D_DSD	Number of HIV-positive individuals receiving a minimum of one clinical service	8,141	8,899	Redacted
C2.5.D_DSD	Number of HIV-positive patients in HIV care who started TB treatment	147	169	Redacted
C2.5.D_DSD	Number of HIV-positive individuals receiving a minimum of one clinical service	8,141	8,899	Redacted
CARE_CURR_DS D	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	7,734	8,454	Redacted
CARE_CURR_DS D	Age/sex: <1 Male	12	13	Redacted



CARE_CURR_DS D	Age/sex: 1-4 Male	84	92	Redacted
CARE_CURR_DS D	Age/sex: 5-9 Male	141	155	Redacted
CARE_CURR_DS D	Age/sex: 10-14 Male	111	122	Redacted
CARE_CURR_DS D	Age/sex: 15-19 Male	59	65	Redacted
CARE_CURR_DS D	Age/sex: 20-24 Male	110	120	Redacted
CARE_CURR_DS D	Age/sex: 25-49 Male	1,653	1,806	Redacted
CARE_CURR_DS D	Age/sex: 50+ Male	571	624	Redacted
CARE_CURR_DS D	Age/sex: <1 Female	12	13	Redacted
CARE_CURR_DS D	Age/sex: 1-4 Female	79	87	Redacted
CARE_CURR_DS D	Age/sex: 5-9 Female	146	160	Redacted
CARE_CURR_DS D	Age/sex: 10-14 Female	111	121	Redacted
CARE_CURR_DS D	Age/sex: 15-19 Female	98	107	Redacted
CARE_CURR_DS D	Age/sex: 20-24 Female	407	444	Redacted
CARE_CURR_DS D	Age/sex: 25-49 Female	3,473	3,795	Redacted
CARE_CURR_DS D	Age/sex: 50+ Female	667	730	Redacted
CARE_CURR_DS D	Sun of Age/Sex disaggregates	7,734	8,454	Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	348	382	Redacted



CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	2,393	2,615	Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	348	381	Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	4,645	5,076	Redacted
CARE_CURR_DS D	Sum of Aggregated Age/Sex disaggregates	7,734	8,454	Redacted
CARE_NEW_DSD	Number of HIV-infected adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load	1,547	1,537	Redacted
CARE_NEW_DSD	Age/sex: <1 Male	2	2	Redacted
CARE_NEW_DSD	Age/sex: 1-4 Male	17	17	Redacted
CARE_NEW_DSD	Age/sex: 5-9 Male	28	28	Redacted
CARE_NEW_DSD	Age/sex: 10-14 Male	23	22	Redacted
CARE_NEW_DSD	Age/sex: 15-19 Male	10	10	Redacted
CARE_NEW_DSD	Age/sex: 20-24 Male	42	42	Redacted
CARE_NEW_DSD	Age/sex: 25-49 Male	358	356	Redacted
CARE_NEW_DSD	Age/sex: 50+ Male	69	68	Redacted
CARE_NEW_DSD	Age/sex: <1 Female	2	2	Redacted
CARE_NEW_DSD	Age/sex: 1-4 Female	16	16	Redacted
CARE_NEW_DSD	Age/sex: 5-9 Female	29	29	Redacted
CARE_NEW_DSD	Age/sex: 10-14 Female	23	22	Redacted
CARE_NEW_DSD	Age/sex: 15-19 Female	23	23	Redacted
CARE_NEW_DSD	Age/sex: 20-24 Female	43	42	Redacted
CARE_NEW_DSD	Age/sex: 25-49 Female	641	637	Redacted
CARE_NEW_DSD	Age/sex: 50+ Female	221	221	Redacted
CARE_NEW_DSD	Sum of Age/sex disaggregates	1,547	1,537	Redacted
CARE_NEW_DSD	Aggregated Age/sex: <15 Male	70	69	Redacted
CARE_NEW_DSD	Aggregated Age/sex: 15+ Male	479	476	Redacted



CARE_NEW_DSD	Aggregated Age/sex: <15 Female	70	69	Redacted
CARE_NEW_DSD	Aggregated Age/sex: 15+ Female	928	923	Redacted
CARE_NEW_DSD	Sum of Aggregated Age/sex disaggregates	1,547	1,537	Redacted
CARE_SITE	Number of PEPFAR-supported HIV clinical care sites at which at least 80% of PLHIV received all of the following during the reporting period: 1) clinical assessment (WHO staging) OR CD4 count OR viral load, AND 2) TB screening at last visit, AND 3) if eligible, cotrimoxazole	2	2	Redacted
CARE_SITE	Total number of PEPFAR supported sites providing clinical care services	2	2	Redacted
CARE_SITE	By site support type: Direct Service Delivery (DSD): Number of PEPFAR-supported HIV clinical care sites at which at least 80% of PLHIV received all of the following during the reporting period: 1) clinical assessment (WHO staging) OR CD4 count OR viral load, AND 2) TB screening at last visit, AND 3) if eligible, cotrimoxazole	2	2	Redacted
CARE_SITE	By site support type: Technical Assistance-only (TA): Number of PEPFAR-supported HIV clinical care sites at which at least 80% of PLHIV received all of the following during the reporting period: 1) clinical assessment (WHO staging) OR CD4 count OR viral load, AND 2) TB screening at last visit, AND 3) if eligible, cotrimoxazole	0	0	Redacted
CARE_SITE	Sum of Numerator Site Support Type disaggregates	2	2	Redacted
CARE_SITE	By site support type: Direct Service	2	2	Redacted



	Delivery (DSD): Total number of PEPFAR supported sites providing clinical care services			
CARE_SITE	By site support type: Technical Assistance-only (TA): Total number of PEPFAR supported sites providing clinical care services	0	0	Redacted
CARE_SITE	Sum of Denominator Site Support Type disaggregates	2	2	Redacted
FN_SITE	Number of PEPFAR-supported sites achieving 90% nutrition assessments that result in accurate categorization of malnutrition	2	2	Redacted
FN_SITE	Total number of PEPFAR-supported sites providing nutrition assessment, counseling and support (NACS) services	2	2	Redacted
FN_SITE	By site support type: Direct Service Delivery (DSD): Number of PEPFAR-supported sites achieving 90% nutrition assessments that result in accurate categorization of malnutrition	2	2	Redacted
FN_SITE	By site support type: Technical Assistance-only (TA): Number of PEPFAR-supported sites achieving 90% nutrition assessments that result in accurate categorization of malnutrition	0	0	Redacted
FN_SITE	Sum of Numerator Support Type disaggregates	2	2	Redacted
FN_SITE	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported sites providing nutrition assessment, counseling and	2	2	Redacted

	support (NACS) services			
FN_SITE	By site support type: Technical Assistance-only (TA): Total number of PEPFAR-supported sites providing nutrition assessment, counseling and support (NACS) services	0	0	Redacted
FN_SITE	Sum of Denominator Support Type disaggregates	2	2	Redacted
FN_THER_DSD	Number of clinically malnourished PLHIV who received therapeutic and/or supplementary food during the reporting period.	1,221	1,335	Redacted
FN_THER_DSD	Number of PLHIV who were nutritionally assessed and found to be clinically undernourished.	1,628	1,780	Redacted
FN_THER_DSD	Age: <1	4	4	Redacted
FN_THER_DSD	Age: 1-4	26	29	Redacted
FN_THER_DSD	Age: 5-14	82	90	Redacted
FN_THER_DSD	Age: 15-17	25	27	Redacted
FN_THER_DSD	Age: 18+	1,084	1,185	Redacted
FN_THER_DSD	Sum of Age disaggregates	1,221	1,335	Redacted
FN_THER_DSD	Aggregated Age: <18	137	150	Redacted
FN_THER_DSD	Aggregated Age: 18+	1,084	1,185	Redacted
FN_THER_DSD	Sum of Aggregated Age disaggregates	1,221	1,335	Redacted
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	311	380	Redacted
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	366	423	Redacted
TB_ART_DSD	Age: 0-4	8	9	Redacted

TB_ART_DSD	Age: 5-14	20	26	Redacted
TB_ART_DSD	Age: 15+	283	345	Redacted
TB_ART_DSD	Male	168	205	Redacted
TB_ART_DSD	Female	143	175	Redacted
TB_ART_DSD	Sum of Sex disaggregates	311	380	Redacted
TB_ART_DSD	Newly tested	186	228	Redacted
TB_ART_DSD	Known HIV-positive	125	152	Redacted
TB_ART_DSD	Sum of Test Status disaggregates	311	380	Redacted
TB_ART_DSD	Aggregated Age: <15	28	35	Redacted
TB_ART_DSD	Aggregated Age: 15+	283	345	Redacted
TB_ART_DSD	Sum of Aggregated Age disaggregates	311	380	Redacted
TB_ARTSITE	The number of PEPFAR-supported TB basic management units at which 80% of registered TB cases who are HIV-positive are on ART, during the reporting period	2	2	Redacted
TB_ARTSITE	The number of PEPFAR-supported TB basic management units	2	2	Redacted
TB_ARTSITE	By site support type: Direct Service Delivery (DSD): The number of PEPFAR-supported TB basic management units at which 80% of registered TB cases who are HIV-positive are on ART, during the reporting period	2	2	Redacted
TB_ARTSITE	By site support type: Technical Assistance-only (TA): The number of PEPFAR-supported TB basic management units at which 80% of registered TB cases who are HIV-positive are on ART, during the reporting period	0	0	Redacted
TB_ARTSITE	Sum of Numerator Site Support Type disaggregates	2	2	Redacted



TB_ARTSITE	By site support type: Direct Service Delivery (DSD): The number of PEPFAR-supported TB basic management units	2	2	Redacted
TB_ARTSITE	By site support type: Technical Assistance-only (TA): The number of PEPFAR-supported TB basic management units	0	0	Redacted
TB_ARTSITE	Sum of Denominator Site Support Type disaggregates	2	2	Redacted
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	963	982	Redacted
PMTCT_EID_DSD	Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT)	1,203	1,228	Redacted
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	722	737	Redacted
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	241	245	Redacted
PMTCT_EID_DSD	Sum of Infant Age disaggregates	963	982	Redacted
PMTCT_EID_DSD	By infants with a positive virologic test result within 12 months of birth	48	49	Redacted
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	6,406	7,281	Redacted
TX_CURR_DSD	Age/Sex: <1 Male	10	11	Redacted
TX_CURR_DSD	Age/Sex: 1-4 Male	67	77	Redacted
TX_CURR_DSD	Age/Sex: 5-14 Male	211	240	Redacted
TX_CURR_DSD	Age/Sex: 15+ Male	1,982	2,319	Redacted
TX_CURR_DSD	Age/Sex: <1 Female	10	11	Redacted
TX_CURR_DSD	Age/Sex: 1-4 Female	67	77	Redacted
TX_CURR_DSD	Age/Sex: 5-14 Female	211	240	Redacted

TX_CURR_DSD	Age/Sex: 15+ Female	3,848	4,306	Redacted
TX_CURR_DSD	Sum of age/sex disaggregates	576	656	Redacted
TX_CURR_DSD	Percent children with advanced HIV infection receiving antiretroviral therapy (ART) [CURRENT]	79	82	Redacted
TX_CURR_DSD	Percent women and girls with advanced HIV infection receiving antiretroviral therapy (ART) [CURRENT]	79	81	Redacted
TX_CURR_DSD	Aggregated Age/Sex: <1 Male	10	11	Redacted
TX_CURR_DSD	Aggregated Age/Sex: <1 Female	10	11	Redacted
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	288	328	Redacted
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	1,982	2,319	Redacted
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	288	328	Redacted
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	3,848	4,306	Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	576	656	Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	5,830	6,625	Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	6,406	7,281	Redacted
TX_CURR_NGI	Number of adults and children receiving antiretroviral therapy (ART)	6,406	7,281	Redacted
TX_CURR_NGI	Age/Sex: <1 Male	10	11	Redacted
TX_CURR_NGI	Age/Sex: 1-4 Male	67	77	Redacted
TX_CURR_NGI	Age/Sex: 5-14 Male	211	240	Redacted
TX_CURR_NGI	Age/Sex: 15+ Male	1,982	2,319	Redacted
TX_CURR_NGI	Age/Sex: <1 Female	10	11	Redacted
TX_CURR_NGI	Age/Sex: 1-4 Female	67	77	Redacted
TX_CURR_NGI	Age/Sex: 5-14 Female	211	240	Redacted
TX_CURR_NGI	Age/Sex: 15+ Female	3,848	4,306	Redacted
TX_CURR_NGI	Sum of Age/Sex disaggregates	6,406	7,281	Redacted
TX_CURR_NGI	Aggregated Age/Sex: <1 Male	10	11	Redacted
TX_CURR_NGI	Aggregated Age/Sex: <1 Female	10	11	Redacted
TX_CURR_NGI	Aggregated Age/Sex: <15 Male	288	328	Redacted



TX_CURR_NGI	Aggregated Age/Sex: 15+ Male	1,982	2,319	Redacted
TX_CURR_NGI	Aggregated Age/Sex: <15 Female	288	328	Redacted
TX_CURR_NGI	Aggregated Age/Sex: 15+ Female	3,848	4,306	Redacted
TX_CURR_NGI	Sum of Aggregated Age/Sex disaggregates	6,406	7,281	Redacted
TX_CURR_NGI	Sum of Aggregated Age/Sex <15	576	656	Redacted
TX_CURR_NGI	Sum of Aggregated Age/Sex 15+	5,830	6,625	Redacted
TX_DIST	Number of Districts with documented routine supportive supervision visits to 75% of HIV care and treatment sites supported by the District	2	2	Redacted
TX_DIST	Total number of PEPFAR supported District Health Offices	2	2	Redacted
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	1,408	1,389	Redacted
TX_NEW_DSD	By Age/Sex: <1 Male	22	29	Redacted
TX_NEW_DSD	By Age/Sex: 1-4 Male	12	17	Redacted
TX_NEW_DSD	By Age/Sex: 5-9 Male	22	29	Redacted
TX_NEW_DSD	By Age/Sex: 10-14 Male	17	23	Redacted
TX_NEW_DSD	By Age/Sex: 15-19 Male	11	10	Redacted
TX_NEW_DSD	By Age/Sex: 20-24 Male	20	19	Redacted
TX_NEW_DSD	By Age/Sex: 25-49 Male	305	288	Redacted
TX_NEW_DSD	By Age/Sex: 50+ Male	105	101	Redacted
TX_NEW_DSD	By Age/Sex: <1 Female	22	29	Redacted
TX_NEW_DSD	By Age/Sex: 1-4 Female	12	17	Redacted
TX_NEW_DSD	By Age/Sex: 5-9 Female	22	29	Redacted
TX_NEW_DSD	By Age/Sex: 10-14 Female	17	22	Redacted
TX_NEW_DSD	By Age/Sex: 15-19 Female	17	16	Redacted
TX_NEW_DSD	By Age/Sex: 20-24 Female	72	68	Redacted
TX_NEW_DSD	By Age/Sex: 25-49 Female	614	580	Redacted
TX_NEW_DSD	By Age/Sex: 50+ Female	118	112	Redacted
TX_NEW_DSD	Sum of Age/Sex disaggregates	1,408	1,389	Redacted
TX_NEW_DSD	Aggregated Grouping by Age: <1 Male	22	29	Redacted



TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	73	98	Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	441	418	Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <1 Female	22	29	Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	73	97	Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	821	776	Redacted
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	1,408	1,389	Redacted
TX_NEW_DSD	Pregnancy status	379	387	Redacted
TX_NEW_DSD	Breastfeeding status	42	43	Redacted
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	949	1,197	Redacted
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	1,116	1,408	Redacted
TX_RET_DSD	Age: 0-4 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	23	30	Redacted
TX_RET_DSD	Age: 5-14 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	64	81	Redacted
TX_RET_DSD	Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	861	1,086	Redacted



TX_RET_DSD	Age: 0-4 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	28	35	Redacted
TX_RET_DSD	Age: 5-14 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	75	95	Redacted
TX_RET_DSD	Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,013	1,278	Redacted
TX_RET_DSD	Aggregated Age: <15 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	87	110	Redacted
TX_RET_DSD	Aggregated Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	861	1,086	Redacted
TX_RET_DSD	Aggregated Age: <15 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	103	130	Redacted



TX_RET_DSD	Aggregated Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,013	1,278	Redacted
TX_RET_DSD	Pregnancy and breastfeeding status (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	384	767	Redacted
TX_RET_DSD	Pregnancy and breastfeeding status (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	451	903	Redacted
TX_SITE	Number of PEPFAR-supported ART sites with a retention rate of 75% or greater for patients 12 months after ART initiation	2	2	Redacted
TX_SITE	Total number of PEPFAR-supported ART sites	2	2	Redacted
TX_SITE	By support type: Direct Service Delivery (DSD): Number of PEPFAR-supported ART sites with a retention rate of 75% or greater for patients 12 months after ART initiation	2	2	Redacted
TX_SITE	By support type: Technical Assistance (TA-only): Number of PEPFAR-supported ART sites with a retention rate of 75% or greater for patients 12 months after ART initiation	0	0	Redacted
TX_SITE	Sum of Numerator Site Support Type	2	2	Redacted

	disaggregates			
TX_SITE	By support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported ART sites	2	2	Redacted
TX_SITE	By support type: Technical Assistance (TA-only): Total number of PEPFAR-supported ART sites	0	0	Redacted
TX_SITE	Sum of Denominator Site Support Type disaggregates	2	2	Redacted
LAB_ACC_DSD	Number of PEPFAR-supported testing facilities (laboratories) that are recognized by national, regional, or international standards for accreditation or have achieved a minimal acceptable level towards attainment of such accreditation	14	17	Redacted
LAB_ACC_DSD	By site support type: Direct Service Delivery (DSD)	7	7	Redacted
LAB_ACC_DSD	By site support type: Technical Assistance-only (TA)	7	10	Redacted
LAB_ACC_DSD	Sum of Support Type disaggregates	14	17	Redacted
LAB_CAP_DSD	Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests	7	10	Redacted
LAB_CAP_DSD	By clinical laboratories	5	0	Redacted
LAB_CAP_DSD	By Point-of-care testing sites	0	0	Redacted
LAB_CAP_DSD	By site support type: Direct Service Delivery (DSD)	0	0	Redacted
LAB_CAP_DSD	By site support type: Technical Assistance-only (TA)	7	10	Redacted
LAB_CAP_DSD	Sum of Site Support Type disaggregates	7	10	Redacted
LAB_PT_DSD	Percentage of laboratories and POC testing sites that perform HIV	75	75	Redacted

	diagnostic testing that participate and successfully pass in an analyte-specific proficiency testing (PT) program			
LAB_PT_DSD	CD4: Number of laboratories that perform this testing	255	255	Redacted
LAB_PT_DSD	CD4: Number of laboratories that participate in this PT program	54	54	Redacted
LAB_PT_DSD	CD4: Number of laboratories that achieve acceptable successful passing criteria in this PT program	41	41	Redacted
LAB_PT_DSD	TB diagnostics (AFB microscopy, Xpert MTB/RIF, Culture/DST): Number of laboratories that perform this testing	1,450	1,450	Redacted
LAB_PT_DSD	TB diagnostics (AFB microscopy, Xpert MTB/RIF, Culture/DST): Number of laboratories that participate in this PT program	25	25	Redacted
LAB_PT_DSD	TB diagnostics (AFB microscopy, Xpert MTB/RIF, Culture/DST): Number of laboratories that achieve acceptable successful passing criteria in this PT program	19	19	Redacted
FPINT_SITE_DSD	Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	2	2	Redacted
FPINT_SITE_DSD	Total number of PEPFAR-supported HIV service delivery points: PMTCT, Care and Treatment	2	2	Redacted
FPINT_SITE_DSD	By site support type: Direct Service Delivery (DSD): Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	2	2	Redacted



FPINT_SITE_DSD	By site support type: Technical Assistance-only (TA): Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	0	0	Redacted
FPINT_SITE_DSD	Sum of Numerator Site Support Type disaggregates	2	2	Redacted
FPINT_SITE_DSD	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported HIV service delivery points	2	2	Redacted
FPINT_SITE_DSD	By site support type: Technical Assistance-only (TA): Total number of PEPFAR-supported HIV service delivery points	0	0	Redacted
FPINT_SITE_DSD	Sum of Denominator Site Support Type disaggregates	2	2	Redacted
FPINT_SITE_DSD	Service delivery type: Clinical	2	2	Redacted
FPINT_SITE_DSD	Sum of Service Delivery Type disaggregates	2	2	Redacted
QI_SITE	Number of PEPFAR-supported clinical service sites with a quality improvement activity completed that addresses clinical HIV programs and has documented process results in the last 6 months	2	2	Redacted
QI_SITE	Total number of PEPFAR-supported sites for any HIV clinical service including HIV Care, HIV Treatment, TB care, PMTCT, VMMC, and HTC	2	2	Redacted
QI_SITE	By site support type: Direct Service Delivery (DSD): Number of PEPFAR-supported clinical service sites with a quality improvement activity	2	2	Redacted



	completed that addresses clinical HIV programs and has documented results in the last 6 months			
QI_SITE	By site support type: Technical Assistance-only (TA): Number of PEPFAR-supported clinical service sites with a quality improvement activity completed that addresses clinical HIV programs and has documented results in the last 6 months	0	0	Redacted
QI_SITE	Sum of Numerator Site Support Type disaggregates	2	2	Redacted
QI_SITE	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported sites for any HIV clinical service including HIV Care, HIV Treatment, TB care, PMTCT, VMMC, HTC	2	2	Redacted
QI_SITE	By site support type: Technical Assistance-only (TA): Total number of PEPFAR-supported sites for any HIV clinical service including HIV Care, HIV Treatment, TB care, PMTCT, VMMC, and HTC	0	0	Redacted
QI_SITE	Sum of Denominator Site Support Type disaggregates	2	2	Redacted
TB_SCREEN_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period	6,961	8,032	Redacted
TB_SCREEN_DSD	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	7,734	8,454	Redacted



TB_SCREEN_DSD	Age: <1	22	26	Redacted
TB_SCREEN_DSD	Age: 1-4	150	173	Redacted
TB_SCREEN_DSD	Age: 5-9	265	306	Redacted
TB_SCREEN_DSD	Age: 10-14	204	236	Redacted
TB_SCREEN_DSD	Age: 15-19	141	162	Redacted
TB_SCREEN_DSD	Age: 20-24	469	541	Redacted
TB_SCREEN_DSD	Age: 25-49	4,610	5,319	Redacted
TB_SCREEN_DSD	Age: 50+	1,100	1,269	Redacted
TB_SCREEN_DSD	Sum of Age disaggregates	782	903	Redacted
TB_SCREEN_DSD	Aggregated Age - USE WITH HQ PERMISSION ONLY: <15	641	741	Redacted
TB_SCREEN_DSD	Aggregated Age - USE WITH HQ PERMISSION ONLY: 15+	6,320	7,291	Redacted
TB_SCREEN_DSD	Sum of Aggregated Age disaggregates	6,961	8,032	Redacted
TB_SCREEN_DSD	Sex: Male	2,469	2,849	Redacted
TB_SCREEN_DSD	Sex: Female	4,492	5,183	Redacted
TB_SCREEN_DSD	Sum of Sex disaggregates	6,961	8,032	Redacted

Implementing Mechanism Details

Mechanism ID: 13307	Mechanism Name: Prevention for Youth and General Population
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Impact Research and Development Organization	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: No	
G2G: No	Managing Agency:

Total All Funding Sources: 1,940,095	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 157,227	
FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount
GHP-State	1,940,095



Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

Human Resources for Health	702,042
Key Populations: MSM and TG	16,200
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Implementation of core HIV prevention interventions for MSM/TG that are consistent with the current PEPFAR technical guidance
Focus Area:	Collection and use of strategic information
Focus Area:	Monitoring and evaluation of MSM/TG programs
Focus Area:	Procurement of condoms, lubricants, and other commodities essential to core HIV services for MSM/TG
Key Populations: FSW	99,960
Focus Area:	Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Collection and use of strategic information on SWs and clients
Focus Area:	Monitoring and evaluation of SW programs
Focus Area:	Procurement of condoms, lubricants, and other commodities essential to core HIV services for SWs
Gender: GBV	95,494
Focus Area:	GBV Prevention
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation



Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Focus Area:	Post GBV Care
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Gender: Gender Equality	190,987
Focus Area:	Changing harmful gender norms and promoting positive gender norms
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Focus Area:	Promoting gender-related policies and laws that increase legal protection
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Focus Area:	Increase gender-equitable access to income and productive resources, including education
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Collection and Use of Gender-related Strategic



	Information
Sub Area:	Implementation
Sub Area:	Capacity building
Condom programming	65,900

Key Issues

Mobile Population
 Family Planning

Budget Code Information

Mechanism ID: 13307			
Mechanism Name: Prevention for Youth and General Population			
Prime Partner Name: Impact Research and Development Organization			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVAB	1,122,750	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	163,385	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	653,960	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2014	2015	Planning Budget Targets
SITE_SUPP	Number of unique sites supported by	14	14	Redacted



	PEPFAR			
SITE_SUPP	By program area/support type: HTC Direct Service Delivery (DSD)	14	14	Redacted
SITE_SUPP	By program area/support type: General Population Prevention Direct Service Delivery (DSD)	7	7	Redacted
SITE_SUPP	By program area/support type: Key Populations Prevention Direct Service Delivery (DSD)	7	7	Redacted
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	21,054	206,447	Redacted
PP_PREV_DSD	Total number of people in the target population	800,937	800,937	Redacted
PP_PREV_DSD	Age/sex: 10-14 Male	773	78,495	Redacted
PP_PREV_DSD	Age/sex: 15-19 Male	4,037		Redacted
PP_PREV_DSD	Age/sex: 20-24 Male	4,037	383	Redacted
PP_PREV_DSD	Age/sex: 25-49 Male	1,180	1,534	Redacted
PP_PREV_DSD	Age/sex: 10-14 Female	973	78,982	Redacted
PP_PREV_DSD	Age/sex: 15-19 Female	4,837	10,781	Redacted
PP_PREV_DSD	Age/sex: 20-24 Female	4,037	35,506	Redacted
PP_PREV_DSD	Age/sex: 25-49 Female	1,180	766	Redacted
PP_PREV_DSD	Sum of Age/Sex disaggregates	21,054	206,447	Redacted
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	5,450	2,541	Redacted
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive	5,000	2,208	Redacted



	interventions that are based on evidence and/or meet the minimum standards required)			
KP_PREV_DSD	By key population type: Men who have sex with men/Transgender (MSM/TG) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	450	333	Redacted
KP_PREV_DSD	By key population type: MSM/TG who are male sex workers (subset MSM/TG) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	180	133	Redacted
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	131,400	48,894	Redacted
HTC_TST_DSD	By Test Result: Negative	126,144	46,938	Redacted
HTC_TST_DSD	By Test Result: Positive	5,256	1,956	Redacted
HTC_TST_DSD	Sum of Test Result disaggregates	131,400	48,894	Redacted
HTC_TST_DSD	Age/sex: <1 Male	0		Redacted
HTC_TST_DSD	Age/sex: 1-4 Male	4,599		Redacted
HTC_TST_DSD	Age/sex: 5-9 Male	1,971		Redacted
HTC_TST_DSD	Age/sex: 10-14 Male	3,285		Redacted
HTC_TST_DSD	Age/sex: 15-19 Male	6,570	305	Redacted
HTC_TST_DSD	Age/sex: 20-24 Male	16,425	1,579	Redacted
HTC_TST_DSD	Age/sex: 25-49 Male	26,280	1,704	Redacted
HTC_TST_DSD	Age/sex: 50+ Male	6,570	180	Redacted
HTC_TST_DSD	Age/sex: <1 Female	0		Redacted



HTC_TST_DSD	Age/sex: 1-4 Female	4,599		Redacted
HTC_TST_DSD	Age/sex: 5-9 Female	1,971		Redacted
HTC_TST_DSD	Age/sex: 10-14 Female	3,285		Redacted
HTC_TST_DSD	Age/sex: 15-19 Female	6,570	12,772	Redacted
HTC_TST_DSD	Age/sex: 20-24 Female	16,425	30,261	Redacted
HTC_TST_DSD	Age/sex: 25-49 Female	26,280	1,981	Redacted
HTC_TST_DSD	Age/sex: 50+ Female	6,570	112	Redacted
HTC_TST_DSD	Sum of Age/Sex disaggregates	131,400	48,894	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	9,855		Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	55,845	3,768	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	9,855		Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	55,845	45,126	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	19,710		Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	111,690	48,894	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	131,400	48,894	Redacted
HTC_TST_NGI	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	131,400	48,894	Redacted
HTC_TST_NGI	By Test Result: Negative	126,144	46,938	Redacted
HTC_TST_NGI	By Test Result: Positive	5,256	1,956	Redacted
HTC_TST_NGI	Sum of Test Result disaggregates	131,400	48,894	Redacted
HTC_TST_NGI	Age/sex: <1 Male	0		Redacted
HTC_TST_NGI	Age/sex: 1-4 Male	4,599		Redacted
HTC_TST_NGI	Age/sex: 5-9 Male	1,971		Redacted
HTC_TST_NGI	Age/sex: 10-14 Male	3,285		Redacted
HTC_TST_NGI	Age/sex: 15-19 Male	6,570	305	Redacted
HTC_TST_NGI	Age/sex: 20-24 Male	16,425	1,579	Redacted
HTC_TST_NGI	Age/sex: 25-49 Male	26,280	1,704	Redacted



HTC_TST_NGI	Age/sex: 50+ Male	6,570	180	Redacted
HTC_TST_NGI	Age/sex: <1 Female	0		Redacted
HTC_TST_NGI	Age/sex: 1-4 Female	4,599		Redacted
HTC_TST_NGI	Age/sex: 5-9 Female	1,971		Redacted
HTC_TST_NGI	Age/sex: 10-14 Female	3,285		Redacted
HTC_TST_NGI	Age/sex: 15-19 Female	6,570	12,772	Redacted
HTC_TST_NGI	Age/sex: 20-24 Female	16,425	30,261	Redacted
HTC_TST_NGI	Age/sex: 25-49 Female	26,280	1,981	Redacted
HTC_TST_NGI	Age/sex: 50+ Female	6,570	112	Redacted
HTC_TST_NGI	Sum of Age/Sex disaggregates	131,400	48,894	Redacted
HTC_TST_NGI	Aggregated Age/sex: <15 Male	9,855		Redacted
HTC_TST_NGI	Aggregated Age/sex: 15+ Male	55,845	3,768	Redacted
HTC_TST_NGI	Aggregated Age/sex: <15 Female	9,855		Redacted
HTC_TST_NGI	Aggregated Age/sex: 15+ Female	55,845	45,126	Redacted
HTC_TST_NGI	Sum of Aggregated Age/Sex <15	19,710		Redacted
HTC_TST_NGI	Sum of Aggregated Age/Sex 15+	111,690	48,894	Redacted
HTC_TST_NGI	Sum of Aggregated Age/Sex disaggregates	131,400	48,894	Redacted
GEND_GBV_DSD	Number of people receiving post-GBV care	1,000	2,440	Redacted
GEND_GBV_DSD	Age: 10-14	200	488	Redacted
GEND_GBV_DSD	Age: 15-17	800	1,952	Redacted
GEND_GBV_DSD	Sum of Age disaggregates	1,000	2,440	Redacted
GEND_GBV_DSD	Sex: Male	0	0	Redacted
GEND_GBV_DSD	Sex: Female	1,000	2,440	Redacted
GEND_GBV_DSD	Sum of Sex disaggregates	1,000	2,440	Redacted
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	1,000	2,440	Redacted
GEND_NORM_DS D	Number of people completing an intervention pertaining to gender norms, that meets minimum criteria	12,000	2,875	Redacted
GEND_NORM_DS	By Age: 20-24	2,400	575	Redacted



D				
GEND_NORM_DS D	By Age: 25+	9,600	2,300	Redacted
GEND_NORM_DS D	Sum of Age disaggregates	12,000	2,875	Redacted
GEND_NORM_DS D	By Sex: Male	6,000	1,917	Redacted
GEND_NORM_DS D	By Sex: Female	6,000	958	Redacted
GEND_NORM_DS D	Sum of Sex disaggregates	12,000	2,875	Redacted
GEND_NORM_DS D	By type of activity: Small Group	12,000	2,875	Redacted

Implementing Mechanism Details

Mechanism ID: 13302	Mechanism Name: HIV Prevention Activities for Youth and General Population
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Hope Worldwide	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: PR/SR	
G2G: No	Managing Agency:

Total All Funding Sources: 789,748	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 61,369	
FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount
GHP-State	789,748

Sub Partner Name(s)

(No data provided.)



Cross-Cutting Budget Attribution(s)

Human Resources for Health	350,000
Gender: GBV	124,500
Focus Area:	GBV Prevention
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Monitoring and Evaluation
Gender: Gender Equality	74,216
Focus Area:	Changing harmful gender norms and promoting positive gender norms
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Monitoring and Evaluation
Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Monitoring and Evaluation
Condom programming	26,800

Key Issues

(No data provided.)

Budget Code Information

Mechanism ID:	13302		
Mechanism Name:	HIV Prevention Activities for Youth and General Population		
Prime Partner Name:	Hope Worldwide		
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Prevention	HVAB	464,669	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	95,093	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	229,986	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2014	2015	Planning Budget Targets
SITE_SUPP	Number of unique sites supported by PEPFAR	3	3	Redacted
SITE_SUPP	By program area/support type: HTC Direct Service Delivery (DSD)	3	3	Redacted
SITE_SUPP	By program area/support type: General Population Prevention Direct Service Delivery (DSD)	3	3	Redacted
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	22,980	86,253	Redacted
PP_PREV_DSD	Total number of people in the target population	334,634	334,634	Redacted
PP_PREV_DSD	Age/sex: 10-14 Male	8,280	29,634	Redacted
PP_PREV_DSD	Age/sex: 15-19 Male	2,210		Redacted
PP_PREV_DSD	Age/sex: 10-14 Female	8,680	30,003	Redacted
PP_PREV_DSD	Age/sex: 15-19 Female	3,810	14,043	Redacted
PP_PREV_DSD	Sum of Age/Sex disaggregates	22,980	86,253	Redacted

HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	38,500	27,237	Redacted
HTC_TST_DSD	By Test Result: Negative	36,960	26,148	Redacted
HTC_TST_DSD	By Test Result: Positive	1,540	1,089	Redacted
HTC_TST_DSD	Sum of Test Result disaggregates	38,500	27,237	Redacted
HTC_TST_DSD	Age/sex: <1 Male	0		Redacted
HTC_TST_DSD	Age/sex: 1-4 Male	1,347		Redacted
HTC_TST_DSD	Age/sex: 5-9 Male	578		Redacted
HTC_TST_DSD	Age/sex: 10-14 Male	962		Redacted
HTC_TST_DSD	Age/sex: 15-19 Male	1,925		Redacted
HTC_TST_DSD	Age/sex: 20-24 Male	4,813		Redacted
HTC_TST_DSD	Age/sex: 25-49 Male	7,700		Redacted
HTC_TST_DSD	Age/sex: 50+ Male	1,925		Redacted
HTC_TST_DSD	Age/sex: <1 Female	0		Redacted
HTC_TST_DSD	Age/sex: 1-4 Female	1,347		Redacted
HTC_TST_DSD	Age/sex: 5-9 Female	578		Redacted
HTC_TST_DSD	Age/sex: 10-14 Female	962		Redacted
HTC_TST_DSD	Age/sex: 15-19 Female	1,925	13,618	Redacted
HTC_TST_DSD	Age/sex: 20-24 Female	4,813	13,619	Redacted
HTC_TST_DSD	Age/sex: 25-49 Female	7,700		Redacted
HTC_TST_DSD	Age/sex: 50+ Female	1,925		Redacted
HTC_TST_DSD	Sum of Age/Sex disaggregates	38,500	27,237	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	2,887		Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	16,363		Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	2,887		Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	16,363	27,237	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	5,774		Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	32,726	27,237	Redacted



HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	38,500	27,237	Redacted
HTC_TST_NGI	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	38,500	27,237	Redacted
HTC_TST_NGI	By Test Result: Negative	36,960	26,148	Redacted
HTC_TST_NGI	By Test Result: Positive	1,540	1,089	Redacted
HTC_TST_NGI	Sum of Test Result disaggregates	38,500	27,237	Redacted
HTC_TST_NGI	Age/sex: <1 Male	0		Redacted
HTC_TST_NGI	Age/sex: 1-4 Male	1,347		Redacted
HTC_TST_NGI	Age/sex: 5-9 Male	578		Redacted
HTC_TST_NGI	Age/sex: 10-14 Male	962		Redacted
HTC_TST_NGI	Age/sex: 15-19 Male	1,925		Redacted
HTC_TST_NGI	Age/sex: 20-24 Male	4,813		Redacted
HTC_TST_NGI	Age/sex: 25-49 Male	7,700		Redacted
HTC_TST_NGI	Age/sex: 50+ Male	1,925		Redacted
HTC_TST_NGI	Age/sex: <1 Female	0		Redacted
HTC_TST_NGI	Age/sex: 1-4 Female	1,347		Redacted
HTC_TST_NGI	Age/sex: 5-9 Female	578		Redacted
HTC_TST_NGI	Age/sex: 10-14 Female	962		Redacted
HTC_TST_NGI	Age/sex: 15-19 Female	1,925	13,618	Redacted
HTC_TST_NGI	Age/sex: 20-24 Female	4,813	13,619	Redacted
HTC_TST_NGI	Age/sex: 25-49 Female	7,700		Redacted
HTC_TST_NGI	Age/sex: 50+ Female	1,925		Redacted
HTC_TST_NGI	Sum of Age/Sex disaggregates	38,500	27,237	Redacted
HTC_TST_NGI	Aggregated Age/sex: <15 Male	2,887		Redacted
HTC_TST_NGI	Aggregated Age/sex: 15+ Male	16,363		Redacted
HTC_TST_NGI	Aggregated Age/sex: <15 Female	2,887		Redacted
HTC_TST_NGI	Aggregated Age/sex: 15+ Female	16,363	27,237	Redacted
HTC_TST_NGI	Sum of Aggregated Age/Sex <15	5,774		Redacted
HTC_TST_NGI	Sum of Aggregated Age/Sex 15+	32,726	27,237	Redacted
HTC_TST_NGI	Sum of Aggregated Age/Sex	38,500	27,237	Redacted



	disaggregates			
GEND_GBV_DSD	Number of people receiving post-GBV care	2,000	1,840	Redacted
GEND_GBV_DSD	Age: 10-14	400	368	Redacted
GEND_GBV_DSD	Age: 15-17	1,600	1,472	Redacted
GEND_GBV_DSD	Sum of Age disaggregates	2,000	1,840	Redacted
GEND_GBV_DSD	Sex: Male	100	90	Redacted
GEND_GBV_DSD	Sex: Female	1,900	1,750	Redacted
GEND_GBV_DSD	Sum of Sex disaggregates	2,000	1,840	Redacted
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	400	400	Redacted
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	1,600	1,600	Redacted
GEND_GBV_DSD	By PEP service provision (related to sexual violence services provided)	10	15	Redacted

Implementing Mechanism Details

Mechanism ID: 13287	Mechanism Name: Establishment of Medical Waste Management Systems in Kenya
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Program for Appropriate Technology in Health	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: No	
G2G: No	Managing Agency:

Total All Funding Sources: 750,000	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 0	
FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount
GHP-State	750,000



Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

Human Resources for Health	300,000
----------------------------	---------

Key Issues

(No data provided.)

Budget Code Information

Mechanism ID:	13287		
Mechanism Name:	Establishment of Medical Waste Management Systems in Kenya		
Prime Partner Name:	Program for Appropriate Technology in Health		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HMIN	750,000	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2014	2015	Planning Budget Targets
SITE_SUPP	Number of unique sites supported by PEPFAR	59	59	Redacted
SITE_SUPP	By program area/support type: Lab Direct Service Delivery (DSD)	59	59	Redacted
SITE_SUPP	By program area/support type: Lab Technical Assistance-only (TA)	0	0	Redacted

Implementing Mechanism Details



Mechanism ID: 13210	Mechanism Name: Strengthening Laboratory Accreditation Services in Kenya
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Global Healthcare Public Foundation	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: No	
G2G: No	Managing Agency:
Total All Funding Sources: 0	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 0	
FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount
GHP-State	0

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

(No data provided.)

Budget Code Information

Mechanism ID:	13210		
Mechanism Name:	Strengthening Laboratory Accreditation Services in Kenya		
Prime Partner Name:	Global Healthcare Public Foundation		
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Governance and Systems	HLAB	0	0
------------------------	------	---	---

Implementing Mechanism Indicator Information

Indicator Number	Label	2014	2015	Planning Budget Targets
SITE_SUPP	Number of unique sites supported by PEPFAR	5	0	Redacted
SITE_SUPP	By program area/support type: Lab Direct Service Delivery (DSD)	5	0	Redacted
LAB_ACC_DSD	Number of PEPFAR-supported testing facilities (laboratories) that are recognized by national, regional, or international standards for accreditation or have achieved a minimal acceptable level towards attainment of such accreditation	5	0	Redacted
LAB_ACC_DSD	By site support type: Direct Service Delivery (DSD)	5	0	Redacted
LAB_ACC_DSD	By site support type: Technical Assistance-only (TA)	0	0	Redacted
LAB_ACC_DSD	Sum of Support Type disaggregates	5	0	Redacted

Implementing Mechanism Details

Mechanism ID: 13179	Mechanism Name: Emory University
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Association of Schools of Public Health	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: No	
G2G: No	Managing Agency:

Approved



Total All Funding Sources: 570,000	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 25,000	
FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount
GHP-State	570,000

Sub Partner Name(s)

Emory University		
------------------	--	--

Cross-Cutting Budget Attribution(s)

Human Resources for Health	570,000
----------------------------	---------

Key Issues

(No data provided.)

Budget Code Information

Mechanism ID:	13179		
Mechanism Name:	Emory University		
Prime Partner Name:	Association of Schools of Public Health		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	570,000	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details



Mechanism ID: 13164	Mechanism Name: Strengthening Public Health Laboratory Systems in Kenya
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Management Sciences for Health	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: No	
G2G: No	Managing Agency:

Total All Funding Sources: 1,963,887	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 0	
FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount
GHP-State	1,963,887

Sub Partner Name(s)

Welcome Trust Kilifi		
----------------------	--	--

Cross-Cutting Budget Attribution(s)

Human Resources for Health	200,000
----------------------------	---------

Key Issues

(No data provided.)

Budget Code Information

Mechanism ID:	13164		
Mechanism Name:	Strengthening Public Health Laboratory Systems in Kenya		
Prime Partner Name:	Management Sciences for Health		
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Governance and Systems	HLAB	1,613,887	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HMIN	350,000	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2014	2015	Planning Budget Targets
SITE_SUPP	Number of unique sites supported by PEPFAR	15	15	Redacted
SITE_SUPP	By program area/support type: Lab Technical Assistance-only (TA)	15	15	Redacted
LAB_ACC_DSD	Number of PEPFAR-supported testing facilities (laboratories) that are recognized by national, regional, or international standards for accreditation or have achieved a minimal acceptable level towards attainment of such accreditation	15	15	Redacted
LAB_ACC_DSD	By site support type: Technical Assistance-only (TA)	15	15	Redacted
LAB_ACC_DSD	Sum of Support Type disaggregates	15	15	Redacted
LAB_PT_DSD	Percentage of laboratories and POC testing sites that perform HIV diagnostic testing that participate and successfully pass in an analyte-specific proficiency testing (PT) program	75	75	Redacted
LAB_PT_DSD	CD4: Number of laboratories that perform this testing	255	255	Redacted
LAB_PT_DSD	CD4: Number of laboratories that	63	63	Redacted



	participate in this PT program			
LAB_PT_DSD	CD4: Number of laboratories that achieve acceptable successful passing criteria in this PT program	47	47	Redacted

Implementing Mechanism Details

Mechanism ID: 13121	Mechanism Name: Partnership in Advanced Clinical Education (PACE)
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: University of Maryland	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: No	
G2G: No	Managing Agency:

Total All Funding Sources: 700,000	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 0	
FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount
GHP-State	700,000

Sub Partner Name(s)

Kenya Pediatric Association	University of Nairobi	
-----------------------------	-----------------------	--

Cross-Cutting Budget Attribution(s)

Gender: GBV	17,500
Focus Area:	Post GBV Care
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Gender: Gender Equality	17,500



Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation

Key Issues

- Malaria (PMI)
- Child Survival Activities
- Safe Motherhood
- TB
- Family Planning

Budget Code Information

Mechanism ID: 13121			
Mechanism Name: Partnership in Advanced Clinical Education (PACE)			
Prime Partner Name: University of Maryland			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	133,630	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	49,548	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	100,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	416,822	0



Implementing Mechanism Indicator Information

Indicator Number	Label	2014	2015	Planning Budget Targets
HRH_PRE	Number of new HCW who graduated from a pre-service training institution or program as a result of PEPFAR-supported strengthening efforts, within the reporting period, by select cadre	510	300	Redacted
HRH_PRE	By Graduates: Doctors	250	200	Redacted
HRH_PRE	By Graduates: Nurses	60	25	Redacted
HRH_PRE	By Graduates: Midwives	60		Redacted
HRH_PRE	By Graduates: Laboratory professionals	140	50	Redacted
HRH_PRE	Sum of Graduates disaggregates	510	300	Redacted
HRH_PRE	By new graduates who are licensed and registered: Doctors	250	200	Redacted
HRH_PRE	By new graduates who are licensed and registered: Nurses	60	25	Redacted
HRH_PRE	By new graduates who are licensed and registered: Midwives	60		Redacted
HRH_PRE	By new graduates who are licensed and registered: Laboratorians	140	50	Redacted
HRH_PRE	By new graduates who are licensed and registered: Other (where applicable)	0	25	Redacted

Implementing Mechanism Details

Mechanism ID: 13097	Mechanism Name: Ungana Project
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Liverpool VCT and Care	
Agreement Start Date: Redacted	Agreement End Date: Redacted

Approved



TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: PR/SR	
G2G: No	Managing Agency:

Total All Funding Sources: 0	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 0	
FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount
GHP-State	0

Sub Partner Name(s)

Action for Research and Development (AFORD)	Bar Hostess Empowerment and Support Programme (BHESP)	Better Poverty Eradication Organization
Blood Link Foundation	Catholic Diocese of Muranga	Discordant Couple of Kenya
Hope Community Centre (Christian Life Centre)	Integrated Development Facility (IDF)	Kenya Long Distance Truck Drivers Union VCT
World Provision Centre	Zinduka Afrika	

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

(No data provided.)

Budget Code Information

Mechanism ID:	13097		
Mechanism Name:	Ungana Project		
Prime Partner Name:	Liverpool VCT and Care		
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Governance and Systems	OHSS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HMBL	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVAB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	0	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2014	2015	Planning Budget Targets
SITE_SUPP	Number of unique sites supported by PEPFAR	438		Redacted
SITE_SUPP	By program area/support type: HTC Direct Service Delivery (DSD)	57		Redacted
SITE_SUPP	By program area/support type: HTC Technical Assistance-only (TA)	438		Redacted
SITE_SUPP	By program area/support type: General Population Prevention Direct Service Delivery (DSD)	8		Redacted
SITE_SUPP	By program area/support type: Key Populations Prevention Direct Service Delivery (DSD)	2		Redacted
PP_PREV_DSD	Number of the target population who	30,502		Redacted



	completed a standardized HIV prevention intervention including the minimum components during the reporting period.			
PP_PREV_DSD	Total number of people in the target population	91,510		Redacted
PP_PREV_DSD	Age/sex: 10-14 Male	170		Redacted
PP_PREV_DSD	Age/sex: 15-19 Male	1,508		Redacted
PP_PREV_DSD	Age/sex: 20-24 Male	3,016		Redacted
PP_PREV_DSD	Age/sex: 25-49 Male	9,049		Redacted
PP_PREV_DSD	Age/sex: 50+ Male	1,508		Redacted
PP_PREV_DSD	Age/sex: 10-14 Female	170		Redacted
PP_PREV_DSD	Age/sex: 15-19 Female	1,508		Redacted
PP_PREV_DSD	Age/sex: 20-24 Female	3,016		Redacted
PP_PREV_DSD	Age/sex: 25-49 Female	9,049		Redacted
PP_PREV_DSD	Age/sex: 50+ Female	1,508		Redacted
PP_PREV_DSD	Sum of Age/Sex disaggregates	30,502		Redacted
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	3,500		Redacted
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	3,500		Redacted
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	120,000		Redacted
HTC_TST_DSD	By Test Result: Negative	115,200		Redacted
HTC_TST_DSD	By Test Result: Positive	4,800		Redacted



HTC_TST_DSD	Sum of Test Result disaggregates	120,000		Redacted
HTC_TST_DSD	Age/sex: <1 Male	0		Redacted
HTC_TST_DSD	Age/sex: 1-4 Male	4,200		Redacted
HTC_TST_DSD	Age/sex: 5-9 Male	1,800		Redacted
HTC_TST_DSD	Age/sex: 10-14 Male	3,000		Redacted
HTC_TST_DSD	Age/sex: 15-19 Male	6,000		Redacted
HTC_TST_DSD	Age/sex: 20-24 Male	15,000		Redacted
HTC_TST_DSD	Age/sex: 25-49 Male	24,000		Redacted
HTC_TST_DSD	Age/sex: 50+ Male	6,000		Redacted
HTC_TST_DSD	Age/sex: <1 Female	0		Redacted
HTC_TST_DSD	Age/sex: 1-4 Female	4,200		Redacted
HTC_TST_DSD	Age/sex: 5-9 Female	1,800		Redacted
HTC_TST_DSD	Age/sex: 10-14 Female	3,000		Redacted
HTC_TST_DSD	Age/sex: 15-19 Female	6,000		Redacted
HTC_TST_DSD	Age/sex: 20-24 Female	15,000		Redacted
HTC_TST_DSD	Age/sex: 25-49 Female	24,000		Redacted
HTC_TST_DSD	Age/sex: 50+ Female	6,000		Redacted
HTC_TST_DSD	Sum of Age/Sex disaggregates	120,000		Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	9,000		Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	51,000		Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	9,000		Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	51,000		Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	18,000		Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	102,000		Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	120,000		Redacted
HTC_TST_NGI	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	200,000		Redacted



HTC_TST_NGI	By Test Result: Negative	192,000		Redacted
HTC_TST_NGI	By Test Result: Positive	8,000		Redacted
HTC_TST_NGI	Sum of Test Result disaggregates	200,000		Redacted
HTC_TST_NGI	Age/sex: 1-4 Male	7,000		Redacted
HTC_TST_NGI	Age/sex: 5-9 Male	3,000		Redacted
HTC_TST_NGI	Age/sex: 10-14 Male	5,000		Redacted
HTC_TST_NGI	Age/sex: 15-19 Male	10,000		Redacted
HTC_TST_NGI	Age/sex: 20-24 Male	25,000		Redacted
HTC_TST_NGI	Age/sex: 25-49 Male	40,000		Redacted
HTC_TST_NGI	Age/sex: 50+ Male	10,000		Redacted
HTC_TST_NGI	Age/sex: <1 Female	0		Redacted
HTC_TST_NGI	Age/sex: 1-4 Female	7,000		Redacted
HTC_TST_NGI	Age/sex: 5-9 Female	3,000		Redacted
HTC_TST_NGI	Age/sex: 10-14 Female	5,000		Redacted
HTC_TST_NGI	Age/sex: 15-19 Female	10,000		Redacted
HTC_TST_NGI	Age/sex: 20-24 Female	25,000		Redacted
HTC_TST_NGI	Age/sex: 25-49 Female	40,000		Redacted
HTC_TST_NGI	Age/sex: 50+ Female	10,000		Redacted
HTC_TST_NGI	Sum of Age/Sex disaggregates	200,000		Redacted
HTC_TST_NGI	Aggregated Age/sex: <15 Male	15,000		Redacted
HTC_TST_NGI	Aggregated Age/sex: 15+ Male	85,000		Redacted
HTC_TST_NGI	Aggregated Age/sex: <15 Female	15,000		Redacted
HTC_TST_NGI	Aggregated Age/sex: 15+ Female	85,000		Redacted
HTC_TST_NGI	Sum of Aggregated Age/Sex <15	30,000		Redacted
HTC_TST_NGI	Sum of Aggregated Age/Sex 15+	170,000		Redacted
HTC_TST_NGI	Sum of Aggregated Age/Sex disaggregates	200,000		Redacted
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	80,000		Redacted
HTC_TST_TA	By Test Result: Negative	76,800		Redacted
HTC_TST_TA	By Test Result: Positive	3,200		Redacted



HTC_TST_TA	Sum of Test Result disaggregates	80,000		Redacted
HTC_TST_TA	Age/sex: <1 Male	0		Redacted
HTC_TST_TA	Age/sex: 1-4 Male	2,800		Redacted
HTC_TST_TA	Age/sex: 5-9 Male	1,200		Redacted
HTC_TST_TA	Age/sex: 10-14 Male	2,000		Redacted
HTC_TST_TA	Age/sex: 15-19 Male	4,000		Redacted
HTC_TST_TA	Age/sex: 20-24 Male	10,000		Redacted
HTC_TST_TA	Age/sex: 25-49 Male	16,000		Redacted
HTC_TST_TA	Age/sex: 50+ Male	4,000		Redacted
HTC_TST_TA	Age/sex: <1 Female	0		Redacted
HTC_TST_TA	Age/sex: 1-4 Female	2,800		Redacted
HTC_TST_TA	Age/sex: 5-9 Female	1,200		Redacted
HTC_TST_TA	Age/sex: 10-14 Female	2,000		Redacted
HTC_TST_TA	Age/sex: 15-19 Female	4,000		Redacted
HTC_TST_TA	Age/sex: 20-24 Female	10,000		Redacted
HTC_TST_TA	Age/sex: 25-49 Female	16,000		Redacted
HTC_TST_TA	Age/sex: 50+ Female	4,000		Redacted
HTC_TST_TA	Sum of Age/Sex disaggregates	80,000		Redacted
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	6,000		Redacted
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	34,000		Redacted
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	6,000		Redacted
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	34,000		Redacted
HTC_TST_TA	Sum of Aggregated Age/Sex <15	12,000		Redacted
HTC_TST_TA	Sum of Aggregated Age/Sex 15+	68,000		Redacted
HTC_TST_TA	Sum of Aggregated Age/Sex disaggregates	80,000		Redacted

Implementing Mechanism Details



Mechanism ID: 13072	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 13061	Mechanism Name: Advancement of Public Health Practices in Kenya
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: MINISTRY OF PUBLIC HEALTH AND SANITATION	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: No	
G2G: Yes	Managing Agency: HHS/CDC

Total All Funding Sources: 3,023,649	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 5,398,205	
FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount
GHP-State	3,023,649

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

Gender: Gender Equality	5,000
Focus Area:	Changing harmful gender norms and promoting positive gender norms
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Sub Area:	Operation Research
Focus Area:	Promoting gender-related policies and laws that



	increase legal protection
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Sub Area:	Operation Research
Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Sub Area:	Operation Research
Human Resources for Health	1,120,000
Key Populations: MSM and TG	10,000
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Collection and use of strategic information
Focus Area:	Conducting epidemiologic, social science, and operational research among MSM/TG and their sex partners
Focus Area:	Monitoring and evaluation of MSM/TG programs
Key Populations: FSW	10,000
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Collection and use of strategic information on SWs and clients
Focus Area:	Conducting epidemiologic, social science, and operational research among SWs, their partners, and clients
Focus Area:	Monitoring and evaluation of SW programs
Food and Nutrition: Policy, Tools, and Service Delivery	251,093



Gender: GBV	5,000
Focus Area:	GBV Prevention
Sub Area:	Collection and Use of Gender-related Strategic Information
Condom programming	10,000

Key Issues

(No data provided.)

Budget Code Information

Mechanism ID: 13061			
Mechanism Name: Advancement of Public Health Practices in Kenya			
Prime Partner Name: MINISTRY OF PUBLIC HEALTH AND SANITATION			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	204,167	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	270,859	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	23,333	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	218,750	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	481,250	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Governance and Systems	OHSS	170,875	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	25,215	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HMIN	160,417	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVAB	50,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	50,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	50,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	IDUP	29,167	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	758,333	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	395,100	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	136,183	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2014	2015	Planning
------------------	-------	------	------	----------



				Budget Targets
SITE_SUPP	Number of unique sites supported by PEPFAR	1,454	1,460	Redacted
SITE_SUPP	By program area/support type: Lab Direct Service Delivery (DSD)	270	300	Redacted
SITE_SUPP	By program area/support type: Lab Technical Assistance-only (TA)	1,184	1,160	Redacted
LAB_ACC_DSD	Number of PEPFAR-supported testing facilities (laboratories) that are recognized by national, regional, or international standards for accreditation or have achieved a minimal acceptable level towards attainment of such accreditation	70	80	Redacted
LAB_ACC_DSD	By site support type: Direct Service Delivery (DSD)	10	15	Redacted
LAB_ACC_DSD	By site support type: Technical Assistance-only (TA)	60	65	Redacted
LAB_ACC_DSD	Sum of Support Type disaggregates	70	80	Redacted
LAB_CAP_DSD	Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests	1,454	1,460	Redacted
LAB_CAP_DSD	By site support type: Direct Service Delivery (DSD)	270	300	Redacted
LAB_CAP_DSD	By site support type: Technical Assistance-only (TA)	1,184	1,160	Redacted
LAB_CAP_DSD	Sum of Site Support Type disaggregates	1,454	1,460	Redacted
LAB_PT_DSD	Percentage of laboratories and POC testing sites that perform HIV diagnostic testing that participate and successfully pass in an analyte-specific proficiency testing (PT) program	75	75	Redacted
LAB_PT_DSD	HIV serologic/diagnostic testing:	5,930	7,000	Redacted



	Number of laboratories that perform this testing			
LAB_PT_DSD	HIV serologic/diagnostic testing: Number of laboratories that participate in this PT program	5,930	7,000	Redacted
LAB_PT_DSD	HIV serologic/diagnostic testing: Number of laboratories that achieve acceptable successful passing criteria in this PT program	4,448	5,250	Redacted
LAB_PT_DSD	CD4: Number of laboratories that perform this testing	255	255	Redacted
LAB_PT_DSD	CD4: Number of laboratories that participate in this PT program	80	80	Redacted
LAB_PT_DSD	CD4: Number of laboratories that achieve acceptable successful passing criteria in this PT program	60	60	Redacted
LAB_PT_DSD	Early infant diagnostics: Number of laboratories that perform this testing	2	6	Redacted
LAB_PT_DSD	Early infant diagnostics: Number of laboratories that participate in this PT program	2	6	Redacted
LAB_PT_DSD	Early infant diagnostics: Number of laboratories that achieve acceptable successful passing criteria in this PT program	2	6	Redacted
LAB_PT_DSD	HIV viral load: Number of laboratories that perform this testing	2	6	Redacted
LAB_PT_DSD	HIV viral load: Number of laboratories that participate in this PT program	2	6	Redacted
LAB_PT_DSD	HIV viral load: Number of laboratories that achieve acceptable successful passing criteria in this PT program	2	6	Redacted
LAB_PT_DSD	TB diagnostics (AFB microscopy, Xpert MTB/RIF, Culture/DST): Number of laboratories that perform this testing	1,450	1,450	Redacted



LAB_PT_DSD	TB diagnostics (AFB microscopy, Xpert MTB/RIF, Culture/DST): Number of laboratories that participate in this PT program	1,450	1,450	Redacted
LAB_PT_DSD	TB diagnostics (AFB microscopy, Xpert MTB/RIF, Culture/DST): Number of laboratories that achieve acceptable successful passing criteria in this PT program	1,088	1,088	Redacted

Implementing Mechanism Details

Mechanism ID: 13050	Mechanism Name: Coptic Hospital / University of Washington Collaborative HIV Care Program
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Coptic Hospital	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: No	
G2G: No	Managing Agency:

Total All Funding Sources: 4,342,000	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 88,000	
FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount
GHP-State	4,342,000

Sub Partner Name(s)

Universtiy of Washington		
--------------------------	--	--

Cross-Cutting Budget Attribution(s)

Human Resources for Health	381,137
Gender: GBV	110,750



Focus Area:	Post GBV Care
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Monitoring and Evaluation
Gender: Gender Equality	110,750
Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Monitoring and Evaluation

Key Issues

- Malaria (PMI)
- Child Survival Activities
- Safe Motherhood
- TB
- Family Planning

Budget Code Information

Mechanism ID:	13050		
Mechanism Name:	Coptic Hospital / University of Washington Collaborative HIV Care		
Prime Partner Name:	Program Coptic Hospital		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	260,658	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Care	HVTB	108,519	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	106,572	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	56,226	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	709,786	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	2,902,046	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	198,193	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2014	2015	Planning Budget Targets
SITE_SUPP	Number of unique sites supported by PEPFAR	3	3	Redacted
SITE_SUPP	By program area/support type: HTC Direct Service Delivery (DSD)	3	3	Redacted
SITE_SUPP	By program area/support type: HTC Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: Treatment Direct Service Delivery (DSD)	3	3	Redacted
SITE_SUPP	By program area/support type: Treatment Technical Assistance-only	0	0	Redacted



	(TA)			
SITE_SUPP	By program area/support type: Care and Support Direct Service Delivery (DSD)	3	3	Redacted
SITE_SUPP	By program area/support type: Care and Support Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: Food and Nutrition Direct Service Delivery (DSD)	3	3	Redacted
SITE_SUPP	By program area/support type: Food and Nutrition Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: PMTCT Direct Service Delivery (DSD)	3	3	Redacted
SITE_SUPP	By program area/support type: PMTCT Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: TB/HIV Direct Service Delivery (DSD)	3	3	Redacted
SITE_SUPP	By program area/support type: TB/HIV Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: VMMC Direct Service Delivery (DSD)	0	0	Redacted
SITE_SUPP	By program area/support type: VMMC Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: General Population Prevention Direct Service Delivery (DSD)	0	0	Redacted
SITE_SUPP	By program area/support type: General Population Prevention Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: Key Populations Prevention Direct Service Delivery (DSD)	0	0	Redacted



SITE_SUPP	By program area/support type: Key Populations Prevention Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: OVC Direct Service Delivery (DSD)	0	0	Redacted
SITE_SUPP	By program area/support type: OVC Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: PHDP/Family Planning & Integration Direct Service Delivery (DSD)	3	3	Redacted
SITE_SUPP	By program area/support type: PHDP/Family Planning & Integration Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: Lab Direct Service Delivery (DSD)	3	3	Redacted
SITE_SUPP	By program area/support type: Lab Technical Assistance-only (TA)	0	0	Redacted
PMTCT_ARV_DS D	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	421	430	Redacted
PMTCT_ARV_DS D	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	421	430	Redacted
PMTCT_ARV_DS D	Life-long ART (including Option B+)	316	323	Redacted
PMTCT_ARV_DS D	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	148	151	Redacted
PMTCT_ARV_DS D	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	168	172	Redacted
PMTCT_ARV_DS D	Maternal triple ARV prophylaxis (provided with the intention to stop at	0	0	Redacted

	the end of the breastfeeding period)			
PMTCT_ARV_DS D	Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)	105	107	Redacted
PMTCT_ARV_DS D	Single-dose nevirapine (with or without tail)	0	0	Redacted
PMTCT_ARV_DS D	Sum of Regimen Type disaggregates	421	430	Redacted
PMTCT_ARV_DS D	Sum of New and Current disaggregates	316	323	Redacted
PMTCT_ARV_NGI	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	421	430	Redacted
PMTCT_ARV_NGI	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	421	430	Redacted
PMTCT_ARV_NGI	Life-long ART (including Option B+)	316	323	Redacted
PMTCT_ARV_NGI	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	148	151	Redacted
PMTCT_ARV_NGI	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	168	172	Redacted
PMTCT_ARV_NGI	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)	0	0	Redacted
PMTCT_ARV_NGI	Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)	105	107	Redacted
PMTCT_ARV_NGI	Single-dose nevirapine (with or without tail)	0	0	Redacted
PMTCT_ARV_NGI	Sum of Regimen disaggregates	421	430	Redacted



PMTCT_ARV_NGI	Sum of New and Current disaggregates	316	323	Redacted
PMTCT_SITE	Number of PEPFAR-supported sites achieving 90% ARV or ART coverage for HIV+ pregnant women	3	3	Redacted
PMTCT_SITE	Total number of PEPFAR supported sites providing PMTCT services (HTC and ARV or ART services)	3	3	Redacted
PMTCT_SITE	By site support type: Direct Service Delivery (DSD): Number of PEPFAR-supported sites achieving 90% ARV or ART coverage for HIV+ pregnant women	3	3	Redacted
PMTCT_SITE	By site support type: Technical Assistance-only (TA): Number of PEPFAR-supported sites achieving 90% ARV or ART coverage for HIV+ pregnant women	0	0	Redacted
PMTCT_SITE	Sum of Numerator Support Type disaggregates	3	3	Redacted
PMTCT_SITE	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR supported sites providing PMTCT services (HTC and ARV or ART services)	3	3	Redacted
PMTCT_SITE	By site support type: Technical Assistance-only (TA): Total number of PEPFAR supported sites providing PMTCT services (HTC and ARV or ART services)	0	0	Redacted
PMTCT_SITE	Sum of Denominator Support Type disaggregates	3	3	Redacted
PMTCT_STAT_DS D	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	968	1,016	Redacted

PMTCT_STAT_DS D	Number of new ANC and L&D clients	968	1,016	Redacted
PMTCT_STAT_DS D	By: Known positives at entry	198	202	Redacted
PMTCT_STAT_DS D	By: Number of new positives identified	223	228	Redacted
PMTCT_STAT_DS D	Sum of Positives Status disaggregates	421	430	Redacted
PMTCT_STAT_NG I	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	968	1,016	Redacted
PMTCT_STAT_NG I	Number of new ANC and L&D clients	968	1,016	Redacted
PMTCT_STAT_NG I	By: Known positives at entry	198	202	Redacted
PMTCT_STAT_NG I	By: Number of new positives identified	223	228	Redacted
PMTCT_STAT_NG I	Sum of Positives Status disaggregates	421	430	Redacted
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	4,500	18,742	Redacted
HTC_TST_DSD	By Test Result: Negative	4,320	17,992	Redacted
HTC_TST_DSD	By Test Result: Positive	180	750	Redacted
HTC_TST_DSD	Sum of Test Result disaggregates	4,500	18,742	Redacted
HTC_TST_DSD	Age/sex: <1 Male	0	0	Redacted
HTC_TST_DSD	Age/sex: 1-4 Male	157	656	Redacted
HTC_TST_DSD	Age/sex: 5-9 Male	68	281	Redacted
HTC_TST_DSD	Age/sex: 10-14 Male	113	469	Redacted
HTC_TST_DSD	Age/sex: 15-19 Male	225	937	Redacted
HTC_TST_DSD	Age/sex: 20-24 Male	563	2,343	Redacted
HTC_TST_DSD	Age/sex: 25-49 Male	900	3,748	Redacted
HTC_TST_DSD	Age/sex: 50+ Male	224	937	Redacted



HTC_TST_DSD	Age/sex: <1 Female	0	0	Redacted
HTC_TST_DSD	Age/sex: 1-4 Female	157	656	Redacted
HTC_TST_DSD	Age/sex: 5-9 Female	68	281	Redacted
HTC_TST_DSD	Age/sex: 10-14 Female	113	469	Redacted
HTC_TST_DSD	Age/sex: 15-19 Female	225	937	Redacted
HTC_TST_DSD	Age/sex: 20-24 Female	563	2,343	Redacted
HTC_TST_DSD	Age/sex: 25-49 Female	900	3,748	Redacted
HTC_TST_DSD	Age/sex: 50+ Female	224	937	Redacted
HTC_TST_DSD	Sum of Age/Sex disaggregates	4,500	18,742	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	338	1,406	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	1,912	7,965	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	338	1,406	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	1,912	7,965	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	676	2,812	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	3,824	15,930	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	4,500	18,742	Redacted
HTC_TST_NGI	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	4,500	18,742	Redacted
HTC_TST_NGI	By Test Result: Negative	4,320	17,992	Redacted
HTC_TST_NGI	By Test Result: Positive	180	750	Redacted
HTC_TST_NGI	Sum of Test Result disaggregates	4,500	18,742	Redacted
HTC_TST_NGI	Age/sex: <1 Male	0	0	Redacted
HTC_TST_NGI	Age/sex: 1-4 Male	157	656	Redacted
HTC_TST_NGI	Age/sex: 5-9 Male	68	281	Redacted
HTC_TST_NGI	Age/sex: 10-14 Male	113	469	Redacted
HTC_TST_NGI	Age/sex: 15-19 Male	225	937	Redacted
HTC_TST_NGI	Age/sex: 20-24 Male	563	2,343	Redacted



HTC_TST_NGI	Age/sex: 25-49 Male	900	3,748	Redacted
HTC_TST_NGI	Age/sex: 50+ Male	224	937	Redacted
HTC_TST_NGI	Age/sex: <1 Female	0	0	Redacted
HTC_TST_NGI	Age/sex: 1-4 Female	157	656	Redacted
HTC_TST_NGI	Age/sex: 5-9 Female	68	281	Redacted
HTC_TST_NGI	Age/sex: 10-14 Female	113	469	Redacted
HTC_TST_NGI	Age/sex: 15-19 Female	225	937	Redacted
HTC_TST_NGI	Age/sex: 20-24 Female	563	2,343	Redacted
HTC_TST_NGI	Age/sex: 25-49 Female	900	3,748	Redacted
HTC_TST_NGI	Age/sex: 50+ Female	224	937	Redacted
HTC_TST_NGI	Sum of Age/Sex disaggregates	4,500	18,742	Redacted
HTC_TST_NGI	Aggregated Age/sex: <15 Male	338	1,406	Redacted
HTC_TST_NGI	Aggregated Age/sex: 15+ Male	1,912	7,965	Redacted
HTC_TST_NGI	Aggregated Age/sex: <15 Female	338	1,406	Redacted
HTC_TST_NGI	Aggregated Age/sex: 15+ Female	1,912	7,965	Redacted
HTC_TST_NGI	Sum of Aggregated Age/Sex <15	676	2,812	Redacted
HTC_TST_NGI	Sum of Aggregated Age/Sex 15+	3,824	15,930	Redacted
HTC_TST_NGI	Sum of Aggregated Age/Sex disaggregates	4,500	18,742	Redacted
C2.1.D_DSD	Number of HIV-positive individuals receiving a minimum of one clinical service	14,340	15,675	Redacted
C2.1.D_DSD	By Age/Sex: <15 Female	645	707	Redacted
C2.1.D_DSD	By Age/Sex: <15 Male	646	707	Redacted
C2.1.D_DSD	By Age/Sex: 15+ Female	8,613	9,412	Redacted
C2.1.D_DSD	By Age/Sex: 15+ Male	4,436	4,849	Redacted
C2.1.D_DSD	Sum of Age/Sex disaggregates	14,340	15,675	Redacted
C2.1.D_DSD	By Age: <15	1,291	1,414	Redacted
C2.1.D_DSD	By Age: 15+	13,049	14,261	Redacted
C2.1.D_DSD	Sum of Age disaggregates	14,340	15,675	Redacted
C2.1.D_DSD	By Sex: Female	9,258	10,119	Redacted
C2.1.D_DSD	By Sex: Male	5,082	5,556	Redacted

C2.1.D_DSD	Sum of Sex disaggregates	14,340	15,675	Redacted
C2.1.D_NGI	Number of HIV-positive individuals receiving a minimum of one clinical service	14,340	15,675	Redacted
C2.1.D_NGI	By Age/Sex: <15 Female	645	707	Redacted
C2.1.D_NGI	By Age/Sex: <15 Male	646	707	Redacted
C2.1.D_NGI	By Age/Sex: 15+ Female	8,613	9,412	Redacted
C2.1.D_NGI	By Age/Sex: 15+ Male	4,436	4,849	Redacted
C2.1.D_NGI	Sum of Age/Sex disaggregates	14,340	15,675	Redacted
C2.1.D_NGI	By Age: <15	1,291	1,414	Redacted
C2.1.D_NGI	By Age: 15+	13,049	14,261	Redacted
C2.1.D_NGI	Sum of Age disaggregates	14,340	15,675	Redacted
C2.1.D_NGI	By Sex: Female	9,258	10,119	Redacted
C2.1.D_NGI	By Sex: Male	5,082	5,556	Redacted
C2.1.D_NGI	Sum of Sex disaggregates	14,340	15,675	Redacted
C2.4.D_DSD	Number of HIV-positive patients who were screened for TB in HIV care or treatment setting	12,906	14,891	Redacted
C2.4.D_DSD	Number of HIV-positive individuals receiving a minimum of one clinical service	14,340	15,675	Redacted
C2.5.D_DSD	Number of HIV-positive patients in HIV care who started TB treatment	258	298	Redacted
C2.5.D_DSD	Number of HIV-positive individuals receiving a minimum of one clinical service	14,340	15,675	Redacted
CARE_CURR_DS D	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	13,623	14,891	Redacted
CARE_CURR_DS D	Age/sex: <1 Male	21	23	Redacted
CARE_CURR_DS	Age/sex: 1-4 Male	147	161	Redacted



D				
CARE_CURR_DS D	Age/sex: 5-9 Male	249	273	Redacted
CARE_CURR_DS D	Age/sex: 10-14 Male	196	215	Redacted
CARE_CURR_DS D	Age/sex: 15-19 Male	105	114	Redacted
CARE_CURR_DS D	Age/sex: 20-24 Male	194	212	Redacted
CARE_CURR_DS D	Age/sex: 25-49 Male	2,911	3,181	Redacted
CARE_CURR_DS D	Age/sex: 50+ Male	1,005	1,099	Redacted
CARE_CURR_DS D	Age/sex: <1 Female	21	23	Redacted
CARE_CURR_DS D	Age/sex: 1-4 Female	140	153	Redacted
CARE_CURR_DS D	Age/sex: 5-9 Female	257	282	Redacted
CARE_CURR_DS D	Age/sex: 10-14 Female	195	214	Redacted
CARE_CURR_DS D	Age/sex: 15-19 Female	173	189	Redacted
CARE_CURR_DS D	Age/sex: 20-24 Female	716	783	Redacted
CARE_CURR_DS D	Age/sex: 25-49 Female	6,117	6,685	Redacted
CARE_CURR_DS D	Age/sex: 50+ Female	1,176	1,284	Redacted
CARE_CURR_DS D	Sun of Age/Sex disaggregates	13,623	14,891	Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	613	672	Redacted
CARE_CURR_DS	Aggregated Age/sex - USE WITH HQ	4,215	4,606	Redacted



D	PERMISSION ONLY: 15+ Male			
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	613	672	Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	8,182	8,941	Redacted
CARE_CURR_DS D	Sum of Aggregated Age/Sex disaggregates	13,623	14,891	Redacted
CARE_NEW_DSD	Number of HIV-infected adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load	2,725	2,708	Redacted
CARE_NEW_DSD	Age/sex: <1 Male	4	4	Redacted
CARE_NEW_DSD	Age/sex: 1-4 Male	29	29	Redacted
CARE_NEW_DSD	Age/sex: 5-9 Male	50	50	Redacted
CARE_NEW_DSD	Age/sex: 10-14 Male	40	39	Redacted
CARE_NEW_DSD	Age/sex: 15-19 Male	18	18	Redacted
CARE_NEW_DSD	Age/sex: 20-24 Male	74	73	Redacted
CARE_NEW_DSD	Age/sex: 25-49 Male	630	626	Redacted
CARE_NEW_DSD	Age/sex: 50+ Male	121	121	Redacted
CARE_NEW_DSD	Age/sex: <1 Female	4	4	Redacted
CARE_NEW_DSD	Age/sex: 1-4 Female	28	28	Redacted
CARE_NEW_DSD	Age/sex: 5-9 Female	51	51	Redacted
CARE_NEW_DSD	Age/sex: 10-14 Female	40	39	Redacted
CARE_NEW_DSD	Age/sex: 15-19 Female	41	40	Redacted
CARE_NEW_DSD	Age/sex: 20-24 Female	75	75	Redacted
CARE_NEW_DSD	Age/sex: 25-49 Female	1,130	1,123	Redacted
CARE_NEW_DSD	Age/sex: 50+ Female	390	388	Redacted
CARE_NEW_DSD	Sum of Age/sex disaggregates	2,725	2,708	Redacted
CARE_NEW_DSD	Aggregated Age/sex: <15 Male	123	122	Redacted
CARE_NEW_DSD	Aggregated Age/sex: 15+ Male	843	838	Redacted
CARE_NEW_DSD	Aggregated Age/sex: <15 Female	123	122	Redacted



CARE_NEW_DSD	Aggregated Age/sex: 15+ Female	1,636	1,626	Redacted
CARE_NEW_DSD	Sum of Aggregated Age/sex disaggregates	2,725	2,708	Redacted
CARE_SITE	Number of PEPFAR-supported HIV clinical care sites at which at least 80% of PLHIV received all of the following during the reporting period: 1) clinical assessment (WHO staging) OR CD4 count OR viral load, AND 2) TB screening at last visit, AND 3) if eligible, cotrimoxazole	3	3	Redacted
CARE_SITE	Total number of PEPFAR supported sites providing clinical care services	3	3	Redacted
CARE_SITE	By site support type: Direct Service Delivery (DSD): Number of PEPFAR-supported HIV clinical care sites at which at least 80% of PLHIV received all of the following during the reporting period: 1) clinical assessment (WHO staging) OR CD4 count OR viral load, AND 2) TB screening at last visit, AND 3) if eligible, cotrimoxazole	3	3	Redacted
CARE_SITE	By site support type: Technical Assistance-only (TA): Number of PEPFAR-supported HIV clinical care sites at which at least 80% of PLHIV received all of the following during the reporting period: 1) clinical assessment (WHO staging) OR CD4 count OR viral load, AND 2) TB screening at last visit, AND 3) if eligible, cotrimoxazole	0	0	Redacted
CARE_SITE	Sum of Numerator Site Support Type disaggregates	3	3	Redacted
CARE_SITE	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR supported sites providing	3	3	Redacted



	clinical care services			
CARE_SITE	By site support type: Technical Assistance-only (TA): Total number of PEPFAR supported sites providing clinical care services	0	0	Redacted
CARE_SITE	Sum of Denominator Site Support Type disaggregates	3	3	Redacted
FN_SITE	Number of PEPFAR-supported sites achieving 90% nutrition assessments that result in accurate categorization of malnutrition	3	3	Redacted
FN_SITE	Total number of PEPFAR-supported sites providing nutrition assessment, counseling and support (NACS) services	3	3	Redacted
FN_SITE	By site support type: Direct Service Delivery (DSD): Number of PEPFAR-supported sites achieving 90% nutrition assessments that result in accurate categorization of malnutrition	3	3	Redacted
FN_SITE	By site support type: Technical Assistance-only (TA): Number of PEPFAR-supported sites achieving 90% nutrition assessments that result in accurate categorization of malnutrition	0	0	Redacted
FN_SITE	Sum of Numerator Support Type disaggregates	3	3	Redacted
FN_SITE	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported sites providing nutrition assessment, counseling and support (NACS) services	3	3	Redacted
FN_SITE	By site support type: Technical	0	0	Redacted

	Assistance-only (TA): Total number of PEPFAR-supported sites providing nutrition assessment, counseling and support (NACS) services			
FN_SITE	Sum of Denominator Support Type disaggregates	3	3	Redacted
FN_THER_DSD	Number of clinically malnourished PLHIV who received therapeutic and/or supplementary food during the reporting period.	2,151	2,351	Redacted
FN_THER_DSD	Number of PLHIV who were nutritionally assessed and found to be clinically undernourished.	2,868	3,135	Redacted
FN_THER_DSD	Age: <1	7	7	Redacted
FN_THER_DSD	Age: 1-4	46	51	Redacted
FN_THER_DSD	Age: 5-14	145	158	Redacted
FN_THER_DSD	Age: 15-17	44	48	Redacted
FN_THER_DSD	Age: 18+	1,909	2,087	Redacted
FN_THER_DSD	Sum of Age disaggregates	2,151	2,351	Redacted
FN_THER_DSD	Aggregated Age: <18	242	264	Redacted
FN_THER_DSD	Aggregated Age: 18+	1,909	2,087	Redacted
FN_THER_DSD	Sum of Aggregated Age disaggregates	2,151	2,351	Redacted
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	549	670	Redacted
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	645	745	Redacted
TB_ART_DSD	Age: 0-4	14	17	Redacted
TB_ART_DSD	Age: 5-14	37	45	Redacted
TB_ART_DSD	Age: 15+	498	608	Redacted



TB_ART_DSD	Male	297	362	Redacted
TB_ART_DSD	Female	252	308	Redacted
TB_ART_DSD	Sum of Sex disaggregates	549	670	Redacted
TB_ART_DSD	Newly tested	330	402	Redacted
TB_ART_DSD	Known HIV-positive	219	268	Redacted
TB_ART_DSD	Sum of Test Status disaggregates	549	670	Redacted
TB_ART_DSD	Aggregated Age: <15	51	62	Redacted
TB_ART_DSD	Aggregated Age: 15+	498	608	Redacted
TB_ART_DSD	Sum of Aggregated Age disaggregates	549	670	Redacted
TB_ARTSITE	The number of PEPFAR-supported TB basic management units at which 80% of registered TB cases who are HIV-positive are on ART, during the reporting period	3	3	Redacted
TB_ARTSITE	The number of PEPFAR-supported TB basic management units	3	3	Redacted
TB_ARTSITE	By site support type: Direct Service Delivery (DSD): The number of PEPFAR-supported TB basic management units at which 80% of registered TB cases who are HIV-positive are on ART, during the reporting period	3	3	Redacted
TB_ARTSITE	By site support type: Technical Assistance-only (TA): The number of PEPFAR-supported TB basic management units at which 80% of registered TB cases who are HIV-positive are on ART, during the reporting period	0	0	Redacted
TB_ARTSITE	Sum of Numerator Site Support Type disaggregates	3	3	Redacted
TB_ARTSITE	By site support type: Direct Service Delivery (DSD): The number of	3	3	Redacted

	PEPFAR-supported TB basic management units			
TB_ARTSITE	By site support type: Technical Assistance-only (TA): The number of PEPFAR-supported TB basic management units	0	0	Redacted
TB_ARTSITE	Sum of Denominator Site Support Type disaggregates	3	3	Redacted
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	337	344	Redacted
PMTCT_EID_DSD	Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT)	421	430	Redacted
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	253	258	Redacted
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	84	86	Redacted
PMTCT_EID_DSD	Sum of Infant Age disaggregates	337	344	Redacted
PMTCT_EID_DSD	By infants with a positive virologic test result within 12 months of birth	17	17	Redacted
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	11,985	13,621	Redacted
TX_CURR_DSD	Age/Sex: <1 Male	19	21	Redacted
TX_CURR_DSD	Age/Sex: 1-4 Male	126	143	Redacted
TX_CURR_DSD	Age/Sex: 5-14 Male	395	449	Redacted
TX_CURR_DSD	Age/Sex: 15+ Male	3,708	4,338	Redacted
TX_CURR_DSD	Age/Sex: <1 Female	19	21	Redacted
TX_CURR_DSD	Age/Sex: 1-4 Female	126	144	Redacted
TX_CURR_DSD	Age/Sex: 5-14 Female	394	449	Redacted
TX_CURR_DSD	Age/Sex: 15+ Female	7,198	8,056	Redacted
TX_CURR_DSD	Sum of age/sex disaggregates	1,079	1,227	Redacted



TX_CURR_DSD	Percent children with advanced HIV infection receiving antiretroviral therapy (ART) [CURRENT]	84	87	Redacted
TX_CURR_DSD	Percent women and girls with advanced HIV infection receiving antiretroviral therapy (ART) [CURRENT]	84	86	Redacted
TX_CURR_DSD	Aggregated Age/Sex: <1 Male	19	21	Redacted
TX_CURR_DSD	Aggregated Age/Sex: <1 Female	19	21	Redacted
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	540	613	Redacted
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	3,708	4,338	Redacted
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	539	614	Redacted
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	7,198	8,056	Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	1,079	1,227	Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	10,906	12,394	Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	11,985	13,621	Redacted
TX_CURR_NGI	Number of adults and children receiving antiretroviral therapy (ART)	11,985	13,621	Redacted
TX_CURR_NGI	Age/Sex: <1 Male	19	21	Redacted
TX_CURR_NGI	Age/Sex: 1-4 Male	126	143	Redacted
TX_CURR_NGI	Age/Sex: 5-14 Male	395	449	Redacted
TX_CURR_NGI	Age/Sex: 15+ Male	3,708	4,338	Redacted
TX_CURR_NGI	Age/Sex: <1 Female	19	21	Redacted
TX_CURR_NGI	Age/Sex: 1-4 Female	126	144	Redacted
TX_CURR_NGI	Age/Sex: 5-14 Female	394	449	Redacted
TX_CURR_NGI	Age/Sex: 15+ Female	7,198	8,056	Redacted
TX_CURR_NGI	Sum of Age/Sex disaggregates	11,985	13,621	Redacted
TX_CURR_NGI	Aggregated Age/Sex: <1 Male	19	21	Redacted
TX_CURR_NGI	Aggregated Age/Sex: <1 Female	19	21	Redacted
TX_CURR_NGI	Aggregated Age/Sex: <15 Male	540	613	Redacted
TX_CURR_NGI	Aggregated Age/Sex: 15+ Male	3,708	4,338	Redacted
TX_CURR_NGI	Aggregated Age/Sex: <15 Female	539	614	Redacted



TX_CURR_NGI	Aggregated Age/Sex: 15+ Female	7,198	8,056	Redacted
TX_CURR_NGI	Sum of Aggregated Age/Sex disaggregates	11,985	13,621	Redacted
TX_CURR_NGI	Sum of Aggregated Age/Sex <15	1,079	1,227	Redacted
TX_CURR_NGI	Sum of Aggregated Age/Sex 15+	10,906	12,394	Redacted
TX_DIST	Number of Districts with documented routine supportive supervision visits to 75% of HIV care and treatment sites supported by the District	2	2	Redacted
TX_DIST	Total number of PEPFAR supported District Health Offices	2	2	Redacted
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	1,130	1,115	Redacted
TX_NEW_DSD	By Age/Sex: <1 Male	18	24	Redacted
TX_NEW_DSD	By Age/Sex: 1-4 Male	10	13	Redacted
TX_NEW_DSD	By Age/Sex: 5-9 Male	17	23	Redacted
TX_NEW_DSD	By Age/Sex: 10-14 Male	13	18	Redacted
TX_NEW_DSD	By Age/Sex: 15-19 Male	9	8	Redacted
TX_NEW_DSD	By Age/Sex: 20-24 Male	16	15	Redacted
TX_NEW_DSD	By Age/Sex: 25-49 Male	245	232	Redacted
TX_NEW_DSD	By Age/Sex: 50+ Male	85	80	Redacted
TX_NEW_DSD	By Age/Sex: <1 Female	18	24	Redacted
TX_NEW_DSD	By Age/Sex: 1-4 Female	10	13	Redacted
TX_NEW_DSD	By Age/Sex: 5-9 Female	17	24	Redacted
TX_NEW_DSD	By Age/Sex: 10-14 Female	13	18	Redacted
TX_NEW_DSD	By Age/Sex: 15-19 Female	14	13	Redacted
TX_NEW_DSD	By Age/Sex: 20-24 Female	58	55	Redacted
TX_NEW_DSD	By Age/Sex: 25-49 Female	493	466	Redacted
TX_NEW_DSD	By Age/Sex: 50+ Female	94	89	Redacted
TX_NEW_DSD	Sum of Age/Sex disaggregates	1,130	1,115	Redacted
TX_NEW_DSD	Aggregated Grouping by Age: <1 Male	18	24	Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	58	78	Redacted

TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	355	335	Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <1 Female	18	24	Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	58	79	Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	659	623	Redacted
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	1,130	1,115	Redacted
TX_NEW_DSD	Pregnancy status	133	135	Redacted
TX_NEW_DSD	Breastfeeding status	15	15	Redacted
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	762	961	Redacted
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	896	1,130	Redacted
TX_RET_DSD	Age: 0-4 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	19	24	Redacted
TX_RET_DSD	Age: 5-14 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	51	65	Redacted
TX_RET_DSD	Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	691	872	Redacted
TX_RET_DSD	Age: 0-4 (Denominator: Total number of adults and children who initiated ART)	22	28	Redacted



	in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)			
TX_RET_DSD	Age: 5-14 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	60	76	Redacted
TX_RET_DSD	Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	813	1,026	Redacted
TX_RET_DSD	Aggregated Age: <15 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	70	89	Redacted
TX_RET_DSD	Aggregated Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	691	872	Redacted
TX_RET_DSD	Aggregated Age: <15 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	83	104	Redacted
TX_RET_DSD	Aggregated Age: 15+ (Denominator: Total number of adults and children	813	1,026	Redacted



	who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)			
TX_RET_DSD	Pregnancy and breastfeeding status (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	134	268	Redacted
TX_RET_DSD	Pregnancy and breastfeeding status (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	158	316	Redacted
TX_SITE	Number of PEPFAR-supported ART sites with a retention rate of 75% or greater for patients 12 months after ART initiation	3	3	Redacted
TX_SITE	Total number of PEPFAR-supported ART sites	3	3	Redacted
TX_SITE	By support type: Direct Service Delivery (DSD): Number of PEPFAR-supported ART sites with a retention rate of 75% or greater for patients 12 months after ART initiation	3	3	Redacted
TX_SITE	By support type: Technical Assistance (TA-only): Number of PEPFAR-supported ART sites with a retention rate of 75% or greater for patients 12 months after ART initiation	0	0	Redacted
TX_SITE	Sum of Numerator Site Support Type disaggregates	3	3	Redacted



TX_SITE	By support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported ART sites	3	3	Redacted
TX_SITE	By support type: Technical Assistance (TA-only): Total number of PEPFAR-supported ART sites	0	0	Redacted
TX_SITE	Sum of Denominator Site Support Type disaggregates	3	3	Redacted
LAB_CAP_DSD	Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests	3	3	Redacted
LAB_CAP_DSD	By site support type: Direct Service Delivery (DSD)	3	3	Redacted
LAB_CAP_DSD	Sum of Site Support Type disaggregates	3	3	Redacted
FPINT_SITE_DSD	Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	3	3	Redacted
FPINT_SITE_DSD	Total number of PEPFAR-supported HIV service delivery points: PMTCT, Care and Treatment	3	3	Redacted
FPINT_SITE_DSD	By site support type: Direct Service Delivery (DSD): Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	3	3	Redacted
FPINT_SITE_DSD	By site support type: Technical Assistance-only (TA): Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	0	0	Redacted
FPINT_SITE_DSD	Sum of Numerator Site Support Type	3	3	Redacted



	disaggregates			
FPINT_SITE_DSD	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported HIV service delivery points	3	3	Redacted
FPINT_SITE_DSD	By site support type: Technical Assistance-only (TA): Total number of PEPFAR-supported HIV service delivery points	0	0	Redacted
FPINT_SITE_DSD	Sum of Denominator Site Support Type disaggregates	3	3	Redacted
FPINT_SITE_DSD	Service delivery type: Clinical	3	3	Redacted
FPINT_SITE_DSD	Sum of Service Delivery Type disaggregates	3	3	Redacted
QI_SITE	Number of PEPFAR-supported clinical service sites with a quality improvement activity completed that addresses clinical HIV programs and has documented process results in the last 6 months	3	3	Redacted
QI_SITE	Total number of PEPFAR-supported sites for any HIV clinical service including HIV Care, HIV Treatment, TB care, PMTCT, VMMC, and HTC	3	3	Redacted
QI_SITE	By site support type: Direct Service Delivery (DSD): Number of PEPFAR-supported clinical service sites with a quality improvement activity completed that addresses clinical HIV programs and has documented results in the last 6 months	3	3	Redacted
QI_SITE	By site support type: Technical Assistance-only (TA): Number of PEPFAR-supported clinical service sites with a quality improvement activity	0	0	Redacted



	completed that addresses clinical HIV programs and has documented results in the last 6 months			
QI_SITE	Sum of Numerator Site Support Type disaggregates	3	3	Redacted
QI_SITE	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported sites for any HIV clinical service including HIV Care, HIV Treatment, TB care, PMTCT, VMMC, HTC	3	3	Redacted
QI_SITE	By site support type: Technical Assistance-only (TA): Total number of PEPFAR-supported sites for any HIV clinical service including HIV Care, HIV Treatment, TB care, PMTCT, VMMC, and HTC	0	0	Redacted
QI_SITE	Sum of Denominator Site Support Type disaggregates	3	3	Redacted
TB_SCREEN_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period	12,261	14,147	Redacted
TB_SCREEN_DSD	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	13,623	14,891	Redacted
TB_SCREEN_DSD	Age: <1	39	45	Redacted
TB_SCREEN_DSD	Age: 1-4	265	305	Redacted
TB_SCREEN_DSD	Age: 5-9	467	539	Redacted
TB_SCREEN_DSD	Age: 10-14	359	415	Redacted
TB_SCREEN_DSD	Age: 15-19	248	286	Redacted
TB_SCREEN_DSD	Age: 20-24	827	954	Redacted
TB_SCREEN_DSD	Age: 25-49	8,119	9,368	Redacted



TB_SCREEN_DSD	Age: 50+	1,937	2,235	Redacted
TB_SCREEN_DSD	Sum of Age disaggregates	1,378	1,590	Redacted
TB_SCREEN_DSD	Aggregated Age - USE WITH HQ PERMISSION ONLY: <15	1,130	1,304	Redacted
TB_SCREEN_DSD	Aggregated Age - USE WITH HQ PERMISSION ONLY: 15+	11,131	12,843	Redacted
TB_SCREEN_DSD	Sum of Aggregated Age disaggregates	12,261	14,147	Redacted
TB_SCREEN_DSD	Sex: Male	4,350	5,019	Redacted
TB_SCREEN_DSD	Sex: Female	7,911	9,128	Redacted
TB_SCREEN_DSD	Sum of Sex disaggregates	12,261	14,147	Redacted

Implementing Mechanism Details

Mechanism ID: 13028	Mechanism Name: TA for Implementation and Expansion of Blood Safety Activities in Kenya
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Community Housing Foundation	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: No	
G2G: No	Managing Agency:

Total All Funding Sources: 500,000	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 0	
FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount
GHP-State	500,000

Sub Partner Name(s)

African Society of Blood Transfusion - Kenya Chapter		
--	--	--

Cross-Cutting Budget Attribution(s)



Human Resources for Health	200,000
----------------------------	---------

Key Issues

Malaria (PMI)
Safe Motherhood

Budget Code Information

Mechanism ID:	13028		
Mechanism Name:	TA for Implementation and Expansion of Blood Safety Activities in		
Prime Partner Name:	Kenya Community Housing Foundation		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HMBL	500,000	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2014	2015	Planning Budget Targets
SITE_SUPP	Number of unique sites supported by PEPFAR	150	367	Redacted
SITE_SUPP	By program area/support type: Lab Direct Service Delivery (DSD)	0	0	Redacted
SITE_SUPP	By program area/support type: Lab Technical Assistance-only (TA)	150	367	Redacted

Implementing Mechanism Details

Mechanism ID: 13025	Mechanism Name: Integrated HIV Prevention Interventions Including Male Circumcision
----------------------------	--

Approved



Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Impact Research and Development Organization	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: No	
G2G: No	Managing Agency:

Total All Funding Sources: 5,874,311	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 12,527	
FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount
GHP-State	5,874,311

Sub Partner Name(s)

Catholic Medical Mission Board		
--------------------------------	--	--

Cross-Cutting Budget Attribution(s)

Human Resources for Health	1,749,130
Renovation	25,266
Condom programming	30,000

Key Issues

Mobile Population

Budget Code Information

Mechanism ID:	13025
Mechanism Name:	Integrated HIV Prevention Interventions Including Male Circumcision
Prime Partner Name:	Impact Research and Development Organization



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	5,679,587	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	28,344	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	IDUP	166,380	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2014	2015	Planning Budget Targets
SITE_SUPP	Number of unique sites supported by PEPFAR	191	191	Redacted
SITE_SUPP	By program area/support type: HTC Direct Service Delivery (DSD)	191	191	Redacted
SITE_SUPP	By program area/support type: VMMC Direct Service Delivery (DSD)	183	183	Redacted
SITE_SUPP	By program area/support type: General Population Prevention Direct Service Delivery (DSD)	2	2	Redacted
KP_MAT_DSD	Number of people who inject drugs (PWID) on medication assisted therapy (MAT) for at least 6 months	0	159	Redacted
KP_MAT_DSD	Sex: Male	0	127	Redacted
KP_MAT_DSD	Sex: Female	0	32	Redacted
KP_MAT_DSD	Sum of Sex disaggregates	0	159	Redacted
VMMC_AE_DSD	By AE type: Number of VMMC clients with one or more moderate or severe surgical intra-operative AE(s)	352	375	Redacted

VMMC_AE_DSD	Sub-Disag: Surgical intra-operative AE(s) by maximum severity category: Number of clients with one or more moderate surgical intra-operative AE(s), but no severe surgical intra-operative AE(s)	317	337	Redacted
VMMC_AE_DSD	Sub-Disag: Surgical intra-operative AE(s) by maximum severity category: Number of clients with one or more severe surgical intra-operative AE(s)	35	38	Redacted
VMMC_AE_DSD	By AE Type: Number of VMMC clients with one or more moderate or severe surgical post-operative AE(s)	352	375	Redacted
VMMC_AE_DSD	Sub-Disag: By Surgical post-operative AE(s) by maximum severity category: Number of clients with one or more moderate surgical post-operative AE(s), but no severe surgical post-operative AE(s)	317	337	Redacted
VMMC_AE_DSD	Sub-Disag: By Surgical post-operative AE(s) by maximum severity category: Number of clients with one or more severe surgical intra-operative AE(s)	35	38	Redacted
VMMC_AE_DSD	By AE Type: Number of VMMC clients with one or more moderate or severe medical device-related AE(s)	35	38	Redacted
VMMC_AE_DSD	Sub-Disag: By Medical device-based AE(s) by maximum severity category: Number of clients with one or more moderate medical device-related AE(s), but no severe medical device-related AE(s)	35	38	Redacted
VMMC_AE_DSD	Sub-Disag: By Medical device-based AE(s) by maximum severity category: Number of clients with one or more severe medical device-related AE(s)	0	0	Redacted

VMMC_CIRC_DS D	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	87,961	93,778	Redacted
VMMC_CIRC_DS D	By Age: <1	440		Redacted
VMMC_CIRC_DS D	By Age: 1-9	0	0	Redacted
VMMC_CIRC_DS D	By Age: 10-14	35,184	37,980	Redacted
VMMC_CIRC_DS D	By Age: 15-19	35,184	37,511	Redacted
VMMC_CIRC_DS D	By Age: 20-24	8,797	9,378	Redacted
VMMC_CIRC_DS D	By Age: 25-49	8,356	8,909	Redacted
VMMC_CIRC_DS D	By Age: 50+	0	0	Redacted
VMMC_CIRC_DS D	Sum of age disaggregates	87,961	93,778	Redacted
VMMC_CIRC_DS D	By HIV status: Number of HIV-positive clients (tested HIV positive at VMMC site)	5,277	5,627	Redacted
VMMC_CIRC_DS D	By HIV status: Number of HIV-negative clients (tested HIV negative at VMMC program)	81,804	87,214	Redacted
VMMC_CIRC_DS D	By HIV status: Number of clients with undocumented/indeterminate HIV status or not tested for HIV at site	880	937	Redacted
VMMC_CIRC_DS D	By circumcision technique: Surgical VMMC	86,961	84,400	Redacted
VMMC_CIRC_DS D	By circumcision technique: Device-based VMMC	1,000	9,378	Redacted

VMMC_CIRC_DS D	By follow-up status: Number of surgically circumcised clients who returned at least once for follow-up care within 14 days of circumcision surgery	87,961	93,778	Redacted
VMMC_CIRC_DS D	By follow-up status: Number of surgically circumcised clients who did NOT return for follow-up care within 14 days of circumcision surgery	0	0	Redacted
VMMC_CIRC_NGI	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	87,961	93,778	Redacted
VMMC_CIRC_NGI	By Age: <1	440		Redacted
VMMC_CIRC_NGI	By Age: 1-9	0	0	Redacted
VMMC_CIRC_NGI	By Age: 10-14	35,184	37,980	Redacted
VMMC_CIRC_NGI	By Age: 15-19	35,184	37,511	Redacted
VMMC_CIRC_NGI	By Age: 20-24	8,797	9,378	Redacted
VMMC_CIRC_NGI	By Age: 25-49	8,356	8,909	Redacted
VMMC_CIRC_NGI	By Age: 50+	0	0	Redacted
VMMC_CIRC_NGI	Sum of Age disaggregates	87,961	93,778	Redacted
VMMC_CIRC_NGI	By HIV status: Number of HIV-positive clients (tested HIV positive at VMMC site)	5,277	5,627	Redacted
VMMC_CIRC_NGI	By HIV status: Number of HIV-negative clients (tested HIV negative at VMMC program)	81,804	87,214	Redacted
VMMC_CIRC_NGI	By HIV status: Number of clients with undocumented/indeterminate HIV status or not tested for HIV at site	880	937	Redacted
VMMC_CIRC_NGI	By circumcision technique: Surgical VMMC	86,961	84,400	Redacted
VMMC_CIRC_NGI	By circumcision technique: Device-based VMMC	1,000	9,378	Redacted

VMMC_CIRC_NGI	By follow-up status: Number of surgically circumcised clients who returned at least once for follow-up care within 14 days of circumcision surgery	87,961	93,778	Redacted
VMMC_CIRC_NGI	By follow-up status: Number of surgically circumcised clients who did NOT return for follow-up care within 14 days of circumcision surgery	0	0	Redacted
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	100	529	Redacted
KP_PREV_DSD	By key population type: Males who inject drugs (Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	80	423	Redacted
KP_PREV_DSD	By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	20	106	Redacted
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	38,700	93,778	Redacted
HTC_TST_DSD	By Test Result: Negative	36,378	88,151	Redacted
HTC_TST_DSD	By Test Result: Positive	2,322	5,627	Redacted
HTC_TST_DSD	Sum of Test Result disaggregates	38,700	93,778	Redacted
HTC_TST_DSD	Age/sex: <1 Male	194	469	Redacted



HTC_TST_DSD	Age/sex: 1-4 Male	0	0	Redacted
HTC_TST_DSD	Age/sex: 5-9 Male	0	0	Redacted
HTC_TST_DSD	Age/sex: 10-14 Male	15,480	37,511	Redacted
HTC_TST_DSD	Age/sex: 15-19 Male	15,480	37,511	Redacted
HTC_TST_DSD	Age/sex: 20-24 Male	3,870	9,378	Redacted
HTC_TST_DSD	Age/sex: 25-49 Male	3,676	8,909	Redacted
HTC_TST_DSD	Age/sex: 50+ Male	0	0	Redacted
HTC_TST_DSD	Age/sex: <1 Female	0	0	Redacted
HTC_TST_DSD	Age/sex: 1-4 Female	0	0	Redacted
HTC_TST_DSD	Age/sex: 5-9 Female	0	0	Redacted
HTC_TST_DSD	Age/sex: 10-14 Female	0	0	Redacted
HTC_TST_DSD	Age/sex: 15-19 Female	0	0	Redacted
HTC_TST_DSD	Age/sex: 20-24 Female	0	0	Redacted
HTC_TST_DSD	Age/sex: 25-49 Female	0	0	Redacted
HTC_TST_DSD	Age/sex: 50+ Female	0	0	Redacted
HTC_TST_DSD	Sum of Age/Sex disaggregates	38,700	93,778	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	15,674	37,980	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	23,026	55,798	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	0	0	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	0	0	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	15,674	37,980	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	23,026	55,798	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	38,700	93,778	Redacted
HTC_TST_NGI	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	38,700	93,778	Redacted
HTC_TST_NGI	By Test Result: Negative	36,378	88,151	Redacted
HTC_TST_NGI	By Test Result: Positive	2,322	5,627	Redacted



HTC_TST_NGI	Sum of Test Result disaggregates	38,700	93,778	Redacted
HTC_TST_NGI	Age/sex: <1 Male	194	469	Redacted
HTC_TST_NGI	Age/sex: 1-4 Male	0	0	Redacted
HTC_TST_NGI	Age/sex: 5-9 Male	0	0	Redacted
HTC_TST_NGI	Age/sex: 10-14 Male	15,480	37,511	Redacted
HTC_TST_NGI	Age/sex: 15-19 Male	15,480	37,511	Redacted
HTC_TST_NGI	Age/sex: 20-24 Male	3,870	9,378	Redacted
HTC_TST_NGI	Age/sex: 25-49 Male	3,676	8,909	Redacted
HTC_TST_NGI	Age/sex: 50+ Male	0	0	Redacted
HTC_TST_NGI	Age/sex: <1 Female	0	0	Redacted
HTC_TST_NGI	Age/sex: 1-4 Female	0	0	Redacted
HTC_TST_NGI	Age/sex: 5-9 Female	0	0	Redacted
HTC_TST_NGI	Age/sex: 10-14 Female	0	0	Redacted
HTC_TST_NGI	Age/sex: 15-19 Female	0	0	Redacted
HTC_TST_NGI	Age/sex: 20-24 Female	0	0	Redacted
HTC_TST_NGI	Age/sex: 25-49 Female	0	0	Redacted
HTC_TST_NGI	Age/sex: 50+ Female	0	0	Redacted
HTC_TST_NGI	Sum of Age/Sex disaggregates	38,700	93,778	Redacted
HTC_TST_NGI	Aggregated Age/sex: <15 Male	15,674	37,980	Redacted
HTC_TST_NGI	Aggregated Age/sex: 15+ Male	23,026	55,798	Redacted
HTC_TST_NGI	Aggregated Age/sex: <15 Female	0	0	Redacted
HTC_TST_NGI	Aggregated Age/sex: 15+ Female	0	0	Redacted
HTC_TST_NGI	Sum of Aggregated Age/Sex <15	15,674	37,980	Redacted
HTC_TST_NGI	Sum of Aggregated Age/Sex 15+	23,026	55,798	Redacted
HTC_TST_NGI	Sum of Aggregated Age/Sex disaggregates	38,700	93,778	Redacted

Implementing Mechanism Details

Mechanism ID: 12994	Mechanism Name: FANIKISHA Institutional Strengthening
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Management Sciences for Health	
Agreement Start Date: Redacted	Agreement End Date: Redacted

Approved



TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: No	
G2G: No	Managing Agency:
Total All Funding Sources: 278,607	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 0	
FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount
GHP-State	278,607

Sub Partner Name(s)

Danya International, Inc	Pact, Inc.	Regional AIDS Training Network (RATN)
--------------------------	------------	---------------------------------------

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

(No data provided.)

Budget Code Information

Mechanism ID:	12994		
Mechanism Name:	FANIKISHA Institutional Strengthening		
Prime Partner Name:	Management Sciences for Health		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	278,607	0

Implementing Mechanism Indicator Information

Approved



(No data provided.)

Implementing Mechanism Details

Mechanism ID: 12970	Mechanism Name: Pre-Service Training
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Johns Hopkins University Bloomberg School of Public Health	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: No	
G2G: No	Managing Agency:

Total All Funding Sources: 0	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 0	
FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount
GHP-State	0

Sub Partner Name(s)

Christian Health Association of Kenya	KMTC	
---------------------------------------	------	--

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

(No data provided.)

Budget Code Information

Mechanism ID: 12970



Mechanism Name: Pre-Service Training			
Prime Partner Name: Johns Hopkins University Bloomberg School of Public Health			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	0	
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HMBL	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HMIN	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	0	0

Implementing Mechanism Indicator Information



Indicator Number	Label	2014	2015	Planning Budget Targets
HRH_PRE	Number of new HCW who graduated from a pre-service training institution or program as a result of PEPFAR-supported strengthening efforts, within the reporting period, by select cadre	2,400		Redacted
HRH_PRE	By Graduates: Nurses	1,500		Redacted
HRH_PRE	By Graduates: Laboratory professionals	50		Redacted
HRH_PRE	By Graduates: Other	850		Redacted
HRH_PRE	Sum of Graduates disaggreagtes	2,400		Redacted

Implementing Mechanism Details

Mechanism ID: 12664	Mechanism Name: Clinical Services
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: African Medical and Research Foundation	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: No	
G2G: No	Managing Agency:

Total All Funding Sources: 1,349,245	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 755	
FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount
GHP-State	1,349,245

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)



Human Resources for Health	782,470
Gender: GBV	33,750
Focus Area:	Post GBV Care
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Gender: Gender Equality	33,750
Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation

Key Issues

- Malaria (PMI)
- Child Survival Activities
- Safe Motherhood
- TB
- Family Planning

Budget Code Information

Mechanism ID: 12664			
Mechanism Name: Clinical Services			
Prime Partner Name: African Medical and Research Foundation			
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Care	HBHC	194,739	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	83,476	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	39,964	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	75,369	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	226,230	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	689,828	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	39,639	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2014	2015	Planning Budget Targets
SITE_SUPP	Number of unique sites supported by PEPFAR	4	4	Redacted
SITE_SUPP	By program area/support type: HTC Direct Service Delivery (DSD)	4	4	Redacted
SITE_SUPP	By program area/support type: HTC Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: Treatment Direct Service Delivery	4	4	Redacted



	(DSD)			
SITE_SUPP	By program area/support type: Treatment Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: Care and Support Direct Service Delivery (DSD)	4	4	Redacted
SITE_SUPP	By program area/support type: Care and Support Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: Food and Nutrition Direct Service Delivery (DSD)	4	4	Redacted
SITE_SUPP	By program area/support type: Food and Nutrition Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: PMTCT Direct Service Delivery (DSD)	4	4	Redacted
SITE_SUPP	By program area/support type: PMTCT Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: TB/HIV Direct Service Delivery (DSD)	4	4	Redacted
SITE_SUPP	By program area/support type: TB/HIV Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: VMMC Direct Service Delivery (DSD)	0	0	Redacted
SITE_SUPP	By program area/support type: VMMC Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: General Population Prevention Direct Service Delivery (DSD)	0	0	Redacted
SITE_SUPP	By program area/support type: General Population Prevention Technical Assistance-only (TA)	0	0	Redacted

SITE_SUPP	By program area/support type: Key Populations Prevention Direct Service Delivery (DSD)	0	0	Redacted
SITE_SUPP	By program area/support type: Key Populations Prevention Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: OVC Direct Service Delivery (DSD)	0	0	Redacted
SITE_SUPP	By program area/support type: OVC Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: PHDP/Family Planning & Integration Direct Service Delivery (DSD)	4	4	Redacted
SITE_SUPP	By program area/support type: PHDP/Family Planning & Integration Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: Lab Direct Service Delivery (DSD)	4	4	Redacted
SITE_SUPP	By program area/support type: Lab Technical Assistance-only (TA)	0	0	Redacted
PMTCT_ARV_DS D	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	356	364	Redacted
PMTCT_ARV_DS D	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	356	364	Redacted
PMTCT_ARV_DS D	Life-long ART (including Option B+)	267	273	Redacted
PMTCT_ARV_DS D	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	124	128	Redacted
PMTCT_ARV_DS D	Sub-Disag of Life-long ART: Already on treatment at the beginning of the	143	145	Redacted



	current pregnancy			
PMTCT_ARV_DS D	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)	0	0	Redacted
PMTCT_ARV_DS D	Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)	89	91	Redacted
PMTCT_ARV_DS D	Single-dose nevirapine (with or without tail)	0	0	Redacted
PMTCT_ARV_DS D	Sum of Regimen Type disaggregates	356	364	Redacted
PMTCT_ARV_DS D	Sum of New and Current disaggregates	267	273	Redacted
PMTCT_ARV_NGI	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	356	364	Redacted
PMTCT_ARV_NGI	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	356	364	Redacted
PMTCT_ARV_NGI	Life-long ART (including Option B+)	267	273	Redacted
PMTCT_ARV_NGI	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	124	128	Redacted
PMTCT_ARV_NGI	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	143	145	Redacted
PMTCT_ARV_NGI	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)	0	0	Redacted
PMTCT_ARV_NGI	Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)	89	91	Redacted
PMTCT_ARV_NGI	Single-dose nevirapine (with or without	0	0	Redacted



	tail)			
PMTCT_ARV_NGI	Sum of Regimen disaggregates	356	364	Redacted
PMTCT_ARV_NGI	Sum of New and Current disaggregates	267	273	Redacted
PMTCT_SITE	Number of PEPFAR-supported sites achieving 90% ARV or ART coverage for HIV+ pregnant women	4	4	Redacted
PMTCT_SITE	Total number of PEPFAR supported sites providing PMTCT services (HTC and ARV or ART services)	4	4	Redacted
PMTCT_SITE	By site support type: Direct Service Delivery (DSD): Number of PEPFAR-supported sites achieving 90% ARV or ART coverage for HIV+ pregnant women	4	4	Redacted
PMTCT_SITE	By site support type: Technical Assistance-only (TA): Number of PEPFAR-supported sites achieving 90% ARV or ART coverage for HIV+ pregnant women	0	0	Redacted
PMTCT_SITE	Sum of Numerator Support Type disaggregates	4	4	Redacted
PMTCT_SITE	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR supported sites providing PMTCT services (HTC and ARV or ART services)	4	4	Redacted
PMTCT_SITE	Sum of Denominator Support Type disaggregates	4	4	Redacted
PMTCT_STAT_DS D	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	4,171	4,379	Redacted
PMTCT_STAT_DS D	Number of new ANC and L&D clients	4,171	4,379	Redacted
PMTCT_STAT_DS	By: Known positives at entry	167	171	Redacted

D				
PMTCT_STAT_DS D	By: Number of new positives identified	189	193	Redacted
PMTCT_STAT_DS D	Sum of Positives Status disaggregates	356	364	Redacted
PMTCT_STAT_NG I	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	4,171	4,379	Redacted
PMTCT_STAT_NG I	Number of new ANC and L&D clients	4,171	4,379	Redacted
PMTCT_STAT_NG I	By: Known positives at entry	167	171	Redacted
PMTCT_STAT_NG I	By: Number of new positives identified	189	193	Redacted
PMTCT_STAT_NG I	Sum of Positives Status disaggregates	356	364	Redacted
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	21,600	25,123	Redacted
HTC_TST_DSD	By Test Result: Negative	20,736	24,118	Redacted
HTC_TST_DSD	By Test Result: Positive	864	1,005	Redacted
HTC_TST_DSD	Sum of Test Result disaggregates	21,600	25,123	Redacted
HTC_TST_DSD	Age/sex: <1 Male	0	0	Redacted
HTC_TST_DSD	Age/sex: 1-4 Male	756	879	Redacted
HTC_TST_DSD	Age/sex: 5-9 Male	324	377	Redacted
HTC_TST_DSD	Age/sex: 10-14 Male	540	628	Redacted
HTC_TST_DSD	Age/sex: 15-19 Male	1,080	1,256	Redacted
HTC_TST_DSD	Age/sex: 20-24 Male	2,700	3,140	Redacted
HTC_TST_DSD	Age/sex: 25-49 Male	4,320	5,025	Redacted
HTC_TST_DSD	Age/sex: 50+ Male	1,080	1,256	Redacted
HTC_TST_DSD	Age/sex: <1 Female	0	0	Redacted
HTC_TST_DSD	Age/sex: 1-4 Female	756	879	Redacted



HTC_TST_DSD	Age/sex: 5-9 Female	324	377	Redacted
HTC_TST_DSD	Age/sex: 10-14 Female	540	628	Redacted
HTC_TST_DSD	Age/sex: 15-19 Female	1,080	1,256	Redacted
HTC_TST_DSD	Age/sex: 20-24 Female	2,700	3,140	Redacted
HTC_TST_DSD	Age/sex: 25-49 Female	4,320	5,025	Redacted
HTC_TST_DSD	Age/sex: 50+ Female	1,080	1,257	Redacted
HTC_TST_DSD	Sum of Age/Sex disaggregates	21,600	25,123	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	1,620	1,884	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	9,180	10,677	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	1,620	1,884	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	9,180	10,678	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	3,240	3,768	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	18,360	21,355	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	21,600	25,123	Redacted
HTC_TST_NGI	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	21,600	25,123	Redacted
HTC_TST_NGI	By Test Result: Negative	20,736	24,118	Redacted
HTC_TST_NGI	By Test Result: Positive	864	1,005	Redacted
HTC_TST_NGI	Sum of Test Result disaggregates	21,600	25,123	Redacted
HTC_TST_NGI	Age/sex: <1 Male	0	0	Redacted
HTC_TST_NGI	Age/sex: 1-4 Male	756	879	Redacted
HTC_TST_NGI	Age/sex: 5-9 Male	324	377	Redacted
HTC_TST_NGI	Age/sex: 10-14 Male	540	628	Redacted
HTC_TST_NGI	Age/sex: 15-19 Male	1,080	1,256	Redacted
HTC_TST_NGI	Age/sex: 20-24 Male	2,700	3,140	Redacted
HTC_TST_NGI	Age/sex: 25-49 Male	4,320	5,025	Redacted
HTC_TST_NGI	Age/sex: 50+ Male	1,080	1,256	Redacted



HTC_TST_NGI	Age/sex: <1 Female	0	0	Redacted
HTC_TST_NGI	Age/sex: 1-4 Female	756	879	Redacted
HTC_TST_NGI	Age/sex: 5-9 Female	324	377	Redacted
HTC_TST_NGI	Age/sex: 10-14 Female	540	628	Redacted
HTC_TST_NGI	Age/sex: 15-19 Female	1,080	1,256	Redacted
HTC_TST_NGI	Age/sex: 20-24 Female	2,700	3,140	Redacted
HTC_TST_NGI	Age/sex: 25-49 Female	4,320	5,025	Redacted
HTC_TST_NGI	Age/sex: 50+ Female	1,080	1,257	Redacted
HTC_TST_NGI	Sum of Age/Sex disaggregates	21,600	25,123	Redacted
HTC_TST_NGI	Aggregated Age/sex: <15 Male	1,620	1,884	Redacted
HTC_TST_NGI	Aggregated Age/sex: 15+ Male	9,180	10,677	Redacted
HTC_TST_NGI	Aggregated Age/sex: <15 Female	1,620	1,884	Redacted
HTC_TST_NGI	Aggregated Age/sex: 15+ Female	9,180	10,678	Redacted
HTC_TST_NGI	Sum of Aggregated Age/Sex <15	3,240	3,768	Redacted
HTC_TST_NGI	Sum of Aggregated Age/Sex 15+	18,360	21,355	Redacted
HTC_TST_NGI	Sum of Aggregated Age/Sex disaggregates	21,600	25,123	Redacted
C2.1.D_DSD	Number of HIV-positive individuals receiving a minimum of one clinical service	3,916	4,281	Redacted
C2.1.D_DSD	By Age/Sex: <15 Female	176	193	Redacted
C2.1.D_DSD	By Age/Sex: <15 Male	176	193	Redacted
C2.1.D_DSD	By Age/Sex: 15+ Female	2,352	2,571	Redacted
C2.1.D_DSD	By Age/Sex: 15+ Male	1,212	1,324	Redacted
C2.1.D_DSD	Sum of Age/Sex disaggregates	3,916	4,281	Redacted
C2.1.D_DSD	By Age: <15	352	386	Redacted
C2.1.D_DSD	By Age: 15+	3,564	3,895	Redacted
C2.1.D_DSD	Sum of Age disaggregates	3,916	4,281	Redacted
C2.1.D_DSD	By Sex: Female	2,528	2,764	Redacted
C2.1.D_DSD	By Sex: Male	1,388	1,517	Redacted
C2.1.D_DSD	Sum of Sex disaggregates	3,916	4,281	Redacted
C2.1.D_NGI	Number of HIV-positive individuals	3,916	4,281	Redacted

	receiving a minimum of one clinical service			
C2.1.D_NGI	By Age/Sex: <15 Female	176	193	Redacted
C2.1.D_NGI	By Age/Sex: <15 Male	176	193	Redacted
C2.1.D_NGI	By Age/Sex: 15+ Female	2,352	2,571	Redacted
C2.1.D_NGI	By Age/Sex: 15+ Male	1,212	1,324	Redacted
C2.1.D_NGI	Sum of Age/Sex disaggregates	3,916	4,281	Redacted
C2.1.D_NGI	By Age: <15	352	386	Redacted
C2.1.D_NGI	By Age: 15+	3,564	3,895	Redacted
C2.1.D_NGI	Sum of Age disaggregates	3,916	4,281	Redacted
C2.1.D_NGI	By Sex: Female	2,528	2,764	Redacted
C2.1.D_NGI	By Sex: Male	1,388	1,517	Redacted
C2.1.D_NGI	Sum of Sex disaggregates	3,916	4,281	Redacted
C2.4.D_DSD	Number of HIV-positive patients who were screened for TB in HIV care or treatment setting	3,525	4,067	Redacted
C2.4.D_DSD	Number of HIV-positive individuals receiving a minimum of one clinical service	3,916	4,281	Redacted
C2.5.D_DSD	Number of HIV-positive patients in HIV care who started TB treatment	70	81	Redacted
C2.5.D_DSD	Number of HIV-positive individuals receiving a minimum of one clinical service	3,916	4,281	Redacted
CARE_CURR_DS D	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	3,721	4,067	Redacted
CARE_CURR_DS D	Age/sex: <1 Male	6	6	Redacted
CARE_CURR_DS D	Age/sex: 1-4 Male	40	44	Redacted
CARE_CURR_DS	Age/sex: 5-9 Male	68	74	Redacted



D				
CARE_CURR_DS D	Age/sex: 10-14 Male	53	59	Redacted
CARE_CURR_DS D	Age/sex: 15-19 Male	29	31	Redacted
CARE_CURR_DS D	Age/sex: 20-24 Male	53	58	Redacted
CARE_CURR_DS D	Age/sex: 25-49 Male	795	869	Redacted
CARE_CURR_DS D	Age/sex: 50+ Male	274	300	Redacted
CARE_CURR_DS D	Age/sex: <1 Female	6	6	Redacted
CARE_CURR_DS D	Age/sex: 1-4 Female	38	42	Redacted
CARE_CURR_DS D	Age/sex: 5-9 Female	70	77	Redacted
CARE_CURR_DS D	Age/sex: 10-14 Female	53	58	Redacted
CARE_CURR_DS D	Age/sex: 15-19 Female	47	52	Redacted
CARE_CURR_DS D	Age/sex: 20-24 Female	196	214	Redacted
CARE_CURR_DS D	Age/sex: 25-49 Female	1,671	1,826	Redacted
CARE_CURR_DS D	Age/sex: 50+ Female	322	351	Redacted
CARE_CURR_DS D	Sun of Age/Sex disaggregates	3,721	4,067	Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	167	183	Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	1,151	1,258	Redacted
CARE_CURR_DS	Aggregated Age/sex - USE WITH HQ	167	183	Redacted



D	PERMISSION ONLY: <15 Female			
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	2,236	2,443	Redacted
CARE_CURR_DS D	Sum of Aggregated Age/Sex disaggregates	3,721	4,067	Redacted
CARE_NEW_DSD	Number of HIV-infected adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load	744	739	Redacted
CARE_NEW_DSD	Age/sex: <1 Male	1	1	Redacted
CARE_NEW_DSD	Age/sex: 1-4 Male	8	8	Redacted
CARE_NEW_DSD	Age/sex: 5-9 Male	14	14	Redacted
CARE_NEW_DSD	Age/sex: 10-14 Male	11	10	Redacted
CARE_NEW_DSD	Age/sex: 15-19 Male	5	5	Redacted
CARE_NEW_DSD	Age/sex: 20-24 Male	20	20	Redacted
CARE_NEW_DSD	Age/sex: 25-49 Male	171	172	Redacted
CARE_NEW_DSD	Age/sex: 50+ Male	34	32	Redacted
CARE_NEW_DSD	Age/sex: <1 Female	1	2	Redacted
CARE_NEW_DSD	Age/sex: 1-4 Female	8	7	Redacted
CARE_NEW_DSD	Age/sex: 5-9 Female	14	13	Redacted
CARE_NEW_DSD	Age/sex: 10-14 Female	11	11	Redacted
CARE_NEW_DSD	Age/sex: 15-19 Female	11	11	Redacted
CARE_NEW_DSD	Age/sex: 20-24 Female	21	20	Redacted
CARE_NEW_DSD	Age/sex: 25-49 Female	309	307	Redacted
CARE_NEW_DSD	Age/sex: 50+ Female	105	106	Redacted
CARE_NEW_DSD	Sum of Age/sex disaggregates	744	739	Redacted
CARE_NEW_DSD	Aggregated Age/sex: <15 Male	34	33	Redacted
CARE_NEW_DSD	Aggregated Age/sex: 15+ Male	230	229	Redacted
CARE_NEW_DSD	Aggregated Age/sex: <15 Female	34	33	Redacted
CARE_NEW_DSD	Aggregated Age/sex: 15+ Female	446	444	Redacted
CARE_NEW_DSD	Sum of Aggregated Age/sex	744	739	Redacted



	disaggregates			
CARE_SITE	Number of PEPFAR-supported HIV clinical care sites at which at least 80% of PLHIV received all of the following during the reporting period: 1) clinical assessment (WHO staging) OR CD4 count OR viral load, AND 2) TB screening at last visit, AND 3) if eligible, cotrimoxazole	4	4	Redacted
CARE_SITE	Total number of PEPFAR supported sites providing clinical care services	4	4	Redacted
CARE_SITE	By site support type: Direct Service Delivery (DSD): Number of PEPFAR-supported HIV clinical care sites at which at least 80% of PLHIV received all of the following during the reporting period: 1) clinical assessment (WHO staging) OR CD4 count OR viral load, AND 2) TB screening at last visit, AND 3) if eligible, cotrimoxazole	4	4	Redacted
CARE_SITE	By site support type: Technical Assistance-only (TA): Number of PEPFAR-supported HIV clinical care sites at which at least 80% of PLHIV received all of the following during the reporting period: 1) clinical assessment (WHO staging) OR CD4 count OR viral load, AND 2) TB screening at last visit, AND 3) if eligible, cotrimoxazole	0	0	Redacted
CARE_SITE	Sum of Numerator Site Support Type disaggregates	4	4	Redacted
CARE_SITE	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR supported sites providing clinical care services	4	4	Redacted
CARE_SITE	By site support type: Technical	0	0	Redacted



	Assistance-only (TA): Total number of PEPFAR supported sites providing clinical care services			
CARE_SITE	Sum of Denominator Site Support Type disaggregates	4	4	Redacted
FN_SITE	Number of PEPFAR-supported sites achieving 90% nutrition assessments that result in accurate categorization of malnutrition	4	4	Redacted
FN_SITE	Total number of PEPFAR-supported sites providing nutrition assessment, counseling and support (NACS) services	4	4	Redacted
FN_SITE	By site support type: Direct Service Delivery (DSD): Number of PEPFAR-supported sites achieving 90% nutrition assessments that result in accurate categorization of malnutrition	4	4	Redacted
FN_SITE	By site support type: Technical Assistance-only (TA): Number of PEPFAR-supported sites achieving 90% nutrition assessments that result in accurate categorization of malnutrition	0	0	Redacted
FN_SITE	Sum of Numerator Support Type disaggregates	4	4	Redacted
FN_SITE	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported sites providing nutrition assessment, counseling and support (NACS) services	4	4	Redacted
FN_SITE	By site support type: Technical Assistance-only (TA): Total number of PEPFAR-supported sites providing	0	0	Redacted

	nutrition assessment, counseling and support (NACS) services			
FN_SITE	Sum of Denominator Support Type disaggregates	4	4	Redacted
FN_THER_DSD	Number of clinically malnourished PLHIV who received therapeutic and/or supplementary food during the reporting period.	587	642	Redacted
FN_THER_DSD	Number of PLHIV who were nutritionally assessed and found to be clinically undernourished.	783	856	Redacted
FN_THER_DSD	Age: <1	2	2	Redacted
FN_THER_DSD	Age: 1-4	13	14	Redacted
FN_THER_DSD	Age: 5-14	39	43	Redacted
FN_THER_DSD	Age: 15-17	12	13	Redacted
FN_THER_DSD	Age: 18+	521	570	Redacted
FN_THER_DSD	Sum of Age disaggregates	587	642	Redacted
FN_THER_DSD	Aggregated Age: <18	66	72	Redacted
FN_THER_DSD	Aggregated Age: 18+	521	570	Redacted
FN_THER_DSD	Sum of Aggregated Age disaggregates	587	642	Redacted
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	150	183	Redacted
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	176	203	Redacted
TB_ART_DSD	Age: 0-4	4	5	Redacted
TB_ART_DSD	Age: 5-14	10	12	Redacted
TB_ART_DSD	Age: 15+	136	166	Redacted
TB_ART_DSD	Male	81	99	Redacted
TB_ART_DSD	Female	69	84	Redacted



TB_ART_DSD	Sum of Sex disaggregates	150	183	Redacted
TB_ART_DSD	Newly tested	90	110	Redacted
TB_ART_DSD	Known HIV-positive	60	73	Redacted
TB_ART_DSD	Sum of Test Status disaggregates	150	183	Redacted
TB_ART_DSD	Aggregated Age: <15	14	17	Redacted
TB_ART_DSD	Aggregated Age: 15+	136	166	Redacted
TB_ART_DSD	Sum of Aggregated Age disaggregates	150	183	Redacted
TB_ARTSITE	The number of PEPFAR-supported TB basic management units at which 80% of registered TB cases who are HIV-positive are on ART, during the reporting period	4	4	Redacted
TB_ARTSITE	The number of PEPFAR-supported TB basic management units	4	4	Redacted
TB_ARTSITE	By site support type: Direct Service Delivery (DSD): The number of PEPFAR-supported TB basic management units at which 80% of registered TB cases who are HIV-positive are on ART, during the reporting period	4	4	Redacted
TB_ARTSITE	By site support type: Technical Assistance-only (TA): The number of PEPFAR-supported TB basic management units at which 80% of registered TB cases who are HIV-positive are on ART, during the reporting period	0	0	Redacted
TB_ARTSITE	Sum of Numerator Site Support Type disaggregates	4	4	Redacted
TB_ARTSITE	By site support type: Direct Service Delivery (DSD): The number of PEPFAR-supported TB basic management units	4	4	Redacted
TB_ARTSITE	By site support type: Technical	0	0	Redacted



	Assistance-only (TA): The number of PEPFAR-supported TB basic management units			
TB_ARTSITE	Sum of Denominator Site Support Type disaggregates	4	4	Redacted
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	285	291	Redacted
PMTCT_EID_DSD	Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT)	356	364	Redacted
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	214	218	Redacted
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	71	73	Redacted
PMTCT_EID_DSD	Sum of Infant Age disaggregates	285	291	Redacted
PMTCT_EID_DSD	By infants with a positive virologic test result within 12 months of birth	14	15	Redacted
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	2,446	2,780	Redacted
TX_CURR_DSD	Age/Sex: <1 Male	4	4	Redacted
TX_CURR_DSD	Age/Sex: 1-4 Male	26	29	Redacted
TX_CURR_DSD	Age/Sex: 5-14 Male	80	92	Redacted
TX_CURR_DSD	Age/Sex: 15+ Male	757	885	Redacted
TX_CURR_DSD	Age/Sex: <1 Female	4	4	Redacted
TX_CURR_DSD	Age/Sex: 1-4 Female	26	29	Redacted
TX_CURR_DSD	Age/Sex: 5-14 Female	80	92	Redacted
TX_CURR_DSD	Age/Sex: 15+ Female	1,469	1,645	Redacted
TX_CURR_DSD	Sum of age/sex disaggregates	220	250	Redacted
TX_CURR_DSD	Percent children with advanced HIV infection receiving antiretroviral therapy (ART) [CURRENT]	62	65	Redacted



TX_CURR_DSD	Percent women and girls with advanced HIV infection receiving antiretroviral therapy (ART) [CURRENT]	62	64	Redacted
TX_CURR_DSD	Aggregated Age/Sex: <1 Male	4	4	Redacted
TX_CURR_DSD	Aggregated Age/Sex: <1 Female	4	4	Redacted
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	110	125	Redacted
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	757	885	Redacted
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	110	125	Redacted
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	1,469	1,645	Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	220	250	Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	2,226	2,530	Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	2,446	2,780	Redacted
TX_CURR_NGI	Number of adults and children receiving antiretroviral therapy (ART)	2,446	2,780	Redacted
TX_CURR_NGI	Age/Sex: <1 Male	4	4	Redacted
TX_CURR_NGI	Age/Sex: 1-4 Male	26	29	Redacted
TX_CURR_NGI	Age/Sex: 5-14 Male	80	92	Redacted
TX_CURR_NGI	Age/Sex: 15+ Male	757	885	Redacted
TX_CURR_NGI	Age/Sex: <1 Female	4	4	Redacted
TX_CURR_NGI	Age/Sex: 1-4 Female	26	29	Redacted
TX_CURR_NGI	Age/Sex: 5-14 Female	80	92	Redacted
TX_CURR_NGI	Age/Sex: 15+ Female	1,469	1,645	Redacted
TX_CURR_NGI	Sum of Age/Sex disaggregates	2,446	2,780	Redacted
TX_CURR_NGI	Aggregated Age/Sex: <1 Male	4	4	Redacted
TX_CURR_NGI	Aggregated Age/Sex: <1 Female	4	4	Redacted
TX_CURR_NGI	Aggregated Age/Sex: <15 Male	110	125	Redacted
TX_CURR_NGI	Aggregated Age/Sex: 15+ Male	757	885	Redacted
TX_CURR_NGI	Aggregated Age/Sex: <15 Female	110	125	Redacted
TX_CURR_NGI	Aggregated Age/Sex: 15+ Female	1,469	1,645	Redacted
TX_CURR_NGI	Sum of Aggregated Age/Sex disaggregates	2,446	2,780	Redacted



TX_CURR_NGI	Sum of Aggregated Age/Sex <15	220	250	Redacted
TX_CURR_NGI	Sum of Aggregated Age/Sex 15+	2,226	2,530	Redacted
TX_DIST	Number of Districts with documented routine supportive supervision visits to 75% of HIV care and treatment sites supported by the District	1	1	Redacted
TX_DIST	Total number of PEPFAR supported District Health Offices	1	1	Redacted
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	670	661	Redacted
TX_NEW_DSD	By Age/Sex: <1 Male	10	14	Redacted
TX_NEW_DSD	By Age/Sex: 1-4 Male	6	8	Redacted
TX_NEW_DSD	By Age/Sex: 5-9 Male	10	14	Redacted
TX_NEW_DSD	By Age/Sex: 10-14 Male	9	11	Redacted
TX_NEW_DSD	By Age/Sex: 15-19 Male	5	5	Redacted
TX_NEW_DSD	By Age/Sex: 20-24 Male	10	9	Redacted
TX_NEW_DSD	By Age/Sex: 25-49 Male	145	138	Redacted
TX_NEW_DSD	By Age/Sex: 50+ Male	50	47	Redacted
TX_NEW_DSD	By Age/Sex: <1 Female	10	14	Redacted
TX_NEW_DSD	By Age/Sex: 1-4 Female	6	8	Redacted
TX_NEW_DSD	By Age/Sex: 5-9 Female	10	14	Redacted
TX_NEW_DSD	By Age/Sex: 10-14 Female	9	11	Redacted
TX_NEW_DSD	By Age/Sex: 15-19 Female	8	8	Redacted
TX_NEW_DSD	By Age/Sex: 20-24 Female	34	32	Redacted
TX_NEW_DSD	By Age/Sex: 25-49 Female	292	275	Redacted
TX_NEW_DSD	By Age/Sex: 50+ Female	56	53	Redacted
TX_NEW_DSD	Sum of Age/Sex disaggregates	670	661	Redacted
TX_NEW_DSD	Aggregated Grouping by Age: <1 Male	10	14	Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	35	47	Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	210	199	Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <1	10	14	Redacted

	Female			
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	35	47	Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	390	368	Redacted
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	670	661	Redacted
TX_NEW_DSD	Pregnancy status	112	115	Redacted
TX_NEW_DSD	Breastfeeding status	12	13	Redacted
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	451	569	Redacted
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	531	670	Redacted
TX_RET_DSD	Age: 0-4 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	11	14	Redacted
TX_RET_DSD	Age: 5-14 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	30	38	Redacted
TX_RET_DSD	Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	410	517	Redacted
TX_RET_DSD	Age: 0-4 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have	13	17	Redacted



	stopped ART, and those lost to follow-up)			
TX_RET_DSD	Age: 5-14 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	36	45	Redacted
TX_RET_DSD	Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	482	608	Redacted
TX_RET_DSD	Aggregated Age: <15 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	42	52	Redacted
TX_RET_DSD	Aggregated Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	410	517	Redacted
TX_RET_DSD	Aggregated Age: <15 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	49	62	Redacted
TX_RET_DSD	Aggregated Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died,	482	608	Redacted



	those who have stopped ART, and those lost to follow-up)			
TX_RET_DSD	Pregnancy and breastfeeding status (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	114	227	Redacted
TX_RET_DSD	Pregnancy and breastfeeding status (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	134	267	Redacted
TX_SITE	Number of PEPFAR-supported ART sites with a retention rate of 75% or greater for patients 12 months after ART initiation	3	3	Redacted
TX_SITE	Total number of PEPFAR-supported ART sites	4	4	Redacted
TX_SITE	By support type: Direct Service Delivery (DSD): Number of PEPFAR-supported ART sites with a retention rate of 75% or greater for patients 12 months after ART initiation	3	3	Redacted
TX_SITE	By support type: Technical Assistance (TA-only): Number of PEPFAR-supported ART sites with a retention rate of 75% or greater for patients 12 months after ART initiation	0	0	Redacted
TX_SITE	Sum of Numerator Site Support Type disaggregates	3	3	Redacted
TX_SITE	By support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported ART sites	4	4	Redacted



TX_SITE	By support type: Technical Assistance (TA-only): Total number of PEPFAR-supported ART sites	0	0	Redacted
TX_SITE	Sum of Denominator Site Support Type disaggregates	4	4	Redacted
LAB_CAP_DSD	Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests	4	4	Redacted
LAB_CAP_DSD	By site support type: Direct Service Delivery (DSD)	4	4	Redacted
LAB_CAP_DSD	Sum of Site Support Type disaggregates	4	4	Redacted
FPINT_SITE_DSD	Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	3	3	Redacted
FPINT_SITE_DSD	Total number of PEPFAR-supported HIV service delivery points: PMTCT, Care and Treatment	4	4	Redacted
FPINT_SITE_DSD	By site support type: Direct Service Delivery (DSD): Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	3	3	Redacted
FPINT_SITE_DSD	By site support type: Technical Assistance-only (TA): Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	0	0	Redacted
FPINT_SITE_DSD	Sum of Numerator Site Support Type disaggregates	3	3	Redacted
FPINT_SITE_DSD	By site support type: Direct Service Delivery (DSD): Total number of	4	4	Redacted



	PEPFAR-supported HIV service delivery points			
FPINT_SITE_DSD	By site support type: Technical Assistance-only (TA): Total number of PEPFAR-supported HIV service delivery points	0	0	Redacted
FPINT_SITE_DSD	Sum of Denominator Site Support Type disaggregates	4	4	Redacted
FPINT_SITE_DSD	Service delivery type: Clinical	3	3	Redacted
FPINT_SITE_DSD	Sum of Service Delivery Type disaggregates	3	3	Redacted
QI_SITE	Number of PEPFAR-supported clinical service sites with a quality improvement activity completed that addresses clinical HIV programs and has documented process results in the last 6 months	3	3	Redacted
QI_SITE	Total number of PEPFAR-supported sites for any HIV clinical service including HIV Care, HIV Treatment, TB care, PMTCT, VMMC, and HTC	4	4	Redacted
QI_SITE	By site support type: Direct Service Delivery (DSD): Number of PEPFAR-supported clinical service sites with a quality improvement activity completed that addresses clinical HIV programs and has documented results in the last 6 months	3	3	Redacted
QI_SITE	By site support type: Technical Assistance-only (TA): Number of PEPFAR-supported clinical service sites with a quality improvement activity completed that addresses clinical HIV programs and has documented results in the last 6 months	0	0	Redacted



QI_SITE	Sum of Numerator Site Support Type disaggregates	3	3	Redacted
QI_SITE	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported sites for any HIV clinical service including HIV Care, HIV Treatment, TB care, PMTCT, VMMC, HTC	4	4	Redacted
QI_SITE	By site support type: Technical Assistance-only (TA): Total number of PEPFAR-supported sites for any HIV clinical service including HIV Care, HIV Treatment, TB care, PMTCT, VMMC, and HTC	0	0	Redacted
QI_SITE	Sum of Denominator Site Support Type disaggregates	4	4	Redacted
TB_SCREEN_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period	3,349	3,864	Redacted
TB_SCREEN_DSD	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	3,721	4,067	Redacted
TB_SCREEN_DSD	Age: <1	11	12	Redacted
TB_SCREEN_DSD	Age: 1-4	75	83	Redacted
TB_SCREEN_DSD	Age: 5-9	126	147	Redacted
TB_SCREEN_DSD	Age: 10-14	97	114	Redacted
TB_SCREEN_DSD	Age: 15-19	68	78	Redacted
TB_SCREEN_DSD	Age: 20-24	226	260	Redacted
TB_SCREEN_DSD	Age: 25-49	2,217	2,560	Redacted
TB_SCREEN_DSD	Age: 50+	529	610	Redacted
TB_SCREEN_DSD	Sum of Age disaggregates	377	434	Redacted



TB_SCREEN_DSD	Aggregated Age - USE WITH HQ PERMISSION ONLY: <15	309	356	Redacted
TB_SCREEN_DSD	Aggregated Age - USE WITH HQ PERMISSION ONLY: 15+	3,040	3,508	Redacted
TB_SCREEN_DSD	Sum of Aggregated Age disaggregates	3,349	3,864	Redacted
TB_SCREEN_DSD	Sex: Male	1,188	1,371	Redacted
TB_SCREEN_DSD	Sex: Female	2,161	2,493	Redacted
TB_SCREEN_DSD	Sum of Sex disaggregates	3,349	3,864	Redacted

Implementing Mechanism Details

Mechanism ID: 12658	Mechanism Name: Clinical Services
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Mkomani Society Clinic	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: No	
G2G: No	Managing Agency:

Total All Funding Sources: 3,589,589	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 0	
FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount
GHP-State	3,589,589

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

Human Resources for Health	960,000
Renovation	100,000
Gender: GBV	90,000
Focus Area:	Post GBV Care



Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Monitoring and Evaluation
Gender: Gender Equality	90,000
Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Monitoring and Evaluation
Economic Strengthening	25,000
Education	60,000

Key Issues

- Malaria (PMI)
- Child Survival Activities
- Safe Motherhood
- TB
- Family Planning

Budget Code Information

Mechanism ID: 12658			
Mechanism Name: Clinical Services			
Prime Partner Name: Mkomani Society Clinic			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	225,658	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Care	HKID	100,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	166,952	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	106,572	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	104,568	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	IDUP	320,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	225,969	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	2,211,044	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	128,826	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2014	2015	Planning Budget Targets
SITE_SUPP	Number of unique sites supported by PEPFAR	9	9	Redacted
SITE_SUPP	By program area/support type: HTC Direct Service Delivery (DSD)	9	9	Redacted
SITE_SUPP	By program area/support type: HTC	0	0	Redacted



	Technical Assistance-only (TA)			
SITE_SUPP	By program area/support type: Treatment Direct Service Delivery (DSD)	9	9	Redacted
SITE_SUPP	By program area/support type: Treatment Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: Care and Support Direct Service Delivery (DSD)	9	9	Redacted
SITE_SUPP	By program area/support type: Care and Support Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: Food and Nutrition Direct Service Delivery (DSD)	9	9	Redacted
SITE_SUPP	By program area/support type: Food and Nutrition Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: PMTCT Direct Service Delivery (DSD)	9	9	Redacted
SITE_SUPP	By program area/support type: PMTCT Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: TB/HIV Direct Service Delivery (DSD)	5	5	Redacted
SITE_SUPP	By program area/support type: TB/HIV Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: VMMC Direct Service Delivery (DSD)	0	0	Redacted
SITE_SUPP	By program area/support type: VMMC Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: General Population Prevention Direct Service Delivery (DSD)	0	0	Redacted



SITE_SUPP	By program area/support type: General Population Prevention Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: Key Populations Prevention Direct Service Delivery (DSD)	0	2	Redacted
SITE_SUPP	By program area/support type: Key Populations Prevention Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: OVC Direct Service Delivery (DSD)	9	9	Redacted
SITE_SUPP	By program area/support type: OVC Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: PHDP/Family Planning & Integration Direct Service Delivery (DSD)	9	9	Redacted
SITE_SUPP	By program area/support type: PHDP/Family Planning & Integration Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: Lab Direct Service Delivery (DSD)	3	3	Redacted
SITE_SUPP	By program area/support type: Lab Technical Assistance-only (TA)	0	0	Redacted
PMTCT_ARV_DS D	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	905	923	Redacted
PMTCT_ARV_DS D	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	905	923	Redacted
PMTCT_ARV_DS D	Life-long ART (including Option B+)	679	692	Redacted
PMTCT_ARV_DS D	Sub-Disag of Life-long ART: Newly initiated on treatment during the current	317	323	Redacted

	pregnancy			
PMTCT_ARV_DS D	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	362	369	Redacted
PMTCT_ARV_DS D	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)	0	0	Redacted
PMTCT_ARV_DS D	Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)	226	231	Redacted
PMTCT_ARV_DS D	Single-dose nevirapine (with or without tail)	0	0	Redacted
PMTCT_ARV_DS D	Sum of Regimen Type disaggregates	905	923	Redacted
PMTCT_ARV_DS D	Sum of New and Current disaggregates	679	692	Redacted
PMTCT_ARV_NGI	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	905	923	Redacted
PMTCT_ARV_NGI	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	905	923	Redacted
PMTCT_ARV_NGI	Life-long ART (including Option B+)	679	692	Redacted
PMTCT_ARV_NGI	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	317	323	Redacted
PMTCT_ARV_NGI	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	362	369	Redacted
PMTCT_ARV_NGI	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)	0	0	Redacted
PMTCT_ARV_NGI	Maternal AZT (prophylaxis component	226	231	Redacted



	of WHO Option A during pregnancy and delivery)			
PMTCT_ARV_NGI	Single-dose nevirapine (with or without tail)	0	0	Redacted
PMTCT_ARV_NGI	Sum of Regimen disaggregates	905	923	Redacted
PMTCT_ARV_NGI	Sum of New and Current disaggregates	679	692	Redacted
PMTCT_SITE	Number of PEPFAR-supported sites achieving 90% ARV or ART coverage for HIV+ pregnant women	9	9	Redacted
PMTCT_SITE	Total number of PEPFAR supported sites providing PMTCT services (HTC and ARV or ART services)	9	9	Redacted
PMTCT_SITE	By site support type: Direct Service Delivery (DSD): Number of PEPFAR-supported sites achieving 90% ARV or ART coverage for HIV+ pregnant women	9	9	Redacted
PMTCT_SITE	By site support type: Technical Assistance-only (TA): Number of PEPFAR-supported sites achieving 90% ARV or ART coverage for HIV+ pregnant women	0	0	Redacted
PMTCT_SITE	Sum of Numerator Support Type disaggregates	9	9	Redacted
PMTCT_SITE	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR supported sites providing PMTCT services (HTC and ARV or ART services)	9	9	Redacted
PMTCT_SITE	By site support type: Technical Assistance-only (TA): Total number of PEPFAR supported sites providing PMTCT services (HTC and ARV or ART services)	0	0	Redacted
PMTCT_SITE	Sum of Denominator Support Type	9	9	Redacted

	disaggregates			
PMTCT_STAT_DS D	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	4,724	4,959	Redacted
PMTCT_STAT_DS D	Number of new ANC and L&D clients	4,724	4,959	Redacted
PMTCT_STAT_DS D	By: Known positives at entry	425	434	Redacted
PMTCT_STAT_DS D	By: Number of new positives identified	480	489	Redacted
PMTCT_STAT_DS D	Sum of Positives Status disaggregates	905	923	Redacted
PMTCT_STAT_NG I	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	4,724	4,959	Redacted
PMTCT_STAT_NG I	Number of new ANC and L&D clients	4,724	4,959	Redacted
PMTCT_STAT_NG I	By: Known positives at entry	425	434	Redacted
PMTCT_STAT_NG I	By: Number of new positives identified	480	489	Redacted
PMTCT_STAT_NG I	Sum of Positives Status disaggregates	905	923	Redacted
KP_MAT_DSD	Number of people who inject drugs (PWID) on medication assisted therapy (MAT) for at least 6 months	100	300	Redacted
KP_MAT_DSD	Sex: Male	80	240	Redacted
KP_MAT_DSD	Sex: Female	20	60	Redacted
KP_MAT_DSD	Sum of Sex disaggregates	100	300	Redacted
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are	533	1,000	Redacted



	based on evidence and/or meet the minimum standards required			
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0	0	Redacted
KP_PREV_DSD	By key population type: Males who inject drugs (Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	426	800	Redacted
KP_PREV_DSD	By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	107	200	Redacted
KP_PREV_DSD	By key population type: Men who have sex with men/Transgender (MSM/TG) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0	0	Redacted
KP_PREV_DSD	By key population type: MSM/TG who are male sex workers (subset MSM/TG) (Numerator: Number of key populations reached with individual	0	0	Redacted



	and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)			
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	24,300	34,856	Redacted
HTC_TST_DSD	By Test Result: Negative	23,328	33,462	Redacted
HTC_TST_DSD	By Test Result: Positive	972	1,394	Redacted
HTC_TST_DSD	Sum of Test Result disaggregates	24,300	34,856	Redacted
HTC_TST_DSD	Age/sex: <1 Male	0	0	Redacted
HTC_TST_DSD	Age/sex: 1-4 Male	850	1,220	Redacted
HTC_TST_DSD	Age/sex: 5-9 Male	364	523	Redacted
HTC_TST_DSD	Age/sex: 10-14 Male	608	871	Redacted
HTC_TST_DSD	Age/sex: 15-19 Male	1,215	1,743	Redacted
HTC_TST_DSD	Age/sex: 20-24 Male	3,038	4,357	Redacted
HTC_TST_DSD	Age/sex: 25-49 Male	4,860	6,971	Redacted
HTC_TST_DSD	Age/sex: 50+ Male	1,215	1,743	Redacted
HTC_TST_DSD	Age/sex: <1 Female	0	0	Redacted
HTC_TST_DSD	Age/sex: 1-4 Female	850	1,220	Redacted
HTC_TST_DSD	Age/sex: 5-9 Female	364	523	Redacted
HTC_TST_DSD	Age/sex: 10-14 Female	608	871	Redacted
HTC_TST_DSD	Age/sex: 15-19 Female	1,215	1,743	Redacted
HTC_TST_DSD	Age/sex: 20-24 Female	3,038	4,357	Redacted
HTC_TST_DSD	Age/sex: 25-49 Female	4,860	6,971	Redacted
HTC_TST_DSD	Age/sex: 50+ Female	1,215	1,743	Redacted
HTC_TST_DSD	Sum of Age/Sex disaggregates	24,300	34,856	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	1,822	2,614	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	10,328	14,814	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	1,822	2,614	Redacted

HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	10,328	14,814	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	3,644	5,228	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	20,656	29,628	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	24,300	34,856	Redacted
HTC_TST_NGI	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	24,300	34,856	Redacted
HTC_TST_NGI	By Test Result: Negative	23,328	33,462	Redacted
HTC_TST_NGI	By Test Result: Positive	972	1,394	Redacted
HTC_TST_NGI	Sum of Test Result disaggregates	24,300	34,856	Redacted
HTC_TST_NGI	Age/sex: <1 Male	0	0	Redacted
HTC_TST_NGI	Age/sex: 1-4 Male	850	1,220	Redacted
HTC_TST_NGI	Age/sex: 5-9 Male	364	523	Redacted
HTC_TST_NGI	Age/sex: 10-14 Male	608	871	Redacted
HTC_TST_NGI	Age/sex: 15-19 Male	1,215	1,743	Redacted
HTC_TST_NGI	Age/sex: 20-24 Male	3,038	4,357	Redacted
HTC_TST_NGI	Age/sex: 25-49 Male	4,860	6,971	Redacted
HTC_TST_NGI	Age/sex: 50+ Male	1,215	1,743	Redacted
HTC_TST_NGI	Age/sex: <1 Female	0	0	Redacted
HTC_TST_NGI	Age/sex: 1-4 Female	850	1,220	Redacted
HTC_TST_NGI	Age/sex: 5-9 Female	364	523	Redacted
HTC_TST_NGI	Age/sex: 10-14 Female	608	871	Redacted
HTC_TST_NGI	Age/sex: 15-19 Female	1,215	1,743	Redacted
HTC_TST_NGI	Age/sex: 20-24 Female	3,038	4,357	Redacted
HTC_TST_NGI	Age/sex: 25-49 Female	4,860	6,971	Redacted
HTC_TST_NGI	Age/sex: 50+ Female	1,215	1,743	Redacted
HTC_TST_NGI	Sum of Age/Sex disaggregates	24,300	34,856	Redacted
HTC_TST_NGI	Aggregated Age/sex: <15 Male	1,822	2,614	Redacted
HTC_TST_NGI	Aggregated Age/sex: 15+ Male	10,328	14,814	Redacted
HTC_TST_NGI	Aggregated Age/sex: <15 Female	1,822	2,614	Redacted



HTC_TST_NGI	Aggregated Age/sex: 15+ Female	10,328	14,814	Redacted
HTC_TST_NGI	Sum of Aggregated Age/Sex <15	3,644	5,228	Redacted
HTC_TST_NGI	Sum of Aggregated Age/Sex 15+	20,656	29,628	Redacted
HTC_TST_NGI	Sum of Aggregated Age/Sex disaggregates	24,300	34,856	Redacted
OVC_ACC_DSD	Number of active beneficiaries receiving support from PEPFAR OVC programs to access HIV services	1,500	1,500	Redacted
OVC_ACC_DSD	Sex: Male	750	750	Redacted
OVC_ACC_DSD	Sex: Female	750	750	Redacted
OVC_ACC_DSD	Sum of Sex disaggregates	1,500	1,500	Redacted
OVC_ACC_DSD	Age: <1	30	30	Redacted
OVC_ACC_DSD	Age: 1-4	180	180	Redacted
OVC_ACC_DSD	Age: 5-9	375	375	Redacted
OVC_ACC_DSD	Age: 10-14	540	540	Redacted
OVC_ACC_DSD	Age: 15-17	300	300	Redacted
OVC_ACC_DSD	Age: 18+	75	75	Redacted
OVC_ACC_DSD	Sum of Age disaggregates	1,500	1,500	Redacted
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	3,000	3,000	Redacted
OVC_SERV_DSD	Sex: Male	1,500	1,500	Redacted
OVC_SERV_DSD	Sex: Female	1,500	1,500	Redacted
OVC_SERV_DSD	Sum of Sex disaggregates	3,000	3,000	Redacted
OVC_SERV_DSD	Age: <1	60	60	Redacted
OVC_SERV_DSD	Age: 1-4	360	360	Redacted
OVC_SERV_DSD	Age: 5-9	750	750	Redacted
OVC_SERV_DSD	Age: 10-14	1,080	1,080	Redacted
OVC_SERV_DSD	Age: 15-17	600	600	Redacted
OVC_SERV_DSD	Age: 18+	150	150	Redacted
OVC_SERV_DSD	Sum of Age disaggregates	3,000	3,000	Redacted
C2.1.D_DSD	Number of HIV-positive individuals receiving a minimum of one clinical	25,172	27,515	Redacted



	service			
C2.1.D_DSD	By Age/Sex: <15 Female	1,133	1,241	Redacted
C2.1.D_DSD	By Age/Sex: <15 Male	1,133	1,241	Redacted
C2.1.D_DSD	By Age/Sex: 15+ Female	15,118	16,522	Redacted
C2.1.D_DSD	By Age/Sex: 15+ Male	7,788	8,511	Redacted
C2.1.D_DSD	Sum of Age/Sex disaggregates	25,172	27,515	Redacted
C2.1.D_DSD	By Age: <15	2,266	2,482	Redacted
C2.1.D_DSD	By Age: 15+	22,906	25,033	Redacted
C2.1.D_DSD	Sum of Age disaggregates	25,172	27,515	Redacted
C2.1.D_DSD	By Sex: Female	16,251	17,763	Redacted
C2.1.D_DSD	By Sex: Male	8,921	9,752	Redacted
C2.1.D_DSD	Sum of Sex disaggregates	25,172	27,515	Redacted
C2.1.D_NGI	Number of HIV-positive individuals receiving a minimum of one clinical service	25,172	27,515	Redacted
C2.1.D_NGI	By Age/Sex: <15 Female	1,133	1,241	Redacted
C2.1.D_NGI	By Age/Sex: <15 Male	1,133	1,241	Redacted
C2.1.D_NGI	By Age/Sex: 15+ Female	15,118	16,522	Redacted
C2.1.D_NGI	By Age/Sex: 15+ Male	7,788	8,511	Redacted
C2.1.D_NGI	Sum of Age/Sex disaggregates	25,172	27,515	Redacted
C2.1.D_NGI	By Age: <15	2,266	2,482	Redacted
C2.1.D_NGI	By Age: 15+	22,906	25,033	Redacted
C2.1.D_NGI	Sum of Age disaggregates	25,172	27,515	Redacted
C2.1.D_NGI	By Sex: Female	16,251	17,763	Redacted
C2.1.D_NGI	By Sex: Male	8,921	9,752	Redacted
C2.1.D_NGI	Sum of Sex disaggregates	25,172	27,515	Redacted
C2.4.D_DSD	Number of HIV-positive patients who were screened for TB in HIV care or treatment setting	22,655	26,139	Redacted
C2.4.D_DSD	Number of HIV-positive individuals receiving a minimum of one clinical service	25,172	27,515	Redacted
C2.5.D_DSD	Number of HIV-positive patients in HIV	453	523	Redacted



	care who started TB treatment			
C2.5.D_DSD	Number of HIV-positive individuals receiving a minimum of one clinical service	25,172	27,515	Redacted
CARE_CURR_DS D	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	23,913	26,139	Redacted
CARE_CURR_DS D	Age/sex: <1 Male	37	41	Redacted
CARE_CURR_DS D	Age/sex: 1-4 Male	259	283	Redacted
CARE_CURR_DS D	Age/sex: 5-9 Male	437	479	Redacted
CARE_CURR_DS D	Age/sex: 10-14 Male	343	376	Redacted
CARE_CURR_DS D	Age/sex: 15-19 Male	183	200	Redacted
CARE_CURR_DS D	Age/sex: 20-24 Male	340	371	Redacted
CARE_CURR_DS D	Age/sex: 25-49 Male	5,110	5,584	Redacted
CARE_CURR_DS D	Age/sex: 50+ Male	1,766	1,931	Redacted
CARE_CURR_DS D	Age/sex: <1 Female	37	41	Redacted
CARE_CURR_DS D	Age/sex: 1-4 Female	246	269	Redacted
CARE_CURR_DS D	Age/sex: 5-9 Female	452	495	Redacted
CARE_CURR_DS D	Age/sex: 10-14 Female	341	373	Redacted
CARE_CURR_DS	Age/sex: 15-19 Female	303	331	Redacted



D				
CARE_CURR_DS D	Age/sex: 20-24 Female	1,257	1,374	Redacted
CARE_CURR_DS D	Age/sex: 25-49 Female	10,738	11,735	Redacted
CARE_CURR_DS D	Age/sex: 50+ Female	2,064	2,256	Redacted
CARE_CURR_DS D	Sun of Age/Sex disaggregates	23,913	26,139	Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	1,076	1,179	Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	7,399	8,086	Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	1,076	1,178	Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	14,362	15,696	Redacted
CARE_CURR_DS D	Sum of Aggregated Age/Sex disaggregates	23,913	26,139	Redacted
CARE_NEW_DSD	Number of HIV-infected adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load	4,783	4,753	Redacted
CARE_NEW_DSD	Age/sex: <1 Male	7	7	Redacted
CARE_NEW_DSD	Age/sex: 1-4 Male	52	52	Redacted
CARE_NEW_DSD	Age/sex: 5-9 Male	87	87	Redacted
CARE_NEW_DSD	Age/sex: 10-14 Male	69	68	Redacted
CARE_NEW_DSD	Age/sex: 15-19 Male	31	31	Redacted
CARE_NEW_DSD	Age/sex: 20-24 Male	130	129	Redacted
CARE_NEW_DSD	Age/sex: 25-49 Male	1,106	1,099	Redacted
CARE_NEW_DSD	Age/sex: 50+ Male	213	211	Redacted
CARE_NEW_DSD	Age/sex: <1 Female	7	7	Redacted



CARE_NEW_DSD	Age/sex: 1-4 Female	50	49	Redacted
CARE_NEW_DSD	Age/sex: 5-9 Female	91	90	Redacted
CARE_NEW_DSD	Age/sex: 10-14 Female	68	69	Redacted
CARE_NEW_DSD	Age/sex: 15-19 Female	71	71	Redacted
CARE_NEW_DSD	Age/sex: 20-24 Female	132	131	Redacted
CARE_NEW_DSD	Age/sex: 25-49 Female	1,984	1,971	Redacted
CARE_NEW_DSD	Age/sex: 50+ Female	685	681	Redacted
CARE_NEW_DSD	Sum of Age/sex disaggregates	4,783	4,753	Redacted
CARE_NEW_DSD	Aggregated Age/sex: <15 Male	215	214	Redacted
CARE_NEW_DSD	Aggregated Age/sex: 15+ Male	1,480	1,470	Redacted
CARE_NEW_DSD	Aggregated Age/sex: <15 Female	216	215	Redacted
CARE_NEW_DSD	Aggregated Age/sex: 15+ Female	2,872	2,854	Redacted
CARE_NEW_DSD	Sum of Aggregated Age/sex disaggregates	4,783	4,753	Redacted
CARE_SITE	Number of PEPFAR-supported HIV clinical care sites at which at least 80% of PLHIV received all of the following during the reporting period: 1) clinical assessment (WHO staging) OR CD4 count OR viral load, AND 2) TB screening at last visit, AND 3) if eligible, cotrimoxazole	9	9	Redacted
CARE_SITE	Total number of PEPFAR supported sites providing clinical care services	9	9	Redacted
CARE_SITE	By site support type: Direct Service Delivery (DSD): Number of PEPFAR-supported HIV clinical care sites at which at least 80% of PLHIV received all of the following during the reporting period: 1) clinical assessment (WHO staging) OR CD4 count OR viral load, AND 2) TB screening at last visit, AND 3) if eligible, cotrimoxazole	9	9	Redacted
CARE_SITE	By site support type: Technical	0	0	Redacted



	Assistance-only (TA): Number of PEPFAR-supported HIV clinical care sites at which at least 80% of PLHIV received all of the following during the reporting period: 1) clinical assessment (WHO staging) OR CD4 count OR viral load, AND 2) TB screening at last visit, AND 3) if eligible, cotrimoxazole			
CARE_SITE	Sum of Numerator Site Support Type disaggregates	9	9	Redacted
CARE_SITE	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR supported sites providing clinical care services	9	9	Redacted
CARE_SITE	By site support type: Technical Assistance-only (TA): Total number of PEPFAR supported sites providing clinical care services	0	0	Redacted
CARE_SITE	Sum of Denominator Site Support Type disaggregates	9	9	Redacted
FN_SITE	Number of PEPFAR-supported sites achieving 90% nutrition assessments that result in accurate categorization of malnutrition	8	8	Redacted
FN_SITE	Total number of PEPFAR-supported sites providing nutrition assessment, counseling and support (NACS) services	9	9	Redacted
FN_SITE	By site support type: Direct Service Delivery (DSD): Number of PEPFAR-supported sites achieving 90% nutrition assessments that result in accurate categorization of malnutrition	8	8	Redacted
FN_SITE	By site support type: Technical	0	0	Redacted



	Assistance-only (TA): Number of PEPFAR-supported sites achieving 90% nutrition assessments that result in accurate categorization of malnutrition			
FN_SITE	Sum of Numerator Support Type disaggregates	8	8	Redacted
FN_SITE	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported sites providing nutrition assessment, counseling and support (NACS) services	9	9	Redacted
FN_SITE	By site support type: Technical Assistance-only (TA): Total number of PEPFAR-supported sites providing nutrition assessment, counseling and support (NACS) services	0	0	Redacted
FN_SITE	Sum of Denominator Support Type disaggregates	9	9	Redacted
FN_THER_DSD	Number of clinically malnourished PLHIV who received therapeutic and/or supplementary food during the reporting period.	3,776	4,127	Redacted
FN_THER_DSD	Number of PLHIV who were nutritionally assessed and found to be clinically undernourished.	5,034	5,503	Redacted
FN_THER_DSD	Age: <1	12	13	Redacted
FN_THER_DSD	Age: 1-4	82	89	Redacted
FN_THER_DSD	Age: 5-14	255	278	Redacted
FN_THER_DSD	Age: 15-17	76	84	Redacted
FN_THER_DSD	Age: 18+	3,351	3,663	Redacted
FN_THER_DSD	Sum of Age disaggregates	3,776	4,127	Redacted
FN_THER_DSD	Aggregated Age: <18	425	464	Redacted
FN_THER_DSD	Aggregated Age: 18+	3,351	3,663	Redacted



FN_THER_DSD	Sum of Aggregated Age disaggregates	3,776	4,127	Redacted
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	963	1,176	Redacted
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	1,133	1,307	Redacted
TB_ART_DSD	Age: 0-4	24	29	Redacted
TB_ART_DSD	Age: 5-14	65	79	Redacted
TB_ART_DSD	Age: 15+	874	1,068	Redacted
TB_ART_DSD	Male	520	635	Redacted
TB_ART_DSD	Female	443	541	Redacted
TB_ART_DSD	Sum of Sex disaggregates	963	1,176	Redacted
TB_ART_DSD	Newly tested	578	705	Redacted
TB_ART_DSD	Known HIV-positive	385	471	Redacted
TB_ART_DSD	Sum of Test Status disaggregates	963	1,176	Redacted
TB_ART_DSD	Aggregated Age: <15	89	108	Redacted
TB_ART_DSD	Aggregated Age: 15+	874	1,068	Redacted
TB_ART_DSD	Sum of Aggregated Age disaggregates	963	1,176	Redacted
TB_ARTSITE	The number of PEPFAR-supported TB basic management units at which 80% of registered TB cases who are HIV-positive are on ART, during the reporting period	5	5	Redacted
TB_ARTSITE	The number of PEPFAR-supported TB basic management units	5	5	Redacted
TB_ARTSITE	By site support type: Direct Service Delivery (DSD): The number of PEPFAR-supported TB basic management units at which 80% of registered TB cases who are	5	5	Redacted

	HIV-positive are on ART, during the reporting period			
TB_ARTSITE	By site support type: Technical Assistance-only (TA): The number of PEPFAR-supported TB basic management units at which 80% of registered TB cases who are HIV-positive are on ART, during the reporting period	0	0	Redacted
TB_ARTSITE	Sum of Numerator Site Support Type disaggregates	5	5	Redacted
TB_ARTSITE	By site support type: Direct Service Delivery (DSD): The number of PEPFAR-supported TB basic management units	5	5	Redacted
TB_ARTSITE	By site support type: Technical Assistance-only (TA): The number of PEPFAR-supported TB basic management units	0	0	Redacted
TB_ARTSITE	Sum of Denominator Site Support Type disaggregates	5	5	Redacted
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	724	738	Redacted
PMTCT_EID_DSD	Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT)	905	923	Redacted
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	543	554	Redacted
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	181	184	Redacted
PMTCT_EID_DSD	Sum of Infant Age disaggregates	724	738	Redacted
PMTCT_EID_DSD	By infants with a positive virologic test	36	37	Redacted

	result within 12 months of birth			
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	17,865	20,305	Redacted
TX_CURR_DSD	Age/Sex: <1 Male	28	32	Redacted
TX_CURR_DSD	Age/Sex: 1-4 Male	188	214	Redacted
TX_CURR_DSD	Age/Sex: 5-14 Male	588	670	Redacted
TX_CURR_DSD	Age/Sex: 15+ Male	5,527	6,466	Redacted
TX_CURR_DSD	Age/Sex: <1 Female	28	32	Redacted
TX_CURR_DSD	Age/Sex: 1-4 Female	188	214	Redacted
TX_CURR_DSD	Age/Sex: 5-14 Female	588	669	Redacted
TX_CURR_DSD	Age/Sex: 15+ Female	10,730	12,008	Redacted
TX_CURR_DSD	Sum of age/sex disaggregates	1,608	1,831	Redacted
TX_CURR_DSD	Percent children with advanced HIV infection receiving antiretroviral therapy (ART) [CURRENT]	71	74	Redacted
TX_CURR_DSD	Percent women and girls with advanced HIV infection receiving antiretroviral therapy (ART) [CURRENT]	71	73	Redacted
TX_CURR_DSD	Aggregated Age/Sex: <1 Male	28	32	Redacted
TX_CURR_DSD	Aggregated Age/Sex: <1 Female	28	32	Redacted
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	804	916	Redacted
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	5,527	6,466	Redacted
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	804	915	Redacted
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	10,730	12,008	Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	1,608	1,831	Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	16,257	18,474	Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	17,865	20,305	Redacted
TX_CURR_NGI	Number of adults and children receiving antiretroviral therapy (ART)	17,865	20,305	Redacted
TX_CURR_NGI	Age/Sex: <1 Male	28	32	Redacted
TX_CURR_NGI	Age/Sex: 1-4 Male	188	214	Redacted



TX_CURR_NGI	Age/Sex: 5-14 Male	588	670	Redacted
TX_CURR_NGI	Age/Sex: 15+ Male	5,527	6,466	Redacted
TX_CURR_NGI	Age/Sex: <1 Female	28	32	Redacted
TX_CURR_NGI	Age/Sex: 1-4 Female	188	214	Redacted
TX_CURR_NGI	Age/Sex: 5-14 Female	588	669	Redacted
TX_CURR_NGI	Age/Sex: 15+ Female	10,730	12,008	Redacted
TX_CURR_NGI	Sum of Age/Sex disaggregates	17,865	20,305	Redacted
TX_CURR_NGI	Aggregated Age/Sex: <1 Male	28	32	Redacted
TX_CURR_NGI	Aggregated Age/Sex: <1 Female	28	32	Redacted
TX_CURR_NGI	Aggregated Age/Sex: <15 Male	804	916	Redacted
TX_CURR_NGI	Aggregated Age/Sex: 15+ Male	5,527	6,466	Redacted
TX_CURR_NGI	Aggregated Age/Sex: <15 Female	804	915	Redacted
TX_CURR_NGI	Aggregated Age/Sex: 15+ Female	10,730	12,008	Redacted
TX_CURR_NGI	Sum of Aggregated Age/Sex disaggregates	17,865	20,305	Redacted
TX_CURR_NGI	Sum of Aggregated Age/Sex <15	1,608	1,831	Redacted
TX_CURR_NGI	Sum of Aggregated Age/Sex 15+	16,257	18,474	Redacted
TX_DIST	Number of Districts with documented routine supportive supervision visits to 75% of HIV care and treatment sites supported by the District	3	3	Redacted
TX_DIST	Total number of PEPFAR supported District Health Offices	3	3	Redacted
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	3,688	3,639	Redacted
TX_NEW_DSD	By Age/Sex: <1 Male	57	77	Redacted
TX_NEW_DSD	By Age/Sex: 1-4 Male	32	44	Redacted
TX_NEW_DSD	By Age/Sex: 5-9 Male	57	77	Redacted
TX_NEW_DSD	By Age/Sex: 10-14 Male	45	58	Redacted
TX_NEW_DSD	By Age/Sex: 15-19 Male	29	27	Redacted
TX_NEW_DSD	By Age/Sex: 20-24 Male	53	50	Redacted
TX_NEW_DSD	By Age/Sex: 25-49 Male	799	756	Redacted
TX_NEW_DSD	By Age/Sex: 50+ Male	276	261	Redacted

TX_NEW_DSD	By Age/Sex: <1 Female	57	77	Redacted
TX_NEW_DSD	By Age/Sex: 1-4 Female	32	44	Redacted
TX_NEW_DSD	By Age/Sex: 5-9 Female	57	77	Redacted
TX_NEW_DSD	By Age/Sex: 10-14 Female	45	59	Redacted
TX_NEW_DSD	By Age/Sex: 15-19 Female	45	43	Redacted
TX_NEW_DSD	By Age/Sex: 20-24 Female	188	178	Redacted
TX_NEW_DSD	By Age/Sex: 25-49 Female	1,607	1,519	Redacted
TX_NEW_DSD	By Age/Sex: 50+ Female	309	292	Redacted
TX_NEW_DSD	Sum of Age/Sex disaggregates	3,688	3,639	Redacted
TX_NEW_DSD	Aggregated Grouping by Age: <1 Male	57	77	Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	191	256	Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	1,157	1,094	Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <1 Female	57	77	Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	191	257	Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	2,149	2,032	Redacted
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	3,688	3,639	Redacted
TX_NEW_DSD	Pregnancy status	285	291	Redacted
TX_NEW_DSD	Breastfeeding status	32	32	Redacted
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	2,493	3,134	Redacted
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	2,933	3,688	Redacted
TX_RET_DSD	Age: 0-4 (Numerator: Number of adults	62	78	Redacted



	and children who are still alive and on treatment at 12 months after initiating ART)			
TX_RET_DSD	Age: 5-14 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	168	211	Redacted
TX_RET_DSD	Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	2,263	2,846	Redacted
TX_RET_DSD	Age: 0-4 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	73	91	Redacted
TX_RET_DSD	Age: 5-14 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	198	249	Redacted
TX_RET_DSD	Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	2,663	3,348	Redacted
TX_RET_DSD	Aggregated Age: <15 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	230	289	Redacted

TX_RET_DSD	Aggregated Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	2,263	2,846	Redacted
TX_RET_DSD	Aggregated Age: <15 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	270	340	Redacted
TX_RET_DSD	Aggregated Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	2,663	3,348	Redacted
TX_RET_DSD	Pregnancy and breastfeeding status (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	288	577	Redacted
TX_RET_DSD	Pregnancy and breastfeeding status (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	339	679	Redacted
TX_SITE	Number of PEPFAR-supported ART sites with a retention rate of 75% or greater for patients 12 months after ART initiation	7	7	Redacted
TX_SITE	Total number of PEPFAR-supported ART sites	9	9	Redacted

TX_SITE	By support type: Direct Service Delivery (DSD): Number of PEPFAR-supported ART sites with a retention rate of 75% or greater for patients 12 months after ART initiation	7	7	Redacted
TX_SITE	By support type: Technical Assistance (TA-only): Number of PEPFAR-supported ART sites with a retention rate of 75% or greater for patients 12 months after ART initiation	0	0	Redacted
TX_SITE	Sum of Numerator Site Support Type disaggregates	7	7	Redacted
TX_SITE	By support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported ART sites	9	9	Redacted
TX_SITE	By support type: Technical Assistance (TA-only): Total number of PEPFAR-supported ART sites	0	0	Redacted
TX_SITE	Sum of Denominator Site Support Type disaggregates	9	9	Redacted
LAB_CAP_DSD	Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests	3	3	Redacted
LAB_CAP_DSD	By site support type: Direct Service Delivery (DSD)	3	3	Redacted
LAB_CAP_DSD	Sum of Site Support Type disaggregates	3	3	Redacted
FPINT_SITE_DSD	Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	7	7	Redacted
FPINT_SITE_DSD	Total number of PEPFAR-supported HIV service delivery points: PMTCT, Care and Treatment	9	9	Redacted
FPINT_SITE_DSD	By site support type: Direct Service	7	7	Redacted

	Delivery (DSD): Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services			
FPINT_SITE_DSD	By site support type: Technical Assistance-only (TA): Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	0	0	Redacted
FPINT_SITE_DSD	Sum of Numerator Site Support Type disaggregates	7	7	Redacted
FPINT_SITE_DSD	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported HIV service delivery points	9	9	Redacted
FPINT_SITE_DSD	By site support type: Technical Assistance-only (TA): Total number of PEPFAR-supported HIV service delivery points	0	0	Redacted
FPINT_SITE_DSD	Sum of Denominator Site Support Type disaggregates	9	9	Redacted
FPINT_SITE_DSD	Service delivery type: Clinical	7	7	Redacted
FPINT_SITE_DSD	Sum of Service Delivery Type disaggregates	7	7	Redacted
QI_SITE	Number of PEPFAR-supported clinical service sites with a quality improvement activity completed that addresses clinical HIV programs and has documented process results in the last 6 months	8	8	Redacted
QI_SITE	Total number of PEPFAR-supported sites for any HIV clinical service including HIV Care, HIV Treatment, TB	9	9	Redacted



	care, PMTCT, VMMC, and HTC			
QI_SITE	By site support type: Direct Service Delivery (DSD): Number of PEPFAR-supported clinical service sites with a quality improvement activity completed that addresses clinical HIV programs and has documented results in the last 6 months	8	8	Redacted
QI_SITE	By site support type: Technical Assistance-only (TA): Number of PEPFAR-supported clinical service sites with a quality improvement activity completed that addresses clinical HIV programs and has documented results in the last 6 months	0	0	Redacted
QI_SITE	Sum of Numerator Site Support Type disaggregates	8	8	Redacted
QI_SITE	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported sites for any HIV clinical service including HIV Care, HIV Treatment, TB care, PMTCT, VMMC, HTC	9	9	Redacted
QI_SITE	By site support type: Technical Assistance-only (TA): Total number of PEPFAR-supported sites for any HIV clinical service including HIV Care, HIV Treatment, TB care, PMTCT, VMMC, and HTC	0	0	Redacted
QI_SITE	Sum of Denominator Site Support Type disaggregates	9	9	Redacted
TB_SCREEN_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period	21,522	24,832	Redacted



TB_SCREEN_DSD	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	23,913	26,139	Redacted
TB_SCREEN_DSD	Age: <1	69	79	Redacted
TB_SCREEN_DSD	Age: 1-4	464	536	Redacted
TB_SCREEN_DSD	Age: 5-9	820	946	Redacted
TB_SCREEN_DSD	Age: 10-14	631	728	Redacted
TB_SCREEN_DSD	Age: 15-19	435	502	Redacted
TB_SCREEN_DSD	Age: 20-24	1,451	1,674	Redacted
TB_SCREEN_DSD	Age: 25-49	14,252	16,444	Redacted
TB_SCREEN_DSD	Age: 50+	3,400	3,923	Redacted
TB_SCREEN_DSD	Sum of Age disaggregates	2,419	2,791	Redacted
TB_SCREEN_DSD	Aggregated Age - USE WITH HQ PERMISSION ONLY: <15	1,984	2,289	Redacted
TB_SCREEN_DSD	Aggregated Age - USE WITH HQ PERMISSION ONLY: 15+	19,538	22,543	Redacted
TB_SCREEN_DSD	Sum of Aggregated Age disaggregates	21,522	24,832	Redacted
TB_SCREEN_DSD	Sex: Male	7,635	8,809	Redacted
TB_SCREEN_DSD	Sex: Female	13,887	16,023	Redacted
TB_SCREEN_DSD	Sum of Sex disaggregates	21,522	24,832	Redacted

Implementing Mechanism Details

Mechanism ID: 12656	Mechanism Name: Clinical Services
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Eastern Deanery AIDS Relief Program	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: No	
G2G: No	Managing Agency:
Total All Funding Sources: 6,769,188	Total Mechanism Pipeline: Redacted



Applied Pipeline Amount: 194,190	
FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount
GHP-State	6,769,188

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

Human Resources for Health	1,922,394
Food and Nutrition: Policy, Tools, and Service Delivery	10,000
Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Monitoring and Evaluation
Gender: GBV	174,084
Focus Area:	GBV Prevention
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Focus Area:	Post GBV Care
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Gender: Gender Equality	174,084
Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Collection and Use of Gender-related Strategic

Approved



	Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Motor Vehicles: Purchased	60,600
Condom procurement	15,000

Key Issues

- Malaria (PMI)
- Child Survival Activities
- Safe Motherhood
- TB
- Family Planning

Budget Code Information

Mechanism ID:	12656		
Mechanism Name:	Clinical Services		
Prime Partner Name:	Eastern Deanery AIDS Relief Program		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	390,988	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	751,284	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	133,215	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	363,377	0



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	550,914	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	493,750	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	3,788,370	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	297,290	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2014	2015	Planning Budget Targets
SITE_SUPP	Number of unique sites supported by PEPFAR	14	14	Redacted
SITE_SUPP	By program area/support type: HTC Direct Service Delivery (DSD)	14	14	Redacted
SITE_SUPP	By program area/support type: HTC Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: Treatment Direct Service Delivery (DSD)	14	14	Redacted
SITE_SUPP	By program area/support type: Treatment Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: Care and Support Direct Service Delivery (DSD)	14	14	Redacted



SITE_SUPP	By program area/support type: Care and Support Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: Food and Nutrition Direct Service Delivery (DSD)	14	14	Redacted
SITE_SUPP	By program area/support type: Food and Nutrition Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: PMTCT Direct Service Delivery (DSD)	14	14	Redacted
SITE_SUPP	By program area/support type: PMTCT Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: TB/HIV Direct Service Delivery (DSD)	14	14	Redacted
SITE_SUPP	By program area/support type: TB/HIV Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: VMMC Direct Service Delivery (DSD)	14	14	Redacted
SITE_SUPP	By program area/support type: VMMC Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: General Population Prevention Direct Service Delivery (DSD)	0	0	Redacted
SITE_SUPP	By program area/support type: General Population Prevention Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: Key Populations Prevention Direct Service Delivery (DSD)	0	0	Redacted
SITE_SUPP	By program area/support type: Key Populations Prevention Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: OVC Direct Service Delivery (DSD)	0	0	Redacted



SITE_SUPP	By program area/support type: OVC Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: PHDP/Family Planning & Integration Direct Service Delivery (DSD)	14	14	Redacted
SITE_SUPP	By program area/support type: PHDP/Family Planning & Integration Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: Lab Direct Service Delivery (DSD)	7	7	Redacted
SITE_SUPP	By program area/support type: Lab Technical Assistance-only (TA)	0	0	Redacted
PMTCT_ARV_DS D	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	1,190	1,214	Redacted
PMTCT_ARV_DS D	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	1,190	1,214	Redacted
PMTCT_ARV_DS D	Life-long ART (including Option B+)	893	910	Redacted
PMTCT_ARV_DS D	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	417	425	Redacted
PMTCT_ARV_DS D	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	476	485	Redacted
PMTCT_ARV_DS D	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)	0	0	Redacted
PMTCT_ARV_DS D	Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)	297	304	Redacted
PMTCT_ARV_DS	Single-dose nevirapine (with or without	0	0	Redacted



D	tail)			
PMTCT_ARV_DS D	Sum of Regimen Type disaggregates	1,190	1,214	Redacted
PMTCT_ARV_DS D	Sum of New and Current disaggregates	893	910	Redacted
PMTCT_ARV_NGI	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	1,190	1,214	Redacted
PMTCT_ARV_NGI	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	1,190	1,214	Redacted
PMTCT_ARV_NGI	Life-long ART (including Option B+)	893	910	Redacted
PMTCT_ARV_NGI	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	417	425	Redacted
PMTCT_ARV_NGI	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	476	485	Redacted
PMTCT_ARV_NGI	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)	0	0	Redacted
PMTCT_ARV_NGI	Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)	297	304	Redacted
PMTCT_ARV_NGI	Single-dose nevirapine (with or without tail)	0	0	Redacted
PMTCT_ARV_NGI	Sum of Regimen disaggregates	1,190	1,214	Redacted
PMTCT_ARV_NGI	Sum of New and Current disaggregates	893	910	Redacted
PMTCT_SITE	Number of PEPFAR-supported sites achieving 90% ARV or ART coverage for HIV+ pregnant women	14	14	Redacted
PMTCT_SITE	Total number of PEPFAR supported	14	14	Redacted

	sites providing PMTCT services (HTC and ARV or ART services)			
PMTCT_SITE	By site support type: Direct Service Delivery (DSD): Number of PEPFAR-supported sites achieving 90% ARV or ART coverage for HIV+ pregnant women	14	14	Redacted
PMTCT_SITE	By site support type: Technical Assistance-only (TA): Number of PEPFAR-supported sites achieving 90% ARV or ART coverage for HIV+ pregnant women	0	0	Redacted
PMTCT_SITE	Sum of Numerator Support Type disaggregates	14	14	Redacted
PMTCT_SITE	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR supported sites providing PMTCT services (HTC and ARV or ART services)	14	14	Redacted
PMTCT_SITE	By site support type: Technical Assistance-only (TA): Total number of PEPFAR supported sites providing PMTCT services (HTC and ARV or ART services)	0	0	Redacted
PMTCT_SITE	Sum of Denominator Support Type disaggregates	14	14	Redacted
PMTCT_STAT_DS D	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	4,764	5,002	Redacted
PMTCT_STAT_DS D	Number of new ANC and L&D clients	4,764	5,002	Redacted
PMTCT_STAT_DS D	By: Known positives at entry	559	571	Redacted
PMTCT_STAT_DS	By: Number of new positives identified	631	643	Redacted

D				
PMTCT_STAT_DS D	Sum of Positives Status disaggregates	1,190	1,214	Redacted
PMTCT_STAT_NG I	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	4,764	5,002	Redacted
PMTCT_STAT_NG I	Number of new ANC and L&D clients	4,764	5,002	Redacted
PMTCT_STAT_NG I	By: Known positives at entry	559	571	Redacted
PMTCT_STAT_NG I	By: Number of new positives identified	631	643	Redacted
PMTCT_STAT_NG I	Sum of Positives Status disaggregates	1,190	1,214	Redacted
VMMC_AE_DSD	Number of males circumcised surgically or by medical device that experienced at least one moderate or severe adverse event(s) (AEs)	88	35	Redacted
VMMC_AE_DSD	By AE type: Number of VMMC clients with one or more moderate or severe surgical intra-operative AE(s)	88	35	Redacted
VMMC_CIRC_DS D	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	12,610	5,957	Redacted
VMMC_CIRC_DS D	By Age: <1	63		Redacted
VMMC_CIRC_DS D	By Age: 1-9	0		Redacted
VMMC_CIRC_DS D	By Age: 10-14	5,044	2,413	Redacted
VMMC_CIRC_DS D	By Age: 15-19	5,044	2,383	Redacted

VMMC_CIRC_DS D	By Age: 20-24	1,261	595	Redacted
VMMC_CIRC_DS D	By Age: 25-49	1,198	566	Redacted
VMMC_CIRC_DS D	By Age: 50+	0	0	Redacted
VMMC_CIRC_DS D	Sum of age disaggregates	12,610	5,957	Redacted
VMMC_CIRC_DS D	By HIV status: Number of HIV-positive clients (tested HIV positive at VMMC site)	624	295	Redacted
VMMC_CIRC_DS D	By HIV status: Number of HIV-negative clients (tested HIV negative at VMMC program)	10,237	4,836	Redacted
VMMC_CIRC_DS D	By HIV status: Number of clients with undocumented/indeterminate HIV status or not tested for HIV at site	1,623	766	Redacted
VMMC_CIRC_DS D	By circumcision technique: Surgical VMMC	12,610	5,957	Redacted
VMMC_CIRC_DS D	By follow-up status: Number of surgically circumcised clients who returned at least once for follow-up care within 14 days of circumcision surgery	4,414	1,772	Redacted
VMMC_CIRC_DS D	By follow-up status: Number of surgically circumcised clients who did NOT return for follow-up care within 14 days of circumcision surgery	6,305	3,291	Redacted
VMMC_CIRC_NGI	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	12,610	5,957	Redacted
VMMC_CIRC_NGI	By Age: <1	63		Redacted
VMMC_CIRC_NGI	By Age: 1-9	0		Redacted
VMMC_CIRC_NGI	By Age: 10-14	5,044	2,413	Redacted



VMMC_CIRC_NGI	By Age: 15-19	5,044	2,383	Redacted
VMMC_CIRC_NGI	By Age: 20-24	1,261	595	Redacted
VMMC_CIRC_NGI	By Age: 25-49	1,198	566	Redacted
VMMC_CIRC_NGI	By Age: 50+	0	0	Redacted
VMMC_CIRC_NGI	Sum of Age disaggregates	12,610	5,957	Redacted
VMMC_CIRC_NGI	By HIV status: Number of HIV-positive clients (tested HIV positive at VMMC site)	624	295	Redacted
VMMC_CIRC_NGI	By HIV status: Number of HIV-negative clients (tested HIV negative at VMMC program)	10,237	4,836	Redacted
VMMC_CIRC_NGI	By HIV status: Number of clients with undocumented/indeterminate HIV status or not tested for HIV at site	1,623	766	Redacted
VMMC_CIRC_NGI	By circumcision technique: Surgical VMMC	12,610	5,957	Redacted
VMMC_CIRC_NGI	By follow-up status: Number of surgically circumcised clients who returned at least once for follow-up care within 14 days of circumcision surgery	4,414	1,772	Redacted
VMMC_CIRC_NGI	By follow-up status: Number of surgically circumcised clients who did NOT return for follow-up care within 14 days of circumcision surgery	6,305	3,291	Redacted
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	117,900	231,235	Redacted
HTC_TST_DSD	By Test Result: Negative	113,184	221,986	Redacted
HTC_TST_DSD	By Test Result: Positive	4,716	9,249	Redacted
HTC_TST_DSD	Sum of Test Result disaggregates	117,900	231,235	Redacted
HTC_TST_DSD	Age/sex: <1 Male	0	0	Redacted
HTC_TST_DSD	Age/sex: 1-4 Male	4,127	8,093	Redacted
HTC_TST_DSD	Age/sex: 5-9 Male	1,769	3,469	Redacted
HTC_TST_DSD	Age/sex: 10-14 Male	2,947	5,781	Redacted

HTC_TST_DSD	Age/sex: 15-19 Male	5,895	11,562	Redacted
HTC_TST_DSD	Age/sex: 20-24 Male	14,738	28,904	Redacted
HTC_TST_DSD	Age/sex: 25-49 Male	23,580	46,247	Redacted
HTC_TST_DSD	Age/sex: 50+ Male	5,894	11,561	Redacted
HTC_TST_DSD	Age/sex: <1 Female	0	0	Redacted
HTC_TST_DSD	Age/sex: 1-4 Female	4,127	8,093	Redacted
HTC_TST_DSD	Age/sex: 5-9 Female	1,769	3,469	Redacted
HTC_TST_DSD	Age/sex: 10-14 Female	2,947	5,781	Redacted
HTC_TST_DSD	Age/sex: 15-19 Female	5,895	11,562	Redacted
HTC_TST_DSD	Age/sex: 20-24 Female	14,738	28,904	Redacted
HTC_TST_DSD	Age/sex: 25-49 Female	23,580	46,247	Redacted
HTC_TST_DSD	Age/sex: 50+ Female	5,894	11,562	Redacted
HTC_TST_DSD	Sum of Age/Sex disaggregates	117,900	231,235	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	8,843	17,343	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	50,107	98,274	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	8,843	17,343	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	50,107	98,275	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	17,686	34,686	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	100,214	196,549	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	117,900	231,235	Redacted
HTC_TST_NGI	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	117,900	231,235	Redacted
HTC_TST_NGI	By Test Result: Negative	113,184	221,986	Redacted
HTC_TST_NGI	By Test Result: Positive	4,716	9,249	Redacted
HTC_TST_NGI	Sum of Test Result disaggregates	117,900	231,235	Redacted
HTC_TST_NGI	Age/sex: <1 Male	0	0	Redacted
HTC_TST_NGI	Age/sex: 1-4 Male	4,127	8,093	Redacted



HTC_TST_NGI	Age/sex: 5-9 Male	1,769	3,469	Redacted
HTC_TST_NGI	Age/sex: 10-14 Male	2,947	5,781	Redacted
HTC_TST_NGI	Age/sex: 15-19 Male	5,895	11,562	Redacted
HTC_TST_NGI	Age/sex: 20-24 Male	14,738	28,904	Redacted
HTC_TST_NGI	Age/sex: 25-49 Male	23,580	46,247	Redacted
HTC_TST_NGI	Age/sex: 50+ Male	5,894	11,561	Redacted
HTC_TST_NGI	Age/sex: <1 Female	0	0	Redacted
HTC_TST_NGI	Age/sex: 1-4 Female	4,127	8,093	Redacted
HTC_TST_NGI	Age/sex: 5-9 Female	1,769	3,469	Redacted
HTC_TST_NGI	Age/sex: 10-14 Female	2,947	5,781	Redacted
HTC_TST_NGI	Age/sex: 15-19 Female	5,895	11,562	Redacted
HTC_TST_NGI	Age/sex: 20-24 Female	14,738	28,904	Redacted
HTC_TST_NGI	Age/sex: 25-49 Female	23,580	46,247	Redacted
HTC_TST_NGI	Age/sex: 50+ Female	5,894	11,562	Redacted
HTC_TST_NGI	Sum of Age/Sex disaggregates	117,900	231,235	Redacted
HTC_TST_NGI	Aggregated Age/sex: <15 Male	8,843	17,343	Redacted
HTC_TST_NGI	Aggregated Age/sex: 15+ Male	50,107	98,274	Redacted
HTC_TST_NGI	Aggregated Age/sex: <15 Female	8,843	17,343	Redacted
HTC_TST_NGI	Aggregated Age/sex: 15+ Female	50,107	98,275	Redacted
HTC_TST_NGI	Sum of Aggregated Age/Sex <15	17,686	34,686	Redacted
HTC_TST_NGI	Sum of Aggregated Age/Sex 15+	100,214	196,549	Redacted
HTC_TST_NGI	Sum of Aggregated Age/Sex disaggregates	117,900	231,235	Redacted
C2.1.D_DSD	Number of HIV-positive individuals receiving a minimum of one clinical service	33,549	36,672	Redacted
C2.1.D_DSD	By Age/Sex: <15 Female	1,510	1,654	Redacted
C2.1.D_DSD	By Age/Sex: <15 Male	1,510	1,654	Redacted
C2.1.D_DSD	By Age/Sex: 15+ Female	20,149	22,020	Redacted
C2.1.D_DSD	By Age/Sex: 15+ Male	10,380	11,344	Redacted
C2.1.D_DSD	Sum of Age/Sex disaggregates	33,549	36,672	Redacted
C2.1.D_DSD	By Age: <15	3,020	3,308	Redacted

C2.1.D_DSD	By Age: 15+	30,529	33,364	Redacted
C2.1.D_DSD	Sum of Age disaggregates	33,549	36,672	Redacted
C2.1.D_DSD	By Sex: Female	21,659	23,674	Redacted
C2.1.D_DSD	By Sex: Male	11,890	12,998	Redacted
C2.1.D_DSD	Sum of Sex disaggregates	33,549	36,672	Redacted
C2.1.D_NGI	Number of HIV-positive individuals receiving a minimum of one clinical service	33,549	36,672	Redacted
C2.1.D_NGI	By Age/Sex: <15 Female	1,510	1,654	Redacted
C2.1.D_NGI	By Age/Sex: <15 Male	1,510	1,654	Redacted
C2.1.D_NGI	By Age/Sex: 15+ Female	20,149	22,020	Redacted
C2.1.D_NGI	By Age/Sex: 15+ Male	10,380	11,344	Redacted
C2.1.D_NGI	Sum of Age/Sex disaggregates	33,549	36,672	Redacted
C2.1.D_NGI	By Age: <15	3,020	3,308	Redacted
C2.1.D_NGI	By Age: 15+	30,529	33,364	Redacted
C2.1.D_NGI	Sum of Age disaggregates	33,549	36,672	Redacted
C2.1.D_NGI	By Sex: Female	21,659	23,674	Redacted
C2.1.D_NGI	By Sex: Male	11,890	12,998	Redacted
C2.1.D_NGI	Sum of Sex disaggregates	33,549	36,672	Redacted
C2.4.D_DSD	Number of HIV-positive patients who were screened for TB in HIV care or treatment setting	30,194	34,838	Redacted
C2.4.D_DSD	Number of HIV-positive individuals receiving a minimum of one clinical service	33,549	36,672	Redacted
C2.5.D_DSD	Number of HIV-positive patients in HIV care who started TB treatment	604	697	Redacted
C2.5.D_DSD	Number of HIV-positive individuals receiving a minimum of one clinical service	33,549	36,672	Redacted
CARE_CURR_DS D	Number of HIV positive adults and children who received at least one of the following during the reporting	31,871	34,838	Redacted



	period: clinical assessment (WHO staging) OR CD4 count OR viral load			
CARE_CURR_DS D	Age/sex: <1 Male	50	54	Redacted
CARE_CURR_DS D	Age/sex: 1-4 Male	345	378	Redacted
CARE_CURR_DS D	Age/sex: 5-9 Male	582	638	Redacted
CARE_CURR_DS D	Age/sex: 10-14 Male	457	502	Redacted
CARE_CURR_DS D	Age/sex: 15-19 Male	244	267	Redacted
CARE_CURR_DS D	Age/sex: 20-24 Male	453	495	Redacted
CARE_CURR_DS D	Age/sex: 25-49 Male	6,810	7,443	Redacted
CARE_CURR_DS D	Age/sex: 50+ Male	2,354	2,571	Redacted
CARE_CURR_DS D	Age/sex: <1 Female	50	54	Redacted
CARE_CURR_DS D	Age/sex: 1-4 Female	327	359	Redacted
CARE_CURR_DS D	Age/sex: 5-9 Female	602	660	Redacted
CARE_CURR_DS D	Age/sex: 10-14 Female	455	498	Redacted
CARE_CURR_DS D	Age/sex: 15-19 Female	404	441	Redacted
CARE_CURR_DS D	Age/sex: 20-24 Female	1,676	1,831	Redacted
CARE_CURR_DS D	Age/sex: 25-49 Female	14,311	15,640	Redacted
CARE_CURR_DS D	Age/sex: 50+ Female	2,751	3,007	Redacted



CARE_CURR_DS D	Sun of Age/Sex disaggregates	31,871	34,838	Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	1,434	1,572	Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	9,861	10,776	Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	1,434	1,571	Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	19,142	20,919	Redacted
CARE_CURR_DS D	Sum of Aggregated Age/Sex disaggregates	31,871	34,838	Redacted
CARE_NEW_DSD	Number of HIV-infected adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load	6,374	6,335	Redacted
CARE_NEW_DSD	Age/sex: <1 Male	10	10	Redacted
CARE_NEW_DSD	Age/sex: 1-4 Male	69	69	Redacted
CARE_NEW_DSD	Age/sex: 5-9 Male	116	116	Redacted
CARE_NEW_DSD	Age/sex: 10-14 Male	92	91	Redacted
CARE_NEW_DSD	Age/sex: 15-19 Male	42	41	Redacted
CARE_NEW_DSD	Age/sex: 20-24 Male	173	172	Redacted
CARE_NEW_DSD	Age/sex: 25-49 Male	1,475	1,465	Redacted
CARE_NEW_DSD	Age/sex: 50+ Male	282	281	Redacted
CARE_NEW_DSD	Age/sex: <1 Female	10	10	Redacted
CARE_NEW_DSD	Age/sex: 1-4 Female	65	65	Redacted
CARE_NEW_DSD	Age/sex: 5-9 Female	120	120	Redacted
CARE_NEW_DSD	Age/sex: 10-14 Female	92	91	Redacted
CARE_NEW_DSD	Age/sex: 15-19 Female	95	94	Redacted
CARE_NEW_DSD	Age/sex: 20-24 Female	176	175	Redacted
CARE_NEW_DSD	Age/sex: 25-49 Female	2,644	2,627	Redacted



CARE_NEW_DSD	Age/sex: 50+ Female	913	908	Redacted
CARE_NEW_DSD	Sum of Age/sex disaggregates	6,374	6,335	Redacted
CARE_NEW_DSD	Aggregated Age/sex: <15 Male	287	286	Redacted
CARE_NEW_DSD	Aggregated Age/sex: 15+ Male	1,972	1,959	Redacted
CARE_NEW_DSD	Aggregated Age/sex: <15 Female	287	286	Redacted
CARE_NEW_DSD	Aggregated Age/sex: 15+ Female	3,828	3,804	Redacted
CARE_NEW_DSD	Sum of Aggregated Age/sex disaggregates	6,374	6,335	Redacted
CARE_SITE	Number of PEPFAR-supported HIV clinical care sites at which at least 80% of PLHIV received all of the following during the reporting period: 1) clinical assessment (WHO staging) OR CD4 count OR viral load, AND 2) TB screening at last visit, AND 3) if eligible, cotrimoxazole	14	14	Redacted
CARE_SITE	Total number of PEPFAR supported sites providing clinical care services	14	14	Redacted
CARE_SITE	By site support type: Direct Service Delivery (DSD): Number of PEPFAR-supported HIV clinical care sites at which at least 80% of PLHIV received all of the following during the reporting period: 1) clinical assessment (WHO staging) OR CD4 count OR viral load, AND 2) TB screening at last visit, AND 3) if eligible, cotrimoxazole	14	14	Redacted
CARE_SITE	By site support type: Technical Assistance-only (TA): Number of PEPFAR-supported HIV clinical care sites at which at least 80% of PLHIV received all of the following during the reporting period: 1) clinical assessment (WHO staging) OR CD4 count OR viral load, AND 2) TB screening at last visit,	0	0	Redacted



	AND 3) if eligible, cotrimoxazole			
CARE_SITE	Sum of Numerator Site Support Type disaggregates	14	14	Redacted
CARE_SITE	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR supported sites providing clinical care services	14	14	Redacted
CARE_SITE	By site support type: Technical Assistance-only (TA): Total number of PEPFAR supported sites providing clinical care services	0	0	Redacted
CARE_SITE	Sum of Denominator Site Support Type disaggregates	14	14	Redacted
FN_SITE	Number of PEPFAR-supported sites achieving 90% nutrition assessments that result in accurate categorization of malnutrition	13	13	Redacted
FN_SITE	Total number of PEPFAR-supported sites providing nutrition assessment, counseling and support (NACS) services	14	14	Redacted
FN_SITE	By site support type: Direct Service Delivery (DSD): Number of PEPFAR-supported sites achieving 90% nutrition assessments that result in accurate categorization of malnutrition	13	13	Redacted
FN_SITE	By site support type: Technical Assistance-only (TA): Number of PEPFAR-supported sites achieving 90% nutrition assessments that result in accurate categorization of malnutrition	0	0	Redacted
FN_SITE	Sum of Numerator Support Type disaggregates	13	13	Redacted

FN_SITE	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported sites providing nutrition assessment, counseling and support (NACS) services	14	14	Redacted
FN_SITE	By site support type: Technical Assistance-only (TA): Total number of PEPFAR-supported sites providing nutrition assessment, counseling and support (NACS) services	0	0	Redacted
FN_SITE	Sum of Denominator Support Type disaggregates	14	14	Redacted
FN_THER_DSD	Number of clinically malnourished PLHIV who received therapeutic and/or supplementary food during the reporting period.	5,032	5,501	Redacted
FN_THER_DSD	Number of PLHIV who were nutritionally assessed and found to be clinically undernourished.	6,710	7,334	Redacted
FN_THER_DSD	Age: <1	16	18	Redacted
FN_THER_DSD	Age: 1-4	109	119	Redacted
FN_THER_DSD	Age: 5-14	339	371	Redacted
FN_THER_DSD	Age: 15-17	102	110	Redacted
FN_THER_DSD	Age: 18+	4,466	4,883	Redacted
FN_THER_DSD	Sum of Age disaggregates	5,032	5,501	Redacted
FN_THER_DSD	Aggregated Age: <18	566	618	Redacted
FN_THER_DSD	Aggregated Age: 18+	4,466	4,883	Redacted
FN_THER_DSD	Sum of Aggregated Age disaggregates	5,032	5,501	Redacted
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	1,283	1,568	Redacted
TB_ART_DSD	The number of registered new and	1,510	1,742	Redacted



	relapse TB cases with documented HIV-positive status during TB treatment during the reporting period			
TB_ART_DSD	Age: 0-4	32	39	Redacted
TB_ART_DSD	Age: 5-14	86	106	Redacted
TB_ART_DSD	Age: 15+	1,165	1,423	Redacted
TB_ART_DSD	Male	693	847	Redacted
TB_ART_DSD	Female	590	721	Redacted
TB_ART_DSD	Sum of Sex disaggregates	1,283	1,568	Redacted
TB_ART_DSD	Newly tested	770	941	Redacted
TB_ART_DSD	Known HIV-positive	513	627	Redacted
TB_ART_DSD	Sum of Test Status disaggregates	1,283	1,568	Redacted
TB_ART_DSD	Aggregated Age: <15	118	145	Redacted
TB_ART_DSD	Aggregated Age: 15+	1,165	1,423	Redacted
TB_ART_DSD	Sum of Aggregated Age disaggregates	1,283	1,568	Redacted
TB_ARTSITE	The number of PEPFAR-supported TB basic management units at which 80% of registered TB cases who are HIV-positive are on ART, during the reporting period	14	14	Redacted
TB_ARTSITE	The number of PEPFAR-supported TB basic management units	14	14	Redacted
TB_ARTSITE	By site support type: Direct Service Delivery (DSD): The number of PEPFAR-supported TB basic management units at which 80% of registered TB cases who are HIV-positive are on ART, during the reporting period	14	14	Redacted
TB_ARTSITE	By site support type: Technical Assistance-only (TA): The number of PEPFAR-supported TB basic management units at which 80% of registered TB cases who are	0	0	Redacted



	HIV-positive are on ART, during the reporting period			
TB_ARTSITE	Sum of Numerator Site Support Type disaggregates	14	14	Redacted
TB_ARTSITE	By site support type: Direct Service Delivery (DSD): The number of PEPFAR-supported TB basic management units	14	14	Redacted
TB_ARTSITE	By site support type: Technical Assistance-only (TA): The number of PEPFAR-supported TB basic management units	0	0	Redacted
TB_ARTSITE	Sum of Denominator Site Support Type disaggregates	14	14	Redacted
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	952	971	Redacted
PMTCT_EID_DSD	Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT)	1,190	1,214	Redacted
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	714	728	Redacted
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	238	243	Redacted
PMTCT_EID_DSD	Sum of Infant Age disaggregates	952	971	Redacted
PMTCT_EID_DSD	By infants with a positive virologic test result within 12 months of birth	48	49	Redacted
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	24,614	27,976	Redacted
TX_CURR_DSD	Age/Sex: <1 Male	38	44	Redacted
TX_CURR_DSD	Age/Sex: 1-4 Male	259	295	Redacted
TX_CURR_DSD	Age/Sex: 5-14 Male	811	922	Redacted



TX_CURR_DSD	Age/Sex: 15+ Male	7,616	8,909	Redacted
TX_CURR_DSD	Age/Sex: <1 Female	38	44	Redacted
TX_CURR_DSD	Age/Sex: 1-4 Female	259	295	Redacted
TX_CURR_DSD	Age/Sex: 5-14 Female	811	922	Redacted
TX_CURR_DSD	Age/Sex: 15+ Female	14,782	16,545	Redacted
TX_CURR_DSD	Sum of age/sex disaggregates	2,216	2,522	Redacted
TX_CURR_DSD	Percent children with advanced HIV infection receiving antiretroviral therapy (ART) [CURRENT]	73	76	Redacted
TX_CURR_DSD	Percent women and girls with advanced HIV infection receiving antiretroviral therapy (ART) [CURRENT]	73	75	Redacted
TX_CURR_DSD	Aggregated Age/Sex: <1 Male	38	44	Redacted
TX_CURR_DSD	Aggregated Age/Sex: <1 Female	38	44	Redacted
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	1,108	1,261	Redacted
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	7,616	8,909	Redacted
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	1,108	1,261	Redacted
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	14,782	16,545	Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	2,216	2,522	Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	22,398	25,454	Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	24,614	27,976	Redacted
TX_CURR_NGI	Number of adults and children receiving antiretroviral therapy (ART)	24,614	27,976	Redacted
TX_CURR_NGI	Age/Sex: <1 Male	38	44	Redacted
TX_CURR_NGI	Age/Sex: 1-4 Male	259	295	Redacted
TX_CURR_NGI	Age/Sex: 5-14 Male	811	922	Redacted
TX_CURR_NGI	Age/Sex: 15+ Male	7,616	8,909	Redacted
TX_CURR_NGI	Age/Sex: <1 Female	38	44	Redacted
TX_CURR_NGI	Age/Sex: 1-4 Female	259	295	Redacted
TX_CURR_NGI	Age/Sex: 5-14 Female	811	922	Redacted
TX_CURR_NGI	Age/Sex: 15+ Female	14,782	16,545	Redacted



TX_CURR_NGI	Sum of Age/Sex disaggregates	24,614	27,976	Redacted
TX_CURR_NGI	Aggregated Age/Sex: <1 Male	38	44	Redacted
TX_CURR_NGI	Aggregated Age/Sex: <1 Female	38	44	Redacted
TX_CURR_NGI	Aggregated Age/Sex: <15 Male	1,108	1,261	Redacted
TX_CURR_NGI	Aggregated Age/Sex: 15+ Male	7,616	8,909	Redacted
TX_CURR_NGI	Aggregated Age/Sex: <15 Female	1,108	1,261	Redacted
TX_CURR_NGI	Aggregated Age/Sex: 15+ Female	14,782	16,545	Redacted
TX_CURR_NGI	Sum of Aggregated Age/Sex disaggregates	24,614	27,976	Redacted
TX_CURR_NGI	Sum of Aggregated Age/Sex <15	2,216	2,522	Redacted
TX_CURR_NGI	Sum of Aggregated Age/Sex 15+	22,398	25,454	Redacted
TX_DIST	Number of Districts with documented routine supportive supervision visits to 75% of HIV care and treatment sites supported by the District	1	1	Redacted
TX_DIST	Total number of PEPFAR supported District Health Offices	1	1	Redacted
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	4,601	4,540	Redacted
TX_NEW_DSD	By Age/Sex: <1 Male	71	96	Redacted
TX_NEW_DSD	By Age/Sex: 1-4 Male	40	54	Redacted
TX_NEW_DSD	By Age/Sex: 5-9 Male	71	96	Redacted
TX_NEW_DSD	By Age/Sex: 10-14 Male	56	74	Redacted
TX_NEW_DSD	By Age/Sex: 15-19 Male	36	34	Redacted
TX_NEW_DSD	By Age/Sex: 20-24 Male	66	63	Redacted
TX_NEW_DSD	By Age/Sex: 25-49 Male	997	943	Redacted
TX_NEW_DSD	By Age/Sex: 50+ Male	344	326	Redacted
TX_NEW_DSD	By Age/Sex: <1 Female	71	96	Redacted
TX_NEW_DSD	By Age/Sex: 1-4 Female	40	54	Redacted
TX_NEW_DSD	By Age/Sex: 5-9 Female	71	96	Redacted
TX_NEW_DSD	By Age/Sex: 10-14 Female	56	74	Redacted
TX_NEW_DSD	By Age/Sex: 15-19 Female	57	53	Redacted
TX_NEW_DSD	By Age/Sex: 20-24 Female	235	222	Redacted

TX_NEW_DSD	By Age/Sex: 25-49 Female	2,005	1,895	Redacted
TX_NEW_DSD	By Age/Sex: 50+ Female	385	364	Redacted
TX_NEW_DSD	Sum of Age/Sex disaggregates	4,601	4,540	Redacted
TX_NEW_DSD	Aggregated Grouping by Age: <1 Male	71	96	Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	238	320	Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	1,443	1,365	Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <1 Female	71	96	Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	238	320	Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	2,682	2,535	Redacted
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	4,601	4,540	Redacted
TX_NEW_DSD	Pregnancy status	375	382	Redacted
TX_NEW_DSD	Breastfeeding status	42	42	Redacted
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	3,100	3,911	Redacted
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	3,647	4,601	Redacted
TX_RET_DSD	Age: 0-4 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	77	97	Redacted
TX_RET_DSD	Age: 5-14 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after	209	264	Redacted



	initiating ART)			
TX_RET_DSD	Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	2,814	3,550	Redacted
TX_RET_DSD	Age: 0-4 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	90	114	Redacted
TX_RET_DSD	Age: 5-14 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	246	310	Redacted
TX_RET_DSD	Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	3,311	4,177	Redacted
TX_RET_DSD	Aggregated Age: <15 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	286	360	Redacted
TX_RET_DSD	Aggregated Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	2,814	3,550	Redacted
TX_RET_DSD	Aggregated Age: <15 (Denominator: Total number of adults and children	336	424	Redacted

	who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)			
TX_RET_DSD	Aggregated Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	3,311	4,177	Redacted
TX_RET_DSD	Pregnancy and breastfeeding status (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	379	758	Redacted
TX_RET_DSD	Pregnancy and breastfeeding status (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	446	892	Redacted
TX_SITE	Number of PEPFAR-supported ART sites with a retention rate of 75% or greater for patients 12 months after ART initiation	10	10	Redacted
TX_SITE	Total number of PEPFAR-supported ART sites	14	14	Redacted
TX_SITE	By support type: Direct Service Delivery (DSD): Number of PEPFAR-supported ART sites with a retention rate of 75% or greater for patients 12 months after ART initiation	10	10	Redacted
TX_SITE	By support type: Technical Assistance	0	0	Redacted



	(TA-only): Number of PEPFAR-supported ART sites with a retention rate of 75% or greater for patients 12 months after ART initiation			
TX_SITE	Sum of Numerator Site Support Type disaggregates	10	10	Redacted
TX_SITE	By support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported ART sites	14	14	Redacted
TX_SITE	By support type: Technical Assistance (TA-only): Total number of PEPFAR-supported ART sites	0	0	Redacted
TX_SITE	Sum of Denominator Site Support Type disaggregates	14	14	Redacted
LAB_CAP_DSD	Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests	7	7	Redacted
LAB_CAP_DSD	By site support type: Direct Service Delivery (DSD)	7	7	Redacted
LAB_CAP_DSD	Sum of Site Support Type disaggregates	7	7	Redacted
FPINT_SITE_DSD	Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	11	11	Redacted
FPINT_SITE_DSD	Total number of PEPFAR-supported HIV service delivery points: PMTCT, Care and Treatment	14	14	Redacted
FPINT_SITE_DSD	By site support type: Direct Service Delivery (DSD): Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	11	11	Redacted
FPINT_SITE_DSD	By site support type: Technical	0	0	Redacted



	Assistance-only (TA): Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services			
FPINT_SITE_DSD	Sum of Numerator Site Support Type disaggregates	11	11	Redacted
FPINT_SITE_DSD	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported HIV service delivery points	14	14	Redacted
FPINT_SITE_DSD	By site support type: Technical Assistance-only (TA): Total number of PEPFAR-supported HIV service delivery points	0	0	Redacted
FPINT_SITE_DSD	Sum of Denominator Site Support Type disaggregates	14	14	Redacted
FPINT_SITE_DSD	Service delivery type: Clinical	11	11	Redacted
FPINT_SITE_DSD	Sum of Service Delivery Type disaggregates	11	11	Redacted
QI_SITE	Number of PEPFAR-supported clinical service sites with a quality improvement activity completed that addresses clinical HIV programs and has documented process results in the last 6 months	11	11	Redacted
QI_SITE	Total number of PEPFAR-supported sites for any HIV clinical service including HIV Care, HIV Treatment, TB care, PMTCT, VMMC, and HTC	14	14	Redacted
QI_SITE	By site support type: Direct Service Delivery (DSD): Number of PEPFAR-supported clinical service sites with a quality improvement activity completed that addresses clinical HIV	11	11	Redacted



	programs and has documented results in the last 6 months			
QI_SITE	By site support type: Technical Assistance-only (TA): Number of PEPFAR-supported clinical service sites with a quality improvement activity completed that addresses clinical HIV programs and has documented results in the last 6 months	0	0	Redacted
QI_SITE	Sum of Numerator Site Support Type disaggregates	11	11	Redacted
QI_SITE	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported sites for any HIV clinical service including HIV Care, HIV Treatment, TB care, PMTCT, VMMC, HTC	14	14	Redacted
QI_SITE	By site support type: Technical Assistance-only (TA): Total number of PEPFAR-supported sites for any HIV clinical service including HIV Care, HIV Treatment, TB care, PMTCT, VMMC, and HTC	0	0	Redacted
QI_SITE	Sum of Denominator Site Support Type disaggregates	14	14	Redacted
TB_SCREEN_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period	28,684	33,096	Redacted
TB_SCREEN_DSD	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	31,871	34,838	Redacted
TB_SCREEN_DSD	Age: <1	91	105	Redacted



TB_SCREEN_DSD	Age: 1-4	619	714	Redacted
TB_SCREEN_DSD	Age: 5-9	1,092	1,260	Redacted
TB_SCREEN_DSD	Age: 10-14	841	971	Redacted
TB_SCREEN_DSD	Age: 15-19	580	669	Redacted
TB_SCREEN_DSD	Age: 20-24	1,934	2,231	Redacted
TB_SCREEN_DSD	Age: 25-49	18,995	21,917	Redacted
TB_SCREEN_DSD	Age: 50+	4,532	5,229	Redacted
TB_SCREEN_DSD	Sum of Age disaggregates	3,223	3,719	Redacted
TB_SCREEN_DSD	Aggregated Age - USE WITH HQ PERMISSION ONLY: <15	2,643	3,050	Redacted
TB_SCREEN_DSD	Aggregated Age - USE WITH HQ PERMISSION ONLY: 15+	26,041	30,046	Redacted
TB_SCREEN_DSD	Sum of Aggregated Age disaggregates	28,684	33,096	Redacted
TB_SCREEN_DSD	Sex: Male	10,175	11,741	Redacted
TB_SCREEN_DSD	Sex: Female	18,509	21,355	Redacted
TB_SCREEN_DSD	Sum of Sex disaggregates	28,684	33,096	Redacted

Implementing Mechanism Details

Mechanism ID: 12637	Mechanism Name: Strengthening Strategic Information in Kenya
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Futures Group	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: No	
G2G: No	Managing Agency:

Total All Funding Sources: 1,950,000	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 50,000	
FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount
GHP-State	1,950,000

Approved



Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

(No data provided.)

Budget Code Information

Mechanism ID:	12637		
Mechanism Name:	Strengthening Strategic Information in Kenya		
Prime Partner Name:	Futures Group		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	1,950,000	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 12612	Mechanism Name: HIVQUAL
Funding Agency: HHS/HRSA	Procurement Type: Cooperative Agreement
Prime Partner Name: New York AIDS Institute	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: No	
G2G: No	Managing Agency:

Approved



Total All Funding Sources: 12,400	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 0	
FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount
GHP-State	12,400

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

(No data provided.)

Budget Code Information

Mechanism ID: 12612			
Mechanism Name: HIVQUAL			
Prime Partner Name: New York AIDS Institute			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	12,400	

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 12605	Mechanism Name: Clinical Services
----------------------------	--



Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Care International	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: No	
G2G: No	Managing Agency:

Total All Funding Sources: 4,418,170	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 64,940	
FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount
GHP-State	4,418,170

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

Human Resources for Health	441,116
Gender: GBV	98,241
Focus Area:	Post GBV Care
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Gender: Gender Equality	98,241
Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation



Key Issues

- Malaria (PMI)
- Child Survival Activities
- Safe Motherhood
- TB
- Family Planning

Budget Code Information

Mechanism ID: 12605			
Mechanism Name: Clinical Services			
Prime Partner Name: Care International			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	195,494	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	208,690	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	66,607	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	570,366	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	993,308	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	2,235,060	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Treatment	PDX	148,645	0
-----------	-----	---------	---

Implementing Mechanism Indicator Information

Indicator Number	Label	2014	2015	Planning Budget Targets
SITE_SUPP	Number of unique sites supported by PEPFAR	124	124	Redacted
SITE_SUPP	By program area/support type: HTC Direct Service Delivery (DSD)	124	124	Redacted
SITE_SUPP	By program area/support type: Treatment Direct Service Delivery (DSD)	124	124	Redacted
SITE_SUPP	By program area/support type: Care and Support Direct Service Delivery (DSD)	124	124	Redacted
SITE_SUPP	By program area/support type: Food and Nutrition Direct Service Delivery (DSD)	124	124	Redacted
SITE_SUPP	By program area/support type: PMTCT Direct Service Delivery (DSD)	124	124	Redacted
SITE_SUPP	By program area/support type: TB/HIV Direct Service Delivery (DSD)	124	124	Redacted
SITE_SUPP	By program area/support type: PHDP/Family Planning & Integration Direct Service Delivery (DSD)	124	124	Redacted
SITE_SUPP	By program area/support type: Lab Direct Service Delivery (DSD)	124	124	Redacted
PMTCT_ARV_DS D	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT)	2,371	2,419	Redacted



	during pregnancy and delivery			
PMTCT_ARV_DS D	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	2,371	2,419	Redacted
PMTCT_ARV_DS D	Life-long ART (including Option B+)	1,779	1,814	Redacted
PMTCT_ARV_DS D	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	830	846	Redacted
PMTCT_ARV_DS D	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	949	968	Redacted
PMTCT_ARV_DS D	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)	0	0	Redacted
PMTCT_ARV_DS D	Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)	592	605	Redacted
PMTCT_ARV_DS D	Single-dose nevirapine (with or without tail)	0	0	Redacted
PMTCT_ARV_DS D	Sum of Regimen Type disaggregates	2,371	2,419	Redacted
PMTCT_ARV_DS D	Sum of New and Current disaggregates	1,779	1,814	Redacted
PMTCT_ARV_NGI	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	2,371	2,419	Redacted
PMTCT_ARV_NGI	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	2,371	2,419	Redacted
PMTCT_ARV_NGI	Life-long ART (including Option B+)	1,779	1,814	Redacted
PMTCT_ARV_NGI	Sub-Disag of Life-long ART: Newly initiated on treatment during the current	830	846	Redacted



	pregnancy			
PMTCT_ARV_NGI	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	949	968	Redacted
PMTCT_ARV_NGI	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)	0	0	Redacted
PMTCT_ARV_NGI	Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)	592	605	Redacted
PMTCT_ARV_NGI	Single-dose nevirapine (with or without tail)	0	0	Redacted
PMTCT_ARV_NGI	Sum of Regimen disaggregates	2,371	2,419	Redacted
PMTCT_ARV_NGI	Sum of New and Current disaggregates	1,779	1,814	Redacted
PMTCT_SITE	Number of PEPFAR-supported sites achieving 90% ARV or ART coverage for HIV+ pregnant women	124	124	Redacted
PMTCT_SITE	Total number of PEPFAR supported sites providing PMTCT services (HTC and ARV or ART services)	124	124	Redacted
PMTCT_SITE	By site support type: Direct Service Delivery (DSD): Number of PEPFAR-supported sites achieving 90% ARV or ART coverage for HIV+ pregnant women	124	124	Redacted
PMTCT_SITE	By site support type: Technical Assistance-only (TA): Number of PEPFAR-supported sites achieving 90% ARV or ART coverage for HIV+ pregnant women	0	0	Redacted
PMTCT_SITE	Sum of Numerator Support Type disaggregates	124	124	Redacted
PMTCT_SITE	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR supported sites providing	124	124	Redacted



	PMTCT services (HTC and ARV or ART services)			
PMTCT_SITE	Sum of Denominator Support Type disaggregates	124	124	Redacted
PMTCT_STAT_DS D	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	51,455	50,641	Redacted
PMTCT_STAT_DS D	Number of new ANC and L&D clients	51,455	50,641	Redacted
PMTCT_STAT_DS D	By: Known positives at entry	1,114	1,137	Redacted
PMTCT_STAT_DS D	By: Number of new positives identified	1,257	1,282	Redacted
PMTCT_STAT_DS D	Sum of Positives Status disaggregates	2,371	2,419	Redacted
PMTCT_STAT_NG I	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	51,455	50,641	Redacted
PMTCT_STAT_NG I	Number of new ANC and L&D clients	51,455	50,641	Redacted
PMTCT_STAT_NG I	By: Known positives at entry	1,114	1,137	Redacted
PMTCT_STAT_NG I	By: Number of new positives identified	1,257	1,282	Redacted
PMTCT_STAT_NG I	Sum of Positives Status disaggregates	2,371	2,419	Redacted
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	99,000	190,122	Redacted
HTC_TST_DSD	By Test Result: Negative	95,040	182,517	Redacted
HTC_TST_DSD	By Test Result: Positive	3,960	7,605	Redacted
HTC_TST_DSD	Sum of Test Result disaggregates	99,000	190,122	Redacted



HTC_TST_DSD	Age/sex: <1 Male	0	0	Redacted
HTC_TST_DSD	Age/sex: 1-4 Male	3,465	6,654	Redacted
HTC_TST_DSD	Age/sex: 5-9 Male	1,485	2,852	Redacted
HTC_TST_DSD	Age/sex: 10-14 Male	2,475	4,753	Redacted
HTC_TST_DSD	Age/sex: 15-19 Male	4,950	9,507	Redacted
HTC_TST_DSD	Age/sex: 20-24 Male	12,375	23,765	Redacted
HTC_TST_DSD	Age/sex: 25-49 Male	19,800	38,024	Redacted
HTC_TST_DSD	Age/sex: 50+ Male	4,950	9,506	Redacted
HTC_TST_DSD	Age/sex: <1 Female	0	0	Redacted
HTC_TST_DSD	Age/sex: 1-4 Female	3,465	6,654	Redacted
HTC_TST_DSD	Age/sex: 5-9 Female	1,485	2,852	Redacted
HTC_TST_DSD	Age/sex: 10-14 Female	2,475	4,753	Redacted
HTC_TST_DSD	Age/sex: 15-19 Female	4,950	9,507	Redacted
HTC_TST_DSD	Age/sex: 20-24 Female	12,375	23,765	Redacted
HTC_TST_DSD	Age/sex: 25-49 Female	19,800	38,024	Redacted
HTC_TST_DSD	Age/sex: 50+ Female	4,950	9,506	Redacted
HTC_TST_DSD	Sum of Age/Sex disaggregates	99,000	190,122	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	7,425	14,259	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	42,075	80,802	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	7,425	14,259	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	42,075	80,802	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	14,850	28,518	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	84,150	161,604	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	99,000	190,122	Redacted
HTC_TST_NGI	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	99,000	190,122	Redacted
HTC_TST_NGI	By Test Result: Negative	95,040	182,517	Redacted

HTC_TST_NGI	By Test Result: Positive	3,960	7,605	Redacted
HTC_TST_NGI	Sum of Test Result disaggregates	99,000	190,122	Redacted
HTC_TST_NGI	Age/sex: <1 Male	0	0	Redacted
HTC_TST_NGI	Age/sex: 1-4 Male	3,465	6,654	Redacted
HTC_TST_NGI	Age/sex: 5-9 Male	1,485	2,852	Redacted
HTC_TST_NGI	Age/sex: 10-14 Male	2,475	4,753	Redacted
HTC_TST_NGI	Age/sex: 15-19 Male	4,950	9,507	Redacted
HTC_TST_NGI	Age/sex: 20-24 Male	12,375	23,765	Redacted
HTC_TST_NGI	Age/sex: 25-49 Male	19,800	38,024	Redacted
HTC_TST_NGI	Age/sex: 50+ Male	4,950	9,506	Redacted
HTC_TST_NGI	Age/sex: <1 Female	0	0	Redacted
HTC_TST_NGI	Age/sex: 1-4 Female	3,465	6,654	Redacted
HTC_TST_NGI	Age/sex: 5-9 Female	1,485	2,852	Redacted
HTC_TST_NGI	Age/sex: 10-14 Female	2,475	4,753	Redacted
HTC_TST_NGI	Age/sex: 15-19 Female	4,950	9,507	Redacted
HTC_TST_NGI	Age/sex: 20-24 Female	12,375	23,765	Redacted
HTC_TST_NGI	Age/sex: 25-49 Female	19,800	38,024	Redacted
HTC_TST_NGI	Age/sex: 50+ Female	4,950	9,506	Redacted
HTC_TST_NGI	Sum of Age/Sex disaggregates	99,000	190,122	Redacted
HTC_TST_NGI	Aggregated Age/sex: <15 Male	7,425	14,259	Redacted
HTC_TST_NGI	Aggregated Age/sex: 15+ Male	42,075	80,802	Redacted
HTC_TST_NGI	Aggregated Age/sex: <15 Female	7,425	14,259	Redacted
HTC_TST_NGI	Aggregated Age/sex: 15+ Female	42,075	80,802	Redacted
HTC_TST_NGI	Sum of Aggregated Age/Sex <15	14,850	28,518	Redacted
HTC_TST_NGI	Sum of Aggregated Age/Sex 15+	84,150	161,604	Redacted
HTC_TST_NGI	Sum of Aggregated Age/Sex disaggregates	99,000	190,122	Redacted
C2.1.D_DSD	Number of HIV-positive individuals receiving a minimum of one clinical service	14,094	15,406	Redacted
C2.1.D_DSD	By Age/Sex: <15 Female	634	695	Redacted
C2.1.D_DSD	By Age/Sex: <15 Male	634	695	Redacted



C2.1.D_DSD	By Age/Sex: 15+ Female	8,465	9,251	Redacted
C2.1.D_DSD	By Age/Sex: 15+ Male	4,361	4,765	Redacted
C2.1.D_DSD	Sum of Age/Sex disaggregates	14,094	15,406	Redacted
C2.1.D_DSD	By Age: <15	1,268	1,390	Redacted
C2.1.D_DSD	By Age: 15+	12,826	14,016	Redacted
C2.1.D_DSD	Sum of Age disaggregates	14,094	15,406	Redacted
C2.1.D_DSD	By Sex: Female	9,099	9,946	Redacted
C2.1.D_DSD	By Sex: Male	4,995	5,460	Redacted
C2.1.D_DSD	Sum of Sex disaggregates	14,094	15,406	Redacted
C2.1.D_NGI	Number of HIV-positive individuals receiving a minimum of one clinical service	14,094	15,406	Redacted
C2.1.D_NGI	By Age/Sex: <15 Female	634	695	Redacted
C2.1.D_NGI	By Age/Sex: <15 Male	634	695	Redacted
C2.1.D_NGI	By Age/Sex: 15+ Female	8,465	9,251	Redacted
C2.1.D_NGI	By Age/Sex: 15+ Male	4,361	4,765	Redacted
C2.1.D_NGI	Sum of Age/Sex disaggregates	14,094	15,406	Redacted
C2.1.D_NGI	By Age: <15	1,268	1,390	Redacted
C2.1.D_NGI	By Age: 15+	12,826	14,016	Redacted
C2.1.D_NGI	Sum of Age disaggregates	14,094	15,406	Redacted
C2.1.D_NGI	By Sex: Female	9,099	9,946	Redacted
C2.1.D_NGI	By Sex: Male	4,995	5,460	Redacted
C2.1.D_NGI	Sum of Sex disaggregates	14,094	15,406	Redacted
C2.4.D_DSD	Number of HIV-positive patients who were screened for TB in HIV care or treatment setting	12,684	14,635	Redacted
C2.4.D_DSD	Number of HIV-positive individuals receiving a minimum of one clinical service	14,094	15,406	Redacted
C2.5.D_DSD	Number of HIV-positive patients in HIV care who started TB treatment	254	293	Redacted
C2.5.D_DSD	Number of HIV-positive individuals receiving a minimum of one clinical	14,094	15,406	Redacted



	service			
CARE_CURR_DS D	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	13,389	14,635	Redacted
CARE_CURR_DS D	Age/sex: <1 Male	21	23	Redacted
CARE_CURR_DS D	Age/sex: 1-4 Male	145	159	Redacted
CARE_CURR_DS D	Age/sex: 5-9 Male	245	268	Redacted
CARE_CURR_DS D	Age/sex: 10-14 Male	192	210	Redacted
CARE_CURR_DS D	Age/sex: 15-19 Male	103	112	Redacted
CARE_CURR_DS D	Age/sex: 20-24 Male	190	208	Redacted
CARE_CURR_DS D	Age/sex: 25-49 Male	2,861	3,127	Redacted
CARE_CURR_DS D	Age/sex: 50+ Male	989	1,080	Redacted
CARE_CURR_DS D	Age/sex: <1 Female	21	23	Redacted
CARE_CURR_DS D	Age/sex: 1-4 Female	138	151	Redacted
CARE_CURR_DS D	Age/sex: 5-9 Female	253	277	Redacted
CARE_CURR_DS D	Age/sex: 10-14 Female	191	209	Redacted
CARE_CURR_DS D	Age/sex: 15-19 Female	170	185	Redacted
CARE_CURR_DS D	Age/sex: 20-24 Female	704	769	Redacted



CARE_CURR_DS D	Age/sex: 25-49 Female	6,012	6,570	Redacted
CARE_CURR_DS D	Age/sex: 50+ Female	1,154	1,264	Redacted
CARE_CURR_DS D	Sun of Age/Sex disaggregates	13,389	14,635	Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	603	660	Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	4,143	4,527	Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	603	660	Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	8,040	8,788	Redacted
CARE_CURR_DS D	Sum of Aggregated Age/Sex disaggregates	13,389	14,635	Redacted
CARE_NEW_DSD	Number of HIV-infected adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load	2,678	2,661	Redacted
CARE_NEW_DSD	Age/sex: <1 Male	4	4	Redacted
CARE_NEW_DSD	Age/sex: 1-4 Male	29	29	Redacted
CARE_NEW_DSD	Age/sex: 5-9 Male	49	49	Redacted
CARE_NEW_DSD	Age/sex: 10-14 Male	39	38	Redacted
CARE_NEW_DSD	Age/sex: 15-19 Male	17	18	Redacted
CARE_NEW_DSD	Age/sex: 20-24 Male	73	72	Redacted
CARE_NEW_DSD	Age/sex: 25-49 Male	619	615	Redacted
CARE_NEW_DSD	Age/sex: 50+ Male	119	118	Redacted
CARE_NEW_DSD	Age/sex: <1 Female	4	4	Redacted
CARE_NEW_DSD	Age/sex: 1-4 Female	28	29	Redacted
CARE_NEW_DSD	Age/sex: 5-9 Female	51	49	Redacted
CARE_NEW_DSD	Age/sex: 10-14 Female	38	38	Redacted



CARE_NEW_DSD	Age/sex: 15-19 Female	40	40	Redacted
CARE_NEW_DSD	Age/sex: 20-24 Female	74	73	Redacted
CARE_NEW_DSD	Age/sex: 25-49 Female	1,111	1,104	Redacted
CARE_NEW_DSD	Age/sex: 50+ Female	383	381	Redacted
CARE_NEW_DSD	Sum of Age/sex disaggregates	2,678	2,661	Redacted
CARE_NEW_DSD	Aggregated Age/sex: <15 Male	121	120	Redacted
CARE_NEW_DSD	Aggregated Age/sex: 15+ Male	828	823	Redacted
CARE_NEW_DSD	Aggregated Age/sex: <15 Female	121	120	Redacted
CARE_NEW_DSD	Aggregated Age/sex: 15+ Female	1,608	1,598	Redacted
CARE_NEW_DSD	Sum of Aggregated Age/sex disaggregates	2,678	2,661	Redacted
CARE_SITE	Number of PEPFAR-supported HIV clinical care sites at which at least 80% of PLHIV received all of the following during the reporting period: 1) clinical assessment (WHO staging) OR CD4 count OR viral load, AND 2) TB screening at last visit, AND 3) if eligible, cotrimoxazole	124	124	Redacted
CARE_SITE	Total number of PEPFAR supported sites providing clinical care services	124	124	Redacted
CARE_SITE	By site support type: Direct Service Delivery (DSD): Number of PEPFAR-supported HIV clinical care sites at which at least 80% of PLHIV received all of the following during the reporting period: 1) clinical assessment (WHO staging) OR CD4 count OR viral load, AND 2) TB screening at last visit, AND 3) if eligible, cotrimoxazole	124	124	Redacted
CARE_SITE	By site support type: Technical Assistance-only (TA): Number of PEPFAR-supported HIV clinical care sites at which at least 80% of PLHIV received all of the following during the	0	0	Redacted



	reporting period: 1) clinical assessment (WHO staging) OR CD4 count OR viral load, AND 2) TB screening at last visit, AND 3) if eligible, cotrimoxazole			
CARE_SITE	Sum of Numerator Site Support Type disaggregates	124	124	Redacted
CARE_SITE	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR supported sites providing clinical care services	124	124	Redacted
CARE_SITE	Sum of Denominator Site Support Type disaggregates	124	124	Redacted
FN_SITE	Number of PEPFAR-supported sites achieving 90% nutrition assessments that result in accurate categorization of malnutrition	112	112	Redacted
FN_SITE	Total number of PEPFAR-supported sites providing nutrition assessment, counseling and support (NACS) services	124	124	Redacted
FN_SITE	By site support type: Direct Service Delivery (DSD): Number of PEPFAR-supported sites achieving 90% nutrition assessments that result in accurate categorization of malnutrition	112	112	Redacted
FN_SITE	By site support type: Technical Assistance-only (TA): Number of PEPFAR-supported sites achieving 90% nutrition assessments that result in accurate categorization of malnutrition	0	0	Redacted
FN_SITE	Sum of Numerator Support Type disaggregates	112	112	Redacted
FN_SITE	By site support type: Direct Service	124	124	Redacted



	Delivery (DSD): Total number of PEPFAR-supported sites providing nutrition assessment, counseling and support (NACS) services			
FN_SITE	Sum of Denominator Support Type disaggregates	124	124	Redacted
FN_THER_DSD	Number of clinically malnourished PLHIV who received therapeutic and/or supplementary food during the reporting period.	2,114	2,311	Redacted
FN_THER_DSD	Number of PLHIV who were nutritionally assessed and found to be clinically undernourished.	2,819	3,081	Redacted
FN_THER_DSD	Age: <1	7	7	Redacted
FN_THER_DSD	Age: 1-4	46	50	Redacted
FN_THER_DSD	Age: 5-14	142	156	Redacted
FN_THER_DSD	Age: 15-17	43	47	Redacted
FN_THER_DSD	Age: 18+	1,876	2,051	Redacted
FN_THER_DSD	Sum of Age disaggregates	2,114	2,311	Redacted
FN_THER_DSD	Aggregated Age: <18	238	260	Redacted
FN_THER_DSD	Aggregated Age: 18+	1,876	2,051	Redacted
FN_THER_DSD	Sum of Aggregated Age disaggregates	2,114	2,311	Redacted
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	539	659	Redacted
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	634	732	Redacted
TB_ART_DSD	Age: 0-4	13	16	Redacted
TB_ART_DSD	Age: 5-14	37	45	Redacted
TB_ART_DSD	Age: 15+	489	598	Redacted

TB_ART_DSD	Male	291	356	Redacted
TB_ART_DSD	Female	248	303	Redacted
TB_ART_DSD	Sum of Sex disaggregates	539	659	Redacted
TB_ART_DSD	Newly tested	323	395	Redacted
TB_ART_DSD	Known HIV-positive	216	264	Redacted
TB_ART_DSD	Sum of Test Status disaggregates	539	659	Redacted
TB_ART_DSD	Aggregated Age: <15	50	61	Redacted
TB_ART_DSD	Aggregated Age: 15+	489	598	Redacted
TB_ART_DSD	Sum of Aggregated Age disaggregates	539	659	Redacted
TB_ARTSITE	The number of PEPFAR-supported TB basic management units at which 80% of registered TB cases who are HIV-positive are on ART, during the reporting period	124	124	Redacted
TB_ARTSITE	The number of PEPFAR-supported TB basic management units	124	124	Redacted
TB_ARTSITE	By site support type: Direct Service Delivery (DSD): The number of PEPFAR-supported TB basic management units at which 80% of registered TB cases who are HIV-positive are on ART, during the reporting period	124	124	Redacted
TB_ARTSITE	By site support type: Technical Assistance-only (TA): The number of PEPFAR-supported TB basic management units at which 80% of registered TB cases who are HIV-positive are on ART, during the reporting period	0	0	Redacted
TB_ARTSITE	Sum of Numerator Site Support Type disaggregates	124	124	Redacted
TB_ARTSITE	By site support type: Direct Service Delivery (DSD): The number of	124	124	Redacted

	PEPFAR-supported TB basic management units			
TB_ARTSITE	Sum of Denominator Site Support Type disaggregates	124	124	Redacted
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	1,897	1,935	Redacted
PMTCT_EID_DSD	Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT)	2,371	2,419	Redacted
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	1,423	1,451	Redacted
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	474	484	Redacted
PMTCT_EID_DSD	Sum of Infant Age disaggregates	1,897	1,935	Redacted
PMTCT_EID_DSD	By infants with a positive virologic test result within 12 months of birth	95	97	Redacted
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	13,193	14,995	Redacted
TX_CURR_DSD	Age/Sex: <1 Male	21	23	Redacted
TX_CURR_DSD	Age/Sex: 1-4 Male	139	158	Redacted
TX_CURR_DSD	Age/Sex: 5-14 Male	434	495	Redacted
TX_CURR_DSD	Age/Sex: 15+ Male	4,082	4,775	Redacted
TX_CURR_DSD	Age/Sex: <1 Female	21	23	Redacted
TX_CURR_DSD	Age/Sex: 1-4 Female	139	158	Redacted
TX_CURR_DSD	Age/Sex: 5-14 Female	434	495	Redacted
TX_CURR_DSD	Age/Sex: 15+ Female	7,923	8,868	Redacted
TX_CURR_DSD	Sum of age/sex disaggregates	1,188	1,352	Redacted
TX_CURR_DSD	Percent children with advanced HIV infection receiving antiretroviral therapy (ART) [CURRENT]	1	1	Redacted
TX_CURR_DSD	Percent women and girls with	1	1	Redacted



	advanced HIV infection receiving antiretroviral therapy (ART) [CURRENT]			
TX_CURR_DSD	Aggregated Age/Sex: <1 Male	21	23	Redacted
TX_CURR_DSD	Aggregated Age/Sex: <1 Female	21	23	Redacted
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	594	676	Redacted
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	4,082	4,775	Redacted
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	594	676	Redacted
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	7,923	8,868	Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	1,188	1,352	Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	12,005	13,643	Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	13,193	14,995	Redacted
TX_CURR_NGI	Number of adults and children receiving antiretroviral therapy (ART)	13,193	14,995	Redacted
TX_CURR_NGI	Age/Sex: <1 Male	21	23	Redacted
TX_CURR_NGI	Age/Sex: 1-4 Male	139	158	Redacted
TX_CURR_NGI	Age/Sex: 5-14 Male	434	495	Redacted
TX_CURR_NGI	Age/Sex: 15+ Male	4,082	4,775	Redacted
TX_CURR_NGI	Age/Sex: <1 Female	21	23	Redacted
TX_CURR_NGI	Age/Sex: 1-4 Female	139	158	Redacted
TX_CURR_NGI	Age/Sex: 5-14 Female	434	495	Redacted
TX_CURR_NGI	Age/Sex: 15+ Female	7,923	8,868	Redacted
TX_CURR_NGI	Sum of Age/Sex disaggregates	13,193	14,995	Redacted
TX_CURR_NGI	Aggregated Age/Sex: <1 Male	21	23	Redacted
TX_CURR_NGI	Aggregated Age/Sex: <1 Female	21	23	Redacted
TX_CURR_NGI	Aggregated Age/Sex: <15 Male	594	676	Redacted
TX_CURR_NGI	Aggregated Age/Sex: 15+ Male	4,082	4,775	Redacted
TX_CURR_NGI	Aggregated Age/Sex: <15 Female	594	676	Redacted
TX_CURR_NGI	Aggregated Age/Sex: 15+ Female	7,923	8,868	Redacted
TX_CURR_NGI	Sum of Aggregated Age/Sex disaggregates	13,193	14,995	Redacted



TX_CURR_NGI	Sum of Aggregated Age/Sex <15	1,188	1,352	Redacted
TX_CURR_NGI	Sum of Aggregated Age/Sex 15+	12,005	13,643	Redacted
TX_DIST	Number of Districts with documented routine supportive supervision visits to 75% of HIV care and treatment sites supported by the District	1	1	Redacted
TX_DIST	Total number of PEPFAR supported District Health Offices	1	1	Redacted
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	3,172	3,129	Redacted
TX_NEW_DSD	By Age/Sex: <1 Male	49	66	Redacted
TX_NEW_DSD	By Age/Sex: 1-4 Male	28	37	Redacted
TX_NEW_DSD	By Age/Sex: 5-9 Male	49	66	Redacted
TX_NEW_DSD	By Age/Sex: 10-14 Male	38	52	Redacted
TX_NEW_DSD	By Age/Sex: 15-19 Male	25	23	Redacted
TX_NEW_DSD	By Age/Sex: 20-24 Male	46	42	Redacted
TX_NEW_DSD	By Age/Sex: 25-49 Male	687	650	Redacted
TX_NEW_DSD	By Age/Sex: 50+ Male	237	225	Redacted
TX_NEW_DSD	By Age/Sex: <1 Female	49	66	Redacted
TX_NEW_DSD	By Age/Sex: 1-4 Female	28	37	Redacted
TX_NEW_DSD	By Age/Sex: 5-9 Female	49	66	Redacted
TX_NEW_DSD	By Age/Sex: 10-14 Female	38	52	Redacted
TX_NEW_DSD	By Age/Sex: 15-19 Female	39	37	Redacted
TX_NEW_DSD	By Age/Sex: 20-24 Female	162	153	Redacted
TX_NEW_DSD	By Age/Sex: 25-49 Female	1,382	1,306	Redacted
TX_NEW_DSD	By Age/Sex: 50+ Female	266	251	Redacted
TX_NEW_DSD	Sum of Age/Sex disaggregates	3,172	3,129	Redacted
TX_NEW_DSD	Aggregated Grouping by Age: <1 Male	49	66	Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	164	221	Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	995	940	Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <1	49	66	Redacted

	Female			
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	164	221	Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	1,849	1,747	Redacted
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	3,172	3,129	Redacted
TX_NEW_DSD	Pregnancy status	747	762	Redacted
TX_NEW_DSD	Breastfeeding status	83	85	Redacted
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	2,137	2,696	Redacted
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	2,514	3,172	Redacted
TX_RET_DSD	Age: 0-4 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	53	67	Redacted
TX_RET_DSD	Age: 5-14 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	144	182	Redacted
TX_RET_DSD	Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,940	2,447	Redacted
TX_RET_DSD	Age: 0-4 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have	62	79	Redacted



	stopped ART, and those lost to follow-up)			
TX_RET_DSD	Age: 5-14 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	169	214	Redacted
TX_RET_DSD	Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	2,282	2,879	Redacted
TX_RET_DSD	Aggregated Age: <15 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	197	248	Redacted
TX_RET_DSD	Aggregated Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,940	2,447	Redacted
TX_RET_DSD	Aggregated Age: <15 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	232	292	Redacted
TX_RET_DSD	Aggregated Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died,	2,282	2,879	Redacted



	those who have stopped ART, and those lost to follow-up)			
TX_RET_DSD	Pregnancy and breastfeeding status (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	756	1,512	Redacted
TX_RET_DSD	Pregnancy and breastfeeding status (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	889	1,779	Redacted
TX_SITE	Number of PEPFAR-supported ART sites with a retention rate of 75% or greater for patients 12 months after ART initiation	87	87	Redacted
TX_SITE	Total number of PEPFAR-supported ART sites	124	124	Redacted
TX_SITE	By support type: Direct Service Delivery (DSD): Number of PEPFAR-supported ART sites with a retention rate of 75% or greater for patients 12 months after ART initiation	87	87	Redacted
TX_SITE	By support type: Technical Assistance (TA-only): Number of PEPFAR-supported ART sites with a retention rate of 75% or greater for patients 12 months after ART initiation	0	0	Redacted
TX_SITE	Sum of Numerator Site Support Type disaggregates	87	87	Redacted
TX_SITE	By support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported ART sites	124	124	Redacted



TX_SITE	By support type: Technical Assistance (TA-only): Total number of PEPFAR-supported ART sites	0	0	Redacted
TX_SITE	Sum of Denominator Site Support Type disaggregates	124	124	Redacted
LAB_CAP_DSD	Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests	124	124	Redacted
LAB_CAP_DSD	By site support type: Direct Service Delivery (DSD)	124	124	Redacted
LAB_CAP_DSD	Sum of Site Support Type disaggregates	124	124	Redacted
FPINT_SITE_DSD	Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	93	93	Redacted
FPINT_SITE_DSD	Total number of PEPFAR-supported HIV service delivery points: PMTCT, Care and Treatment	124	124	Redacted
FPINT_SITE_DSD	By site support type: Direct Service Delivery (DSD): Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	93	93	Redacted
FPINT_SITE_DSD	By site support type: Technical Assistance-only (TA): Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	0	0	Redacted
FPINT_SITE_DSD	Sum of Numerator Site Support Type disaggregates	93	93	Redacted
FPINT_SITE_DSD	By site support type: Direct Service Delivery (DSD): Total number of	124	124	Redacted



	PEPFAR-supported HIV service delivery points			
FPINT_SITE_DSD	Sum of Denominator Site Support Type disaggregates	124	124	Redacted
FPINT_SITE_DSD	Service delivery type: Community	0	0	Redacted
FPINT_SITE_DSD	Service delivery type: Clinical	93	93	Redacted
FPINT_SITE_DSD	Sum of Service Delivery Type disaggregates	93	93	Redacted
QI_SITE	Number of PEPFAR-supported clinical service sites with a quality improvement activity completed that addresses clinical HIV programs and has documented process results in the last 6 months	99	99	Redacted
QI_SITE	Total number of PEPFAR-supported sites for any HIV clinical service including HIV Care, HIV Treatment, TB care, PMTCT, VMMC, and HTC	124	124	Redacted
QI_SITE	By site support type: Direct Service Delivery (DSD): Number of PEPFAR-supported clinical service sites with a quality improvement activity completed that addresses clinical HIV programs and has documented results in the last 6 months	99	99	Redacted
QI_SITE	By site support type: Technical Assistance-only (TA): Number of PEPFAR-supported clinical service sites with a quality improvement activity completed that addresses clinical HIV programs and has documented results in the last 6 months	0	0	Redacted
QI_SITE	Sum of Numerator Site Support Type disaggregates	99	99	Redacted
QI_SITE	By site support type: Direct Service	124	124	Redacted



	Delivery (DSD): Total number of PEPFAR-supported sites for any HIV clinical service including HIV Care, HIV Treatment, TB care, PMTCT, VMMC, HTC			
QI_SITE	Sum of Denominator Site Support Type disaggregates	124	124	Redacted
TB_SCREEN_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period	12,050	13,904	Redacted
TB_SCREEN_DSD	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	13,389	14,635	Redacted
TB_SCREEN_DSD	Age: <1	38	44	Redacted
TB_SCREEN_DSD	Age: 1-4	260	300	Redacted
TB_SCREEN_DSD	Age: 5-9	459	529	Redacted
TB_SCREEN_DSD	Age: 10-14	353	408	Redacted
TB_SCREEN_DSD	Age: 15-19	244	281	Redacted
TB_SCREEN_DSD	Age: 20-24	812	939	Redacted
TB_SCREEN_DSD	Age: 25-49	7,980	9,207	Redacted
TB_SCREEN_DSD	Age: 50+	1,904	2,196	Redacted
TB_SCREEN_DSD	Sum of Age disaggregates	1,354	1,562	Redacted
TB_SCREEN_DSD	Aggregated Age - USE WITH HQ PERMISSION ONLY: <15	1,110	1,281	Redacted
TB_SCREEN_DSD	Aggregated Age - USE WITH HQ PERMISSION ONLY: 15+	10,940	12,623	Redacted
TB_SCREEN_DSD	Sum of Aggregated Age disaggregates	12,050	13,904	Redacted
TB_SCREEN_DSD	Sex: Male	4,275	4,933	Redacted
TB_SCREEN_DSD	Sex: Female	7,775	8,971	Redacted
TB_SCREEN_DSD	Sum of Sex disaggregates	12,050	13,904	Redacted



Implementing Mechanism Details

Mechanism ID: 12598	Mechanism Name: HIV Prevention in the General Population and Youth
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: International Rescue Committee	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: No	
G2G: No	Managing Agency:

Total All Funding Sources: 802,639	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 113,617	
FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount
GHP-State	802,639

Sub Partner Name(s)

African Inland Churches - Lokichoggio	Diocese of Lodwar	
---------------------------------------	-------------------	--

Cross-Cutting Budget Attribution(s)

Gender: Gender Equality	66,658
Focus Area:	Changing harmful gender norms and promoting positive gender norms
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Implementation
Sub Area:	Monitoring and Evaluation



Human Resources for Health	10,000
Key Populations: FSW	11,600
Focus Area:	Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention
Focus Area:	Training of health workers and community outreach workers
Gender: GBV	33,328
Focus Area:	GBV Prevention
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Condom programming	34,500

Key Issues

(No data provided.)

Budget Code Information

Mechanism ID: 12598			
Mechanism Name: HIV Prevention in the General Population and Youth			
Prime Partner Name: International Rescue Committee			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVAB	293,342	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	164,297	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	345,000	0



Implementing Mechanism Indicator Information

Indicator Number	Label	2014	2015	Planning Budget Targets
SITE_SUPP	Number of unique sites supported by PEPFAR	44	44	Redacted
SITE_SUPP	By program area/support type: HTC Direct Service Delivery (DSD)	31	36	Redacted
SITE_SUPP	By program area/support type: General Population Prevention Direct Service Delivery (DSD)	44	44	Redacted
SITE_SUPP	By program area/support type: Key Populations Prevention Direct Service Delivery (DSD)	1	1	Redacted
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	17,526	87,912	Redacted
PP_PREV_DSD	Total number of people in the target population	341,065	341,065	Redacted
PP_PREV_DSD	Age/sex: 10-14 Male	3,750	20,099	Redacted
PP_PREV_DSD	Age/sex: 15-19 Male	2,560		Redacted
PP_PREV_DSD	Age/sex: 20-24 Male	1,203		Redacted
PP_PREV_DSD	Age/sex: 25-49 Male	1,250		Redacted
PP_PREV_DSD	Age/sex: 10-14 Female	3,750	20,098	Redacted
PP_PREV_DSD	Age/sex: 15-19 Female	2,560	23,858	Redacted
PP_PREV_DSD	Age/sex: 20-24 Female	1,203	23,857	Redacted
PP_PREV_DSD	Age/sex: 25-49 Female	1,250		Redacted
PP_PREV_DSD	Sum of Age/Sex disaggregates	17,526	87,912	Redacted
KP_PREV_DSD	Number of key populations reached with individual and/or small group level	271	271	Redacted



	HIV preventive interventions that are based on evidence and/or meet the minimum standards required			
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	271	271	Redacted
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	48,578	71,044	Redacted
HTC_TST_DSD	By Test Result: Negative	46,635	68,203	Redacted
HTC_TST_DSD	By Test Result: Positive	1,943	2,841	Redacted
HTC_TST_DSD	Sum of Test Result disaggregates	48,578	71,044	Redacted
HTC_TST_DSD	Age/sex: <1 Male	0	0	Redacted
HTC_TST_DSD	Age/sex: 1-4 Male	1,700	2,477	Redacted
HTC_TST_DSD	Age/sex: 5-9 Male	729	1,061	Redacted
HTC_TST_DSD	Age/sex: 10-14 Male	1,214	1,769	Redacted
HTC_TST_DSD	Age/sex: 15-19 Male	2,429	3,538	Redacted
HTC_TST_DSD	Age/sex: 20-24 Male	6,072	8,986	Redacted
HTC_TST_DSD	Age/sex: 25-49 Male	9,716	14,152	Redacted
HTC_TST_DSD	Age/sex: 50+ Male	2,429	3,538	Redacted
HTC_TST_DSD	Age/sex: <1 Female	0	0	Redacted
HTC_TST_DSD	Age/sex: 1-4 Female	1,700	2,477	Redacted
HTC_TST_DSD	Age/sex: 5-9 Female	729	1,061	Redacted
HTC_TST_DSD	Age/sex: 10-14 Female	1,214	1,769	Redacted
HTC_TST_DSD	Age/sex: 15-19 Female	2,429	3,538	Redacted
HTC_TST_DSD	Age/sex: 20-24 Female	6,072	8,986	Redacted
HTC_TST_DSD	Age/sex: 25-49 Female	9,716	14,153	Redacted
HTC_TST_DSD	Age/sex: 50+ Female	2,429	3,539	Redacted
HTC_TST_DSD	Sum of Age/Sex disaggregates	48,578	71,044	Redacted



HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	3,643	5,307	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	20,646	30,214	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	3,643	5,307	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	20,646	30,216	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	7,286	10,614	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	41,292	60,430	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	48,578	71,044	Redacted
HTC_TST_NGI	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	48,578	71,044	Redacted
HTC_TST_NGI	By Test Result: Negative	46,635	68,203	Redacted
HTC_TST_NGI	By Test Result: Positive	1,943	2,841	Redacted
HTC_TST_NGI	Sum of Test Result disaggregates	48,578	71,044	Redacted
HTC_TST_NGI	Age/sex: <1 Male	0	0	Redacted
HTC_TST_NGI	Age/sex: 1-4 Male	1,700	2,477	Redacted
HTC_TST_NGI	Age/sex: 5-9 Male	729	1,061	Redacted
HTC_TST_NGI	Age/sex: 10-14 Male	1,214	1,769	Redacted
HTC_TST_NGI	Age/sex: 15-19 Male	2,429	3,538	Redacted
HTC_TST_NGI	Age/sex: 20-24 Male	6,072	8,986	Redacted
HTC_TST_NGI	Age/sex: 25-49 Male	9,716	14,152	Redacted
HTC_TST_NGI	Age/sex: 50+ Male	2,429	3,538	Redacted
HTC_TST_NGI	Age/sex: <1 Female	0	0	Redacted
HTC_TST_NGI	Age/sex: 1-4 Female	1,700	2,477	Redacted
HTC_TST_NGI	Age/sex: 5-9 Female	729	1,061	Redacted
HTC_TST_NGI	Age/sex: 10-14 Female	1,214	1,769	Redacted
HTC_TST_NGI	Age/sex: 15-19 Female	2,429	3,538	Redacted
HTC_TST_NGI	Age/sex: 20-24 Female	6,072	8,986	Redacted
HTC_TST_NGI	Age/sex: 25-49 Female	9,716	14,153	Redacted



HTC_TST_NGI	Age/sex: 50+ Female	2,429	3,539	Redacted
HTC_TST_NGI	Sum of Age/Sex disaggregates	48,578	71,044	Redacted
HTC_TST_NGI	Aggregated Age/sex: <15 Male	3,643	5,307	Redacted
HTC_TST_NGI	Aggregated Age/sex: 15+ Male	20,646	30,214	Redacted
HTC_TST_NGI	Aggregated Age/sex: <15 Female	3,643	5,307	Redacted
HTC_TST_NGI	Aggregated Age/sex: 15+ Female	20,646	30,216	Redacted
HTC_TST_NGI	Sum of Aggregated Age/Sex <15	7,286	10,614	Redacted
HTC_TST_NGI	Sum of Aggregated Age/Sex 15+	41,292	60,430	Redacted
HTC_TST_NGI	Sum of Aggregated Age/Sex disaggregates	48,578	71,044	Redacted

Implementing Mechanism Details

Mechanism ID: 12585	Mechanism Name: Eastern Province
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Columbia University Mailman School of Public Health	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: No	
G2G: No	Managing Agency:

Total All Funding Sources: 17,456,390	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 310,070	
FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount
GHP-State	17,456,390

Sub Partner Name(s)

Matibabu Foundation	Ogra Foundation	University of Nairobi
---------------------	-----------------	-----------------------

Cross-Cutting Budget Attribution(s)

Human Resources for Health	4,955,515
----------------------------	-----------

Approved



Gender: GBV	432,462
Focus Area:	GBV Prevention
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Focus Area:	Post GBV Care
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Gender: Gender Equality	432,462
Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation

Key Issues

- Malaria (PMI)
- Child Survival Activities
- Safe Motherhood
- TB
- Family Planning

Budget Code Information

Custom
2015-03-30 11:50 EDT



Mechanism ID: 12585			
Mechanism Name: Eastern Province			
Prime Partner Name: Columbia University Mailman School of Public Health			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	1,151,633	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	1,264,130	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	306,394	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	873,154	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	1,793,091	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	2,728,166	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	8,442,093	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	897,729	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2014	2015	Planning Budget Targets
------------------	-------	------	------	-------------------------



SITE_SUPP	Number of unique sites supported by PEPFAR	760	760	Redacted
SITE_SUPP	By program area/support type: HTC Direct Service Delivery (DSD)	164	288	Redacted
SITE_SUPP	By program area/support type: HTC Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: Treatment Direct Service Delivery (DSD)	288	315	Redacted
SITE_SUPP	By program area/support type: Treatment Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: Care and Support Direct Service Delivery (DSD)	288	315	Redacted
SITE_SUPP	By program area/support type: Care and Support Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: Food and Nutrition Direct Service Delivery (DSD)	288	315	Redacted
SITE_SUPP	By program area/support type: Food and Nutrition Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: PMTCT Direct Service Delivery (DSD)	574	601	Redacted
SITE_SUPP	By program area/support type: PMTCT Technical Assistance-only (TA)	186	159	Redacted
SITE_SUPP	By program area/support type: TB/HIV Direct Service Delivery (DSD)	288	315	Redacted
SITE_SUPP	By program area/support type: TB/HIV Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: VMMC Direct Service Delivery (DSD)	37	37	Redacted



SITE_SUPP	By program area/support type: VMMC Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: General Population Prevention Direct Service Delivery (DSD)	0	0	Redacted
SITE_SUPP	By program area/support type: General Population Prevention Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: Key Populations Prevention Direct Service Delivery (DSD)	0	0	Redacted
SITE_SUPP	By program area/support type: Key Populations Prevention Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: OVC Direct Service Delivery (DSD)	0	0	Redacted
SITE_SUPP	By program area/support type: OVC Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: PHDP/Family Planning & Integration Direct Service Delivery (DSD)	288	315	Redacted
SITE_SUPP	By program area/support type: PHDP/Family Planning & Integration Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: Lab Direct Service Delivery (DSD)	212	212	Redacted
SITE_SUPP	By program area/support type: Lab Technical Assistance-only (TA)	0	0	Redacted
PMTCT_ARV_DS D	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	12,564	12,816	Redacted
PMTCT_ARV_DS D	Number of HIV- positive pregnant women identified in the reporting period	12,564	12,816	Redacted

	(including known HIV-positive at entry)			
PMTCT_ARV_DS D	Life-long ART (including Option B+)	9,423	9,612	Redacted
PMTCT_ARV_DS D	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	4,397	4,486	Redacted
PMTCT_ARV_DS D	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	5,026	5,126	Redacted
PMTCT_ARV_DS D	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)	0	0	Redacted
PMTCT_ARV_DS D	Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)	3,141	3,204	Redacted
PMTCT_ARV_DS D	Single-dose nevirapine (with or without tail)	0	0	Redacted
PMTCT_ARV_DS D	Sum of Regimen Type disaggregates	12,564	12,816	Redacted
PMTCT_ARV_DS D	Sum of New and Current disaggregates	9,423	9,612	Redacted
PMTCT_ARV_NGI	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	13,657	13,930	Redacted
PMTCT_ARV_NGI	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	13,657	13,930	Redacted
PMTCT_ARV_NGI	Life-long ART (including Option B+)	10,242	10,448	Redacted
PMTCT_ARV_NGI	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	4,779	4,876	Redacted
PMTCT_ARV_NGI	Sub-Disag of Life-long ART: Already on treatment at the beginning of the	5,463	5,572	Redacted

	current pregnancy			
PMTCT_ARV_NGI	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)	0	0	Redacted
PMTCT_ARV_NGI	Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)	3,415	3,482	Redacted
PMTCT_ARV_NGI	Single-dose nevirapine (with or without tail)	0	0	Redacted
PMTCT_ARV_NGI	Sum of Regimen disaggregates	13,657	13,930	Redacted
PMTCT_ARV_NGI	Sum of New and Current disaggregates	10,242	10,448	Redacted
PMTCT_ARV_TA	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	1,093	1,114	Redacted
PMTCT_ARV_TA	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	1,093	1,114	Redacted
PMTCT_ARV_TA	Life-long ART (including Option B+)	819	836	Redacted
PMTCT_ARV_TA	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	382	390	Redacted
PMTCT_ARV_TA	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	437	446	Redacted
PMTCT_ARV_TA	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)	0	0	Redacted
PMTCT_ARV_TA	Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)	274	278	Redacted
PMTCT_ARV_TA	Single-dose nevirapine (with or without tail)	0	0	Redacted



PMTCT_ARV_TA	Sum of Regimen Type disaggregates	1,093	1,114	Redacted
PMTCT_ARV_TA	Sum of New and Current disaggregates	819	836	Redacted
PMTCT_SITE	Number of PEPFAR-supported sites achieving 90% ARV or ART coverage for HIV+ pregnant women	760	760	Redacted
PMTCT_SITE	Total number of PEPFAR supported sites providing PMTCT services (HTC and ARV or ART services)	760	760	Redacted
PMTCT_SITE	By site support type: Direct Service Delivery (DSD): Number of PEPFAR-supported sites achieving 90% ARV or ART coverage for HIV+ pregnant women	574	601	Redacted
PMTCT_SITE	By site support type: Technical Assistance-only (TA): Number of PEPFAR-supported sites achieving 90% ARV or ART coverage for HIV+ pregnant women	186	159	Redacted
PMTCT_SITE	Sum of Numerator Support Type disaggregates	760	760	Redacted
PMTCT_SITE	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR supported sites providing PMTCT services (HTC and ARV or ART services)	574	601	Redacted
PMTCT_SITE	By site support type: Technical Assistance-only (TA): Total number of PEPFAR supported sites providing PMTCT services (HTC and ARV or ART services)	186	159	Redacted
PMTCT_SITE	Sum of Denominator Support Type disaggregates	760	760	Redacted
PMTCT_STAT_DS D	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their	105,184	107,914	Redacted

	results)			
PMTCT_STAT_DS D	Number of new ANC and L&D clients	105,184	107,914	Redacted
PMTCT_STAT_DS D	By: Known positives at entry	5,905	6,024	Redacted
PMTCT_STAT_DS D	By: Number of new positives identified	6,659	6,792	Redacted
PMTCT_STAT_DS D	Sum of Positives Status disaggregates	12,564	12,816	Redacted
PMTCT_STAT_NG I	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	119,527	122,972	Redacted
PMTCT_STAT_NG I	Number of new ANC and L&D clients	119,527	122,972	Redacted
PMTCT_STAT_NG I	By: Known positives at entry	6,419	6,548	Redacted
PMTCT_STAT_NG I	By: Number of new positives identified	7,238	7,382	Redacted
PMTCT_STAT_NG I	Sum of Positives Status disaggregates	13,657	13,930	Redacted
PMTCT_STAT_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	14,343	15,058	Redacted
PMTCT_STAT_TA	Number of new ANC and L&D clients	14,343	15,058	Redacted
PMTCT_STAT_TA	By: Known positives at entry	514	524	Redacted
PMTCT_STAT_TA	By: Number of new positives identified	579	590	Redacted
PMTCT_STAT_TA	Sum of Positives Status disaggregates	1,093	1,114	Redacted
VMMC_AE_DSD	Number of males circumcised surgically or by medical device that experienced at least one moderate or severe adverse event(s) (AEs)	13	39	Redacted
VMMC_AE_DSD	By AE type: Number of VMMC clients	13	39	Redacted

	with one or more moderate or severe surgical intra-operative AE(s)			
VMMC_AE_DSD	Sub-Disag: Surgical intra-operative AE(s) by maximum severity category: Number of clients with one or more moderate surgical intra-operative AE(s), but no severe surgical intra-operative AE(s)	12	11	Redacted
VMMC_AE_DSD	Sub-Disag: Surgical intra-operative AE(s) by maximum severity category: Number of clients with one or more severe surgical intra-operative AE(s)	1	1	Redacted
VMMC_AE_DSD	By AE Type: Number of VMMC clients with one or more moderate or severe surgical post-operative AE(s)	28	28	Redacted
VMMC_AE_DSD	Sub-Disag: By Surgical post-operative AE(s) by maximum severity category: Number of clients with one or more moderate surgical post-operative AE(s), but no severe surgical post-operative AE(s)	21	22	Redacted
VMMC_AE_DSD	Sub-Disag: By Surgical post-operative AE(s) by maximum severity category: Number of clients with one or more severe surgical intra-operative AE(s)	7	6	Redacted
VMMC_CIRC_DS D	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	11,119	14,314	Redacted
VMMC_CIRC_DS D	By Age: <1	56		Redacted
VMMC_CIRC_DS D	By Age: 1-9	0	0	Redacted
VMMC_CIRC_DS	By Age: 10-14	4,448	5,798	Redacted

D				
VMMC_CIRC_DS D	By Age: 15-19	4,448	5,726	Redacted
VMMC_CIRC_DS D	By Age: 20-24	1,111	1,431	Redacted
VMMC_CIRC_DS D	By Age: 25-49	1,056	1,359	Redacted
VMMC_CIRC_DS D	By Age: 50+	0	0	Redacted
VMMC_CIRC_DS D	Sum of age disaggregates	11,119	14,314	Redacted
VMMC_CIRC_DS D	By HIV status: Number of HIV-positive clients (tested HIV positive at VMMC site)	102	132	Redacted
VMMC_CIRC_DS D	By HIV status: Number of HIV-negative clients (tested HIV negative at VMMC program)	9,309	11,984	Redacted
VMMC_CIRC_DS D	By HIV status: Number of clients with undocumented/indeterminate HIV status or not tested for HIV at site	818	1,053	Redacted
VMMC_CIRC_DS D	By circumcision technique: Surgical VMMC	11,119	14,314	Redacted
VMMC_CIRC_DS D	By follow-up status: Number of surgically circumcised clients who returned at least once for follow-up care within 14 days of circumcision surgery	4,336	5,582	Redacted
VMMC_CIRC_DS D	By follow-up status: Number of surgically circumcised clients who did NOT return for follow-up care within 14 days of circumcision surgery	6,783	8,732	Redacted
VMMC_CIRC_NGI	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	11,119	14,314	Redacted

VMMC_CIRC_NGI	By Age: <1	56		Redacted
VMMC_CIRC_NGI	By Age: 1-9	0	0	Redacted
VMMC_CIRC_NGI	By Age: 10-14	4,448	5,798	Redacted
VMMC_CIRC_NGI	By Age: 15-19	4,448	5,726	Redacted
VMMC_CIRC_NGI	By Age: 20-24	1,111	1,431	Redacted
VMMC_CIRC_NGI	By Age: 25-49	1,056	1,359	Redacted
VMMC_CIRC_NGI	By Age: 50+	0	0	Redacted
VMMC_CIRC_NGI	Sum of Age disaggregates	11,119	14,314	Redacted
VMMC_CIRC_NGI	By HIV status: Number of HIV-positive clients (tested HIV positive at VMMC site)	102	132	Redacted
VMMC_CIRC_NGI	By HIV status: Number of HIV-negative clients (tested HIV negative at VMMC program)	9,309	11,984	Redacted
VMMC_CIRC_NGI	By HIV status: Number of clients with undocumented/indeterminate HIV status or not tested for HIV at site	818	1,053	Redacted
VMMC_CIRC_NGI	By circumcision technique: Surgical VMMC	11,119	14,314	Redacted
VMMC_CIRC_NGI	By follow-up status: Number of surgically circumcised clients who returned at least once for follow-up care within 14 days of circumcision surgery	4,336	5,582	Redacted
VMMC_CIRC_NGI	By follow-up status: Number of surgically circumcised clients who did NOT return for follow-up care within 14 days of circumcision surgery	6,783	8,732	Redacted
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	119,700	622,949	Redacted
HTC_TST_DSD	By Test Result: Negative	114,912	598,031	Redacted
HTC_TST_DSD	By Test Result: Positive	4,788	24,918	Redacted
HTC_TST_DSD	Sum of Test Result disaggregates	119,700	622,949	Redacted
HTC_TST_DSD	Age/sex: <1 Male	0	0	Redacted



HTC_TST_DSD	Age/sex: 1-4 Male	4,190	21,803	Redacted
HTC_TST_DSD	Age/sex: 5-9 Male	1,796	9,344	Redacted
HTC_TST_DSD	Age/sex: 10-14 Male	2,992	15,574	Redacted
HTC_TST_DSD	Age/sex: 15-19 Male	5,985	31,148	Redacted
HTC_TST_DSD	Age/sex: 20-24 Male	14,963	77,869	Redacted
HTC_TST_DSD	Age/sex: 25-49 Male	23,939	124,590	Redacted
HTC_TST_DSD	Age/sex: 50+ Male	5,985	31,146	Redacted
HTC_TST_DSD	Age/sex: <1 Female	0	0	Redacted
HTC_TST_DSD	Age/sex: 1-4 Female	4,190	21,803	Redacted
HTC_TST_DSD	Age/sex: 5-9 Female	1,796	9,344	Redacted
HTC_TST_DSD	Age/sex: 10-14 Female	2,992	15,574	Redacted
HTC_TST_DSD	Age/sex: 15-19 Female	5,985	31,148	Redacted
HTC_TST_DSD	Age/sex: 20-24 Female	14,963	77,869	Redacted
HTC_TST_DSD	Age/sex: 25-49 Female	23,939	124,590	Redacted
HTC_TST_DSD	Age/sex: 50+ Female	5,985	31,147	Redacted
HTC_TST_DSD	Sum of Age/Sex disaggregates	119,700	622,949	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	8,978	46,721	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	50,872	264,753	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	8,978	46,721	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	50,872	264,754	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	17,956	93,442	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	101,744	529,507	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	119,700	622,949	Redacted
HTC_TST_NGI	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	119,700	622,949	Redacted
HTC_TST_NGI	By Test Result: Negative	114,912	598,031	Redacted
HTC_TST_NGI	By Test Result: Positive	4,788	24,918	Redacted



HTC_TST_NGI	Sum of Test Result disaggregates	119,700	622,949	Redacted
HTC_TST_NGI	Age/sex: <1 Male	0	0	Redacted
HTC_TST_NGI	Age/sex: 1-4 Male	4,190	21,803	Redacted
HTC_TST_NGI	Age/sex: 5-9 Male	1,796	9,344	Redacted
HTC_TST_NGI	Age/sex: 10-14 Male	2,992	15,574	Redacted
HTC_TST_NGI	Age/sex: 15-19 Male	5,984	31,148	Redacted
HTC_TST_NGI	Age/sex: 20-24 Male	14,963	77,869	Redacted
HTC_TST_NGI	Age/sex: 25-49 Male	23,940	124,590	Redacted
HTC_TST_NGI	Age/sex: 50+ Male	5,985	31,146	Redacted
HTC_TST_NGI	Age/sex: <1 Female	0	0	Redacted
HTC_TST_NGI	Age/sex: 1-4 Female	4,190	21,803	Redacted
HTC_TST_NGI	Age/sex: 5-9 Female	1,796	9,344	Redacted
HTC_TST_NGI	Age/sex: 10-14 Female	2,992	15,574	Redacted
HTC_TST_NGI	Age/sex: 15-19 Female	5,984	31,148	Redacted
HTC_TST_NGI	Age/sex: 20-24 Female	14,963	77,869	Redacted
HTC_TST_NGI	Age/sex: 25-49 Female	23,940	124,590	Redacted
HTC_TST_NGI	Age/sex: 50+ Female	5,985	31,147	Redacted
HTC_TST_NGI	Sum of Age/Sex disaggregates	119,700	622,949	Redacted
HTC_TST_NGI	Aggregated Age/sex: <15 Male	8,978	46,721	Redacted
HTC_TST_NGI	Aggregated Age/sex: 15+ Male	50,872	264,753	Redacted
HTC_TST_NGI	Aggregated Age/sex: <15 Female	8,978	46,721	Redacted
HTC_TST_NGI	Aggregated Age/sex: 15+ Female	50,872	264,754	Redacted
HTC_TST_NGI	Sum of Aggregated Age/Sex <15	17,956	93,442	Redacted
HTC_TST_NGI	Sum of Aggregated Age/Sex 15+	101,744	529,507	Redacted
HTC_TST_NGI	Sum of Aggregated Age/Sex disaggregates	119,700	622,949	Redacted
C2.1.D_DSD	Number of HIV-positive individuals receiving a minimum of one clinical service	143,512	156,872	Redacted
C2.1.D_DSD	By Age/Sex: <15 Female	6,458	7,076	Redacted
C2.1.D_DSD	By Age/Sex: <15 Male	6,458	7,076	Redacted
C2.1.D_DSD	By Age/Sex: 15+ Female	86,193	94,195	Redacted



C2.1.D_DSD	By Age/Sex: 15+ Male	44,403	48,525	Redacted
C2.1.D_DSD	Sum of Age/Sex disaggregates	143,512	156,872	Redacted
C2.1.D_DSD	By Age: <15	12,916	14,152	Redacted
C2.1.D_DSD	By Age: 15+	130,596	142,720	Redacted
C2.1.D_DSD	Sum of Age disaggregates	143,512	156,872	Redacted
C2.1.D_DSD	By Sex: Female	92,651	101,271	Redacted
C2.1.D_DSD	By Sex: Male	50,861	55,601	Redacted
C2.1.D_DSD	Sum of Sex disaggregates	143,512	156,872	Redacted
C2.1.D_NGI	Number of HIV-positive individuals receiving a minimum of one clinical service	143,512	156,872	Redacted
C2.1.D_NGI	By Age/Sex: <15 Female	6,458	7,076	Redacted
C2.1.D_NGI	By Age/Sex: <15 Male	6,458	7,076	Redacted
C2.1.D_NGI	By Age/Sex: 15+ Female	86,193	94,195	Redacted
C2.1.D_NGI	By Age/Sex: 15+ Male	44,403	48,525	Redacted
C2.1.D_NGI	Sum of Age/Sex disaggregates	143,512	156,872	Redacted
C2.1.D_NGI	By Age: <15	12,916	14,152	Redacted
C2.1.D_NGI	By Age: 15+	130,596	142,720	Redacted
C2.1.D_NGI	Sum of Age disaggregates	143,512	156,872	Redacted
C2.1.D_NGI	By Sex: Female	92,651	101,271	Redacted
C2.1.D_NGI	By Sex: Male	50,861	55,601	Redacted
C2.1.D_NGI	Sum of Sex disaggregates	143,512	156,872	Redacted
C2.4.D_DSD	Number of HIV-positive patients who were screened for TB in HIV care or treatment setting	129,161	149,027	Redacted
C2.4.D_DSD	Number of HIV-positive individuals receiving a minimum of one clinical service	143,512	156,872	Redacted
C2.5.D_DSD	Number of HIV-positive patients in HIV care who started TB treatment	2,583	2,981	Redacted
C2.5.D_DSD	Number of HIV-positive individuals receiving a minimum of one clinical service	143,512	156,872	Redacted



CARE_CURR_DS D	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	136,336	149,027	Redacted
CARE_CURR_DS D	Age/sex: <1 Male	212	233	Redacted
CARE_CURR_DS D	Age/sex: 1-4 Male	1,474	1,615	Redacted
CARE_CURR_DS D	Age/sex: 5-9 Male	2,491	2,729	Redacted
CARE_CURR_DS D	Age/sex: 10-14 Male	1,958	2,145	Redacted
CARE_CURR_DS D	Age/sex: 15-19 Male	1,046	1,143	Redacted
CARE_CURR_DS D	Age/sex: 20-24 Male	1,938	2,118	Redacted
CARE_CURR_DS D	Age/sex: 25-49 Male	29,132	31,837	Redacted
CARE_CURR_DS D	Age/sex: 50+ Male	10,066	11,000	Redacted
CARE_CURR_DS D	Age/sex: <1 Female	212	232	Redacted
CARE_CURR_DS D	Age/sex: 1-4 Female	1,400	1,534	Redacted
CARE_CURR_DS D	Age/sex: 5-9 Female	2,577	2,823	Redacted
CARE_CURR_DS D	Age/sex: 10-14 Female	1,946	2,133	Redacted
CARE_CURR_DS D	Age/sex: 15-19 Female	1,728	1,888	Redacted
CARE_CURR_DS D	Age/sex: 20-24 Female	7,168	7,834	Redacted
CARE_CURR_DS	Age/sex: 25-49 Female	61,220	66,903	Redacted



D				
CARE_CURR_DS D	Age/sex: 50+ Female	11,768	12,860	Redacted
CARE_CURR_DS D	Sun of Age/Sex disaggregates	136,336	149,027	Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	6,135	6,722	Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	42,182	46,098	Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	6,135	6,722	Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	81,884	89,485	Redacted
CARE_CURR_DS D	Sum of Aggregated Age/Sex disaggregates	136,336	149,027	Redacted
CARE_NEW_DSD	Number of HIV-infected adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load	27,267	27,097	Redacted
CARE_NEW_DSD	Age/sex: <1 Male	42	42	Redacted
CARE_NEW_DSD	Age/sex: 1-4 Male	295	294	Redacted
CARE_NEW_DSD	Age/sex: 5-9 Male	498	496	Redacted
CARE_NEW_DSD	Age/sex: 10-14 Male	392	390	Redacted
CARE_NEW_DSD	Age/sex: 15-19 Male	178	177	Redacted
CARE_NEW_DSD	Age/sex: 20-24 Male	739	734	Redacted
CARE_NEW_DSD	Age/sex: 25-49 Male	6,307	6,266	Redacted
CARE_NEW_DSD	Age/sex: 50+ Male	1,212	1,205	Redacted
CARE_NEW_DSD	Age/sex: <1 Female	42	42	Redacted
CARE_NEW_DSD	Age/sex: 1-4 Female	280	279	Redacted
CARE_NEW_DSD	Age/sex: 5-9 Female	515	513	Redacted
CARE_NEW_DSD	Age/sex: 10-14 Female	390	388	Redacted



CARE_NEW_DSD	Age/sex: 15-19 Female	406	403	Redacted
CARE_NEW_DSD	Age/sex: 20-24 Female	752	748	Redacted
CARE_NEW_DSD	Age/sex: 25-49 Female	11,311	11,237	Redacted
CARE_NEW_DSD	Age/sex: 50+ Female	3,908	3,883	Redacted
CARE_NEW_DSD	Sum of Age/sex disaggregates	27,267	27,097	Redacted
CARE_NEW_DSD	Aggregated Age/sex: <15 Male	1,227	1,222	Redacted
CARE_NEW_DSD	Aggregated Age/sex: 15+ Male	8,436	8,382	Redacted
CARE_NEW_DSD	Aggregated Age/sex: <15 Female	1,227	1,222	Redacted
CARE_NEW_DSD	Aggregated Age/sex: 15+ Female	16,377	16,271	Redacted
CARE_NEW_DSD	Sum of Aggregated Age/sex disaggregates	27,267	27,097	Redacted
CARE_SITE	Number of PEPFAR-supported HIV clinical care sites at which at least 80% of PLHIV received all of the following during the reporting period: 1) clinical assessment (WHO staging) OR CD4 count OR viral load, AND 2) TB screening at last visit, AND 3) if eligible, cotrimoxazole	288	315	Redacted
CARE_SITE	Total number of PEPFAR supported sites providing clinical care services	288	315	Redacted
CARE_SITE	By site support type: Direct Service Delivery (DSD): Number of PEPFAR-supported HIV clinical care sites at which at least 80% of PLHIV received all of the following during the reporting period: 1) clinical assessment (WHO staging) OR CD4 count OR viral load, AND 2) TB screening at last visit, AND 3) if eligible, cotrimoxazole	288	315	Redacted
CARE_SITE	By site support type: Technical Assistance-only (TA): Number of PEPFAR-supported HIV clinical care sites at which at least 80% of PLHIV received all of the following during the	0	0	Redacted



	reporting period: 1) clinical assessment (WHO staging) OR CD4 count OR viral load, AND 2) TB screening at last visit, AND 3) if eligible, cotrimoxazole			
CARE_SITE	Sum of Numerator Site Support Type disaggregates	288	315	Redacted
CARE_SITE	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR supported sites providing clinical care services	288	315	Redacted
CARE_SITE	By site support type: Technical Assistance-only (TA): Total number of PEPFAR supported sites providing clinical care services	0	0	Redacted
CARE_SITE	Sum of Denominator Site Support Type disaggregates	288	315	Redacted
FN_SITE	Number of PEPFAR-supported sites achieving 90% nutrition assessments that result in accurate categorization of malnutrition	259	284	Redacted
FN_SITE	Total number of PEPFAR-supported sites providing nutrition assessment, counseling and support (NACS) services	288	315	Redacted
FN_SITE	By site support type: Direct Service Delivery (DSD): Number of PEPFAR-supported sites achieving 90% nutrition assessments that result in accurate categorization of malnutrition	259	284	Redacted
FN_SITE	By site support type: Technical Assistance-only (TA): Number of PEPFAR-supported sites achieving 90% nutrition assessments that result in accurate categorization of	0	0	Redacted



	malnutrition			
FN_SITE	Sum of Numerator Support Type disaggregates	259	284	Redacted
FN_SITE	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported sites providing nutrition assessment, counseling and support (NACS) services	288	315	Redacted
FN_SITE	By site support type: Technical Assistance-only (TA): Total number of PEPFAR-supported sites providing nutrition assessment, counseling and support (NACS) services	0	0	Redacted
FN_SITE	Sum of Denominator Support Type disaggregates	288	315	Redacted
FN_THER_DSD	Number of clinically malnourished PLHIV who received therapeutic and/or supplementary food during the reporting period.	21,526	23,531	Redacted
FN_THER_DSD	Number of PLHIV who were nutritionally assessed and found to be clinically undernourished.	28,702	31,374	Redacted
FN_THER_DSD	Age: <1	69	75	Redacted
FN_THER_DSD	Age: 1-4	464	508	Redacted
FN_THER_DSD	Age: 5-14	1,451	1,586	Redacted
FN_THER_DSD	Age: 15-17	435	476	Redacted
FN_THER_DSD	Age: 18+	19,107	20,886	Redacted
FN_THER_DSD	Sum of Age disaggregates	21,526	23,531	Redacted
FN_THER_DSD	Aggregated Age: <18	2,419	2,645	Redacted
FN_THER_DSD	Aggregated Age: 18+	19,107	20,886	Redacted
FN_THER_DSD	Sum of Aggregated Age disaggregates	21,526	23,531	Redacted
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART	5,489	6,706	Redacted

	during TB treatment during the reporting period			
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	6,458	7,451	Redacted
TB_ART_DSD	Age: 0-4	136	166	Redacted
TB_ART_DSD	Age: 5-14	370	452	Redacted
TB_ART_DSD	Age: 15+	4,983	6,088	Redacted
TB_ART_DSD	Male	2,964	3,621	Redacted
TB_ART_DSD	Female	2,525	3,085	Redacted
TB_ART_DSD	Sum of Sex disaggregates	5,489	6,706	Redacted
TB_ART_DSD	Newly tested	3,294	4,024	Redacted
TB_ART_DSD	Known HIV-positive	2,195	2,682	Redacted
TB_ART_DSD	Sum of Test Status disaggregates	5,489	6,706	Redacted
TB_ART_DSD	Aggregated Age: <15	506	618	Redacted
TB_ART_DSD	Aggregated Age: 15+	4,983	6,088	Redacted
TB_ART_DSD	Sum of Aggregated Age disaggregates	5,489	6,706	Redacted
TB_ARTSITE	The number of PEPFAR-supported TB basic management units at which 80% of registered TB cases who are HIV-positive are on ART, during the reporting period	288	315	Redacted
TB_ARTSITE	The number of PEPFAR-supported TB basic management units	288	315	Redacted
TB_ARTSITE	By site support type: Direct Service Delivery (DSD): The number of PEPFAR-supported TB basic management units at which 80% of registered TB cases who are HIV-positive are on ART, during the reporting period	288	315	Redacted
TB_ARTSITE	By site support type: Technical Assistance-only (TA): The number of	0	0	Redacted



	PEPFAR-supported TB basic management units at which 80% of registered TB cases who are HIV-positive are on ART, during the reporting period			
TB_ARTSITE	Sum of Numerator Site Support Type disaggregates	288	315	Redacted
TB_ARTSITE	By site support type: Direct Service Delivery (DSD): The number of PEPFAR-supported TB basic management units	288	315	Redacted
TB_ARTSITE	By site support type: Technical Assistance-only (TA): The number of PEPFAR-supported TB basic management units	0	0	Redacted
TB_ARTSITE	Sum of Denominator Site Support Type disaggregates	288	315	Redacted
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	10,925	11,144	Redacted
PMTCT_EID_DSD	Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT)	13,657	13,930	Redacted
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	8,194	8,358	Redacted
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	2,731	2,786	Redacted
PMTCT_EID_DSD	Sum of Infant Age disaggregates	10,925	11,144	Redacted
PMTCT_EID_DSD	By infants with a positive virologic test result within 12 months of birth	546	557	Redacted
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	105,106	122,044	Redacted
TX_CURR_DSD	Age/Sex: <1 Male	164	190	Redacted



TX_CURR_DSD	Age/Sex: 1-4 Male	1,107	1,288	Redacted
TX_CURR_DSD	Age/Sex: 5-14 Male	3,458	4,024	Redacted
TX_CURR_DSD	Age/Sex: 15+ Male	32,520	38,864	Redacted
TX_CURR_DSD	Age/Sex: <1 Female	164	190	Redacted
TX_CURR_DSD	Age/Sex: 1-4 Female	1,107	1,288	Redacted
TX_CURR_DSD	Age/Sex: 5-14 Female	3,459	4,024	Redacted
TX_CURR_DSD	Age/Sex: 15+ Female	63,127	72,176	Redacted
TX_CURR_DSD	Sum of age/sex disaggregates	9,459	11,004	Redacted
TX_CURR_DSD	Percent children with advanced HIV infection receiving antiretroviral therapy (ART) [CURRENT]	1	1	Redacted
TX_CURR_DSD	Percent women and girls with advanced HIV infection receiving antiretroviral therapy (ART) [CURRENT]	1	1	Redacted
TX_CURR_DSD	Aggregated Age/Sex: <1 Male	164	190	Redacted
TX_CURR_DSD	Aggregated Age/Sex: <1 Female	164	190	Redacted
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	4,729	5,502	Redacted
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	32,520	38,864	Redacted
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	4,730	5,502	Redacted
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	63,127	72,176	Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	9,459	11,004	Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	95,647	111,040	Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	105,106	122,044	Redacted
TX_CURR_NGI	Number of adults and children receiving antiretroviral therapy (ART)	105,106	122,044	Redacted
TX_CURR_NGI	Age/Sex: <1 Male	164	190	Redacted
TX_CURR_NGI	Age/Sex: 1-4 Male	1,107	1,288	Redacted
TX_CURR_NGI	Age/Sex: 5-14 Male	3,458	4,024	Redacted
TX_CURR_NGI	Age/Sex: 15+ Male	32,520	38,864	Redacted
TX_CURR_NGI	Age/Sex: <1 Female	164	190	Redacted
TX_CURR_NGI	Age/Sex: 1-4 Female	1,107	1,288	Redacted



TX_CURR_NGI	Age/Sex: 5-14 Female	3,459	4,024	Redacted
TX_CURR_NGI	Age/Sex: 15+ Female	63,127	72,176	Redacted
TX_CURR_NGI	Sum of Age/Sex disaggregates	105,106	122,044	Redacted
TX_CURR_NGI	Aggregated Age/Sex: <1 Male	164	190	Redacted
TX_CURR_NGI	Aggregated Age/Sex: <1 Female	164	190	Redacted
TX_CURR_NGI	Aggregated Age/Sex: <15 Male	4,729	5,502	Redacted
TX_CURR_NGI	Aggregated Age/Sex: 15+ Male	32,520	38,864	Redacted
TX_CURR_NGI	Aggregated Age/Sex: <15 Female	4,730	5,502	Redacted
TX_CURR_NGI	Aggregated Age/Sex: 15+ Female	63,127	72,176	Redacted
TX_CURR_NGI	Sum of Aggregated Age/Sex disaggregates	105,106	122,044	Redacted
TX_CURR_NGI	Sum of Aggregated Age/Sex <15	9,459	11,004	Redacted
TX_CURR_NGI	Sum of Aggregated Age/Sex 15+	95,647	111,040	Redacted
TX_DIST	Number of Districts with documented routine supportive supervision visits to 75% of HIV care and treatment sites supported by the District	4	4	Redacted
TX_DIST	Total number of PEPFAR supported District Health Offices	5	5	Redacted
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	24,413	24,088	Redacted
TX_NEW_DSD	By Age/Sex: <1 Male	378	509	Redacted
TX_NEW_DSD	By Age/Sex: 1-4 Male	214	288	Redacted
TX_NEW_DSD	By Age/Sex: 5-9 Male	378	509	Redacted
TX_NEW_DSD	By Age/Sex: 10-14 Male	291	392	Redacted
TX_NEW_DSD	By Age/Sex: 15-19 Male	190	180	Redacted
TX_NEW_DSD	By Age/Sex: 20-24 Male	352	333	Redacted
TX_NEW_DSD	By Age/Sex: 25-49 Male	5,291	5,002	Redacted
TX_NEW_DSD	By Age/Sex: 50+ Male	1,829	1,727	Redacted
TX_NEW_DSD	By Age/Sex: <1 Female	378	509	Redacted
TX_NEW_DSD	By Age/Sex: 1-4 Female	214	288	Redacted
TX_NEW_DSD	By Age/Sex: 5-9 Female	378	509	Redacted
TX_NEW_DSD	By Age/Sex: 10-14 Female	291	392	Redacted

TX_NEW_DSD	By Age/Sex: 15-19 Female	300	284	Redacted
TX_NEW_DSD	By Age/Sex: 20-24 Female	1,246	1,177	Redacted
TX_NEW_DSD	By Age/Sex: 25-49 Female	10,638	10,055	Redacted
TX_NEW_DSD	By Age/Sex: 50+ Female	2,045	1,934	Redacted
TX_NEW_DSD	Sum of Age/Sex disaggregates	24,413	24,088	Redacted
TX_NEW_DSD	Aggregated Grouping by Age: <1 Male	378	509	Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	1,261	1,698	Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	7,662	7,242	Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <1 Female	378	509	Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	1,261	1,698	Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	14,229	13,450	Redacted
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	24,413	24,088	Redacted
TX_NEW_DSD	Pregnancy status	4,302	4,388	Redacted
TX_NEW_DSD	Breastfeeding status	478	488	Redacted
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	7,154	20,751	Redacted
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	8,417	24,413	Redacted
TX_RET_DSD	Age: 0-4 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	177	514	Redacted
TX_RET_DSD	Age: 5-14 (Numerator: Number of	482	1,399	Redacted

	adults and children who are still alive and on treatment at 12 months after initiating ART)			
TX_RET_DSD	Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	6,495	18,838	Redacted
TX_RET_DSD	Age: 0-4 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	208	605	Redacted
TX_RET_DSD	Age: 5-14 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	567	1,645	Redacted
TX_RET_DSD	Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	7,641	22,163	Redacted
TX_RET_DSD	Aggregated Age: <15 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	659	1,913	Redacted
TX_RET_DSD	Aggregated Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	6,495	18,838	Redacted



TX_RET_DSD	Aggregated Age: <15 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	776	2,250	Redacted
TX_RET_DSD	Aggregated Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	7,641	22,163	Redacted
TX_RET_DSD	Pregnancy and breastfeeding status (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	4,353	8,706	Redacted
TX_RET_DSD	Pregnancy and breastfeeding status (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	5,121	10,242	Redacted
TX_SITE	Number of PEPFAR-supported ART sites with a retention rate of 75% or greater for patients 12 months after ART initiation	202	221	Redacted
TX_SITE	Total number of PEPFAR-supported ART sites	288	315	Redacted
TX_SITE	By support type: Direct Service Delivery (DSD): Number of PEPFAR-supported ART sites with a retention rate of 75% or greater for patients 12 months after	202	221	Redacted



	ART initiation			
TX_SITE	By support type: Technical Assistance (TA-only): Number of PEPFAR-supported ART sites with a retention rate of 75% or greater for patients 12 months after ART initiation	0	0	Redacted
TX_SITE	Sum of Numerator Site Support Type disaggregates	202	221	Redacted
TX_SITE	By support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported ART sites	288	315	Redacted
TX_SITE	By support type: Technical Assistance (TA-only): Total number of PEPFAR-supported ART sites	0	0	Redacted
TX_SITE	Sum of Denominator Site Support Type disaggregates	288	315	Redacted
LAB_CAP_DSD	Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests	212	212	Redacted
LAB_CAP_DSD	By site support type: Direct Service Delivery (DSD)	212	212	Redacted
LAB_CAP_DSD	Sum of Site Support Type disaggregates	212	212	Redacted
FPINT_SITE_DSD	Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	570	570	Redacted
FPINT_SITE_DSD	Total number of PEPFAR-supported HIV service delivery points: PMTCT, Care and Treatment	760	760	Redacted
FPINT_SITE_DSD	By site support type: Direct Service Delivery (DSD): Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family	430	451	Redacted



	planning services			
FPINT_SITE_DSD	By site support type: Technical Assistance-only (TA): Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	140	119	Redacted
FPINT_SITE_DSD	Sum of Numerator Site Support Type disaggregates	570	570	Redacted
FPINT_SITE_DSD	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported HIV service delivery points	574	601	Redacted
FPINT_SITE_DSD	By site support type: Technical Assistance-only (TA): Total number of PEPFAR-supported HIV service delivery points	186	159	Redacted
FPINT_SITE_DSD	Sum of Denominator Site Support Type disaggregates	760	760	Redacted
FPINT_SITE_DSD	Service delivery type: Clinical	570	570	Redacted
FPINT_SITE_DSD	Sum of Service Delivery Type disaggregates	570	570	Redacted
QI_SITE	Number of PEPFAR-supported clinical service sites with a quality improvement activity completed that addresses clinical HIV programs and has documented process results in the last 6 months	608	608	Redacted
QI_SITE	Total number of PEPFAR-supported sites for any HIV clinical service including HIV Care, HIV Treatment, TB care, PMTCT, VMMC, and HTC	760	760	Redacted
QI_SITE	By site support type: Direct Service Delivery (DSD): Number of PEPFAR-supported clinical service	459	481	Redacted



	sites with a quality improvement activity completed that addresses clinical HIV programs and has documented results in the last 6 months			
QI_SITE	By site support type: Technical Assistance-only (TA): Number of PEPFAR-supported clinical service sites with a quality improvement activity completed that addresses clinical HIV programs and has documented results in the last 6 months	149	127	Redacted
QI_SITE	Sum of Numerator Site Support Type disaggregates	608	608	Redacted
QI_SITE	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported sites for any HIV clinical service including HIV Care, HIV Treatment, TB care, PMTCT, VMMC, HTC	574	601	Redacted
QI_SITE	By site support type: Technical Assistance-only (TA): Total number of PEPFAR-supported sites for any HIV clinical service including HIV Care, HIV Treatment, TB care, PMTCT, VMMC, and HTC	186	159	Redacted
QI_SITE	Sum of Denominator Site Support Type disaggregates	760	760	Redacted
TB_SCREEN_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period	122,703	141,576	Redacted
TB_SCREEN_DSD	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	136,336	149,027	Redacted



TB_SCREEN_DSD	Age: <1	391	451	Redacted
TB_SCREEN_DSD	Age: 1-4	2,648	3,055	Redacted
TB_SCREEN_DSD	Age: 5-9	4,672	5,391	Redacted
TB_SCREEN_DSD	Age: 10-14	3,598	4,152	Redacted
TB_SCREEN_DSD	Age: 15-19	2,482	2,864	Redacted
TB_SCREEN_DSD	Age: 20-24	8,273	9,545	Redacted
TB_SCREEN_DSD	Age: 25-49	81,256	93,754	Redacted
TB_SCREEN_DSD	Age: 50+	19,383	22,364	Redacted
TB_SCREEN_DSD	Sum of Age disaggregates	13,791	15,913	Redacted
TB_SCREEN_DSD	Aggregated Age - USE WITH HQ PERMISSION ONLY: <15	11,309	13,049	Redacted
TB_SCREEN_DSD	Aggregated Age - USE WITH HQ PERMISSION ONLY: 15+	111,394	128,527	Redacted
TB_SCREEN_DSD	Sum of Aggregated Age disaggregates	122,703	141,576	Redacted
TB_SCREEN_DSD	Sex: Male	43,528	50,224	Redacted
TB_SCREEN_DSD	Sex: Female	79,175	91,352	Redacted
TB_SCREEN_DSD	Sum of Sex disaggregates	122,703	141,576	Redacted

Implementing Mechanism Details

Mechanism ID: 12555	Mechanism Name: Clinical Services/Centers of Excellence
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: University of Nairobi	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: No	
G2G: Yes	Managing Agency: HHS/CDC

Total All Funding Sources: 3,572,255	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 0	
FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount
GHP-State	3,572,255

Approved



Sub Partner Name(s)

Futures Group	Kenyatta National Hospital, Kenya	Pumwani Maternity Hospital
University of Maryland School of medicine		

Cross-Cutting Budget Attribution(s)

Human Resources for Health	1,198,678
Gender: GBV	80,556
Focus Area:	GBV Prevention
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Monitoring and Evaluation
Gender: Gender Equality	80,556
Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Monitoring and Evaluation

Key Issues

Child Survival Activities
Safe Motherhood
TB
Family Planning



Budget Code Information

Mechanism ID: 12555			
Mechanism Name: Clinical Services/Centers of Excellence			
Prime Partner Name: University of Nairobi			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	195,494	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	125,214	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	93,250	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	350,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	201,876	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	333,818	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	2,074,410	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	198,193	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2014	2015	Planning Budget
------------------	-------	------	------	-----------------



				Targets
SITE_SUPP	Number of unique sites supported by PEPFAR	2	2	Redacted
SITE_SUPP	By program area/support type: HTC Direct Service Delivery (DSD)	2	2	Redacted
SITE_SUPP	By program area/support type: HTC Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: Treatment Direct Service Delivery (DSD)	2	2	Redacted
SITE_SUPP	By program area/support type: Treatment Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: Care and Support Direct Service Delivery (DSD)	2	2	Redacted
SITE_SUPP	By program area/support type: Care and Support Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: Food and Nutrition Direct Service Delivery (DSD)	2	2	Redacted
SITE_SUPP	By program area/support type: Food and Nutrition Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: PMTCT Direct Service Delivery (DSD)	2	2	Redacted
SITE_SUPP	By program area/support type: PMTCT Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: TB/HIV Direct Service Delivery (DSD)	2	2	Redacted
SITE_SUPP	By program area/support type: TB/HIV Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: VMMC	0	0	Redacted



	Direct Service Delivery (DSD)			
SITE_SUPP	By program area/support type: VMMC Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: General Population Prevention Direct Service Delivery (DSD)	0	0	Redacted
SITE_SUPP	By program area/support type: General Population Prevention Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: Key Populations Prevention Direct Service Delivery (DSD)	0	0	Redacted
SITE_SUPP	By program area/support type: Key Populations Prevention Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: OVC Direct Service Delivery (DSD)	0	0	Redacted
SITE_SUPP	By program area/support type: OVC Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: PHDP/Family Planning & Integration Direct Service Delivery (DSD)	2	2	Redacted
SITE_SUPP	By program area/support type: PHDP/Family Planning & Integration Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: Lab Direct Service Delivery (DSD)	2	2	Redacted
SITE_SUPP	By program area/support type: Lab Technical Assistance-only (TA)	0	0	Redacted
PMTCT_ARV_DS D	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	1,155	1,178	Redacted
PMTCT_ARV_DS	Number of HIV- positive pregnant	1,155	1,178	Redacted

D	women identified in the reporting period (including known HIV-positive at entry)			
PMTCT_ARV_DS D	Life-long ART (including Option B+)	866	884	Redacted
PMTCT_ARV_DS D	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	404	413	Redacted
PMTCT_ARV_DS D	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	462	471	Redacted
PMTCT_ARV_DS D	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)	0	0	Redacted
PMTCT_ARV_DS D	Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)	289	294	Redacted
PMTCT_ARV_DS D	Single-dose nevirapine (with or without tail)	0	0	Redacted
PMTCT_ARV_DS D	Sum of Regimen Type disaggregates	1,155	1,178	Redacted
PMTCT_ARV_DS D	Sum of New and Current disaggregates	866	884	Redacted
PMTCT_ARV_NGI	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	1,155	1,178	Redacted
PMTCT_ARV_NGI	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	1,155	1,178	Redacted
PMTCT_ARV_NGI	Life-long ART (including Option B+)	866	884	Redacted
PMTCT_ARV_NGI	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	404	413	Redacted
PMTCT_ARV_NGI	Sub-Disag of Life-long ART: Already on	462	471	Redacted



	treatment at the beginning of the current pregnancy			
PMTCT_ARV_NGI	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)	0	0	Redacted
PMTCT_ARV_NGI	Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)	289	294	Redacted
PMTCT_ARV_NGI	Single-dose nevirapine (with or without tail)	0	0	Redacted
PMTCT_ARV_NGI	Sum of Regimen disaggregates	1,155	1,178	Redacted
PMTCT_ARV_NGI	Sum of New and Current disaggregates	866	884	Redacted
PMTCT_SITE	Number of PEPFAR-supported sites achieving 90% ARV or ART coverage for HIV+ pregnant women	2	2	Redacted
PMTCT_SITE	Total number of PEPFAR supported sites providing PMTCT services (HTC and ARV or ART services)	2	2	Redacted
PMTCT_SITE	By site support type: Direct Service Delivery (DSD): Number of PEPFAR-supported sites achieving 90% ARV or ART coverage for HIV+ pregnant women	2	2	Redacted
PMTCT_SITE	By site support type: Technical Assistance-only (TA): Number of PEPFAR-supported sites achieving 90% ARV or ART coverage for HIV+ pregnant women	0	0	Redacted
PMTCT_SITE	Sum of Numerator Support Type disaggregates	2	2	Redacted
PMTCT_SITE	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR supported sites providing PMTCT services (HTC and ARV or ART services)	2	2	Redacted



PMTCT_SITE	By site support type: Technical Assistance-only (TA): Total number of PEPFAR supported sites providing PMTCT services (HTC and ARV or ART services)	0	0	Redacted
PMTCT_SITE	Sum of Denominator Support Type disaggregates	2	2	Redacted
PMTCT_STAT_DS D	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	13,434	14,103	Redacted
PMTCT_STAT_DS D	Number of new ANC and L&D clients	13,434	14,103	Redacted
PMTCT_STAT_DS D	By: Known positives at entry	543	554	Redacted
PMTCT_STAT_DS D	By: Number of new positives identified	612	624	Redacted
PMTCT_STAT_DS D	Sum of Positives Status disaggregates	1,155	1,178	Redacted
PMTCT_STAT_NG I	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	13,434	14,103	Redacted
PMTCT_STAT_NG I	Number of new ANC and L&D clients	13,434	14,103	Redacted
PMTCT_STAT_NG I	By: Known positives at entry	543	554	Redacted
PMTCT_STAT_NG I	By: Number of new positives identified	612	624	Redacted
PMTCT_STAT_NG I	Sum of Positives Status disaggregates	1,155	1,178	Redacted
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	80,000	67,292	Redacted
HTC_TST_DSD	By Test Result: Negative	76,800	64,600	Redacted



HTC_TST_DSD	By Test Result: Positive	3,200	2,692	Redacted
HTC_TST_DSD	Sum of Test Result disaggregates	80,000	67,292	Redacted
HTC_TST_DSD	Age/sex: <1 Male	0	0	Redacted
HTC_TST_DSD	Age/sex: 1-4 Male	2,800	2,355	Redacted
HTC_TST_DSD	Age/sex: 5-9 Male	1,200	1,009	Redacted
HTC_TST_DSD	Age/sex: 10-14 Male	2,000	1,683	Redacted
HTC_TST_DSD	Age/sex: 15-19 Male	4,000	3,365	Redacted
HTC_TST_DSD	Age/sex: 20-24 Male	10,000	8,412	Redacted
HTC_TST_DSD	Age/sex: 25-49 Male	16,000	13,458	Redacted
HTC_TST_DSD	Age/sex: 50+ Male	4,000	3,364	Redacted
HTC_TST_DSD	Age/sex: <1 Female	0	0	Redacted
HTC_TST_DSD	Age/sex: 1-4 Female	2,800	2,355	Redacted
HTC_TST_DSD	Age/sex: 5-9 Female	1,200	1,009	Redacted
HTC_TST_DSD	Age/sex: 10-14 Female	2,000	1,683	Redacted
HTC_TST_DSD	Age/sex: 15-19 Female	4,000	3,365	Redacted
HTC_TST_DSD	Age/sex: 20-24 Female	10,000	8,412	Redacted
HTC_TST_DSD	Age/sex: 25-49 Female	16,000	13,458	Redacted
HTC_TST_DSD	Age/sex: 50+ Female	4,000	3,364	Redacted
HTC_TST_DSD	Sum of Age/Sex disaggregates	80,000	67,292	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	6,000	5,047	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	34,000	28,599	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	6,000	5,047	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	34,000	28,599	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	12,000	10,094	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	68,000	57,198	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	80,000	67,292	Redacted
HTC_TST_NGI	Number of individuals who received T&C services for HIV and received their	80,000	67,292	Redacted



	test results during the past 12 months			
HTC_TST_NGI	By Test Result: Negative	76,800	64,600	Redacted
HTC_TST_NGI	By Test Result: Positive	3,200	2,692	Redacted
HTC_TST_NGI	Sum of Test Result disaggregates	80,000	67,292	Redacted
HTC_TST_NGI	Age/sex: <1 Male	0	0	Redacted
HTC_TST_NGI	Age/sex: 1-4 Male	2,800	2,355	Redacted
HTC_TST_NGI	Age/sex: 5-9 Male	1,200	1,009	Redacted
HTC_TST_NGI	Age/sex: 10-14 Male	2,000	1,683	Redacted
HTC_TST_NGI	Age/sex: 15-19 Male	4,000	3,365	Redacted
HTC_TST_NGI	Age/sex: 20-24 Male	10,000	8,412	Redacted
HTC_TST_NGI	Age/sex: 25-49 Male	16,000	13,458	Redacted
HTC_TST_NGI	Age/sex: 50+ Male	4,000	3,364	Redacted
HTC_TST_NGI	Age/sex: <1 Female	0	0	Redacted
HTC_TST_NGI	Age/sex: 1-4 Female	2,800	2,355	Redacted
HTC_TST_NGI	Age/sex: 5-9 Female	1,200	1,009	Redacted
HTC_TST_NGI	Age/sex: 10-14 Female	2,000	1,683	Redacted
HTC_TST_NGI	Age/sex: 15-19 Female	4,000	3,365	Redacted
HTC_TST_NGI	Age/sex: 20-24 Female	10,000	8,412	Redacted
HTC_TST_NGI	Age/sex: 25-49 Female	16,000	13,458	Redacted
HTC_TST_NGI	Age/sex: 50+ Female	4,000	3,364	Redacted
HTC_TST_NGI	Sum of Age/Sex disaggregates	80,000	67,292	Redacted
HTC_TST_NGI	Aggregated Age/sex: <15 Male	6,000	5,047	Redacted
HTC_TST_NGI	Aggregated Age/sex: 15+ Male	34,000	28,599	Redacted
HTC_TST_NGI	Aggregated Age/sex: <15 Female	6,000	5,047	Redacted
HTC_TST_NGI	Aggregated Age/sex: 15+ Female	34,000	28,599	Redacted
HTC_TST_NGI	Sum of Aggregated Age/Sex <15	12,000	10,094	Redacted
HTC_TST_NGI	Sum of Aggregated Age/Sex 15+	68,000	57,198	Redacted
HTC_TST_NGI	Sum of Aggregated Age/Sex disaggregates	80,000	67,292	Redacted
C2.1.D_DSD	Number of HIV-positive individuals receiving a minimum of one clinical service	8,117	8,873	Redacted



C2.1.D_DSD	By Age/Sex: <15 Female	365	400	Redacted
C2.1.D_DSD	By Age/Sex: <15 Male	365	400	Redacted
C2.1.D_DSD	By Age/Sex: 15+ Female	4,875	5,328	Redacted
C2.1.D_DSD	By Age/Sex: 15+ Male	2,512	2,745	Redacted
C2.1.D_DSD	Sum of Age/Sex disaggregates	8,117	8,873	Redacted
C2.1.D_DSD	By Age: <15	730	800	Redacted
C2.1.D_DSD	By Age: 15+	7,387	8,073	Redacted
C2.1.D_DSD	Sum of Age disaggregates	8,117	8,873	Redacted
C2.1.D_DSD	By Sex: Female	5,240	5,728	Redacted
C2.1.D_DSD	By Sex: Male	2,877	3,145	Redacted
C2.1.D_DSD	Sum of Sex disaggregates	8,117	8,873	Redacted
C2.1.D_NGI	Number of HIV-positive individuals receiving a minimum of one clinical service	8,117	8,873	Redacted
C2.1.D_NGI	By Age/Sex: <15 Female	365	400	Redacted
C2.1.D_NGI	By Age/Sex: <15 Male	365	400	Redacted
C2.1.D_NGI	By Age/Sex: 15+ Female	4,875	5,328	Redacted
C2.1.D_NGI	By Age/Sex: 15+ Male	2,512	2,745	Redacted
C2.1.D_NGI	Sum of Age/Sex disaggregates	8,117	8,873	Redacted
C2.1.D_NGI	By Age: <15	730	800	Redacted
C2.1.D_NGI	By Age: 15+	7,387	8,073	Redacted
C2.1.D_NGI	Sum of Age disaggregates	8,117	8,873	Redacted
C2.1.D_NGI	By Sex: Female	5,240	5,728	Redacted
C2.1.D_NGI	By Sex: Male	2,877	3,145	Redacted
C2.1.D_NGI	Sum of Sex disaggregates	8,117	8,873	Redacted
C2.4.D_DSD	Number of HIV-positive patients who were screened for TB in HIV care or treatment setting	7,305	8,429	Redacted
C2.4.D_DSD	Number of HIV-positive individuals receiving a minimum of one clinical service	8,117	8,873	Redacted
C2.5.D_DSD	Number of HIV-positive patients in HIV care who started TB treatment	146	169	Redacted



C2.5.D_DSD	Number of HIV-positive individuals receiving a minimum of one clinical service	8,117	8,873	Redacted
CARE_CURR_DS D	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	7,711	8,429	Redacted
CARE_CURR_DS D	Age/sex: <1 Male	12	13	Redacted
CARE_CURR_DS D	Age/sex: 1-4 Male	83	91	Redacted
CARE_CURR_DS D	Age/sex: 5-9 Male	141	154	Redacted
CARE_CURR_DS D	Age/sex: 10-14 Male	111	122	Redacted
CARE_CURR_DS D	Age/sex: 15-19 Male	59	65	Redacted
CARE_CURR_DS D	Age/sex: 20-24 Male	110	121	Redacted
CARE_CURR_DS D	Age/sex: 25-49 Male	1,648	1,801	Redacted
CARE_CURR_DS D	Age/sex: 50+ Male	569	621	Redacted
CARE_CURR_DS D	Age/sex: <1 Female	12	13	Redacted
CARE_CURR_DS D	Age/sex: 1-4 Female	79	87	Redacted
CARE_CURR_DS D	Age/sex: 5-9 Female	146	160	Redacted
CARE_CURR_DS D	Age/sex: 10-14 Female	110	120	Redacted
CARE_CURR_DS D	Age/sex: 15-19 Female	98	107	Redacted



CARE_CURR_DS D	Age/sex: 20-24 Female	405	443	Redacted
CARE_CURR_DS D	Age/sex: 25-49 Female	3,463	3,784	Redacted
CARE_CURR_DS D	Age/sex: 50+ Female	665	727	Redacted
CARE_CURR_DS D	Sun of Age/Sex disaggregates	7,711	8,429	Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	347	380	Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	2,386	2,608	Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	347	380	Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	4,631	5,061	Redacted
CARE_CURR_DS D	Sum of Aggregated Age/Sex disaggregates	7,711	8,429	Redacted
CARE_NEW_DSD	Number of HIV-infected adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load	1,542	1,533	Redacted
CARE_NEW_DSD	Age/sex: <1 Male	2	2	Redacted
CARE_NEW_DSD	Age/sex: 1-4 Male	17	17	Redacted
CARE_NEW_DSD	Age/sex: 5-9 Male	28	28	Redacted
CARE_NEW_DSD	Age/sex: 10-14 Male	22	22	Redacted
CARE_NEW_DSD	Age/sex: 15-19 Male	10	10	Redacted
CARE_NEW_DSD	Age/sex: 20-24 Male	42	42	Redacted
CARE_NEW_DSD	Age/sex: 25-49 Male	357	354	Redacted
CARE_NEW_DSD	Age/sex: 50+ Male	68	68	Redacted
CARE_NEW_DSD	Age/sex: <1 Female	2	2	Redacted
CARE_NEW_DSD	Age/sex: 1-4 Female	16	16	Redacted



CARE_NEW_DSD	Age/sex: 5-9 Female	29	29	Redacted
CARE_NEW_DSD	Age/sex: 10-14 Female	22	22	Redacted
CARE_NEW_DSD	Age/sex: 15-19 Female	23	23	Redacted
CARE_NEW_DSD	Age/sex: 20-24 Female	43	42	Redacted
CARE_NEW_DSD	Age/sex: 25-49 Female	640	636	Redacted
CARE_NEW_DSD	Age/sex: 50+ Female	221	220	Redacted
CARE_NEW_DSD	Sum of Age/sex disaggregates	1,542	1,533	Redacted
CARE_NEW_DSD	Aggregated Age/sex: <15 Male	69	69	Redacted
CARE_NEW_DSD	Aggregated Age/sex: 15+ Male	477	474	Redacted
CARE_NEW_DSD	Aggregated Age/sex: <15 Female	69	69	Redacted
CARE_NEW_DSD	Aggregated Age/sex: 15+ Female	927	921	Redacted
CARE_NEW_DSD	Sum of Aggregated Age/sex disaggregates	1,542	1,533	Redacted
CARE_SITE	Number of PEPFAR-supported HIV clinical care sites at which at least 80% of PLHIV received all of the following during the reporting period: 1) clinical assessment (WHO staging) OR CD4 count OR viral load, AND 2) TB screening at last visit, AND 3) if eligible, cotrimoxazole	2	2	Redacted
CARE_SITE	Total number of PEPFAR supported sites providing clinical care services	2	2	Redacted
CARE_SITE	By site support type: Direct Service Delivery (DSD): Number of PEPFAR-supported HIV clinical care sites at which at least 80% of PLHIV received all of the following during the reporting period: 1) clinical assessment (WHO staging) OR CD4 count OR viral load, AND 2) TB screening at last visit, AND 3) if eligible, cotrimoxazole	2	2	Redacted
CARE_SITE	By site support type: Technical Assistance-only (TA): Number of	0	0	Redacted



	PEPFAR-supported HIV clinical care sites at which at least 80% of PLHIV received all of the following during the reporting period: 1) clinical assessment (WHO staging) OR CD4 count OR viral load, AND 2) TB screening at last visit, AND 3) if eligible, cotrimoxazole			
CARE_SITE	Sum of Numerator Site Support Type disaggregates	2	2	Redacted
CARE_SITE	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR supported sites providing clinical care services	2	2	Redacted
CARE_SITE	By site support type: Technical Assistance-only (TA): Total number of PEPFAR supported sites providing clinical care services	0	0	Redacted
CARE_SITE	Sum of Denominator Site Support Type disaggregates	2	2	Redacted
FN_SITE	Number of PEPFAR-supported sites achieving 90% nutrition assessments that result in accurate categorization of malnutrition	2	2	Redacted
FN_SITE	Total number of PEPFAR-supported sites providing nutrition assessment, counseling and support (NACS) services	2	2	Redacted
FN_SITE	By site support type: Direct Service Delivery (DSD): Number of PEPFAR-supported sites achieving 90% nutrition assessments that result in accurate categorization of malnutrition	2	2	Redacted
FN_SITE	Sum of Numerator Support Type disaggregates	2	2	Redacted

FN_SITE	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported sites providing nutrition assessment, counseling and support (NACS) services	2	2	Redacted
FN_SITE	By site support type: Technical Assistance-only (TA): Total number of PEPFAR-supported sites providing nutrition assessment, counseling and support (NACS) services	0	0	Redacted
FN_SITE	Sum of Denominator Support Type disaggregates	2	2	Redacted
FN_THER_DSD	Number of clinically malnourished PLHIV who received therapeutic and/or supplementary food during the reporting period.	1,218	1,331	Redacted
FN_THER_DSD	Number of PLHIV who were nutritionally assessed and found to be clinically undernourished.	1,623	1,775	Redacted
FN_THER_DSD	Age: <1	4	4	Redacted
FN_THER_DSD	Age: 1-4	26	29	Redacted
FN_THER_DSD	Age: 5-14	82	90	Redacted
FN_THER_DSD	Age: 15-17	25	27	Redacted
FN_THER_DSD	Age: 18+	1,081	1,181	Redacted
FN_THER_DSD	Sum of Age disaggregates	1,218	1,331	Redacted
FN_THER_DSD	Aggregated Age: <18	137	150	Redacted
FN_THER_DSD	Aggregated Age: 18+	1,081	1,181	Redacted
FN_THER_DSD	Sum of Aggregated Age disaggregates	1,218	1,331	Redacted
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	310	379	Redacted
TB_ART_DSD	The number of registered new and	365	421	Redacted

	relapse TB cases with documented HIV-positive status during TB treatment during the reporting period			
TB_ART_DSD	Age: 0-4	8	9	Redacted
TB_ART_DSD	Age: 5-14	20	26	Redacted
TB_ART_DSD	Age: 15+	282	344	Redacted
TB_ART_DSD	Male	168	205	Redacted
TB_ART_DSD	Female	142	174	Redacted
TB_ART_DSD	Sum of Sex disaggregates	310	379	Redacted
TB_ART_DSD	Newly tested	186	228	Redacted
TB_ART_DSD	Known HIV-positive	124	151	Redacted
TB_ART_DSD	Sum of Test Status disaggregates	310	379	Redacted
TB_ART_DSD	Aggregated Age: <15	28	35	Redacted
TB_ART_DSD	Aggregated Age: 15+	282	344	Redacted
TB_ART_DSD	Sum of Aggregated Age disaggregates	310	379	Redacted
TB_ARTSITE	The number of PEPFAR-supported TB basic management units at which 80% of registered TB cases who are HIV-positive are on ART, during the reporting period	2	2	Redacted
TB_ARTSITE	The number of PEPFAR-supported TB basic management units	2	2	Redacted
TB_ARTSITE	By site support type: Direct Service Delivery (DSD): The number of PEPFAR-supported TB basic management units at which 80% of registered TB cases who are HIV-positive are on ART, during the reporting period	2	2	Redacted
TB_ARTSITE	By site support type: Technical Assistance-only (TA): The number of PEPFAR-supported TB basic management units at which 80% of registered TB cases who are	0	0	Redacted

	HIV-positive are on ART, during the reporting period			
TB_ARTSITE	Sum of Numerator Site Support Type disaggregates	2	2	Redacted
TB_ARTSITE	By site support type: Direct Service Delivery (DSD): The number of PEPFAR-supported TB basic management units	2	2	Redacted
TB_ARTSITE	By site support type: Technical Assistance-only (TA): The number of PEPFAR-supported TB basic management units	0	0	Redacted
TB_ARTSITE	Sum of Denominator Site Support Type disaggregates	2	2	Redacted
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	924	943	Redacted
PMTCT_EID_DSD	Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT)	1,155	1,178	Redacted
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	693	707	Redacted
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	231	236	Redacted
PMTCT_EID_DSD	Sum of Infant Age disaggregates	924	943	Redacted
PMTCT_EID_DSD	By infants with a positive virologic test result within 12 months of birth	46	47	Redacted
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	7,930	9,013	Redacted
TX_CURR_DSD	Age/Sex: <1 Male	12	14	Redacted
TX_CURR_DSD	Age/Sex: 1-4 Male	84	95	Redacted
TX_CURR_DSD	Age/Sex: 5-14 Male	261	297	Redacted



TX_CURR_DSD	Age/Sex: 15+ Male	2,453	2,870	Redacted
TX_CURR_DSD	Age/Sex: <1 Female	12	14	Redacted
TX_CURR_DSD	Age/Sex: 1-4 Female	84	95	Redacted
TX_CURR_DSD	Age/Sex: 5-14 Female	261	298	Redacted
TX_CURR_DSD	Age/Sex: 15+ Female	4,763	5,330	Redacted
TX_CURR_DSD	Sum of age/sex disaggregates	714	813	Redacted
TX_CURR_DSD	Percent children with advanced HIV infection receiving antiretroviral therapy (ART) [CURRENT]	98	98	Redacted
TX_CURR_DSD	Percent women and girls with advanced HIV infection receiving antiretroviral therapy (ART) [CURRENT]	98	98	Redacted
TX_CURR_DSD	Aggregated Age/Sex: <1 Male	12	14	Redacted
TX_CURR_DSD	Aggregated Age/Sex: <1 Female	12	14	Redacted
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	357	406	Redacted
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	2,453	2,870	Redacted
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	357	407	Redacted
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	4,763	5,330	Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	714	813	Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	7,216	8,200	Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	7,930	9,013	Redacted
TX_CURR_NGI	Number of adults and children receiving antiretroviral therapy (ART)	7,930	9,013	Redacted
TX_CURR_NGI	Age/Sex: <1 Male	12	14	Redacted
TX_CURR_NGI	Age/Sex: 1-4 Male	84	95	Redacted
TX_CURR_NGI	Age/Sex: 5-14 Male	261	297	Redacted
TX_CURR_NGI	Age/Sex: 15+ Male	2,453	2,870	Redacted
TX_CURR_NGI	Age/Sex: <1 Female	12	14	Redacted
TX_CURR_NGI	Age/Sex: 1-4 Female	84	95	Redacted
TX_CURR_NGI	Age/Sex: 5-14 Female	261	298	Redacted
TX_CURR_NGI	Age/Sex: 15+ Female	4,763	5,330	Redacted



TX_CURR_NGI	Sum of Age/Sex disaggregates	7,930	9,013	Redacted
TX_CURR_NGI	Aggregated Age/Sex: <1 Male	12	14	Redacted
TX_CURR_NGI	Aggregated Age/Sex: <1 Female	12	14	Redacted
TX_CURR_NGI	Aggregated Age/Sex: <15 Male	357	406	Redacted
TX_CURR_NGI	Aggregated Age/Sex: 15+ Male	2,453	2,870	Redacted
TX_CURR_NGI	Aggregated Age/Sex: <15 Female	357	407	Redacted
TX_CURR_NGI	Aggregated Age/Sex: 15+ Female	4,763	5,330	Redacted
TX_CURR_NGI	Sum of Aggregated Age/Sex disaggregates	7,930	9,013	Redacted
TX_CURR_NGI	Sum of Aggregated Age/Sex <15	714	813	Redacted
TX_CURR_NGI	Sum of Aggregated Age/Sex 15+	7,216	8,200	Redacted
TX_DIST	Number of Districts with documented routine supportive supervision visits to 75% of HIV care and treatment sites supported by the District	1	1	Redacted
TX_DIST	Total number of PEPFAR supported District Health Offices	1	1	Redacted
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	993	980	Redacted
TX_NEW_DSD	By Age/Sex: <1 Male	15	21	Redacted
TX_NEW_DSD	By Age/Sex: 1-4 Male	9	12	Redacted
TX_NEW_DSD	By Age/Sex: 5-9 Male	15	21	Redacted
TX_NEW_DSD	By Age/Sex: 10-14 Male	12	15	Redacted
TX_NEW_DSD	By Age/Sex: 15-19 Male	8	7	Redacted
TX_NEW_DSD	By Age/Sex: 20-24 Male	14	14	Redacted
TX_NEW_DSD	By Age/Sex: 25-49 Male	215	203	Redacted
TX_NEW_DSD	By Age/Sex: 50+ Male	75	71	Redacted
TX_NEW_DSD	By Age/Sex: <1 Female	15	21	Redacted
TX_NEW_DSD	By Age/Sex: 1-4 Female	9	12	Redacted
TX_NEW_DSD	By Age/Sex: 5-9 Female	15	21	Redacted
TX_NEW_DSD	By Age/Sex: 10-14 Female	12	15	Redacted
TX_NEW_DSD	By Age/Sex: 15-19 Female	12	12	Redacted
TX_NEW_DSD	By Age/Sex: 20-24 Female	51	48	Redacted

TX_NEW_DSD	By Age/Sex: 25-49 Female	433	409	Redacted
TX_NEW_DSD	By Age/Sex: 50+ Female	83	78	Redacted
TX_NEW_DSD	Sum of Age/Sex disaggregates	993	980	Redacted
TX_NEW_DSD	Aggregated Grouping by Age: <1 Male	15	21	Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	51	69	Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	312	295	Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <1 Female	15	21	Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	51	69	Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	579	547	Redacted
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	993	980	Redacted
TX_NEW_DSD	Pregnancy status	364	371	Redacted
TX_NEW_DSD	Breastfeeding status	40	41	Redacted
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	669	844	Redacted
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	787	993	Redacted
TX_RET_DSD	Age: 0-4 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	17	21	Redacted
TX_RET_DSD	Age: 5-14 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after	45	57	Redacted



	initiating ART)			
TX_RET_DSD	Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	607	766	Redacted
TX_RET_DSD	Age: 0-4 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	19	25	Redacted
TX_RET_DSD	Age: 5-14 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	53	67	Redacted
TX_RET_DSD	Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	714	901	Redacted
TX_RET_DSD	Aggregated Age: <15 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	62	78	Redacted
TX_RET_DSD	Aggregated Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	607	766	Redacted
TX_RET_DSD	Aggregated Age: <15 (Denominator: Total number of adults and children	73	92	Redacted



	who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)			
TX_RET_DSD	Aggregated Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	714	901	Redacted
TX_RET_DSD	Pregnancy and breastfeeding status (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	368	736	Redacted
TX_RET_DSD	Pregnancy and breastfeeding status (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	433	866	Redacted
TX_SITE	Number of PEPFAR-supported ART sites with a retention rate of 75% or greater for patients 12 months after ART initiation	2	2	Redacted
TX_SITE	Total number of PEPFAR-supported ART sites	2	2	Redacted
TX_SITE	By support type: Direct Service Delivery (DSD): Number of PEPFAR-supported ART sites with a retention rate of 75% or greater for patients 12 months after ART initiation	2	2	Redacted
TX_SITE	By support type: Technical Assistance	0	0	Redacted



	(TA-only): Number of PEPFAR-supported ART sites with a retention rate of 75% or greater for patients 12 months after ART initiation			
TX_SITE	Sum of Numerator Site Support Type disaggregates	2	2	Redacted
TX_SITE	By support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported ART sites	2	2	Redacted
TX_SITE	By support type: Technical Assistance (TA-only): Total number of PEPFAR-supported ART sites	0	0	Redacted
TX_SITE	Sum of Denominator Site Support Type disaggregates	2	2	Redacted
LAB_CAP_DSD	Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests	2	2	Redacted
LAB_CAP_DSD	By clinical laboratories	0	0	Redacted
LAB_CAP_DSD	By Point-of-care testing sites	0	0	Redacted
LAB_CAP_DSD	By site support type: Direct Service Delivery (DSD)	2	2	Redacted
LAB_CAP_DSD	By site support type: Technical Assistance-only (TA)	0	0	Redacted
LAB_CAP_DSD	Sum of Site Support Type disaggregates	2	2	Redacted
FPINT_SITE_DSD	Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	2	2	Redacted
FPINT_SITE_DSD	Total number of PEPFAR-supported HIV service delivery points: PMTCT, Care and Treatment	2	2	Redacted
FPINT_SITE_DSD	By site support type: Direct Service Delivery (DSD): Number of service delivery points supported by PEPFAR	2	2	Redacted



	for HIV services that are directly providing integrated voluntary family planning services			
FPINT_SITE_DSD	By site support type: Technical Assistance-only (TA): Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	0	0	Redacted
FPINT_SITE_DSD	Sum of Numerator Site Support Type disaggregates	2	2	Redacted
FPINT_SITE_DSD	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported HIV service delivery points	2	2	Redacted
FPINT_SITE_DSD	By site support type: Technical Assistance-only (TA): Total number of PEPFAR-supported HIV service delivery points	0	0	Redacted
FPINT_SITE_DSD	Sum of Denominator Site Support Type disaggregates	2	2	Redacted
FPINT_SITE_DSD	Service delivery type: Clinical	2	2	Redacted
FPINT_SITE_DSD	Sum of Service Delivery Type disaggregates	2	2	Redacted
QI_SITE	Number of PEPFAR-supported clinical service sites with a quality improvement activity completed that addresses clinical HIV programs and has documented process results in the last 6 months	2	2	Redacted
QI_SITE	Total number of PEPFAR-supported sites for any HIV clinical service including HIV Care, HIV Treatment, TB care, PMTCT, VMMC, and HTC	2	2	Redacted
QI_SITE	By site support type: Direct Service	2	2	Redacted



	Delivery (DSD): Number of PEPFAR-supported clinical service sites with a quality improvement activity completed that addresses clinical HIV programs and has documented results in the last 6 months			
QI_SITE	Sum of Numerator Site Support Type disaggregates	2	2	Redacted
QI_SITE	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported sites for any HIV clinical service including HIV Care, HIV Treatment, TB care, PMTCT, VMMC, HTC	2	2	Redacted
QI_SITE	By site support type: Technical Assistance-only (TA): Total number of PEPFAR-supported sites for any HIV clinical service including HIV Care, HIV Treatment, TB care, PMTCT, VMMC, and HTC	0	0	Redacted
QI_SITE	Sum of Denominator Site Support Type disaggregates	2	2	Redacted
TB_SCREEN_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period	6,940	8,008	Redacted
TB_SCREEN_DSD	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	7,711	8,429	Redacted
TB_SCREEN_DSD	Age: <1	22	26	Redacted
TB_SCREEN_DSD	Age: 1-4	150	173	Redacted
TB_SCREEN_DSD	Age: 5-9	264	305	Redacted
TB_SCREEN_DSD	Age: 10-14	204	234	Redacted



TB_SCREEN_DSD	Age: 15-19	140	162	Redacted
TB_SCREEN_DSD	Age: 20-24	468	540	Redacted
TB_SCREEN_DSD	Age: 25-49	4,596	5,303	Redacted
TB_SCREEN_DSD	Age: 50+	1,096	1,265	Redacted
TB_SCREEN_DSD	Sum of Age disaggregates	780	900	Redacted
TB_SCREEN_DSD	Aggregated Age - USE WITH HQ PERMISSION ONLY: <15	640	738	Redacted
TB_SCREEN_DSD	Aggregated Age - USE WITH HQ PERMISSION ONLY: 15+	6,300	7,270	Redacted
TB_SCREEN_DSD	Sum of Aggregated Age disaggregates	6,940	8,008	Redacted
TB_SCREEN_DSD	Sex: Male	2,462	2,841	Redacted
TB_SCREEN_DSD	Sex: Female	4,478	5,167	Redacted
TB_SCREEN_DSD	Sum of Sex disaggregates	6,940	8,008	Redacted

Implementing Mechanism Details

Mechanism ID: 12551	Mechanism Name: Clinical Services
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: University of California at San Francisco	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: No	
G2G: No	Managing Agency:

Total All Funding Sources: 9,247,622	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 0	
FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount
GHP-State	9,247,622

Sub Partner Name(s)

Kenya Medical Research Institute	University of Colorado	
----------------------------------	------------------------	--



Cross-Cutting Budget Attribution(s)

Human Resources for Health	2,302,520
Gender: GBV	172,500
Focus Area:	Post GBV Care
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Gender: Gender Equality	172,500
Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation

Key Issues

- Malaria (PMI)
- Child Survival Activities
- Safe Motherhood
- TB
- Family Planning

Budget Code Information

Mechanism ID: 12551			
Mechanism Name: Clinical Services			
Prime Partner Name: University of California at San Francisco			
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Care	HBHC	586,481	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	417,380	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	200,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	1,352,919	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	825,604	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	952,972	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	4,415,879	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	496,387	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2014	2015	Planning Budget Targets
SITE_SUPP	Number of unique sites supported by PEPFAR	140	140	Redacted
SITE_SUPP	By program area/support type: HTC Direct Service Delivery (DSD)	140	140	Redacted
SITE_SUPP	By program area/support type: HTC	0	0	Redacted



	Technical Assistance-only (TA)			
SITE_SUPP	By program area/support type: Treatment Direct Service Delivery (DSD)	123	123	Redacted
SITE_SUPP	By program area/support type: Treatment Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: Care and Support Direct Service Delivery (DSD)	128	128	Redacted
SITE_SUPP	By program area/support type: Care and Support Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: Food and Nutrition Direct Service Delivery (DSD)	128	128	Redacted
SITE_SUPP	By program area/support type: Food and Nutrition Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: PMTCT Direct Service Delivery (DSD)	140	140	Redacted
SITE_SUPP	By program area/support type: PMTCT Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: TB/HIV Direct Service Delivery (DSD)	140	140	Redacted
SITE_SUPP	By program area/support type: TB/HIV Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: VMMC Direct Service Delivery (DSD)	28	28	Redacted
SITE_SUPP	By program area/support type: VMMC Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: General Population Prevention Direct Service Delivery (DSD)	0	0	Redacted



SITE_SUPP	By program area/support type: General Population Prevention Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: Key Populations Prevention Direct Service Delivery (DSD)	0	0	Redacted
SITE_SUPP	By program area/support type: Key Populations Prevention Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: OVC Direct Service Delivery (DSD)	0	0	Redacted
SITE_SUPP	By program area/support type: OVC Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: PHDP/Family Planning & Integration Direct Service Delivery (DSD)	140	140	Redacted
SITE_SUPP	By program area/support type: PHDP/Family Planning & Integration Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: Lab Direct Service Delivery (DSD)	140	140	Redacted
SITE_SUPP	By program area/support type: Lab Technical Assistance-only (TA)	0	0	Redacted
PMTCT_ARV_DS D	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	8,729	8,904	Redacted
PMTCT_ARV_DS D	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	8,729	8,904	Redacted
PMTCT_ARV_DS D	Life-long ART (including Option B+)	6,547	6,678	Redacted
PMTCT_ARV_DS D	Sub-Disag of Life-long ART: Newly initiated on treatment during the current	3,055	3,116	Redacted

	pregnancy			
PMTCT_ARV_DS D	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	3,492	3,562	Redacted
PMTCT_ARV_DS D	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)	0	0	Redacted
PMTCT_ARV_DS D	Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)	2,182	2,226	Redacted
PMTCT_ARV_DS D	Single-dose nevirapine (with or without tail)	0	0	Redacted
PMTCT_ARV_DS D	Sum of Regimen Type disaggregates	8,729	8,904	Redacted
PMTCT_ARV_DS D	Sum of New and Current disaggregates	6,547	6,678	Redacted
PMTCT_ARV_NGI	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	8,729	8,904	Redacted
PMTCT_ARV_NGI	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	8,729	8,904	Redacted
PMTCT_ARV_NGI	Life-long ART (including Option B+)	6,547	6,678	Redacted
PMTCT_ARV_NGI	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	3,055	3,116	Redacted
PMTCT_ARV_NGI	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	3,492	3,562	Redacted
PMTCT_ARV_NGI	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)	0	0	Redacted
PMTCT_ARV_NGI	Maternal AZT (prophylaxis component	2,182	2,226	Redacted



	of WHO Option A during pregnancy and delivery)			
PMTCT_ARV_NGI	Single-dose nevirapine (with or without tail)	0	0	Redacted
PMTCT_ARV_NGI	Sum of Regimen disaggregates	8,729	8,904	Redacted
PMTCT_ARV_NGI	Sum of New and Current disaggregates	6,547	6,678	Redacted
PMTCT_SITE	Number of PEPFAR-supported sites achieving 90% ARV or ART coverage for HIV+ pregnant women	140	140	Redacted
PMTCT_SITE	Total number of PEPFAR supported sites providing PMTCT services (HTC and ARV or ART services)	140	140	Redacted
PMTCT_SITE	By site support type: Direct Service Delivery (DSD): Number of PEPFAR-supported sites achieving 90% ARV or ART coverage for HIV+ pregnant women	140	140	Redacted
PMTCT_SITE	By site support type: Technical Assistance-only (TA): Number of PEPFAR-supported sites achieving 90% ARV or ART coverage for HIV+ pregnant women	0	0	Redacted
PMTCT_SITE	Sum of Numerator Support Type disaggregates	140	140	Redacted
PMTCT_SITE	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR supported sites providing PMTCT services (HTC and ARV or ART services)	140	140	Redacted
PMTCT_SITE	By site support type: Technical Assistance-only (TA): Total number of PEPFAR supported sites providing PMTCT services (HTC and ARV or ART services)	0	0	Redacted
PMTCT_SITE	Sum of Denominator Support Type	140	140	Redacted

	disaggregates			
PMTCT_STAT_DS D	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	48,183	54,403	Redacted
PMTCT_STAT_DS D	Number of new ANC and L&D clients	48,183	54,403	Redacted
PMTCT_STAT_DS D	By: Known positives at entry	4,103	4,185	Redacted
PMTCT_STAT_DS D	By: Number of new positives identified	4,626	4,719	Redacted
PMTCT_STAT_DS D	Sum of Positives Status disaggregates	8,729	8,904	Redacted
PMTCT_STAT_NG I	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	48,183	54,403	Redacted
PMTCT_STAT_NG I	Number of new ANC and L&D clients	48,183	54,403	Redacted
PMTCT_STAT_NG I	By: Known positives at entry	4,103	4,185	Redacted
PMTCT_STAT_NG I	By: Number of new positives identified	4,626	4,719	Redacted
PMTCT_STAT_NG I	Sum of Positives Status disaggregates	8,729	8,904	Redacted
VMMC_AE_DSD	Number of males circumcised surgically or by medical device that experienced at least one moderate or severe adverse event(s) (AEs)	2	6	Redacted
VMMC_AE_DSD	By AE type: Number of VMMC clients with one or more moderate or severe surgical intra-operative AE(s)	2	6	Redacted
VMMC_AE_DSD	Sub-Disag: Surgical intra-operative AE(s) by maximum severity category: Number of clients with one or more	1	3	Redacted

	moderate surgical intra-operative AE(s), but no severe surgical intra-operative AE(s)			
VMMC_AE_DSD	Sub-Disag: Surgical intra-operative AE(s) by maximum severity category: Number of clients with one or more severe surgical intra-operative AE(s)	0	1	Redacted
VMMC_AE_DSD	By AE Type: Number of VMMC clients with one or more moderate or severe surgical post-operative AE(s)	1	3	Redacted
VMMC_AE_DSD	Sub-Disag: By Surgical post-operative AE(s) by maximum severity category: Number of clients with one or more moderate surgical post-operative AE(s), but no severe surgical post-operative AE(s)	1	3	Redacted
VMMC_AE_DSD	Sub-Disag: By Surgical post-operative AE(s) by maximum severity category: Number of clients with one or more severe surgical intra-operative AE(s)	0	0	Redacted
VMMC_CIRC_DS D	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	9,404	22,179	Redacted
VMMC_CIRC_DS D	By Age: <1	47		Redacted
VMMC_CIRC_DS D	By Age: 1-9	0	0	Redacted
VMMC_CIRC_DS D	By Age: 10-14	3,762	8,983	Redacted
VMMC_CIRC_DS D	By Age: 15-19	3,762	8,872	Redacted
VMMC_CIRC_DS D	By Age: 20-24	940	2,217	Redacted

VMMC_CIRC_DS D	By Age: 25-49	893	2,107	Redacted
VMMC_CIRC_DS D	By Age: 50+	0	0	Redacted
VMMC_CIRC_DS D	Sum of age disaggregates	9,404	22,179	Redacted
VMMC_CIRC_DS D	By HIV status: Number of HIV-positive clients (tested HIV positive at VMMC site)	184	435	Redacted
VMMC_CIRC_DS D	By HIV status: Number of HIV-negative clients (tested HIV negative at VMMC program)	8,571	20,214	Redacted
VMMC_CIRC_DS D	By HIV status: Number of clients with undocumented/indeterminate HIV status or not tested for HIV at site	461	1,086	Redacted
VMMC_CIRC_DS D	By circumcision technique: Surgical VMMC	9,404	22,179	Redacted
VMMC_CIRC_DS D	By follow-up status: Number of surgically circumcised clients who returned at least once for follow-up care within 14 days of circumcision surgery	3,291	7,763	Redacted
VMMC_CIRC_DS D	By follow-up status: Number of surgically circumcised clients who did NOT return for follow-up care within 14 days of circumcision surgery	6,113	14,416	Redacted
VMMC_CIRC_NGI	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	9,404	22,179	Redacted
VMMC_CIRC_NGI	By Age: <1	47		Redacted
VMMC_CIRC_NGI	By Age: 1-9	0	0	Redacted
VMMC_CIRC_NGI	By Age: 10-14	3,762	8,983	Redacted
VMMC_CIRC_NGI	By Age: 15-19	3,762	8,872	Redacted

VMMC_CIRC_NGI	By Age: 20-24	940	2,217	Redacted
VMMC_CIRC_NGI	By Age: 25-49	893	2,107	Redacted
VMMC_CIRC_NGI	By Age: 50+	0	0	Redacted
VMMC_CIRC_NGI	Sum of Age disaggregates	9,404	22,179	Redacted
VMMC_CIRC_NGI	By HIV status: Number of HIV-positive clients (tested HIV positive at VMMC site)	184	435	Redacted
VMMC_CIRC_NGI	By HIV status: Number of HIV-negative clients (tested HIV negative at VMMC program)	8,571	20,214	Redacted
VMMC_CIRC_NGI	By HIV status: Number of clients with undocumented/indeterminate HIV status or not tested for HIV at site	461	1,086	Redacted
VMMC_CIRC_NGI	By circumcision technique: Surgical VMMC	9,404	22,179	Redacted
VMMC_CIRC_NGI	By follow-up status: Number of surgically circumcised clients who returned at least once for follow-up care within 14 days of circumcision surgery	3,291	7,763	Redacted
VMMC_CIRC_NGI	By follow-up status: Number of surgically circumcised clients who did NOT return for follow-up care within 14 days of circumcision surgery	6,113	14,416	Redacted
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	103,500	282,750	Redacted
HTC_TST_DSD	By Test Result: Negative	99,360	271,440	Redacted
HTC_TST_DSD	By Test Result: Positive	4,140	11,310	Redacted
HTC_TST_DSD	Sum of Test Result disaggregates	103,500	282,750	Redacted
HTC_TST_DSD	Age/sex: <1 Male	0	0	Redacted
HTC_TST_DSD	Age/sex: 1-4 Male	3,622	9,897	Redacted
HTC_TST_DSD	Age/sex: 5-9 Male	1,553	4,242	Redacted
HTC_TST_DSD	Age/sex: 10-14 Male	2,588	7,068	Redacted
HTC_TST_DSD	Age/sex: 15-19 Male	5,175	14,137	Redacted

HTC_TST_DSD	Age/sex: 20-24 Male	12,937	35,344	Redacted
HTC_TST_DSD	Age/sex: 25-49 Male	20,700	56,550	Redacted
HTC_TST_DSD	Age/sex: 50+ Male	5,175	14,137	Redacted
HTC_TST_DSD	Age/sex: <1 Female	0	0	Redacted
HTC_TST_DSD	Age/sex: 1-4 Female	3,622	9,897	Redacted
HTC_TST_DSD	Age/sex: 5-9 Female	1,553	4,242	Redacted
HTC_TST_DSD	Age/sex: 10-14 Female	2,588	7,068	Redacted
HTC_TST_DSD	Age/sex: 15-19 Female	5,175	14,137	Redacted
HTC_TST_DSD	Age/sex: 20-24 Female	12,937	35,344	Redacted
HTC_TST_DSD	Age/sex: 25-49 Female	20,700	56,550	Redacted
HTC_TST_DSD	Age/sex: 50+ Female	5,175	14,137	Redacted
HTC_TST_DSD	Sum of Age/Sex disaggregates	103,500	282,750	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	7,763	21,207	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	43,987	120,168	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	7,763	21,207	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	43,987	120,168	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	15,526	42,414	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	87,974	240,336	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	103,500	282,750	Redacted
HTC_TST_NGI	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	103,500	282,750	Redacted
HTC_TST_NGI	By Test Result: Negative	99,360	271,440	Redacted
HTC_TST_NGI	By Test Result: Positive	4,140	11,310	Redacted
HTC_TST_NGI	Sum of Test Result disaggregates	103,500	282,750	Redacted
HTC_TST_NGI	Age/sex: <1 Male	0	0	Redacted
HTC_TST_NGI	Age/sex: 1-4 Male	3,623	9,897	Redacted
HTC_TST_NGI	Age/sex: 5-9 Male	1,553	4,242	Redacted



HTC_TST_NGI	Age/sex: 10-14 Male	2,588	7,068	Redacted
HTC_TST_NGI	Age/sex: 15-19 Male	5,175	14,137	Redacted
HTC_TST_NGI	Age/sex: 20-24 Male	12,938	35,344	Redacted
HTC_TST_NGI	Age/sex: 25-49 Male	20,700	56,550	Redacted
HTC_TST_NGI	Age/sex: 50+ Male	5,175	14,137	Redacted
HTC_TST_NGI	Age/sex: <1 Female	0	0	Redacted
HTC_TST_NGI	Age/sex: 1-4 Female	3,623	9,897	Redacted
HTC_TST_NGI	Age/sex: 5-9 Female	1,553	4,242	Redacted
HTC_TST_NGI	Age/sex: 10-14 Female	2,588	7,068	Redacted
HTC_TST_NGI	Age/sex: 15-19 Female	5,175	14,137	Redacted
HTC_TST_NGI	Age/sex: 20-24 Female	12,938	35,344	Redacted
HTC_TST_NGI	Age/sex: 25-49 Female	20,700	56,550	Redacted
HTC_TST_NGI	Age/sex: 50+ Female	5,171	14,137	Redacted
HTC_TST_NGI	Sum of Age/Sex disaggregates	103,500	282,750	Redacted
HTC_TST_NGI	Aggregated Age/sex: <15 Male	7,763	21,207	Redacted
HTC_TST_NGI	Aggregated Age/sex: 15+ Male	43,988	120,168	Redacted
HTC_TST_NGI	Aggregated Age/sex: <15 Female	7,763	21,207	Redacted
HTC_TST_NGI	Aggregated Age/sex: 15+ Female	43,986	120,168	Redacted
HTC_TST_NGI	Sum of Aggregated Age/Sex <15	15,526	42,414	Redacted
HTC_TST_NGI	Sum of Aggregated Age/Sex 15+	87,974	240,336	Redacted
HTC_TST_NGI	Sum of Aggregated Age/Sex disaggregates	103,500	282,750	Redacted
C2.1.D_DSD	Number of HIV-positive individuals receiving a minimum of one clinical service	91,439	99,951	Redacted
C2.1.D_DSD	By Age/Sex: <15 Female	4,115	4,508	Redacted
C2.1.D_DSD	By Age/Sex: <15 Male	4,115	4,509	Redacted
C2.1.D_DSD	By Age/Sex: 15+ Female	54,918	60,017	Redacted
C2.1.D_DSD	By Age/Sex: 15+ Male	28,291	30,917	Redacted
C2.1.D_DSD	Sum of Age/Sex disaggregates	91,439	99,951	Redacted
C2.1.D_DSD	By Age: <15	8,230	9,017	Redacted
C2.1.D_DSD	By Age: 15+	83,209	90,934	Redacted

C2.1.D_DSD	Sum of Age disaggregates	91,439	99,951	Redacted
C2.1.D_DSD	By Sex: Female	59,033	64,525	Redacted
C2.1.D_DSD	By Sex: Male	32,406	35,426	Redacted
C2.1.D_DSD	Sum of Sex disaggregates	91,439	99,951	Redacted
C2.1.D_NGI	Number of HIV-positive individuals receiving a minimum of one clinical service	91,439	99,951	Redacted
C2.1.D_NGI	By Age/Sex: <15 Female	4,115	4,508	Redacted
C2.1.D_NGI	By Age/Sex: <15 Male	4,115	4,508	Redacted
C2.1.D_NGI	By Age/Sex: 15+ Female	54,918	60,017	Redacted
C2.1.D_NGI	By Age/Sex: 15+ Male	28,291	30,918	Redacted
C2.1.D_NGI	Sum of Age/Sex disaggregates	91,439	99,951	Redacted
C2.1.D_NGI	By Age: <15	8,230	9,017	Redacted
C2.1.D_NGI	By Age: 15+	83,209	90,934	Redacted
C2.1.D_NGI	Sum of Age disaggregates	91,439	99,951	Redacted
C2.1.D_NGI	By Sex: Female	59,033	64,525	Redacted
C2.1.D_NGI	By Sex: Male	32,406	35,426	Redacted
C2.1.D_NGI	Sum of Sex disaggregates	91,439	99,951	Redacted
C2.4.D_DSD	Number of HIV-positive patients who were screened for TB in HIV care or treatment setting	82,295	94,953	Redacted
C2.4.D_DSD	Number of HIV-positive individuals receiving a minimum of one clinical service	91,439	99,951	Redacted
C2.5.D_DSD	Number of HIV-positive patients in HIV care who started TB treatment	1,646	1,899	Redacted
C2.5.D_DSD	Number of HIV-positive individuals receiving a minimum of one clinical service	91,439	99,951	Redacted
CARE_CURR_DS D	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	86,867	94,953	Redacted



CARE_CURR_DS D	Age/sex: <1 Male	135	148	Redacted
CARE_CURR_DS D	Age/sex: 1-4 Male	939	1,029	Redacted
CARE_CURR_DS D	Age/sex: 5-9 Male	1,587	1,739	Redacted
CARE_CURR_DS D	Age/sex: 10-14 Male	1,248	1,367	Redacted
CARE_CURR_DS D	Age/sex: 15-19 Male	666	728	Redacted
CARE_CURR_DS D	Age/sex: 20-24 Male	1,235	1,349	Redacted
CARE_CURR_DS D	Age/sex: 25-49 Male	18,562	20,285	Redacted
CARE_CURR_DS D	Age/sex: 50+ Male	6,414	7,010	Redacted
CARE_CURR_DS D	Age/sex: <1 Female	135	148	Redacted
CARE_CURR_DS D	Age/sex: 1-4 Female	892	978	Redacted
CARE_CURR_DS D	Age/sex: 5-9 Female	1,642	1,799	Redacted
CARE_CURR_DS D	Age/sex: 10-14 Female	1,240	1,358	Redacted
CARE_CURR_DS D	Age/sex: 15-19 Female	1,101	1,203	Redacted
CARE_CURR_DS D	Age/sex: 20-24 Female	4,567	4,991	Redacted
CARE_CURR_DS D	Age/sex: 25-49 Female	39,007	42,628	Redacted
CARE_CURR_DS D	Age/sex: 50+ Female	7,497	8,193	Redacted
CARE_CURR_DS D	Sun of Age/Sex disaggregates	86,867	94,953	Redacted



CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	3,909	4,283	Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	26,877	29,372	Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	3,909	4,283	Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	52,172	57,015	Redacted
CARE_CURR_DS D	Sum of Aggregated Age/Sex disaggregates	86,867	94,953	Redacted
CARE_NEW_DSD	Number of HIV-infected adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load	17,373	17,265	Redacted
CARE_NEW_DSD	Age/sex: <1 Male	27	27	Redacted
CARE_NEW_DSD	Age/sex: 1-4 Male	188	187	Redacted
CARE_NEW_DSD	Age/sex: 5-9 Male	317	316	Redacted
CARE_NEW_DSD	Age/sex: 10-14 Male	250	249	Redacted
CARE_NEW_DSD	Age/sex: 15-19 Male	113	113	Redacted
CARE_NEW_DSD	Age/sex: 20-24 Male	471	468	Redacted
CARE_NEW_DSD	Age/sex: 25-49 Male	4,017	3,993	Redacted
CARE_NEW_DSD	Age/sex: 50+ Male	773	766	Redacted
CARE_NEW_DSD	Age/sex: <1 Female	28	27	Redacted
CARE_NEW_DSD	Age/sex: 1-4 Female	178	178	Redacted
CARE_NEW_DSD	Age/sex: 5-9 Female	328	327	Redacted
CARE_NEW_DSD	Age/sex: 10-14 Female	248	247	Redacted
CARE_NEW_DSD	Age/sex: 15-19 Female	259	257	Redacted
CARE_NEW_DSD	Age/sex: 20-24 Female	479	476	Redacted
CARE_NEW_DSD	Age/sex: 25-49 Female	7,207	7,160	Redacted
CARE_NEW_DSD	Age/sex: 50+ Female	2,490	2,474	Redacted
CARE_NEW_DSD	Sum of Age/sex disaggregates	17,373	17,265	Redacted



CARE_NEW_DSD	Aggregated Age/sex: <15 Male	782	779	Redacted
CARE_NEW_DSD	Aggregated Age/sex: 15+ Male	5,374	5,340	Redacted
CARE_NEW_DSD	Aggregated Age/sex: <15 Female	782	779	Redacted
CARE_NEW_DSD	Aggregated Age/sex: 15+ Female	10,435	10,367	Redacted
CARE_NEW_DSD	Sum of Aggregated Age/sex disaggregates	17,373	17,265	Redacted
CARE_SITE	Number of PEPFAR-supported HIV clinical care sites at which at least 80% of PLHIV received all of the following during the reporting period: 1) clinical assessment (WHO staging) OR CD4 count OR viral load, AND 2) TB screening at last visit, AND 3) if eligible, cotrimoxazole	128	128	Redacted
CARE_SITE	Total number of PEPFAR supported sites providing clinical care services	128	128	Redacted
CARE_SITE	By site support type: Direct Service Delivery (DSD): Number of PEPFAR-supported HIV clinical care sites at which at least 80% of PLHIV received all of the following during the reporting period: 1) clinical assessment (WHO staging) OR CD4 count OR viral load, AND 2) TB screening at last visit, AND 3) if eligible, cotrimoxazole	128	128	Redacted
CARE_SITE	By site support type: Technical Assistance-only (TA): Number of PEPFAR-supported HIV clinical care sites at which at least 80% of PLHIV received all of the following during the reporting period: 1) clinical assessment (WHO staging) OR CD4 count OR viral load, AND 2) TB screening at last visit, AND 3) if eligible, cotrimoxazole	0	0	Redacted
CARE_SITE	Sum of Numerator Site Support Type	128	128	Redacted



	disaggregates			
CARE_SITE	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR supported sites providing clinical care services	128	128	Redacted
CARE_SITE	Sum of Denominator Site Support Type disaggregates	128	128	Redacted
FN_SITE	Number of PEPFAR-supported sites achieving 90% nutrition assessments that result in accurate categorization of malnutrition	115	115	Redacted
FN_SITE	Total number of PEPFAR-supported sites providing nutrition assessment, counseling and support (NACS) services	128	128	Redacted
FN_SITE	By site support type: Direct Service Delivery (DSD): Number of PEPFAR-supported sites achieving 90% nutrition assessments that result in accurate categorization of malnutrition	115	115	Redacted
FN_SITE	By site support type: Technical Assistance-only (TA): Number of PEPFAR-supported sites achieving 90% nutrition assessments that result in accurate categorization of malnutrition	0	0	Redacted
FN_SITE	Sum of Numerator Support Type disaggregates	115	115	Redacted
FN_SITE	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported sites providing nutrition assessment, counseling and support (NACS) services	128	128	Redacted
FN_SITE	By site support type: Technical	0	0	Redacted

	Assistance-only (TA): Total number of PEPFAR-supported sites providing nutrition assessment, counseling and support (NACS) services			
FN_SITE	Sum of Denominator Support Type disaggregates	128	128	Redacted
FN_THER_DSD	Number of clinically malnourished PLHIV who received therapeutic and/or supplementary food during the reporting period.	13,716	14,993	Redacted
FN_THER_DSD	Number of PLHIV who were nutritionally assessed and found to be clinically undernourished.	18,288	19,990	Redacted
FN_THER_DSD	Age: <1	44	48	Redacted
FN_THER_DSD	Age: 1-4	296	323	Redacted
FN_THER_DSD	Age: 5-14	924	1,011	Redacted
FN_THER_DSD	Age: 15-17	278	303	Redacted
FN_THER_DSD	Age: 18+	12,174	13,308	Redacted
FN_THER_DSD	Sum of Age disaggregates	13,716	14,993	Redacted
FN_THER_DSD	Aggregated Age: <18	1,542	1,685	Redacted
FN_THER_DSD	Aggregated Age: 18+	12,174	13,308	Redacted
FN_THER_DSD	Sum of Aggregated Age disaggregates	13,716	14,993	Redacted
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	3,498	4,273	Redacted
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	4,115	4,748	Redacted
TB_ART_DSD	Age: 0-4	87	106	Redacted
TB_ART_DSD	Age: 5-14	235	288	Redacted
TB_ART_DSD	Age: 15+	3,176	3,879	Redacted



TB_ART_DSD	Male	1,889	2,307	Redacted
TB_ART_DSD	Female	1,609	1,966	Redacted
TB_ART_DSD	Sum of Sex disaggregates	3,498	4,273	Redacted
TB_ART_DSD	Newly tested	2,099	2,564	Redacted
TB_ART_DSD	Known HIV-positive	1,399	1,709	Redacted
TB_ART_DSD	Sum of Test Status disaggregates	3,498	4,273	Redacted
TB_ART_DSD	Aggregated Age: <15	322	394	Redacted
TB_ART_DSD	Aggregated Age: 15+	3,176	3,879	Redacted
TB_ART_DSD	Sum of Aggregated Age disaggregates	3,498	4,273	Redacted
TB_ARTSITE	The number of PEPFAR-supported TB basic management units at which 80% of registered TB cases who are HIV-positive are on ART, during the reporting period	140	140	Redacted
TB_ARTSITE	The number of PEPFAR-supported TB basic management units	140	140	Redacted
TB_ARTSITE	By site support type: Direct Service Delivery (DSD): The number of PEPFAR-supported TB basic management units at which 80% of registered TB cases who are HIV-positive are on ART, during the reporting period	140	140	Redacted
TB_ARTSITE	By site support type: Technical Assistance-only (TA): The number of PEPFAR-supported TB basic management units at which 80% of registered TB cases who are HIV-positive are on ART, during the reporting period	0	0	Redacted
TB_ARTSITE	Sum of Numerator Site Support Type disaggregates	140	140	Redacted
TB_ARTSITE	By site support type: Direct Service Delivery (DSD): The number of	140	140	Redacted

	PEPFAR-supported TB basic management units			
TB_ARTSITE	By site support type: Technical Assistance-only (TA): The number of PEPFAR-supported TB basic management units	0	0	Redacted
TB_ARTSITE	Sum of Denominator Site Support Type disaggregates	140	140	Redacted
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	6,983	7,123	Redacted
PMTCT_EID_DSD	Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT)	8,729	8,904	Redacted
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	5,237	5,342	Redacted
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	1,746	1,781	Redacted
PMTCT_EID_DSD	Sum of Infant Age disaggregates	6,983	7,123	Redacted
PMTCT_EID_DSD	By infants with a positive virologic test result within 12 months of birth	349	356	Redacted
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	58,370	67,905	Redacted
TX_CURR_DSD	Age/Sex: <1 Male	91	105	Redacted
TX_CURR_DSD	Age/Sex: 1-4 Male	615	716	Redacted
TX_CURR_DSD	Age/Sex: 5-14 Male	1,921	2,240	Redacted
TX_CURR_DSD	Age/Sex: 15+ Male	18,060	21,624	Redacted
TX_CURR_DSD	Age/Sex: <1 Female	91	106	Redacted
TX_CURR_DSD	Age/Sex: 1-4 Female	615	716	Redacted
TX_CURR_DSD	Age/Sex: 5-14 Female	1,921	2,239	Redacted
TX_CURR_DSD	Age/Sex: 15+ Female	35,056	40,159	Redacted
TX_CURR_DSD	Sum of age/sex disaggregates	5,254	6,122	Redacted

TX_CURR_DSD	Percent children with advanced HIV infection receiving antiretroviral therapy (ART) [CURRENT]	1	1	Redacted
TX_CURR_DSD	Percent women and girls with advanced HIV infection receiving antiretroviral therapy (ART) [CURRENT]	1	1	Redacted
TX_CURR_DSD	Aggregated Age/Sex: <1 Male	91	105	Redacted
TX_CURR_DSD	Aggregated Age/Sex: <1 Female	91	105	Redacted
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	2,627	3,061	Redacted
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	18,060	21,624	Redacted
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	2,627	3,061	Redacted
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	35,056	40,159	Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	5,254	6,122	Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	53,116	61,783	Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	58,370	67,905	Redacted
TX_CURR_NGI	Number of adults and children receiving antiretroviral therapy (ART)	58,370	67,905	Redacted
TX_CURR_NGI	Age/Sex: <1 Male	91	105	Redacted
TX_CURR_NGI	Age/Sex: 1-4 Male	615	716	Redacted
TX_CURR_NGI	Age/Sex: 5-14 Male	1,921	2,240	Redacted
TX_CURR_NGI	Age/Sex: 15+ Male	18,060	21,624	Redacted
TX_CURR_NGI	Age/Sex: <1 Female	91	106	Redacted
TX_CURR_NGI	Age/Sex: 1-4 Female	615	716	Redacted
TX_CURR_NGI	Age/Sex: 5-14 Female	1,921	2,239	Redacted
TX_CURR_NGI	Age/Sex: 15+ Female	35,056	40,159	Redacted
TX_CURR_NGI	Sum of Age/Sex disaggregates	58,370	67,905	Redacted
TX_CURR_NGI	Aggregated Age/Sex: <1 Male	91	105	Redacted
TX_CURR_NGI	Aggregated Age/Sex: <1 Female	91	105	Redacted
TX_CURR_NGI	Aggregated Age/Sex: <15 Male	2,627	3,061	Redacted
TX_CURR_NGI	Aggregated Age/Sex: 15+ Male	18,060	21,624	Redacted
TX_CURR_NGI	Aggregated Age/Sex: <15 Female	2,627	3,061	Redacted



TX_CURR_NGI	Aggregated Age/Sex: 15+ Female	35,056	40,159	Redacted
TX_CURR_NGI	Sum of Aggregated Age/Sex disaggregates	58,370	67,905	Redacted
TX_CURR_NGI	Sum of Aggregated Age/Sex <15	5,254	6,122	Redacted
TX_CURR_NGI	Sum of Aggregated Age/Sex 15+	53,116	61,783	Redacted
TX_DIST	Number of Districts with documented routine supportive supervision visits to 75% of HIV care and treatment sites supported by the District	3	3	Redacted
TX_DIST	Total number of PEPFAR supported District Health Offices	4	4	Redacted
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	10,948	10,802	Redacted
TX_NEW_DSD	By Age/Sex: <1 Male	170	229	Redacted
TX_NEW_DSD	By Age/Sex: 1-4 Male	96	129	Redacted
TX_NEW_DSD	By Age/Sex: 5-9 Male	169	228	Redacted
TX_NEW_DSD	By Age/Sex: 10-14 Male	131	176	Redacted
TX_NEW_DSD	By Age/Sex: 15-19 Male	85	81	Redacted
TX_NEW_DSD	By Age/Sex: 20-24 Male	158	149	Redacted
TX_NEW_DSD	By Age/Sex: 25-49 Male	2,373	2,243	Redacted
TX_NEW_DSD	By Age/Sex: 50+ Male	820	775	Redacted
TX_NEW_DSD	By Age/Sex: <1 Female	170	229	Redacted
TX_NEW_DSD	By Age/Sex: 1-4 Female	96	129	Redacted
TX_NEW_DSD	By Age/Sex: 5-9 Female	169	228	Redacted
TX_NEW_DSD	By Age/Sex: 10-14 Female	131	176	Redacted
TX_NEW_DSD	By Age/Sex: 15-19 Female	134	126	Redacted
TX_NEW_DSD	By Age/Sex: 20-24 Female	558	527	Redacted
TX_NEW_DSD	By Age/Sex: 25-49 Female	4,771	4,509	Redacted
TX_NEW_DSD	By Age/Sex: 50+ Female	917	868	Redacted
TX_NEW_DSD	Sum of Age/Sex disaggregates	10,948	10,802	Redacted
TX_NEW_DSD	Aggregated Grouping by Age: <1 Male	170	228	Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	566	762	Redacted

TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	3,436	3,248	Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <1 Female	170	228	Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	566	762	Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	6,380	6,030	Redacted
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	10,948	10,802	Redacted
TX_NEW_DSD	Pregnancy status	2,750	2,805	Redacted
TX_NEW_DSD	Breastfeeding status	306	312	Redacted
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	7,558	9,306	Redacted
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	8,892	10,948	Redacted
TX_RET_DSD	Age: 0-4 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	187	230	Redacted
TX_RET_DSD	Age: 5-14 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	509	627	Redacted
TX_RET_DSD	Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	6,862	8,448	Redacted
TX_RET_DSD	Age: 0-4 (Denominator: Total number of adults and children who initiated ART)	220	271	Redacted



	in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)			
TX_RET_DSD	Age: 5-14 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	599	738	Redacted
TX_RET_DSD	Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	8,072	9,939	Redacted
TX_RET_DSD	Aggregated Age: <15 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	697	858	Redacted
TX_RET_DSD	Aggregated Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	6,862	8,448	Redacted
TX_RET_DSD	Aggregated Age: <15 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	820	1,009	Redacted
TX_RET_DSD	Aggregated Age: 15+ (Denominator: Total number of adults and children	8,072	9,939	Redacted



	who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)			
TX_RET_DSD	Pregnancy and breastfeeding status (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	2,782	5,565	Redacted
TX_RET_DSD	Pregnancy and breastfeeding status (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	3,273	6,547	Redacted
TX_SITE	Number of PEPFAR-supported ART sites with a retention rate of 75% or greater for patients 12 months after ART initiation	86	86	Redacted
TX_SITE	Total number of PEPFAR-supported ART sites	123	123	Redacted
TX_SITE	By support type: Direct Service Delivery (DSD): Number of PEPFAR-supported ART sites with a retention rate of 75% or greater for patients 12 months after ART initiation	86	86	Redacted
TX_SITE	By support type: Technical Assistance (TA-only): Number of PEPFAR-supported ART sites with a retention rate of 75% or greater for patients 12 months after ART initiation	0	0	Redacted
TX_SITE	Sum of Numerator Site Support Type disaggregates	86	86	Redacted



TX_SITE	By support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported ART sites	123	123	Redacted
TX_SITE	By support type: Technical Assistance (TA-only): Total number of PEPFAR-supported ART sites	0	0	Redacted
TX_SITE	Sum of Denominator Site Support Type disaggregates	123	123	Redacted
LAB_CAP_DSD	Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests	140	140	Redacted
LAB_CAP_DSD	By site support type: Direct Service Delivery (DSD)	140	140	Redacted
LAB_CAP_DSD	Sum of Site Support Type disaggregates	140	140	Redacted
FPINT_SITE_DSD	Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	105	105	Redacted
FPINT_SITE_DSD	Total number of PEPFAR-supported HIV service delivery points: PMTCT, Care and Treatment	140	140	Redacted
FPINT_SITE_DSD	By site support type: Direct Service Delivery (DSD): Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	105	105	Redacted
FPINT_SITE_DSD	By site support type: Technical Assistance-only (TA): Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	0	0	Redacted
FPINT_SITE_DSD	Sum of Numerator Site Support Type	105	105	Redacted



	disaggregates			
FPINT_SITE_DSD	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported HIV service delivery points	140	140	Redacted
FPINT_SITE_DSD	By site support type: Technical Assistance-only (TA): Total number of PEPFAR-supported HIV service delivery points	0	0	Redacted
FPINT_SITE_DSD	Sum of Denominator Site Support Type disaggregates	140	140	Redacted
FPINT_SITE_DSD	Service delivery type: Clinical	105	105	Redacted
FPINT_SITE_DSD	Sum of Service Delivery Type disaggregates	105	105	Redacted
QI_SITE	Number of PEPFAR-supported clinical service sites with a quality improvement activity completed that addresses clinical HIV programs and has documented process results in the last 6 months	112	112	Redacted
QI_SITE	Total number of PEPFAR-supported sites for any HIV clinical service including HIV Care, HIV Treatment, TB care, PMTCT, VMMC, and HTC	140	140	Redacted
QI_SITE	By site support type: Direct Service Delivery (DSD): Number of PEPFAR-supported clinical service sites with a quality improvement activity completed that addresses clinical HIV programs and has documented results in the last 6 months	112	112	Redacted
QI_SITE	By site support type: Technical Assistance-only (TA): Number of PEPFAR-supported clinical service sites with a quality improvement activity	0	0	Redacted



	completed that addresses clinical HIV programs and has documented results in the last 6 months			
QI_SITE	Sum of Numerator Site Support Type disaggregates	112	112	Redacted
QI_SITE	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported sites for any HIV clinical service including HIV Care, HIV Treatment, TB care, PMTCT, VMMC, HTC	140	140	Redacted
QI_SITE	By site support type: Technical Assistance-only (TA): Total number of PEPFAR-supported sites for any HIV clinical service including HIV Care, HIV Treatment, TB care, PMTCT, VMMC, and HTC	0	0	Redacted
QI_SITE	Sum of Denominator Site Support Type disaggregates	140	140	Redacted
TB_SCREEN_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period	78,180	90,206	Redacted
TB_SCREEN_DSD	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	86,867	94,953	Redacted
TB_SCREEN_DSD	Age: <1	249	288	Redacted
TB_SCREEN_DSD	Age: 1-4	1,687	1,946	Redacted
TB_SCREEN_DSD	Age: 5-9	2,977	3,435	Redacted
TB_SCREEN_DSD	Age: 10-14	2,293	2,645	Redacted
TB_SCREEN_DSD	Age: 15-19	1,581	1,824	Redacted
TB_SCREEN_DSD	Age: 20-24	5,271	6,082	Redacted
TB_SCREEN_DSD	Age: 25-49	51,773	59,736	Redacted



TB_SCREEN_DSD	Age: 50+	12,349	14,250	Redacted
TB_SCREEN_DSD	Sum of Age disaggregates	8,787	10,138	Redacted
TB_SCREEN_DSD	Aggregated Age - USE WITH HQ PERMISSION ONLY: <15	7,206	8,314	Redacted
TB_SCREEN_DSD	Aggregated Age - USE WITH HQ PERMISSION ONLY: 15+	70,974	81,892	Redacted
TB_SCREEN_DSD	Sum of Aggregated Age disaggregates	78,180	90,206	Redacted
TB_SCREEN_DSD	Sex: Male	27,734	32,000	Redacted
TB_SCREEN_DSD	Sex: Female	50,446	58,206	Redacted
TB_SCREEN_DSD	Sum of Sex disaggregates	78,180	90,206	Redacted

Implementing Mechanism Details

Mechanism ID: 12540	Mechanism Name: MEASURE Evaluation
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: University of North Carolina	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: No	
G2G: No	Managing Agency:

Total All Funding Sources: 3,450,000	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 0	
FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount
GHP-State	3,450,000

Sub Partner Name(s)

Futures International	ICF Macro	Management Sciences for Health
Tulane University		

Cross-Cutting Budget Attribution(s)

(No data provided.)



Key Issues

Malaria (PMI)

Budget Code Information

Mechanism ID: 12540			
Mechanism Name: MEASURE Evaluation			
Prime Partner Name: University of North Carolina			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	200,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	3,250,000	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2014	2015
SITE_SUPP	Number of unique sites supported by PEPFAR	0	0
PMTCT_ARV_DSD	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	0	0
PMTCT_ARV_DSD	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	0	0
PMTCT_ARV_NA	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of	0	0



	mother-to-child-transmission (MTCT) during pregnancy and delivery		
PMTCT_ARV_NA	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	0	0
PMTCT_ARV_NGI	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	0	0
PMTCT_ARV_NGI	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	0	0
PMTCT_ARV_TA	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	0	0
PMTCT_ARV_TA	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	0	0
PMTCT_SITE	Number of PEPFAR-supported sites achieving 90% ARV or ART coverage for HIV+ pregnant women	0	0
PMTCT_SITE	Total number of PEPFAR supported sites providing PMTCT services (HTC and ARV or ART services)	0	0
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	0	0
PMTCT_STAT_DSD	Number of new ANC and L&D clients	0	0
PMTCT_STAT_NA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	0	0
PMTCT_STAT_NA	Number of new ANC and L&D clients	0	0
PMTCT_STAT_NGI	Number of pregnant women with known HIV status (includes women who were tested for	0	0

	HIV and received their results)		
PMTCT_STAT_NGI	Number of new ANC and L&D clients	0	0
BS_COLL	Number of whole blood collections each year by the NBTS network	0	0
KP_MAT_DSD	Number of people who inject drugs (PWID) on medication assisted therapy (MAT) for at least 6 months	0	0
VMMC_AE_DSD	Number of males circumcised surgically or by medical device that experienced at least one moderate or severe adverse event(s) (AEs)	0	0
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	0	0
VMMC_CIRC_NA	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	0	0
VMMC_CIRC_NGI	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	0	0
VMMC_CIRC_TA	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	0	0
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	0	0
PP_PREV_DSD	Total number of people in the target population	0	0
PP_PREV_TA	Number of the target population who completed a standardized HIV prevention intervention including the minimum	0	0



	components during the reporting period.		
PP_PREV_TA	Total number of people in the target population	0	0
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	0	0
KP_PREV_TA	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	0	0
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	0	0
HTC_TST_NA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	0	0
HTC_TST_NGI	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	0	0
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	0	0
GEND_GBV_DSD	Number of people receiving post-GBV care	0	0
GEND_NORM_DSD	Number of people completing an intervention pertaining to gender norms, that meets minimum criteria	0	0
OVC_ACC_DSD	Number of active beneficiaries receiving support from PEPFAR OVC programs to access HIV services	0	0
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	0	0



OVC_SERV_TA	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	0	0
C2.1.D_DSD	Number of HIV-positive individuals receiving a minimum of one clinical service	0	0
C2.1.D_NA	Number of HIV-positive individuals receiving a minimum of one clinical service	0	0
C2.1.D_NGI	Number of HIV-positive individuals receiving a minimum of one clinical service	0	0
C2.1.D_TA	Number of HIV-positive individuals receiving a minimum of one clinical service	0	0
C2.4.D_DSD	Number of HIV-positive patients who were screened for TB in HIV care or treatment setting	0	0
C2.4.D_DSD	Number of HIV-positive individuals receiving a minimum of one clinical service	0	0
C2.5.D_DSD	Number of HIV-positive patients in HIV care who started TB treatment	0	0
C2.5.D_DSD	Number of HIV-positive individuals receiving a minimum of one clinical service	0	0
CARE_CURR_DSD	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	0	0
CARE_CURR_TA	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	0	0
CARE_NEW_DSD	Number of HIV-infected adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count	0	0



	OR viral load		
CARE_SITE	Number of PEPFAR-supported HIV clinical care sites at which at least 80% of PLHIV received all of the following during the reporting period: 1) clinical assessment (WHO staging) OR CD4 count OR viral load, AND 2) TB screening at last visit, AND 3) if eligible, cotrimoxazole	0	0
CARE_SITE	Total number of PEPFAR supported sites providing clinical care services	0	0
FN_SITE	Number of PEPFAR-supported sites achieving 90% nutrition assessments that result in accurate categorization of malnutrition	0	0
FN_SITE	Total number of PEPFAR-supported sites providing nutrition assessment, counseling and support (NACS) services	0	0
FN_THER_DSD	Number of clinically malnourished PLHIV who received therapeutic and/or supplementary food during the reporting period.	0	0
FN_THER_DSD	Number of PLHIV who were nutritionally assessed and found to be clinically undernourished.	0	0
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	0	0
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	0	0
TB_ARTSITE	The number of PEPFAR-supported TB basic management units at which 80% of registered TB cases who are HIV-positive are on ART, during the reporting period	0	0
TB_ARTSITE	The number of PEPFAR-supported TB basic	0	0



	management units		
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	0	0
PMTCT_EID_DSD	Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT)	0	0
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	0	0
TX_CURR_NA	Number of adults and children receiving antiretroviral therapy (ART)	0	0
TX_CURR_NGI	Number of adults and children receiving antiretroviral therapy (ART)	0	0
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	0	0
TX_DIST	Number of Districts with documented routine supportive supervision visits to 75% of HIV care and treatment sites supported by the District	0	0
TX_DIST	Total number of PEPFAR supported District Health Offices	0	0
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	0	0
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	0	0
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	0	0
TX_SITE	Number of PEPFAR-supported ART sites with a retention rate of 75% or greater for patients 12 months after ART initiation	0	0



TX_SITE	Total number of PEPFAR-supported ART sites	0	0
LAB_ACC_DSD	Number of PEPFAR-supported testing facilities (laboratories) that are recognized by national, regional, or international standards for accreditation or have achieved a minimal acceptable level towards attainment of such accreditation	0	0
LAB_CAP_DSD	Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests	0	0
LAB_PT_DSD	Percentage of laboratories and POC testing sites that perform HIV diagnostic testing that participate and successfully pass in an analyte-specific proficiency testing (PT) program	0	0
HRH_PRE	Number of new HCW who graduated from a pre-service training institution or program as a result of PEPFAR-supported strengthening efforts, within the reporting period, by select cadre	0	0
SC_TRAIN	Number of individuals who received competency-based, certificate or higher-level training to conduct or support supply chain, inventory management, supportive supervision or distribution activities	0	0
SC_TRAIN	Number of individuals who conduct or support supply chain, inventory management, supportive supervision or distribution activities	0	0
FPINT_SITE_DSD	Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	0	0
FPINT_SITE_DSD	Total number of PEPFAR-supported HIV service delivery points: PMTCT, Care and	0	0



	Treatment		
QI_SITE	Number of PEPFAR-supported clinical service sites with a quality improvement activity completed that addresses clinical HIV programs and has documented process results in the last 6 months	0	0
QI_SITE	Total number of PEPFAR-supported sites for any HIV clinical service including HIV Care, HIV Treatment, TB care, PMTCT, VMMC, and HTC	0	0
SC_STOCK	Number of stock status observations for one or more tracer commodities that are between the designed minimum and maximum quantities/months of stock from storage sites within at a given level (Central, Regional, etc.) of the system.	0	0
SC_STOCK	Total number of stock status observations for one or more tracer commodities from storage sites within at a given level (Central, Regional, etc.) of the system	0	0
SI_HIS	Existence of a national registry of health facilities that is updated annually	1	1
SI_ME	Existence of a national HIV/AIDS M&E system based on the UNAIDS 12 components model	1	1
TB_SCREEN_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period	0	0
TB_SCREEN_DSD	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	0	0

Implementing Mechanism Details

Mechanism ID: 12530	Mechanism Name: Provision of VMMC
----------------------------	--



Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Nyanza Reproductive Health Society	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: No	
G2G: No	Managing Agency:

Total All Funding Sources: 525,515	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 0	
FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount
GHP-State	525,515

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

Human Resources for Health	112,057
Condom programming	40,000

Key Issues

(No data provided.)

Budget Code Information

Mechanism ID: 12530			
Mechanism Name: Provision of VMMC			
Prime Partner Name: Nyanza Reproductive Health Society			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	525,515	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2014	2015	Planning Budget Targets
SITE_SUPP	Number of unique sites supported by PEPFAR	22	22	Redacted
SITE_SUPP	By program area/support type: HTC Direct Service Delivery (DSD)	22	22	Redacted
SITE_SUPP	By program area/support type: VMMC Direct Service Delivery (DSD)	22	22	Redacted
VMMC_AE_DSD	Number of males circumcised surgically or by medical device that experienced at least one moderate or severe adverse event(s) (AEs)	63	61	Redacted
VMMC_AE_DSD	By AE type: Number of VMMC clients with one or more moderate or severe surgical intra-operative AE(s)	20	20	Redacted
VMMC_AE_DSD	Sub-Disag: Surgical intra-operative AE(s) by maximum severity category: Number of clients with one or more moderate surgical intra-operative AE(s), but no severe surgical intra-operative AE(s)	14	15	Redacted
VMMC_AE_DSD	Sub-Disag: Surgical intra-operative AE(s) by maximum severity category: Number of clients with one or more severe surgical intra-operative AE(s)	6	5	Redacted
VMMC_AE_DSD	By AE Type: Number of VMMC clients with one or more moderate or severe surgical post-operative AE(s)	43	46	Redacted
VMMC_AE_DSD	Sub-Disag: By Surgical post-operative AE(s) by maximum severity category:	34	36	Redacted

	Number of clients with one or more moderate surgical post-operative AE(s), but no severe surgical post-operative AE(s)			
VMMC_AE_DSD	Sub-Disag: By Surgical post-operative AE(s) by maximum severity category: Number of clients with one or more severe surgical intra-operative AE(s)	6	5	Redacted
VMMC_CIRC_DS D	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	12,331	8,615	Redacted
VMMC_CIRC_DS D	By Age: <1	62		Redacted
VMMC_CIRC_DS D	By Age: 1-9	0	0	Redacted
VMMC_CIRC_DS D	By Age: 10-14	4,932	3,489	Redacted
VMMC_CIRC_DS D	By Age: 15-19	4,932	3,446	Redacted
VMMC_CIRC_DS D	By Age: 20-24	1,233	862	Redacted
VMMC_CIRC_DS D	By Age: 25-49	1,172	818	Redacted
VMMC_CIRC_DS D	By Age: 50+	0	0	Redacted
VMMC_CIRC_DS D	Sum of age disaggregates	12,331	8,615	Redacted
VMMC_CIRC_DS D	By HIV status: Number of HIV-positive clients (tested HIV positive at VMMC site)	177	86	Redacted
VMMC_CIRC_DS D	By HIV status: Number of HIV-negative clients (tested HIV negative at VMMC program)	8,120	5,686	Redacted



VMMC_CIRC_DS D	By HIV status: Number of clients with undocumented/indeterminate HIV status or not tested for HIV at site	318	258	Redacted
VMMC_CIRC_DS D	By circumcision technique: Surgical VMMC	12,331	8,615	Redacted
VMMC_CIRC_DS D	By follow-up status: Number of surgically circumcised clients who returned at least once for follow-up care within 14 days of circumcision surgery	5,074	5,514	Redacted
VMMC_CIRC_DS D	By follow-up status: Number of surgically circumcised clients who did NOT return for follow-up care within 14 days of circumcision surgery	3,541	1,378	Redacted
VMMC_CIRC_NGI	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	12,331	8,615	Redacted
VMMC_CIRC_NGI	By Age: <1	62		Redacted
VMMC_CIRC_NGI	By Age: 1-9	0	0	Redacted
VMMC_CIRC_NGI	By Age: 10-14	4,932	3,489	Redacted
VMMC_CIRC_NGI	By Age: 15-19	4,932	3,446	Redacted
VMMC_CIRC_NGI	By Age: 20-24	1,233	862	Redacted
VMMC_CIRC_NGI	By Age: 25-49	1,172	818	Redacted
VMMC_CIRC_NGI	By Age: 50+	0	0	Redacted
VMMC_CIRC_NGI	Sum of Age disaggregates	12,331	8,615	Redacted
VMMC_CIRC_NGI	By HIV status: Number of HIV-positive clients (tested HIV positive at VMMC site)	177	86	Redacted
VMMC_CIRC_NGI	By HIV status: Number of HIV-negative clients (tested HIV negative at VMMC program)	8,120	5,686	Redacted
VMMC_CIRC_NGI	By HIV status: Number of clients with undocumented/indeterminate HIV	318	258	Redacted



	status or not tested for HIV at site			
VMMC_CIRC_NGI	By circumcision technique: Surgical VMMC	12,331	8,615	Redacted
VMMC_CIRC_NGI	By follow-up status: Number of surgically circumcised clients who returned at least once for follow-up care within 14 days of circumcision surgery	5,074	5,514	Redacted
VMMC_CIRC_NGI	By follow-up status: Number of surgically circumcised clients who did NOT return for follow-up care within 14 days of circumcision surgery	3,541	1,378	Redacted
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	12,331	8,615	Redacted
HTC_TST_DSD	By Test Result: Negative	12,154	8,270	Redacted
HTC_TST_DSD	By Test Result: Positive	177	345	Redacted
HTC_TST_DSD	Sum of Test Result disaggregates	12,331	8,615	Redacted
HTC_TST_DSD	Age/sex: <1 Male	62		Redacted
HTC_TST_DSD	Age/sex: 1-4 Male	0	0	Redacted
HTC_TST_DSD	Age/sex: 5-9 Male	0	0	Redacted
HTC_TST_DSD	Age/sex: 10-14 Male	4,932	3,489	Redacted
HTC_TST_DSD	Age/sex: 15-19 Male	4,932	3,446	Redacted
HTC_TST_DSD	Age/sex: 20-24 Male	1,233	862	Redacted
HTC_TST_DSD	Age/sex: 25-49 Male	1,172	818	Redacted
HTC_TST_DSD	Age/sex: 50+ Male	0	0	Redacted
HTC_TST_DSD	Age/sex: <1 Female	0	0	Redacted
HTC_TST_DSD	Age/sex: 1-4 Female	0	0	Redacted
HTC_TST_DSD	Age/sex: 5-9 Female	0	0	Redacted
HTC_TST_DSD	Age/sex: 10-14 Female	0	0	Redacted
HTC_TST_DSD	Age/sex: 15-19 Female	0	0	Redacted
HTC_TST_DSD	Age/sex: 20-24 Female	0	0	Redacted
HTC_TST_DSD	Age/sex: 25-49 Female	0	0	Redacted
HTC_TST_DSD	Age/sex: 50+ Female	0	0	Redacted

HTC_TST_DSD	Sum of Age/Sex disaggregates	12,331	8,615	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	4,994	3,489	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	7,337	5,126	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	0	0	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	0	0	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	4,994	3,489	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	7,337	5,126	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	12,331	8,615	Redacted
HTC_TST_NGI	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	12,331	8,615	Redacted
HTC_TST_NGI	By Test Result: Negative	12,154	8,270	Redacted
HTC_TST_NGI	By Test Result: Positive	177	345	Redacted
HTC_TST_NGI	Sum of Test Result disaggregates	12,331	8,615	Redacted
HTC_TST_NGI	Age/sex: <1 Male	62		Redacted
HTC_TST_NGI	Age/sex: 1-4 Male	0	0	Redacted
HTC_TST_NGI	Age/sex: 5-9 Male	0	0	Redacted
HTC_TST_NGI	Age/sex: 10-14 Male	4,932	3,489	Redacted
HTC_TST_NGI	Age/sex: 15-19 Male	4,932	3,446	Redacted
HTC_TST_NGI	Age/sex: 20-24 Male	1,233	862	Redacted
HTC_TST_NGI	Age/sex: 25-49 Male	1,172	818	Redacted
HTC_TST_NGI	Age/sex: 50+ Male	0	0	Redacted
HTC_TST_NGI	Age/sex: <1 Female	0	0	Redacted
HTC_TST_NGI	Age/sex: 1-4 Female	0	0	Redacted
HTC_TST_NGI	Age/sex: 5-9 Female	0	0	Redacted
HTC_TST_NGI	Age/sex: 10-14 Female	0	0	Redacted
HTC_TST_NGI	Age/sex: 15-19 Female	0	0	Redacted
HTC_TST_NGI	Age/sex: 20-24 Female	0	0	Redacted



HTC_TST_NGI	Age/sex: 25-49 Female	0	0	Redacted
HTC_TST_NGI	Age/sex: 50+ Female	0	0	Redacted
HTC_TST_NGI	Sum of Age/Sex disaggregates	12,331	8,615	Redacted
HTC_TST_NGI	Aggregated Age/sex: <15 Male	4,994	3,489	Redacted
HTC_TST_NGI	Aggregated Age/sex: 15+ Male	7,337	5,126	Redacted
HTC_TST_NGI	Aggregated Age/sex: <15 Female	0	0	Redacted
HTC_TST_NGI	Aggregated Age/sex: 15+ Female	0	0	Redacted
HTC_TST_NGI	Sum of Aggregated Age/Sex <15	4,994	3,489	Redacted
HTC_TST_NGI	Sum of Aggregated Age/Sex 15+	7,337	5,126	Redacted
HTC_TST_NGI	Sum of Aggregated Age/Sex disaggregates	12,331	8,615	Redacted

Implementing Mechanism Details

Mechanism ID: 12083	Mechanism Name: Community HTC
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Liverpool VCT and Care	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: No	
G2G: No	Managing Agency:

Total All Funding Sources: 760,048	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 228,508	
FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount
GHP-State	760,048

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

Human Resources for Health	100,000
----------------------------	---------



Key Populations: FSW	301,000
Focus Area:	Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Collection and use of strategic information on SWs and clients
Focus Area:	Monitoring and evaluation of SW programs
Gender: GBV	202,500
Focus Area:	Post GBV Care
Sub Area:	Monitoring and Evaluation
Gender: Gender Equality	31,500
Focus Area:	Equity in HIV prevention, care, treatment and support
Condom programming	63,000

Key Issues

(No data provided.)

Budget Code Information

Mechanism ID: 12083			
Mechanism Name: Community HTC			
Prime Partner Name: Liverpool VCT and Care			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	337,556	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	422,492	0



Implementing Mechanism Indicator Information

Indicator Number	Label	2014	2015	Planning Budget Targets
SITE_SUPP	Number of unique sites supported by PEPFAR	42	21	Redacted
SITE_SUPP	By program area/support type: HTC Direct Service Delivery (DSD)	42	21	Redacted
SITE_SUPP	By program area/support type: General Population Prevention Direct Service Delivery (DSD)	24	21	Redacted
SITE_SUPP	By program area/support type: PHDP/Family Planning & Integration Direct Service Delivery (DSD)	5	5	Redacted
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	7,826	30,583	Redacted
PP_PREV_DSD	Total number of people in the target population	118,651	118,651	Redacted
PP_PREV_DSD	Age/sex: 10-14 Male	750		Redacted
PP_PREV_DSD	Age/sex: 15-19 Male	425		Redacted
PP_PREV_DSD	Age/sex: 20-24 Male	1,000	859	Redacted
PP_PREV_DSD	Age/sex: 25-49 Male	1,000	7,738	Redacted
PP_PREV_DSD	Age/sex: 50+ Male	260		Redacted
PP_PREV_DSD	Age/sex: 10-14 Female	950	464	Redacted
PP_PREV_DSD	Age/sex: 15-19 Female	1,000	6,595	Redacted
PP_PREV_DSD	Age/sex: 20-24 Female	1,000	13,765	Redacted
PP_PREV_DSD	Age/sex: 25-49 Female	1,181	1,162	Redacted
PP_PREV_DSD	Age/sex: 50+ Female	260		Redacted
PP_PREV_DSD	Sum of Age/Sex disaggregates	7,826	30,583	Redacted



HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	130,000	96,022	Redacted
HTC_TST_DSD	By Test Result: Negative	124,800	92,181	Redacted
HTC_TST_DSD	By Test Result: Positive	5,200	3,841	Redacted
HTC_TST_DSD	Sum of Test Result disaggregates	130,000	96,022	Redacted
HTC_TST_DSD	Age/sex: <1 Male	0	0	Redacted
HTC_TST_DSD	Age/sex: 1-4 Male	0	0	Redacted
HTC_TST_DSD	Age/sex: 5-9 Male	0	0	Redacted
HTC_TST_DSD	Age/sex: 10-14 Male	0	0	Redacted
HTC_TST_DSD	Age/sex: 15-19 Male	2,500	0	Redacted
HTC_TST_DSD	Age/sex: 20-24 Male	26,050	500	Redacted
HTC_TST_DSD	Age/sex: 25-49 Male	29,950	12,973	Redacted
HTC_TST_DSD	Age/sex: 50+ Male	6,500	1,821	Redacted
HTC_TST_DSD	Age/sex: <1 Female	0	0	Redacted
HTC_TST_DSD	Age/sex: 1-4 Female	0	0	Redacted
HTC_TST_DSD	Age/sex: 5-9 Female	0	0	Redacted
HTC_TST_DSD	Age/sex: 10-14 Female	0	500	Redacted
HTC_TST_DSD	Age/sex: 15-19 Female	2,500	14,599	Redacted
HTC_TST_DSD	Age/sex: 20-24 Female	26,050	57,345	Redacted
HTC_TST_DSD	Age/sex: 25-49 Female	29,950	6,463	Redacted
HTC_TST_DSD	Age/sex: 50+ Female	6,500	1,821	Redacted
HTC_TST_DSD	Sum of Age/Sex disaggregates	130,000	96,022	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	0		Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	65,000	15,294	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	0	500	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	65,000	80,228	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	0	500	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	130,000	95,522	Redacted



HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	130,000	96,022	Redacted
HTC_TST_NGI	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	130,000	96,022	Redacted
HTC_TST_NGI	By Test Result: Negative	124,800	92,181	Redacted
HTC_TST_NGI	By Test Result: Positive	5,200	3,841	Redacted
HTC_TST_NGI	Sum of Test Result disaggregates	130,000	96,022	Redacted
HTC_TST_NGI	Age/sex: <1 Male	0	0	Redacted
HTC_TST_NGI	Age/sex: 1-4 Male	0	0	Redacted
HTC_TST_NGI	Age/sex: 5-9 Male	0	0	Redacted
HTC_TST_NGI	Age/sex: 10-14 Male	0	0	Redacted
HTC_TST_NGI	Age/sex: 15-19 Male	2,500	0	Redacted
HTC_TST_NGI	Age/sex: 20-24 Male	26,050	500	Redacted
HTC_TST_NGI	Age/sex: 25-49 Male	29,950	12,973	Redacted
HTC_TST_NGI	Age/sex: 50+ Male	6,500	1,821	Redacted
HTC_TST_NGI	Age/sex: <1 Female	0	0	Redacted
HTC_TST_NGI	Age/sex: 1-4 Female	0	0	Redacted
HTC_TST_NGI	Age/sex: 5-9 Female	0	0	Redacted
HTC_TST_NGI	Age/sex: 10-14 Female	0	500	Redacted
HTC_TST_NGI	Age/sex: 15-19 Female	2,500	14,599	Redacted
HTC_TST_NGI	Age/sex: 20-24 Female	26,050	57,345	Redacted
HTC_TST_NGI	Age/sex: 25-49 Female	29,950	6,463	Redacted
HTC_TST_NGI	Age/sex: 50+ Female	6,500	1,821	Redacted
HTC_TST_NGI	Sum of Age/Sex disaggregates	130,000	96,022	Redacted
HTC_TST_NGI	Aggregated Age/sex: <15 Male	0		Redacted
HTC_TST_NGI	Aggregated Age/sex: 15+ Male	65,000	15,294	Redacted
HTC_TST_NGI	Aggregated Age/sex: 15+ Female	65,000	80,228	Redacted
HTC_TST_NGI	Sum of Aggregated Age/Sex <15	0	500	Redacted
HTC_TST_NGI	Sum of Aggregated Age/Sex 15+	130,000	95,522	Redacted
HTC_TST_NGI	Sum of Aggregated Age/Sex disaggregates	130,000	96,022	Redacted



GEND_GBV_DSD	Number of people receiving post-GBV care	1,065	2,386	Redacted
GEND_GBV_DSD	Age: 10-14	200	464	Redacted
GEND_GBV_DSD	Age: 15-17	800	1,857	Redacted
GEND_GBV_DSD	Age: 18-24	20	20	Redacted
GEND_GBV_DSD	Age: 25+	45	45	Redacted
GEND_GBV_DSD	Sum of Age disaggregates	1,065	2,386	Redacted
GEND_GBV_DSD	Sex: Female	1,065	2,386	Redacted
GEND_GBV_DSD	Sum of Sex disaggregates	1,065	2,386	Redacted
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	1,000	2,321	Redacted
GEND_GBV_DSD	By PEP service provision (related to sexual violence services provided)	65	65	Redacted

Implementing Mechanism Details

Mechanism ID: 12082	Mechanism Name: Refugee Health
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: United Nations High Commissioner for Refugees	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: No	
G2G: No	Managing Agency:

Total All Funding Sources: 483,857	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 22,793	
FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount
GHP-State	483,857

Sub Partner Name(s)

International Rescue Committee	Save the Children UK	
--------------------------------	----------------------	--



Cross-Cutting Budget Attribution(s)

Gender: Gender Equality	12,716
Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Monitoring and Evaluation
Human Resources for Health	353,186
Economic Strengthening	5,197
Education	10,000
Gender: GBV	12,716
Focus Area:	Post GBV Care
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Monitoring and Evaluation
Condom programming	5,000

Key Issues

(No data provided.)

Budget Code Information

Mechanism ID:	12082		
Mechanism Name:	Refugee Health		
Prime Partner Name:	United Nations High Commissioner for Refugees		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	6,516	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Care	HKID	100,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	37,564	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	10,657	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	84,273	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	50,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	133,006	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	56,886	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	4,955	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2014	2015	Planning Budget Targets
SITE_SUPP	Number of unique sites supported by PEPFAR	2	2	Redacted
SITE_SUPP	By program area/support type: HTC Direct Service Delivery (DSD)	2	2	Redacted
SITE_SUPP	By program area/support type: HTC	0	0	Redacted



	Technical Assistance-only (TA)			
SITE_SUPP	By program area/support type: Treatment Direct Service Delivery (DSD)	2	2	Redacted
SITE_SUPP	By program area/support type: Treatment Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: Care and Support Direct Service Delivery (DSD)	2	2	Redacted
SITE_SUPP	By program area/support type: Care and Support Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: Food and Nutrition Direct Service Delivery (DSD)	2	2	Redacted
SITE_SUPP	By program area/support type: Food and Nutrition Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: PMTCT Direct Service Delivery (DSD)	2	2	Redacted
SITE_SUPP	By program area/support type: PMTCT Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: TB/HIV Direct Service Delivery (DSD)	2	2	Redacted
SITE_SUPP	By program area/support type: TB/HIV Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: VMMC Direct Service Delivery (DSD)	0	0	Redacted
SITE_SUPP	By program area/support type: VMMC Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: General Population Prevention Direct Service Delivery (DSD)	2	2	Redacted



SITE_SUPP	By program area/support type: General Population Prevention Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: Key Populations Prevention Direct Service Delivery (DSD)	0	0	Redacted
SITE_SUPP	By program area/support type: Key Populations Prevention Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: OVC Direct Service Delivery (DSD)	2	2	Redacted
SITE_SUPP	By program area/support type: OVC Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: PHDP/Family Planning & Integration Direct Service Delivery (DSD)	2	2	Redacted
SITE_SUPP	By program area/support type: PHDP/Family Planning & Integration Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: Lab Direct Service Delivery (DSD)	2	2	Redacted
SITE_SUPP	By program area/support type: Lab Technical Assistance-only (TA)	0	0	Redacted
PMTCT_ARV_DS D	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	79	81	Redacted
PMTCT_ARV_DS D	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	79	81	Redacted
PMTCT_ARV_DS D	Life-long ART (including Option B+)	60	61	Redacted
PMTCT_ARV_DS D	Sub-Disag of Life-long ART: Newly initiated on treatment during the current	28	29	Redacted



	pregnancy			
PMTCT_ARV_DS D	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	32	32	Redacted
PMTCT_ARV_DS D	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)	0	0	Redacted
PMTCT_ARV_DS D	Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)	19	20	Redacted
PMTCT_ARV_DS D	Single-dose nevirapine (with or without tail)	0	0	Redacted
PMTCT_ARV_DS D	Sum of Regimen Type disaggregates	79	81	Redacted
PMTCT_ARV_DS D	Sum of New and Current disaggregates	60	61	Redacted
PMTCT_ARV_NGI	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	79	81	Redacted
PMTCT_ARV_NGI	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	79	81	Redacted
PMTCT_ARV_NGI	Life-long ART (including Option B+)	60	61	Redacted
PMTCT_ARV_NGI	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	28	29	Redacted
PMTCT_ARV_NGI	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	32	32	Redacted
PMTCT_ARV_NGI	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)	0	0	Redacted
PMTCT_ARV_NGI	Maternal AZT (prophylaxis component	19	20	Redacted



	of WHO Option A during pregnancy and delivery)			
PMTCT_ARV_NGI	Single-dose nevirapine (with or without tail)	0	0	Redacted
PMTCT_ARV_NGI	Sum of Regimen disaggregates	79	81	Redacted
PMTCT_ARV_NGI	Sum of New and Current disaggregates	60	61	Redacted
PMTCT_SITE	Number of PEPFAR-supported sites achieving 90% ARV or ART coverage for HIV+ pregnant women	2	2	Redacted
PMTCT_SITE	Total number of PEPFAR supported sites providing PMTCT services (HTC and ARV or ART services)	2	2	Redacted
PMTCT_SITE	By site support type: Direct Service Delivery (DSD): Number of PEPFAR-supported sites achieving 90% ARV or ART coverage for HIV+ pregnant women	2	2	Redacted
PMTCT_SITE	By site support type: Technical Assistance-only (TA): Number of PEPFAR-supported sites achieving 90% ARV or ART coverage for HIV+ pregnant women	0	0	Redacted
PMTCT_SITE	Sum of Numerator Support Type disaggregates	2	2	Redacted
PMTCT_SITE	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR supported sites providing PMTCT services (HTC and ARV or ART services)	2	2	Redacted
PMTCT_SITE	By site support type: Technical Assistance-only (TA): Total number of PEPFAR supported sites providing PMTCT services (HTC and ARV or ART services)	0	0	Redacted
PMTCT_SITE	Sum of Denominator Support Type	2	2	Redacted

	disaggregates			
PMTCT_STAT_DS D	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	19,781	20,767	Redacted
PMTCT_STAT_DS D	Number of new ANC and L&D clients	19,781	20,767	Redacted
PMTCT_STAT_DS D	By: Known positives at entry	37	38	Redacted
PMTCT_STAT_DS D	By: Number of new positives identified	42	43	Redacted
PMTCT_STAT_DS D	Sum of Positives Status disaggregates	79	81	Redacted
PMTCT_STAT_NG I	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	19,781	20,767	Redacted
PMTCT_STAT_NG I	Number of new ANC and L&D clients	19,781	20,767	Redacted
PMTCT_STAT_NG I	By: Known positives at entry	37	38	Redacted
PMTCT_STAT_NG I	By: Number of new positives identified	42	43	Redacted
PMTCT_STAT_NG I	Sum of Positives Status disaggregates	79	81	Redacted
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	2,500	7,143	Redacted
PP_PREV_DSD	Total number of people in the target population	27,712	27,712	Redacted
PP_PREV_DSD	Age/sex: 10-14 Male	1,250	0	Redacted
PP_PREV_DSD	Age/sex: 10-14 Female	1,250	0	Redacted



PP_PREV_DSD	Sum of Age/Sex disaggregates	2,500	7,143	Redacted
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	40,000	33,903	Redacted
HTC_TST_DSD	By Test Result: Negative	38,400	32,547	Redacted
HTC_TST_DSD	By Test Result: Positive	1,600	1,356	Redacted
HTC_TST_DSD	Sum of Test Result disaggregates	40,000	33,903	Redacted
HTC_TST_DSD	Age/sex: <1 Male	0	0	Redacted
HTC_TST_DSD	Age/sex: 1-4 Male	1,400	1,186	Redacted
HTC_TST_DSD	Age/sex: 5-9 Male	600	509	Redacted
HTC_TST_DSD	Age/sex: 10-14 Male	1,000	848	Redacted
HTC_TST_DSD	Age/sex: 15-19 Male	2,000	1,694	Redacted
HTC_TST_DSD	Age/sex: 20-24 Male	5,000	4,238	Redacted
HTC_TST_DSD	Age/sex: 25-49 Male	8,000	6,781	Redacted
HTC_TST_DSD	Age/sex: 50+ Male	2,000	1,695	Redacted
HTC_TST_DSD	Age/sex: <1 Female	0	0	Redacted
HTC_TST_DSD	Age/sex: 1-4 Female	1,400	1,186	Redacted
HTC_TST_DSD	Age/sex: 5-9 Female	600	509	Redacted
HTC_TST_DSD	Age/sex: 10-14 Female	1,000	848	Redacted
HTC_TST_DSD	Age/sex: 15-19 Female	2,000	1,695	Redacted
HTC_TST_DSD	Age/sex: 20-24 Female	5,000	4,238	Redacted
HTC_TST_DSD	Age/sex: 25-49 Female	8,000	6,781	Redacted
HTC_TST_DSD	Age/sex: 50+ Female	2,000	1,695	Redacted
HTC_TST_DSD	Sum of Age/Sex disaggregates	40,000	33,903	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	3,000	2,543	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	17,000	14,408	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	3,000	2,543	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	17,000	14,409	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	6,000	5,086	Redacted



HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	34,000	28,817	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	40,000	33,903	Redacted
HTC_TST_NGI	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	40,000	33,903	Redacted
HTC_TST_NGI	By Test Result: Negative	38,400	32,547	Redacted
HTC_TST_NGI	By Test Result: Positive	1,600	1,356	Redacted
HTC_TST_NGI	Sum of Test Result disaggregates	40,000	33,903	Redacted
HTC_TST_NGI	Age/sex: <1 Male	0	0	Redacted
HTC_TST_NGI	Age/sex: 1-4 Male	1,400	1,186	Redacted
HTC_TST_NGI	Age/sex: 5-9 Male	600	509	Redacted
HTC_TST_NGI	Age/sex: 10-14 Male	1,000	848	Redacted
HTC_TST_NGI	Age/sex: 15-19 Male	2,000	1,694	Redacted
HTC_TST_NGI	Age/sex: 20-24 Male	5,000	4,238	Redacted
HTC_TST_NGI	Age/sex: 25-49 Male	8,000	6,781	Redacted
HTC_TST_NGI	Age/sex: 50+ Male	2,000	1,695	Redacted
HTC_TST_NGI	Age/sex: <1 Female	0	0	Redacted
HTC_TST_NGI	Age/sex: 1-4 Female	1,400	1,186	Redacted
HTC_TST_NGI	Age/sex: 5-9 Female	600	509	Redacted
HTC_TST_NGI	Age/sex: 10-14 Female	1,000	848	Redacted
HTC_TST_NGI	Age/sex: 15-19 Female	2,000	1,695	Redacted
HTC_TST_NGI	Age/sex: 20-24 Female	5,000	4,238	Redacted
HTC_TST_NGI	Age/sex: 25-49 Female	8,000	6,781	Redacted
HTC_TST_NGI	Age/sex: 50+ Female	2,000	1,695	Redacted
HTC_TST_NGI	Sum of Age/Sex disaggregates	40,000	33,903	Redacted
HTC_TST_NGI	Aggregated Age/sex: <15 Male	3,000	2,543	Redacted
HTC_TST_NGI	Aggregated Age/sex: 15+ Male	17,000	14,408	Redacted
HTC_TST_NGI	Aggregated Age/sex: <15 Female	3,000	2,543	Redacted
HTC_TST_NGI	Aggregated Age/sex: 15+ Female	17,000	14,409	Redacted
HTC_TST_NGI	Sum of Aggregated Age/Sex <15	6,000	5,086	Redacted
HTC_TST_NGI	Sum of Aggregated Age/Sex 15+	34,000	28,817	Redacted



HTC_TST_NGI	Sum of Aggregated Age/Sex disaggregates	40,000	33,903	Redacted
OVC_ACC_DSD	Number of active beneficiaries receiving support from PEPFAR OVC programs to access HIV services	26	26	Redacted
OVC_ACC_DSD	Sex: Male	13	13	Redacted
OVC_ACC_DSD	Sex: Female	13	13	Redacted
OVC_ACC_DSD	Sum of Sex disaggregates	26	26	Redacted
OVC_ACC_DSD	Age: <1	1	1	Redacted
OVC_ACC_DSD	Age: 1-4	3	3	Redacted
OVC_ACC_DSD	Age: 5-9	7	7	Redacted
OVC_ACC_DSD	Age: 10-14	9	9	Redacted
OVC_ACC_DSD	Age: 15-17	5	5	Redacted
OVC_ACC_DSD	Age: 18+	1	1	Redacted
OVC_ACC_DSD	Sum of Age disaggregates	26	26	Redacted
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	2,900	2,900	Redacted
OVC_SERV_DSD	Sex: Male	1,450	1,450	Redacted
OVC_SERV_DSD	Sex: Female	1,450	1,450	Redacted
OVC_SERV_DSD	Sum of Sex disaggregates	2,900	2,900	Redacted
OVC_SERV_DSD	Age: <1	58	58	Redacted
OVC_SERV_DSD	Age: 1-4	348	348	Redacted
OVC_SERV_DSD	Age: 5-9	725	725	Redacted
OVC_SERV_DSD	Age: 10-14	1,044	1,044	Redacted
OVC_SERV_DSD	Age: 15-17	580	580	Redacted
OVC_SERV_DSD	Age: 18+	145	145	Redacted
OVC_SERV_DSD	Sum of Age disaggregates	2,900	2,900	Redacted
C2.1.D_DSD	Number of HIV-positive individuals receiving a minimum of one clinical service	779	852	Redacted
C2.1.D_DSD	By Age/Sex: <15 Female	35	38	Redacted
C2.1.D_DSD	By Age/Sex: <15 Male	35	39	Redacted



C2.1.D_DSD	By Age/Sex: 15+ Female	468	512	Redacted
C2.1.D_DSD	By Age/Sex: 15+ Male	241	263	Redacted
C2.1.D_DSD	Sum of Age/Sex disaggregates	779	852	Redacted
C2.1.D_DSD	By Age: <15	70	77	Redacted
C2.1.D_DSD	By Age: 15+	709	775	Redacted
C2.1.D_DSD	Sum of Age disaggregates	779	852	Redacted
C2.1.D_DSD	By Sex: Female	503	550	Redacted
C2.1.D_DSD	By Sex: Male	276	302	Redacted
C2.1.D_DSD	Sum of Sex disaggregates	779	852	Redacted
C2.1.D_NGI	Number of HIV-positive individuals receiving a minimum of one clinical service	779	852	Redacted
C2.1.D_NGI	By Age/Sex: <15 Female	35	38	Redacted
C2.1.D_NGI	By Age/Sex: <15 Male	35	39	Redacted
C2.1.D_NGI	By Age/Sex: 15+ Female	468	512	Redacted
C2.1.D_NGI	By Age/Sex: 15+ Male	241	263	Redacted
C2.1.D_NGI	Sum of Age/Sex disaggregates	779	852	Redacted
C2.1.D_NGI	By Age: <15	70	77	Redacted
C2.1.D_NGI	By Age: 15+	709	775	Redacted
C2.1.D_NGI	Sum of Age disaggregates	779	852	Redacted
C2.1.D_NGI	By Sex: Female	503	550	Redacted
C2.1.D_NGI	By Sex: Male	276	302	Redacted
C2.1.D_NGI	Sum of Sex disaggregates	779	852	Redacted
C2.4.D_DSD	Number of HIV-positive patients who were screened for TB in HIV care or treatment setting	701	809	Redacted
C2.4.D_DSD	Number of HIV-positive individuals receiving a minimum of one clinical service	779	852	Redacted
C2.5.D_DSD	Number of HIV-positive patients in HIV care who started TB treatment	14	16	Redacted
C2.5.D_DSD	Number of HIV-positive individuals receiving a minimum of one clinical	779	852	Redacted



	service			
CARE_CURR_DS D	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	740	809	Redacted
CARE_CURR_DS D	Age/sex: <1 Male	1	1	Redacted
CARE_CURR_DS D	Age/sex: 1-4 Male	8	9	Redacted
CARE_CURR_DS D	Age/sex: 5-9 Male	13	15	Redacted
CARE_CURR_DS D	Age/sex: 10-14 Male	11	12	Redacted
CARE_CURR_DS D	Age/sex: 15-19 Male	6	6	Redacted
CARE_CURR_DS D	Age/sex: 20-24 Male	11	12	Redacted
CARE_CURR_DS D	Age/sex: 25-49 Male	157	172	Redacted
CARE_CURR_DS D	Age/sex: 50+ Male	55	60	Redacted
CARE_CURR_DS D	Age/sex: <1 Female	1	1	Redacted
CARE_CURR_DS D	Age/sex: 1-4 Female	8	8	Redacted
CARE_CURR_DS D	Age/sex: 5-9 Female	13	16	Redacted
CARE_CURR_DS D	Age/sex: 10-14 Female	11	12	Redacted
CARE_CURR_DS D	Age/sex: 15-19 Female	9	10	Redacted
CARE_CURR_DS D	Age/sex: 20-24 Female	39	43	Redacted



CARE_CURR_DS D	Age/sex: 25-49 Female	333	362	Redacted
CARE_CURR_DS D	Age/sex: 50+ Female	64	70	Redacted
CARE_CURR_DS D	Sun of Age/Sex disaggregates	740	809	Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	33	37	Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	229	250	Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	33	37	Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	445	485	Redacted
CARE_CURR_DS D	Sum of Aggregated Age/Sex disaggregates	740	809	Redacted
CARE_NEW_DSD	Number of HIV-infected adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load	148	147	Redacted
CARE_NEW_DSD	Age/sex: <1 Male	0	0	Redacted
CARE_NEW_DSD	Age/sex: 1-4 Male	2	2	Redacted
CARE_NEW_DSD	Age/sex: 5-9 Male	3	3	Redacted
CARE_NEW_DSD	Age/sex: 10-14 Male	2	2	Redacted
CARE_NEW_DSD	Age/sex: 15-19 Male	1	1	Redacted
CARE_NEW_DSD	Age/sex: 20-24 Male	4	4	Redacted
CARE_NEW_DSD	Age/sex: 25-49 Male	34	33	Redacted
CARE_NEW_DSD	Age/sex: 50+ Male	7	7	Redacted
CARE_NEW_DSD	Age/sex: <1 Female	0	0	Redacted
CARE_NEW_DSD	Age/sex: 1-4 Female	2	2	Redacted
CARE_NEW_DSD	Age/sex: 5-9 Female	3	3	Redacted
CARE_NEW_DSD	Age/sex: 10-14 Female	2	2	Redacted



CARE_NEW_DSD	Age/sex: 15-19 Female	2	2	Redacted
CARE_NEW_DSD	Age/sex: 20-24 Female	4	4	Redacted
CARE_NEW_DSD	Age/sex: 25-49 Female	61	61	Redacted
CARE_NEW_DSD	Age/sex: 50+ Female	21	21	Redacted
CARE_NEW_DSD	Sum of Age/sex disaggregates	148	147	Redacted
CARE_NEW_DSD	Aggregated Age/sex: <15 Male	7	7	Redacted
CARE_NEW_DSD	Aggregated Age/sex: 15+ Male	46	45	Redacted
CARE_NEW_DSD	Aggregated Age/sex: <15 Female	7	7	Redacted
CARE_NEW_DSD	Aggregated Age/sex: 15+ Female	88	88	Redacted
CARE_NEW_DSD	Sum of Aggregated Age/sex disaggregates	148	147	Redacted
CARE_SITE	Number of PEPFAR-supported HIV clinical care sites at which at least 80% of PLHIV received all of the following during the reporting period: 1) clinical assessment (WHO staging) OR CD4 count OR viral load, AND 2) TB screening at last visit, AND 3) if eligible, cotrimoxazole	2	2	Redacted
CARE_SITE	Total number of PEPFAR supported sites providing clinical care services	2	2	Redacted
CARE_SITE	By site support type: Direct Service Delivery (DSD): Number of PEPFAR-supported HIV clinical care sites at which at least 80% of PLHIV received all of the following during the reporting period: 1) clinical assessment (WHO staging) OR CD4 count OR viral load, AND 2) TB screening at last visit, AND 3) if eligible, cotrimoxazole	2	2	Redacted
CARE_SITE	By site support type: Technical Assistance-only (TA): Number of PEPFAR-supported HIV clinical care sites at which at least 80% of PLHIV received all of the following during the	0	0	Redacted



	reporting period: 1) clinical assessment (WHO staging) OR CD4 count OR viral load, AND 2) TB screening at last visit, AND 3) if eligible, cotrimoxazole			
CARE_SITE	Sum of Numerator Site Support Type disaggregates	2	2	Redacted
CARE_SITE	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR supported sites providing clinical care services	2	2	Redacted
CARE_SITE	By site support type: Technical Assistance-only (TA): Total number of PEPFAR supported sites providing clinical care services	0	0	Redacted
CARE_SITE	Sum of Denominator Site Support Type disaggregates	2	2	Redacted
FN_SITE	Number of PEPFAR-supported sites achieving 90% nutrition assessments that result in accurate categorization of malnutrition	2	2	Redacted
FN_SITE	Total number of PEPFAR-supported sites providing nutrition assessment, counseling and support (NACS) services	2	2	Redacted
FN_SITE	By site support type: Direct Service Delivery (DSD): Number of PEPFAR-supported sites achieving 90% nutrition assessments that result in accurate categorization of malnutrition	2	2	Redacted
FN_SITE	By site support type: Technical Assistance-only (TA): Number of PEPFAR-supported sites achieving 90% nutrition assessments that result in accurate categorization of	0	0	Redacted

	malnutrition			
FN_SITE	Sum of Numerator Support Type disaggregates	2	2	Redacted
FN_SITE	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported sites providing nutrition assessment, counseling and support (NACS) services	2	2	Redacted
FN_SITE	By site support type: Technical Assistance-only (TA): Total number of PEPFAR-supported sites providing nutrition assessment, counseling and support (NACS) services	0	0	Redacted
FN_SITE	Sum of Denominator Support Type disaggregates	2	2	Redacted
FN_THER_DSD	Number of clinically malnourished PLHIV who received therapeutic and/or supplementary food during the reporting period.	117	128	Redacted
FN_THER_DSD	Number of PLHIV who were nutritionally assessed and found to be clinically undernourished.	156	170	Redacted
FN_THER_DSD	Age: <1	0	0	Redacted
FN_THER_DSD	Age: 1-4	3	3	Redacted
FN_THER_DSD	Age: 5-14	8	9	Redacted
FN_THER_DSD	Age: 15-17	2	3	Redacted
FN_THER_DSD	Age: 18+	104	113	Redacted
FN_THER_DSD	Sum of Age disaggregates	117	128	Redacted
FN_THER_DSD	Aggregated Age: <18	13	15	Redacted
FN_THER_DSD	Aggregated Age: 18+	104	113	Redacted
FN_THER_DSD	Sum of Aggregated Age disaggregates	117	128	Redacted
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART	30	36	Redacted

	during TB treatment during the reporting period			
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	35	40	Redacted
TB_ART_DSD	Age: 0-4	1	1	Redacted
TB_ART_DSD	Age: 5-14	2	2	Redacted
TB_ART_DSD	Age: 15+	27	33	Redacted
TB_ART_DSD	Male	16	19	Redacted
TB_ART_DSD	Female	14	17	Redacted
TB_ART_DSD	Sum of Sex disaggregates	30	36	Redacted
TB_ART_DSD	Newly tested	18	21	Redacted
TB_ART_DSD	Known HIV-positive	12	15	Redacted
TB_ART_DSD	Sum of Test Status disaggregates	30	36	Redacted
TB_ART_DSD	Aggregated Age: <15	3	3	Redacted
TB_ART_DSD	Aggregated Age: 15+	27	33	Redacted
TB_ART_DSD	Sum of Aggregated Age disaggregates	30	36	Redacted
TB_ARTSITE	The number of PEPFAR-supported TB basic management units at which 80% of registered TB cases who are HIV-positive are on ART, during the reporting period	2	2	Redacted
TB_ARTSITE	The number of PEPFAR-supported TB basic management units	2	2	Redacted
TB_ARTSITE	By site support type: Direct Service Delivery (DSD): The number of PEPFAR-supported TB basic management units at which 80% of registered TB cases who are HIV-positive are on ART, during the reporting period	2	2	Redacted
TB_ARTSITE	By site support type: Technical Assistance-only (TA): The number of	0	0	Redacted

	PEPFAR-supported TB basic management units at which 80% of registered TB cases who are HIV-positive are on ART, during the reporting period			
TB_ARTSITE	Sum of Numerator Site Support Type disaggregates	2	2	Redacted
TB_ARTSITE	By site support type: Direct Service Delivery (DSD): The number of PEPFAR-supported TB basic management units	2	2	Redacted
TB_ARTSITE	By site support type: Technical Assistance-only (TA): The number of PEPFAR-supported TB basic management units	0	0	Redacted
TB_ARTSITE	Sum of Denominator Site Support Type disaggregates	2	2	Redacted
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	64	65	Redacted
PMTCT_EID_DSD	Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT)	79	81	Redacted
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	48	49	Redacted
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	16	16	Redacted
PMTCT_EID_DSD	Sum of Infant Age disaggregates	64	65	Redacted
PMTCT_EID_DSD	By infants with a positive virologic test result within 12 months of birth	3	3	Redacted
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	598	680	Redacted
TX_CURR_DSD	Age/Sex: <1 Male	1	1	Redacted

TX_CURR_DSD	Age/Sex: 1-4 Male	6	7	Redacted
TX_CURR_DSD	Age/Sex: 5-14 Male	20	23	Redacted
TX_CURR_DSD	Age/Sex: 15+ Male	185	216	Redacted
TX_CURR_DSD	Age/Sex: <1 Female	1	1	Redacted
TX_CURR_DSD	Age/Sex: 1-4 Female	6	7	Redacted
TX_CURR_DSD	Age/Sex: 5-14 Female	20	23	Redacted
TX_CURR_DSD	Age/Sex: 15+ Female	359	402	Redacted
TX_CURR_DSD	Sum of age/sex disaggregates	54	62	Redacted
TX_CURR_DSD	Percent children with advanced HIV infection receiving antiretroviral therapy (ART) [CURRENT]	77	80	Redacted
TX_CURR_DSD	Percent women and girls with advanced HIV infection receiving antiretroviral therapy (ART) [CURRENT]	77	79	Redacted
TX_CURR_DSD	Aggregated Age/Sex: <1 Male	1	1	Redacted
TX_CURR_DSD	Aggregated Age/Sex: <1 Female	1	1	Redacted
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	27	31	Redacted
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	185	216	Redacted
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	27	31	Redacted
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	359	402	Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	54	62	Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	544	618	Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	598	680	Redacted
TX_CURR_NGI	Number of adults and children receiving antiretroviral therapy (ART)	598	680	Redacted
TX_CURR_NGI	Age/Sex: <1 Male	1	1	Redacted
TX_CURR_NGI	Age/Sex: 1-4 Male	6	7	Redacted
TX_CURR_NGI	Age/Sex: 5-14 Male	20	23	Redacted
TX_CURR_NGI	Age/Sex: 15+ Male	185	216	Redacted
TX_CURR_NGI	Age/Sex: <1 Female	1	1	Redacted
TX_CURR_NGI	Age/Sex: 1-4 Female	6	7	Redacted



TX_CURR_NGI	Age/Sex: 5-14 Female	20	23	Redacted
TX_CURR_NGI	Age/Sex: 15+ Female	359	402	Redacted
TX_CURR_NGI	Sum of Age/Sex disaggregates	598	680	Redacted
TX_CURR_NGI	Aggregated Age/Sex: <1 Male	1	1	Redacted
TX_CURR_NGI	Aggregated Age/Sex: <1 Female	1	1	Redacted
TX_CURR_NGI	Aggregated Age/Sex: <15 Male	27	31	Redacted
TX_CURR_NGI	Aggregated Age/Sex: 15+ Male	185	216	Redacted
TX_CURR_NGI	Aggregated Age/Sex: <15 Female	27	31	Redacted
TX_CURR_NGI	Aggregated Age/Sex: 15+ Female	359	402	Redacted
TX_CURR_NGI	Sum of Aggregated Age/Sex disaggregates	598	680	Redacted
TX_CURR_NGI	Sum of Aggregated Age/Sex <15	54	62	Redacted
TX_CURR_NGI	Sum of Aggregated Age/Sex 15+	544	618	Redacted
TX_DIST	Number of Districts with documented routine supportive supervision visits to 75% of HIV care and treatment sites supported by the District	2	2	Redacted
TX_DIST	Total number of PEPFAR supported District Health Offices	2	2	Redacted
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	159	157	Redacted
TX_NEW_DSD	By Age/Sex: <1 Male	2	3	Redacted
TX_NEW_DSD	By Age/Sex: 1-4 Male	1	2	Redacted
TX_NEW_DSD	By Age/Sex: 5-9 Male	2	3	Redacted
TX_NEW_DSD	By Age/Sex: 10-14 Male	3	3	Redacted
TX_NEW_DSD	By Age/Sex: 15-19 Male	1	1	Redacted
TX_NEW_DSD	By Age/Sex: 20-24 Male	3	2	Redacted
TX_NEW_DSD	By Age/Sex: 25-49 Male	34	33	Redacted
TX_NEW_DSD	By Age/Sex: 50+ Male	12	11	Redacted
TX_NEW_DSD	By Age/Sex: <1 Female	2	3	Redacted
TX_NEW_DSD	By Age/Sex: 1-4 Female	1	2	Redacted
TX_NEW_DSD	By Age/Sex: 5-9 Female	2	3	Redacted
TX_NEW_DSD	By Age/Sex: 10-14 Female	3	3	Redacted

TX_NEW_DSD	By Age/Sex: 15-19 Female	3	2	Redacted
TX_NEW_DSD	By Age/Sex: 20-24 Female	8	8	Redacted
TX_NEW_DSD	By Age/Sex: 25-49 Female	69	65	Redacted
TX_NEW_DSD	By Age/Sex: 50+ Female	13	13	Redacted
TX_NEW_DSD	Sum of Age/Sex disaggregates	159	157	Redacted
TX_NEW_DSD	Aggregated Grouping by Age: <1 Male	2	3	Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	8	11	Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	50	47	Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <1 Female	2	3	Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	8	11	Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	93	88	Redacted
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	159	157	Redacted
TX_NEW_DSD	Pregnancy status	25	26	Redacted
TX_NEW_DSD	Breastfeeding status	3	3	Redacted
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	107	135	Redacted
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	126	159	Redacted
TX_RET_DSD	Age: 0-4 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	3	3	Redacted
TX_RET_DSD	Age: 5-14 (Numerator: Number of	7	9	Redacted



	adults and children who are still alive and on treatment at 12 months after initiating ART)			
TX_RET_DSD	Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	97	123	Redacted
TX_RET_DSD	Age: 0-4 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	3	4	Redacted
TX_RET_DSD	Age: 5-14 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	8	11	Redacted
TX_RET_DSD	Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	114	144	Redacted
TX_RET_DSD	Aggregated Age: <15 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	10	12	Redacted
TX_RET_DSD	Aggregated Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	97	123	Redacted

TX_RET_DSD	Aggregated Age: <15 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	12	15	Redacted
TX_RET_DSD	Aggregated Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	114	144	Redacted
TX_RET_DSD	Pregnancy and breastfeeding status (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	25	51	Redacted
TX_RET_DSD	Pregnancy and breastfeeding status (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	30	60	Redacted
TX_SITE	Number of PEPFAR-supported ART sites with a retention rate of 75% or greater for patients 12 months after ART initiation	2	2	Redacted
TX_SITE	Total number of PEPFAR-supported ART sites	2	2	Redacted
TX_SITE	By support type: Direct Service Delivery (DSD): Number of PEPFAR-supported ART sites with a retention rate of 75% or greater for patients 12 months after	2	2	Redacted



	ART initiation			
TX_SITE	By support type: Technical Assistance (TA-only): Number of PEPFAR-supported ART sites with a retention rate of 75% or greater for patients 12 months after ART initiation	0	0	Redacted
TX_SITE	Sum of Numerator Site Support Type disaggregates	2	2	Redacted
TX_SITE	By support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported ART sites	2	2	Redacted
TX_SITE	By support type: Technical Assistance (TA-only): Total number of PEPFAR-supported ART sites	0	0	Redacted
TX_SITE	Sum of Denominator Site Support Type disaggregates	2	2	Redacted
LAB_CAP_DSD	Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests	2	2	Redacted
LAB_CAP_DSD	By site support type: Direct Service Delivery (DSD)	2	2	Redacted
LAB_CAP_DSD	Sum of Site Support Type disaggregates	2	2	Redacted
FPINT_SITE_DSD	Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	2	2	Redacted
FPINT_SITE_DSD	Total number of PEPFAR-supported HIV service delivery points: PMTCT, Care and Treatment	2	2	Redacted
FPINT_SITE_DSD	By site support type: Direct Service Delivery (DSD): Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family	2	2	Redacted



	planning services			
FPINT_SITE_DSD	By site support type: Technical Assistance-only (TA): Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	0	0	Redacted
FPINT_SITE_DSD	Sum of Numerator Site Support Type disaggregates	2	2	Redacted
FPINT_SITE_DSD	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported HIV service delivery points	2	2	Redacted
FPINT_SITE_DSD	By site support type: Technical Assistance-only (TA): Total number of PEPFAR-supported HIV service delivery points	0	0	Redacted
FPINT_SITE_DSD	Sum of Denominator Site Support Type disaggregates	2	2	Redacted
FPINT_SITE_DSD	Service delivery type: Clinical	2	2	Redacted
FPINT_SITE_DSD	Sum of Service Delivery Type disaggregates	2	2	Redacted
QI_SITE	Number of PEPFAR-supported clinical service sites with a quality improvement activity completed that addresses clinical HIV programs and has documented process results in the last 6 months	2	2	Redacted
QI_SITE	Total number of PEPFAR-supported sites for any HIV clinical service including HIV Care, HIV Treatment, TB care, PMTCT, VMMC, and HTC	2	2	Redacted
QI_SITE	By site support type: Direct Service Delivery (DSD): Number of PEPFAR-supported clinical service	2	2	Redacted



	sites with a quality improvement activity completed that addresses clinical HIV programs and has documented results in the last 6 months			
QI_SITE	By site support type: Technical Assistance-only (TA): Number of PEPFAR-supported clinical service sites with a quality improvement activity completed that addresses clinical HIV programs and has documented results in the last 6 months	0	0	Redacted
QI_SITE	Sum of Numerator Site Support Type disaggregates	2	2	Redacted
QI_SITE	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported sites for any HIV clinical service including HIV Care, HIV Treatment, TB care, PMTCT, VMMC, HTC	2	2	Redacted
QI_SITE	By site support type: Technical Assistance-only (TA): Total number of PEPFAR-supported sites for any HIV clinical service including HIV Care, HIV Treatment, TB care, PMTCT, VMMC, and HTC	0	0	Redacted
QI_SITE	Sum of Denominator Site Support Type disaggregates	2	2	Redacted
TB_SCREEN_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period	666	769	Redacted
TB_SCREEN_DSD	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	740	809	Redacted



TB_SCREEN_DSD	Age: <1	2	2	Redacted
TB_SCREEN_DSD	Age: 1-4	14	17	Redacted
TB_SCREEN_DSD	Age: 5-9	25	29	Redacted
TB_SCREEN_DSD	Age: 10-14	20	23	Redacted
TB_SCREEN_DSD	Age: 15-19	13	16	Redacted
TB_SCREEN_DSD	Age: 20-24	45	52	Redacted
TB_SCREEN_DSD	Age: 25-49	442	509	Redacted
TB_SCREEN_DSD	Age: 50+	105	121	Redacted
TB_SCREEN_DSD	Sum of Age disaggregates	74	87	Redacted
TB_SCREEN_DSD	Aggregated Age - USE WITH HQ PERMISSION ONLY: <15	61	71	Redacted
TB_SCREEN_DSD	Aggregated Age - USE WITH HQ PERMISSION ONLY: 15+	605	698	Redacted
TB_SCREEN_DSD	Sum of Aggregated Age disaggregates	666	769	Redacted
TB_SCREEN_DSD	Sex: Male	236	273	Redacted
TB_SCREEN_DSD	Sex: Female	430	496	Redacted
TB_SCREEN_DSD	Sum of Sex disaggregates	666	769	Redacted

Implementing Mechanism Details

Mechanism ID: 12056	Mechanism Name: Inuka Community Based OVC Project (ICOP)
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Ananda Marga Universal Relief Teams	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: No	
G2G: No	Managing Agency:

Total All Funding Sources: 300,000	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 0	
FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount
GHP-State	300,000

Approved



Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

Economic Strengthening	200,000
Education	100,000
Gender: Gender Equality	50,000
Focus Area:	Changing harmful gender norms and promoting positive gender norms
Sub Area:	Implementation
Sub Area:	Capacity building
Focus Area:	Promoting gender-related policies and laws that increase legal protection
Sub Area:	Implementation
Sub Area:	Capacity building
Focus Area:	Increase gender-equitable access to income and productive resources, including education
Sub Area:	Implementation
Sub Area:	Capacity building
Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Implementation
Sub Area:	Capacity building

Key Issues

(No data provided.)

Budget Code Information



Mechanism ID: 12056			
Mechanism Name: Inuka Community Based OVC Project (ICOP)			
Prime Partner Name: Ananda Marga Universal Relief Teams			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	300,000	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2014	2015
SITE_SUPP	By program area/support type: OVC Direct Service Delivery (DSD)	2	2
PMTCT_ARV_DSD	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	0	0
PMTCT_ARV_DSD	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	0	0
PMTCT_ARV_NA	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	0	0
PMTCT_ARV_NA	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	0	0
PMTCT_ARV_NGI	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	0	0
PMTCT_ARV_NGI	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	0	0
PMTCT_ARV_TA	Number of HIV-positive pregnant women who	0	0



	received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery		
PMTCT_ARV_TA	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	0	0
PMTCT_SITE	Number of PEPFAR-supported sites achieving 90% ARV or ART coverage for HIV+ pregnant women	0	0
PMTCT_SITE	Total number of PEPFAR supported sites providing PMTCT services (HTC and ARV or ART services)	0	0
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	0	0
PMTCT_STAT_DSD	Number of new ANC and L&D clients	0	0
PMTCT_STAT_NA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	0	0
PMTCT_STAT_NA	Number of new ANC and L&D clients	0	0
PMTCT_STAT_NGI	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	0	0
PMTCT_STAT_NGI	Number of new ANC and L&D clients	0	0
KP_MAT_DSD	Number of people who inject drugs (PWID) on medication assisted therapy (MAT) for at least 6 months	0	0
VMMC_AE_DSD	Number of males circumcised surgically or by medical device that experienced at least one moderate or severe adverse event(s) (AEs)	0	0
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	0	0
VMMC_CIRC_NA	Number of males circumcised as part of the	0	0



	voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period		
VMMC_CIRC_NGI	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	0	0
VMMC_CIRC_TA	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	0	0
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	0	0
PP_PREV_DSD	Total number of people in the target population	0	0
PP_PREV_TA	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	0	0
PP_PREV_TA	Total number of people in the target population	0	0
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	0	0
KP_PREV_TA	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	0	0
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results	0	0



	during the past 12 months		
HTC_TST_NA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	0	0
HTC_TST_NGI	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	0	0
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	0	0
GEND_GBV_DSD	Number of people receiving post-GBV care	0	0
GEND_NORM_DSD	Number of people completing an intervention pertaining to gender norms, that meets minimum criteria	0	0
OVC_ACC_DSD	Number of active beneficiaries receiving support from PEPFAR OVC programs to access HIV services	549	549
OVC_ACC_DSD	Sex: Male	274	274
OVC_ACC_DSD	Sex: Female	275	275
OVC_ACC_DSD	Sum of Sex disaggregates	549	549
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	6,000	6,000
OVC_SERV_DSD	Sex: Male	3,000	3,000
OVC_SERV_DSD	Sex: Female	3,000	3,000
OVC_SERV_DSD	Sum of Sex disaggregates	6,000	6,000
OVC_SERV_DSD	Age: 1-4	500	500
OVC_SERV_DSD	Age: 5-9	1,000	1,000
OVC_SERV_DSD	Age: 10-14	2,500	2,500
OVC_SERV_DSD	Age: 15-17	2,000	2,000
OVC_SERV_DSD	Sum of Age disaggregates	6,000	6,000
OVC_SERV_TA	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	0	0



C2.1.D_DSD	Number of HIV-positive individuals receiving a minimum of one clinical service	0	0
C2.1.D_NA	Number of HIV-positive individuals receiving a minimum of one clinical service	0	0
C2.1.D_NGI	Number of HIV-positive individuals receiving a minimum of one clinical service	0	0
C2.1.D_TA	Number of HIV-positive individuals receiving a minimum of one clinical service	0	0
C2.4.D_DSD	Number of HIV-positive patients who were screened for TB in HIV care or treatment setting	0	0
C2.4.D_DSD	Number of HIV-positive individuals receiving a minimum of one clinical service	0	0
C2.5.D_DSD	Number of HIV-positive patients in HIV care who started TB treatment	0	0
C2.5.D_DSD	Number of HIV-positive individuals receiving a minimum of one clinical service	0	0
CARE_CURR_DSD	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	0	0
CARE_CURR_TA	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	0	0
CARE_NEW_DSD	Number of HIV-infected adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load	0	0
CARE_SITE	Number of PEPFAR-supported HIV clinical care sites at which at least 80% of PLHIV	0	0



	received all of the following during the reporting period: 1) clinical assessment (WHO staging) OR CD4 count OR viral load, AND 2) TB screening at last visit, AND 3) if eligible, cotrimoxazole		
CARE_SITE	Total number of PEPFAR supported sites providing clinical care services	0	0
FN_SITE	Number of PEPFAR-supported sites achieving 90% nutrition assessments that result in accurate categorization of malnutrition	0	0
FN_SITE	Total number of PEPFAR-supported sites providing nutrition assessment, counseling and support (NACS) services	0	0
FN_THER_DSD	Number of clinically malnourished PLHIV who received therapeutic and/or supplementary food during the reporting period.	0	0
FN_THER_DSD	Number of PLHIV who were nutritionally assessed and found to be clinically undernourished.	0	0
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	0	0
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	0	0
TB_ARTSITE	The number of PEPFAR-supported TB basic management units at which 80% of registered TB cases who are HIV-positive are on ART, during the reporting period	0	0
TB_ARTSITE	The number of PEPFAR-supported TB basic management units	0	0
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting	0	0



	period		
PMTCT_EID_DSD	Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT)	0	0
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	0	0
TX_CURR_NA	Number of adults and children receiving antiretroviral therapy (ART)	0	0
TX_CURR_NGI	Number of adults and children receiving antiretroviral therapy (ART)	0	0
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	0	0
TX_DIST	Number of Districts with documented routine supportive supervision visits to 75% of HIV care and treatment sites supported by the District	0	0
TX_DIST	Total number of PEPFAR supported District Health Offices	0	0
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	0	0
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	0	0
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	0	0
TX_SITE	Number of PEPFAR-supported ART sites with a retention rate of 75% or greater for patients 12 months after ART initiation	0	0
TX_SITE	Total number of PEPFAR-supported ART sites	0	0
LAB_ACC_DSD	Number of PEPFAR-supported testing	0	0



	facilities (laboratories) that are recognized by national, regional, or international standards for accreditation or have achieved a minimal acceptable level towards attainment of such accreditation		
LAB_CAP_DSD	Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests	0	0
LAB_PT_DSD	Percentage of laboratories and POC testing sites that perform HIV diagnostic testing that participate and successfully pass in an analyte-specific proficiency testing (PT) program	0	0
HRH_PRE	Number of new HCW who graduated from a pre-service training institution or program as a result of PEPFAR-supported strengthening efforts, within the reporting period, by select cadre	0	0
SC_TRAIN	Number of individuals who received competency-based, certificate or higher-level training to conduct or support supply chain, inventory management, supportive supervision or distribution activities	0	0
SC_TRAIN	Number of individuals who conduct or support supply chain, inventory management, supportive supervision or distribution activities	0	0
FPINT_SITE_DSD	Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	0	0
FPINT_SITE_DSD	Total number of PEPFAR-supported HIV service delivery points: PMTCT, Care and Treatment	0	0
QI_SITE	Number of PEPFAR-supported clinical service sites with a quality improvement activity	0	0



	completed that addresses clinical HIV programs and has documented process results in the last 6 months		
QI_SITE	Total number of PEPFAR-supported sites for any HIV clinical service including HIV Care, HIV Treatment, TB care, PMTCT, VMMC, and HTC	0	0
SC_STOCK	Number of stock status observations for one or more tracer commodities that are between the designed minimum and maximum quantities/months of stock from storage sites within at a given level (Central, Regional, etc.) of the system.	0	0
SC_STOCK	Total number of stock status observations for one or more tracer commodities from storage sites within at a given level (Central, Regional, etc.) of the system	0	0
SI_HIS	Existence of a national registry of health facilities that is updated annually	1	1
SI_HIS	Full national facility list coordinated with PEPFAR	1	1
SI_ME	Existence of a national HIV/AIDS M&E system based on the UNAIDS 12 components model	1	1
TB_SCREEN_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period	0	0
TB_SCREEN_DSD	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	0	0

Implementing Mechanism Details

Mechanism ID: 11406	Mechanism Name: Community Grants Program
Funding Agency: State/AF	Procurement Type: Grant



Prime Partner Name: U.S. Department of State	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: No	
G2G: No	Managing Agency:

Total All Funding Sources: 100,956	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 0	
FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount
GHP-State	100,956

Sub Partner Name(s)

Cosdep Self Help Group	Dagolight Agape Christian Community Deve. Centre	Fountain of Hope Mercy S.H.G
Hequeendo Compassionate Friends (CBO)	Ithanga Community Health Care	Jitahidi Self Help Group-Namirama
Kisiwani Widows and Orphans Care Support Group	Londiani Community Health Advocacy Group	Nabunasi Women Group
Ogande Women Group	Okoa Community Project	Rays of Hope-Kenya
Seito Community Based Organization	Taper Africa	Tumaini Women's Group
Ukambani Christian CBO		

Cross-Cutting Budget Attribution(s)

Economic Strengthening	20,000
Education	15,000

Key Issues

(No data provided.)



Budget Code Information

Mechanism ID: 11406			
Mechanism Name: Community Grants Program			
Prime Partner Name: U.S. Department of State			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	50,956	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	50,000	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2014	2015
OVC_SERV_TA	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	3,000	3,000
OVC_SERV_TA	Sex: Male	1,200	1,200
OVC_SERV_TA	Sex: Female	1,800	1,800
OVC_SERV_TA	Sum of Sex disaggregates	3,000	3,000
OVC_SERV_TA	Age: <1	0	0
OVC_SERV_TA	Age: 1-4	150	150
OVC_SERV_TA	Age: 5-9	150	150
OVC_SERV_TA	Age: 10-14	2,100	2,100
OVC_SERV_TA	Age: 15-17	450	450
OVC_SERV_TA	Age: 18+	150	150
OVC_SERV_TA	Sum of Age disaggregates	3,000	3,000

Implementing Mechanism Details

Mechanism ID: 10826	Mechanism Name: Umbrella
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement



Prime Partner Name: Elizabeth Glaser Pediatric AIDS Foundation	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: No	
G2G: No	Managing Agency:

Total All Funding Sources: 0	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 0	
FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount
GHP-State	0

Sub Partner Name(s)

Beacon of Hope	Center for AIDS Awareness, Youth & Environment	Community Action for Rural Development (CARD)
Development Knowledge Link Africa (DEVLINK)	Diocese of Lodwar	Food for the Hungry
Gethsemane Garden of Hope for Africa (GGCHA)	Kakuma Mission Hospital	Kenya Association for the Prevention of Tuberculosis & Lung Diseases
KURIA District Disability Network (KDDN)	Mwafarikia Institute of Development	National Empowerment Network of people living with HIV/AIDS
North Star Alliance	Nyarami VCT Center	OleMila VCT
Our Lady of Perpetual Support for People Living with AIDS & Orphans, Kenya	Program for Appropriate Technology in Health	Rongai Social Economic Women's Organization (ROSEWO)
Siaya Peasant Community Outreach Project	SOI AIDS	SOS Villages
Upendo Widows Group	Victoria Agricultural & Environmental Conservation Organization	Xposha Self Help Theatre Group



Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

(No data provided.)

Budget Code Information

Mechanism ID: 10826			
Mechanism Name: Umbrella			
Prime Partner Name: Elizabeth Glaser Pediatric AIDS Foundation			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVAB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	0	0



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	0	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2014	2015	Planning Budget Targets
SITE_SUPP	Number of unique sites supported by PEPFAR	82		Redacted
SITE_SUPP	By program area/support type: HTC Direct Service Delivery (DSD)	78		Redacted
SITE_SUPP	By program area/support type: HTC Technical Assistance-only (TA)	0		Redacted
SITE_SUPP	By program area/support type: Treatment Direct Service Delivery (DSD)	35		Redacted
SITE_SUPP	By program area/support type: Treatment Technical Assistance-only (TA)	0		Redacted
SITE_SUPP	By program area/support type: Care and Support Direct Service Delivery (DSD)	72		Redacted



SITE_SUPP	By program area/support type: Care and Support Technical Assistance-only (TA)	0		Redacted
SITE_SUPP	By program area/support type: Food and Nutrition Direct Service Delivery (DSD)	72		Redacted
SITE_SUPP	By program area/support type: Food and Nutrition Technical Assistance-only (TA)	0		Redacted
SITE_SUPP	By program area/support type: PMTCT Direct Service Delivery (DSD)	56		Redacted
SITE_SUPP	By program area/support type: PMTCT Technical Assistance-only (TA)	0		Redacted
SITE_SUPP	By program area/support type: TB/HIV Direct Service Delivery (DSD)	64		Redacted
SITE_SUPP	By program area/support type: TB/HIV Technical Assistance-only (TA)	0		Redacted
SITE_SUPP	By program area/support type: VMMC Direct Service Delivery (DSD)	0		Redacted
SITE_SUPP	By program area/support type: VMMC Technical Assistance-only (TA)	0		Redacted
SITE_SUPP	By program area/support type: General Population Prevention Direct Service Delivery (DSD)	21		Redacted
SITE_SUPP	By program area/support type: General Population Prevention Technical Assistance-only (TA)	0		Redacted
SITE_SUPP	By program area/support type: Key Populations Prevention Direct Service Delivery (DSD)	6		Redacted
SITE_SUPP	By program area/support type: Key Populations Prevention Technical Assistance-only (TA)	0		Redacted
SITE_SUPP	By program area/support type: OVC Direct Service Delivery (DSD)	4		Redacted



SITE_SUPP	By program area/support type: OVC Technical Assistance-only (TA)	0		Redacted
SITE_SUPP	By program area/support type: PHDP/Family Planning & Integration Direct Service Delivery (DSD)	0		Redacted
SITE_SUPP	By program area/support type: PHDP/Family Planning & Integration Technical Assistance-only (TA)	0		Redacted
SITE_SUPP	By program area/support type: Lab Direct Service Delivery (DSD)	35		Redacted
SITE_SUPP	By program area/support type: Lab Technical Assistance-only (TA)	31		Redacted
PMTCT_ARV_DS D	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	731		Redacted
PMTCT_ARV_DS D	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	731		Redacted
PMTCT_ARV_DS D	Life-long ART (including Option B+)	548		Redacted
PMTCT_ARV_DS D	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	256		Redacted
PMTCT_ARV_DS D	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	292		Redacted
PMTCT_ARV_DS D	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)	0		Redacted
PMTCT_ARV_DS D	Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)	183		Redacted
PMTCT_ARV_DS	Single-dose nevirapine (with or without	0		Redacted

D	tail)			
PMTCT_ARV_DS D	Sum of Regimen Type disaggregates	731		Redacted
PMTCT_ARV_DS D	Sum of New and Current disaggregates	548		Redacted
PMTCT_ARV_NGI	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	731		Redacted
PMTCT_ARV_NGI	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	731		Redacted
PMTCT_ARV_NGI	Life-long ART (including Option B+)	548		Redacted
PMTCT_ARV_NGI	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	256		Redacted
PMTCT_ARV_NGI	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	292		Redacted
PMTCT_ARV_NGI	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)	0		Redacted
PMTCT_ARV_NGI	Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)	183		Redacted
PMTCT_ARV_NGI	Single-dose nevirapine (with or without tail)	0		Redacted
PMTCT_ARV_NGI	Sum of Regimen disaggregates	731		Redacted
PMTCT_ARV_NGI	Sum of New and Current disaggregates	548		Redacted
PMTCT_SITE	Number of PEPFAR-supported sites achieving 90% ARV or ART coverage for HIV+ pregnant women	56		Redacted
PMTCT_SITE	Total number of PEPFAR supported	56		Redacted

	sites providing PMTCT services (HTC and ARV or ART services)			
PMTCT_SITE	By site support type: Direct Service Delivery (DSD): Number of PEPFAR-supported sites achieving 90% ARV or ART coverage for HIV+ pregnant women	56		Redacted
PMTCT_SITE	By site support type: Technical Assistance-only (TA): Number of PEPFAR-supported sites achieving 90% ARV or ART coverage for HIV+ pregnant women	0		Redacted
PMTCT_SITE	Sum of Numerator Support Type disaggregates	56		Redacted
PMTCT_SITE	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR supported sites providing PMTCT services (HTC and ARV or ART services)	56		Redacted
PMTCT_SITE	By site support type: Technical Assistance-only (TA): Total number of PEPFAR supported sites providing PMTCT services (HTC and ARV or ART services)	0		Redacted
PMTCT_SITE	Sum of Denominator Support Type disaggregates	56		Redacted
PMTCT_STAT_DS D	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	16,772		Redacted
PMTCT_STAT_DS D	Number of new ANC and L&D clients	16,772		Redacted
PMTCT_STAT_DS D	By: Known positives at entry	344		Redacted
PMTCT_STAT_DS	By: Number of new positives identified	387		Redacted



D				
PMTCT_STAT_DS D	Sum of Positives Status disaggregates	731		Redacted
PMTCT_STAT_NG I	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	16,772		Redacted
PMTCT_STAT_NG I	Number of new ANC and L&D clients	16,772		Redacted
PMTCT_STAT_NG I	By: Known positives at entry	344		Redacted
PMTCT_STAT_NG I	By: Number of new positives identified	387		Redacted
PMTCT_STAT_NG I	Sum of Positives Status disaggregates	731		Redacted
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	114,628		Redacted
PP_PREV_DSD	Total number of people in the target population	400,000		Redacted
PP_PREV_DSD	Age/sex: 10-14 Male	32,439		Redacted
PP_PREV_DSD	Age/sex: 15-19 Male	12,875		Redacted
PP_PREV_DSD	Age/sex: 20-24 Male	3,000		Redacted
PP_PREV_DSD	Age/sex: 25-49 Male	20,000		Redacted
PP_PREV_DSD	Age/sex: 50+ Male	0		Redacted
PP_PREV_DSD	Age/sex: 10-14 Female	32,439		Redacted
PP_PREV_DSD	Age/sex: 15-19 Female	12,875		Redacted
PP_PREV_DSD	Age/sex: 20-24 Female	1,000		Redacted
PP_PREV_DSD	Age/sex: 25-49 Female	0		Redacted
PP_PREV_DSD	Age/sex: 50+ Female	0		Redacted
PP_PREV_DSD	Sum of Age/Sex disaggregates	114,628		Redacted
KP_PREV_DSD	Number of key populations reached	2,000		Redacted



	with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required			
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	2,000		Redacted
KP_PREV_DSD	By key population type: Males who inject drugs (Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0		Redacted
KP_PREV_DSD	By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0		Redacted
KP_PREV_DSD	By key population type: Men who have sex with men/Transgender (MSM/TG) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0		Redacted
KP_PREV_DSD	By key population type: MSM/TG who are male sex workers (subset	0		Redacted



	MSM/TG) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)			
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	117,000		Redacted
HTC_TST_DSD	By Test Result: Negative	112,320		Redacted
HTC_TST_DSD	By Test Result: Positive	4,680		Redacted
HTC_TST_DSD	Sum of Test Result disaggregates	117,000		Redacted
HTC_TST_DSD	Age/sex: <1 Male	0		Redacted
HTC_TST_DSD	Age/sex: 1-4 Male	4,095		Redacted
HTC_TST_DSD	Age/sex: 5-9 Male	1,755		Redacted
HTC_TST_DSD	Age/sex: 10-14 Male	2,925		Redacted
HTC_TST_DSD	Age/sex: 15-19 Male	5,850		Redacted
HTC_TST_DSD	Age/sex: 20-24 Male	14,625		Redacted
HTC_TST_DSD	Age/sex: 25-49 Male	23,400		Redacted
HTC_TST_DSD	Age/sex: 50+ Male	5,850		Redacted
HTC_TST_DSD	Age/sex: <1 Female	0		Redacted
HTC_TST_DSD	Age/sex: 1-4 Female	4,095		Redacted
HTC_TST_DSD	Age/sex: 5-9 Female	1,755		Redacted
HTC_TST_DSD	Age/sex: 10-14 Female	2,925		Redacted
HTC_TST_DSD	Age/sex: 15-19 Female	5,850		Redacted
HTC_TST_DSD	Age/sex: 20-24 Female	14,625		Redacted
HTC_TST_DSD	Age/sex: 25-49 Female	23,400		Redacted
HTC_TST_DSD	Age/sex: 50+ Female	5,850		Redacted
HTC_TST_DSD	Sum of Age/Sex disaggregates	117,000		Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	8,775		Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	49,725		Redacted



HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	8,775		Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	49,725		Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	17,550		Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	99,450		Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	117,000		Redacted
HTC_TST_NGI	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	117,000		Redacted
HTC_TST_NGI	By Test Result: Negative	112,320		Redacted
HTC_TST_NGI	By Test Result: Positive	4,680		Redacted
HTC_TST_NGI	Sum of Test Result disaggregates	117,000		Redacted
HTC_TST_NGI	Age/sex: <1 Male	0		Redacted
HTC_TST_NGI	Age/sex: 1-4 Male	4,095		Redacted
HTC_TST_NGI	Age/sex: 5-9 Male	1,755		Redacted
HTC_TST_NGI	Age/sex: 10-14 Male	2,925		Redacted
HTC_TST_NGI	Age/sex: 15-19 Male	5,850		Redacted
HTC_TST_NGI	Age/sex: 20-24 Male	14,625		Redacted
HTC_TST_NGI	Age/sex: 25-49 Male	23,400		Redacted
HTC_TST_NGI	Age/sex: 50+ Male	5,850		Redacted
HTC_TST_NGI	Age/sex: <1 Female	0		Redacted
HTC_TST_NGI	Age/sex: 1-4 Female	4,095		Redacted
HTC_TST_NGI	Age/sex: 5-9 Female	1,755		Redacted
HTC_TST_NGI	Age/sex: 10-14 Female	2,925		Redacted
HTC_TST_NGI	Age/sex: 15-19 Female	5,850		Redacted
HTC_TST_NGI	Age/sex: 20-24 Female	14,625		Redacted
HTC_TST_NGI	Age/sex: 25-49 Female	23,400		Redacted
HTC_TST_NGI	Age/sex: 50+ Female	5,850		Redacted
HTC_TST_NGI	Sum of Age/Sex disaggregates	117,000		Redacted
HTC_TST_NGI	Aggregated Age/sex: <15 Male	8,775		Redacted



HTC_TST_NGI	Aggregated Age/sex: 15+ Male	49,725		Redacted
HTC_TST_NGI	Aggregated Age/sex: <15 Female	8,775		Redacted
HTC_TST_NGI	Aggregated Age/sex: 15+ Female	49,725		Redacted
HTC_TST_NGI	Sum of Aggregated Age/Sex <15	17,550		Redacted
HTC_TST_NGI	Sum of Aggregated Age/Sex 15+	99,450		Redacted
HTC_TST_NGI	Sum of Aggregated Age/Sex disaggregates	117,000		Redacted
GEND_NORM_DS D	Number of people completing an intervention pertaining to gender norms, that meets minimum criteria	12,000		Redacted
GEND_NORM_DS D	By Age: 20-24	2,000		Redacted
GEND_NORM_DS D	By Age: 25+	10,000		Redacted
GEND_NORM_DS D	Sum of Age disaggregates	12,000		Redacted
OVC_ACC_DSD	Number of active beneficiaries receiving support from PEPFAR OVC programs to access HIV services	300		Redacted
OVC_ACC_DSD	Sex: Male	150		Redacted
OVC_ACC_DSD	Sex: Female	150		Redacted
OVC_ACC_DSD	Sum of Sex disaggregates	300		Redacted
OVC_ACC_DSD	Age: <1	6		Redacted
OVC_ACC_DSD	Age: 1-4	36		Redacted
OVC_ACC_DSD	Age: 5-9	75		Redacted
OVC_ACC_DSD	Age: 10-14	108		Redacted
OVC_ACC_DSD	Age: 15-17	60		Redacted
OVC_ACC_DSD	Age: 18+	15		Redacted
OVC_ACC_DSD	Sum of Age disaggregates	300		Redacted
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	5,500		Redacted
OVC_SERV_DSD	Sex: Male	2,750		Redacted



OVC_SERV_DSD	Sex: Female	2,750		Redacted
OVC_SERV_DSD	Sum of Sex disaggregates	5,500		Redacted
OVC_SERV_DSD	Age: <1	110		Redacted
OVC_SERV_DSD	Age: 1-4	660		Redacted
OVC_SERV_DSD	Age: 5-9	1,375		Redacted
OVC_SERV_DSD	Age: 10-14	1,980		Redacted
OVC_SERV_DSD	Age: 15-17	1,100		Redacted
OVC_SERV_DSD	Age: 18+	275		Redacted
OVC_SERV_DSD	Sum of Age disaggregates	5,500		Redacted
C2.1.D_DSD	Number of HIV-positive individuals receiving a minimum of one clinical service	10,508		Redacted
C2.1.D_DSD	By Age/Sex: <15 Female	473		Redacted
C2.1.D_DSD	By Age/Sex: <15 Male	473		Redacted
C2.1.D_DSD	By Age/Sex: 15+ Female	6,311		Redacted
C2.1.D_DSD	By Age/Sex: 15+ Male	3,251		Redacted
C2.1.D_DSD	Sum of Age/Sex disaggregates	10,508		Redacted
C2.1.D_DSD	By Age: <15	946		Redacted
C2.1.D_DSD	By Age: 15+	9,562		Redacted
C2.1.D_DSD	Sum of Age disaggregates	10,508		Redacted
C2.1.D_DSD	By Sex: Female	6,784		Redacted
C2.1.D_DSD	By Sex: Male	3,724		Redacted
C2.1.D_DSD	Sum of Sex disaggregates	10,508		Redacted
C2.1.D_NGI	Number of HIV-positive individuals receiving a minimum of one clinical service	10,508		Redacted
C2.1.D_NGI	By Age/Sex: <15 Female	473		Redacted
C2.1.D_NGI	By Age/Sex: <15 Male	473		Redacted
C2.1.D_NGI	By Age/Sex: 15+ Female	6,311		Redacted
C2.1.D_NGI	By Age/Sex: 15+ Male	3,251		Redacted
C2.1.D_NGI	Sum of Age/Sex disaggregates	10,508		Redacted
C2.1.D_NGI	By Age: <15	946		Redacted



C2.1.D_NGI	By Age: 15+	9,562		Redacted
C2.1.D_NGI	Sum of Age disaggregates	10,508		Redacted
C2.1.D_NGI	By Sex: Female	6,784		Redacted
C2.1.D_NGI	By Sex: Male	3,724		Redacted
C2.1.D_NGI	Sum of Sex disaggregates	10,508		Redacted
C2.4.D_DSD	Number of HIV-positive patients who were screened for TB in HIV care or treatment setting	9,457		Redacted
C2.4.D_DSD	Number of HIV-positive individuals receiving a minimum of one clinical service	10,508		Redacted
C2.5.D_DSD	Number of HIV-positive patients in HIV care who started TB treatment	189		Redacted
C2.5.D_DSD	Number of HIV-positive individuals receiving a minimum of one clinical service	10,508		Redacted
CARE_CURR_DS D	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	9,982		Redacted
CARE_CURR_DS D	Age/sex: <1 Male	16		Redacted
CARE_CURR_DS D	Age/sex: 1-4 Male	108		Redacted
CARE_CURR_DS D	Age/sex: 5-9 Male	182		Redacted
CARE_CURR_DS D	Age/sex: 10-14 Male	143		Redacted
CARE_CURR_DS D	Age/sex: 15-19 Male	77		Redacted
CARE_CURR_DS D	Age/sex: 20-24 Male	142		Redacted
CARE_CURR_DS	Age/sex: 25-49 Male	2,133		Redacted



D				
CARE_CURR_DS D	Age/sex: 50+ Male	737		Redacted
CARE_CURR_DS D	Age/sex: <1 Female	15		Redacted
CARE_CURR_DS D	Age/sex: 1-4 Female	103		Redacted
CARE_CURR_DS D	Age/sex: 5-9 Female	189		Redacted
CARE_CURR_DS D	Age/sex: 10-14 Female	142		Redacted
CARE_CURR_DS D	Age/sex: 15-19 Female	126		Redacted
CARE_CURR_DS D	Age/sex: 20-24 Female	525		Redacted
CARE_CURR_DS D	Age/sex: 25-49 Female	4,482		Redacted
CARE_CURR_DS D	Age/sex: 50+ Female	862		Redacted
CARE_CURR_DS D	Sun of Age/Sex disaggregates	9,982		Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	449		Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	3,089		Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	449		Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	5,995		Redacted
CARE_CURR_DS D	Sum of Aggregated Age/Sex disaggregates	9,982		Redacted
CARE_NEW_DSD	Number of HIV-infected adults and children newly enrolled in clinical care during the reporting period and	1,996		Redacted



	received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load			
CARE_NEW_DSD	Age/sex: <1 Male	3		Redacted
CARE_NEW_DSD	Age/sex: 1-4 Male	22		Redacted
CARE_NEW_DSD	Age/sex: 5-9 Male	36		Redacted
CARE_NEW_DSD	Age/sex: 10-14 Male	29		Redacted
CARE_NEW_DSD	Age/sex: 15-19 Male	13		Redacted
CARE_NEW_DSD	Age/sex: 20-24 Male	54		Redacted
CARE_NEW_DSD	Age/sex: 25-49 Male	462		Redacted
CARE_NEW_DSD	Age/sex: 50+ Male	88		Redacted
CARE_NEW_DSD	Age/sex: <1 Female	3		Redacted
CARE_NEW_DSD	Age/sex: 1-4 Female	20		Redacted
CARE_NEW_DSD	Age/sex: 5-9 Female	38		Redacted
CARE_NEW_DSD	Age/sex: 10-14 Female	29		Redacted
CARE_NEW_DSD	Age/sex: 15-19 Female	30		Redacted
CARE_NEW_DSD	Age/sex: 20-24 Female	55		Redacted
CARE_NEW_DSD	Age/sex: 25-49 Female	828		Redacted
CARE_NEW_DSD	Age/sex: 50+ Female	286		Redacted
CARE_NEW_DSD	Sum of Age/sex disaggregates	1,996		Redacted
CARE_NEW_DSD	Aggregated Age/sex: <15 Male	90		Redacted
CARE_NEW_DSD	Aggregated Age/sex: 15+ Male	617		Redacted
CARE_NEW_DSD	Aggregated Age/sex: <15 Female	90		Redacted
CARE_NEW_DSD	Aggregated Age/sex: 15+ Female	1,199		Redacted
CARE_NEW_DSD	Sum of Aggregated Age/sex disaggregates	1,996		Redacted
CARE_SITE	Number of PEPFAR-supported HIV clinical care sites at which at least 80% of PLHIV received all of the following during the reporting period: 1) clinical assessment (WHO staging) OR CD4 count OR viral load, AND 2) TB screening at last visit, AND 3) if eligible,	72		Redacted



	cotrimoxazole			
CARE_SITE	Total number of PEPFAR supported sites providing clinical care services	72		Redacted
CARE_SITE	By site support type: Direct Service Delivery (DSD): Number of PEPFAR-supported HIV clinical care sites at which at least 80% of PLHIV received all of the following during the reporting period: 1) clinical assessment (WHO staging) OR CD4 count OR viral load, AND 2) TB screening at last visit, AND 3) if eligible, cotrimoxazole	72		Redacted
CARE_SITE	By site support type: Technical Assistance-only (TA): Number of PEPFAR-supported HIV clinical care sites at which at least 80% of PLHIV received all of the following during the reporting period: 1) clinical assessment (WHO staging) OR CD4 count OR viral load, AND 2) TB screening at last visit, AND 3) if eligible, cotrimoxazole	0		Redacted
CARE_SITE	Sum of Numerator Site Support Type disaggregates	72		Redacted
CARE_SITE	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR supported sites providing clinical care services	72		Redacted
CARE_SITE	By site support type: Technical Assistance-only (TA): Total number of PEPFAR supported sites providing clinical care services	0		Redacted
CARE_SITE	Sum of Denominator Site Support Type disaggregates	72		Redacted
FN_SITE	Number of PEPFAR-supported sites achieving 90% nutrition assessments	65		Redacted



	that result in accurate categorization of malnutrition			
FN_SITE	Total number of PEPFAR-supported sites providing nutrition assessment, counseling and support (NACS) services	72		Redacted
FN_SITE	By site support type: Direct Service Delivery (DSD): Number of PEPFAR-supported sites achieving 90% nutrition assessments that result in accurate categorization of malnutrition	65		Redacted
FN_SITE	By site support type: Technical Assistance-only (TA): Number of PEPFAR-supported sites achieving 90% nutrition assessments that result in accurate categorization of malnutrition	0		Redacted
FN_SITE	Sum of Numerator Support Type disaggregates	65		Redacted
FN_SITE	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported sites providing nutrition assessment, counseling and support (NACS) services	72		Redacted
FN_SITE	By site support type: Technical Assistance-only (TA): Total number of PEPFAR-supported sites providing nutrition assessment, counseling and support (NACS) services	0		Redacted
FN_SITE	Sum of Denominator Support Type disaggregates	72		Redacted
FN_THER_DSD	Number of clinically malnourished PLHIV who received therapeutic and/or supplementary food during the	1,576		Redacted



	reporting period.			
FN_THER_DSD	Number of PLHIV who were nutritionally assessed and found to be clinically undernourished.	2,102		Redacted
FN_THER_DSD	Age: <1	5		Redacted
FN_THER_DSD	Age: 1-4	34		Redacted
FN_THER_DSD	Age: 5-14	106		Redacted
FN_THER_DSD	Age: 15-17	32		Redacted
FN_THER_DSD	Age: 18+	1,399		Redacted
FN_THER_DSD	Sum of Age disaggregates	1,576		Redacted
FN_THER_DSD	Aggregated Age: <18	177		Redacted
FN_THER_DSD	Aggregated Age: 18+	1,399		Redacted
FN_THER_DSD	Sum of Aggregated Age disaggregates	1,576		Redacted
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	402		Redacted
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	473		Redacted
TB_ART_DSD	Age: 0-4	10		Redacted
TB_ART_DSD	Age: 5-14	27		Redacted
TB_ART_DSD	Age: 15+	365		Redacted
TB_ART_DSD	Male	217		Redacted
TB_ART_DSD	Female	185		Redacted
TB_ART_DSD	Sum of Sex disaggregates	402		Redacted
TB_ART_DSD	Newly tested	241		Redacted
TB_ART_DSD	Known HIV-positive	161		Redacted
TB_ART_DSD	Sum of Test Status disaggregates	402		Redacted
TB_ART_DSD	Aggregated Age: <15	37		Redacted
TB_ART_DSD	Aggregated Age: 15+	365		Redacted



TB_ART_DSD	Sum of Aggregated Age disaggregates	402		Redacted
TB_ARTSITE	The number of PEPFAR-supported TB basic management units at which 80% of registered TB cases who are HIV-positive are on ART, during the reporting period	64		Redacted
TB_ARTSITE	The number of PEPFAR-supported TB basic management units	64		Redacted
TB_ARTSITE	By site support type: Direct Service Delivery (DSD): The number of PEPFAR-supported TB basic management units at which 80% of registered TB cases who are HIV-positive are on ART, during the reporting period	64		Redacted
TB_ARTSITE	By site support type: Technical Assistance-only (TA): The number of PEPFAR-supported TB basic management units at which 80% of registered TB cases who are HIV-positive are on ART, during the reporting period	0		Redacted
TB_ARTSITE	Sum of Numerator Site Support Type disaggregates	64		Redacted
TB_ARTSITE	By site support type: Direct Service Delivery (DSD): The number of PEPFAR-supported TB basic management units	64		Redacted
TB_ARTSITE	By site support type: Technical Assistance-only (TA): The number of PEPFAR-supported TB basic management units	0		Redacted
TB_ARTSITE	Sum of Denominator Site Support Type disaggregates	64		Redacted
PMTCT_EID_DSD	Number of infants who had a virologic	585		Redacted

	HIV test within 12 months of birth during the reporting period			
PMTCT_EID_DSD	Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT)	731		Redacted
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	439		Redacted
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	146		Redacted
PMTCT_EID_DSD	Sum of Infant Age disaggregates	585		Redacted
PMTCT_EID_DSD	By infants with a positive virologic test result within 12 months of birth	29		Redacted
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	6,451		Redacted
TX_CURR_DSD	Age/Sex: <1 Male	10		Redacted
TX_CURR_DSD	Age/Sex: 1-4 Male	68		Redacted
TX_CURR_DSD	Age/Sex: 5-14 Male	212		Redacted
TX_CURR_DSD	Age/Sex: 15+ Male	1,996		Redacted
TX_CURR_DSD	Age/Sex: <1 Female	10		Redacted
TX_CURR_DSD	Age/Sex: 1-4 Female	68		Redacted
TX_CURR_DSD	Age/Sex: 5-14 Female	212		Redacted
TX_CURR_DSD	Age/Sex: 15+ Female	3,875		Redacted
TX_CURR_DSD	Sum of age/sex disaggregates	580		Redacted
TX_CURR_DSD	Percent children with advanced HIV infection receiving antiretroviral therapy (ART) [CURRENT]	61		Redacted
TX_CURR_DSD	Percent women and girls with advanced HIV infection receiving antiretroviral therapy (ART) [CURRENT]	61		Redacted
TX_CURR_DSD	Aggregated Age/Sex: <1 Male	10		Redacted
TX_CURR_DSD	Aggregated Age/Sex: <1 Female	10		Redacted



TX_CURR_DSD	Aggregated Age/Sex: <15 Male	290		Redacted
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	1,996		Redacted
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	290		Redacted
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	3,875		Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	580		Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	5,871		Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	6,451		Redacted
TX_CURR_NGI	Number of adults and children receiving antiretroviral therapy (ART)	6,451		Redacted
TX_CURR_NGI	Age/Sex: <1 Male	10		Redacted
TX_CURR_NGI	Age/Sex: 1-4 Male	68		Redacted
TX_CURR_NGI	Age/Sex: 5-14 Male	212		Redacted
TX_CURR_NGI	Age/Sex: 15+ Male	1,996		Redacted
TX_CURR_NGI	Age/Sex: <1 Female	10		Redacted
TX_CURR_NGI	Age/Sex: 1-4 Female	68		Redacted
TX_CURR_NGI	Age/Sex: 5-14 Female	212		Redacted
TX_CURR_NGI	Age/Sex: 15+ Female	3,875		Redacted
TX_CURR_NGI	Sum of Age/Sex disaggregates	6,451		Redacted
TX_CURR_NGI	Aggregated Age/Sex: <1 Male	10		Redacted
TX_CURR_NGI	Aggregated Age/Sex: <1 Female	10		Redacted
TX_CURR_NGI	Aggregated Age/Sex: <15 Male	290		Redacted
TX_CURR_NGI	Aggregated Age/Sex: 15+ Male	1,996		Redacted
TX_CURR_NGI	Aggregated Age/Sex: <15 Female	290		Redacted
TX_CURR_NGI	Aggregated Age/Sex: 15+ Female	3,875		Redacted
TX_CURR_NGI	Sum of Aggregated Age/Sex disaggregates	6,451		Redacted
TX_CURR_NGI	Sum of Aggregated Age/Sex <15	580		Redacted
TX_CURR_NGI	Sum of Aggregated Age/Sex 15+	5,871		Redacted
TX_DIST	Number of Districts with documented routine supportive supervision visits to 75% of HIV care and treatment sites supported by the District	3		Redacted



TX_DIST	Total number of PEPFAR supported District Health Offices	4		Redacted
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	1,875		Redacted
TX_NEW_DSD	By Age/Sex: <1 Male	29		Redacted
TX_NEW_DSD	By Age/Sex: 1-4 Male	16		Redacted
TX_NEW_DSD	By Age/Sex: 5-9 Male	29		Redacted
TX_NEW_DSD	By Age/Sex: 10-14 Male	23		Redacted
TX_NEW_DSD	By Age/Sex: 15-19 Male	15		Redacted
TX_NEW_DSD	By Age/Sex: 20-24 Male	27		Redacted
TX_NEW_DSD	By Age/Sex: 25-49 Male	406		Redacted
TX_NEW_DSD	By Age/Sex: 50+ Male	140		Redacted
TX_NEW_DSD	By Age/Sex: <1 Female	29		Redacted
TX_NEW_DSD	By Age/Sex: 1-4 Female	16		Redacted
TX_NEW_DSD	By Age/Sex: 5-9 Female	29		Redacted
TX_NEW_DSD	By Age/Sex: 10-14 Female	23		Redacted
TX_NEW_DSD	By Age/Sex: 15-19 Female	23		Redacted
TX_NEW_DSD	By Age/Sex: 20-24 Female	96		Redacted
TX_NEW_DSD	By Age/Sex: 25-49 Female	817		Redacted
TX_NEW_DSD	By Age/Sex: 50+ Female	157		Redacted
TX_NEW_DSD	Sum of Age/Sex disaggregates	1,875		Redacted
TX_NEW_DSD	Aggregated Grouping by Age: <1 Male	29		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	97		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	588		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <1 Female	29		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	97		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	1,093		Redacted
TX_NEW_DSD	Sum of Aggregated Age/Sex	1,875		Redacted



	disaggregates			
TX_NEW_DSD	Pregnancy status	230		Redacted
TX_NEW_DSD	Breastfeeding status	26		Redacted
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	1,139		Redacted
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	1,340		Redacted
TX_RET_DSD	Age: 0-4 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	28		Redacted
TX_RET_DSD	Age: 5-14 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	77		Redacted
TX_RET_DSD	Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,034		Redacted
TX_RET_DSD	Age: 0-4 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	33		Redacted
TX_RET_DSD	Age: 5-14 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those	90		Redacted



	who have died, those who have stopped ART, and those lost to follow-up)			
TX_RET_DSD	Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,216		Redacted
TX_RET_DSD	Aggregated Age: <15 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	105		Redacted
TX_RET_DSD	Aggregated Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,034		Redacted
TX_RET_DSD	Aggregated Age: <15 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	124		Redacted
TX_RET_DSD	Aggregated Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,216		Redacted
TX_RET_DSD	Pregnancy and breastfeeding status (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating	233		Redacted



	ART)			
TX_RET_DSD	Pregnancy and breastfeeding status (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	274		Redacted
TX_SITE	Number of PEPFAR-supported ART sites with a retention rate of 75% or greater for patients 12 months after ART initiation	25		Redacted
TX_SITE	Total number of PEPFAR-supported ART sites	35		Redacted
TX_SITE	By support type: Direct Service Delivery (DSD): Number of PEPFAR-supported ART sites with a retention rate of 75% or greater for patients 12 months after ART initiation	25		Redacted
TX_SITE	By support type: Technical Assistance (TA-only): Number of PEPFAR-supported ART sites with a retention rate of 75% or greater for patients 12 months after ART initiation	0		Redacted
TX_SITE	Sum of Numerator Site Support Type disaggregates	25		Redacted
TX_SITE	By support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported ART sites	35		Redacted
TX_SITE	By support type: Technical Assistance (TA-only): Total number of PEPFAR-supported ART sites	0		Redacted
TX_SITE	Sum of Denominator Site Support Type disaggregates	35		Redacted
LAB_CAP_DSD	Number of PEPFAR-supported testing	66		Redacted



	facilities with capacity to perform clinical laboratory tests			
LAB_CAP_DSD	By site support type: Direct Service Delivery (DSD)	35		Redacted
LAB_CAP_DSD	By site support type: Technical Assistance-only (TA)	31		Redacted
LAB_CAP_DSD	Sum of Site Support Type disaggregates	66		Redacted
FPINT_SITE_DSD	Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	42		Redacted
FPINT_SITE_DSD	Total number of PEPFAR-supported HIV service delivery points: PMTCT, Care and Treatment	56		Redacted
FPINT_SITE_DSD	By site support type: Direct Service Delivery (DSD): Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	42		Redacted
FPINT_SITE_DSD	By site support type: Technical Assistance-only (TA): Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	0		Redacted
FPINT_SITE_DSD	Sum of Numerator Site Support Type disaggregates	42		Redacted
FPINT_SITE_DSD	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported HIV service delivery points	56		Redacted
FPINT_SITE_DSD	By site support type: Technical Assistance-only (TA): Total number of	0		Redacted



	PEPFAR-supported HIV service delivery points			
FPINT_SITE_DSD	Sum of Denominator Site Support Type disaggregates	56		Redacted
FPINT_SITE_DSD	Service delivery type: Clinical	42		Redacted
FPINT_SITE_DSD	Sum of Service Delivery Type disaggregates	42		Redacted
QI_SITE	Number of PEPFAR-supported clinical service sites with a quality improvement activity completed that addresses clinical HIV programs and has documented process results in the last 6 months	45		Redacted
QI_SITE	Total number of PEPFAR-supported sites for any HIV clinical service including HIV Care, HIV Treatment, TB care, PMTCT, VMMC, and HTC	56		Redacted
QI_SITE	By site support type: Direct Service Delivery (DSD): Number of PEPFAR-supported clinical service sites with a quality improvement activity completed that addresses clinical HIV programs and has documented results in the last 6 months	45		Redacted
QI_SITE	By site support type: Technical Assistance-only (TA): Number of PEPFAR-supported clinical service sites with a quality improvement activity completed that addresses clinical HIV programs and has documented results in the last 6 months	0		Redacted
QI_SITE	Sum of Numerator Site Support Type disaggregates	45		Redacted
QI_SITE	By site support type: Direct Service Delivery (DSD): Total number of	56		Redacted



	PEPFAR-supported sites for any HIV clinical service including HIV Care, HIV Treatment, TB care, PMTCT, VMMC, HTC			
QI_SITE	By site support type: Technical Assistance-only (TA): Total number of PEPFAR-supported sites for any HIV clinical service including HIV Care, HIV Treatment, TB care, PMTCT, VMMC, and HTC	0		Redacted
QI_SITE	Sum of Denominator Site Support Type disaggregates	56		Redacted
TB_SCREEN_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period	8,984		Redacted
TB_SCREEN_DSD	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	9,982		Redacted
TB_SCREEN_DSD	Age: <1	29		Redacted
TB_SCREEN_DSD	Age: 1-4	194		Redacted
TB_SCREEN_DSD	Age: 5-9	342		Redacted
TB_SCREEN_DSD	Age: 10-14	263		Redacted
TB_SCREEN_DSD	Age: 15-19	182		Redacted
TB_SCREEN_DSD	Age: 20-24	606		Redacted
TB_SCREEN_DSD	Age: 25-49	5,949		Redacted
TB_SCREEN_DSD	Age: 50+	1,419		Redacted
TB_SCREEN_DSD	Sum of Age disaggregates	1,010		Redacted
TB_SCREEN_DSD	Aggregated Age - USE WITH HQ PERMISSION ONLY: <15	828		Redacted
TB_SCREEN_DSD	Aggregated Age - USE WITH HQ PERMISSION ONLY: 15+	8,156		Redacted



TB_SCREEN_DSD	Sum of Aggregated Age disaggregates	8,984		Redacted
TB_SCREEN_DSD	Sex: Male	3,187		Redacted
TB_SCREEN_DSD	Sex: Female	5,797		Redacted
TB_SCREEN_DSD	Sum of Sex disaggregates	8,984		Redacted

Implementing Mechanism Details

Mechanism ID: 9171	Mechanism Name: South Rift Valley
Funding Agency: DOD	Procurement Type: Cooperative Agreement
Prime Partner Name: Henry Jackson Foundation	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: No	
G2G: No	Managing Agency:

Total All Funding Sources: 16,090,907	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 0	
FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount
GHP-State	16,090,907

Sub Partner Name(s)

Africa Inland Church Litein Hospital	I Choose Life	James Finlay Limited
Kapkatet District Hospital	Kapsabet District Hospital	Kericho District Hospital, Kenya
Kericho Youth Centre	Kilgoris District Hospital	Live With Hope Centre
Londiani District Hospital	Longisa District Hospital	Nandi Hills District Hospital
Samoei Community Development Programme	Tenwek Hospital	Unilever Tea Kenya

Cross-Cutting Budget Attribution(s)

Human Resources for Health	150,000
Food and Nutrition: Policy, Tools, and Service	15,000

Approved



Delivery	
Food and Nutrition: Commodities	30,000
Education	18,000
Water	5,000
Key Populations: FSW	500,000
Focus Area:	Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Collection and use of strategic information on SWs and clients
Focus Area:	Monitoring and evaluation of SW programs
Gender: Gender Equality	5,000
Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Implementation
Condom programming	100,000

Key Issues

Malaria (PMI)
Child Survival Activities
Safe Motherhood
TB
Workplace Programs
Family Planning

Budget Code Information

Mechanism ID: 9171



Mechanism Name: South Rift Valley			
Prime Partner Name: Henry Jackson Foundation			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	642,538	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	881,531	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	903,538	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	310,513	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	1,061,113	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	560,900	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	1,203,042	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	924,157	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	394,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	2,538,177	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Treatment	HTXS	5,970,340	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	701,058	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2014	2015
SITE_SUPP	Number of unique sites supported by PEPFAR	415	415
SITE_SUPP	By program area/support type: HTC Direct Service Delivery (DSD)	367	367
SITE_SUPP	By program area/support type: Treatment Direct Service Delivery (DSD)	81	81
SITE_SUPP	By program area/support type: Care and Support Direct Service Delivery (DSD)	86	86
SITE_SUPP	By program area/support type: PMTCT Direct Service Delivery (DSD)	415	415
SITE_SUPP	By program area/support type: TB/HIV Direct Service Delivery (DSD)	113	113
SITE_SUPP	By program area/support type: VMMC Direct Service Delivery (DSD)	40	40
SITE_SUPP	By program area/support type: General Population Prevention Direct Service Delivery (DSD)	5	2
SITE_SUPP	By program area/support type: Key Populations Prevention Direct Service Delivery (DSD)	2	2
SITE_SUPP	By program area/support type: OVC Direct Service Delivery (DSD)	4	4
SITE_SUPP	By program area/support type: Lab Direct Service Delivery (DSD)	17	19



PMTCT_ARV_DSD	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	3,322	5,282
PMTCT_ARV_DSD	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	3,322	5,282
PMTCT_ARV_DSD	Life-long ART (including Option B+)	2,492	3,962
PMTCT_ARV_DSD	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	1,163	1,849
PMTCT_ARV_DSD	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	1,329	2,113
PMTCT_ARV_DSD	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)	0	0
PMTCT_ARV_DSD	Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)	830	1,320
PMTCT_ARV_DSD	Sum of Regimen Type disaggregates	3,322	5,282
PMTCT_ARV_DSD	Sum of New and Current disaggregates	2,492	3,962
PMTCT_ARV_NGI	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	3,322	5,282
PMTCT_ARV_NGI	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	3,322	5,282
PMTCT_ARV_NGI	Life-long ART (including Option B+)	2,492	3,962
PMTCT_ARV_NGI	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	1,163	1,849
PMTCT_ARV_NGI	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	1,329	2,113



PMTCT_ARV_NGI	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)	0	0
PMTCT_ARV_NGI	Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)	830	1,320
PMTCT_ARV_NGI	Sum of Regimen disaggregates	3,322	5,282
PMTCT_ARV_NGI	Sum of New and Current disaggregates	2,492	3,962
PMTCT_SITE	Number of PEPFAR-supported sites achieving 90% ARV or ART coverage for HIV+ pregnant women	415	415
PMTCT_SITE	Total number of PEPFAR supported sites providing PMTCT services (HTC and ARV or ART services)	415	415
PMTCT_SITE	By site support type: Direct Service Delivery (DSD): Number of PEPFAR-supported sites achieving 90% ARV or ART coverage for HIV+ pregnant women	415	415
PMTCT_SITE	Sum of Numerator Support Type disaggregates	415	415
PMTCT_SITE	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR supported sites providing PMTCT services (HTC and ARV or ART services)	415	415
PMTCT_SITE	Sum of Denominator Support Type disaggregates	415	415
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	97,798	105,872
PMTCT_STAT_DSD	Number of new ANC and L&D clients	97,798	105,872
PMTCT_STAT_DSD	By: Known positives at entry	1,329	2,113
PMTCT_STAT_DSD	By: Number of new positives identified	1,993	3,169
PMTCT_STAT_DSD	Sum of Positives Status disaggregates	3,322	5,282
PMTCT_STAT_NGI	Number of pregnant women with known HIV	97,798	105,872



	status (includes women who were tested for HIV and received their results)		
PMTCT_STAT_NGI	Number of new ANC and L&D clients	97,798	105,872
PMTCT_STAT_NGI	By: Known positives at entry	1,329	2,113
PMTCT_STAT_NGI	By: Number of new positives identified	1,993	3,169
PMTCT_STAT_NGI	Sum of Positives Status disaggregates	3,322	5,282
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	18,700	19,722
VMMC_CIRC_DSD	By Age: <1	0	0
VMMC_CIRC_DSD	By Age: 1-9	0	0
VMMC_CIRC_DSD	By Age: 10-14	7,480	7,889
VMMC_CIRC_DSD	By Age: 15-19	7,480	7,889
VMMC_CIRC_DSD	By Age: 20-24	1,964	2,071
VMMC_CIRC_DSD	By Age: 25-49	1,776	1,873
VMMC_CIRC_DSD	By Age: 50+	0	0
VMMC_CIRC_DSD	Sum of age disaggregates	18,700	19,722
VMMC_CIRC_DSD	By HIV status: Number of HIV-positive clients (tested HIV positive at VMMC site)	3,740	3,944
VMMC_CIRC_DSD	By HIV status: Number of HIV-negative clients (tested HIV negative at VMMC program)	14,025	14,792
VMMC_CIRC_DSD	By HIV status: Number of clients with undocumented/indeterminate HIV status or not tested for HIV at site	935	986
VMMC_CIRC_DSD	By circumcision technique: Surgical VMMC	18,700	19,722
VMMC_CIRC_DSD	By follow-up status: Number of surgically circumcised clients who returned at least once for follow-up care within 14 days of circumcision surgery	18,700	19,722
VMMC_CIRC_NGI	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	18,700	19,722



VMMC_CIRC_NGI	By Age: <1	0	0
VMMC_CIRC_NGI	By Age: 1-9	0	0
VMMC_CIRC_NGI	By Age: 10-14	7,480	7,889
VMMC_CIRC_NGI	By Age: 15-19	7,480	7,889
VMMC_CIRC_NGI	By Age: 20-24	1,964	2,071
VMMC_CIRC_NGI	By Age: 25-49	1,776	1,873
VMMC_CIRC_NGI	By Age: 50+	0	0
VMMC_CIRC_NGI	Sum of Age disaggregates	18,700	19,722
VMMC_CIRC_NGI	By HIV status: Number of HIV-positive clients (tested HIV positive at VMMC site)	3,740	3,944
VMMC_CIRC_NGI	By HIV status: Number of HIV-negative clients (tested HIV negative at VMMC program)	14,025	14,792
VMMC_CIRC_NGI	By HIV status: Number of clients with undocumented/indeterminate HIV status or not tested for HIV at site	935	986
VMMC_CIRC_NGI	By circumcision technique: Surgical VMMC	18,700	19,722
VMMC_CIRC_NGI	By follow-up status: Number of surgically circumcised clients who returned at least once for follow-up care within 14 days of circumcision surgery	18,700	19,722
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	52,427	31,429
PP_PREV_DSD	Total number of people in the target population	2,249,206	2,249,206
PP_PREV_DSD	Age/sex: 10-14 Male	9,437	5,657
PP_PREV_DSD	Age/sex: 15-19 Male	5,242	3,143
PP_PREV_DSD	Age/sex: 20-24 Male	3,146	1,886
PP_PREV_DSD	Age/sex: 25-49 Male	3,146	1,886
PP_PREV_DSD	Age/sex: 50+ Male	1,049	629
PP_PREV_DSD	Age/sex: 10-14 Female	11,534	6,914
PP_PREV_DSD	Age/sex: 15-19 Female	5,767	3,457



PP_PREV_DSD	Age/sex: 20-24 Female	8,388	5,029
PP_PREV_DSD	Age/sex: 25-49 Female	3,146	1,886
PP_PREV_DSD	Age/sex: 50+ Female	1,572	942
PP_PREV_DSD	Sum of Age/Sex disaggregates	52,427	31,429
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	3,328	4,278
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	3,328	4,278
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	318,000	317,450
HTC_TST_DSD	By Test Result: Negative	305,280	304,752
HTC_TST_DSD	By Test Result: Positive	12,720	12,698
HTC_TST_DSD	Sum of Test Result disaggregates	318,000	317,450
HTC_TST_DSD	Age/sex: <1 Male	0	0
HTC_TST_DSD	Age/sex: 1-4 Male	11,130	11,110
HTC_TST_DSD	Age/sex: 5-9 Male	4,770	4,762
HTC_TST_DSD	Age/sex: 10-14 Male	7,950	7,937
HTC_TST_DSD	Age/sex: 15-19 Male	15,900	15,873
HTC_TST_DSD	Age/sex: 20-24 Male	39,750	39,682
HTC_TST_DSD	Age/sex: 25-49 Male	63,600	63,491
HTC_TST_DSD	Age/sex: 50+ Male	15,900	15,870
HTC_TST_DSD	Age/sex: <1 Female	0	0
HTC_TST_DSD	Age/sex: 1-4 Female	11,130	11,110
HTC_TST_DSD	Age/sex: 5-9 Female	4,770	4,762
HTC_TST_DSD	Age/sex: 10-14 Female	7,950	7,937



HTC_TST_DSD	Age/sex: 15-19 Female	15,900	15,873
HTC_TST_DSD	Age/sex: 20-24 Female	39,750	39,682
HTC_TST_DSD	Age/sex: 25-49 Female	63,600	63,491
HTC_TST_DSD	Age/sex: 50+ Female	15,900	15,870
HTC_TST_DSD	Sum of Age/Sex disaggregates	318,000	317,450
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	23,850	23,809
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	135,150	134,916
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	23,850	23,809
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	135,150	134,916
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	47,700	47,618
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	270,300	269,832
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	318,000	317,450
HTC_TST_NGI	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	318,000	317,450
HTC_TST_NGI	By Test Result: Negative	305,280	304,752
HTC_TST_NGI	By Test Result: Positive	12,720	12,698
HTC_TST_NGI	Sum of Test Result disaggregates	318,000	317,450
HTC_TST_NGI	Age/sex: <1 Male	0	0
HTC_TST_NGI	Age/sex: 1-4 Male	11,130	11,110
HTC_TST_NGI	Age/sex: 5-9 Male	4,770	4,762
HTC_TST_NGI	Age/sex: 10-14 Male	7,950	7,937
HTC_TST_NGI	Age/sex: 15-19 Male	15,900	15,873
HTC_TST_NGI	Age/sex: 20-24 Male	39,750	39,682
HTC_TST_NGI	Age/sex: 25-49 Male	63,600	63,491
HTC_TST_NGI	Age/sex: 50+ Male	15,900	15,870
HTC_TST_NGI	Age/sex: <1 Female	0	0
HTC_TST_NGI	Age/sex: 1-4 Female	11,130	11,110
HTC_TST_NGI	Age/sex: 5-9 Female	4,770	4,762



HTC_TST_NGI	Age/sex: 10-14 Female	7,950	7,937
HTC_TST_NGI	Age/sex: 15-19 Female	15,900	15,873
HTC_TST_NGI	Age/sex: 20-24 Female	39,750	39,682
HTC_TST_NGI	Age/sex: 25-49 Female	63,600	63,491
HTC_TST_NGI	Age/sex: 50+ Female	15,900	15,870
HTC_TST_NGI	Sum of Age/Sex disaggregates	318,000	317,450
HTC_TST_NGI	Aggregated Age/sex: <15 Male	23,850	23,809
HTC_TST_NGI	Aggregated Age/sex: 15+ Male	135,150	134,916
HTC_TST_NGI	Aggregated Age/sex: <15 Female	23,850	23,809
HTC_TST_NGI	Aggregated Age/sex: 15+ Female	135,150	134,916
HTC_TST_NGI	Sum of Aggregated Age/Sex <15	47,700	47,618
HTC_TST_NGI	Sum of Aggregated Age/Sex 15+	270,300	269,832
HTC_TST_NGI	Sum of Aggregated Age/Sex disaggregates	318,000	317,450
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	13,028	18,700
OVC_SERV_DSD	Sex: Male	6,514	9,350
OVC_SERV_DSD	Sex: Female	6,514	9,350
OVC_SERV_DSD	Sum of Sex disaggregates	13,028	18,700
OVC_SERV_DSD	Age: <1	261	374
OVC_SERV_DSD	Age: 1-4	2,084	2,992
OVC_SERV_DSD	Age: 5-9	2,866	4,114
OVC_SERV_DSD	Age: 10-14	3,388	4,862
OVC_SERV_DSD	Age: 15-17	3,908	5,610
OVC_SERV_DSD	Age: 18+	521	748
OVC_SERV_DSD	Sum of Age disaggregates	13,028	18,700
C2.1.D_DSD	Number of HIV-positive individuals receiving a minimum of one clinical service	36,113	39,834
C2.1.D_DSD	By Age/Sex: <15 Female	1,625	1,749
C2.1.D_DSD	By Age/Sex: <15 Male	1,625	1,749
C2.1.D_DSD	By Age/Sex: 15+ Female	21,361	23,618
C2.1.D_DSD	By Age/Sex: 15+ Male	11,502	12,718



C2.1.D_DSD	Sum of Age/Sex disaggregates	36,113	39,834
C2.1.D_DSD	By Age: <15	3,250	3,498
C2.1.D_DSD	By Age: 15+	32,863	36,336
C2.1.D_DSD	Sum of Age disaggregates	36,113	39,834
C2.1.D_DSD	By Sex: Female	22,986	25,367
C2.1.D_DSD	By Sex: Male	13,127	14,467
C2.1.D_DSD	Sum of Sex disaggregates	36,113	39,834
C2.1.D_NGI	Number of HIV-positive individuals receiving a minimum of one clinical service	36,113	39,834
C2.1.D_NGI	By Age/Sex: <15 Female	1,625	1,749
C2.1.D_NGI	By Age/Sex: <15 Male	1,625	1,749
C2.1.D_NGI	By Age/Sex: 15+ Female	21,361	23,618
C2.1.D_NGI	By Age/Sex: 15+ Male	11,502	12,718
C2.1.D_NGI	Sum of Age/Sex disaggregates	36,113	39,834
C2.1.D_NGI	By Age: <15	3,250	3,498
C2.1.D_NGI	By Age: 15+	32,863	36,336
C2.1.D_NGI	Sum of Age disaggregates	36,113	39,834
C2.1.D_NGI	By Sex: Female	22,986	25,367
C2.1.D_NGI	By Sex: Male	13,127	14,467
C2.1.D_NGI	Sum of Sex disaggregates	36,113	39,834
C2.4.D_DSD	Number of HIV-positive patients who were screened for TB in HIV care or treatment setting	28,890	31,867
C2.4.D_DSD	Number of HIV-positive individuals receiving a minimum of one clinical service	36,113	39,834
C2.5.D_DSD	Number of HIV-positive patients in HIV care who started TB treatment	1,806	2,000
C2.5.D_DSD	Number of HIV-positive individuals receiving a minimum of one clinical service	36,113	39,834
CARE_CURR_DSD	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count	36,113	39,834



	OR viral load		
CARE_CURR_DSD	Age/sex: <1 Male	36	40
CARE_CURR_DSD	Age/sex: 1-4 Male	831	916
CARE_CURR_DSD	Age/sex: 5-9 Male	831	916
CARE_CURR_DSD	Age/sex: 10-14 Male	469	518
CARE_CURR_DSD	Age/sex: 15-19 Male	253	279
CARE_CURR_DSD	Age/sex: 20-24 Male	469	518
CARE_CURR_DSD	Age/sex: 25-49 Male	7,764	8,564
CARE_CURR_DSD	Age/sex: 50+ Male	1,228	1,354
CARE_CURR_DSD	Age/sex: <1 Female	144	159
CARE_CURR_DSD	Age/sex: 1-4 Female	867	956
CARE_CURR_DSD	Age/sex: 5-9 Female	722	797
CARE_CURR_DSD	Age/sex: 10-14 Female	506	558
CARE_CURR_DSD	Age/sex: 15-19 Female	1,300	1,434
CARE_CURR_DSD	Age/sex: 20-24 Female	3,611	3,983
CARE_CURR_DSD	Age/sex: 25-49 Female	15,385	16,970
CARE_CURR_DSD	Age/sex: 50+ Female	1,697	1,872
CARE_CURR_DSD	Sun of Age/Sex disaggregates	36,113	39,834
CARE_CURR_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	2,167	2,390
CARE_CURR_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	9,714	10,715
CARE_CURR_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	2,239	2,470
CARE_CURR_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	21,993	24,259
CARE_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	36,113	39,834
CARE_NEW_DSD	Number of HIV-infected adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load	7,076	7,076



CARE_NEW_DSD	Age/sex: <1 Male	21	21
CARE_NEW_DSD	Age/sex: 1-4 Male	149	149
CARE_NEW_DSD	Age/sex: 5-9 Male	156	156
CARE_NEW_DSD	Age/sex: 10-14 Male	78	78
CARE_NEW_DSD	Age/sex: 15-19 Male	57	57
CARE_NEW_DSD	Age/sex: 20-24 Male	85	85
CARE_NEW_DSD	Age/sex: 25-49 Male	1,486	1,486
CARE_NEW_DSD	Age/sex: 50+ Male	212	212
CARE_NEW_DSD	Age/sex: <1 Female	57	57
CARE_NEW_DSD	Age/sex: 1-4 Female	170	170
CARE_NEW_DSD	Age/sex: 5-9 Female	127	127
CARE_NEW_DSD	Age/sex: 10-14 Female	120	120
CARE_NEW_DSD	Age/sex: 15-19 Female	255	255
CARE_NEW_DSD	Age/sex: 20-24 Female	778	778
CARE_NEW_DSD	Age/sex: 25-49 Female	3,042	3,042
CARE_NEW_DSD	Age/sex: 50+ Female	283	283
CARE_NEW_DSD	Sum of Age/sex disaggregates	7,076	7,076
CARE_NEW_DSD	Aggregated Age/sex: <15 Male	404	404
CARE_NEW_DSD	Aggregated Age/sex: 15+ Male	1,840	1,840
CARE_NEW_DSD	Aggregated Age/sex: <15 Female	474	474
CARE_NEW_DSD	Aggregated Age/sex: 15+ Female	4,358	4,358
CARE_NEW_DSD	Sum of Aggregated Age/sex disaggregates	7,076	7,076
CARE_SITE	Number of PEPFAR-supported HIV clinical care sites at which at least 80% of PLHIV received all of the following during the reporting period: 1) clinical assessment (WHO staging) OR CD4 count OR viral load, AND 2) TB screening at last visit, AND 3) if eligible, cotrimoxazole	86	86
CARE_SITE	Total number of PEPFAR supported sites providing clinical care services	86	86
CARE_SITE	By site support type: Direct Service Delivery (DSD): Number of PEPFAR-supported HIV	86	86



	clinical care sites at which at least 80% of PLHIV received all of the following during the reporting period: 1) clinical assessment (WHO staging) OR CD4 count OR viral load, AND 2) TB screening at last visit, AND 3) if eligible, cotrimoxazole		
CARE_SITE	Sum of Numerator Site Support Type disaggregates	86	86
CARE_SITE	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR supported sites providing clinical care services	86	86
CARE_SITE	Sum of Denominator Site Support Type disaggregates	86	86
FN_SITE	Number of PEPFAR-supported sites achieving 90% nutrition assessments that result in accurate categorization of malnutrition	310	330
FN_SITE	Total number of PEPFAR-supported sites providing nutrition assessment, counseling and support (NACS) services	415	415
FN_SITE	By site support type: Direct Service Delivery (DSD): Number of PEPFAR-supported sites achieving 90% nutrition assessments that result in accurate categorization of malnutrition	310	330
FN_SITE	Sum of Numerator Support Type disaggregates	310	330
FN_SITE	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported sites providing nutrition assessment, counseling and support (NACS) services	415	415
FN_SITE	Sum of Denominator Support Type disaggregates	415	415
FN_THER_DSD	Number of clinically malnourished PLHIV who received therapeutic and/or supplementary food during the reporting period.	5,417	5,975



FN_THER_DSD	Number of PLHIV who were nutritionally assessed and found to be clinically undernourished.	10,834	11,950
FN_THER_DSD	Age: <1	867	956
FN_THER_DSD	Age: 1-4	1,192	1,315
FN_THER_DSD	Age: 5-14	1,733	1,912
FN_THER_DSD	Age: 15-17	975	1,075
FN_THER_DSD	Age: 18+	650	717
FN_THER_DSD	Sum of Age disaggregates	5,417	5,975
FN_THER_DSD	Aggregated Age: <18	4,767	5,258
FN_THER_DSD	Aggregated Age: 18+	650	717
FN_THER_DSD	Sum of Aggregated Age disaggregates	5,417	5,975
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	1,535	1,793
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	1,806	1,992
TB_ART_DSD	Age: 0-4	29	34
TB_ART_DSD	Age: 5-14	155	181
TB_ART_DSD	Age: 15+	1,351	1,578
TB_ART_DSD	Male	829	968
TB_ART_DSD	Female	706	825
TB_ART_DSD	Sum of Sex disaggregates	1,535	1,793
TB_ART_DSD	Newly tested	921	1,076
TB_ART_DSD	Known HIV-positive	614	717
TB_ART_DSD	Sum of Test Status disaggregates	1,535	1,793
TB_ART_DSD	Aggregated Age: <15	184	215
TB_ART_DSD	Aggregated Age: 15+	1,351	1,578
TB_ART_DSD	Sum of Aggregated Age disaggregates	1,535	1,793
TB_ARTSITE	The number of PEPFAR-supported TB basic	113	113



	management units at which 80% of registered TB cases who are HIV-positive are on ART, during the reporting period		
TB_ARTSITE	The number of PEPFAR-supported TB basic management units	113	113
TB_ARTSITE	By site support type: Direct Service Delivery (DSD): The number of PEPFAR-supported TB basic management units at which 80% of registered TB cases who are HIV-positive are on ART, during the reporting period	113	113
TB_ARTSITE	Sum of Numerator Site Support Type disaggregates	113	113
TB_ARTSITE	By site support type: Direct Service Delivery (DSD): The number of PEPFAR-supported TB basic management units	113	113
TB_ARTSITE	Sum of Denominator Site Support Type disaggregates	113	113
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	2,658	4,226
PMTCT_EID_DSD	Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT)	3,322	5,282
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	1,661	2,641
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	997	1,585
PMTCT_EID_DSD	Sum of Infant Age disaggregates	2,658	4,226
PMTCT_EID_DSD	By infants with a positive virologic test result within 12 months of birth	27	42
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	26,126	29,712
TX_CURR_DSD	Age/Sex: <1 Male	131	147



TX_CURR_DSD	Age/Sex: 1-4 Male	1,019	1,149
TX_CURR_DSD	Age/Sex: 5-14 Male	1,097	1,237
TX_CURR_DSD	Age/Sex: 15+ Male	14,787	16,800
TX_CURR_DSD	Age/Sex: <1 Female	209	235
TX_CURR_DSD	Age/Sex: 1-4 Female	967	1,090
TX_CURR_DSD	Age/Sex: 5-14 Female	993	1,119
TX_CURR_DSD	Age/Sex: 15+ Female	6,923	7,935
TX_CURR_DSD	Sum of age/sex disaggregates	4,416	4,977
TX_CURR_DSD	Percent children with advanced HIV infection receiving antiretroviral therapy (ART) [CURRENT]	9	9
TX_CURR_DSD	Percent women and girls with advanced HIV infection receiving antiretroviral therapy (ART) [CURRENT]	64	64
TX_CURR_DSD	Aggregated Age/Sex: <1 Male	123	139
TX_CURR_DSD	Aggregated Age/Sex: <1 Female	123	139
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	1,234	1,387
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	8,280	9,467
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	1,234	1,387
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	15,378	17,471
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	2,468	2,774
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	23,658	26,938
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	26,126	29,712
TX_CURR_NGI	Number of adults and children receiving antiretroviral therapy (ART)	26,126	29,712
TX_CURR_NGI	Age/Sex: <1 Male	131	147
TX_CURR_NGI	Age/Sex: 1-4 Male	1,019	1,149
TX_CURR_NGI	Age/Sex: 5-14 Male	1,097	1,237
TX_CURR_NGI	Age/Sex: 15+ Male	14,787	16,800
TX_CURR_NGI	Age/Sex: <1 Female	209	235
TX_CURR_NGI	Age/Sex: 1-4 Female	967	1,090
TX_CURR_NGI	Age/Sex: 5-14 Female	993	1,119



TX_CURR_NGI	Age/Sex: 15+ Female	6,923	7,935
TX_CURR_NGI	Sum of Age/Sex disaggregates	26,126	29,712
TX_CURR_NGI	Aggregated Age/Sex: <1 Male	123	139
TX_CURR_NGI	Aggregated Age/Sex: <1 Female	123	139
TX_CURR_NGI	Aggregated Age/Sex: <15 Male	1,234	1,387
TX_CURR_NGI	Aggregated Age/Sex: 15+ Male	8,280	9,467
TX_CURR_NGI	Aggregated Age/Sex: <15 Female	1,234	1,387
TX_CURR_NGI	Aggregated Age/Sex: 15+ Female	15,378	17,471
TX_CURR_NGI	Sum of Aggregated Age/Sex disaggregates	26,126	29,712
TX_CURR_NGI	Sum of Aggregated Age/Sex <15	2,468	2,774
TX_CURR_NGI	Sum of Aggregated Age/Sex 15+	23,658	26,938
TX_DIST	Number of Districts with documented routine supportive supervision visits to 75% of HIV care and treatment sites supported by the District	15	15
TX_DIST	Total number of PEPFAR supported District Health Offices	15	15
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	4,394	4,394
TX_NEW_DSD	By Age/Sex: <1 Male	44	44
TX_NEW_DSD	By Age/Sex: 1-4 Male	154	154
TX_NEW_DSD	By Age/Sex: 5-9 Male	88	88
TX_NEW_DSD	By Age/Sex: 10-14 Male	62	62
TX_NEW_DSD	By Age/Sex: 15-19 Male	9	9
TX_NEW_DSD	By Age/Sex: 20-24 Male	40	40
TX_NEW_DSD	By Age/Sex: 25-49 Male	1,845	1,845
TX_NEW_DSD	By Age/Sex: 50+ Male	149	149
TX_NEW_DSD	By Age/Sex: <1 Female	44	44
TX_NEW_DSD	By Age/Sex: 1-4 Female	154	154
TX_NEW_DSD	By Age/Sex: 5-9 Female	57	57
TX_NEW_DSD	By Age/Sex: 10-14 Female	101	101
TX_NEW_DSD	By Age/Sex: 15-19 Female	158	158



TX_NEW_DSD	By Age/Sex: 20-24 Female	417	417
TX_NEW_DSD	By Age/Sex: 25-49 Female	923	923
TX_NEW_DSD	By Age/Sex: 50+ Female	149	149
TX_NEW_DSD	Sum of Age/Sex disaggregates	4,394	4,394
TX_NEW_DSD	Aggregated Grouping by Age: <1 Male	74	99
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	248	332
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	1,364	1,306
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <1 Female	74	99
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	248	332
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	2,534	2,425
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	4,394	4,395
TX_NEW_DSD	Pregnancy status	1,230	1,230
TX_NEW_DSD	Breastfeeding status	439	439
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	3,515	3,515
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	4,394	4,394
TX_RET_DSD	Age: 0-4 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	281	281
TX_RET_DSD	Age: 5-14 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	562	562
TX_RET_DSD	Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	2,671	2,671
TX_RET_DSD	Age: 0-4 (Denominator: Total number of adults and children who initiated ART in the	352	352



	12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)		
TX_RET_DSD	Age: 5-14 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	703	703
TX_RET_DSD	Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	3,339	3,339
TX_RET_DSD	Aggregated Age: <15 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	844	844
TX_RET_DSD	Aggregated Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	2,671	2,671
TX_RET_DSD	Aggregated Age: <15 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,055	1,055
TX_RET_DSD	Aggregated Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	3,339	3,339
TX_RET_DSD	Pregnancy and breastfeeding status (Numerator: Number of adults and children	2,812	2,812



	who are still alive and on treatment at 12 months after initiating ART)		
TX_RET_DSD	Pregnancy and breastfeeding status (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	3,515	3,515
TX_SITE	Number of PEPFAR-supported ART sites with a retention rate of 75% or greater for patients 12 months after ART initiation	81	81
TX_SITE	Total number of PEPFAR-supported ART sites	81	81
TX_SITE	By support type: Direct Service Delivery (DSD): Number of PEPFAR-supported ART sites with a retention rate of 75% or greater for patients 12 months after ART initiation	81	81
TX_SITE	Sum of Numerator Site Support Type disaggregates	81	81
TX_SITE	By support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported ART sites	81	81
TX_SITE	Sum of Denominator Site Support Type disaggregates	81	81
LAB_ACC_DSD	Number of PEPFAR-supported testing facilities (laboratories) that are recognized by national, regional, or international standards for accreditation or have achieved a minimal acceptable level towards attainment of such accreditation	5	7
LAB_ACC_DSD	By site support type: Direct Service Delivery (DSD)	5	7
LAB_ACC_DSD	Sum of Support Type disaggregates	5	7
LAB_CAP_DSD	Number of PEPFAR-supported testing	17	19



	facilities with capacity to perform clinical laboratory tests		
LAB_CAP_DSD	By clinical laboratories	12	12
LAB_CAP_DSD	By Point-of-care testing sites	5	7
LAB_CAP_DSD	By site support type: Direct Service Delivery (DSD)	17	19
LAB_CAP_DSD	Sum of Site Support Type disaggregates	17	19
LAB_PT_DSD	Percentage of laboratories and POC testing sites that perform HIV diagnostic testing that participate and successfully pass in an analyte-specific proficiency testing (PT) program	71	71
LAB_PT_DSD	CD4: Number of laboratories that perform this testing	12	12
LAB_PT_DSD	CD4: Number of laboratories that participate in this PT program	6	8
LAB_PT_DSD	CD4: Number of laboratories that achieve acceptable successful passing criteria in this PT program	5	
LAB_PT_DSD	Early infant diagnostics: Number of laboratories that perform this testing	1	1
LAB_PT_DSD	Early infant diagnostics: Number of laboratories that participate in this PT program	1	1
LAB_PT_DSD	Early infant diagnostics: Number of laboratories that achieve acceptable successful passing criteria in this PT program	1	1
LAB_PT_DSD	HIV viral load: Number of laboratories that perform this testing	1	1
LAB_PT_DSD	HIV viral load: Number of laboratories that participate in this PT program	1	1
LAB_PT_DSD	HIV viral load: Number of laboratories that achieve acceptable successful passing criteria in this PT program	1	1
QI_SITE	Number of PEPFAR-supported clinical service	11	11



	sites with a quality improvement activity completed that addresses clinical HIV programs and has documented process results in the last 6 months		
QI_SITE	Total number of PEPFAR-supported sites for any HIV clinical service including HIV Care, HIV Treatment, TB care, PMTCT, VMMC, and HTC	415	415
QI_SITE	By site support type: Direct Service Delivery (DSD): Number of PEPFAR-supported clinical service sites with a quality improvement activity completed that addresses clinical HIV programs and has documented results in the last 6 months	11	11
QI_SITE	Sum of Numerator Site Support Type disaggregates	11	11
QI_SITE	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported sites for any HIV clinical service including HIV Care, HIV Treatment, TB care, PMTCT, VMMC, HTC	415	415
QI_SITE	Sum of Denominator Site Support Type disaggregates	415	415
TB_SCREEN_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period	28,890	31,867
TB_SCREEN_DSD	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	36,113	39,834
TB_SCREEN_DSD	Age: <1	549	605
TB_SCREEN_DSD	Age: 1-4	1,011	1,115
TB_SCREEN_DSD	Age: 5-9	1,040	1,147
TB_SCREEN_DSD	Age: 10-14	867	956



TB_SCREEN_DSD	Age: 15-19	2,080	2,295
TB_SCREEN_DSD	Age: 20-24	5,345	5,896
TB_SCREEN_DSD	Age: 25-49	16,265	17,941
TB_SCREEN_DSD	Age: 50+	1,733	1,912
TB_SCREEN_DSD	Sum of Age disaggregates	5,547	6,118
TB_SCREEN_DSD	Aggregated Age - USE WITH HQ PERMISSION ONLY: <15	3,467	3,823
TB_SCREEN_DSD	Aggregated Age - USE WITH HQ PERMISSION ONLY: 15+	25,423	28,044
TB_SCREEN_DSD	Sum of Aggregated Age disaggregates	28,890	31,867
TB_SCREEN_DSD	Sex: Male	10,112	11,153
TB_SCREEN_DSD	Sex: Female	18,778	20,714
TB_SCREEN_DSD	Sum of Sex disaggregates	28,890	31,867

Implementing Mechanism Details

Mechanism ID: 9150	Mechanism Name: Prisons Project
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: International Medical Corps	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: No	
G2G: No	Managing Agency:

Total All Funding Sources: 0	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 0	
FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount
GHP-State	0

Sub Partner Name(s)

(No data provided.)



Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

(No data provided.)

Budget Code Information

Mechanism ID: 9150			
Mechanism Name: Prisons Project			
Prime Partner Name: International Medical Corps			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	0	0

Implementing Mechanism Indicator Information



Indicator Number	Label	2014	2015	Planning Budget Targets
SITE_SUPP	Number of unique sites supported by PEPFAR	59		Redacted
SITE_SUPP	By program area/support type: HTC Direct Service Delivery (DSD)	2		Redacted
SITE_SUPP	By program area/support type: HTC Technical Assistance-only (TA)	59		Redacted
SITE_SUPP	By program area/support type: Treatment Direct Service Delivery (DSD)	5		Redacted
SITE_SUPP	By program area/support type: Treatment Technical Assistance-only (TA)	20		Redacted
SITE_SUPP	By program area/support type: Care and Support Direct Service Delivery (DSD)	6		Redacted
SITE_SUPP	By program area/support type: Care and Support Technical Assistance-only (TA)	20		Redacted
SITE_SUPP	By program area/support type: Food and Nutrition Direct Service Delivery (DSD)	0		Redacted
SITE_SUPP	By program area/support type: Food and Nutrition Technical Assistance-only (TA)	26		Redacted
SITE_SUPP	By program area/support type: PMTCT Direct Service Delivery (DSD)	4		Redacted
SITE_SUPP	By program area/support type: PMTCT Technical Assistance-only (TA)	20		Redacted
SITE_SUPP	By program area/support type: TB/HIV Direct Service Delivery (DSD)	7		Redacted
SITE_SUPP	By program area/support type: TB/HIV Technical Assistance-only (TA)	31		Redacted

SITE_SUPP	By program area/support type: VMMC Direct Service Delivery (DSD)	0		Redacted
SITE_SUPP	By program area/support type: VMMC Technical Assistance-only (TA)	0		Redacted
SITE_SUPP	By program area/support type: General Population Prevention Direct Service Delivery (DSD)	0		Redacted
SITE_SUPP	By program area/support type: General Population Prevention Technical Assistance-only (TA)	0		Redacted
SITE_SUPP	By program area/support type: Key Populations Prevention Direct Service Delivery (DSD)	0		Redacted
SITE_SUPP	By program area/support type: Key Populations Prevention Technical Assistance-only (TA)	0		Redacted
SITE_SUPP	By program area/support type: OVC Direct Service Delivery (DSD)	0		Redacted
SITE_SUPP	By program area/support type: OVC Technical Assistance-only (TA)	0		Redacted
SITE_SUPP	By program area/support type: PHDP/Family Planning & Integration Direct Service Delivery (DSD)	26		Redacted
SITE_SUPP	By program area/support type: PHDP/Family Planning & Integration Technical Assistance-only (TA)	0		Redacted
SITE_SUPP	By program area/support type: Lab Direct Service Delivery (DSD)	0		Redacted
SITE_SUPP	By program area/support type: Lab Technical Assistance-only (TA)	0		Redacted
PMTCT_ARV_DS D	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	70		Redacted



PMTCT_ARV_DS D	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	70		Redacted
PMTCT_ARV_DS D	Life-long ART (including Option B+)	52		Redacted
PMTCT_ARV_DS D	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	24		Redacted
PMTCT_ARV_DS D	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	28		Redacted
PMTCT_ARV_DS D	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)	0		Redacted
PMTCT_ARV_DS D	Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)	18		Redacted
PMTCT_ARV_DS D	Single-dose nevirapine (with or without tail)	0		Redacted
PMTCT_ARV_DS D	Sum of Regimen Type disaggregates	70		Redacted
PMTCT_ARV_DS D	Sum of New and Current disaggregates	52		Redacted
PMTCT_ARV_NGI	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	250		Redacted
PMTCT_ARV_NGI	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	250		Redacted
PMTCT_ARV_NGI	Life-long ART (including Option B+)	187		Redacted
PMTCT_ARV_NGI	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	87		Redacted

PMTCT_ARV_NGI	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	100		Redacted
PMTCT_ARV_NGI	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)	0		Redacted
PMTCT_ARV_NGI	Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)	63		Redacted
PMTCT_ARV_NGI	Single-dose nevirapine (with or without tail)	0		Redacted
PMTCT_ARV_NGI	Sum of Regimen disaggregates	250		Redacted
PMTCT_ARV_NGI	Sum of New and Current disaggregates	187		Redacted
PMTCT_ARV_TA	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	180		Redacted
PMTCT_ARV_TA	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	180		Redacted
PMTCT_ARV_TA	Life-long ART (including Option B+)	135		Redacted
PMTCT_ARV_TA	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	63		Redacted
PMTCT_ARV_TA	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	72		Redacted
PMTCT_ARV_TA	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)	0		Redacted
PMTCT_ARV_TA	Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)	45		Redacted
PMTCT_ARV_TA	Single-dose nevirapine (with or without	0		Redacted



	tail)			
PMTCT_ARV_TA	Sum of Regimen Type disaggregates	180		Redacted
PMTCT_ARV_TA	Sum of New and Current disaggregates	135		Redacted
PMTCT_SITE	Number of PEPFAR-supported sites achieving 90% ARV or ART coverage for HIV+ pregnant women	24		Redacted
PMTCT_SITE	Total number of PEPFAR supported sites providing PMTCT services (HTC and ARV or ART services)	24		Redacted
PMTCT_SITE	By site support type: Direct Service Delivery (DSD): Number of PEPFAR-supported sites achieving 90% ARV or ART coverage for HIV+ pregnant women	4		Redacted
PMTCT_SITE	By site support type: Technical Assistance-only (TA): Number of PEPFAR-supported sites achieving 90% ARV or ART coverage for HIV+ pregnant women	20		Redacted
PMTCT_SITE	Sum of Numerator Support Type disaggregates	24		Redacted
PMTCT_SITE	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR supported sites providing PMTCT services (HTC and ARV or ART services)	4		Redacted
PMTCT_SITE	By site support type: Technical Assistance-only (TA): Total number of PEPFAR supported sites providing PMTCT services (HTC and ARV or ART services)	20		Redacted
PMTCT_SITE	Sum of Denominator Support Type disaggregates	24		Redacted
PMTCT_STAT_DS D	Number of pregnant women with known HIV status (includes women who were	1,780		Redacted

	tested for HIV and received their results)			
PMTCT_STAT_DS D	Number of new ANC and L&D clients	1,780		Redacted
PMTCT_STAT_DS D	By: Known positives at entry	33		Redacted
PMTCT_STAT_DS D	By: Number of new positives identified	37		Redacted
PMTCT_STAT_DS D	Sum of Positives Status disaggregates	70		Redacted
PMTCT_STAT_NG I	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	6,358		Redacted
PMTCT_STAT_NG I	Number of new ANC and L&D clients	6,358		Redacted
PMTCT_STAT_NG I	By: Known positives at entry	118		Redacted
PMTCT_STAT_NG I	By: Number of new positives identified	132		Redacted
PMTCT_STAT_NG I	Sum of Positives Status disaggregates	250		Redacted
PMTCT_STAT_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	4,578		Redacted
PMTCT_STAT_TA	Number of new ANC and L&D clients	4,578		Redacted
PMTCT_STAT_TA	By: Known positives at entry	85		Redacted
PMTCT_STAT_TA	By: Number of new positives identified	95		Redacted
PMTCT_STAT_TA	Sum of Positives Status disaggregates	180		Redacted
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the	26,324		Redacted



	reporting period.			
PP_PREV_DSD	Total number of people in the target population	250,000		Redacted
PP_PREV_DSD	Age/sex: 10-14 Male	0		Redacted
PP_PREV_DSD	Age/sex: 15-19 Male	1,316		Redacted
PP_PREV_DSD	Age/sex: 20-24 Male	7,898		Redacted
PP_PREV_DSD	Age/sex: 25-49 Male	7,898		Redacted
PP_PREV_DSD	Age/sex: 50+ Male	1,316		Redacted
PP_PREV_DSD	Age/sex: 10-14 Female	0		Redacted
PP_PREV_DSD	Age/sex: 15-19 Female	1,316		Redacted
PP_PREV_DSD	Age/sex: 20-24 Female	2,632		Redacted
PP_PREV_DSD	Age/sex: 25-49 Female	2,632		Redacted
PP_PREV_DSD	Age/sex: 50+ Female	1,316		Redacted
PP_PREV_DSD	Sum of Age/Sex disaggregates	26,324		Redacted
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	10,080		Redacted
HTC_TST_DSD	By Test Result: Negative	9,677		Redacted
HTC_TST_DSD	By Test Result: Positive	403		Redacted
HTC_TST_DSD	Sum of Test Result disaggregates	10,080		Redacted
HTC_TST_DSD	Age/sex: <1 Male	0		Redacted
HTC_TST_DSD	Age/sex: 1-4 Male	353		Redacted
HTC_TST_DSD	Age/sex: 5-9 Male	151		Redacted
HTC_TST_DSD	Age/sex: 10-14 Male	252		Redacted
HTC_TST_DSD	Age/sex: 15-19 Male	504		Redacted
HTC_TST_DSD	Age/sex: 20-24 Male	1,260		Redacted
HTC_TST_DSD	Age/sex: 25-49 Male	2,016		Redacted
HTC_TST_DSD	Age/sex: 50+ Male	504		Redacted
HTC_TST_DSD	Age/sex: <1 Female	0		Redacted
HTC_TST_DSD	Age/sex: 1-4 Female	353		Redacted
HTC_TST_DSD	Age/sex: 5-9 Female	151		Redacted
HTC_TST_DSD	Age/sex: 10-14 Female	252		Redacted



HTC_TST_DSD	Age/sex: 15-19 Female	504		Redacted
HTC_TST_DSD	Age/sex: 20-24 Female	1,260		Redacted
HTC_TST_DSD	Age/sex: 25-49 Female	2,016		Redacted
HTC_TST_DSD	Age/sex: 50+ Female	504		Redacted
HTC_TST_DSD	Sum of Age/Sex disaggregates	10,080		Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	756		Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	4,284		Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	756		Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	4,284		Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	1,512		Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	8,568		Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	10,080		Redacted
HTC_TST_NGI	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	36,000		Redacted
HTC_TST_NGI	By Test Result: Negative	34,560		Redacted
HTC_TST_NGI	By Test Result: Positive	1,440		Redacted
HTC_TST_NGI	Sum of Test Result disaggregates	36,000		Redacted
HTC_TST_NGI	Age/sex: <1 Male	0		Redacted
HTC_TST_NGI	Age/sex: 1-4 Male	1,260		Redacted
HTC_TST_NGI	Age/sex: 5-9 Male	540		Redacted
HTC_TST_NGI	Age/sex: 10-14 Male	900		Redacted
HTC_TST_NGI	Age/sex: 15-19 Male	1,800		Redacted
HTC_TST_NGI	Age/sex: 20-24 Male	4,500		Redacted
HTC_TST_NGI	Age/sex: 25-49 Male	7,200		Redacted
HTC_TST_NGI	Age/sex: 50+ Male	1,800		Redacted
HTC_TST_NGI	Age/sex: <1 Female	0		Redacted
HTC_TST_NGI	Age/sex: 1-4 Female	1,260		Redacted



HTC_TST_NGI	Age/sex: 5-9 Female	540		Redacted
HTC_TST_NGI	Age/sex: 10-14 Female	900		Redacted
HTC_TST_NGI	Age/sex: 15-19 Female	1,800		Redacted
HTC_TST_NGI	Age/sex: 20-24 Female	4,500		Redacted
HTC_TST_NGI	Age/sex: 25-49 Female	7,200		Redacted
HTC_TST_NGI	Age/sex: 50+ Female	1,800		Redacted
HTC_TST_NGI	Sum of Age/Sex disaggregates	36,000		Redacted
HTC_TST_NGI	Aggregated Age/sex: <15 Male	2,700		Redacted
HTC_TST_NGI	Aggregated Age/sex: 15+ Male	15,300		Redacted
HTC_TST_NGI	Aggregated Age/sex: <15 Female	2,700		Redacted
HTC_TST_NGI	Aggregated Age/sex: 15+ Female	15,300		Redacted
HTC_TST_NGI	Sum of Aggregated Age/Sex <15	5,400		Redacted
HTC_TST_NGI	Sum of Aggregated Age/Sex 15+	30,600		Redacted
HTC_TST_NGI	Sum of Aggregated Age/Sex disaggregates	36,000		Redacted
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	25,920		Redacted
HTC_TST_TA	By Test Result: Negative	24,883		Redacted
HTC_TST_TA	By Test Result: Positive	1,037		Redacted
HTC_TST_TA	Sum of Test Result disaggregates	25,920		Redacted
HTC_TST_TA	Age/sex: <1 Male	0		Redacted
HTC_TST_TA	Age/sex: 1-4 Male	907		Redacted
HTC_TST_TA	Age/sex: 5-9 Male	389		Redacted
HTC_TST_TA	Age/sex: 10-14 Male	648		Redacted
HTC_TST_TA	Age/sex: 15-19 Male	1,296		Redacted
HTC_TST_TA	Age/sex: 20-24 Male	3,240		Redacted
HTC_TST_TA	Age/sex: 25-49 Male	5,184		Redacted
HTC_TST_TA	Age/sex: 50+ Male	1,296		Redacted
HTC_TST_TA	Age/sex: <1 Female	0		Redacted
HTC_TST_TA	Age/sex: 1-4 Female	907		Redacted
HTC_TST_TA	Age/sex: 5-9 Female	389		Redacted



HTC_TST_TA	Age/sex: 10-14 Female	648		Redacted
HTC_TST_TA	Age/sex: 15-19 Female	1,296		Redacted
HTC_TST_TA	Age/sex: 20-24 Female	3,240		Redacted
HTC_TST_TA	Age/sex: 25-49 Female	5,184		Redacted
HTC_TST_TA	Age/sex: 50+ Female	1,296		Redacted
HTC_TST_TA	Sum of Age/Sex disaggregates	25,920		Redacted
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	1,944		Redacted
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	11,016		Redacted
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	1,944		Redacted
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	11,016		Redacted
HTC_TST_TA	Sum of Aggregated Age/Sex <15	3,888		Redacted
HTC_TST_TA	Sum of Aggregated Age/Sex 15+	22,032		Redacted
HTC_TST_TA	Sum of Aggregated Age/Sex disaggregates	25,920		Redacted
C2.1.D_DSD	Number of HIV-positive individuals receiving a minimum of one clinical service	4,201		Redacted
C2.1.D_DSD	By Age/Sex: <15 Female	189		Redacted
C2.1.D_DSD	By Age/Sex: <15 Male	189		Redacted
C2.1.D_DSD	By Age/Sex: 15+ Female	2,523		Redacted
C2.1.D_DSD	By Age/Sex: 15+ Male	1,300		Redacted
C2.1.D_DSD	Sum of Age/Sex disaggregates	4,201		Redacted
C2.1.D_DSD	By Age: <15	378		Redacted
C2.1.D_DSD	By Age: 15+	3,823		Redacted
C2.1.D_DSD	Sum of Age disaggregates	4,201		Redacted
C2.1.D_DSD	By Sex: Female	2,712		Redacted
C2.1.D_DSD	By Sex: Male	1,489		Redacted
C2.1.D_DSD	Sum of Sex disaggregates	4,201		Redacted
C2.1.D_NGI	Number of HIV-positive individuals	8,401		Redacted



	receiving a minimum of one clinical service			
C2.1.D_NGI	By Age/Sex: <15 Female	378		Redacted
C2.1.D_NGI	By Age/Sex: <15 Male	378		Redacted
C2.1.D_NGI	By Age/Sex: 15+ Female	5,046		Redacted
C2.1.D_NGI	By Age/Sex: 15+ Male	2,599		Redacted
C2.1.D_NGI	Sum of Age/Sex disaggregates	8,401		Redacted
C2.1.D_NGI	By Age: <15	756		Redacted
C2.1.D_NGI	By Age: 15+	7,645		Redacted
C2.1.D_NGI	Sum of Age disaggregates	8,401		Redacted
C2.1.D_NGI	By Sex: Female	5,424		Redacted
C2.1.D_NGI	By Sex: Male	2,977		Redacted
C2.1.D_NGI	Sum of Sex disaggregates	8,401		Redacted
C2.1.D_TA	Number of HIV-positive individuals receiving a minimum of one clinical service	4,200		Redacted
C2.1.D_TA	By Age/Sex: <15 Female	188		Redacted
C2.1.D_TA	By Age/Sex: <15 Male	189		Redacted
C2.1.D_TA	By Age/Sex: 15+ Female	2,523		Redacted
C2.1.D_TA	By Age/Sex: 15+ Male	1,300		Redacted
C2.1.D_TA	Sum of Age/Sex disaggregates	4,200		Redacted
C2.1.D_TA	By Age: <15	377		Redacted
C2.1.D_TA	By Age: 15+	3,823		Redacted
C2.1.D_TA	Sum of Age disaggregates	4,200		Redacted
C2.1.D_TA	By Sex: Female	2,711		Redacted
C2.1.D_TA	By Sex: Male	1,489		Redacted
C2.1.D_TA	Sum of Sex disaggregates	4,200		Redacted
C2.4.D_DSD	Number of HIV-positive patients who were screened for TB in HIV care or treatment setting	3,781		Redacted
C2.4.D_DSD	Number of HIV-positive individuals receiving a minimum of one clinical service	4,201		Redacted



C2.5.D_DSD	Number of HIV-positive patients in HIV care who started TB treatment	76		Redacted
C2.5.D_DSD	Number of HIV-positive individuals receiving a minimum of one clinical service	4,201		Redacted
CARE_CURR_DS D	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	3,991		Redacted
CARE_CURR_DS D	Age/sex: <1 Male	6		Redacted
CARE_CURR_DS D	Age/sex: 1-4 Male	43		Redacted
CARE_CURR_DS D	Age/sex: 5-9 Male	73		Redacted
CARE_CURR_DS D	Age/sex: 10-14 Male	57		Redacted
CARE_CURR_DS D	Age/sex: 15-19 Male	31		Redacted
CARE_CURR_DS D	Age/sex: 20-24 Male	57		Redacted
CARE_CURR_DS D	Age/sex: 25-49 Male	853		Redacted
CARE_CURR_DS D	Age/sex: 50+ Male	295		Redacted
CARE_CURR_DS D	Age/sex: <1 Female	6		Redacted
CARE_CURR_DS D	Age/sex: 1-4 Female	41		Redacted
CARE_CURR_DS D	Age/sex: 5-9 Female	75		Redacted
CARE_CURR_DS D	Age/sex: 10-14 Female	57		Redacted



CARE_CURR_DS D	Age/sex: 15-19 Female	51		Redacted
CARE_CURR_DS D	Age/sex: 20-24 Female	210		Redacted
CARE_CURR_DS D	Age/sex: 25-49 Female	1,792		Redacted
CARE_CURR_DS D	Age/sex: 50+ Female	344		Redacted
CARE_CURR_DS D	Sun of Age/Sex disaggregates	3,991		Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	179		Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	1,236		Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	179		Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	2,397		Redacted
CARE_CURR_DS D	Sum of Aggregated Age/Sex disaggregates	3,991		Redacted
CARE_CURR_TA	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	3,991		Redacted
CARE_CURR_TA	Age/sex: <1 Male	6		Redacted
CARE_CURR_TA	Age/sex: 1-4 Male	43		Redacted
CARE_CURR_TA	Age/sex: 5-9 Male	73		Redacted
CARE_CURR_TA	Age/sex: 10-14 Male	57		Redacted
CARE_CURR_TA	Age/sex: 15-19 Male	31		Redacted
CARE_CURR_TA	Age/sex: 20-24 Male	57		Redacted
CARE_CURR_TA	Age/sex: 25-49 Male	853		Redacted
CARE_CURR_TA	Age/sex: 50+ Male	295		Redacted
CARE_CURR_TA	Age/sex: <1 Female	6		Redacted



CARE_CURR_TA	Age/sex: 1-4 Female	41		Redacted
CARE_CURR_TA	Age/sex: 5-9 Female	75		Redacted
CARE_CURR_TA	Age/sex: 10-14 Female	57		Redacted
CARE_CURR_TA	Age/sex: 15-19 Female	51		Redacted
CARE_CURR_TA	Age/sex: 20-24 Female	210		Redacted
CARE_CURR_TA	Age/sex: 25-49 Female	1,792		Redacted
CARE_CURR_TA	Age/sex: 50+ Female	344		Redacted
CARE_CURR_TA	Sum of Age/Sex disaggregates	3,991		Redacted
CARE_CURR_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	179		Redacted
CARE_CURR_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	1,236		Redacted
CARE_CURR_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	179		Redacted
CARE_CURR_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	2,397		Redacted
CARE_CURR_TA	Sum of Aggregated Age/Sex disaggregates	3,991		Redacted
CARE_NEW_DSD	Number of HIV-infected adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load	1,596		Redacted
CARE_NEW_DSD	Age/sex: <1 Male	2		Redacted
CARE_NEW_DSD	Age/sex: 1-4 Male	17		Redacted
CARE_NEW_DSD	Age/sex: 5-9 Male	29		Redacted
CARE_NEW_DSD	Age/sex: 10-14 Male	23		Redacted
CARE_NEW_DSD	Age/sex: 15-19 Male	10		Redacted
CARE_NEW_DSD	Age/sex: 20-24 Male	43		Redacted
CARE_NEW_DSD	Age/sex: 25-49 Male	369		Redacted
CARE_NEW_DSD	Age/sex: 50+ Male	72		Redacted
CARE_NEW_DSD	Age/sex: <1 Female	2		Redacted



CARE_NEW_DSD	Age/sex: 1-4 Female	16		Redacted
CARE_NEW_DSD	Age/sex: 5-9 Female	30		Redacted
CARE_NEW_DSD	Age/sex: 10-14 Female	23		Redacted
CARE_NEW_DSD	Age/sex: 15-19 Female	24		Redacted
CARE_NEW_DSD	Age/sex: 20-24 Female	44		Redacted
CARE_NEW_DSD	Age/sex: 25-49 Female	662		Redacted
CARE_NEW_DSD	Age/sex: 50+ Female	230		Redacted
CARE_NEW_DSD	Sum of Age/sex disaggregates	1,596		Redacted
CARE_NEW_DSD	Aggregated Age/sex: <15 Male	71		Redacted
CARE_NEW_DSD	Aggregated Age/sex: 15+ Male	494		Redacted
CARE_NEW_DSD	Aggregated Age/sex: <15 Female	71		Redacted
CARE_NEW_DSD	Aggregated Age/sex: 15+ Female	960		Redacted
CARE_NEW_DSD	Sum of Aggregated Age/sex disaggregates	1,596		Redacted
CARE_SITE	Number of PEPFAR-supported HIV clinical care sites at which at least 80% of PLHIV received all of the following during the reporting period: 1) clinical assessment (WHO staging) OR CD4 count OR viral load, AND 2) TB screening at last visit, AND 3) if eligible, cotrimoxazole	26		Redacted
CARE_SITE	Total number of PEPFAR supported sites providing clinical care services	26		Redacted
CARE_SITE	By site support type: Direct Service Delivery (DSD): Number of PEPFAR-supported HIV clinical care sites at which at least 80% of PLHIV received all of the following during the reporting period: 1) clinical assessment (WHO staging) OR CD4 count OR viral load, AND 2) TB screening at last visit, AND 3) if eligible, cotrimoxazole	6		Redacted
CARE_SITE	By site support type: Technical	20		Redacted



	Assistance-only (TA): Number of PEPFAR-supported HIV clinical care sites at which at least 80% of PLHIV received all of the following during the reporting period: 1) clinical assessment (WHO staging) OR CD4 count OR viral load, AND 2) TB screening at last visit, AND 3) if eligible, cotrimoxazole			
CARE_SITE	Sum of Numerator Site Support Type disaggregates	26		Redacted
CARE_SITE	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR supported sites providing clinical care services	6		Redacted
CARE_SITE	By site support type: Technical Assistance-only (TA): Total number of PEPFAR supported sites providing clinical care services	20		Redacted
CARE_SITE	Sum of Denominator Site Support Type disaggregates	26		Redacted
FN_SITE	Number of PEPFAR-supported sites achieving 90% nutrition assessments that result in accurate categorization of malnutrition	24		Redacted
FN_SITE	Total number of PEPFAR-supported sites providing nutrition assessment, counseling and support (NACS) services	26		Redacted
FN_SITE	By site support type: Direct Service Delivery (DSD): Number of PEPFAR-supported sites achieving 90% nutrition assessments that result in accurate categorization of malnutrition	0		Redacted
FN_SITE	By site support type: Technical	24		Redacted



	Assistance-only (TA): Number of PEPFAR-supported sites achieving 90% nutrition assessments that result in accurate categorization of malnutrition			
FN_SITE	Sum of Numerator Support Type disaggregates	24		Redacted
FN_SITE	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported sites providing nutrition assessment, counseling and support (NACS) services	0		Redacted
FN_SITE	By site support type: Technical Assistance-only (TA): Total number of PEPFAR-supported sites providing nutrition assessment, counseling and support (NACS) services	26		Redacted
FN_SITE	Sum of Denominator Support Type disaggregates	26		Redacted
FN_THER_DSD	Number of clinically malnourished PLHIV who received therapeutic and/or supplementary food during the reporting period.	1,260		Redacted
FN_THER_DSD	Number of PLHIV who were nutritionally assessed and found to be clinically undernourished.	1,680		Redacted
FN_THER_DSD	Age: <1	4		Redacted
FN_THER_DSD	Age: 1-4	27		Redacted
FN_THER_DSD	Age: 5-14	85		Redacted
FN_THER_DSD	Age: 15-17	25		Redacted
FN_THER_DSD	Age: 18+	1,119		Redacted
FN_THER_DSD	Sum of Age disaggregates	1,260		Redacted
FN_THER_DSD	Aggregated Age: <18	141		Redacted
FN_THER_DSD	Aggregated Age: 18+	1,119		Redacted



FN_THER_DSD	Sum of Aggregated Age disaggregates	1,260		Redacted
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	161		Redacted
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	189		Redacted
TB_ART_DSD	Age: 0-4	4		Redacted
TB_ART_DSD	Age: 5-14	11		Redacted
TB_ART_DSD	Age: 15+	146		Redacted
TB_ART_DSD	Male	87		Redacted
TB_ART_DSD	Female	74		Redacted
TB_ART_DSD	Sum of Sex disaggregates	161		Redacted
TB_ART_DSD	Newly tested	97		Redacted
TB_ART_DSD	Known HIV-positive	64		Redacted
TB_ART_DSD	Sum of Test Status disaggregates	161		Redacted
TB_ART_DSD	Aggregated Age: <15	15		Redacted
TB_ART_DSD	Aggregated Age: 15+	146		Redacted
TB_ART_DSD	Sum of Aggregated Age disaggregates	161		Redacted
TB_ARTSITE	The number of PEPFAR-supported TB basic management units at which 80% of registered TB cases who are HIV-positive are on ART, during the reporting period	38		Redacted
TB_ARTSITE	The number of PEPFAR-supported TB basic management units	38		Redacted
TB_ARTSITE	By site support type: Direct Service Delivery (DSD): The number of PEPFAR-supported TB basic management units at which 80% of registered TB cases who are	7		Redacted



	HIV-positive are on ART, during the reporting period			
TB_ARTSITE	By site support type: Technical Assistance-only (TA): The number of PEPFAR-supported TB basic management units at which 80% of registered TB cases who are HIV-positive are on ART, during the reporting period	31		Redacted
TB_ARTSITE	Sum of Numerator Site Support Type disaggregates	38		Redacted
TB_ARTSITE	By site support type: Direct Service Delivery (DSD): The number of PEPFAR-supported TB basic management units	7		Redacted
TB_ARTSITE	By site support type: Technical Assistance-only (TA): The number of PEPFAR-supported TB basic management units	31		Redacted
TB_ARTSITE	Sum of Denominator Site Support Type disaggregates	38		Redacted
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	200		Redacted
PMTCT_EID_DSD	Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT)	250		Redacted
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	150		Redacted
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	50		Redacted
PMTCT_EID_DSD	Sum of Infant Age disaggregates	200		Redacted
PMTCT_EID_DSD	By infants with a positive virologic test	10		Redacted

	result within 12 months of birth			
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	2,087		Redacted
TX_CURR_DSD	Age/Sex: <1 Male	3		Redacted
TX_CURR_DSD	Age/Sex: 1-4 Male	22		Redacted
TX_CURR_DSD	Age/Sex: 5-14 Male	69		Redacted
TX_CURR_DSD	Age/Sex: 15+ Male	646		Redacted
TX_CURR_DSD	Age/Sex: <1 Female	3		Redacted
TX_CURR_DSD	Age/Sex: 1-4 Female	22		Redacted
TX_CURR_DSD	Age/Sex: 5-14 Female	69		Redacted
TX_CURR_DSD	Age/Sex: 15+ Female	1,253		Redacted
TX_CURR_DSD	Sum of age/sex disaggregates	188		Redacted
TX_CURR_DSD	Percent children with advanced HIV infection receiving antiretroviral therapy (ART) [CURRENT]	50		Redacted
TX_CURR_DSD	Percent women and girls with advanced HIV infection receiving antiretroviral therapy (ART) [CURRENT]	50		Redacted
TX_CURR_DSD	Aggregated Age/Sex: <1 Male	3		Redacted
TX_CURR_DSD	Aggregated Age/Sex: <1 Female	3		Redacted
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	94		Redacted
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	646		Redacted
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	94		Redacted
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	1,253		Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	188		Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	1,899		Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	2,087		Redacted
TX_CURR_NGI	Number of adults and children receiving antiretroviral therapy (ART)	4,173		Redacted
TX_CURR_NGI	Age/Sex: <1 Male	6		Redacted
TX_CURR_NGI	Age/Sex: 1-4 Male	44		Redacted



TX_CURR_NGI	Age/Sex: 5-14 Male	137		Redacted
TX_CURR_NGI	Age/Sex: 15+ Male	1,292		Redacted
TX_CURR_NGI	Age/Sex: <1 Female	6		Redacted
TX_CURR_NGI	Age/Sex: 1-4 Female	44		Redacted
TX_CURR_NGI	Age/Sex: 5-14 Female	137		Redacted
TX_CURR_NGI	Age/Sex: 15+ Female	2,507		Redacted
TX_CURR_NGI	Sum of Age/Sex disaggregates	4,173		Redacted
TX_CURR_NGI	Aggregated Age/Sex: <1 Male	6		Redacted
TX_CURR_NGI	Aggregated Age/Sex: <1 Female	6		Redacted
TX_CURR_NGI	Aggregated Age/Sex: <15 Male	187		Redacted
TX_CURR_NGI	Aggregated Age/Sex: 15+ Male	1,292		Redacted
TX_CURR_NGI	Aggregated Age/Sex: <15 Female	187		Redacted
TX_CURR_NGI	Aggregated Age/Sex: 15+ Female	2,507		Redacted
TX_CURR_NGI	Sum of Aggregated Age/Sex disaggregates	4,173		Redacted
TX_CURR_NGI	Sum of Aggregated Age/Sex <15	374		Redacted
TX_CURR_NGI	Sum of Aggregated Age/Sex 15+	3,799		Redacted
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	2,086		Redacted
TX_CURR_TA	Age/Sex: <1 Male	3		Redacted
TX_CURR_TA	Age/Sex: 1-4 Male	21		Redacted
TX_CURR_TA	Age/Sex: 5-14 Male	69		Redacted
TX_CURR_TA	Age/Sex: 15+ Male	646		Redacted
TX_CURR_TA	Age/Sex: <1 Female	3		Redacted
TX_CURR_TA	Age/Sex: 1-4 Female	22		Redacted
TX_CURR_TA	Age/Sex: 5-14 Female	69		Redacted
TX_CURR_TA	Age/Sex: 15+ Female	1,253		Redacted
TX_CURR_TA	Sum of Age/Sex disaggregations	187		Redacted
TX_CURR_TA	Aggregated Age/Sex: <1 Male	3		Redacted
TX_CURR_TA	Aggregated Age/Sex: <1 Female	3		Redacted
TX_CURR_TA	Aggregated Age/Sex: <15 Male	93		Redacted
TX_CURR_TA	Aggregated Age/Sex: 15+ Male	646		Redacted



TX_CURR_TA	Aggregated Age/Sex: <15 Female	94		Redacted
TX_CURR_TA	Aggregated Age/Sex: 15+ Female	1,253		Redacted
TX_CURR_TA	Sum of Aggregated Age/Sex <15	187		Redacted
TX_CURR_TA	Sum of Aggregated Age/Sex 15+	1,899		Redacted
TX_CURR_TA	Sum of Aggregated Age/Sex disaggregates	2,086		Redacted
TX_DIST	Number of Districts with documented routine supportive supervision visits to 75% of HIV care and treatment sites supported by the District	26		Redacted
TX_DIST	Total number of PEPFAR supported District Health Offices	33		Redacted
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	520		Redacted
TX_NEW_DSD	By Age/Sex: <1 Male	8		Redacted
TX_NEW_DSD	By Age/Sex: 1-4 Male	5		Redacted
TX_NEW_DSD	By Age/Sex: 5-9 Male	8		Redacted
TX_NEW_DSD	By Age/Sex: 10-14 Male	6		Redacted
TX_NEW_DSD	By Age/Sex: 15-19 Male	4		Redacted
TX_NEW_DSD	By Age/Sex: 20-24 Male	7		Redacted
TX_NEW_DSD	By Age/Sex: 25-49 Male	113		Redacted
TX_NEW_DSD	By Age/Sex: 50+ Male	39		Redacted
TX_NEW_DSD	By Age/Sex: <1 Female	8		Redacted
TX_NEW_DSD	By Age/Sex: 1-4 Female	5		Redacted
TX_NEW_DSD	By Age/Sex: 5-9 Female	8		Redacted
TX_NEW_DSD	By Age/Sex: 10-14 Female	6		Redacted
TX_NEW_DSD	By Age/Sex: 15-19 Female	6		Redacted
TX_NEW_DSD	By Age/Sex: 20-24 Female	27		Redacted
TX_NEW_DSD	By Age/Sex: 25-49 Female	226		Redacted
TX_NEW_DSD	By Age/Sex: 50+ Female	44		Redacted
TX_NEW_DSD	Sum of Age/Sex disaggregates	520		Redacted
TX_NEW_DSD	Aggregated Grouping by Age: <1 Male	8		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15	27		Redacted

	Male			
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	163		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <1 Female	8		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	27		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	303		Redacted
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	520		Redacted
TX_NEW_DSD	Pregnancy status	79		Redacted
TX_NEW_DSD	Breastfeeding status	9		Redacted
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	293		Redacted
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	345		Redacted
TX_RET_DSD	Age: 0-4 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	7		Redacted
TX_RET_DSD	Age: 5-14 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	20		Redacted
TX_RET_DSD	Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	266		Redacted
TX_RET_DSD	Age: 0-4 (Denominator: Total number	9		Redacted



	of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)			
TX_RET_DSD	Age: 5-14 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	23		Redacted
TX_RET_DSD	Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	313		Redacted
TX_RET_DSD	Aggregated Age: <15 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	27		Redacted
TX_RET_DSD	Aggregated Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	266		Redacted
TX_RET_DSD	Aggregated Age: <15 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	32		Redacted
TX_RET_DSD	Aggregated Age: 15+ (Denominator:	313		Redacted

	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)			
TX_RET_DSD	Pregnancy and breastfeeding status (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	80		Redacted
TX_RET_DSD	Pregnancy and breastfeeding status (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	94		Redacted
TX_SITE	Number of PEPFAR-supported ART sites with a retention rate of 75% or greater for patients 12 months after ART initiation	18		Redacted
TX_SITE	Total number of PEPFAR-supported ART sites	25		Redacted
TX_SITE	By support type: Direct Service Delivery (DSD): Number of PEPFAR-supported ART sites with a retention rate of 75% or greater for patients 12 months after ART initiation	4		Redacted
TX_SITE	By support type: Technical Assistance (TA-only): Number of PEPFAR-supported ART sites with a retention rate of 75% or greater for patients 12 months after ART initiation	14		Redacted
TX_SITE	Sum of Numerator Site Support Type disaggregates	18		Redacted



TX_SITE	By support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported ART sites	5		Redacted
TX_SITE	By support type: Technical Assistance (TA-only): Total number of PEPFAR-supported ART sites	20		Redacted
TX_SITE	Sum of Denominator Site Support Type disaggregates	25		Redacted
FPINT_SITE_DSD	Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	18		Redacted
FPINT_SITE_DSD	Total number of PEPFAR-supported HIV service delivery points: PMTCT, Care and Treatment	24		Redacted
FPINT_SITE_DSD	By site support type: Direct Service Delivery (DSD): Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	3		Redacted
FPINT_SITE_DSD	By site support type: Technical Assistance-only (TA): Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	15		Redacted
FPINT_SITE_DSD	Sum of Numerator Site Support Type disaggregates	18		Redacted
FPINT_SITE_DSD	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported HIV service delivery points	4		Redacted
FPINT_SITE_DSD	By site support type: Technical Assistance-only (TA): Total number of	20		Redacted



	PEPFAR-supported HIV service delivery points			
FPINT_SITE_DSD	Sum of Denominator Site Support Type disaggregates	24		Redacted
FPINT_SITE_DSD	Service delivery type: Clinical	18		Redacted
FPINT_SITE_DSD	Sum of Service Delivery Type disaggregates	18		Redacted
QI_SITE	Number of PEPFAR-supported clinical service sites with a quality improvement activity completed that addresses clinical HIV programs and has documented process results in the last 6 months	19		Redacted
QI_SITE	Total number of PEPFAR-supported sites for any HIV clinical service including HIV Care, HIV Treatment, TB care, PMTCT, VMMC, and HTC	24		Redacted
QI_SITE	By site support type: Direct Service Delivery (DSD): Number of PEPFAR-supported clinical service sites with a quality improvement activity completed that addresses clinical HIV programs and has documented results in the last 6 months	3		Redacted
QI_SITE	By site support type: Technical Assistance-only (TA): Number of PEPFAR-supported clinical service sites with a quality improvement activity completed that addresses clinical HIV programs and has documented results in the last 6 months	16		Redacted
QI_SITE	Sum of Numerator Site Support Type disaggregates	19		Redacted
QI_SITE	By site support type: Direct Service Delivery (DSD): Total number of	4		Redacted



	PEPFAR-supported sites for any HIV clinical service including HIV Care, HIV Treatment, TB care, PMTCT, VMMC, HTC			
QI_SITE	By site support type: Technical Assistance-only (TA): Total number of PEPFAR-supported sites for any HIV clinical service including HIV Care, HIV Treatment, TB care, PMTCT, VMMC, and HTC	20		Redacted
QI_SITE	Sum of Denominator Site Support Type disaggregates	24		Redacted
TB_SCREEN_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period	3,591		Redacted
TB_SCREEN_DSD	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	3,991		Redacted
TB_SCREEN_DSD	Age: <1	11		Redacted
TB_SCREEN_DSD	Age: 1-4	77		Redacted
TB_SCREEN_DSD	Age: 5-9	137		Redacted
TB_SCREEN_DSD	Age: 10-14	105		Redacted
TB_SCREEN_DSD	Age: 15-19	73		Redacted
TB_SCREEN_DSD	Age: 20-24	242		Redacted
TB_SCREEN_DSD	Age: 25-49	2,378		Redacted
TB_SCREEN_DSD	Age: 50+	568		Redacted
TB_SCREEN_DSD	Sum of Age disaggregates	403		Redacted
TB_SCREEN_DSD	Aggregated Age - USE WITH HQ PERMISSION ONLY: <15	330		Redacted
TB_SCREEN_DSD	Aggregated Age - USE WITH HQ PERMISSION ONLY: 15+	3,261		Redacted



TB_SCREEN_DSD	Sum of Aggregated Age disaggregates	3,591		Redacted
TB_SCREEN_DSD	Sex: Male	1,274		Redacted
TB_SCREEN_DSD	Sex: Female	2,317		Redacted
TB_SCREEN_DSD	Sum of Sex disaggregates	3,591		Redacted

Implementing Mechanism Details

Mechanism ID: 9143	Mechanism Name: Kenya Department of Defense
Funding Agency: DOD	Procurement Type: Cooperative Agreement
Prime Partner Name: Henry Jackson Foundation	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: No	
G2G: No	Managing Agency:

Total All Funding Sources: 2,167,403	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 0	
FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount
GHP-State	2,167,403

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

Human Resources for Health	300,000
Food and Nutrition: Policy, Tools, and Service Delivery	50,000
Food and Nutrition: Commodities	50,000



Key Issues

- Child Survival Activities
- Military Population
- Mobile Population
- Safe Motherhood
- TB
- Family Planning

Budget Code Information

Mechanism ID: 9143			
Mechanism Name: Kenya Department of Defense			
Prime Partner Name: Henry Jackson Foundation			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	103,825	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	20,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	151,304	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	55,583	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	285,294	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	20,514	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Prevention	HVCT	117,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	273,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	121,894	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	923,454	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	95,535	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2014	2015
SITE_SUPP	Number of unique sites supported by PEPFAR	31	31
SITE_SUPP	By program area/support type: HTC Direct Service Delivery (DSD)	31	31
SITE_SUPP	By program area/support type: Treatment Direct Service Delivery (DSD)	10	10
SITE_SUPP	By program area/support type: Care and Support Direct Service Delivery (DSD)	10	10
SITE_SUPP	By program area/support type: Food and Nutrition Direct Service Delivery (DSD)	17	17
SITE_SUPP	By program area/support type: PMTCT Direct Service Delivery (DSD)	14	17
SITE_SUPP	By program area/support type: TB/HIV Direct Service Delivery (DSD)	10	10
SITE_SUPP	By program area/support type: VMMC Direct Service Delivery (DSD)	10	10



SITE_SUPP	By program area/support type: General Population Prevention Direct Service Delivery (DSD)	31	31
SITE_SUPP	By program area/support type: OVC Direct Service Delivery (DSD)	31	31
SITE_SUPP	By program area/support type: PHDP/Family Planning & Integration Direct Service Delivery (DSD)	17	17
SITE_SUPP	By program area/support type: Lab Direct Service Delivery (DSD)	15	15
PMTCT_ARV_DSD	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	127	143
PMTCT_ARV_DSD	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	127	143
PMTCT_ARV_DSD	Life-long ART (including Option B+)	95	107
PMTCT_ARV_DSD	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	44	50
PMTCT_ARV_DSD	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	51	57
PMTCT_ARV_DSD	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)	0	0
PMTCT_ARV_DSD	Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)	32	36
PMTCT_ARV_DSD	Sum of Regimen Type disaggregates	127	143
PMTCT_ARV_DSD	Sum of New and Current disaggregates	95	107
PMTCT_ARV_NGI	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	127	143



PMTCT_ARV_NGI	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	127	143
PMTCT_ARV_NGI	Life-long ART (including Option B+)	95	107
PMTCT_ARV_NGI	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	44	50
PMTCT_ARV_NGI	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	51	57
PMTCT_ARV_NGI	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)	0	0
PMTCT_ARV_NGI	Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)	32	36
PMTCT_ARV_NGI	Sum of Regimen disaggregates	127	143
PMTCT_ARV_NGI	Sum of New and Current disaggregates	95	107
PMTCT_SITE	Number of PEPFAR-supported sites achieving 90% ARV or ART coverage for HIV+ pregnant women	14	17
PMTCT_SITE	Total number of PEPFAR supported sites providing PMTCT services (HTC and ARV or ART services)	14	17
PMTCT_SITE	By site support type: Direct Service Delivery (DSD): Number of PEPFAR-supported sites achieving 90% ARV or ART coverage for HIV+ pregnant women	14	17
PMTCT_SITE	Sum of Numerator Support Type disaggregates	14	17
PMTCT_SITE	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR supported sites providing PMTCT services (HTC and ARV or ART services)	14	17
PMTCT_SITE	Sum of Denominator Support Type disaggregates	14	17



PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	2,700	3,050
PMTCT_STAT_DSD	Number of new ANC and L&D clients	2,700	3,050
PMTCT_STAT_DSD	By: Known positives at entry	51	57
PMTCT_STAT_DSD	By: Number of new positives identified	76	86
PMTCT_STAT_DSD	Sum of Positives Status disaggregates	127	143
PMTCT_STAT_NGI	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	2,700	3,050
PMTCT_STAT_NGI	Number of new ANC and L&D clients	2,700	3,050
PMTCT_STAT_NGI	By: Known positives at entry	51	57
PMTCT_STAT_NGI	By: Number of new positives identified	76	86
PMTCT_STAT_NGI	Sum of Positives Status disaggregates	127	143
VMMC_AE_DSD	Number of males circumcised surgically or by medical device that experienced at least one moderate or severe adverse event(s) (AEs)	2	0
VMMC_AE_DSD	By AE type: Number of VMMC clients with one or more moderate or severe surgical intra-operative AE(s)	1	0
VMMC_AE_DSD	Sub-Disag: Surgical intra-operative AE(s) by maximum severity category: Number of clients with one or more moderate surgical intra-operative AE(s), but no severe surgical intra-operative AE(s)	1	0
VMMC_AE_DSD	Sub-Disag: Surgical intra-operative AE(s) by maximum severity category: Number of clients with one or more severe surgical intra-operative AE(s)	1	0
VMMC_AE_DSD	By AE Type: Number of VMMC clients with one or more moderate or severe surgical post-operative AE(s)	1	0
VMMC_AE_DSD	Sub-Disag: By Surgical post-operative AE(s) by maximum severity category: Number of	1	0

	clients with one or more moderate surgical post-operative AE(s), but no severe surgical post-operative AE(s)		
VMMC_AE_DSD	Sub-Disag: By Surgical post-operative AE(s) by maximum severity category: Number of clients with one or more severe surgical intra-operative AE(s)	0	0
VMMC_AE_DSD	By AE Type: Number of VMMC clients with one or more moderate or severe medical device-related AE(s)	1	0
VMMC_AE_DSD	Sub-Disag: By Medical device-based AE(s) by maximum severity category: Number of clients with one or more moderate medical device-related AE(s), but no severe medical device-related AE(s)	1	0
VMMC_AE_DSD	Sub-Disag: By Medical device-based AE(s) by maximum severity category: Number of clients with one or more severe medical device-related AE(s)	0	0
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	120	75
VMMC_CIRC_DSD	By Age: <1	0	0
VMMC_CIRC_DSD	By Age: 1-9	0	0
VMMC_CIRC_DSD	By Age: 10-14	66	42
VMMC_CIRC_DSD	By Age: 15-19	22	14
VMMC_CIRC_DSD	By Age: 20-24	18	11
VMMC_CIRC_DSD	By Age: 25-49	9	5
VMMC_CIRC_DSD	By Age: 50+	5	3
VMMC_CIRC_DSD	Sum of age disaggregates	120	75
VMMC_CIRC_DSD	By HIV status: Number of HIV-positive clients (tested HIV positive at VMMC site)	2	1
VMMC_CIRC_DSD	By HIV status: Number of HIV-negative clients	118	73

	(tested HIV negative at VMMC program)		
VMMC_CIRC_DSD	By HIV status: Number of clients with undocumented/indeterminate HIV status or not tested for HIV at site	0	0
VMMC_CIRC_DSD	By circumcision technique: Surgical VMMC	120	74
VMMC_CIRC_DSD	By follow-up status: Number of surgically circumcised clients who returned at least once for follow-up care within 14 days of circumcision surgery	120	74
VMMC_CIRC_DSD	By follow-up status: Number of surgically circumcised clients who did NOT return for follow-up care within 14 days of circumcision surgery	0	0
VMMC_CIRC_NGI	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	120	75
VMMC_CIRC_NGI	By Age: <1	0	0
VMMC_CIRC_NGI	By Age: 1-9	0	0
VMMC_CIRC_NGI	By Age: 10-14	66	42
VMMC_CIRC_NGI	By Age: 15-19	22	14
VMMC_CIRC_NGI	By Age: 20-24	18	11
VMMC_CIRC_NGI	By Age: 25-49	9	5
VMMC_CIRC_NGI	By Age: 50+	5	3
VMMC_CIRC_NGI	Sum of Age disaggregates	120	75
VMMC_CIRC_NGI	By HIV status: Number of HIV-positive clients (tested HIV positive at VMMC site)	2	1
VMMC_CIRC_NGI	By HIV status: Number of HIV-negative clients (tested HIV negative at VMMC program)	118	73
VMMC_CIRC_NGI	By HIV status: Number of clients with undocumented/indeterminate HIV status or not tested for HIV at site	0	0
VMMC_CIRC_NGI	By circumcision technique: Surgical VMMC	120	74
VMMC_CIRC_NGI	By circumcision technique: Device-based	0	0



	VMMC		
VMMC_CIRC_NGI	By follow-up status: Number of surgically circumcised clients who returned at least once for follow-up care within 14 days of circumcision surgery	120	74
VMMC_CIRC_NGI	By follow-up status: Number of surgically circumcised clients who did NOT return for follow-up care within 14 days of circumcision surgery	0	0
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	39,000	39,000
PP_PREV_DSD	Total number of people in the target population	135,000	135,000
PP_PREV_DSD	Age/sex: 10-14 Male	1,083	1,083
PP_PREV_DSD	Age/sex: 15-19 Male	2,167	2,167
PP_PREV_DSD	Age/sex: 20-24 Male	5,417	5,417
PP_PREV_DSD	Age/sex: 25-49 Male	8,667	8,667
PP_PREV_DSD	Age/sex: 50+ Male	2,167	2,167
PP_PREV_DSD	Age/sex: 10-14 Female	1,083	1,083
PP_PREV_DSD	Age/sex: 15-19 Female	2,167	2,167
PP_PREV_DSD	Age/sex: 20-24 Female	5,417	5,417
PP_PREV_DSD	Age/sex: 25-49 Female	8,665	8,665
PP_PREV_DSD	Age/sex: 50+ Female	2,167	2,167
PP_PREV_DSD	Sum of Age/Sex disaggregates	39,000	39,000
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	20,000	39,000
HTC_TST_DSD	By Test Result: Negative	19,630	38,300
HTC_TST_DSD	By Test Result: Positive	370	700
HTC_TST_DSD	Sum of Test Result disaggregates	20,000	39,000
HTC_TST_DSD	Age/sex: <1 Male	0	0



HTC_TST_DSD	Age/sex: 1-4 Male	882	1,720
HTC_TST_DSD	Age/sex: 5-9 Male	378	737
HTC_TST_DSD	Age/sex: 10-14 Male	630	1,229
HTC_TST_DSD	Age/sex: 15-19 Male	1,260	2,457
HTC_TST_DSD	Age/sex: 20-24 Male	3,150	6,143
HTC_TST_DSD	Age/sex: 25-49 Male	5,040	9,826
HTC_TST_DSD	Age/sex: 50+ Male	1,260	2,457
HTC_TST_DSD	Age/sex: <1 Female	0	0
HTC_TST_DSD	Age/sex: 1-4 Female	518	1,010
HTC_TST_DSD	Age/sex: 5-9 Female	222	433
HTC_TST_DSD	Age/sex: 10-14 Female	370	722
HTC_TST_DSD	Age/sex: 15-19 Female	740	1,443
HTC_TST_DSD	Age/sex: 20-24 Female	1,850	3,608
HTC_TST_DSD	Age/sex: 25-49 Female	2,960	5,772
HTC_TST_DSD	Age/sex: 50+ Female	740	1,443
HTC_TST_DSD	Sum of Age/Sex disaggregates	20,000	39,000
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	1,890	3,685
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	10,710	20,885
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	1,110	2,164
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	6,290	12,266
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	3,000	5,849
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	17,000	33,151
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	20,000	39,000
HTC_TST_NGI	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	20,000	39,000
HTC_TST_NGI	By Test Result: Negative	19,630	38,300
HTC_TST_NGI	By Test Result: Positive	370	700
HTC_TST_NGI	Sum of Test Result disaggregates	20,000	39,000



HTC_TST_NGI	Age/sex: <1 Male	0	0
HTC_TST_NGI	Age/sex: 1-4 Male	882	1,720
HTC_TST_NGI	Age/sex: 5-9 Male	378	737
HTC_TST_NGI	Age/sex: 10-14 Male	630	1,229
HTC_TST_NGI	Age/sex: 15-19 Male	1,260	2,457
HTC_TST_NGI	Age/sex: 20-24 Male	3,150	6,143
HTC_TST_NGI	Age/sex: 25-49 Male	5,040	9,826
HTC_TST_NGI	Age/sex: 50+ Male	1,260	2,457
HTC_TST_NGI	Age/sex: <1 Female	0	0
HTC_TST_NGI	Age/sex: 1-4 Female	518	1,010
HTC_TST_NGI	Age/sex: 5-9 Female	222	433
HTC_TST_NGI	Age/sex: 10-14 Female	370	722
HTC_TST_NGI	Age/sex: 15-19 Female	740	1,443
HTC_TST_NGI	Age/sex: 20-24 Female	1,850	3,608
HTC_TST_NGI	Age/sex: 25-49 Female	2,960	5,772
HTC_TST_NGI	Age/sex: 50+ Female	740	1,443
HTC_TST_NGI	Sum of Age/Sex disaggregates	20,000	39,000
HTC_TST_NGI	Aggregated Age/sex: <15 Male	1,890	3,685
HTC_TST_NGI	Aggregated Age/sex: 15+ Male	10,710	20,885
HTC_TST_NGI	Aggregated Age/sex: <15 Female	1,110	2,164
HTC_TST_NGI	Aggregated Age/sex: 15+ Female	6,290	12,266
HTC_TST_NGI	Sum of Aggregated Age/Sex <15	3,000	5,849
HTC_TST_NGI	Sum of Aggregated Age/Sex 15+	17,000	33,151
HTC_TST_NGI	Sum of Aggregated Age/Sex disaggregates	20,000	39,000
OVC_ACC_DSD	Number of active beneficiaries receiving support from PEPFAR OVC programs to access HIV services	200	220
OVC_ACC_DSD	Sex: Male	106	114
OVC_ACC_DSD	Sex: Female	94	106
OVC_ACC_DSD	Sum of Sex disaggregates	200	220
OVC_ACC_DSD	Age: <1	5	7
OVC_ACC_DSD	Age: 1-4	47	54



OVC_ACC_DSD	Age: 5-9	60	65
OVC_ACC_DSD	Age: 10-14	88	94
OVC_ACC_DSD	Age: 15-17	0	0
OVC_ACC_DSD	Age: 18+	0	0
OVC_ACC_DSD	Sum of Age disaggregates	200	220
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	250	250
OVC_SERV_DSD	Sex: Male	157	157
OVC_SERV_DSD	Sex: Female	93	93
OVC_SERV_DSD	Sum of Sex disaggregates	250	250
OVC_SERV_DSD	Age: <1	10	10
OVC_SERV_DSD	Age: 1-4	42	42
OVC_SERV_DSD	Age: 5-9	52	52
OVC_SERV_DSD	Age: 10-14	52	52
OVC_SERV_DSD	Age: 15-17	52	52
OVC_SERV_DSD	Age: 18+	42	42
OVC_SERV_DSD	Sum of Age disaggregates	250	250
C2.1.D_DSD	Number of HIV-positive individuals receiving a minimum of one clinical service	3,000	3,200
C2.1.D_DSD	By Age/Sex: <15 Female	94	106
C2.1.D_DSD	By Age/Sex: <15 Male	106	114
C2.1.D_DSD	By Age/Sex: 15+ Female	1,386	1,472
C2.1.D_DSD	By Age/Sex: 15+ Male	1,414	1,508
C2.1.D_DSD	Sum of Age/Sex disaggregates	3,000	3,200
C2.1.D_DSD	By Age: <15	200	220
C2.1.D_DSD	By Age: 15+	2,800	2,980
C2.1.D_DSD	Sum of Age disaggregates	3,000	3,200
C2.1.D_DSD	By Sex: Female	1,480	1,578
C2.1.D_DSD	By Sex: Male	1,520	1,622
C2.1.D_DSD	Sum of Sex disaggregates	3,000	3,200
C2.1.D_NGI	Number of HIV-positive individuals receiving a	3,000	3,200



	minimum of one clinical service		
C2.1.D_NGI	By Age/Sex: <15 Female	94	106
C2.1.D_NGI	By Age/Sex: <15 Male	106	114
C2.1.D_NGI	By Age/Sex: 15+ Female	1,386	1,472
C2.1.D_NGI	By Age/Sex: 15+ Male	1,414	1,508
C2.1.D_NGI	Sum of Age/Sex disaggregates	3,000	3,200
C2.1.D_NGI	By Age: <15	200	220
C2.1.D_NGI	By Age: 15+	2,800	2,980
C2.1.D_NGI	Sum of Age disaggregates	3,000	3,200
C2.1.D_NGI	By Sex: Female	1,480	1,578
C2.1.D_NGI	By Sex: Male	1,520	1,622
C2.1.D_NGI	Sum of Sex disaggregates	3,000	3,200
C2.4.D_DSD	Number of HIV-positive patients who were screened for TB in HIV care or treatment setting	3,000	3,200
C2.4.D_DSD	Number of HIV-positive individuals receiving a minimum of one clinical service	3,000	3,200
C2.5.D_DSD	Number of HIV-positive patients in HIV care who started TB treatment	105	112
C2.5.D_DSD	Number of HIV-positive individuals receiving a minimum of one clinical service	3,000	3,200
CARE_CURR_DSD	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	3,000	3,200
CARE_CURR_DSD	Age/sex: <1 Male	2	3
CARE_CURR_DSD	Age/sex: 1-4 Male	18	20
CARE_CURR_DSD	Age/sex: 5-9 Male	35	37
CARE_CURR_DSD	Age/sex: 10-14 Male	50	54
CARE_CURR_DSD	Age/sex: 15-19 Male	18	20
CARE_CURR_DSD	Age/sex: 20-24 Male	22	23
CARE_CURR_DSD	Age/sex: 25-49 Male	1,027	1,095



CARE_CURR_DSD	Age/sex: 50+ Male	347	370
CARE_CURR_DSD	Age/sex: <1 Female	3	4
CARE_CURR_DSD	Age/sex: 1-4 Female	29	34
CARE_CURR_DSD	Age/sex: 5-9 Female	25	28
CARE_CURR_DSD	Age/sex: 10-14 Female	38	40
CARE_CURR_DSD	Age/sex: 15-19 Female	44	47
CARE_CURR_DSD	Age/sex: 20-24 Female	117	124
CARE_CURR_DSD	Age/sex: 25-49 Female	1,156	1,227
CARE_CURR_DSD	Age/sex: 50+ Female	69	74
CARE_CURR_DSD	Sun of Age/Sex disaggregates	3,000	3,200
CARE_CURR_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	105	114
CARE_CURR_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	1,414	1,508
CARE_CURR_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	95	106
CARE_CURR_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	1,386	1,472
CARE_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	3,000	3,200
CARE_NEW_DSD	Number of HIV-infected adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load	250	250
CARE_NEW_DSD	Age/sex: <1 Male	1	3
CARE_NEW_DSD	Age/sex: 1-4 Male	4	5
CARE_NEW_DSD	Age/sex: 5-9 Male	1	2
CARE_NEW_DSD	Age/sex: 10-14 Male	3	4
CARE_NEW_DSD	Age/sex: 15-19 Male	2	2
CARE_NEW_DSD	Age/sex: 20-24 Male	3	3
CARE_NEW_DSD	Age/sex: 25-49 Male	75	71
CARE_NEW_DSD	Age/sex: 50+ Male	20	19



CARE_NEW_DSD	Age/sex: <1 Female	2	2
CARE_NEW_DSD	Age/sex: 1-4 Female	5	6
CARE_NEW_DSD	Age/sex: 5-9 Female	3	4
CARE_NEW_DSD	Age/sex: 10-14 Female	1	3
CARE_NEW_DSD	Age/sex: 15-19 Female	5	4
CARE_NEW_DSD	Age/sex: 20-24 Female	21	20
CARE_NEW_DSD	Age/sex: 25-49 Female	98	96
CARE_NEW_DSD	Age/sex: 50+ Female	6	6
CARE_NEW_DSD	Sum of Age/sex disaggregates	250	250
CARE_NEW_DSD	Aggregated Age/sex: <15 Male	9	14
CARE_NEW_DSD	Aggregated Age/sex: 15+ Male	100	95
CARE_NEW_DSD	Aggregated Age/sex: <15 Female	11	15
CARE_NEW_DSD	Aggregated Age/sex: 15+ Female	130	126
CARE_NEW_DSD	Sum of Aggregated Age/sex disaggregates	250	250
CARE_SITE	Number of PEPFAR-supported HIV clinical care sites at which at least 80% of PLHIV received all of the following during the reporting period: 1) clinical assessment (WHO staging) OR CD4 count OR viral load, AND 2) TB screening at last visit, AND 3) if eligible, cotrimoxazole	10	10
CARE_SITE	Total number of PEPFAR supported sites providing clinical care services	10	10
CARE_SITE	By site support type: Direct Service Delivery (DSD): Number of PEPFAR-supported HIV clinical care sites at which at least 80% of PLHIV received all of the following during the reporting period: 1) clinical assessment (WHO staging) OR CD4 count OR viral load, AND 2) TB screening at last visit, AND 3) if eligible, cotrimoxazole	10	10
CARE_SITE	Sum of Numerator Site Support Type disaggregates	10	10
CARE_SITE	By site support type: Direct Service Delivery	10	10



	(DSD): Total number of PEPFAR supported sites providing clinical care services		
CARE_SITE	Sum of Denominator Site Support Type disaggregates	10	10
FN_SITE	Number of PEPFAR-supported sites achieving 90% nutrition assessments that result in accurate categorization of malnutrition	15	16
FN_SITE	Total number of PEPFAR-supported sites providing nutrition assessment, counseling and support (NACS) services	17	17
FN_SITE	By site support type: Direct Service Delivery (DSD): Number of PEPFAR-supported sites achieving 90% nutrition assessments that result in accurate categorization of malnutrition	15	16
FN_SITE	Sum of Numerator Support Type disaggregates	15	16
FN_SITE	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported sites providing nutrition assessment, counseling and support (NACS) services	17	17
FN_SITE	Sum of Denominator Support Type disaggregates	17	17
FN_THER_DSD	Number of clinically malnourished PLHIV who received therapeutic and/or supplementary food during the reporting period.	2,284	2,436
FN_THER_DSD	Number of PLHIV who were nutritionally assessed and found to be clinically undernourished.	3,000	3,200
FN_THER_DSD	Age: <1	2	2
FN_THER_DSD	Age: 1-4	33	35
FN_THER_DSD	Age: 5-14	113	120
FN_THER_DSD	Age: 15-17	66	71
FN_THER_DSD	Age: 18+	2,070	2,208



FN_THER_DSD	Sum of Age disaggregates	2,284	2,436
FN_THER_DSD	Aggregated Age: <18	214	228
FN_THER_DSD	Aggregated Age: 18+	2,070	2,208
FN_THER_DSD	Sum of Aggregated Age disaggregates	2,284	2,436
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	105	112
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	105	112
TB_ART_DSD	Age: 5-14	1	2
TB_ART_DSD	Age: 15+	104	110
TB_ART_DSD	Male	66	71
TB_ART_DSD	Female	39	41
TB_ART_DSD	Sum of Sex disaggregates	105	112
TB_ART_DSD	Newly tested	63	67
TB_ART_DSD	Known HIV-positive	42	45
TB_ART_DSD	Sum of Test Status disaggregates	105	112
TB_ART_DSD	Aggregated Age: <15	1	2
TB_ART_DSD	Aggregated Age: 15+	104	110
TB_ART_DSD	Sum of Aggregated Age disaggregates	105	112
TB_ARTSITE	The number of PEPFAR-supported TB basic management units at which 80% of registered TB cases who are HIV-positive are on ART, during the reporting period	10	10
TB_ARTSITE	The number of PEPFAR-supported TB basic management units	10	10
TB_ARTSITE	By site support type: Direct Service Delivery (DSD): The number of PEPFAR-supported TB basic management units at which 80% of registered TB cases who are HIV-positive are on ART, during the reporting period	10	10



TB_ARTSITE	Sum of Numerator Site Support Type disaggregates	10	10
TB_ARTSITE	By site support type: Direct Service Delivery (DSD): The number of PEPFAR-supported TB basic management units	10	10
TB_ARTSITE	Sum of Denominator Site Support Type disaggregates	10	10
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	127	143
PMTCT_EID_DSD	Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT)	127	143
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	102	136
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	25	7
PMTCT_EID_DSD	Sum of Infant Age disaggregates	127	143
PMTCT_EID_DSD	By infants with a positive virologic test result within 12 months of birth	3	2
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	2,320	2,739
TX_CURR_DSD	Age/Sex: <1 Male	2	4
TX_CURR_DSD	Age/Sex: 1-4 Male	20	23
TX_CURR_DSD	Age/Sex: 5-14 Male	82	88
TX_CURR_DSD	Age/Sex: 15+ Male	1,160	1,374
TX_CURR_DSD	Age/Sex: <1 Female	2	3
TX_CURR_DSD	Age/Sex: 1-4 Female	25	28
TX_CURR_DSD	Age/Sex: 5-14 Female	49	54
TX_CURR_DSD	Age/Sex: 15+ Female	980	1,165
TX_CURR_DSD	Sum of age/sex disaggregates	180	200
TX_CURR_DSD	Percent children with advanced HIV infection receiving antiretroviral therapy (ART)	8	8



	[CURRENT]		
TX_CURR_DSD	Percent women and girls with advanced HIV infection receiving antiretroviral therapy (ART) [CURRENT]	42	42
TX_CURR_DSD	Aggregated Age/Sex: <1 Male	2	4
TX_CURR_DSD	Aggregated Age/Sex: <1 Female	2	3
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	104	115
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	1,160	1,374
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	76	85
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	980	1,165
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	180	200
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	2,140	2,539
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	2,320	2,739
TX_CURR_NGI	Number of adults and children receiving antiretroviral therapy (ART)	2,320	2,641
TX_CURR_NGI	Age/Sex: <1 Male	2	4
TX_CURR_NGI	Age/Sex: 1-4 Male	20	23
TX_CURR_NGI	Age/Sex: 5-14 Male	82	88
TX_CURR_NGI	Age/Sex: 15+ Male	1,160	1,325
TX_CURR_NGI	Age/Sex: <1 Female	2	3
TX_CURR_NGI	Age/Sex: 1-4 Female	25	28
TX_CURR_NGI	Age/Sex: 5-14 Female	49	54
TX_CURR_NGI	Age/Sex: 15+ Female	980	1,116
TX_CURR_NGI	Sum of Age/Sex disaggregates	2,320	2,641
TX_CURR_NGI	Aggregated Age/Sex: <1 Male	2	4
TX_CURR_NGI	Aggregated Age/Sex: <1 Female	2	3
TX_CURR_NGI	Aggregated Age/Sex: <15 Male	104	115
TX_CURR_NGI	Aggregated Age/Sex: 15+ Male	1,160	1,325
TX_CURR_NGI	Aggregated Age/Sex: <15 Female	76	85
TX_CURR_NGI	Aggregated Age/Sex: 15+ Female	980	1,116
TX_CURR_NGI	Sum of Aggregated Age/Sex disaggregates	2,320	2,641
TX_CURR_NGI	Sum of Aggregated Age/Sex <15	180	200



TX_CURR_NGI	Sum of Aggregated Age/Sex 15+	2,140	2,441
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	250	341
TX_NEW_DSD	By Age/Sex: <1 Male	2	4
TX_NEW_DSD	By Age/Sex: 1-4 Male	4	2
TX_NEW_DSD	By Age/Sex: 5-9 Male	2	2
TX_NEW_DSD	By Age/Sex: 10-14 Male	4	3
TX_NEW_DSD	By Age/Sex: 15-19 Male	2	3
TX_NEW_DSD	By Age/Sex: 20-24 Male	2	4
TX_NEW_DSD	By Age/Sex: 25-49 Male	77	109
TX_NEW_DSD	By Age/Sex: 50+ Male	23	31
TX_NEW_DSD	By Age/Sex: <1 Female	2	3
TX_NEW_DSD	By Age/Sex: 1-4 Female	4	2
TX_NEW_DSD	By Age/Sex: 5-9 Female	3	2
TX_NEW_DSD	By Age/Sex: 10-14 Female	1	2
TX_NEW_DSD	By Age/Sex: 15-19 Female	2	3
TX_NEW_DSD	By Age/Sex: 20-24 Female	14	20
TX_NEW_DSD	By Age/Sex: 25-49 Female	98	137
TX_NEW_DSD	By Age/Sex: 50+ Female	10	14
TX_NEW_DSD	Sum of Age/Sex disaggregates	250	341
TX_NEW_DSD	Aggregated Grouping by Age: <1 Male	2	4
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	12	11
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	104	147
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <1 Female	2	3
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	10	9
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	124	174
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	250	341
TX_NEW_DSD	Pregnancy status	69	34
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after	200	273



	initiating ART		
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	250	341
TX_RET_DSD	Age: 0-4 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	10	9
TX_RET_DSD	Age: 5-14 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	8	7
TX_RET_DSD	Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	182	257
TX_RET_DSD	Age: 0-4 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	12	11
TX_RET_DSD	Age: 5-14 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	10	9
TX_RET_DSD	Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	228	321
TX_RET_DSD	Aggregated Age: <15 (Numerator: Number of adults and children who are still alive and on	18	16



	treatment at 12 months after initiating ART)		
TX_RET_DSD	Aggregated Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	22	20
TX_RET_DSD	Aggregated Age: <15 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	182	257
TX_RET_DSD	Aggregated Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	228	321
TX_RET_DSD	Pregnancy and breastfeeding status (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	55	27
TX_RET_DSD	Pregnancy and breastfeeding status (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	69	34
TX_SITE	Number of PEPFAR-supported ART sites with a retention rate of 75% or greater for patients 12 months after ART initiation	10	10
TX_SITE	Total number of PEPFAR-supported ART sites	10	10
TX_SITE	By support type: Direct Service Delivery (DSD): Number of PEPFAR-supported ART sites with a retention rate of 75% or greater for	10	10



	patients 12 months after ART initiation		
TX_SITE	Sum of Numerator Site Support Type disaggregates	10	10
TX_SITE	By support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported ART sites	10	10
TX_SITE	Sum of Denominator Site Support Type disaggregates	10	10
LAB_ACC_DSD	Number of PEPFAR-supported testing facilities (laboratories) that are recognized by national, regional, or international standards for accreditation or have achieved a minimal acceptable level towards attainment of such accreditation	1	2
LAB_ACC_DSD	By site support type: Direct Service Delivery (DSD)	1	2
LAB_ACC_DSD	Sum of Support Type disaggregates	1	2
LAB_CAP_DSD	Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests	15	15
LAB_CAP_DSD	By clinical laboratories	15	15
LAB_CAP_DSD	By Point-of-care testing sites	3	5
LAB_CAP_DSD	By site support type: Direct Service Delivery (DSD)	15	15
LAB_CAP_DSD	Sum of Site Support Type disaggregates	15	15
LAB_PT_DSD	Percentage of laboratories and POC testing sites that perform HIV diagnostic testing that participate and successfully pass in an analyte-specific proficiency testing (PT) program	100	100
LAB_PT_DSD	HIV serologic/diagnostic testing: Number of laboratories that perform this testing	7	8
LAB_PT_DSD	HIV serologic/diagnostic testing: Number of laboratories that participate in this PT program	2	8



LAB_PT_DSD	HIV serologic/diagnostic testing: Number of laboratories that achieve acceptable successful passing criteria in this PT program	2	8
LAB_PT_DSD	CD4: Number of laboratories that perform this testing	4	4
LAB_PT_DSD	CD4: Number of laboratories that participate in this PT program	4	4
LAB_PT_DSD	CD4: Number of laboratories that achieve acceptable successful passing criteria in this PT program	4	4
LAB_PT_DSD	Early infant diagnostics: Number of laboratories that perform this testing	8	8
LAB_PT_DSD	Early infant diagnostics: Number of laboratories that participate in this PT program	0	0
LAB_PT_DSD	Early infant diagnostics: Number of laboratories that achieve acceptable successful passing criteria in this PT program	0	0
LAB_PT_DSD	HIV viral load: Number of laboratories that perform this testing	0	1
LAB_PT_DSD	HIV viral load: Number of laboratories that participate in this PT program	0	1
LAB_PT_DSD	HIV viral load: Number of laboratories that achieve acceptable successful passing criteria in this PT program	0	1
LAB_PT_DSD	TB diagnostics (AFB microscopy, Xpert MTB/RIF, Culture/DST): Number of laboratories that perform this testing	8	8
LAB_PT_DSD	TB diagnostics (AFB microscopy, Xpert MTB/RIF, Culture/DST): Number of laboratories that participate in this PT program	8	8
LAB_PT_DSD	TB diagnostics (AFB microscopy, Xpert MTB/RIF, Culture/DST): Number of laboratories that achieve acceptable successful passing criteria in this PT program	8	8
FPINT_SITE_DSD	Number of service delivery points supported	14	17



	by PEPFAR for HIV services that are directly providing integrated voluntary family planning services		
FPINT_SITE_DSD	Total number of PEPFAR-supported HIV service delivery points: PMTCT, Care and Treatment	14	17
FPINT_SITE_DSD	By site support type: Direct Service Delivery (DSD): Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	14	17
FPINT_SITE_DSD	Sum of Numerator Site Support Type disaggregates	14	17
FPINT_SITE_DSD	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported HIV service delivery points	14	17
FPINT_SITE_DSD	Sum of Denominator Site Support Type disaggregates	14	17
FPINT_SITE_DSD	Service delivery type: Clinical	14	17
FPINT_SITE_DSD	Sum of Service Delivery Type disaggregates	14	17
QI_SITE	Number of PEPFAR-supported clinical service sites with a quality improvement activity completed that addresses clinical HIV programs and has documented process results in the last 6 months	8	10
QI_SITE	Total number of PEPFAR-supported sites for any HIV clinical service including HIV Care, HIV Treatment, TB care, PMTCT, VMMC, and HTC	10	10
QI_SITE	By site support type: Direct Service Delivery (DSD): Number of PEPFAR-supported clinical service sites with a quality improvement activity completed that addresses clinical HIV programs and has documented results in the last 6 months	8	10



QI_SITE	Sum of Numerator Site Support Type disaggregates	8	10
QI_SITE	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported sites for any HIV clinical service including HIV Care, HIV Treatment, TB care, PMTCT, VMMC, HTC	10	10
QI_SITE	Sum of Denominator Site Support Type disaggregates	10	10
TB_SCREEN_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period	3,000	3,200
TB_SCREEN_DSD	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	3,000	3,200
TB_SCREEN_DSD	Age: <1	5	7
TB_SCREEN_DSD	Age: 1-4	47	54
TB_SCREEN_DSD	Age: 5-9	59	64
TB_SCREEN_DSD	Age: 10-14	89	94
TB_SCREEN_DSD	Age: 15-19	63	67
TB_SCREEN_DSD	Age: 20-24	138	148
TB_SCREEN_DSD	Age: 25-49	2,183	2,322
TB_SCREEN_DSD	Age: 50+	416	444
TB_SCREEN_DSD	Sum of Age disaggregates	263	286
TB_SCREEN_DSD	Aggregated Age - USE WITH HQ PERMISSION ONLY: <15	200	219
TB_SCREEN_DSD	Aggregated Age - USE WITH HQ PERMISSION ONLY: 15+	2,800	2,981
TB_SCREEN_DSD	Sum of Aggregated Age disaggregates	3,000	3,200
TB_SCREEN_DSD	Sex: Male	1,480	1,578
TB_SCREEN_DSD	Sex: Female	1,520	1,622
TB_SCREEN_DSD	Sum of Sex disaggregates	3,000	3,200



Implementing Mechanism Details

Mechanism ID: 9139	Mechanism Name: Capacity Kenya
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: IntraHealth International, Inc	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: No	
G2G: No	Managing Agency:
Total All Funding Sources: 5,152,112	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 0	
FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount
GHP-State	5,152,112

Sub Partner Name(s)

African Medical and Research Foundation	Deloitte Consulting Limited	Management Sciences for Health
Training Resources Group		

Cross-Cutting Budget Attribution(s)

Human Resources for Health	2,000,000
----------------------------	-----------

Key Issues

(No data provided.)

Budget Code Information

Mechanism ID: 9139



Mechanism Name: Capacity Kenya			
Prime Partner Name: IntraHealth International, Inc			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	162,911	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	0	
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	0	
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	0	
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	786,633	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVAB	0	
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	400,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	200,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	3,602,568	0

Approved



Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 9138	Mechanism Name: Health Media project
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Internews	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: No	
G2G: No	Managing Agency:

Total All Funding Sources: 400,000	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 0	
FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount
GHP-State	400,000

Sub Partner Name(s)

Kenya AIDS NGO Consortium		
---------------------------	--	--

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

(No data provided.)



Budget Code Information

Mechanism ID: 9138			
Mechanism Name: Health Media project			
Prime Partner Name: Internews			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	50,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	100,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	150,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	IDUP	50,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	50,000	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 9136	Mechanism Name: IMC MARPS
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: International Medical Corps	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: No	
G2G: No	Managing Agency:
Total All Funding Sources: 1,028,798	Total Mechanism Pipeline: Redacted



Applied Pipeline Amount: 0	
FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount
GHP-State	1,028,798

Sub Partner Name(s)

Mildmay International		
-----------------------	--	--

Cross-Cutting Budget Attribution(s)

Human Resources for Health	340,986
Key Populations: MSM and TG	14,200
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Implementation of core HIV prevention interventions for MSM/TG that are consistent with the current PEPFAR technical guidance
Focus Area:	Conducting epidemiologic, social science, and operational research among MSM/TG and their sex partners
Key Populations: FSW	330,318
Focus Area:	Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Collection and use of strategic information on SWs and clients
Focus Area:	Monitoring and evaluation of SW programs
Gender: GBV	46,352
Focus Area:	GBV Prevention
Sub Area:	Collection and Use of Gender-related Strategic Information



Sub Area:	Implementation
Sub Area:	Capacity building
Focus Area:	Post GBV Care
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Gender: Gender Equality	92,707
Focus Area:	Changing harmful gender norms and promoting positive gender norms
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Focus Area:	Promoting gender-related policies and laws that increase legal protection
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Focus Area:	Increase gender-equitable access to income and productive resources, including education
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Collection and Use of Gender-related Strategic



	Information
Sub Area:	Implementation
Sub Area:	Capacity building
Condom programming	92,707

Key Issues

Mobile Population
 Family Planning

Budget Code Information

Mechanism ID: 9136			
Mechanism Name: IMC MARPS			
Prime Partner Name: International Medical Corps			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	101,758	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	927,040	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2014	2015	Planning Budget Targets
SITE_SUPP	Number of unique sites supported by PEPFAR	9	9	Redacted
SITE_SUPP	By program area/support type: HTC Direct Service Delivery (DSD)	9	9	Redacted

SITE_SUPP	By program area/support type: General Population Prevention Direct Service Delivery (DSD)	3	3	Redacted
SITE_SUPP	By program area/support type: Key Populations Prevention Direct Service Delivery (DSD)	6	6	Redacted
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	23,903	18,121	Redacted
PP_PREV_DSD	Total number of people in the target population	70,303	70,303	Redacted
PP_PREV_DSD	Age/sex: 20-24 Male	2,560	2,400	Redacted
PP_PREV_DSD	Age/sex: 25-49 Male	10,235	7,203	Redacted
PP_PREV_DSD	Age/sex: 15-19 Female	5,554	3,915	Redacted
PP_PREV_DSD	Age/sex: 20-24 Female	5,554	3,711	Redacted
PP_PREV_DSD	Sum of Age/Sex disaggregates	23,903	18,121	Redacted
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	8,380	8,620	Redacted
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	8,000	8,331	Redacted
KP_PREV_DSD	By key population type: Men who have sex with men/Transgender (MSM/TG) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive	380	289	Redacted



	interventions that are based on evidence and/or meet the minimum standards required)			
KP_PREV_DSD	By key population type: MSM/TG who are male sex workers (subset MSM/TG) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	152	115	Redacted
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	96,000	31,971	Redacted
HTC_TST_DSD	By Test Result: Negative	92,160	30,692	Redacted
HTC_TST_DSD	By Test Result: Positive	3,840	1,279	Redacted
HTC_TST_DSD	Sum of Test Result disaggregates	96,000	31,971	Redacted
HTC_TST_DSD	Age/sex: 1-4 Male	3,360		Redacted
HTC_TST_DSD	Age/sex: 5-9 Male	1,440		Redacted
HTC_TST_DSD	Age/sex: 10-14 Male	2,400		Redacted
HTC_TST_DSD	Age/sex: 15-19 Male	4,800		Redacted
HTC_TST_DSD	Age/sex: 20-24 Male	12,000	3,000	Redacted
HTC_TST_DSD	Age/sex: 25-49 Male	19,200	9,000	Redacted
HTC_TST_DSD	Age/sex: 50+ Male	4,800		Redacted
HTC_TST_DSD	Age/sex: 1-4 Female	3,360		Redacted
HTC_TST_DSD	Age/sex: 5-9 Female	1,440		Redacted
HTC_TST_DSD	Age/sex: 10-14 Female	2,400		Redacted
HTC_TST_DSD	Age/sex: 15-19 Female	4,800	2,191	Redacted
HTC_TST_DSD	Age/sex: 20-24 Female	12,000	8,896	Redacted
HTC_TST_DSD	Age/sex: 25-49 Female	19,200	8,503	Redacted
HTC_TST_DSD	Age/sex: 50+ Female	4,800	381	Redacted
HTC_TST_DSD	Sum of Age/Sex disaggregates	96,000	31,971	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ	7,200		Redacted



	PERMISSION ONLY: <15 Male			
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	40,800	12,000	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	7,200		Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	40,800	19,971	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	14,400		Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	81,600	31,971	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	96,000	31,971	Redacted
HTC_TST_NGI	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	96,000	31,971	Redacted
HTC_TST_NGI	By Test Result: Negative	92,160	30,692	Redacted
HTC_TST_NGI	By Test Result: Positive	3,840	1,279	Redacted
HTC_TST_NGI	Sum of Test Result disaggregates	96,000	31,971	Redacted
HTC_TST_NGI	Age/sex: <1 Male	0		Redacted
HTC_TST_NGI	Age/sex: 1-4 Male	3,360		Redacted
HTC_TST_NGI	Age/sex: 5-9 Male	1,440		Redacted
HTC_TST_NGI	Age/sex: 10-14 Male	2,400		Redacted
HTC_TST_NGI	Age/sex: 15-19 Male	4,800		Redacted
HTC_TST_NGI	Age/sex: 20-24 Male	12,000	3,000	Redacted
HTC_TST_NGI	Age/sex: 25-49 Male	19,200	9,000	Redacted
HTC_TST_NGI	Age/sex: 50+ Male	4,800		Redacted
HTC_TST_NGI	Age/sex: <1 Female	0	0	Redacted
HTC_TST_NGI	Age/sex: 1-4 Female	3,360		Redacted
HTC_TST_NGI	Age/sex: 5-9 Female	1,440		Redacted
HTC_TST_NGI	Age/sex: 10-14 Female	2,400		Redacted
HTC_TST_NGI	Age/sex: 15-19 Female	4,800	2,191	Redacted
HTC_TST_NGI	Age/sex: 20-24 Female	12,000	8,896	Redacted
HTC_TST_NGI	Age/sex: 25-49 Female	19,200	8,503	Redacted
HTC_TST_NGI	Age/sex: 50+ Female	4,800	381	Redacted



HTC_TST_NGI	Sum of Age/Sex disaggregates	96,000	31,971	Redacted
HTC_TST_NGI	Aggregated Age/sex: <15 Male	7,200		Redacted
HTC_TST_NGI	Aggregated Age/sex: 15+ Male	40,800	12,000	Redacted
HTC_TST_NGI	Aggregated Age/sex: <15 Female	7,200		Redacted
HTC_TST_NGI	Aggregated Age/sex: 15+ Female	40,800	19,971	Redacted
HTC_TST_NGI	Sum of Aggregated Age/Sex <15	14,400		Redacted
HTC_TST_NGI	Sum of Aggregated Age/Sex 15+	81,600	31,971	Redacted
HTC_TST_NGI	Sum of Aggregated Age/Sex disaggregates	96,000	31,971	Redacted
GEND_NORM_DS D	Number of people completing an intervention pertaining to gender norms, that meets minimum criteria	11,000	14,550	Redacted
GEND_NORM_DS D	By Age: 20-24	4,000	3,637	Redacted
GEND_NORM_DS D	By Age: 25+	7,000	10,913	Redacted
GEND_NORM_DS D	Sum of Age disaggregates	11,000	14,550	Redacted
GEND_NORM_DS D	By Sex: Male	7,000	9,603	Redacted
GEND_NORM_DS D	By Sex: Female	4,000	4,947	Redacted
GEND_NORM_DS D	Sum of Sex disaggregates	11,000	14,550	Redacted

Implementing Mechanism Details

Mechanism ID: 9110	Mechanism Name: APHL
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Association of Public Health Laboratories	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: No	
G2G: No	Managing Agency:

Approved



Total All Funding Sources: 450,000	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 0	
FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount
GHP-State	450,000

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

Human Resources for Health	110,000
----------------------------	---------

Key Issues

Malaria (PMI)

TB

Budget Code Information

Mechanism ID: 9110			
Mechanism Name: APHL			
Prime Partner Name: Association of Public Health Laboratories			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	450,000	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2014	2015	Planning
-------------------------	--------------	-------------	-------------	-----------------



				Budget Targets
SITE_SUPP	Number of unique sites supported by PEPFAR	14	14	Redacted
SITE_SUPP	By program area/support type: Lab Direct Service Delivery (DSD)	0	0	Redacted
SITE_SUPP	By program area/support type: Lab Technical Assistance-only (TA)	14	14	Redacted
LAB_PT_DSD	Percentage of laboratories and POC testing sites that perform HIV diagnostic testing that participate and successfully pass in an analyte-specific proficiency testing (PT) program	75	75	Redacted
LAB_PT_DSD	CD4: Number of laboratories that participate in this PT program	70	80	Redacted
LAB_PT_DSD	CD4: Number of laboratories that achieve acceptable successful passing criteria in this PT program	53	60	Redacted
LAB_PT_DSD	HIV viral load: Number of laboratories that participate in this PT program	2	2	Redacted
LAB_PT_DSD	HIV viral load: Number of laboratories that achieve acceptable successful passing criteria in this PT program	2	2	Redacted
LAB_PT_DSD	TB diagnostics (AFB microscopy, Xpert MTB/RIF, Culture/DST): Number of laboratories that participate in this PT program	1	1	Redacted
LAB_PT_DSD	TB diagnostics (AFB microscopy, Xpert MTB/RIF, Culture/DST): Number of laboratories that achieve acceptable successful passing criteria in this PT program	1	1	Redacted

Implementing Mechanism Details

Mechanism ID: 9108	Mechanism Name: American International
---------------------------	---



	Alliance, Twinning Center
Funding Agency: HHS/HRSA	Procurement Type: Cooperative Agreement
Prime Partner Name: American International Health Alliance Twinning Center	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: No	
G2G: No	Managing Agency:

Total All Funding Sources: 308,000	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 0	
FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount
GHP-State	308,000

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

Human Resources for Health	125,000
Gender: Gender Equality	26,250
Focus Area:	Changing harmful gender norms and promoting positive gender norms
Sub Area:	Implementation
Sub Area:	Monitoring and Evaluation
Focus Area:	Increase gender-equitable access to income and productive resources, including education
Sub Area:	Implementation
Sub Area:	Monitoring and Evaluation
Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Implementation
Sub Area:	Monitoring and Evaluation



Education	10,000
Gender: GBV	13,250
Focus Area:	GBV Prevention
Sub Area:	Implementation
Sub Area:	Monitoring and Evaluation

Key Issues

(No data provided.)

Budget Code Information

Mechanism ID: 9108			
Mechanism Name: American International Alliance, Twinning Center			
Prime Partner Name: American International Health Alliance Twinning Center			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVAB	308,000	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2014	2015	Planning Budget Targets
SITE_SUPP	Number of unique sites supported by PEPFAR	175	175	Redacted
SITE_SUPP	By program area/support type: HTC Technical Assistance-only (TA)	175	175	Redacted
PP_PREV_TA	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the	42,016	20,000	Redacted



	reporting period.			
PP_PREV_TA	Total number of people in the target population	1,201,299	1,201,299	Redacted
PP_PREV_TA	Age/sex: 10-14 Male	21,008	10,000	Redacted
PP_PREV_TA	Age/sex: 10-14 Female	21,008	10,000	Redacted
PP_PREV_TA	Sum of Age/Sex disaggregates	42,016	20,000	Redacted

Implementing Mechanism Details

Mechanism ID: 9097	Mechanism Name: HIV Fellowships
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: University of Nairobi	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: No	
G2G: No	Managing Agency:

Total All Funding Sources: 0	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 0	
FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount
GHP-State	0

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

(No data provided.)



Budget Code Information

Mechanism ID: 9097			
Mechanism Name: HIV Fellowships			
Prime Partner Name: University of Nairobi			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	0	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2014	2015	Planning Budget Targets
HRH_PRE	Number of new HCW who graduated from a pre-service training institution or program as a result of PEPFAR-supported strengthening efforts, within the reporting period, by select cadre	0		Redacted
HRH_PRE	By Graduates: Doctors	0		Redacted
HRH_PRE	By Graduates: Nurses	0		Redacted
HRH_PRE	By Graduates: Midwives	0		Redacted
HRH_PRE	By Graduates: Social service workers	0		Redacted
HRH_PRE	By Graduates: Laboratory professionals	0		Redacted
HRH_PRE	By Graduates: Other	7		Redacted
HRH_PRE	Sum of Graduates disaggreagtes	7		Redacted
HRH_PRE	By new graduates who are licensed and registered: Doctors	0		Redacted
HRH_PRE	By new graduates who are licensed and registered: Nurses	0		Redacted
HRH_PRE	By new graduates who are licensed	0		Redacted



	and registered: Midwives			
HRH_PRE	By new graduates who are licensed and registered: Social service workers	0		Redacted
HRH_PRE	By new graduates who are licensed and registered: Laboratorians	0		Redacted
HRH_PRE	By new graduates who are licensed and registered: Other (where applicable)	0		Redacted

Implementing Mechanism Details

Mechanism ID: 9093	Mechanism Name: Phones for Health
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: CDC Foundation	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: No	
G2G: No	Managing Agency:

Total All Funding Sources: 250,000	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 100,000	
FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount
GHP-State	250,000

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues



Mobile Population

Budget Code Information

Mechanism ID: 9093			
Mechanism Name: Phones for Health			
Prime Partner Name: CDC Foundation			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	250,000	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 9092	Mechanism Name: Support and Assistance to Indigenous Implementing Agencies (SAIDIA)
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Catholic Relief Services	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: No	
G2G: No	Managing Agency:

Total All Funding Sources: 0	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 0	
FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount
GHP-State	0

Sub Partner Name(s)



Adventist Centre for Care and Support (ACCS)	African Brotherhood Church	African Inland Church (AIC)
Anglican church of Kenya: Narok Integrated Development Program	Apostles of Jesus AIDS Ministry	Archdiocese of Nyeri
Christian Mission Fellowship (CMF)	Dream Kenya	Faraja Trust
JHPIEGO	Kenya Hospices and Palliative Care Association (KEHPCA)	Kenya Widows And Orphans Support Programme (KWOSP)
Movement of Men Against AIDS in Kenya (MMAAK)	Nomadic Communities Trust	Scriptures Union Centre-Hurlingham
The Kenya Scouts Association	UZIMA Foundation- Africa	

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

(No data provided.)

Budget Code Information

Mechanism ID: 9092			
Mechanism Name: Support and Assistance to Indigenous Implementing Agencies (SAIDIA)			
Prime Partner Name: Catholic Relief Services			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Prevention	HVAB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	0	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2014	2015	Planning Budget Targets
SITE_SUPP	Number of unique sites supported by PEPFAR	29		Redacted
SITE_SUPP	By program area/support type: HTC Direct Service Delivery (DSD)	5		Redacted
SITE_SUPP	By program area/support type: HTC Technical Assistance-only (TA)	0		Redacted
SITE_SUPP	By program area/support type: PMTCT Direct Service Delivery (DSD)	16		Redacted
SITE_SUPP	By program area/support type: General Population Prevention Direct Service Delivery (DSD)	9		Redacted
SITE_SUPP	By program area/support type: OVC Direct Service Delivery (DSD)	4		Redacted
SITE_SUPP	By program area/support type: PHDP/Family Planning & Integration Direct Service Delivery (DSD)	16		Redacted
PMTCT_ARV_DS D	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	321		Redacted
PMTCT_ARV_DS D	Number of HIV- positive pregnant women identified in the reporting period	321		Redacted



	(including known HIV-positive at entry)			
PMTCT_ARV_DS D	Life-long ART (including Option B+)	241		Redacted
PMTCT_ARV_DS D	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	112		Redacted
PMTCT_ARV_DS D	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	129		Redacted
PMTCT_ARV_DS D	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)	0		Redacted
PMTCT_ARV_DS D	Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)	80		Redacted
PMTCT_ARV_DS D	Single-dose nevirapine (with or without tail)	0		Redacted
PMTCT_ARV_DS D	Sum of Regimen Type disaggregates	321		Redacted
PMTCT_ARV_DS D	Sum of New and Current disaggregates	241		Redacted
PMTCT_ARV_NGI	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	321		Redacted
PMTCT_ARV_NGI	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	321		Redacted
PMTCT_ARV_NGI	Life-long ART (including Option B+)	241		Redacted
PMTCT_ARV_NGI	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	112		Redacted
PMTCT_ARV_NGI	Sub-Disag of Life-long ART: Already on treatment at the beginning of the	129		Redacted



	current pregnancy			
PMTCT_ARV_NGI	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)	0		Redacted
PMTCT_ARV_NGI	Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)	80		Redacted
PMTCT_ARV_NGI	Single-dose nevirapine (with or without tail)	0		Redacted
PMTCT_ARV_NGI	Sum of Regimen disaggregates	321		Redacted
PMTCT_ARV_NGI	Sum of New and Current disaggregates	241		Redacted
PMTCT_SITE	Number of PEPFAR-supported sites achieving 90% ARV or ART coverage for HIV+ pregnant women	16		Redacted
PMTCT_SITE	Total number of PEPFAR supported sites providing PMTCT services (HTC and ARV or ART services)	16		Redacted
PMTCT_SITE	By site support type: Direct Service Delivery (DSD): Number of PEPFAR-supported sites achieving 90% ARV or ART coverage for HIV+ pregnant women	16		Redacted
PMTCT_SITE	By site support type: Technical Assistance-only (TA): Number of PEPFAR-supported sites achieving 90% ARV or ART coverage for HIV+ pregnant women	0		Redacted
PMTCT_SITE	Sum of Numerator Support Type disaggregates	16		Redacted
PMTCT_SITE	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR supported sites providing PMTCT services (HTC and ARV or ART services)	16		Redacted
PMTCT_SITE	By site support type: Technical	0		Redacted



	Assistance-only (TA): Total number of PEPFAR supported sites providing PMTCT services (HTC and ARV or ART services)			
PMTCT_SITE	Sum of Denominator Support Type disaggregates	16		Redacted
PMTCT_STAT_DS D	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	6,204		Redacted
PMTCT_STAT_DS D	Number of new ANC and L&D clients	6,204		Redacted
PMTCT_STAT_DS D	By: Known positives at entry	151		Redacted
PMTCT_STAT_DS D	By: Number of new positives identified	170		Redacted
PMTCT_STAT_DS D	Sum of Positives Status disaggregates	321		Redacted
PMTCT_STAT_NG I	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	6,204		Redacted
PMTCT_STAT_NG I	Number of new ANC and L&D clients	6,204		Redacted
PMTCT_STAT_NG I	By: Known positives at entry	151		Redacted
PMTCT_STAT_NG I	By: Number of new positives identified	170		Redacted
PMTCT_STAT_NG I	Sum of Positives Status disaggregates	321		Redacted
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	22,613		Redacted



PP_PREV_DSD	Total number of people in the target population	56,532		Redacted
PP_PREV_DSD	Age/sex: 10-14 Male	11,306		Redacted
PP_PREV_DSD	Age/sex: 10-14 Female	11,307		Redacted
PP_PREV_DSD	Sum of Age/Sex disaggregates	22,613		Redacted
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	27,720		Redacted
HTC_TST_DSD	By Test Result: Negative	26,611		Redacted
HTC_TST_DSD	By Test Result: Positive	1,109		Redacted
HTC_TST_DSD	Sum of Test Result disaggregates	27,720		Redacted
HTC_TST_DSD	Age/sex: <1 Male	0		Redacted
HTC_TST_DSD	Age/sex: 1-4 Male	970		Redacted
HTC_TST_DSD	Age/sex: 5-9 Male	416		Redacted
HTC_TST_DSD	Age/sex: 10-14 Male	693		Redacted
HTC_TST_DSD	Age/sex: 15-19 Male	1,386		Redacted
HTC_TST_DSD	Age/sex: 20-24 Male	3,465		Redacted
HTC_TST_DSD	Age/sex: 25-49 Male	5,544		Redacted
HTC_TST_DSD	Age/sex: 50+ Male	1,386		Redacted
HTC_TST_DSD	Age/sex: <1 Female	0		Redacted
HTC_TST_DSD	Age/sex: 1-4 Female	970		Redacted
HTC_TST_DSD	Age/sex: 5-9 Female	416		Redacted
HTC_TST_DSD	Age/sex: 10-14 Female	693		Redacted
HTC_TST_DSD	Age/sex: 15-19 Female	1,386		Redacted
HTC_TST_DSD	Age/sex: 20-24 Female	3,465		Redacted
HTC_TST_DSD	Age/sex: 25-49 Female	5,544		Redacted
HTC_TST_DSD	Age/sex: 50+ Female	1,386		Redacted
HTC_TST_DSD	Sum of Age/Sex disaggregates	27,720		Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	2,079		Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	11,781		Redacted



HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	2,079		Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	11,781		Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	4,158		Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	23,562		Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	27,720		Redacted
HTC_TST_NGI	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	27,720		Redacted
HTC_TST_NGI	By Test Result: Negative	26,611		Redacted
HTC_TST_NGI	By Test Result: Positive	1,109		Redacted
HTC_TST_NGI	Sum of Test Result disaggregates	27,720		Redacted
HTC_TST_NGI	Age/sex: <1 Male	0		Redacted
HTC_TST_NGI	Age/sex: 1-4 Male	970		Redacted
HTC_TST_NGI	Age/sex: 5-9 Male	416		Redacted
HTC_TST_NGI	Age/sex: 10-14 Male	693		Redacted
HTC_TST_NGI	Age/sex: 15-19 Male	1,386		Redacted
HTC_TST_NGI	Age/sex: 20-24 Male	3,465		Redacted
HTC_TST_NGI	Age/sex: 25-49 Male	5,544		Redacted
HTC_TST_NGI	Age/sex: 50+ Male	1,386		Redacted
HTC_TST_NGI	Age/sex: <1 Female	0		Redacted
HTC_TST_NGI	Age/sex: 1-4 Female	970		Redacted
HTC_TST_NGI	Age/sex: 5-9 Female	416		Redacted
HTC_TST_NGI	Age/sex: 10-14 Female	693		Redacted
HTC_TST_NGI	Age/sex: 15-19 Female	1,386		Redacted
HTC_TST_NGI	Age/sex: 20-24 Female	3,465		Redacted
HTC_TST_NGI	Age/sex: 25-49 Female	5,544		Redacted
HTC_TST_NGI	Age/sex: 50+ Female	1,386		Redacted
HTC_TST_NGI	Sum of Age/Sex disaggregates	27,720		Redacted
HTC_TST_NGI	Aggregated Age/sex: <15 Male	2,079		Redacted



HTC_TST_NGI	Aggregated Age/sex: 15+ Male	11,781		Redacted
HTC_TST_NGI	Aggregated Age/sex: <15 Female	2,079		Redacted
HTC_TST_NGI	Aggregated Age/sex: 15+ Female	11,781		Redacted
HTC_TST_NGI	Sum of Aggregated Age/Sex <15	4,158		Redacted
HTC_TST_NGI	Sum of Aggregated Age/Sex 15+	23,562		Redacted
HTC_TST_NGI	Sum of Aggregated Age/Sex disaggregates	27,720		Redacted
OVC_ACC_DSD	Number of active beneficiaries receiving support from PEPFAR OVC programs to access HIV services	200		Redacted
OVC_ACC_DSD	Sex: Male	100		Redacted
OVC_ACC_DSD	Sex: Female	100		Redacted
OVC_ACC_DSD	Sum of Sex disaggregates	200		Redacted
OVC_ACC_DSD	Age: <1	4		Redacted
OVC_ACC_DSD	Age: 1-4	24		Redacted
OVC_ACC_DSD	Age: 5-9	50		Redacted
OVC_ACC_DSD	Age: 10-14	72		Redacted
OVC_ACC_DSD	Age: 15-17	40		Redacted
OVC_ACC_DSD	Age: 18+	10		Redacted
OVC_ACC_DSD	Sum of Age disaggregates	200		Redacted
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	6,000		Redacted
OVC_SERV_DSD	Sex: Male	3,000		Redacted
OVC_SERV_DSD	Sex: Female	3,000		Redacted
OVC_SERV_DSD	Sum of Sex disaggregates	6,000		Redacted
OVC_SERV_DSD	Age: <1	120		Redacted
OVC_SERV_DSD	Age: 1-4	720		Redacted
OVC_SERV_DSD	Age: 5-9	1,500		Redacted
OVC_SERV_DSD	Age: 10-14	2,160		Redacted
OVC_SERV_DSD	Age: 15-17	1,200		Redacted
OVC_SERV_DSD	Age: 18+	300		Redacted



OVC_SERV_DSD	Sum of Age disaggregates	6,000		Redacted
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	257		Redacted
PMTCT_EID_DSD	Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT)	321		Redacted
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	193		Redacted
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	64		Redacted
PMTCT_EID_DSD	Sum of Infant Age disaggregates	257		Redacted
PMTCT_EID_DSD	By infants with a positive virologic test result within 12 months of birth	13		Redacted
FPINT_SITE_DSD	Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	12		Redacted
FPINT_SITE_DSD	Total number of PEPFAR-supported HIV service delivery points: PMTCT, Care and Treatment	16		Redacted
FPINT_SITE_DSD	By site support type: Direct Service Delivery (DSD): Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	12		Redacted
FPINT_SITE_DSD	By site support type: Technical Assistance-only (TA): Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	0		Redacted



FPINT_SITE_DSD	Sum of Numerator Site Support Type disaggregates	12		Redacted
FPINT_SITE_DSD	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported HIV service delivery points	16		Redacted
FPINT_SITE_DSD	By site support type: Technical Assistance-only (TA): Total number of PEPFAR-supported HIV service delivery points	0		Redacted
FPINT_SITE_DSD	Sum of Denominator Site Support Type disaggregates	16		Redacted
FPINT_SITE_DSD	Service delivery type: Clinical	12		Redacted
FPINT_SITE_DSD	Sum of Service Delivery Type disaggregates	12		Redacted
QI_SITE	Number of PEPFAR-supported clinical service sites with a quality improvement activity completed that addresses clinical HIV programs and has documented process results in the last 6 months	13		Redacted
QI_SITE	Total number of PEPFAR-supported sites for any HIV clinical service including HIV Care, HIV Treatment, TB care, PMTCT, VMMC, and HTC	16		Redacted
QI_SITE	By site support type: Direct Service Delivery (DSD): Number of PEPFAR-supported clinical service sites with a quality improvement activity completed that addresses clinical HIV programs and has documented results in the last 6 months	13		Redacted
QI_SITE	By site support type: Technical Assistance-only (TA): Number of PEPFAR-supported clinical service	0		Redacted



	sites with a quality improvement activity completed that addresses clinical HIV programs and has documented results in the last 6 months			
QI_SITE	Sum of Numerator Site Support Type disaggregates	13		Redacted
QI_SITE	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported sites for any HIV clinical service including HIV Care, HIV Treatment, TB care, PMTCT, VMMC, HTC	16		Redacted
QI_SITE	By site support type: Technical Assistance-only (TA): Total number of PEPFAR-supported sites for any HIV clinical service including HIV Care, HIV Treatment, TB care, PMTCT, VMMC, and HTC	0		Redacted
QI_SITE	Sum of Denominator Site Support Type disaggregates	16		Redacted

Implementing Mechanism Details

Mechanism ID: 9076	Mechanism Name: Demographic and Health Surveys - 7
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: ICF Macro	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: No	
G2G: No	Managing Agency:

Total All Funding Sources: 279,445	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 0	
FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount

Approved



GHP-State	279,445
-----------	---------

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

- Malaria (PMI)
- Child Survival Activities
- Safe Motherhood
- TB
- Workplace Programs
- Family Planning

Budget Code Information

Mechanism ID:	9076		
Mechanism Name:	Demographic and Health Surveys - 7		
Prime Partner Name:	ICF Macro		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	83,475	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	100,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	95,970	0



Implementing Mechanism Indicator Information

Indicator Number	Label	2014	2015
SITE_SUPP	Number of unique sites supported by PEPFAR	0	0
PMTCT_ARV_DSD	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	0	0
PMTCT_ARV_DSD	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	0	0
PMTCT_ARV_NA	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	0	0
PMTCT_ARV_NA	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	0	0
PMTCT_ARV_NGI	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	0	0
PMTCT_ARV_NGI	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	0	0
PMTCT_ARV_TA	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	0	0
PMTCT_ARV_TA	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	0	0



PMTCT_SITE	Number of PEPFAR-supported sites achieving 90% ARV or ART coverage for HIV+ pregnant women	0	0
PMTCT_SITE	Total number of PEPFAR supported sites providing PMTCT services (HTC and ARV or ART services)	0	0
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	0	0
PMTCT_STAT_DSD	Number of new ANC and L&D clients	0	0
PMTCT_STAT_NA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	0	0
PMTCT_STAT_NA	Number of new ANC and L&D clients	0	0
PMTCT_STAT_NGI	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	0	0
PMTCT_STAT_NGI	Number of new ANC and L&D clients	0	0
BS_COLL	Number of whole blood collections each year by the NBTS network	0	0
KP_MAT_DSD	Number of people who inject drugs (PWID) on medication assisted therapy (MAT) for at least 6 months	0	0
VMMC_AE_DSD	Number of males circumcised surgically or by medical device that experienced at least one moderate or severe adverse event(s) (AEs)	0	0
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	0	0
VMMC_CIRC_NA	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	0	0
VMMC_CIRC_NGI	Number of males circumcised as part of the	0	0



	voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period		
VMMC_CIRC_TA	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	0	0
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	0	0
PP_PREV_DSD	Total number of people in the target population	0	0
PP_PREV_TA	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	0	0
PP_PREV_TA	Total number of people in the target population	0	0
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	0	0
KP_PREV_TA	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	0	0
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	0	0
HTC_TST_NA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	0	0



HTC_TST_NGI	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	0	0
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	0	0
GEND_GBV_DSD	Number of people receiving post-GBV care	0	0
GEND_NORM_DSD	Number of people completing an intervention pertaining to gender norms, that meets minimum criteria	0	0
OVC_ACC_DSD	Number of active beneficiaries receiving support from PEPFAR OVC programs to access HIV services	0	0
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	0	0
OVC_SERV_TA	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	0	0
C2.1.D_DSD	Number of HIV-positive individuals receiving a minimum of one clinical service	0	0
C2.1.D_NA	Number of HIV-positive individuals receiving a minimum of one clinical service	0	0
C2.1.D_NGI	Number of HIV-positive individuals receiving a minimum of one clinical service	0	0
C2.1.D_TA	Number of HIV-positive individuals receiving a minimum of one clinical service	0	0
C2.4.D_DSD	Number of HIV-positive patients who were screened for TB in HIV care or treatment setting	0	0
C2.4.D_DSD	Number of HIV-positive individuals receiving a minimum of one clinical service	0	0
C2.5.D_DSD	Number of HIV-positive patients in HIV care who started TB treatment	0	0



C2.5.D_DSD	Number of HIV-positive individuals receiving a minimum of one clinical service	0	0
CARE_CURR_DSD	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	0	0
CARE_CURR_TA	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	0	0
CARE_NEW_DSD	Number of HIV-infected adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load	0	0
CARE_SITE	Number of PEPFAR-supported HIV clinical care sites at which at least 80% of PLHIV received all of the following during the reporting period: 1) clinical assessment (WHO staging) OR CD4 count OR viral load, AND 2) TB screening at last visit, AND 3) if eligible, cotrimoxazole	0	0
CARE_SITE	Total number of PEPFAR supported sites providing clinical care services	0	0
FN_SITE	Number of PEPFAR-supported sites achieving 90% nutrition assessments that result in accurate categorization of malnutrition	0	0
FN_SITE	Total number of PEPFAR-supported sites providing nutrition assessment, counseling and support (NACS) services	0	0
FN_THER_DSD	Number of clinically malnourished PLHIV who received therapeutic and/or supplementary	0	0



	food during the reporting period.		
FN_THER_DSD	Number of PLHIV who were nutritionally assessed and found to be clinically undernourished.	0	0
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	0	0
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	0	0
TB_ARTSITE	The number of PEPFAR-supported TB basic management units at which 80% of registered TB cases who are HIV-positive are on ART, during the reporting period	0	0
TB_ARTSITE	The number of PEPFAR-supported TB basic management units	0	0
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	0	0
PMTCT_EID_DSD	Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT)	0	0
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	0	0
TX_CURR_NA	Number of adults and children receiving antiretroviral therapy (ART)	0	0
TX_CURR_NGI	Number of adults and children receiving antiretroviral therapy (ART)	0	0
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	0	0
TX_DIST	Number of Districts with documented routine supportive supervision visits to 75% of HIV	0	0



	care and treatment sites supported by the District		
TX_DIST	Total number of PEPFAR supported District Health Offices	0	0
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	0	0
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	0	0
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	0	0
TX_SITE	Number of PEPFAR-supported ART sites with a retention rate of 75% or greater for patients 12 months after ART initiation	0	0
TX_SITE	Total number of PEPFAR-supported ART sites	0	0
LAB_ACC_DSD	Number of PEPFAR-supported testing facilities (laboratories) that are recognized by national, regional, or international standards for accreditation or have achieved a minimal acceptable level towards attainment of such accreditation	0	0
LAB_CAP_DSD	Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests	0	0
LAB_PT_DSD	Percentage of laboratories and POC testing sites that perform HIV diagnostic testing that participate and successfully pass in an analyte-specific proficiency testing (PT) program	0	0
HRH_PRE	Number of new HCW who graduated from a pre-service training institution or program as a	0	0



	result of PEPFAR-supported strengthening efforts, within the reporting period, by select cadre		
SC_TRAIN	Number of individuals who received competency-based, certificate or higher-level training to conduct or support supply chain, inventory management, supportive supervision or distribution activities	0	0
SC_TRAIN	Number of individuals who conduct or support supply chain, inventory management, supportive supervision or distribution activities	0	0
FPINT_SITE_DSD	Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	0	0
FPINT_SITE_DSD	Total number of PEPFAR-supported HIV service delivery points: PMTCT, Care and Treatment	0	0
QI_SITE	Number of PEPFAR-supported clinical service sites with a quality improvement activity completed that addresses clinical HIV programs and has documented process results in the last 6 months	0	0
QI_SITE	Total number of PEPFAR-supported sites for any HIV clinical service including HIV Care, HIV Treatment, TB care, PMTCT, VMMC, and HTC	0	0
SC_STOCK	Number of stock status observations for one or more tracer commodities that are between the designed minimum and maximum quantities/months of stock from storage sites within at a given level (Central, Regional, etc.) of the system.	0	0
SC_STOCK	Total number of stock status observations for one or more tracer commodities from storage	0	0



	sites within at a given level (Central, Regional, etc.) of the system		
SI_HIS	Existence of a national registry of health facilities that is updated annually	1	1
SI_ME	Existence of a national HIV/AIDS M&E system based on the UNAIDS 12 components model	1	1
TB_SCREEN_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period	0	0
TB_SCREEN_DSD	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	0	0

Implementing Mechanism Details

Mechanism ID: 9039	Mechanism Name: Capacity Building for LAB
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: American Society for Microbiology	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: No	
G2G: No	Managing Agency:

Total All Funding Sources: 0	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 0	
FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount
GHP-State	0

Sub Partner Name(s)

(No data provided.)

Approved



Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

(No data provided.)

Budget Code Information

Mechanism ID:	9039		
Mechanism Name:	Capacity Building for LAB		
Prime Partner Name:	American Society for Microbiology		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 7305	Mechanism Name: Applying Science to Strengthen and Improve Systems-ASSIST
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: University Research Corporation, LLC	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: TA	
G2G: No	Managing Agency:
Total All Funding Sources: 1,219,281	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 0	
FY 2013 Burn Rate: Redacted	



Funding Source	Funding Amount
GHP-State	1,219,281

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

Family Planning

Budget Code Information

Mechanism ID: 7305			
Mechanism Name: Applying Science to Strengthen and Improve Systems-ASSIST			
Prime Partner Name: University Research Corporation, LLC			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	229,076	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	100,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	240,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	446,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount

Approved



Treatment	HTXS	204,205	0
-----------	------	---------	---

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 7142	Mechanism Name: Kenya Pharma Project
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: Chemonics International	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: No	
G2G: No	Managing Agency:

Total All Funding Sources: 42,029,278	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 41,118,285	
FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount
GHP-State	42,029,278

Sub Partner Name(s)

DHL Exel	Mission for Essential Drugs and Supplies	Phillips Pharmaceuticals, Kenya
Vimta Labs		

Cross-Cutting Budget Attribution(s)

(No data provided.)



Key Issues

(No data provided.)

Budget Code Information

Mechanism ID: 7142			
Mechanism Name: Kenya Pharma Project			
Prime Partner Name: Chemonics International			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	9,500,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXD	32,529,278	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 7139		Mechanism Name: Health Policy Project	
Funding Agency: USAID		Procurement Type: Contract	
Prime Partner Name: Futures Group			
Agreement Start Date: Redacted		Agreement End Date: Redacted	
TBD: No		New Mechanism: No	
Global Fund / Multilateral Engagement: No			
G2G: No		Managing Agency:	
Total All Funding Sources: 4,627,995		Total Mechanism Pipeline: Redacted	
Applied Pipeline Amount: 0			
FY 2013 Burn Rate: Redacted			

Approved



Funding Source	Funding Amount
GHP-State	4,627,995

Sub Partner Name(s)

PLAN International	RTI International	University of Nairobi
--------------------	-------------------	-----------------------

Cross-Cutting Budget Attribution(s)

Human Resources for Health	500,000
----------------------------	---------

Key Issues

- Malaria (PMI)
- Child Survival Activities
- Safe Motherhood
- TB
- Family Planning

Budget Code Information

Mechanism ID:	7139		
Mechanism Name:	Health Policy Project		
Prime Partner Name:	Futures Group		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	454,242	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	1,795,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Prevention	MTCT	1,101,088	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	1,277,665	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 2866	Mechanism Name: DUMISHA/TEGEMEZA
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: CENTERS FOR HEALTH SOLUTIONS	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: No	
G2G: No	Managing Agency:

Total All Funding Sources: 5,072,572	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 51,103	
FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount
GHP-State	5,072,572

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

Human Resources for Health	1,923,423
Gender: GBV	130,000
Focus Area:	Post GBV Care
Sub Area:	Collection and Use of Gender-related Strategic



	Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Gender: Gender Equality	130,000
Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation

Key Issues

- Malaria (PMI)
- Child Survival Activities
- Safe Motherhood
- TB
- Family Planning

Budget Code Information

Mechanism ID: 2866			
Mechanism Name: DUMISHA/TEGEMEZA			
Prime Partner Name: CENTERS FOR HEALTH SOLUTIONS			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	390,988	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	417,380	0



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	133,215	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	676,700	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	1,326,557	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	1,830,442	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	297,290	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2014	2015	Planning Budget Targets
SITE_SUPP	Number of unique sites supported by PEPFAR	190	190	Redacted
SITE_SUPP	By program area/support type: HTC Direct Service Delivery (DSD)	190	190	Redacted
SITE_SUPP	By program area/support type: HTC Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: Treatment Direct Service Delivery (DSD)	66	66	Redacted
SITE_SUPP	By program area/support type: Treatment Technical Assistance-only (TA)	0	0	Redacted



SITE_SUPP	By program area/support type: Care and Support Direct Service Delivery (DSD)	66	66	Redacted
SITE_SUPP	By program area/support type: Care and Support Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: Food and Nutrition Direct Service Delivery (DSD)	66	66	Redacted
SITE_SUPP	By program area/support type: Food and Nutrition Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: PMTCT Direct Service Delivery (DSD)	190	190	Redacted
SITE_SUPP	By program area/support type: PMTCT Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: TB/HIV Direct Service Delivery (DSD)	65	65	Redacted
SITE_SUPP	By program area/support type: TB/HIV Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: VMMC Direct Service Delivery (DSD)	0	0	Redacted
SITE_SUPP	By program area/support type: VMMC Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: General Population Prevention Direct Service Delivery (DSD)	0	0	Redacted
SITE_SUPP	By program area/support type: General Population Prevention Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: Key Populations Prevention Direct Service Delivery (DSD)	0	0	Redacted
SITE_SUPP	By program area/support type: Key Populations Prevention Technical	0	0	Redacted



	Assistance-only (TA)			
SITE_SUPP	By program area/support type: OVC Direct Service Delivery (DSD)	0	0	Redacted
SITE_SUPP	By program area/support type: OVC Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: PHDP/Family Planning & Integration Direct Service Delivery (DSD)	190	190	Redacted
SITE_SUPP	By program area/support type: PHDP/Family Planning & Integration Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: Lab Direct Service Delivery (DSD)	0	0	Redacted
SITE_SUPP	By program area/support type: Lab Technical Assistance-only (TA)	67	67	Redacted
PMTCT_ARV_DS D	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	2,680	2,734	Redacted
PMTCT_ARV_DS D	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	2,680	2,734	Redacted
PMTCT_ARV_DS D	Life-long ART (including Option B+)	2,010	2,050	Redacted
PMTCT_ARV_DS D	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	938	957	Redacted
PMTCT_ARV_DS D	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	1,072	1,093	Redacted
PMTCT_ARV_DS D	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)	0	0	Redacted
PMTCT_ARV_DS	Maternal AZT (prophylaxis component)	670	684	Redacted



D	of WHO Option A during pregnancy and delivery)			
PMTCT_ARV_DS D	Single-dose nevirapine (with or without tail)	0	0	Redacted
PMTCT_ARV_DS D	Sum of Regimen Type disaggregates	2,680	2,734	Redacted
PMTCT_ARV_DS D	Sum of New and Current disaggregates	2,010	2,050	Redacted
PMTCT_ARV_NGI	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	2,680	2,734	Redacted
PMTCT_ARV_NGI	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	2,680	2,734	Redacted
PMTCT_ARV_NGI	Life-long ART (including Option B+)	2,010	2,050	Redacted
PMTCT_ARV_NGI	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	938	957	Redacted
PMTCT_ARV_NGI	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	1,072	1,093	Redacted
PMTCT_ARV_NGI	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)	0	0	Redacted
PMTCT_ARV_NGI	Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)	670	684	Redacted
PMTCT_ARV_NGI	Single-dose nevirapine (with or without tail)	0	0	Redacted
PMTCT_ARV_NGI	Sum of Regimen disaggregates	2,680	2,734	Redacted
PMTCT_ARV_NGI	Sum of New and Current disaggregates	2,010	2,050	Redacted
PMTCT_SITE	Number of PEPFAR-supported sites	190	190	Redacted



	achieving 90% ARV or ART coverage for HIV+ pregnant women			
PMTCT_SITE	Total number of PEPFAR supported sites providing PMTCT services (HTC and ARV or ART services)	190	190	Redacted
PMTCT_SITE	By site support type: Direct Service Delivery (DSD): Number of PEPFAR-supported sites achieving 90% ARV or ART coverage for HIV+ pregnant women	190	190	Redacted
PMTCT_SITE	By site support type: Technical Assistance-only (TA): Number of PEPFAR-supported sites achieving 90% ARV or ART coverage for HIV+ pregnant women	0	0	Redacted
PMTCT_SITE	Sum of Numerator Support Type disaggregates	190	190	Redacted
PMTCT_SITE	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR supported sites providing PMTCT services (HTC and ARV or ART services)	190	190	Redacted
PMTCT_SITE	By site support type: Technical Assistance-only (TA): Total number of PEPFAR supported sites providing PMTCT services (HTC and ARV or ART services)	0	0	Redacted
PMTCT_SITE	Sum of Denominator Support Type disaggregates	190	190	Redacted
PMTCT_STAT_DS D	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	42,830	41,144	Redacted
PMTCT_STAT_DS D	Number of new ANC and L&D clients	42,830	41,144	Redacted

PMTCT_STAT_DS D	By: Known positives at entry	1,260	1,285	Redacted
PMTCT_STAT_DS D	By: Number of new positives identified	1,420	1,449	Redacted
PMTCT_STAT_DS D	Sum of Positives Status disaggregates	2,680	2,734	Redacted
PMTCT_STAT_NG I	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	41,144	41,144	Redacted
PMTCT_STAT_NG I	Number of new ANC and L&D clients	41,144	41,144	Redacted
PMTCT_STAT_NG I	By: Known positives at entry	1,260	1,285	Redacted
PMTCT_STAT_NG I	By: Number of new positives identified	1,420	1,449	Redacted
PMTCT_STAT_NG I	Sum of Positives Status disaggregates	2,680	2,734	Redacted
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	160,269	233,197	Redacted
HTC_TST_DSD	By Test Result: Negative	153,859	223,869	Redacted
HTC_TST_DSD	By Test Result: Positive	6,410	9,328	Redacted
HTC_TST_DSD	Sum of Test Result disaggregates	160,269	233,197	Redacted
HTC_TST_DSD	Age/sex: <1 Male	0	0	Redacted
HTC_TST_DSD	Age/sex: 1-4 Male	5,609	8,161	Redacted
HTC_TST_DSD	Age/sex: 5-9 Male	2,404	3,498	Redacted
HTC_TST_DSD	Age/sex: 10-14 Male	4,007	5,830	Redacted
HTC_TST_DSD	Age/sex: 15-19 Male	8,013	11,660	Redacted
HTC_TST_DSD	Age/sex: 20-24 Male	20,034	29,149	Redacted
HTC_TST_DSD	Age/sex: 25-49 Male	32,054	46,639	Redacted
HTC_TST_DSD	Age/sex: 50+ Male	8,013	11,661	Redacted
HTC_TST_DSD	Age/sex: <1 Female	0	0	Redacted



HTC_TST_DSD	Age/sex: 1-4 Female	5,609	8,161	Redacted
HTC_TST_DSD	Age/sex: 5-9 Female	2,404	3,498	Redacted
HTC_TST_DSD	Age/sex: 10-14 Female	4,008	5,830	Redacted
HTC_TST_DSD	Age/sex: 15-19 Female	8,013	11,660	Redacted
HTC_TST_DSD	Age/sex: 20-24 Female	20,034	29,151	Redacted
HTC_TST_DSD	Age/sex: 25-49 Female	32,055	46,638	Redacted
HTC_TST_DSD	Age/sex: 50+ Female	8,012	11,661	Redacted
HTC_TST_DSD	Sum of Age/Sex disaggregates	160,269	233,197	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	12,020	17,489	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	68,114	99,109	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	12,021	17,489	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	68,114	99,110	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	24,041	34,978	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	136,228	198,219	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	160,269	233,197	Redacted
HTC_TST_NGI	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	160,269	233,197	Redacted
HTC_TST_NGI	By Test Result: Negative	153,858	223,869	Redacted
HTC_TST_NGI	By Test Result: Positive	6,411	9,328	Redacted
HTC_TST_NGI	Sum of Test Result disaggregates	160,269	233,197	Redacted
HTC_TST_NGI	Age/sex: <1 Male	0	0	Redacted
HTC_TST_NGI	Age/sex: 1-4 Male	5,609	8,161	Redacted
HTC_TST_NGI	Age/sex: 5-9 Male	2,404	3,498	Redacted
HTC_TST_NGI	Age/sex: 10-14 Male	4,007	5,830	Redacted
HTC_TST_NGI	Age/sex: 15-19 Male	8,013	11,660	Redacted
HTC_TST_NGI	Age/sex: 20-24 Male	20,034	29,149	Redacted
HTC_TST_NGI	Age/sex: 25-49 Male	32,054	46,639	Redacted



HTC_TST_NGI	Age/sex: 50+ Male	8,013	11,661	Redacted
HTC_TST_NGI	Age/sex: <1 Female	0	0	Redacted
HTC_TST_NGI	Age/sex: 1-4 Female	5,609	8,161	Redacted
HTC_TST_NGI	Age/sex: 5-9 Female	2,404	3,498	Redacted
HTC_TST_NGI	Age/sex: 10-14 Female	4,008	5,830	Redacted
HTC_TST_NGI	Age/sex: 15-19 Female	8,013	11,660	Redacted
HTC_TST_NGI	Age/sex: 20-24 Female	20,034	29,151	Redacted
HTC_TST_NGI	Age/sex: 25-49 Female	32,055	46,638	Redacted
HTC_TST_NGI	Age/sex: 50+ Female	8,012	11,661	Redacted
HTC_TST_NGI	Sum of Age/Sex disaggregates	160,269	233,197	Redacted
HTC_TST_NGI	Aggregated Age/sex: <15 Male	12,020	17,489	Redacted
HTC_TST_NGI	Aggregated Age/sex: 15+ Male	68,114	99,109	Redacted
HTC_TST_NGI	Aggregated Age/sex: <15 Female	12,021	17,489	Redacted
HTC_TST_NGI	Aggregated Age/sex: 15+ Female	68,114	99,110	Redacted
HTC_TST_NGI	Sum of Aggregated Age/Sex <15	24,041	34,978	Redacted
HTC_TST_NGI	Sum of Aggregated Age/Sex 15+	136,228	198,219	Redacted
HTC_TST_NGI	Sum of Aggregated Age/Sex disaggregates	160,269	233,197	Redacted
C2.1.D_DSD	Number of HIV-positive individuals receiving a minimum of one clinical service	28,218	30,845	Redacted
C2.1.D_DSD	By Age/Sex: <15 Female	1,270	1,391	Redacted
C2.1.D_DSD	By Age/Sex: <15 Male	1,270	1,391	Redacted
C2.1.D_DSD	By Age/Sex: 15+ Female	16,948	18,521	Redacted
C2.1.D_DSD	By Age/Sex: 15+ Male	8,730	9,542	Redacted
C2.1.D_DSD	Sum of Age/Sex disaggregates	28,218	30,845	Redacted
C2.1.D_DSD	By Age: <15	2,540	2,783	Redacted
C2.1.D_DSD	By Age: 15+	25,678	28,062	Redacted
C2.1.D_DSD	Sum of Age disaggregates	28,218	30,845	Redacted
C2.1.D_DSD	By Sex: Female	18,218	19,912	Redacted
C2.1.D_DSD	By Sex: Male	10,000	10,933	Redacted
C2.1.D_DSD	Sum of Sex disaggregates	28,218	30,845	Redacted



C2.1.D_NGI	Number of HIV-positive individuals receiving a minimum of one clinical service	28,218	30,845	Redacted
C2.1.D_NGI	By Age/Sex: <15 Female	1,270	1,391	Redacted
C2.1.D_NGI	By Age/Sex: <15 Male	1,270	1,392	Redacted
C2.1.D_NGI	By Age/Sex: 15+ Female	16,948	18,521	Redacted
C2.1.D_NGI	By Age/Sex: 15+ Male	8,730	9,541	Redacted
C2.1.D_NGI	Sum of Age/Sex disaggregates	28,218	30,845	Redacted
C2.1.D_NGI	By Age: <15	2,540	2,783	Redacted
C2.1.D_NGI	By Age: 15+	25,678	28,062	Redacted
C2.1.D_NGI	Sum of Age disaggregates	28,218	30,845	Redacted
C2.1.D_NGI	By Sex: Female	18,218	19,912	Redacted
C2.1.D_NGI	By Sex: Male	10,000	10,933	Redacted
C2.1.D_NGI	Sum of Sex disaggregates	28,218	30,845	Redacted
C2.4.D_DSD	Number of HIV-positive patients who were screened for TB in HIV care or treatment setting	25,396	29,302	Redacted
C2.4.D_DSD	Number of HIV-positive individuals receiving a minimum of one clinical service	28,218	30,845	Redacted
C2.5.D_DSD	Number of HIV-positive patients in HIV care who started TB treatment	508	586	Redacted
C2.5.D_DSD	Number of HIV-positive individuals receiving a minimum of one clinical service	28,218	30,845	Redacted
CARE_CURR_DS D	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	26,807	29,302	Redacted
CARE_CURR_DS D	Age/sex: <1 Male	42	46	Redacted
CARE_CURR_DS D	Age/sex: 1-4 Male	290	318	Redacted



CARE_CURR_DS D	Age/sex: 5-9 Male	490	537	Redacted
CARE_CURR_DS D	Age/sex: 10-14 Male	384	421	Redacted
CARE_CURR_DS D	Age/sex: 15-19 Male	206	225	Redacted
CARE_CURR_DS D	Age/sex: 20-24 Male	381	416	Redacted
CARE_CURR_DS D	Age/sex: 25-49 Male	5,728	6,260	Redacted
CARE_CURR_DS D	Age/sex: 50+ Male	1,979	2,163	Redacted
CARE_CURR_DS D	Age/sex: <1 Female	42	46	Redacted
CARE_CURR_DS D	Age/sex: 1-4 Female	275	302	Redacted
CARE_CURR_DS D	Age/sex: 5-9 Female	507	555	Redacted
CARE_CURR_DS D	Age/sex: 10-14 Female	382	419	Redacted
CARE_CURR_DS D	Age/sex: 15-19 Female	340	371	Redacted
CARE_CURR_DS D	Age/sex: 20-24 Female	1,409	1,540	Redacted
CARE_CURR_DS D	Age/sex: 25-49 Female	12,038	13,155	Redacted
CARE_CURR_DS D	Age/sex: 50+ Female	2,314	2,528	Redacted
CARE_CURR_DS D	Sun of Age/Sex disaggregates	26,807	29,302	Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	1,206	1,322	Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	8,294	9,064	Redacted



CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	1,206	1,322	Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	16,101	17,594	Redacted
CARE_CURR_DS D	Sum of Aggregated Age/Sex disaggregates	26,807	29,302	Redacted
CARE_NEW_DSD	Number of HIV-infected adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load	5,361	5,328	Redacted
CARE_NEW_DSD	Age/sex: <1 Male	8	8	Redacted
CARE_NEW_DSD	Age/sex: 1-4 Male	58	58	Redacted
CARE_NEW_DSD	Age/sex: 5-9 Male	98	98	Redacted
CARE_NEW_DSD	Age/sex: 10-14 Male	77	77	Redacted
CARE_NEW_DSD	Age/sex: 15-19 Male	35	35	Redacted
CARE_NEW_DSD	Age/sex: 20-24 Male	145	144	Redacted
CARE_NEW_DSD	Age/sex: 25-49 Male	1,241	1,233	Redacted
CARE_NEW_DSD	Age/sex: 50+ Male	238	237	Redacted
CARE_NEW_DSD	Age/sex: <1 Female	8	8	Redacted
CARE_NEW_DSD	Age/sex: 1-4 Female	55	55	Redacted
CARE_NEW_DSD	Age/sex: 5-9 Female	101	101	Redacted
CARE_NEW_DSD	Age/sex: 10-14 Female	77	76	Redacted
CARE_NEW_DSD	Age/sex: 15-19 Female	80	79	Redacted
CARE_NEW_DSD	Age/sex: 20-24 Female	148	147	Redacted
CARE_NEW_DSD	Age/sex: 25-49 Female	2,224	2,209	Redacted
CARE_NEW_DSD	Age/sex: 50+ Female	768	763	Redacted
CARE_NEW_DSD	Sum of Age/sex disaggregates	5,361	5,328	Redacted
CARE_NEW_DSD	Aggregated Age/sex: <15 Male	241	240	Redacted
CARE_NEW_DSD	Aggregated Age/sex: 15+ Male	1,659	1,648	Redacted
CARE_NEW_DSD	Aggregated Age/sex: <15 Female	241	241	Redacted
CARE_NEW_DSD	Aggregated Age/sex: 15+ Female	3,220	3,199	Redacted



CARE_NEW_DSD	Sum of Aggregated Age/sex disaggregates	5,361	5,328	Redacted
CARE_SITE	Number of PEPFAR-supported HIV clinical care sites at which at least 80% of PLHIV received all of the following during the reporting period: 1) clinical assessment (WHO staging) OR CD4 count OR viral load, AND 2) TB screening at last visit, AND 3) if eligible, cotrimoxazole	66	66	Redacted
CARE_SITE	Total number of PEPFAR supported sites providing clinical care services	66	66	Redacted
CARE_SITE	By site support type: Direct Service Delivery (DSD): Number of PEPFAR-supported HIV clinical care sites at which at least 80% of PLHIV received all of the following during the reporting period: 1) clinical assessment (WHO staging) OR CD4 count OR viral load, AND 2) TB screening at last visit, AND 3) if eligible, cotrimoxazole	66	66	Redacted
CARE_SITE	By site support type: Technical Assistance-only (TA): Number of PEPFAR-supported HIV clinical care sites at which at least 80% of PLHIV received all of the following during the reporting period: 1) clinical assessment (WHO staging) OR CD4 count OR viral load, AND 2) TB screening at last visit, AND 3) if eligible, cotrimoxazole	0	0	Redacted
CARE_SITE	Sum of Numerator Site Support Type disaggregates	66	66	Redacted
CARE_SITE	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR supported sites providing clinical care services	66	66	Redacted



CARE_SITE	By site support type: Technical Assistance-only (TA): Total number of PEPFAR supported sites providing clinical care services	0	0	Redacted
CARE_SITE	Sum of Denominator Site Support Type disaggregates	66	66	Redacted
FN_SITE	Number of PEPFAR-supported sites achieving 90% nutrition assessments that result in accurate categorization of malnutrition	59	59	Redacted
FN_SITE	Total number of PEPFAR-supported sites providing nutrition assessment, counseling and support (NACS) services	66	66	Redacted
FN_SITE	By site support type: Direct Service Delivery (DSD): Number of PEPFAR-supported sites achieving 90% nutrition assessments that result in accurate categorization of malnutrition	59	59	Redacted
FN_SITE	By site support type: Technical Assistance-only (TA): Number of PEPFAR-supported sites achieving 90% nutrition assessments that result in accurate categorization of malnutrition	0	0	Redacted
FN_SITE	Sum of Numerator Support Type disaggregates	59	59	Redacted
FN_SITE	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported sites providing nutrition assessment, counseling and support (NACS) services	66	66	Redacted
FN_SITE	By site support type: Technical Assistance-only (TA): Total number of	0	0	Redacted



	PEPFAR-supported sites providing nutrition assessment, counseling and support (NACS) services			
FN_SITE	Sum of Denominator Support Type disaggregates	66	66	Redacted
FN_THER_DSD	Number of clinically malnourished PLHIV who received therapeutic and/or supplementary food during the reporting period.	4,233	4,627	Redacted
FN_THER_DSD	Number of PLHIV who were nutritionally assessed and found to be clinically undernourished.	5,644	6,169	Redacted
FN_THER_DSD	Age: <1	13	15	Redacted
FN_THER_DSD	Age: 1-4	91	100	Redacted
FN_THER_DSD	Age: 5-14	285	312	Redacted
FN_THER_DSD	Age: 15-17	87	93	Redacted
FN_THER_DSD	Age: 18+	3,757	4,107	Redacted
FN_THER_DSD	Sum of Age disaggregates	4,233	4,627	Redacted
FN_THER_DSD	Aggregated Age: <18	476	520	Redacted
FN_THER_DSD	Aggregated Age: 18+	3,757	4,107	Redacted
FN_THER_DSD	Sum of Aggregated Age disaggregates	4,233	4,627	Redacted
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	1,079	1,319	Redacted
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	1,270	1,465	Redacted
TB_ART_DSD	Age: 0-4	27	33	Redacted
TB_ART_DSD	Age: 5-14	72	89	Redacted
TB_ART_DSD	Age: 15+	980	1,197	Redacted
TB_ART_DSD	Male	583	712	Redacted



TB_ART_DSD	Female	496	607	Redacted
TB_ART_DSD	Sum of Sex disaggregates	1,079	1,319	Redacted
TB_ART_DSD	Newly tested	648	791	Redacted
TB_ART_DSD	Known HIV-positive	431	528	Redacted
TB_ART_DSD	Sum of Test Status disaggregates	1,079	1,319	Redacted
TB_ART_DSD	Aggregated Age: <15	99	122	Redacted
TB_ART_DSD	Aggregated Age: 15+	980	1,197	Redacted
TB_ART_DSD	Sum of Aggregated Age disaggregates	1,079	1,319	Redacted
TB_ARTSITE	The number of PEPFAR-supported TB basic management units at which 80% of registered TB cases who are HIV-positive are on ART, during the reporting period	65	65	Redacted
TB_ARTSITE	The number of PEPFAR-supported TB basic management units	65	65	Redacted
TB_ARTSITE	By site support type: Direct Service Delivery (DSD): The number of PEPFAR-supported TB basic management units at which 80% of registered TB cases who are HIV-positive are on ART, during the reporting period	65	65	Redacted
TB_ARTSITE	By site support type: Technical Assistance-only (TA): The number of PEPFAR-supported TB basic management units at which 80% of registered TB cases who are HIV-positive are on ART, during the reporting period	0	0	Redacted
TB_ARTSITE	Sum of Numerator Site Support Type disaggregates	65	65	Redacted
TB_ARTSITE	By site support type: Direct Service Delivery (DSD): The number of PEPFAR-supported TB basic management units	65	65	Redacted



TB_ARTSITE	By site support type: Technical Assistance-only (TA): The number of PEPFAR-supported TB basic management units	0	0	Redacted
TB_ARTSITE	Sum of Denominator Site Support Type disaggregates	65	65	Redacted
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	2,144	2,187	Redacted
PMTCT_EID_DSD	Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT)	2,680	2,734	Redacted
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	1,608	1,640	Redacted
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	536	547	Redacted
PMTCT_EID_DSD	Sum of Infant Age disaggregates	2,144	2,187	Redacted
PMTCT_EID_DSD	By infants with a positive virologic test result within 12 months of birth	107	109	Redacted
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	23,161	26,325	Redacted
TX_CURR_DSD	Age/Sex: <1 Male	36	41	Redacted
TX_CURR_DSD	Age/Sex: 1-4 Male	244	278	Redacted
TX_CURR_DSD	Age/Sex: 5-14 Male	762	868	Redacted
TX_CURR_DSD	Age/Sex: 15+ Male	7,166	8,383	Redacted
TX_CURR_DSD	Age/Sex: <1 Female	36	41	Redacted
TX_CURR_DSD	Age/Sex: 1-4 Female	244	278	Redacted
TX_CURR_DSD	Age/Sex: 5-14 Female	762	868	Redacted
TX_CURR_DSD	Age/Sex: 15+ Female	13,911	15,568	Redacted
TX_CURR_DSD	Sum of age/sex disaggregates	2,084	2,374	Redacted
TX_CURR_DSD	Percent children with advanced HIV infection receiving antiretroviral therapy	1	1	Redacted



	(ART) [CURRENT]			
TX_CURR_DSD	Percent women and girls with advanced HIV infection receiving antiretroviral therapy (ART) [CURRENT]	1	1	Redacted
TX_CURR_DSD	Aggregated Age/Sex: <1 Male	36	41	Redacted
TX_CURR_DSD	Aggregated Age/Sex: <1 Female	36	41	Redacted
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	1,042	1,187	Redacted
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	7,166	8,383	Redacted
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	1,042	1,187	Redacted
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	13,911	15,568	Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	2,084	2,374	Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	21,077	23,951	Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	23,161	26,325	Redacted
TX_CURR_NGI	Number of adults and children receiving antiretroviral therapy (ART)	23,161	26,325	Redacted
TX_CURR_NGI	Age/Sex: <1 Male	36	41	Redacted
TX_CURR_NGI	Age/Sex: 1-4 Male	244	278	Redacted
TX_CURR_NGI	Age/Sex: 5-14 Male	762	868	Redacted
TX_CURR_NGI	Age/Sex: 15+ Male	7,166	8,383	Redacted
TX_CURR_NGI	Age/Sex: <1 Female	36	41	Redacted
TX_CURR_NGI	Age/Sex: 1-4 Female	244	278	Redacted
TX_CURR_NGI	Age/Sex: 5-14 Female	762	868	Redacted
TX_CURR_NGI	Age/Sex: 15+ Female	13,911	15,568	Redacted
TX_CURR_NGI	Sum of Age/Sex disaggregates	23,161	26,325	Redacted
TX_CURR_NGI	Aggregated Age/Sex: <1 Male	36	41	Redacted
TX_CURR_NGI	Aggregated Age/Sex: <1 Female	36	41	Redacted
TX_CURR_NGI	Aggregated Age/Sex: <15 Male	1,042	1,187	Redacted
TX_CURR_NGI	Aggregated Age/Sex: 15+ Male	7,166	8,383	Redacted
TX_CURR_NGI	Aggregated Age/Sex: <15 Female	1,042	1,187	Redacted
TX_CURR_NGI	Aggregated Age/Sex: 15+ Female	13,911	15,568	Redacted



TX_CURR_NGI	Sum of Aggregated Age/Sex disaggregates	23,161	26,325	Redacted
TX_CURR_NGI	Sum of Aggregated Age/Sex <15	2,084	2,374	Redacted
TX_CURR_NGI	Sum of Aggregated Age/Sex 15+	21,077	23,951	Redacted
TX_DIST	Number of Districts with documented routine supportive supervision visits to 75% of HIV care and treatment sites supported by the District	4	4	Redacted
TX_DIST	Total number of PEPFAR supported District Health Offices	5	5	Redacted
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	3,588	3,540	Redacted
TX_NEW_DSD	By Age/Sex: <1 Male	56	75	Redacted
TX_NEW_DSD	By Age/Sex: 1-4 Male	31	42	Redacted
TX_NEW_DSD	By Age/Sex: 5-9 Male	56	75	Redacted
TX_NEW_DSD	By Age/Sex: 10-14 Male	42	58	Redacted
TX_NEW_DSD	By Age/Sex: 15-19 Male	28	26	Redacted
TX_NEW_DSD	By Age/Sex: 20-24 Male	52	49	Redacted
TX_NEW_DSD	By Age/Sex: 25-49 Male	778	735	Redacted
TX_NEW_DSD	By Age/Sex: 50+ Male	268	254	Redacted
TX_NEW_DSD	By Age/Sex: <1 Female	56	75	Redacted
TX_NEW_DSD	By Age/Sex: 1-4 Female	31	42	Redacted
TX_NEW_DSD	By Age/Sex: 5-9 Female	56	75	Redacted
TX_NEW_DSD	By Age/Sex: 10-14 Female	42	58	Redacted
TX_NEW_DSD	By Age/Sex: 15-19 Female	44	42	Redacted
TX_NEW_DSD	By Age/Sex: 20-24 Female	183	173	Redacted
TX_NEW_DSD	By Age/Sex: 25-49 Female	1,564	1,478	Redacted
TX_NEW_DSD	By Age/Sex: 50+ Female	301	283	Redacted
TX_NEW_DSD	Sum of Age/Sex disaggregates	3,588	3,540	Redacted
TX_NEW_DSD	Aggregated Grouping by Age: <1 Male	56	75	Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	185	250	Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+	1,126	1,064	Redacted

	Male			
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <1 Female	56	75	Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	185	250	Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	2,092	1,976	Redacted
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	3,588	3,540	Redacted
TX_NEW_DSD	Pregnancy status	844	861	Redacted
TX_NEW_DSD	Breastfeeding status	94	96	Redacted
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	2,416	3,050	Redacted
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	2,842	3,588	Redacted
TX_RET_DSD	Age: 0-4 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	60	76	Redacted
TX_RET_DSD	Age: 5-14 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	163	206	Redacted
TX_RET_DSD	Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	2,193	2,769	Redacted
TX_RET_DSD	Age: 0-4 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning	70	89	Redacted

	of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)			
TX_RET_DSD	Age: 5-14 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	192	242	Redacted
TX_RET_DSD	Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	2,580	3,257	Redacted
TX_RET_DSD	Aggregated Age: <15 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	223	281	Redacted
TX_RET_DSD	Aggregated Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	2,193	2,769	Redacted
TX_RET_DSD	Aggregated Age: <15 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	262	331	Redacted
TX_RET_DSD	Aggregated Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months	2,580	3,257	Redacted



	prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)			
TX_RET_DSD	Pregnancy and breastfeeding status (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	854	1,708	Redacted
TX_RET_DSD	Pregnancy and breastfeeding status (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,005	2,010	Redacted
TX_SITE	Number of PEPFAR-supported ART sites with a retention rate of 75% or greater for patients 12 months after ART initiation	46	46	Redacted
TX_SITE	Total number of PEPFAR-supported ART sites	66	66	Redacted
TX_SITE	By support type: Direct Service Delivery (DSD): Number of PEPFAR-supported ART sites with a retention rate of 75% or greater for patients 12 months after ART initiation	46	46	Redacted
TX_SITE	By support type: Technical Assistance (TA-only): Number of PEPFAR-supported ART sites with a retention rate of 75% or greater for patients 12 months after ART initiation	0	0	Redacted
TX_SITE	Sum of Numerator Site Support Type disaggregates	46	46	Redacted
TX_SITE	By support type: Direct Service Delivery	66	66	Redacted



	(DSD): Total number of PEPFAR-supported ART sites			
TX_SITE	By support type: Technical Assistance (TA-only): Total number of PEPFAR-supported ART sites	0	0	Redacted
TX_SITE	Sum of Denominator Site Support Type disaggregates	66	66	Redacted
LAB_CAP_DSD	Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests	67	67	Redacted
LAB_CAP_DSD	By site support type: Technical Assistance-only (TA)	67	67	Redacted
LAB_CAP_DSD	Sum of Site Support Type disaggregates	67	67	Redacted
FPINT_SITE_DSD	Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	143	143	Redacted
FPINT_SITE_DSD	Total number of PEPFAR-supported HIV service delivery points: PMTCT, Care and Treatment	190	190	Redacted
FPINT_SITE_DSD	By site support type: Direct Service Delivery (DSD): Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	143	143	Redacted
FPINT_SITE_DSD	By site support type: Technical Assistance-only (TA): Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	0	0	Redacted
FPINT_SITE_DSD	Sum of Numerator Site Support Type disaggregates	143	143	Redacted



FPINT_SITE_DSD	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported HIV service delivery points	190	190	Redacted
FPINT_SITE_DSD	By site support type: Technical Assistance-only (TA): Total number of PEPFAR-supported HIV service delivery points	0	0	Redacted
FPINT_SITE_DSD	Sum of Denominator Site Support Type disaggregates	190	190	Redacted
FPINT_SITE_DSD	Service delivery type: Clinical	143	143	Redacted
FPINT_SITE_DSD	Sum of Service Delivery Type disaggregates	143	143	Redacted
QI_SITE	Number of PEPFAR-supported clinical service sites with a quality improvement activity completed that addresses clinical HIV programs and has documented process results in the last 6 months	152	152	Redacted
QI_SITE	Total number of PEPFAR-supported sites for any HIV clinical service including HIV Care, HIV Treatment, TB care, PMTCT, VMMC, and HTC	190	190	Redacted
QI_SITE	By site support type: Direct Service Delivery (DSD): Number of PEPFAR-supported clinical service sites with a quality improvement activity completed that addresses clinical HIV programs and has documented results in the last 6 months	152	152	Redacted
QI_SITE	By site support type: Technical Assistance-only (TA): Number of PEPFAR-supported clinical service sites with a quality improvement activity completed that addresses clinical HIV	0	0	Redacted



	programs and has documented results in the last 6 months			
QI_SITE	Sum of Numerator Site Support Type disaggregates	152	152	Redacted
QI_SITE	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported sites for any HIV clinical service including HIV Care, HIV Treatment, TB care, PMTCT, VMMC, HTC	190	190	Redacted
QI_SITE	By site support type: Technical Assistance-only (TA): Total number of PEPFAR-supported sites for any HIV clinical service including HIV Care, HIV Treatment, TB care, PMTCT, VMMC, and HTC	0	0	Redacted
QI_SITE	Sum of Denominator Site Support Type disaggregates	190	190	Redacted
TB_SCREEN_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period	24,126	27,837	Redacted
TB_SCREEN_DSD	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	26,807	29,302	Redacted
TB_SCREEN_DSD	Age: <1	77	89	Redacted
TB_SCREEN_DSD	Age: 1-4	521	601	Redacted
TB_SCREEN_DSD	Age: 5-9	919	1,060	Redacted
TB_SCREEN_DSD	Age: 10-14	707	816	Redacted
TB_SCREEN_DSD	Age: 15-19	488	563	Redacted
TB_SCREEN_DSD	Age: 20-24	1,627	1,877	Redacted
TB_SCREEN_DSD	Age: 25-49	15,977	18,434	Redacted

Approved



TB_SCREEN_DSD	Age: 50+	3,810	4,397	Redacted
TB_SCREEN_DSD	Sum of Age disaggregates	2,712	3,129	Redacted
TB_SCREEN_DSD	Aggregated Age - USE WITH HQ PERMISSION ONLY: <15	2,224	2,566	Redacted
TB_SCREEN_DSD	Aggregated Age - USE WITH HQ PERMISSION ONLY: 15+	21,902	25,271	Redacted
TB_SCREEN_DSD	Sum of Aggregated Age disaggregates	24,126	27,837	Redacted
TB_SCREEN_DSD	Sex: Male	8,559	9,875	Redacted
TB_SCREEN_DSD	Sex: Female	15,567	17,962	Redacted
TB_SCREEN_DSD	Sum of Sex disaggregates	24,126	27,837	Redacted



**Agency Information - Costs of Doing Business
U.S. Agency for International Development**

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Planned Amount As Of Last Q1	Cost of Doing Business Category Total	Applied Pipeline
Computers/IT Services		0		Redacted	0	0
ICASS		0		Redacted	0	0
Management Meetings/Professional Development		0		Redacted	0	0
Non-ICASS Administrative Costs		0		Redacted	0	0
Staff Program Travel		0		Redacted	0	0
USG Staff Salaries and Benefits		0		Redacted	0	9,709,230
Total	0	0	0	0	0	9,709,230

U.S. Agency for International Development Other Costs Details

Category	Item	Funding Source	Description	Planned Amount As Of Last Q1	Amount	Applied Pipeline
Computers/IT Services		GHP-State		Redacted	0	0
ICASS		GHP-State		Redacted	0	0
Management		GHP-State		Redacted	0	0



Meetings/Professional Development						
Non-ICASS Administrative Costs		GHP-State		Redacted	0	0

U.S. Department of Defense

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Planned Amount As Of Last Q1	Cost of Doing Business Category Total	Applied Pipeline
Computers/IT Services		37,555		Redacted	37,555	0
ICASS		138,920		Redacted	138,920	0
Institutional Contractors		820,391		Redacted	820,391	0
Management Meetings/Professional Development		42,211		Redacted	42,211	0
Non-ICASS Administrative Costs		206,378		Redacted	206,378	0
Peace Corps Volunteer Costs				Redacted	0	0
Staff Program Travel		54,545		Redacted	54,545	0
USG Staff Salaries and Benefits		0		Redacted	0	0
Total	0	1,300,000	0	0	1,300,000	0



U.S. Department of Defense Other Costs Details

Category	Item	Funding Source	Description	Planned Amount As Of Last Q1	Amount	Applied Pipeline
Computers/IT Services		GHP-State		Redacted	37,555	0
ICASS		GHP-State		Redacted	138,920	0
Management Meetings/Professional Development		GHP-State		Redacted	42,211	0
Non-ICASS Administrative Costs		GHP-State		Redacted	206,378	0

U.S. Department of Health and Human Services/Centers for Disease Control and Prevention

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Planned Amount As Of Last Q1	Cost of Doing Business Category Total	Applied Pipeline
Capital Security Cost Sharing		22,265		Redacted	22,265	77,735
Computers/IT Services		701,463		Redacted	701,463	248,537
ICASS		747,904		Redacted	747,904	452,096
Management Meetings/Professional Development		0		Redacted	0	60,850
Non-ICASS Administrative Costs		2,298,250		Redacted	2,298,250	912,624



Staff Program Travel	20,150	344,354		Redacted	364,504	1,514,896
USG Staff Salaries and Benefits	3,299,850	4,687,257		Redacted	7,987,107	154,134
Total	3,320,000	8,801,493	0	0	12,121,493	3,420,872

U.S. Department of Health and Human Services/Centers for Disease Control and Prevention Other Costs Details

Category	Item	Funding Source	Description	Planned Amount As Of Last Q1	Amount	Applied Pipeline
Capital Security Cost Sharing		GHP-State		Redacted	22,265	77,735
Computers/IT Services		GHP-State		Redacted	701,463	248,537
ICASS		GHP-State		Redacted	747,904	452,096
Management Meetings/Professional Development		GHP-State		Redacted	0	60,850
Non-ICASS Administrative Costs		GHP-State		Redacted	2,298,250	912,624

U.S. Department of State

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Planned Amount As Of Last Q1	Cost of Doing Business Category Total	Applied Pipeline
ICASS		237,000		Redacted	237,000	0
Management		143,000		Redacted	143,000	72,000



Meetings/Professional Development						
Non-ICASS Administrative Costs		20,000		Redacted	20,000	25,000
Staff Program Travel		35,000		Redacted	35,000	32,000
USG Staff Salaries and Benefits		476,000		Redacted	476,000	65,000
Total	0	911,000	0	0	911,000	194,000

U.S. Department of State Other Costs Details

Category	Item	Funding Source	Description	Planned Amount As Of Last Q1	Amount	Applied Pipeline
ICASS		GHP-State		Redacted	237,000	0
Management Meetings/Professional Development		GHP-State		Redacted	143,000	72,000
Non-ICASS Administrative Costs		GHP-State		Redacted	20,000	25,000

U.S. Peace Corps

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Planned Amount As Of Last Q1	Cost of Doing Business Category Total	Applied Pipeline
Computers/IT Services		0		Redacted	0	2,266



Management Meetings/Professional Development		0		Redacted	0	3,310
Non-ICASS Administrative Costs		0		Redacted	0	146,187
Peace Corps Volunteer Costs				Redacted	0	437,030
Staff Program Travel		0		Redacted	0	28,291
USG Staff Salaries and Benefits		0		Redacted	0	289,916
Total	0	0	0	0	0	907,000

U.S. Peace Corps Other Costs Details

Category	Item	Funding Source	Description	Planned Amount As Of Last Q1	Amount	Applied Pipeline
Computers/IT Services		GHP-State		Redacted	0	2,266
Management Meetings/Professional Development		GHP-State		Redacted	0	3,310
Non-ICASS Administrative Costs		GHP-State		Redacted	0	146,187